The O
patient O
was O
a O
34-yr-old B-Age
man B-Sex
who O
presented B-Clinical_event
with O
complaints O
of O
fever B-Sign_symptom
and O
a O
chronic B-Detailed_description
cough B-Sign_symptom
. O

He O
was O
a O
smoker B-History
and O
had O
a O
history B-History
of I-History
pulmonary I-History
tuberculosis I-History
that O
had O
been O
treated B-Lab_value
and I-Lab_value
cured I-Lab_value
. O

A O
computed B-Diagnostic_procedure
tomographic I-Diagnostic_procedure
( B-Diagnostic_procedure
CT I-Diagnostic_procedure
) I-Diagnostic_procedure
scan O
revealed O
multiple B-Detailed_description
tiny B-Detailed_description
nodules B-Sign_symptom
in O
both B-Biological_structure
lungs I-Biological_structure
. O

A O
thoracoscopic B-Detailed_description
lung B-Biological_structure
biopsy B-Diagnostic_procedure
was O
taken O
from O
the O
right B-Biological_structure
upper I-Biological_structure
lobe I-Biological_structure
. O

The O
microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
typical O
LCH B-Sign_symptom
. O

The O
tumor B-Coreference
cells I-Coreference
had O
vesicular B-Detailed_description
and O
grooved B-Texture
nuclei B-Biological_structure
, O
and O
they O
formed O
small B-Biological_attribute
aggregations B-Biological_attribute
around B-Biological_structure
the I-Biological_structure
bronchioles I-Biological_structure
( O
Fig. O
1 O
) O
. O

The O
tumor B-Coreference
cells I-Coreference
were O
strongly B-Severity
positive B-Lab_value
for O
S-100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
, O
vimentin B-Diagnostic_procedure
, O
CD68 B-Diagnostic_procedure
and O
CD1a B-Diagnostic_procedure
. O

There O
were O
infiltrations B-Biological_structure
of O
lymphocytes B-Biological_structure
and O
eosinophils B-Biological_structure
around O
the O
tumor B-Coreference
cells I-Coreference
. O

With O
performing O
additional O
radiologic B-Diagnostic_procedure
examinations I-Diagnostic_procedure
, O
no B-Sign_symptom
other I-Sign_symptom
organs I-Sign_symptom
were I-Sign_symptom
thought I-Sign_symptom
to I-Sign_symptom
be I-Sign_symptom
involved I-Sign_symptom
. O

He O
quit B-Activity
smoking I-Activity
, O
but O
he O
received O
no O
other O
specific O
treatment O
. O

He O
was O
well B-Sign_symptom
for B-Duration
the I-Duration
following I-Duration
one I-Duration
year I-Duration
. O

After O
this O
, O
a O
follow-up O
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
was O
performed O
and O
it O
showed O
a O
4 B-Shape
cm-sized I-Shape
mass B-Sign_symptom
in O
the O
left B-Biological_structure
lower I-Biological_structure
lobe I-Biological_structure
, O
in O
addition O
to O
the O
multiple B-Detailed_description
tiny B-Detailed_description
nodules B-Sign_symptom
in O
both B-Biological_structure
lungs I-Biological_structure
( O
Fig. O
2 O
) O
. O

A O
needle B-Detailed_description
biopsy B-Diagnostic_procedure
specimen O
revealed O
the O
possibility B-Sign_symptom
of I-Sign_symptom
a I-Sign_symptom
sarcoma I-Sign_symptom
; O
therefore O
, O
a O
lobectomy B-Therapeutic_procedure
was O
performed O
. O

Grossly O
, O
a O
4 B-Shape
cm-sized I-Shape
poorly-circumscribed B-Detailed_description
lobulated B-Detailed_description
gray-white B-Color
mass B-Sign_symptom
was O
found O
( O
Fig. O
3 O
) O
, O
and O
there O
were O
a O
few O
small B-Detailed_description
satellite B-Detailed_description
nodules B-Sign_symptom
around O
the O
main B-Coreference
mass I-Coreference
. O

Microscopically B-Diagnostic_procedure
, O
the O
tumor B-Coreference
cells I-Coreference
were O
aggregated B-Detailed_description
in I-Detailed_description
large I-Detailed_description
sheets I-Detailed_description
and O
they O
showed O
an O
infiltrative B-Biological_structure
growth I-Biological_structure
. O

The O
cytologic B-Biological_attribute
features I-Biological_attribute
of O
some O
of O
the O
tumor B-Coreference
cells I-Coreference
were O
similar B-Detailed_description
to I-Detailed_description
those I-Detailed_description
seen I-Detailed_description
in I-Detailed_description
a I-Detailed_description
typical I-Detailed_description
LCH I-Detailed_description
. O

However O
, O
many O
tumor B-Coreference
cells I-Coreference
showed O
overtly O
malignant O
cytologic B-Biological_attribute
features I-Biological_attribute
such O
as O
pleomorphic/hyperchromatic B-Detailed_description
nuclei B-Biological_structure
and O
prominent B-Detailed_description
nucleoli B-Biological_attribute
( O
Fig. O
4 O
) O
, O
and O
multinucleated B-Detailed_description
tumor B-Biological_structure
giant I-Biological_structure
cells I-Biological_structure
were O
also O
found O
. O

There O
were O
numerous B-Detailed_description
mitotic B-Biological_structure
figures I-Biological_structure
ranging O
from O
30 B-Lab_value
to I-Lab_value
60 I-Lab_value
per I-Lab_value
10 I-Lab_value
high I-Lab_value
power I-Lab_value
fields I-Lab_value
, O
and O
some B-Detailed_description
of I-Detailed_description
them I-Detailed_description
were I-Detailed_description
abnormal I-Detailed_description
. O

A O
few B-Detailed_description
foci I-Detailed_description
of O
typical B-Sign_symptom
LCH I-Sign_symptom
remained O
around B-Detailed_description
the I-Detailed_description
main I-Detailed_description
tumor I-Detailed_description
mass I-Detailed_description
. O

Immunohistochemically B-Diagnostic_procedure
, O
the O
tumor O
cells O
were O
strongly B-Severity
positive B-Lab_value
for O
S-100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
Fig. O
5 O
) O
and O
vimentin B-Diagnostic_procedure
; O
they O
were O
also O
positive B-Lab_value
for O
CD68 B-Diagnostic_procedure
( O
Dako O
N1577 O
, O
Clone O
KPI O
) O
, O
and O
focally B-Detailed_description
positive B-Lab_value
for O
CD1a B-Diagnostic_procedure
( O
Fig. O
6 O
) O
, O
and O
they O
were O
negative B-Lab_value
for O
cytokeratin B-Diagnostic_procedure
, O
epithelial B-Diagnostic_procedure
membrane I-Diagnostic_procedure
antigen I-Diagnostic_procedure
, O
CD3 B-Diagnostic_procedure
, O
CD20 B-Diagnostic_procedure
and O
HMB45 B-Diagnostic_procedure
. O

The O
ultrastructural B-Diagnostic_procedure
analysis I-Diagnostic_procedure
failed B-Sign_symptom
to I-Sign_symptom
demonstrate I-Sign_symptom
any I-Sign_symptom
Birbeck I-Sign_symptom
granules I-Sign_symptom
in O
the O
cytoplasm B-Biological_structure
of O
the O
tumor B-Sign_symptom
cells I-Sign_symptom
. O

Now O
, O
at O
five B-Date
months I-Date
after I-Date
lobectomy B-Coreference
, O
the O
patient O
is O
doing B-Outcome
well I-Outcome
with O
no B-Sign_symptom
significant I-Sign_symptom
change I-Sign_symptom
in I-Sign_symptom
the I-Sign_symptom
radiologic I-Sign_symptom
findings I-Sign_symptom
. O

A O
23 B-Age
year I-Age
old I-Age
white B-Personal_background
male B-Sex
with O
a O
4 B-History
year I-History
history I-History
of I-History
Crohn I-History
's I-History
disease I-History
presented B-Clinical_event
with O
an O
acute O
two B-Duration
day I-Duration
history O
of O
malaise B-Sign_symptom
, O
fever B-Sign_symptom
, O
abdominal B-Biological_structure
pain B-Sign_symptom
, O
vomiting B-Sign_symptom
and O
stomal B-Biological_structure
diarrhoea B-Sign_symptom
. O

He O
complained O
of O
joint B-Biological_structure
pains B-Sign_symptom
affecting O
the O
shoulders B-Biological_structure
, O
elbows B-Biological_structure
, O
wrists B-Biological_structure
, O
metacarpophalangeals B-Biological_structure
, O
knees B-Biological_structure
and O
ankles B-Biological_structure
. O

There O
was O
also O
a O
rash B-Sign_symptom
on O
the O
elbows B-Biological_structure
, O
ankles B-Biological_structure
and O
feet B-Biological_structure
, O
which O
began O
as O
erythematous B-Detailed_description
macules B-Sign_symptom
and O
evolved O
to O
vesico-pustular B-Detailed_description
lesions B-Sign_symptom
followed O
by O
crusting B-Sign_symptom
. O

There O
was O
no B-History
history I-History
of I-History
sexual I-History
exposure I-History
or O
any O
intercurrent O
infection B-Sign_symptom
. O

He O
was O
on O
no B-Medication
regular I-Medication
medication I-Medication
, O
but O
had O
discontinued O
Pentasa B-Medication
4 B-Date
months I-Date
earlier I-Date
. O

One B-Date
month I-Date
earlier I-Date
he O
had O
undergone O
a O
laparotomy B-Therapeutic_procedure
to O
excise O
a O
complex B-Detailed_description
ileo-cutaneous B-Detailed_description
fistula B-Sign_symptom
with O
blind B-Detailed_description
tracts I-Detailed_description
, O
and O
two B-Date
weeks I-Date
earlier I-Date
a O
defunctioning B-Detailed_description
ileostomy B-Therapeutic_procedure
had O
been O
created O
in O
view O
of O
persistent B-Detailed_description
abdominal B-Biological_structure
pain B-Sign_symptom
. O

The O
cutaneous B-Biological_structure
fistula B-Sign_symptom
had B-Duration
been I-Duration
present I-Duration
for I-Duration
a I-Duration
year I-Duration
, O
but O
was O
associated O
with O
a O
terminal B-Detailed_description
ileal B-Biological_structure
stricture B-Sign_symptom
and O
ileo-rectal B-Biological_structure
fistula B-Sign_symptom
of B-Duration
at I-Duration
least I-Duration
2 I-Duration
years I-Duration
duration I-Duration
. O

His O
bowel B-Coreference
disease I-Coreference
had O
been O
resistant O
to O
immunosuppressive O
drugs O
including O
azathioprine B-Medication
, O
corticosteroiods B-Medication
and O
three B-Dosage
infusions I-Dosage
of O
Infliximab B-Medication
a B-Date
year I-Date
earlier I-Date
. O

There O
had O
been O
no B-Sign_symptom
extra-intestinal I-Sign_symptom
manifestations I-Sign_symptom
. O

On O
admission B-Clinical_event
to O
the O
hospital B-Nonbiological_location
, O
he O
was O
thin B-Sign_symptom
, O
afebrile B-Sign_symptom
with O
a O
resting B-Detailed_description
tachycardia B-Sign_symptom
of O
125/minute B-Lab_value
. O

The O
rest O
of O
the O
cardio-respiratory B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
. O

The O
abdomen B-Biological_structure
was O
minimally B-Severity
tender B-Sign_symptom
around O
the O
ileostomy B-Biological_structure
without B-Detailed_description
guarding I-Detailed_description
or B-Detailed_description
rebound I-Detailed_description
tenderness I-Detailed_description
. O

Examination B-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
skin I-Diagnostic_procedure
revealed O
some O
pustules B-Sign_symptom
and O
crusts B-Sign_symptom
around O
the O
elbows B-Biological_structure
, O
ankles B-Biological_structure
and O
feet B-Biological_structure
( O
Fig O
1 O
and O
2 O
) O
. O

The B-Other_event
buttocks I-Other_event
were I-Other_event
spared I-Other_event
. I-Other_event

There O
were O
clinical O
signs O
of O
synovitis B-Sign_symptom
of O
the O
wrists B-Biological_structure
, O
proximal B-Biological_structure
interphalangeal I-Biological_structure
and O
metacarpophalangeal B-Biological_structure
joints B-Biological_structure
, O
and O
also O
both B-Biological_structure
ankles I-Biological_structure
. O

Results O
of O
the O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
a O
haemoglobin B-Diagnostic_procedure
of O
13.1 B-Lab_value
gm/dl I-Lab_value
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
15.8 B-Lab_value
× I-Lab_value
109/L I-Lab_value
, O
platelets B-Diagnostic_procedure
585 B-Lab_value
× I-Lab_value
109/L I-Lab_value
, O
C B-Diagnostic_procedure
- I-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein I-Diagnostic_procedure
37.7 B-Lab_value
mg/L I-Lab_value
and O
erythrocyte B-Diagnostic_procedure
sedimentation I-Diagnostic_procedure
rate I-Diagnostic_procedure
69 B-Lab_value
mm/hr I-Lab_value
. O

Urea B-Diagnostic_procedure
and O
electrolytes B-Diagnostic_procedure
, O
complement B-Diagnostic_procedure
, O
urine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
and O
microscopy B-Diagnostic_procedure
were O
normal B-Lab_value
. O

Rheumatoid B-Diagnostic_procedure
factor I-Diagnostic_procedure
, O
antinuclear B-Detailed_description
and O
antineutrophil B-Detailed_description
cytoplasmic B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
, O
cryoglobulins B-Diagnostic_procedure
and O
Hepatitis B-Diagnostic_procedure
B I-Diagnostic_procedure
and I-Diagnostic_procedure
C I-Diagnostic_procedure
serology I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Transthoracic B-Biological_structure
echocardiogram B-Diagnostic_procedure
showed O
no B-Sign_symptom
signs I-Sign_symptom
of I-Sign_symptom
endocarditis I-Sign_symptom
, O
and O
multiple B-Diagnostic_procedure
blood I-Diagnostic_procedure
cultures I-Diagnostic_procedure
were O
sterile B-Lab_value
. O

A O
skin B-Biological_structure
biopsy B-Diagnostic_procedure
from O
the O
ankle O
revealed O
a O
perivascular B-Biological_structure
lymphohistiocytic B-Biological_structure
infiltrate B-Biological_structure
with O
prominent O
neutrophils B-Biological_structure
and O
associated O
fibrinoid B-Detailed_description
necrosis B-Sign_symptom
of O
vessels B-Biological_structure
consistent O
with O
' O
leukocytoclastic B-Detailed_description
' O
vasculitis B-Disease_disorder
. O

He O
was O
commenced O
on O
60 B-Dosage
mg I-Dosage
prednisolone B-Medication
per B-Dosage
day I-Dosage
leading O
to O
prompt B-Detailed_description
and O
complete B-Detailed_description
resolution B-Sign_symptom
of I-Sign_symptom
all I-Sign_symptom
features I-Sign_symptom
. O

The O
dose O
of O
prednisolone B-Medication
was O
rapidly O
tapered B-Clinical_event
over B-Duration
the I-Duration
course I-Duration
of I-Duration
one I-Duration
month I-Duration
by O
the O
patient O
, O
faster O
than O
advised O
but O
without B-Sign_symptom
any I-Sign_symptom
recurrence I-Sign_symptom
over B-Duration
the I-Duration
following I-Duration
3 I-Duration
years I-Duration
. O

A O
30-year-old B-Age
female B-Sex
( O
65 O
kg O
) O
underwent O
rhinoplasty B-Therapeutic_procedure
under O
general B-Medication
anaesthesia I-Medication
, O
which O
was O
induced O
using O
a O
combination O
of O
a O
bolus O
of O
Remifentanyl B-Medication
( O
0.5 B-Dosage
μg/kg I-Dosage
) O
and O
Propofol B-Medication
2 B-Dosage
mg/kg I-Dosage
. O

Muscle B-Disease_disorder
paralysis I-Disease_disorder
was O
obtained O
with O
Cisatracurium B-Medication
( O
0.15 B-Dosage
μg/kg I-Dosage
) O
. O

Transoral B-Detailed_description
intubation B-Therapeutic_procedure
was O
performed O
with O
a O
Macintosh B-Therapeutic_procedure
blade I-Therapeutic_procedure
( O
No. B-Detailed_description
3 I-Detailed_description
) O
and O
a O
size O
7 B-Detailed_description
mm I-Detailed_description
diameter I-Detailed_description
reinforced B-Detailed_description
tracheal B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
easily O
and O
gently O
placed O
in O
the O
trachea B-Biological_structure
, O
on O
the O
first O
attempt O
and O
was O
then O
fixed O
to O
the O
right B-Biological_structure
corner I-Biological_structure
of I-Biological_structure
the I-Biological_structure
mouth I-Biological_structure
. O

No O
problems B-Disease_disorder
were O
encountered O
during O
laryngoscopy B-Therapeutic_procedure
and O
intubation B-Coreference
. O

The O
cuff O
of O
the O
tube B-Coreference
was O
inflated O
with O
a O
pressure B-Lab_value
≤ I-Lab_value
20 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
. O

No O
adjustment B-Therapeutic_procedure
of I-Therapeutic_procedure
cuff I-Therapeutic_procedure
volume I-Therapeutic_procedure
was O
made O
intra-operatively O
. O

N2O B-Medication
was O
not O
used O
for O
inhalation B-Detailed_description
anaesthesia B-Medication
. O

The O
throat B-Therapeutic_procedure
pack I-Therapeutic_procedure
was O
placed O
in O
the O
pharynx B-Biological_structure
to O
avoid O
the O
passage O
of O
blood O
in O
the O
aero-digestive O
tract O
. O

General B-Medication
anaesthesia I-Medication
was O
maintained O
with O
Sevofluorane B-Medication
in B-Administration
oxygen/air I-Administration
and O
Remifentanyl B-Medication
in O
continuous B-Administration
infusion I-Administration
0.25 B-Dosage
μg/kg/min I-Dosage
. O

Moderate B-Severity
arterial B-Sign_symptom
hypotension I-Sign_symptom
was O
maintained O
with O
a O
cuff O
systolic B-Diagnostic_procedure
artery I-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
approximately O
90 B-Lab_value
mmHg I-Lab_value
. O

The O
operation O
was O
carried O
out O
in O
a O
semi-supine B-Therapeutic_procedure
position I-Therapeutic_procedure
with O
the O
head B-Detailed_description
slightly I-Detailed_description
inclined I-Detailed_description
forward I-Detailed_description
and O
laterally O
and O
trunk B-Detailed_description
slightly I-Detailed_description
elevated I-Detailed_description
. O

Duration O
of O
the O
operation B-Therapeutic_procedure
was O
100 B-Duration
minutes I-Duration
. O

The O
patient O
was O
extubated B-Therapeutic_procedure
, O
after O
removal O
of O
the O
throat B-Therapeutic_procedure
pack I-Therapeutic_procedure
without O
problems B-Disease_disorder
. O

The O
following B-Date
day I-Date
the O
patient O
complained O
of O
difficulty B-Sign_symptom
in I-Sign_symptom
swallowing I-Sign_symptom
, O
dysphonia B-Sign_symptom
and O
hoarseness B-Sign_symptom
. O

Examination B-Diagnostic_procedure
revealed O
deviation B-Sign_symptom
of O
the O
tongue B-Biological_structure
to O
the O
right B-Detailed_description
side I-Detailed_description
and O
vocal B-Biological_structure
cord I-Biological_structure
paralysis B-Disease_disorder
, O
expression O
of O
hypoglossal B-Biological_structure
and O
recurrent B-Detailed_description
laryngeal B-Biological_structure
nerve B-Disease_disorder
injury I-Disease_disorder
without O
local B-Detailed_description
oedema B-Sign_symptom
or O
haematoma B-Sign_symptom
. O

The O
movements B-Diagnostic_procedure
of O
the O
pharynx B-Biological_structure
and O
soft B-Biological_structure
palate I-Biological_structure
were O
normal B-Lab_value
. O

Meticulous O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
including O
also O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRN B-Diagnostic_procedure
) O
revealed O
no O
other O
evidence O
of O
central B-Biological_structure
or O
cranial B-Biological_structure
nerve B-Sign_symptom
involvement I-Sign_symptom
. O

Conservative O
management O
included O
steroids B-Medication
, O
vitamins B-Medication
together O
with O
speech B-Detailed_description
and O
swallowing B-Detailed_description
therapy B-Therapeutic_procedure
. O

Full B-Outcome
recovery I-Outcome
of O
lingual B-Biological_structure
and O
laryngeal B-Biological_structure
functions B-Diagnostic_procedure
was O
obtained O
within B-Date
four I-Date
months I-Date
after I-Date
surgery O
. O

A O
74-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
in O
November B-Date
2000 I-Date
because O
of O
liver B-Sign_symptom
dysfunction I-Sign_symptom
detected O
during O
a O
medical B-Clinical_event
checkup I-Clinical_event
. O

The O
patient O
had O
been O
diagnosed O
with O
nephrotic B-Disease_disorder
syndrome I-Disease_disorder
in O
1995 B-Date
. O

Laboratory B-Diagnostic_procedure
examinations I-Diagnostic_procedure
showed O
elevated B-Lab_value
serum B-Diagnostic_procedure
hepatobiliary I-Diagnostic_procedure
enzymes I-Diagnostic_procedure
and O
IgM B-Diagnostic_procedure
, O
and O
the O
presence B-Lab_value
of O
antimitochondrial B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
. O

Serologic B-Diagnostic_procedure
markers I-Diagnostic_procedure
for O
Hepatitis B-Diagnostic_procedure
B I-Diagnostic_procedure
and B-Diagnostic_procedure
C I-Diagnostic_procedure
viruses O
were O
negative B-Lab_value
. O

Histopathologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
a O
liver B-Biological_structure
biopsy B-Diagnostic_procedure
specimen I-Diagnostic_procedure
obtained O
at O
laparoscopy B-Therapeutic_procedure
revealed O
non-suppurative B-Detailed_description
destructive B-Detailed_description
cholangitis B-Disease_disorder
in O
the O
portal B-Biological_structure
area I-Biological_structure
( O
Figure O
1 O
) O
. O

The O
diagnosis O
of O
PBC B-Disease_disorder
( O
Scheuer B-Disease_disorder
stage I-Disease_disorder
3 I-Disease_disorder
) O
was O
confirmed O
and O
ursodeoxycholic B-Medication
acid I-Medication
, O
900 B-Dosage
mg I-Dosage
daily B-Frequency
, O
was O
started O
. O

In O
January B-Date
and I-Date
June I-Date
2002 I-Date
, O
the O
patient O
underwent O
endoscopic B-Therapeutic_procedure
variceal I-Therapeutic_procedure
ligation I-Therapeutic_procedure
plus O
endoscopic B-Therapeutic_procedure
injection I-Therapeutic_procedure
sclerotherapy I-Therapeutic_procedure
as O
well O
as O
argon B-Therapeutic_procedure
plasma I-Therapeutic_procedure
coagulation I-Therapeutic_procedure
for O
worsening B-Severity
esophageal B-Sign_symptom
varices I-Sign_symptom
. O

In O
September B-Date
2007 I-Date
, O
the O
patient O
was O
admitted B-Clinical_event
for O
the O
treatment O
of O
recurrent B-Severity
esophageal B-Sign_symptom
varices I-Sign_symptom
. O

The O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
had O
ranged O
between O
52 B-Lab_value
× I-Lab_value
109/L I-Lab_value
and O
69 B-Lab_value
× I-Lab_value
109/L I-Lab_value
for O
several B-Duration
years I-Duration
, O
but O
it B-Coreference
was O
noted O
to O
decrease B-Lab_value
from O
61 B-Lab_value
× I-Lab_value
109/L I-Lab_value
in O
June B-Date
2007 I-Date
to O
8 B-Lab_value
× I-Lab_value
109/L I-Lab_value
just B-Date
before I-Date
admission I-Date
. O

Before O
the O
deterioration B-Detailed_description
of O
thrombocytopenia B-Sign_symptom
, O
the O
patient O
had O
no O
infectious B-Disease_disorder
diseases I-Disease_disorder
and O
received O
no O
other O
medication B-Medication
. O

On O
admission B-Date
, O
the O
patient O
had O
neither O
purpura B-Sign_symptom
nor O
bleeding B-Sign_symptom
episodes I-Sign_symptom
. O

Table O
1 O
shows O
the O
laboratory O
data O
on O
admission O
. O

The O
platelet-associated B-Diagnostic_procedure
IgG I-Diagnostic_procedure
level I-Diagnostic_procedure
was O
markedly B-Detailed_description
high B-Lab_value
. O

Bone B-Biological_structure
marrow I-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
normocellular B-Sign_symptom
marrow I-Sign_symptom
without O
cellular B-Sign_symptom
atypia I-Sign_symptom
. O

Ultrasonography B-Diagnostic_procedure
and O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
revealed O
a O
cirrhotic B-Sign_symptom
liver B-Biological_structure
with O
splenomegaly B-Sign_symptom
, O
ascites B-Sign_symptom
, O
and O
gallstones B-Sign_symptom
. O

The O
spleen B-Diagnostic_procedure
size I-Diagnostic_procedure
had O
remained O
unchanged B-Lab_value
from O
previous B-Detailed_description
imaging B-Diagnostic_procedure
examinations I-Diagnostic_procedure
. O

Based O
on O
these O
findings O
, O
the O
association O
of O
PBC B-Disease_disorder
( O
decompensated B-Disease_disorder
liver I-Disease_disorder
cirrhosis I-Disease_disorder
) O
with O
ITP B-Disease_disorder
was O
diagnosed O
. O

Human B-Diagnostic_procedure
leukocyte I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( I-Diagnostic_procedure
HLA I-Diagnostic_procedure
) I-Diagnostic_procedure
genotyping I-Diagnostic_procedure
determined O
by O
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction-sequencing-based I-Diagnostic_procedure
typing I-Diagnostic_procedure
or O
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction-sequence I-Diagnostic_procedure
specific I-Diagnostic_procedure
primers I-Diagnostic_procedure
( O
SRL O
, O
Inc. O
, O
Tokyo O
, O
Japan O
) O
detected O
A B-Sign_symptom
* I-Sign_symptom
02010101 I-Sign_symptom
, O
B B-Sign_symptom
* I-Sign_symptom
400201 I-Sign_symptom
, O
C B-Sign_symptom
* I-Sign_symptom
030401 I-Sign_symptom
, O
C B-Sign_symptom
* I-Sign_symptom
07020101 I-Sign_symptom
, O
DPB1 B-Sign_symptom
* I-Sign_symptom
0501 I-Sign_symptom
, O
DQA1 B-Sign_symptom
* I-Sign_symptom
0103 I-Sign_symptom
, O
DQA1 B-Sign_symptom
* I-Sign_symptom
030101 I-Sign_symptom
, O
DQB1 B-Sign_symptom
* I-Sign_symptom
030201 I-Sign_symptom
, O
DQB1 B-Sign_symptom
* I-Sign_symptom
060101 I-Sign_symptom
, O
DRB1 B-Sign_symptom
* I-Sign_symptom
080201 I-Sign_symptom
, O
and O
DRB1 B-Sign_symptom
* I-Sign_symptom
080302 I-Sign_symptom
. O

The O
13C B-Diagnostic_procedure
urea I-Diagnostic_procedure
breath I-Diagnostic_procedure
test I-Diagnostic_procedure
for O
H B-Diagnostic_procedure
pylori I-Diagnostic_procedure
infection I-Diagnostic_procedure
was O
negative B-Lab_value
. O

Figure O
2 O
shows O
the O
clinical O
course O
. O

Oral B-Administration
prednisolone B-Medication
, O
30 B-Dosage
mg I-Dosage
daily B-Frequency
, O
for O
ITP B-Coreference
was O
started O
on O
day B-Date
11 I-Date
, O
and O
diuretic B-Medication
therapy I-Medication
combined O
with O
albumin B-Medication
infusion I-Medication
for O
ascites B-Sign_symptom
was O
performed O
. O

As O
the O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
increase I-Lab_value
notably I-Lab_value
, O
pulse B-Medication
therapy I-Medication
with O
intravenous B-Administration
methylprednisolone B-Medication
, O
1 B-Dosage
g I-Dosage
daily B-Frequency
, O
was O
added O
on O
d B-Duration
22 I-Duration
to I-Duration
24 I-Duration
. O

However O
, O
the O
response B-Coreference
was O
weak B-Lab_value
and O
temporary B-Detailed_description
. O

On O
d B-Date
31 I-Date
, O
mild B-Severity
melena B-Sign_symptom
was O
identified O
. O

The O
patient O
was O
given O
a O
trial B-Detailed_description
of O
intravenous B-Administration
immune B-Medication
gamma I-Medication
globulin I-Medication
therapy I-Medication
, O
25 B-Dosage
g I-Dosage
daily B-Frequency
, O
on O
d B-Duration
32 I-Duration
to I-Duration
36 I-Duration
, O
combined O
with O
a O
second B-Detailed_description
round I-Detailed_description
of O
intravenous B-Administration
methylprednisolone B-Medication
pulse I-Medication
therapy I-Medication
on O
d B-Duration
32 I-Duration
to I-Duration
34 I-Duration
. O

Because O
a O
moderate B-Lab_value
response B-Coreference
was O
observed O
, O
prednisolone B-Medication
was O
continued B-Clinical_event
, O
and O
the O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
increased B-Lab_value
slowly I-Lab_value
. O

The O
ascites B-Sign_symptom
was I-Sign_symptom
relatively I-Sign_symptom
well I-Sign_symptom
controlled I-Sign_symptom
with O
diuretics B-Medication
at O
discharge B-Clinical_event
. O

Considering O
the O
decompensated B-Disease_disorder
liver I-Disease_disorder
cirrhosis I-Disease_disorder
and O
the O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
, O
we O
determined O
the O
patient O
required O
careful O
follow-up B-Clinical_event
of O
esophageal B-Sign_symptom
varices I-Sign_symptom
without O
prophylactic B-Therapeutic_procedure
endoscopic I-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

A O
19-year-old B-Age
man B-Sex
presented B-Clinical_event
at O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
, O
12 B-Time
h I-Time
after I-Time
insertion B-Activity
of O
a O
high B-Detailed_description
pressure I-Detailed_description
container I-Detailed_description
with O
tanning O
spray O
into O
his O
rectum B-Biological_structure
. O

A O
plain B-Detailed_description
abdominal B-Biological_structure
radiograph B-Diagnostic_procedure
( O
Figure O
1 O
) O
showed O
the O
container B-Sign_symptom
in O
the O
rectosigmoid B-Biological_structure
region I-Biological_structure
. O

There O
were O
no O
signs O
of O
perforation B-Disease_disorder
. O

A O
flexible B-Detailed_description
sigmoidoscopy B-Diagnostic_procedure
was O
performed O
under O
conscious B-Medication
sedation I-Medication
. O

The O
object B-Sign_symptom
was O
located O
just O
above B-Biological_structure
the I-Biological_structure
rectosigmoid I-Biological_structure
junction I-Biological_structure
. O

The O
container B-Coreference
could O
not O
be O
extracted B-Therapeutic_procedure
by O
bimanual B-Therapeutic_procedure
manipulation I-Therapeutic_procedure
. O

An O
attempt O
to O
remove B-Therapeutic_procedure
the O
object B-Coreference
with O
conventional B-Detailed_description
endoscopic I-Detailed_description
instruments I-Detailed_description
, O
such O
as O
polypectomy B-Detailed_description
snares I-Detailed_description
, O
was O
unsuccessful B-Lab_value
. O

The O
sigmoidoscope B-Diagnostic_procedure
could O
be O
passed O
alongside O
the O
foreign B-Coreference
body I-Coreference
to O
its O
proximal O
end O
. O

A O
guide B-Diagnostic_procedure
wire I-Diagnostic_procedure
was O
left O
behind O
with O
the O
sigmoidoscope B-Diagnostic_procedure
removed O
. O

Subsequently O
, O
a O
40 B-Distance
mm I-Distance
pneumatic B-Diagnostic_procedure
dilatation I-Diagnostic_procedure
balloon I-Diagnostic_procedure
( O
Rigiflex O
® O
, O
Boston O
Scientific O
) O
, O
normally O
used O
in O
achalasia O
patients O
, O
was O
inserted O
over O
the O
guide B-Diagnostic_procedure
wire I-Diagnostic_procedure
and O
inflated O
just O
above O
the O
container B-Coreference
( O
Figure O
2 O
) O
. O

For O
safety O
purposes O
, O
the O
sigmoidoscope B-Diagnostic_procedure
was O
reintroduced O
alongside O
the O
catheter O
of O
the O
balloon B-Coreference
to O
allow O
endoscopic O
visual O
control O
of O
the O
distal O
end O
of O
the O
container B-Coreference
in O
the O
rectum B-Biological_structure
. O

Gentle O
traction O
was O
exerted O
on O
the O
balloon B-Coreference
catheter O
, O
and O
the O
container B-Coreference
was O
successfully B-Lab_value
removed B-Therapeutic_procedure
under O
fluoroscopic B-Detailed_description
and I-Detailed_description
endoscopic I-Detailed_description
control I-Detailed_description
( O
Figure O
3 O
) O
. O

A O
63-year-old B-Age
woman B-Sex
with O
no B-History
known I-History
cardiac I-History
history I-History
presented B-Clinical_event
with O
a O
sudden B-Detailed_description
onset I-Detailed_description
of O
dyspnea B-Sign_symptom
requiring O
intubation B-Therapeutic_procedure
and O
ventilatory B-Therapeutic_procedure
support I-Therapeutic_procedure
out B-Nonbiological_location
of I-Nonbiological_location
hospital I-Nonbiological_location
. O

She O
denied O
preceding O
symptoms O
of O
chest B-Biological_structure
discomfort B-Sign_symptom
, O
palpitations B-Sign_symptom
, O
syncope B-Sign_symptom
or O
infection B-Disease_disorder
. O

The O
patient O
was O
afebrile B-Sign_symptom
and O
normotensive B-Sign_symptom
, O
with O
a O
sinus B-Detailed_description
tachycardia B-Sign_symptom
of O
140 B-Lab_value
beats/min I-Lab_value
. O

The O
cardiorespiratory B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
remarkable O
for O
an O
elevated B-Lab_value
jugular B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
at O
the O
angle B-Biological_structure
of I-Biological_structure
the I-Biological_structure
jaw I-Biological_structure
, O
a O
left-sided B-Detailed_description
third B-Sign_symptom
heart I-Sign_symptom
sound I-Sign_symptom
and O
bibasilar B-Detailed_description
crackles B-Sign_symptom
in O
both B-Biological_structure
lung I-Biological_structure
fields O
. O

The O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
electrolytes B-Diagnostic_procedure
and O
cardiac B-Diagnostic_procedure
biomarkers I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

An O
initial O
electrocardiogram B-Diagnostic_procedure
revealed O
ST B-Sign_symptom
depression I-Sign_symptom
in O
leads B-Diagnostic_procedure
V2 I-Diagnostic_procedure
to I-Diagnostic_procedure
V6 I-Diagnostic_procedure
, O
suggestive O
of O
anterolateral B-Disease_disorder
ischemia I-Disease_disorder
( O
Figure O
1 O
) O
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
demonstrated O
pulmonary B-Biological_structure
vascular B-Sign_symptom
congestion I-Sign_symptom
consistent O
with O
a O
diagnosis O
of O
pulmonary B-Disease_disorder
edema I-Disease_disorder
( O
Figure O
2 O
) O
. O

An O
echocardiographic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
normal B-Lab_value
cardiac B-Diagnostic_procedure
dimensions I-Diagnostic_procedure
, O
normal B-Lab_value
wall B-Diagnostic_procedure
motion I-Diagnostic_procedure
and O
mild B-Severity
diastolic B-Disease_disorder
dysfunction I-Disease_disorder
with O
an O
early B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
to I-Diagnostic_procedure
late I-Diagnostic_procedure
diastolic I-Diagnostic_procedure
transmitral I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
less B-Lab_value
than I-Lab_value
1 I-Lab_value
, O
prolonged B-Lab_value
deceleration B-Diagnostic_procedure
time I-Diagnostic_procedure
( O
250 B-Lab_value
ms I-Lab_value
) O
and O
a O
reduced B-Lab_value
early B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
annular I-Diagnostic_procedure
velocity I-Diagnostic_procedure
of O
the O
lateral B-Biological_structure
mitral I-Biological_structure
valve I-Biological_structure
annulus I-Biological_structure
. O

Following O
aggressive B-Lab_value
diuresis B-Sign_symptom
and O
requiring O
minimal B-Lab_value
ventilatory B-Therapeutic_procedure
support I-Therapeutic_procedure
, O
the O
patient O
was O
extubated B-Therapeutic_procedure
one B-Date
day I-Date
following I-Date
her O
initial O
presentation O
. O

Within B-Time
1 I-Time
h I-Time
of O
extubation B-Coreference
, O
the O
patient O
developed O
recurrent B-Detailed_description
pulmonary B-Disease_disorder
edema I-Disease_disorder
clinically O
and O
radiographically B-Diagnostic_procedure
, O
requiring O
mechanical B-Therapeutic_procedure
ventilation I-Therapeutic_procedure
. O

Cardiac B-Diagnostic_procedure
catheterization I-Diagnostic_procedure
was O
performed O
and O
revealed O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O

On B-Date
day I-Date
4 I-Date
of O
the O
coronary B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
admission B-Clinical_event
, O
the O
patient O
failed B-Clinical_event
a O
repeat O
attempt O
at O
extubation B-Therapeutic_procedure
. O

A O
computed B-Diagnostic_procedure
tomographic I-Diagnostic_procedure
scan O
revealed O
a O
4 B-Area
cm I-Area
× I-Area
9 I-Area
cm I-Area
multinodular B-Detailed_description
goiter B-Disease_disorder
extending O
into O
the O
mediastinum B-Biological_structure
and O
suspected O
associated O
tracheal B-Biological_structure
stenosis B-Sign_symptom
( O
Figure O
3 O
) O
. O

With O
a O
diagnosis O
of O
NPPE B-Disease_disorder
secondary O
to O
an O
enlarged B-Severity
goiter B-Disease_disorder
, O
the O
patient O
underwent O
surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
for O
a O
thyroidectomy B-Therapeutic_procedure
. O

Intraoperative B-Detailed_description
bronchoscopy B-Diagnostic_procedure
revealed O
tracheal B-Biological_structure
stenosis B-Sign_symptom
of O
greater B-Lab_value
than I-Lab_value
50 I-Lab_value
% I-Lab_value
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uncomplicated B-Lab_value
, O
and O
three B-Date
months I-Date
following I-Date
discharge B-Clinical_event
, O
the O
patient O
returned B-Outcome
to O
her O
previous B-Detailed_description
activity I-Detailed_description
level I-Detailed_description
without O
subjective O
dyspnea B-Sign_symptom
. O

A O
49-year-old B-Age
woman B-Sex
was O
admitted B-Clinical_event
to O
the O
Department B-Nonbiological_location
of I-Nonbiological_location
Radiology I-Nonbiological_location
of O
the O
Second B-Nonbiological_location
Affiliated I-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Zhejiang I-Nonbiological_location
University I-Nonbiological_location
in O
October B-Date
2004 I-Date
with O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
and O
weight B-Sign_symptom
loss I-Sign_symptom
. O

She O
was O
a O
hepatitis B-History
B I-History
virus I-History
carrier I-History
. O

Her O
α-fetoprotein B-Diagnostic_procedure
level O
was O
1185.3 B-Lab_value
ng/mL I-Lab_value
. O

Ultrasonography B-Diagnostic_procedure
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
revealed O
a O
10-cm B-Distance
mass B-Sign_symptom
in O
the O
posterior B-Biological_structure
segments I-Biological_structure
of O
the O
right B-Biological_structure
liver I-Biological_structure
lobe I-Biological_structure
. O

A O
1.5-cm B-Distance
mass B-Sign_symptom
was O
also O
found O
in O
the O
left B-Biological_structure
lateral I-Biological_structure
segment I-Biological_structure
. O

These O
clinical O
signs O
indicated O
that O
the O
patient O
had O
inoperable B-Detailed_description
HCC B-Disease_disorder
and O
Child-Pugh B-Detailed_description
class I-Detailed_description
A I-Detailed_description
cirrhosis B-Disease_disorder
. O

TACE B-Therapeutic_procedure
was O
offered O
to O
the O
patient O
. O

Angiogram B-Diagnostic_procedure
demonstrated O
no O
obvious O
hepatic B-Biological_structure
arterio-venous B-Sign_symptom
shunt I-Sign_symptom
, O
but O
multiple B-Detailed_description
smaller B-Detailed_description
masses B-Sign_symptom
in O
both B-Biological_structure
lobes I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
. O

An O
emulsion B-Administration
of O
oxaliplatin B-Medication
, O
pirarubicin B-Medication
, O
hydroxycamptothecin B-Medication
and O
lipiodol B-Medication
were O
prepared O
, O
35 B-Dosage
mL I-Dosage
and O
3 B-Dosage
mL I-Dosage
of O
the O
mixture B-Medication
were O
administered O
intra-arterially B-Administration
to O
the O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
hepatic I-Biological_structure
artery I-Biological_structure
, O
respectively O
. O

The O
patient O
experienced O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
after O
TACE O
and O
had O
an O
uneventful B-Lab_value
recovery B-Diagnostic_procedure
. O

One B-Date
month I-Date
later I-Date
, O
a O
second B-Detailed_description
TACE B-Therapeutic_procedure
procedure O
was O
performed O
via O
the O
right B-Biological_structure
hepatic I-Biological_structure
artery I-Biological_structure
and O
40 B-Dosage
mL I-Dosage
of O
the O
mixture B-Coreference
was O
administered O
. O

On O
the O
next B-Date
day I-Date
, O
she O
experienced O
sudden B-Detailed_description
acute B-Detailed_description
dyspnoea B-Sign_symptom
and O
the O
peripheral B-Diagnostic_procedure
oxygen I-Diagnostic_procedure
saturation I-Diagnostic_procedure
decreased B-Lab_value
to O
90 B-Lab_value
% I-Lab_value
. O

The O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
some O
increased B-Detailed_description
reticular B-Detailed_description
shadows B-Sign_symptom
in O
the O
left B-Biological_structure
lung I-Biological_structure
, O
especially O
in O
the O
lower B-Biological_structure
zones I-Biological_structure
, O
and O
a O
chest B-Biological_structure
CT B-Diagnostic_procedure
scan O
revealed O
multiple B-Detailed_description
iodized B-Detailed_description
oil-like B-Detailed_description
high-density B-Detailed_description
materials B-Sign_symptom
in O
parenchyma B-Biological_structure
of I-Biological_structure
the I-Biological_structure
lung I-Biological_structure
( O
Figure O
1 O
) O
. O

After O
10 B-Dosage
mg I-Dosage
dexamethasone B-Medication
i.v. B-Administration
and O
other O
supportive B-Therapeutic_procedure
therapies I-Therapeutic_procedure
were O
administered O
, O
the O
respiratory B-Coreference
symptom I-Coreference
was O
attenuated O
. O

Two B-Date
days I-Date
later I-Date
, O
the O
patient O
suffered O
from O
a O
serious B-Severity
headache B-Sign_symptom
and O
transient B-Detailed_description
consciousness B-Sign_symptom
loss I-Sign_symptom
, O
accompanying O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
followed O
by O
confusion B-Sign_symptom
, O
lower B-Biological_structure
extremity I-Biological_structure
weakness B-Sign_symptom
. O

Non-contrast B-Detailed_description
enhanced I-Detailed_description
CT B-Diagnostic_procedure
scanning O
showed O
multiple B-Detailed_description
disseminated B-Detailed_description
hyper-intense B-Detailed_description
lesions B-Sign_symptom
in O
the O
brain B-Biological_structure
, O
consistent O
with O
deposition B-Sign_symptom
of O
iodized B-Detailed_description
oil I-Detailed_description
( O
Figure O
2 O
) O
. O

One B-Date
week I-Date
later I-Date
, O
her O
respiratory B-Biological_structure
and O
neurologic B-Biological_structure
symptoms B-Sign_symptom
disappeared O
completely O
, O
and O
she O
was O
discharged B-Clinical_event
. O

The O
patient O
also O
consequently O
completed O
the O
other B-Detailed_description
three I-Detailed_description
TACE B-Therapeutic_procedure
procedures O
, O
during O
which O
no O
similar B-Detailed_description
symptoms B-Sign_symptom
occurred O
. O

A O
71-year-old B-Age
woman B-Sex
with O
known O
diastolic B-Detailed_description
congestive B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
( B-Disease_disorder
CHF I-Disease_disorder
) I-Disease_disorder
presented O
to O
the O
ER B-Nonbiological_location
with O
exacerbation B-Detailed_description
of O
CHF B-Disease_disorder
and O
a O
decreased B-Lab_value
level B-Sign_symptom
of I-Sign_symptom
consciousness I-Sign_symptom
. O

Brachial B-Biological_structure
blood B-Sign_symptom
pressure I-Sign_symptom
( B-Sign_symptom
BP I-Sign_symptom
) I-Sign_symptom
was O
measured O
at O
55/40 B-Lab_value
mmHg I-Lab_value
. O

The O
patient O
had O
four B-Lab_value
recent B-History
admissions I-History
with I-History
exacerbation I-History
of I-History
CHF I-History
. O

Her O
medical B-History
history I-History
was I-History
also I-History
significant I-History
for I-History
autoimmune I-History
hepatitis I-History
, I-History
but I-History
preserved I-History
liver I-History
function I-History
; O
esophageal B-History
varices I-History
with I-History
a I-History
bleeding I-History
episode I-History
; O
and O
long-term B-Detailed_description
corticosteroid B-History
therapy I-History
complicated I-History
by I-History
adrenal I-History
insufficiency I-History
, I-History
type I-History
2 I-History
diabetes I-History
mellitus I-History
and I-History
osteoporosis I-History
. O

Recent O
echocardiography B-Diagnostic_procedure
had O
revealed O
moderate B-Severity
concentric B-Detailed_description
left B-Biological_structure
ventricular I-Biological_structure
hypertrophy B-Disease_disorder
with O
diastolic B-Detailed_description
dysfunction I-Detailed_description
, O
and O
mild B-Severity
to O
moderate B-Severity
mitral B-Disease_disorder
regurgitation I-Disease_disorder
. O

Cardiac B-Diagnostic_procedure
catheterization I-Diagnostic_procedure
in O
a O
recent O
admission B-Clinical_event
demonstrated O
50 B-Lab_value
% I-Lab_value
stenosis B-Disease_disorder
in O
the O
second B-Biological_structure
diagonal I-Biological_structure
artery I-Biological_structure
, O
with O
mild B-Severity
diffuse B-Detailed_description
disease B-Coreference
in O
the O
other B-Biological_structure
coronary I-Biological_structure
arteries I-Biological_structure
. O

Right B-Detailed_description
ventricular I-Detailed_description
endomyocardial I-Detailed_description
biopsy B-Diagnostic_procedure
had O
ruled O
out O
myocarditis B-Disease_disorder
and O
infiltrative B-Detailed_description
cardiomyopathies B-Disease_disorder
, O
but O
healing B-Detailed_description
ischemic B-Disease_disorder
microinfarcts I-Disease_disorder
with O
atheroemboli B-Disease_disorder
were O
observed O
. O

Previous O
BP B-Sign_symptom
values I-Sign_symptom
were O
also O
low B-Lab_value
; O
systolic B-Sign_symptom
BP I-Sign_symptom
was O
between O
60 B-Lab_value
mmHg I-Lab_value
and O
65 B-Lab_value
mmHg I-Lab_value
, O
and O
diastolic B-Sign_symptom
BP I-Sign_symptom
was O
between O
40 B-Lab_value
mmHg I-Lab_value
and O
45 B-Lab_value
mmHg I-Lab_value
. O

Following O
intubation B-Therapeutic_procedure
, O
dopamine B-Medication
was O
started O
for O
hypotension B-Therapeutic_procedure
management I-Therapeutic_procedure
and O
was O
later O
replaced B-Clinical_event
with O
noradrenaline B-Medication
. O

The O
patient O
developed O
atrial B-Disease_disorder
flutter I-Disease_disorder
but O
successfully O
converted B-Clinical_event
to O
sinus B-Sign_symptom
rhythm I-Sign_symptom
with O
two B-Lab_value
direct B-Detailed_description
current I-Detailed_description
electric B-Therapeutic_procedure
shocks I-Therapeutic_procedure
. O

Cardiology B-Diagnostic_procedure
consultation I-Diagnostic_procedure
resulted O
in O
admission B-Clinical_event
to O
the O
coronary B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
( B-Nonbiological_location
CCU I-Nonbiological_location
) I-Nonbiological_location
. O

On O
admission B-Coreference
to O
the O
CCU B-Biological_structure
, O
BP B-Sign_symptom
was O
measured O
at O
56/36 B-Lab_value
mmHg I-Lab_value
in O
the O
left B-Biological_structure
arm I-Biological_structure
but O
was O
not B-Lab_value
detectable I-Lab_value
in O
the O
right B-Biological_structure
arm I-Biological_structure
. O

An O
arterial B-Diagnostic_procedure
line I-Diagnostic_procedure
was O
inserted O
via O
the O
femoral B-Biological_structure
artery I-Biological_structure
, O
and O
BP B-Sign_symptom
was O
measured O
at O
191/92 B-Lab_value
mmHg I-Lab_value
. O

BP B-Sign_symptom
values I-Sign_symptom
were O
consistently B-Detailed_description
much B-Severity
higher B-Lab_value
through B-Detailed_description
the I-Detailed_description
femoral I-Detailed_description
arterial I-Detailed_description
line I-Detailed_description
than I-Detailed_description
the I-Detailed_description
cuff I-Detailed_description
on I-Detailed_description
the I-Detailed_description
arms I-Detailed_description
, O
and O
was O
higher B-Lab_value
in B-Detailed_description
the I-Detailed_description
left I-Detailed_description
arm I-Detailed_description
than I-Detailed_description
in I-Detailed_description
the I-Detailed_description
right I-Detailed_description
arm I-Detailed_description
. O

For O
instance O
, O
on B-Date
the I-Date
first I-Date
day I-Date
post-CCU I-Date
admission I-Date
, O
BP B-Sign_symptom
at B-Time
one I-Time
point I-Time
was O
measured O
at O
170/80 B-Lab_value
mmHg I-Lab_value
through O
the O
arterial B-Coreference
line I-Coreference
, O
while O
cuff B-Coreference
readings I-Coreference
on O
the B-Coreference
arms I-Coreference
were O
83/74 B-Lab_value
mmHg I-Lab_value
on O
the O
left B-Biological_structure
and I-Biological_structure
60/39 I-Biological_structure
mmHg I-Biological_structure
on I-Biological_structure
the I-Biological_structure
right I-Biological_structure
arm I-Biological_structure
. O

To O
investigate O
the O
inconsistency O
between O
brachial B-Biological_structure
and O
femoral B-Biological_structure
BP B-Sign_symptom
values I-Sign_symptom
, O
a O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( I-Diagnostic_procedure
CT I-Diagnostic_procedure
) I-Diagnostic_procedure
scan I-Diagnostic_procedure
of O
the O
thorax B-Biological_structure
was O
obtained O
using O
1.25 B-Distance
mm I-Distance
slices B-Diagnostic_procedure
, O
both O
before O
and O
after O
intravenous B-Administration
contrast B-Diagnostic_procedure
injection I-Diagnostic_procedure
with O
sagittal B-Detailed_description
and I-Detailed_description
coronal I-Detailed_description
planar I-Detailed_description
reformatting I-Detailed_description
of O
maximum-intensity B-Diagnostic_procedure
projection I-Diagnostic_procedure
images I-Diagnostic_procedure
. O

Analysis O
of O
the O
initial B-Detailed_description
unenhanced B-Detailed_description
CT B-Coreference
images I-Coreference
showed O
densely B-Severity
calcified B-Detailed_description
plaque B-Sign_symptom
or O
thrombus B-Sign_symptom
at O
the O
origins B-Biological_structure
of I-Biological_structure
both I-Biological_structure
subclavian I-Biological_structure
arteries I-Biological_structure
and B-Biological_structure
the I-Biological_structure
right I-Biological_structure
common I-Biological_structure
carotid I-Biological_structure
artery I-Biological_structure
. O

The O
CT B-Diagnostic_procedure
angiogram I-Diagnostic_procedure
showed O
absence O
of O
flow B-Sign_symptom
in O
the O
right B-Coreference
subclavian I-Coreference
artery I-Coreference
, O
a O
very B-Severity
tight B-Detailed_description
stenosis B-Disease_disorder
at O
the O
origin B-Coreference
of I-Coreference
the I-Coreference
left I-Coreference
subclavian I-Coreference
artery I-Coreference
and O
a O
tight B-Detailed_description
stenosis B-Disease_disorder
at O
the O
origin B-Coreference
of I-Coreference
the I-Coreference
right I-Coreference
common I-Coreference
carotid I-Coreference
artery I-Coreference
. O

Both B-Coreference
vertebral I-Coreference
arteries I-Coreference
showed O
normal B-Lab_value
calibre B-Sign_symptom
and O
flow B-Sign_symptom
( O
Figure O
1 O
) O
. O

Further B-Therapeutic_procedure
management I-Therapeutic_procedure
following O
the O
insertion O
of O
the O
femoral B-Diagnostic_procedure
arterial I-Diagnostic_procedure
line I-Diagnostic_procedure
was O
based O
on O
femoral B-Detailed_description
BP B-Diagnostic_procedure
readings I-Diagnostic_procedure
with O
diuretics B-Medication
and O
BP-lowering B-Medication
agents I-Medication
. O

The O
patient O
was O
eventually O
discharged B-Clinical_event
in O
stable B-Lab_value
condition B-Diagnostic_procedure
. O

She O
remained B-Clinical_event
stable I-Clinical_event
during B-Duration
the I-Duration
eight I-Duration
months I-Duration
between I-Duration
discharge I-Duration
and I-Duration
the I-Duration
time I-Duration
the I-Duration
present I-Duration
report I-Duration
was I-Duration
written I-Duration
, O
without O
further B-Detailed_description
exacerbation I-Detailed_description
of O
CHF B-Disease_disorder
or O
related O
ER B-Clinical_event
visits I-Clinical_event
. O

A O
newborn B-Age
boy B-Sex
of O
healthy B-Family_history
nonconsanguineous I-Family_history
parents I-Family_history
was O
delivered B-Clinical_event
at O
37 B-Date
weeks I-Date
’ I-Date
gestation I-Date
by O
cesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
. O

His O
mother B-Subject
( O
primipara B-Family_history
, O
32 B-Family_history
years I-Family_history
old I-Family_history
) O
had O
been O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
2 B-Date
weeks I-Date
previously I-Date
because O
of O
reduced B-Lab_value
fetal B-Sign_symptom
intrauterine I-Sign_symptom
movements I-Sign_symptom
and O
polyhydramnios B-Sign_symptom
. O

The O
child O
’s O
birthweight B-Diagnostic_procedure
was O
2,330 B-Lab_value
g I-Lab_value
( O
< B-Lab_value
10th I-Lab_value
percentile I-Lab_value
) O
, O
length B-Diagnostic_procedure
47 B-Lab_value
cm I-Lab_value
, O
and O
head B-Diagnostic_procedure
circumference I-Diagnostic_procedure
33.2 B-Lab_value
cm I-Lab_value
( O
25th O
percentile O
) O
. O

He O
had O
low-set B-Sign_symptom
ears I-Sign_symptom
and O
bilateral B-Sign_symptom
clubfoot I-Sign_symptom
. O

Apgar B-Diagnostic_procedure
scores I-Diagnostic_procedure
were O
2 B-Lab_value
, O
6 B-Lab_value
, O
and O
7 B-Lab_value
at O
1 B-Detailed_description
, I-Detailed_description
5 I-Detailed_description
, I-Detailed_description
and I-Detailed_description
10 I-Detailed_description
minutes I-Detailed_description
. O

The O
child O
presented B-Clinical_event
with O
severe B-Severity
hypotonia B-Sign_symptom
and O
generalized B-Sign_symptom
muscle I-Sign_symptom
weakness I-Sign_symptom
, O
requiring O
ventilatory B-Therapeutic_procedure
assistance I-Therapeutic_procedure
and O
total B-Therapeutic_procedure
parenteral I-Therapeutic_procedure
nutrition I-Therapeutic_procedure
. O

Weaning O
failed O
because O
of O
inadequate O
pulmonary O
ventilation O
and O
respiratory B-Disease_disorder
acidosis I-Disease_disorder
. O

Hearing B-Sign_symptom
loss I-Sign_symptom
was O
detected O
by O
auditory B-Diagnostic_procedure
evoked I-Diagnostic_procedure
potentials I-Diagnostic_procedure
, O
while O
cranial B-Biological_structure
MRI B-Diagnostic_procedure
showed O
mildly B-Lab_value
enlarged I-Lab_value
ventricles B-Biological_structure
and O
liquor B-Biological_structure
spaces I-Biological_structure
. O

Two B-Date
days I-Date
after I-Date
birth I-Date
, O
the O
infant O
presented O
with O
severe B-Severity
abdominal B-Sign_symptom
distension I-Sign_symptom
with O
a O
hypoactive B-Sign_symptom
bowel I-Sign_symptom
. O

MRI B-Diagnostic_procedure
revealed O
marked B-Severity
intestinal B-Sign_symptom
dilation I-Sign_symptom
without O
mechanical B-Sign_symptom
obstruction I-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
investigations I-Diagnostic_procedure
showed O
hypoglycemia B-Sign_symptom
( O
27 B-Lab_value
mg/dL I-Lab_value
) O
, O
hypomagnesemia B-Sign_symptom
( O
0.58 B-Lab_value
mmol/L I-Lab_value
) O
, O
and O
hypokalemia B-Sign_symptom
( O
2.4 B-Lab_value
mmol/L I-Lab_value
) O
. O

Blood B-Diagnostic_procedure
lactate I-Diagnostic_procedure
was O
normal B-Lab_value
( O
1.3 B-Lab_value
mmol/L I-Lab_value
, O
normal B-Detailed_description
range I-Detailed_description
0.5 I-Detailed_description
– I-Detailed_description
2.2 I-Detailed_description
mmol/L I-Detailed_description
) O
and O
liver B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
were O
unremarkable B-Lab_value
. O

A O
skeletal B-Biological_structure
muscle I-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
and O
showed O
scattered B-Detailed_description
, O
hypertrophic B-Detailed_description
cytochrome B-Diagnostic_procedure
c I-Diagnostic_procedure
oxidase I-Diagnostic_procedure
( O
COX B-Diagnostic_procedure
) O
- O
deficient B-Lab_value
and O
succinate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
– O
positive B-Lab_value
muscle B-Biological_structure
fibers I-Biological_structure
( O
figure O
) O
, O
suggesting O
a O
mitochondrial B-Disease_disorder
disorder I-Disease_disorder
. O

Molecular B-Diagnostic_procedure
genetic I-Diagnostic_procedure
studies I-Diagnostic_procedure
revealed O
marked B-Severity
mtDNA B-Sign_symptom
depletion I-Sign_symptom
in O
muscle O
( O
93 B-Lab_value
% I-Lab_value
decrease I-Lab_value
as O
compared B-Detailed_description
to I-Detailed_description
age-matched I-Detailed_description
controls I-Detailed_description
) O
, O
while O
a O
screen B-Diagnostic_procedure
for I-Diagnostic_procedure
mtDNA I-Diagnostic_procedure
rearrangements I-Diagnostic_procedure
within O
individual B-Biological_structure
COX-positive I-Biological_structure
and I-Biological_structure
COX-deficient I-Biological_structure
fibers4 I-Biological_structure
was O
negative B-Lab_value
. O

We O
sequenced B-Diagnostic_procedure
the O
entire B-Detailed_description
coding I-Detailed_description
region I-Detailed_description
and I-Detailed_description
intron-exon I-Detailed_description
boundaries I-Detailed_description
of O
the O
POLG1 B-Biological_structure
gene I-Biological_structure
, O
identifying O
two B-Lab_value
reported O
heterozygous B-Sign_symptom
missense I-Sign_symptom
mutations I-Sign_symptom
in O
compound O
c. B-Sign_symptom
679C I-Sign_symptom
> I-Sign_symptom
T I-Sign_symptom
predicting I-Sign_symptom
p.R227W I-Sign_symptom
and O
c. B-Sign_symptom
2542G I-Sign_symptom
> I-Sign_symptom
A I-Sign_symptom
predicting I-Sign_symptom
p.G848S I-Sign_symptom
. O

Sequencing B-Diagnostic_procedure
of I-Diagnostic_procedure
parental I-Diagnostic_procedure
samples I-Diagnostic_procedure
confirmed O
recessive B-Sign_symptom
inheritance I-Sign_symptom
. O

The O
infant O
died B-Outcome
at O
20 B-Date
days I-Date
of O
respiratory B-Disease_disorder
failure I-Disease_disorder
. O

At O
autopsy B-Diagnostic_procedure
, O
the O
brain B-Biological_structure
did O
not O
show O
remarkable B-Sign_symptom
changes I-Sign_symptom
on O
gross B-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

Histology B-Diagnostic_procedure
was O
not B-Lab_value
informative I-Lab_value
due O
to O
poor O
preservation O
of O
tissue O
; O
there O
was O
no O
evidence O
of O
neuronal B-Sign_symptom
damage I-Sign_symptom
in O
the O
spinal B-Biological_structure
cord I-Biological_structure
. O

The O
liver B-Biological_structure
showed O
diffuse B-Detailed_description
cholestasis B-Sign_symptom
, O
consistent O
with O
total B-Therapeutic_procedure
parenteral I-Therapeutic_procedure
nutrition I-Therapeutic_procedure
; O
hepatocyte B-Biological_structure
steatosis B-Sign_symptom
, O
necrosis B-Sign_symptom
, O
or O
liver B-Biological_structure
fibrosis B-Sign_symptom
were O
not O
observed O
. O

The O
testicles B-Biological_structure
were O
undescended B-Sign_symptom
, O
while O
remaining O
visceral B-Biological_structure
organs I-Biological_structure
were O
normal B-Sign_symptom
except O
for O
a O
marked O
dilation B-Sign_symptom
and O
thinning B-Sign_symptom
of O
the O
bowel B-Biological_structure
wall I-Biological_structure
. O

Despite O
normal B-Lab_value
histology B-Diagnostic_procedure
, O
analysis O
of O
stomach B-Biological_structure
, O
ileum B-Biological_structure
, O
and O
colon B-Biological_structure
homogenates O
revealed O
severe B-Severity
mtDNA B-Sign_symptom
depletion I-Sign_symptom
( O
up B-Lab_value
to I-Lab_value
94 I-Lab_value
% I-Lab_value
decrease I-Lab_value
; O
table O
e-1 O
on O
the O
Neurology O
® O
Web O
site O
at O
www.neurology.org O
) O
. O

Laser B-Diagnostic_procedure
capture I-Diagnostic_procedure
microdissection I-Diagnostic_procedure
analysis5 I-Diagnostic_procedure
revealed O
that O
the O
mtDNA B-Coreference
depletion I-Coreference
was O
confined O
to O
the O
muscularis B-Biological_structure
propria I-Biological_structure
, O
being O
most O
prominent O
in O
its O
external B-Detailed_description
layer I-Detailed_description
( O
figure O
) O
. O

Ganglion B-Biological_structure
cells I-Biological_structure
from O
the O
myenteric B-Biological_structure
plexus I-Biological_structure
showed O
milder B-Severity
mtDNA B-Coreference
depletion I-Coreference
, O
restricted O
to O
the O
small B-Biological_structure
intestine I-Biological_structure
( O
figure O
) O
. O

There O
was O
no O
mtDNA B-Sign_symptom
depletion I-Sign_symptom
in O
liver B-Biological_structure
( O
not O
shown O
) O
. O

A O
46-year-old B-Age
woman B-Sex
presented B-Clinical_event
with O
severe B-Severity
acute B-Detailed_description
pain B-Sign_symptom
in O
the O
right B-Biological_structure
iliac I-Biological_structure
fossa I-Biological_structure
and O
periumbilical B-Biological_structure
region I-Biological_structure
. O

Ultrasound B-Diagnostic_procedure
and O
a O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan I-Diagnostic_procedure
revealed O
a O
mucocele B-Sign_symptom
in O
the O
vermiform B-Biological_structure
appendix I-Biological_structure
, O
with O
a O
well B-Detailed_description
defined I-Detailed_description
lesion B-Sign_symptom
located O
at O
the O
mid B-Biological_structure
zone I-Biological_structure
of I-Biological_structure
the I-Biological_structure
appendix I-Biological_structure
. O

The O
patient O
underwent O
right B-Therapeutic_procedure
hemicolectomy I-Therapeutic_procedure
, O
and O
her O
postoperative B-Diagnostic_procedure
clinical I-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
. O

Gross B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
surgical B-Biological_structure
specimen I-Biological_structure
showed O
an O
enlarged B-Lab_value
appendix B-Biological_structure
, O
which O
was O
filled O
with O
thick B-Texture
mucinous B-Sign_symptom
material I-Sign_symptom
. O

A O
distinct B-Detailed_description
lesion B-Coreference
which O
involved O
the O
appendiceal B-Biological_structure
wall I-Biological_structure
, O
and O
measured O
1.5 B-Distance
cm I-Distance
maximally O
, O
was O
identified O
in O
the O
mid-portion B-Biological_structure
of I-Biological_structure
the I-Biological_structure
appendix I-Biological_structure
. O

There O
was O
no O
evidence O
of O
perforation B-Sign_symptom
, O
extravasation B-Sign_symptom
of O
mucin B-Biological_structure
into O
the O
periappendiceal B-Biological_structure
tissue I-Biological_structure
, O
or O
pseudomyxoma B-Disease_disorder
peritonei I-Disease_disorder
during O
surgery O
. O

Histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
combined O
GCC B-Disease_disorder
and O
MCA B-Disease_disorder
of O
the O
vermiform B-Biological_structure
appendix I-Biological_structure
( O
Figure O
1A O
) O
. O

The O
appendiceal B-Biological_structure
lumen I-Biological_structure
was O
dilated B-Sign_symptom
and O
lined O
by O
mucin-containing B-Sign_symptom
columnar B-Biological_structure
epithelial I-Biological_structure
cells I-Biological_structure
( O
Figure O
1B O
) O
. O

There O
was O
no O
significant O
cytologic B-Sign_symptom
atypia I-Sign_symptom
, O
and O
no O
mitotic B-Sign_symptom
figures I-Sign_symptom
were O
identified O
. O

Focal B-Sign_symptom
papillary I-Sign_symptom
configurations I-Sign_symptom
of O
the O
lining B-Biological_structure
epithelium I-Biological_structure
, O
and O
mild B-Severity
epithelial B-Sign_symptom
pseudostratification I-Sign_symptom
were O
present O
. O

In O
addition O
, O
the O
appendiceal B-Biological_structure
wall I-Biological_structure
was O
infiltrated O
by O
glandular B-Sign_symptom
structures I-Sign_symptom
of O
various B-Area
sizes I-Area
which O
were O
arranged O
in O
nests B-Shape
and O
tubules B-Shape
. O

These O
glandular B-Coreference
structures I-Coreference
comprised O
2 O
distinct O
types O
of O
cells O
: O
( O
1 O
) O
small B-Area
to I-Area
intermediate I-Area
sized I-Area
monotonous B-Detailed_description
neuroendocrine B-Biological_structure
cells I-Biological_structure
with O
a O
small B-Detailed_description
amount I-Detailed_description
of I-Detailed_description
finely I-Detailed_description
granular I-Detailed_description
eosinophilic I-Detailed_description
cytoplasm I-Detailed_description
, O
and O
mild B-Severity
cytonuclear B-Sign_symptom
atypia I-Sign_symptom
( O
Figure O
( O
Figure1C O
) O
; O
1C O
) O
; O
( O
2 O
) O
mucin-filled B-Detailed_description
intermediate B-Area
sized I-Area
cells O
( O
goblet B-Biological_structure
cells I-Biological_structure
) O
, O
with O
peripherally B-Detailed_description
located I-Detailed_description
small B-Area
, O
crescent-like B-Shape
hyperchromatic B-Sign_symptom
nuclei I-Sign_symptom
, O
and O
indistinct B-Detailed_description
nucleoli B-Biological_structure
( O
Figure O
( O
Figure1D O
) O
.1 O
D O
) O
. O

Scattered B-Texture
infiltrating B-Detailed_description
single B-Detailed_description
goblet B-Biological_structure
neoplastic I-Biological_structure
cells I-Biological_structure
were O
focally B-Sign_symptom
present I-Sign_symptom
. O

As O
previously O
described O
[ O
1 O
] O
the O
tumor B-Sign_symptom
nests I-Sign_symptom
appeared O
to O
arise O
from O
the O
basiglandular B-Biological_structure
region I-Biological_structure
of O
the O
intestinal B-Biological_structure
crypts I-Biological_structure
in O
close B-Detailed_description
proximity I-Detailed_description
to I-Detailed_description
the I-Detailed_description
MCA B-Disease_disorder
( O
Figure O
( O
Figure1E O
) O
.1 O
E O
) O
. O

There O
was O
no O
lymphovascular B-Detailed_description
invasion B-Sign_symptom
, O
although O
perineural B-Detailed_description
and O
intraneural B-Detailed_description
invasion B-Sign_symptom
was O
present O
. O

The O
tumor B-Coreference
infiltrated O
the O
full B-Biological_structure
thickness I-Biological_structure
of O
the O
appendiceal B-Biological_structure
wall I-Biological_structure
and O
extended O
to O
the O
mesoappendix B-Biological_structure
. O

Ten B-Quantitative_concept
lymph B-Biological_structure
nodes I-Biological_structure
were O
histologically B-Diagnostic_procedure
identified I-Diagnostic_procedure
, O
of O
which O
all O
were O
negative O
for O
malignancy B-Disease_disorder
. O

Immunohistochemically B-Diagnostic_procedure
( O
Table O
1 O
) O
, O
the O
tumor B-Sign_symptom
cells I-Sign_symptom
of O
the O
GCC B-Disease_disorder
were O
positive B-Lab_value
for O
chromogranin B-Diagnostic_procedure
, O
synaptophysin B-Diagnostic_procedure
, O
and O
serotonin B-Diagnostic_procedure
, O
which O
are O
neuroendocrine B-Detailed_description
markers I-Detailed_description
. O

Diffuse B-Lab_value
staining I-Lab_value
for O
cytokeratin B-Diagnostic_procedure
( O
CK O
) O
20 O
( O
Figure O
2 O
) O
, O
CK19 B-Diagnostic_procedure
, I-Diagnostic_procedure
and O
CD99 B-Diagnostic_procedure
was O
also O
present O
. O

The O
Ki67 B-Diagnostic_procedure
proliferating I-Diagnostic_procedure
index I-Diagnostic_procedure
revealed O
nuclear B-Sign_symptom
staining I-Sign_symptom
in O
approximately O
15 B-Lab_value
% I-Lab_value
of O
the O
tumor B-Sign_symptom
cells I-Sign_symptom
. O

There O
was O
no B-Lab_value
staining I-Lab_value
for O
CK7 B-Diagnostic_procedure
. I-Diagnostic_procedure

A O
60-year-old B-Age
man B-Sex
who O
underwent O
colonoscopy B-Diagnostic_procedure
was O
found O
to O
have O
a O
2 B-Distance
cm I-Distance
sessile B-Sign_symptom
polyp I-Sign_symptom
that O
was O
located O
10 B-Distance
cm I-Distance
from O
the O
anal B-Biological_structure
verge I-Biological_structure
and O
successfully B-Therapeutic_procedure
removed I-Therapeutic_procedure
. O

The O
polyp B-Coreference
was O
a O
tubulovillous B-Disease_disorder
adenoma I-Disease_disorder
with O
focal O
high-grade B-Sign_symptom
dysplasia I-Sign_symptom
. O

A O
flexible B-Diagnostic_procedure
sigmoidoscopy I-Diagnostic_procedure
performed O
three B-Date
months I-Date
later I-Date
, O
as O
well O
as O
a O
repeat B-Detailed_description
colonoscopy B-Diagnostic_procedure
one B-Date
year I-Date
after I-Date
the I-Date
initial I-Date
colonoscopy I-Date
, O
were O
both O
negative B-Lab_value
for O
recurrence O
. O

A O
colonoscopy B-Diagnostic_procedure
performed O
three B-Date
years I-Date
after I-Date
the I-Date
initial I-Date
colonoscopy I-Date
revealed O
a O
sessile B-Sign_symptom
polyp I-Sign_symptom
, O
3 B-Distance
cm I-Distance
in O
size O
, O
at O
10 B-Distance
cm I-Distance
from O
the O
anal B-Biological_structure
verge I-Biological_structure
. O

Biopsies B-Diagnostic_procedure
were O
taken O
and O
reported O
to O
be O
fragments O
of O
a O
villous B-Disease_disorder
adenoma I-Disease_disorder
with O
low-grade B-Sign_symptom
dysplasia I-Sign_symptom
. O

Due O
to O
the O
previous O
high-grade B-Severity
dysplasia B-Sign_symptom
, O
relatively B-Severity
rapid I-Severity
recurrence B-Sign_symptom
and O
concern O
that O
a O
cancer B-Disease_disorder
may O
have O
been O
missed O
by O
sampling O
error O
, O
a O
pelvic B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
scan O
and O
an O
endoscopic B-Diagnostic_procedure
ultrasound I-Diagnostic_procedure
( O
EUS B-Diagnostic_procedure
) O
were O
performed O
before O
definitive O
excision O
. O

The O
MRI B-Coreference
revealed O
an O
invasive B-Detailed_description
rectal B-Biological_structure
mass B-Sign_symptom
involving O
the O
muscularis B-Biological_structure
propria I-Biological_structure
but O
without O
breach B-Sign_symptom
of O
the O
adventitia B-Biological_structure
, O
consistent O
with O
a O
T2 B-Detailed_description
rectal B-Disease_disorder
carcinoma I-Disease_disorder
( O
Figure O
1 O
) O
. O

No O
pelvic B-Biological_structure
lymphadenopathy B-Sign_symptom
was O
detected O
. O

The O
EUS B-Coreference
revealed O
a O
rectal B-Biological_structure
mass B-Sign_symptom
involving O
the O
mucosa B-Biological_structure
and O
submucosa B-Biological_structure
, O
with O
no O
involvement B-Sign_symptom
of O
the O
muscularis B-Biological_structure
propria I-Biological_structure
( O
Figure O
2 O
) O
. O

The O
results O
of O
the O
MRI B-Diagnostic_procedure
and O
EUS B-Diagnostic_procedure
, O
as O
well O
as O
the O
surgical O
versus O
endoscopic O
resection O
treatment O
options O
, O
were O
discussed O
with O
the O
patient O
, O
who O
opted O
for O
a O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
. O

The O
patient O
underwent O
a O
low B-Therapeutic_procedure
anterior I-Therapeutic_procedure
resection I-Therapeutic_procedure
and O
end-to-end B-Therapeutic_procedure
anastomosis I-Therapeutic_procedure
with O
loop B-Therapeutic_procedure
ileostomy I-Therapeutic_procedure
. O

Pathology B-Diagnostic_procedure
review I-Diagnostic_procedure
of O
the O
resected B-Biological_structure
rectosigmoid I-Biological_structure
revealed O
a O
villous B-Disease_disorder
adenoma I-Disease_disorder
with O
low-grade B-Sign_symptom
dyplasia I-Sign_symptom
. O

There O
was O
no O
evidence O
of O
muscularis B-Biological_structure
propria I-Biological_structure
invasion B-Sign_symptom
, O
and O
a O
total O
of O
five B-Detailed_description
pericolic I-Detailed_description
and I-Detailed_description
two I-Detailed_description
mesorectal I-Detailed_description
lymph B-Biological_structure
nodes I-Biological_structure
were O
excised B-Therapeutic_procedure
and O
deemed O
benign B-Sign_symptom
. O

The O
patient O
underwent O
ileostomy B-Therapeutic_procedure
reversal I-Therapeutic_procedure
five B-Date
months I-Date
later I-Date
. O

He O
remains O
asymptomatic B-Sign_symptom
with O
no O
recurrence B-Sign_symptom
of I-Sign_symptom
tumours I-Sign_symptom
. O

A O
72-year-old B-Age
woman B-Sex
underwent O
RF B-Therapeutic_procedure
ablation I-Therapeutic_procedure
for O
the O
treatment O
of O
a O
metachronous B-Detailed_description
solitary B-Detailed_description
liver B-Biological_structure
metastasis B-Disease_disorder
from O
rectal B-Biological_structure
adenocarcinoma B-Disease_disorder
, O
which O
had O
been O
treated B-Clinical_event
18 B-Date
mo I-Date
before I-Date
with O
preoperative B-Detailed_description
chemoradiotherapy B-Medication
and O
anterior B-Therapeutic_procedure
resection I-Therapeutic_procedure
. O

The O
lesion B-Coreference
was O
located O
in O
segment B-Biological_structure
VIII I-Biological_structure
. O

The O
procedure B-Coreference
went O
well B-Lab_value
and O
the O
patient O
was O
initially O
haemodynamically B-Diagnostic_procedure
stable B-Lab_value
. O

One B-Time
hour I-Time
later I-Time
her O
condition B-Diagnostic_procedure
suddenly B-Severity
worsened I-Severity
. O

She O
was O
clinically O
dizzy B-Sign_symptom
and O
had O
fatigue B-Sign_symptom
and O
pallor B-Sign_symptom
. O

We O
detected O
hypotension B-Sign_symptom
and O
tachycardia B-Sign_symptom
. O

Emergency O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
a O
haemoglobin B-Diagnostic_procedure
level I-Diagnostic_procedure
of O
< B-Lab_value
7 I-Lab_value
g/dL I-Lab_value
and O
markedly O
elevated B-Lab_value
transaminase B-Diagnostic_procedure
levels I-Diagnostic_procedure
. O

A O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
accumulation O
of O
intraperitoneal B-Biological_structure
fluid I-Biological_structure
in O
the O
pelvis B-Biological_structure
and O
two B-Lab_value
liver B-Biological_structure
haematomas B-Disease_disorder
. O

The O
images B-Coreference
showed O
two B-Lab_value
liver B-Biological_structure
lacerations B-Sign_symptom
, O
one B-Detailed_description
following I-Detailed_description
the I-Detailed_description
path I-Detailed_description
of I-Detailed_description
the I-Detailed_description
needle I-Detailed_description
( O
Figure O
( O
Figure1A1A O
- O
- O
C O
) O
C O
) O
and O
another O
, O
unexplained B-Detailed_description
laceration I-Detailed_description
leading I-Detailed_description
away I-Detailed_description
from I-Detailed_description
the I-Detailed_description
first I-Detailed_description
( O
Figure O
( O
Figure2 O
) O
.2 O
) O
. O

The O
patient O
had O
no O
serious O
coughing B-Sign_symptom
or O
hiccupping B-Sign_symptom
after O
the O
RF B-Coreference
treatment I-Coreference
, O
or O
any O
other O
complications O
that O
might O
have O
caused O
increased O
abdominal O
pressure O
and O
tumour O
rupture O
. O

Subsequently O
, O
the O
patient O
received O
a O
blood B-Therapeutic_procedure
transfusion I-Therapeutic_procedure
and O
close B-Diagnostic_procedure
monitoring I-Diagnostic_procedure
. O

She O
was O
haemodynamically B-Diagnostic_procedure
stable B-Lab_value
after O
the O
second B-Lab_value
blood B-Therapeutic_procedure
transfusion I-Therapeutic_procedure
and O
completely B-Sign_symptom
recovered I-Sign_symptom
24 B-Time
h I-Time
later I-Time
. O

The O
patient O
remained B-Activity
in I-Activity
bed I-Activity
for O
1 B-Duration
wk I-Duration
. O

No O
surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
required O
. O

Our O
24-year-old B-Age
non-smoking B-History
male B-Sex
patient O
presented B-Clinical_event
with O
repeated B-Detailed_description
hemoptysis B-Sign_symptom
in O
May B-Date
2008 I-Date
with O
4 B-Duration
days I-Duration
of O
concomitant B-Detailed_description
right B-Biological_structure
thoracic I-Biological_structure
pain B-Sign_symptom
which B-Detailed_description
intensified I-Detailed_description
while I-Detailed_description
breathing I-Detailed_description
. O

During O
holidays B-History
in I-History
his I-History
home I-History
country I-History
, O
this O
Cuban B-Personal_background
patient O
suffered O
from O
a O
cold B-Sign_symptom
with O
fever B-Sign_symptom
and O
a O
strong B-Severity
cough B-Sign_symptom
. O

The O
strong B-Severity
dry B-Texture
cough B-Coreference
persisted B-Detailed_description
after B-Date
recovery I-Date
from I-Date
the I-Date
cold I-Date
. I-Date

The O
patient O
did O
not O
report O
any O
loss B-Sign_symptom
of I-Sign_symptom
weight I-Sign_symptom
. O

The O
initial O
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
of O
the O
thorax B-Biological_structure
showed O
a O
12 B-Area
× I-Area
4 I-Area
cm I-Area
solid B-Detailed_description
mass B-Sign_symptom
paravertebral B-Biological_structure
right I-Biological_structure
in O
the O
lower B-Biological_structure
thorax I-Biological_structure
without O
any O
signs O
of O
metastases B-Sign_symptom
( O
Figure O
1 O
) O
. O

The O
bronchoscopy B-Diagnostic_procedure
( O
Figure O
2 O
) O
with O
non-bleeding B-Detailed_description
biopsy B-Diagnostic_procedure
revealed O
a O
mass B-Coreference
of O
the O
lower B-Biological_structure
right I-Biological_structure
bronchus I-Biological_structure
which O
histologically B-Diagnostic_procedure
and O
immunohistologically B-Diagnostic_procedure
provided O
evidence O
of O
a O
granular B-Disease_disorder
cell I-Disease_disorder
or I-Disease_disorder
Abrikossoff I-Disease_disorder
tumor I-Disease_disorder
[ O
1 O
] O
. O

The O
bronchial B-Diagnostic_procedure
lavage I-Diagnostic_procedure
which O
followed O
was O
negative B-Lab_value
for O
malignant B-Biological_structure
cells I-Biological_structure
. O

The O
patient O
was O
discharged B-Clinical_event
and O
surgical O
intervention O
was O
planned O
. O

Four B-Date
days I-Date
after I-Date
discharge I-Date
a O
spontaneous B-Detailed_description
hemothorax B-Sign_symptom
developed O
. O

The O
patient O
needed O
to O
be O
readmitted B-Clinical_event
and O
the O
hemothorax B-Coreference
was O
drained B-Therapeutic_procedure
. O

No O
malignant B-Sign_symptom
cells I-Sign_symptom
were O
detected O
in O
the O
cytological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
drained B-Biological_structure
liquid I-Biological_structure
. O

After O
an O
uneventful O
course O
and O
decreasing B-Lab_value
of O
the O
hematoma B-Sign_symptom
, O
the O
tumor B-Sign_symptom
was O
excised B-Therapeutic_procedure
by O
performing O
a O
lower B-Therapeutic_procedure
right I-Therapeutic_procedure
lobectomy I-Therapeutic_procedure
6 B-Date
months I-Date
after I-Date
the I-Date
initial I-Date
admission I-Date
. I-Date

The O
final O
histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
confirmed O
a O
peribronchial B-Biological_structure
and O
infiltrating B-Detailed_description
S100 B-Diagnostic_procedure
positive B-Lab_value
tumor B-Coreference
supporting O
the O
Schwann O
cell O
origin O
theory O
with O
very B-Lab_value
low I-Lab_value
growth B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
2 B-Lab_value
% I-Lab_value
and O
a O
size B-Diagnostic_procedure
of O
15 B-Distance
mm I-Distance
( O
Figure O
3 O
) O
. O

A O
54-year-old B-Age
woman B-Sex
with O
stage B-Detailed_description
IV I-Detailed_description
NSCLC B-Disease_disorder
was O
treated O
with O
carboplatin B-Medication
and O
paclitaxel B-Medication
without B-Detailed_description
disease I-Detailed_description
response I-Detailed_description
. O

Molecular B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
tumor B-Diagnostic_procedure
tissue I-Diagnostic_procedure
was O
unavailable B-Detailed_description
at O
that O
time O
. O

However O
, O
her O
demographic O
profile O
( O
Asian B-Personal_background
, O
minimal B-Severity
smoking B-History
history I-History
, O
non-small B-Detailed_description
cell I-Detailed_description
histology B-Diagnostic_procedure
) O
predicted O
her B-Coreference
disease I-Coreference
would O
harbor O
EGFR B-Diagnostic_procedure
TKI I-Diagnostic_procedure
sensitive I-Diagnostic_procedure
cells I-Diagnostic_procedure
[ O
2 O
] O
. O

Therefore O
, O
she O
then O
initiated O
standard B-Detailed_description
daily B-Dosage
dosing I-Dosage
of O
erlotinib B-Medication
( O
150 B-Lab_value
mg I-Lab_value
) O
and O
her B-Coreference
disease I-Coreference
responded B-Detailed_description
. O

Twenty-eight B-Date
months I-Date
later I-Date
, O
she O
acquired O
resistance B-Other_event
to O
erlotinib B-Medication
with O
progression B-Detailed_description
of O
disease B-Coreference
systemically B-Detailed_description
. O

Following O
further O
progression O
through O
an O
experimental B-Detailed_description
angiogenesis B-Medication
inhibitor I-Medication
, O
she O
initiated O
pemetrexed B-Medication
and O
resumed O
standard B-Coreference
dose I-Coreference
erlotinib I-Coreference
. O

After O
initial O
response O
, O
11 B-Date
months I-Date
later I-Date
, O
her B-Coreference
disease I-Coreference
again O
progressed B-Detailed_description
. O

DNA B-Biological_structure
was O
extracted O
from O
biopsy B-Diagnostic_procedure
of O
a O
progressing B-Detailed_description
lung B-Biological_structure
lesion B-Disease_disorder
and O
examined O
using O
established O
techniques O
for O
analysis O
of O
EGFR B-Diagnostic_procedure
mutations I-Diagnostic_procedure
[ O
5 O
] O
. O

Direct B-Diagnostic_procedure
sequencing I-Diagnostic_procedure
of O
exons B-Detailed_description
18 I-Detailed_description
– I-Detailed_description
21 I-Detailed_description
encoding O
the O
kinase B-Detailed_description
domain I-Detailed_description
of O
EGFR B-Diagnostic_procedure
revealed O
the O
L858R B-Diagnostic_procedure
mutation I-Diagnostic_procedure
associated O
with O
EGFR B-Detailed_description
TKI I-Detailed_description
sensitivity I-Detailed_description
( O
Fig. O
1 O
) O
[ O
2 O
] O
. O

It B-Coreference
also O
demonstrated O
the O
T790M B-Diagnostic_procedure
mutation I-Diagnostic_procedure
associated O
with O
acquired B-Detailed_description
EGFR I-Detailed_description
TKI I-Detailed_description
resistance I-Detailed_description
( O
Fig. O
1 O
) O
[ O
2 O
] O
. O

She O
also O
developed O
headaches B-Sign_symptom
and O
there O
was O
a O
high O
clinical O
suspicion O
of O
CNS B-Biological_structure
metastases B-Disease_disorder
despite O
negative B-Lab_value
imaging B-Diagnostic_procedure
( O
not O
shown O
) O
. O

She O
refused O
a O
lumbar B-Therapeutic_procedure
puncture I-Therapeutic_procedure
. O

She O
initiated O
empiric B-Detailed_description
temozolomide B-Medication
plus O
standard B-Detailed_description
dose I-Detailed_description
erlotinib B-Medication
( O
150 B-Dosage
mg I-Dosage
daily I-Dosage
) O
for O
presumed O
CNS B-Disease_disorder
disease I-Disease_disorder
, O
but O
after B-Time
one I-Time
cycle I-Time
her O
headaches B-Sign_symptom
worsened B-Lab_value
, O
and O
she O
developed O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
concerning O
for O
CNS B-Disease_disorder
metastases I-Disease_disorder
with O
associated O
raised B-Lab_value
intracranial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( B-Diagnostic_procedure
MRI I-Diagnostic_procedure
) I-Diagnostic_procedure
of O
the O
brain B-Biological_structure
now O
demonstrated O
LM B-Disease_disorder
( O
Fig. O
2 O
) O
confirmed O
by O
CSF B-Diagnostic_procedure
cytology I-Diagnostic_procedure
( O
not O
shown O
) O
. O

By O
direct B-Detailed_description
sequencing B-Diagnostic_procedure
, O
DNA B-Biological_structure
from O
CSF B-Diagnostic_procedure
cells I-Diagnostic_procedure
harbored O
L858R B-Diagnostic_procedure
predicting O
EGFR B-Diagnostic_procedure
TKI I-Diagnostic_procedure
sensitivity I-Diagnostic_procedure
( O
Fig. O
3 O
, O
left O
panel O
) O
but O
not O
the O
T790M B-Diagnostic_procedure
resistance I-Diagnostic_procedure
mutation I-Diagnostic_procedure
( O
data O
not O
shown O
) O
. O

Because O
the O
result O
for O
T790M B-Diagnostic_procedure
was O
negative B-Lab_value
in O
this B-Coreference
sample I-Coreference
, O
we O
performed O
a O
more B-Lab_value
sensitive I-Lab_value
fluorescence B-Detailed_description
detection I-Detailed_description
PCR-based B-Detailed_description
assay B-Diagnostic_procedure
that O
takes O
advantage O
of O
a O
PCR B-Diagnostic_procedure
restriction I-Diagnostic_procedure
fragment I-Diagnostic_procedure
length I-Diagnostic_procedure
polymorphism I-Diagnostic_procedure
generated O
by O
the B-Coreference
specific I-Coreference
missense I-Coreference
mutation I-Coreference
( O
Fig. O
3 O
, O
right O
panel O
, O
arrow O
, O
positive O
control O
) O
[ O
6 O
] O
. O

That B-Coreference
result I-Coreference
was O
also O
negative B-Lab_value
, O
as O
only O
the O
wild B-Diagnostic_procedure
type I-Diagnostic_procedure
peak I-Diagnostic_procedure
was O
detected O
( O
Fig. O
3 O
, O
right O
panel O
, O
bottom O
) O
. O

Therefore O
, O
we O
hypothesized O
that O
the O
LM O
remained O
sensitive O
to O
an O
EGFR O
TKI O
if O
sufficiently O
high O
concentrations O
of O
drug O
could O
be O
achieved O
in O
the O
CSF O
. O

The O
erlotinib O
concentration O
required O
to O
inhibit O
growth O
of O
cell O
lines O
harboring O
L858R O
by O
50 O
% O
( O
IC50 O
) O
is O
100 O
nM O
( O
nM O
) O
[ O
2 O
] O
. O

Standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
achieves O
3000 O
nM O
in O
plasma O
[ O
7 O
] O
, O
but O
CSF O
concentrations O
of O
EGFR O
TKIs O
are O
as O
low O
as O
1 O
% O
plasma O
levels O
below O
the O
IC50 O
[ O
3 O
, O
8 O
] O
. O

Increasing O
the O
daily O
dose O
of O
gefitinib O
to O
enhance O
CSF O
penetration O
has O
been O
an O
effective O
strategy O
[ O
3 O
] O
, O
but O
gefitinib O
is O
no O
longer O
available O
in O
the O
United O
States O
following O
failure O
in O
phase O
III O
NSCLC O
trials O
. O

An O
analogous O
increase O
of O
the O
daily O
erlotinib O
dose O
above O
150 O
– O
200 O
mg O
daily O
induces O
unacceptable O
toxicity O
. O

However O
, O
weekly O
high-dose O
erlotinib O
up O
to O
2000 O
mg O
is O
tolerable O
[ O
4 O
] O
. O

Pharmacokinetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
CSF B-Biological_structure
from O
another B-Subject
patient I-Subject
with O
NSCLC B-Disease_disorder
LM B-Disease_disorder
( O
not O
shown O
) O
treated O
with O
1500 B-Dosage
mg I-Dosage
erlotinib I-Dosage
weekly I-Dosage
demonstrated O
a O
peak B-Diagnostic_procedure
plasma I-Diagnostic_procedure
concentration I-Diagnostic_procedure
of O
11,300 B-Lab_value
nM I-Lab_value
with O
a O
concurrent O
CSF B-Diagnostic_procedure
concentration I-Diagnostic_procedure
of O
130 B-Lab_value
nM I-Lab_value
. O

Therefore O
, O
such O
high O
dose O
weekly O
administration O
of O
erlotinib O
achieved O
a O
CSF O
concentration O
exceeding B-Detailed_description
the I-Detailed_description
IC50 I-Detailed_description
. O

Therefore O
, O
to O
increase O
CSF O
penetrance O
over O
standard O
daily O
erlotinib O
dosing O
in O
this O
patient O
, O
we O
initiated O
high-dose B-Dosage
weekly I-Dosage
erlotinib B-Medication
at O
1000 B-Lab_value
mg I-Lab_value
then O
1200 B-Lab_value
mg I-Lab_value
; O
persistent B-Detailed_description
nausea B-Sign_symptom
precluded O
higher O
doses O
. O

Pharmacokinetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
not O
undertaken O
in O
this O
patient O
. O

After B-Date
1 I-Date
month I-Date
there O
was O
a O
partial B-Diagnostic_procedure
radiographic I-Diagnostic_procedure
response I-Diagnostic_procedure
of O
LM B-Disease_disorder
on O
brain B-Biological_structure
MRI B-Diagnostic_procedure
( O
Fig. O
2b O
) O
and O
after B-Date
2 I-Date
months I-Date
in O
the O
cauda B-Biological_structure
equina I-Biological_structure
( O
not O
shown O
) O
. O

However O
, O
hydrocephalus B-Disease_disorder
and O
persistent B-Detailed_description
symptoms B-Sign_symptom
referable O
to O
increased B-Lab_value
intracranial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
led O
to O
a O
VP B-Therapeutic_procedure
shunt I-Therapeutic_procedure
and O
whole-brain B-Biological_structure
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
, O
after O
which O
she O
resumed O
treatment O
with O
1500 B-Dosage
mg I-Dosage
weekly I-Dosage
erlotinib B-Medication
. O

One B-Date
month I-Date
later I-Date
, O
progressive B-Detailed_description
intra-thoracic B-Disease_disorder
disease I-Disease_disorder
led O
to O
initiation O
of O
cetixumab B-Medication
and O
erlotinib B-Medication
was O
continued O
but O
changed O
to O
low B-Dosage
dose I-Dosage
( I-Dosage
100 I-Dosage
mg I-Dosage
) I-Dosage
daily I-Dosage
. O

She O
survived B-Sign_symptom
14 B-Date
months I-Date
following I-Date
the I-Date
diagnosis I-Date
of I-Date
CNS I-Date
disease I-Date
. O

A O
21-year-old B-Age
male B-Sex
presented B-Clinical_event
with O
a O
2-year B-Duration
history O
of O
progressive B-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
on O
exertion B-Detailed_description
and O
dry B-Sign_symptom
cough I-Sign_symptom
. O

At O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
auscultation B-Diagnostic_procedure
of O
the O
lungs B-Biological_structure
has O
revealed O
random B-Detailed_description
wheezes B-Sign_symptom
and O
coarse B-Sign_symptom
crackles I-Sign_symptom
. O

Cardiac B-Biological_structure
auscultation B-Diagnostic_procedure
was O
normal O
, O
and O
no O
cyanosis B-Sign_symptom
or O
peripheral B-Sign_symptom
edema I-Sign_symptom
was O
observed O
. O

There O
was O
no B-History
history I-History
of I-History
smoking I-History
or O
previous O
known O
pulmonary B-Disease_disorder
disease I-Disease_disorder
. O

On O
routine B-Detailed_description
blood B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
blood B-Diagnostic_procedure
counts I-Diagnostic_procedure
and O
serum B-Diagnostic_procedure
chemistries I-Diagnostic_procedure
were O
found O
to O
be O
normal B-Lab_value
. O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis I-Diagnostic_procedure
and O
echocardiography B-Diagnostic_procedure
showed O
no B-Lab_value
important I-Lab_value
abnormalities I-Lab_value
. O

Pulmonary B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
( O
PFT B-Diagnostic_procedure
) O
showed O
a O
mild B-Severity
restrictive B-Sign_symptom
ventilatory I-Sign_symptom
defect I-Sign_symptom
, O
with O
a O
reduced B-Lab_value
total B-Diagnostic_procedure
lung I-Diagnostic_procedure
capacity I-Diagnostic_procedure
of O
79 B-Lab_value
% I-Lab_value
( O
5.94 B-Lab_value
L I-Lab_value
) O
, O
forced B-Diagnostic_procedure
vital I-Diagnostic_procedure
capacity I-Diagnostic_procedure
of O
80 B-Lab_value
% I-Lab_value
( O
4.18 B-Lab_value
L I-Lab_value
) O
and O
a O
forced B-Diagnostic_procedure
expiratory I-Diagnostic_procedure
volume I-Diagnostic_procedure
in I-Diagnostic_procedure
one I-Diagnostic_procedure
second I-Diagnostic_procedure
of O
83 B-Lab_value
% I-Lab_value
( O
3.72 B-Lab_value
L I-Lab_value
) O
. O

The O
sputum B-Biological_structure
was O
negative B-Lab_value
for O
acid-alcohol B-Diagnostic_procedure
resistant I-Diagnostic_procedure
bacillus I-Diagnostic_procedure
and O
human B-Diagnostic_procedure
immunodeficiency I-Diagnostic_procedure
virus I-Diagnostic_procedure
testing I-Diagnostic_procedure
was O
negative B-Lab_value
as O
well O
. O

The O
chest B-Diagnostic_procedure
plain I-Diagnostic_procedure
films I-Diagnostic_procedure
revealed O
a O
diffuse B-Detailed_description
symmetric B-Detailed_description
dense B-Texture
bilateral B-Biological_structure
micronodular B-Sign_symptom
pattern I-Sign_symptom
( O
Figure O
1 O
) O
. O

Based O
on O
this O
finding O
, O
HRCT B-Diagnostic_procedure
scan I-Diagnostic_procedure
was O
obtained O
, O
revealing O
diffuse O
ground B-Sign_symptom
glass I-Sign_symptom
attenuation I-Sign_symptom
and O
septal B-Sign_symptom
thickening I-Sign_symptom
, O
more O
pronounced O
in O
lower B-Biological_structure
pulmonary I-Biological_structure
regions I-Biological_structure
, O
with O
calcifications B-Sign_symptom
along O
the O
interlobar B-Biological_structure
septa I-Biological_structure
and O
subpleural B-Biological_structure
regions I-Biological_structure
. O

Subpleural B-Biological_structure
cysts B-Sign_symptom
were O
also O
noticed O
( O
Figure O
2 O
) O
. O

The O
patient O
underwent O
a O
fiberoptic B-Diagnostic_procedure
bronchoscopy I-Diagnostic_procedure
with O
bronchoalveolar B-Diagnostic_procedure
lavage I-Diagnostic_procedure
and O
transbronchial B-Biological_structure
lung B-Biological_structure
biopsy B-Diagnostic_procedure
. O

The O
lavage B-Biological_structure
fluid I-Biological_structure
was O
negative B-Lab_value
for O
tuberculosis B-Diagnostic_procedure
or O
fungi B-Diagnostic_procedure
. O

Microliths B-Sign_symptom
were O
not O
found O
. O

Histology B-Diagnostic_procedure
revealed O
round B-Shape
, O
concentrically B-Detailed_description
laminated I-Detailed_description
microliths B-Sign_symptom
in O
the O
alveoli B-Biological_structure
associated O
with O
slightly B-Severity
thickened B-Sign_symptom
interstitial I-Sign_symptom
septa I-Sign_symptom
, O
consistent O
with O
the O
diagnosis O
of O
PAM B-Disease_disorder
. O

A O
48-year-old B-Age
man B-Sex
presented B-Clinical_event
at O
our O
hospital B-Nonbiological_location
complaining O
of O
intracranial B-Biological_structure
bruits B-Sign_symptom
. O

The O
cranial B-Diagnostic_procedure
nerve I-Diagnostic_procedure
and O
laboratory B-Diagnostic_procedure
examinations I-Diagnostic_procedure
were O
normal B-Lab_value
. O

A O
DVAF B-Disease_disorder
was O
considered O
, O
conventional B-Diagnostic_procedure
digital I-Diagnostic_procedure
subtraction I-Diagnostic_procedure
angiography I-Diagnostic_procedure
was O
performed O
, O
which O
showed O
a O
Cognard B-Disease_disorder
II I-Disease_disorder
DVAF I-Disease_disorder
in O
the O
location O
of O
right B-Biological_structure
hypoglossal I-Biological_structure
canal I-Biological_structure
( O
HC B-Biological_structure
) O
. O

The O
DVAF B-Coreference
was O
fed O
by O
the O
meningeal B-Biological_structure
branches I-Biological_structure
of O
the O
bilateral B-Biological_structure
ascending I-Biological_structure
pharyngeal I-Biological_structure
arteries I-Biological_structure
, O
and O
the O
right B-Biological_structure
anterior I-Biological_structure
condylar I-Biological_structure
veins I-Biological_structure
within O
the O
hypoglossal B-Biological_structure
canal I-Biological_structure
that O
was O
the O
fistulous B-Sign_symptom
point I-Sign_symptom
mainly O
drained B-Detailed_description
into I-Detailed_description
the I-Detailed_description
jugular I-Detailed_description
vein I-Detailed_description
. O

Endovascular B-Therapeutic_procedure
treatment I-Therapeutic_procedure
was O
insisted O
upon O
by O
the O
patient O
because O
of O
the O
associated O
intolerable B-Detailed_description
intracranial B-Biological_structure
bruit B-Coreference
. O

Treatment O
was O
performed O
by O
transarterial B-Therapeutic_procedure
approach I-Therapeutic_procedure
under O
general B-Medication
anesthesia I-Medication
using O
a O
biplane B-Therapeutic_procedure
angiographic I-Therapeutic_procedure
unit I-Therapeutic_procedure
. O

Standard B-Therapeutic_procedure
coaxial I-Therapeutic_procedure
techniques I-Therapeutic_procedure
were O
used O
. O

The O
guide B-Therapeutic_procedure
catheter I-Therapeutic_procedure
was I-Therapeutic_procedure
navigated I-Therapeutic_procedure
into O
the O
left B-Biological_structure
ascendingtrawt I-Biological_structure
pharyngeal I-Biological_structure
artery I-Biological_structure
. O

Marathon B-Therapeutic_procedure
flow I-Therapeutic_procedure
directed I-Therapeutic_procedure
catheter I-Therapeutic_procedure
( I-Therapeutic_procedure
eV3 I-Therapeutic_procedure
) I-Therapeutic_procedure
was I-Therapeutic_procedure
subsequently I-Therapeutic_procedure
navigated I-Therapeutic_procedure
over O
a O
Mirage O
.008 O
microwire O
( O
eV3 O
) O
to O
reach O
as O
near O
as O
possible O
to O
the O
fistula B-Sign_symptom
. O

The O
microcatheter B-Therapeutic_procedure
was I-Therapeutic_procedure
flushed I-Therapeutic_procedure
with O
10 B-Volume
mL I-Volume
of O
normal B-Biological_structure
saline I-Biological_structure
. O

The O
dead O
space O
of O
the O
microcatheter B-Therapeutic_procedure
was I-Therapeutic_procedure
subsequently I-Therapeutic_procedure
filled I-Therapeutic_procedure
with O
dimethyl B-Medication
sulfoxide I-Medication
( O
DMSO O
) O
. O

Onyx-18 B-Medication
was O
then O
injected B-Therapeutic_procedure
over O
two B-Duration
minutes I-Duration
to O
fill O
the O
microcatheter O
and O
to O
replace O
the O
DMSO O
in O
the O
dead O
space O
. O

The O
injection B-Therapeutic_procedure
was I-Therapeutic_procedure
stopped I-Therapeutic_procedure
until O
unwanted O
flow O
into O
branches O
of O
the O
right O
ascending O
pharyngeal O
artery O
was O
observed O
. O

The O
follow-up B-Detailed_description
angiogram B-Diagnostic_procedure
showed O
no O
residual B-Sign_symptom
shunt I-Sign_symptom
( O
Figure O
1 O
) O
. O

The O
intracranial B-Biological_structure
bruits B-Sign_symptom
disappeared O
immediately O
after O
the O
operation O
. O

For O
the O
toxicity O
of O
DMSO O
, O
10 B-Dosage
mg I-Dosage
dexamethasone B-Medication
was O
intravenously B-Administration
injected I-Administration
for O
three B-Duration
days I-Duration
. O

On O
the O
second B-Date
day I-Date
after I-Date
endovascular I-Date
treatment I-Date
, O
the O
patient O
complainted O
of O
difficulty B-Sign_symptom
moving I-Sign_symptom
his I-Sign_symptom
tongue I-Sign_symptom
to O
the O
left O
. O

Cranial B-Biological_structure
nerve I-Biological_structure
examination B-Diagnostic_procedure
was O
only O
significant O
for O
a O
right B-Sign_symptom
hypoglossal I-Sign_symptom
nerve I-Sign_symptom
palsy I-Sign_symptom
. O

The O
patient O
was O
discharged B-Clinical_event
from O
our O
hospital B-Nonbiological_location
four B-Date
days I-Date
after I-Date
treatment I-Date
without O
continuative B-Medication
pharmacotherapy I-Medication
. O

At O
two B-Date
months I-Date
follow-up I-Date
, O
the O
patient O
's O
main O
complaint O
were O
difficulty O
swallowing O
( O
dysphagia B-Sign_symptom
) O
and O
slurred O
speech O
( O
dysarthria B-Sign_symptom
) O
. O

In O
addition O
, O
his O
tongue B-Lab_value
deviated I-Lab_value
toward I-Lab_value
the I-Lab_value
right I-Lab_value
during O
tongue B-Diagnostic_procedure
protrusion I-Diagnostic_procedure
, O
and O
marked B-Detailed_description
right-sided B-Detailed_description
hemiatrophy B-Sign_symptom
was O
observed O
( O
Figure O
2 O
) O
. O

The O
cranial B-Biological_structure
nerve I-Biological_structure
examation B-Diagnostic_procedure
showed O
right B-Coreference
hypoglossal I-Coreference
nerve I-Coreference
palsy I-Coreference
persisted O
. O

We O
telephone O
the O
patient O
at O
three B-Date
months I-Date
follow-up I-Date
and O
requested O
a O
vocal B-Diagnostic_procedure
cord I-Diagnostic_procedure
evaluation I-Diagnostic_procedure
by O
an O
ENT B-Subject
specialist I-Subject
in O
a O
local B-Nonbiological_location
hospital I-Nonbiological_location
. O

Vocal B-Biological_structure
cord I-Biological_structure
paralysis B-Sign_symptom
was O
not O
found O
, O
and O
there O
was O
no O
evidence O
of O
vagus B-Biological_structure
nerve I-Biological_structure
dysfunction B-Sign_symptom
. O

Oral B-Medication
Vitamin I-Medication
B12 I-Medication
was O
used O
and O
his O
prognosis O
was O
still O
at O
a O
long O
follow-up B-Clinical_event
. O

A O
41-year-old B-Age
man B-Sex
with O
weight B-Sign_symptom
loss I-Sign_symptom
, O
nausea B-Sign_symptom
, O
vomiting B-Sign_symptom
, O
and O
abdominal B-Biological_structure
pain B-Sign_symptom
was O
referred B-Clinical_event
for O
an O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
to O
rule O
out O
intraabdominal B-Disease_disorder
pathology I-Disease_disorder
. O

A O
dedicated O
CT B-Diagnostic_procedure
of O
the O
abdomen B-Biological_structure
was O
performed O
at O
our O
institution B-Nonbiological_location
according O
to O
our O
standard B-Detailed_description
venous I-Detailed_description
phase I-Detailed_description
protocol I-Detailed_description
. O

Following O
ingestion B-Administration
of O
positive B-Diagnostic_procedure
oral I-Diagnostic_procedure
contrast I-Diagnostic_procedure
material O
( O
barium B-Medication
sulfate I-Medication
suspension I-Medication
2.1 B-Dosage
% I-Dosage
w/v I-Dosage
, O
Mallinckrodt B-Detailed_description
) O
and O
injection B-Administration
of O
125 B-Dosage
ml I-Dosage
of O
iopromide B-Medication
, O
300 B-Dosage
mg I-Dosage
I/mL I-Dosage
( O
Ultravist B-Detailed_description
, I-Detailed_description
Bayer I-Detailed_description
HealthCare I-Detailed_description
) O
, O
helical B-Detailed_description
CT B-Coreference
was O
obtained O
with O
a O
65-s B-Detailed_description
delays I-Detailed_description
using O
a O
64-slice B-Detailed_description
GE I-Detailed_description
Lightspeed I-Detailed_description
VCT I-Detailed_description
scanner I-Detailed_description
( O
GE B-Detailed_description
Medical I-Detailed_description
Systems I-Detailed_description
; I-Detailed_description
Milwaukee I-Detailed_description
, I-Detailed_description
WI I-Detailed_description
) O
. O

Axial B-Diagnostic_procedure
sections I-Diagnostic_procedure
of O
the O
abdomen B-Biological_structure
showed O
a O
large B-Lab_value
( O
18 B-Volume
× I-Volume
22 I-Volume
× I-Volume
22 I-Volume
cm I-Volume
) O
heterogeneous B-Detailed_description
retroperitoneal B-Biological_structure
mass B-Sign_symptom
probably O
arising O
from O
the O
left B-Biological_structure
adrenal I-Biological_structure
gland I-Biological_structure
containing O
multiple B-Detailed_description
areas I-Detailed_description
of I-Detailed_description
macroscopic I-Detailed_description
fat I-Detailed_description
( O
Fig. O
1 O
) O
. O

The O
patient O
had O
no B-History
documented I-History
clinical I-History
or I-History
laboratory I-History
evidence I-History
of I-History
adrenal I-History
hormonal I-History
excess I-History
. O

On O
the O
basis O
of O
the O
clinical O
history O
and O
CT O
findings O
, O
the O
patient O
underwent O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
of O
the O
left B-Biological_structure
adrenal I-Biological_structure
mass B-Sign_symptom
, O
which O
was O
found O
on O
pathologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
to O
represent O
a O
low-grade B-Severity
adrenocortical B-Disease_disorder
carcinoma I-Disease_disorder
. O

A O
48 B-Age
year-old I-Age
female B-Sex
presented B-Clinical_event
with O
vaginal B-Biological_structure
bleeding B-Sign_symptom
and O
abnormal B-Lab_value
Pap B-Diagnostic_procedure
smears I-Diagnostic_procedure
. O

Upon O
diagnosis O
of O
invasive B-Detailed_description
non-keratinizing B-Detailed_description
SCC B-Disease_disorder
of O
the O
cervix B-Biological_structure
, O
she O
underwent O
a O
radical B-Detailed_description
hysterectomy B-Therapeutic_procedure
with O
salpingo-oophorectomy B-Therapeutic_procedure
which O
demonstrated O
positive B-Sign_symptom
spread I-Sign_symptom
to O
the O
pelvic B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
and O
the O
parametrium B-Biological_structure
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
that O
the O
tumour B-Coreference
also O
extensively O
involved O
the O
lower B-Biological_structure
uterine I-Biological_structure
segment I-Biological_structure
. O

5 B-Date
months I-Date
after I-Date
this I-Date
surgery I-Date
, O
the O
woman O
underwent O
external B-Detailed_description
beam I-Detailed_description
radiotherapy B-Therapeutic_procedure
and O
intracavitary B-Detailed_description
brachytherapy B-Therapeutic_procedure
. O

Two B-Date
years I-Date
later I-Date
, O
the O
patient O
presented O
with O
a O
three-month B-Duration
history O
of O
a O
productive B-Detailed_description
cough B-Sign_symptom
, O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
, O
and O
a O
2-3 B-Duration
week I-Duration
history O
of O
progressive B-Detailed_description
exertional B-Detailed_description
dyspnea B-Sign_symptom
. O

X-rays B-Diagnostic_procedure
of O
the O
chest B-Biological_structure
demonstrated O
a O
reticular B-Lab_value
nodular I-Lab_value
pattern I-Lab_value
, O
and O
CT B-Diagnostic_procedure
scans I-Diagnostic_procedure
revealed O
multiple O
bilateral B-Detailed_description
patchy I-Detailed_description
areas I-Detailed_description
of O
ground B-Texture
glass I-Texture
opacity I-Texture
scarring B-Sign_symptom
with O
focal O
areas O
of O
subsegmental B-Detailed_description
atelectasis B-Sign_symptom
within O
both B-Biological_structure
lungs I-Biological_structure
. O

A O
differential O
diagnosis O
included O
interstitial B-Detailed_description
pneumonia B-Disease_disorder
versus O
non-cardiogenic B-Detailed_description
edema B-Sign_symptom
. O

The O
woman O
underwent O
a O
bronchoscopy B-Diagnostic_procedure
, O
left B-Detailed_description
thoracoscopy B-Diagnostic_procedure
, O
and O
an O
open B-Detailed_description
wedge I-Detailed_description
left B-Biological_structure
lung I-Biological_structure
biopsy B-Diagnostic_procedure
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
left B-Biological_structure
lung I-Biological_structure
biopsy B-Coreference
confirmed O
the O
presence O
of O
neoplastic B-Sign_symptom
sheets I-Sign_symptom
of I-Sign_symptom
cells I-Sign_symptom
classically O
distributed O
along B-Biological_structure
the I-Biological_structure
septal I-Biological_structure
vessels I-Biological_structure
, O
perivascular B-Biological_structure
, O
peribronchial B-Biological_structure
, O
and O
subpleural B-Biological_structure
lymphatics B-Biological_structure
. O

Subpleural B-Biological_structure
nodules B-Sign_symptom
were O
also O
identified O
with O
the O
presence O
of O
neoplastic B-Coreference
cells I-Coreference
distending O
the O
subpleural B-Biological_structure
lymphatics I-Biological_structure
confirming O
LC B-Disease_disorder
( O
Figures O
1A O
, O
1B O
, O
1C O
) O
. O

On O
immunohistochemical B-Diagnostic_procedure
analysis I-Diagnostic_procedure
, O
the O
lesional B-Coreference
cells I-Coreference
were O
strongly O
positive B-Lab_value
to O
p16 B-Diagnostic_procedure
( O
Figure O
1D O
) O
, O
high B-Diagnostic_procedure
and I-Diagnostic_procedure
low I-Diagnostic_procedure
molecular I-Diagnostic_procedure
weight I-Diagnostic_procedure
keratins I-Diagnostic_procedure
( O
Figure O
1E O
) O
, O
cytokeratin-7 B-Diagnostic_procedure
( O
CK7 B-Diagnostic_procedure
) O
( O
Figure O
1F O
) O
, O
CK19 B-Diagnostic_procedure
, O
and O
pan B-Diagnostic_procedure
keratin I-Diagnostic_procedure
, O
and O
negative B-Lab_value
to O
CK20 B-Diagnostic_procedure
, O
p63 B-Diagnostic_procedure
, O
and O
EGFR B-Diagnostic_procedure
. O

Based O
on O
these O
findings O
, O
she O
was O
diagnosed O
to O
have O
lymphangitic B-Disease_disorder
carcinomatosis I-Disease_disorder
in O
the O
lung B-Biological_structure
metastatic B-Sign_symptom
from O
SCC B-Disease_disorder
of O
the O
cervix B-Biological_structure
. O

She O
was O
started O
on O
chemotherapy B-Medication
( O
Carbo/Taxol B-Medication
) O
with O
corticosteroids B-Medication
while O
in O
the O
hospital O
, O
and O
was O
discharged B-Clinical_event
ten B-Date
days I-Date
later I-Date
. O

Post-treatment O
improvement B-Lab_value
of O
clinical B-Sign_symptom
symptoms I-Sign_symptom
was O
paralleled O
by O
radiographic B-Diagnostic_procedure
imaging I-Diagnostic_procedure
that O
showed O
marked O
interval O
improvement B-Lab_value
of O
the O
nodular B-Sign_symptom
opacifications I-Sign_symptom
and O
the O
interstitial B-Sign_symptom
thickening I-Sign_symptom
that O
had O
previously O
been O
noted O
. O

Despite O
this O
improvement O
, O
she O
subsequently O
died B-Outcome
13 B-Date
months I-Date
after I-Date
the I-Date
initial I-Date
diagnosis I-Date
. O

A O
27 B-Age
years I-Age
old I-Age
, O
male B-Sex
, O
right B-History
handed I-History
, O
was O
admitted B-Clinical_event
for O
a O
2 B-Duration
years I-Duration
history O
of O
very B-History
frequent I-History
gelastic I-History
seizures I-History
. O

The O
patient O
described O
aura B-Sign_symptom
– I-Sign_symptom
like I-Sign_symptom
symptoms I-Sign_symptom
: O
especially O
warmth B-Sign_symptom
throughout O
the O
face B-Biological_structure
and O
dizziness B-Sign_symptom
that O
preceded O
the O
seizure B-Sign_symptom
and O
he O
denied O
any O
affective B-Sign_symptom
connotation I-Sign_symptom
. O

Some B-Detailed_description
of O
the O
seizures B-Sign_symptom
consisted O
only O
of O
a O
brief B-Detailed_description
period O
of O
laughter B-Sign_symptom
without O
any O
motor B-Sign_symptom
involvement I-Sign_symptom
, O
but O
a O
typical O
seizure B-Sign_symptom
would O
consist O
of O
sudden B-Detailed_description
laughter B-Sign_symptom
accompanied O
by O
simple B-Sign_symptom
motor I-Sign_symptom
partial I-Sign_symptom
seizures I-Sign_symptom
in O
both B-Biological_structure
arms I-Biological_structure
, O
more O
often O
being O
involved O
his O
left B-Biological_structure
arm I-Biological_structure
, O
without O
impairment B-Sign_symptom
of I-Sign_symptom
his I-Sign_symptom
consciousness I-Sign_symptom
state I-Sign_symptom
, O
which O
lasted O
less B-Detailed_description
than I-Detailed_description
1 I-Detailed_description
minute I-Detailed_description
. O

He O
had O
no B-History
previous I-History
past I-History
medical I-History
or I-History
social I-History
history I-History
other O
than O
being O
a O
smoker B-History
: O
10 B-Quantitative_concept
– I-Quantitative_concept
15 I-Quantitative_concept
cigarettes I-Quantitative_concept
per I-Quantitative_concept
day I-Quantitative_concept
. O

The O
frequency O
of O
the O
seizures B-Sign_symptom
was O
initially B-Detailed_description
low B-Frequency
, O
but O
increased B-Detailed_description
progressively I-Detailed_description
over I-Detailed_description
time I-Detailed_description
to O
about O
8 B-Frequency
– I-Frequency
10 I-Frequency
seizures/day I-Frequency
, O
despite O
anti B-Therapeutic_procedure
– I-Therapeutic_procedure
epileptic I-Therapeutic_procedure
treatment I-Therapeutic_procedure
– O
at O
the O
time O
of O
admission B-Clinical_event
he O
was O
taking O
Keppra B-Medication
– O
Levetiracetam B-Medication
3 B-Dosage
x I-Dosage
250 I-Dosage
mg/day I-Dosage
and O
Phenytoin B-Medication
3 B-Dosage
x I-Dosage
100 I-Dosage
mg/day I-Dosage
. O

With O
the O
Neurology B-Nonbiological_location
Electrophysiology I-Nonbiological_location
Department I-Nonbiological_location
assistance B-Clinical_event
we O
have O
been O
able O
to O
record O
a O
couple O
of O
seizures B-Sign_symptom
on O
the O
Video B-Diagnostic_procedure
– I-Diagnostic_procedure
EEG I-Diagnostic_procedure
His O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Diagnosis O
was O
made O
on O
native B-Detailed_description
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
: O
minimal B-Detailed_description
hypodense B-Detailed_description
frontal B-Biological_structure
right I-Biological_structure
paramedian I-Biological_structure
lesion B-Sign_symptom
( O
Figure O
1A O
) O
, O
cerebral B-Biological_structure
MRI B-Diagnostic_procedure
( O
Figure O
1 O
B O
– O
F O
) O
showed O
a O
small B-Detailed_description
right B-Detailed_description
parenchymal I-Detailed_description
homogeneous B-Detailed_description
lesion B-Sign_symptom
16/22/15mm B-Volume
, O
well B-Detailed_description
delimited I-Detailed_description
, O
involving O
gyrus B-Biological_structure
cinguli I-Biological_structure
, O
without O
perilesional B-Detailed_description
edema B-Sign_symptom
and O
mass B-Sign_symptom
effect I-Sign_symptom
, O
hyperintense B-Detailed_description
both I-Detailed_description
on I-Detailed_description
T1 I-Detailed_description
and I-Detailed_description
T2 I-Detailed_description
MR I-Detailed_description
sequences I-Detailed_description
, O
non B-Detailed_description
– I-Detailed_description
enhancing I-Detailed_description
after I-Detailed_description
Gadolinium I-Detailed_description
. O

The O
cerebral B-Biological_structure
lesion B-Sign_symptom
was O
also O
documented O
on O
EEG B-Diagnostic_procedure
and O
video B-Diagnostic_procedure
– I-Diagnostic_procedure
EEG I-Diagnostic_procedure
recordings O
: O
3 B-Lab_value
seizures B-Sign_symptom
with O
medio B-Detailed_description
– I-Detailed_description
frontal I-Detailed_description
origin I-Detailed_description
and O
rare B-Detailed_description
interictal I-Detailed_description
epileptiform I-Detailed_description
elements I-Detailed_description
were O
recorded O
( O
Figure O
1I O
) O
Using O
an O
interhemispheric B-Biological_structure
microsurgical B-Therapeutic_procedure
approach I-Therapeutic_procedure
, O
above B-Biological_structure
the I-Biological_structure
corpus I-Biological_structure
callosum I-Biological_structure
and O
the O
right B-Biological_structure
pericallosal I-Biological_structure
artery I-Biological_structure
, O
at O
the O
level O
of O
gyrus B-Biological_structure
cinguli I-Biological_structure
, O
a O
yellow B-Color
– I-Color
gray I-Color
, O
infiltrative B-Detailed_description
tumour B-Sign_symptom
, O
having O
a O
moderate B-Severity
vascularisation B-Detailed_description
had O
been O
identified O
and O
totally O
removed B-Therapeutic_procedure
. O

The O
anatomo B-Diagnostic_procedure
– I-Diagnostic_procedure
pathological I-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
a O
grade B-Lab_value
Ⅱ I-Lab_value
astrocytoma B-Disease_disorder
. O

The O
patient O
recovered B-Sign_symptom
very O
well O
, O
without O
deficits B-Sign_symptom
, O
no O
gelastic B-Disease_disorder
seizures I-Disease_disorder
or O
epileptic B-Sign_symptom
manifestations I-Sign_symptom
; O
three B-Date
months I-Date
after I-Date
operation I-Date
he O
is O
still O
free O
of O
seizures B-Sign_symptom
. O

A O
control O
postop O
CT B-Diagnostic_procedure
revealed O
no O
tumor B-Sign_symptom
( O
1 O
G O
, O
H O
) O

The O
patient O
was O
a O
3-year-old B-Age
girl B-Sex
with O
the O
following O
features O
of O
VACTERL B-Diagnostic_procedure
association I-Diagnostic_procedure
: O
absent B-Detailed_description
C1 B-Biological_structure
vertebra I-Biological_structure
, O
supernumerary B-Detailed_description
lumbar B-Biological_structure
vertebrae I-Biological_structure
, O
hypoplastic B-Detailed_description
sacrum/coccyx B-Biological_structure
, O
fatty B-Detailed_description
filum B-Biological_structure
terminale I-Biological_structure
with O
tethered B-Detailed_description
spinal B-Biological_structure
cord I-Biological_structure
, O
and O
three B-Lab_value
fused B-Detailed_description
ribs B-Biological_structure
; O
an O
anorectal B-Disease_disorder
malformation I-Disease_disorder
including O
a O
cloaca B-Biological_structure
consisting O
of O
a O
common B-Detailed_description
urogenital B-Biological_structure
sinus I-Biological_structure
and O
a O
duplex B-Detailed_description
vagina B-Biological_structure
with O
midline B-Detailed_description
septum I-Detailed_description
; O
type B-Detailed_description
C I-Detailed_description
TE B-Disease_disorder
fistula I-Disease_disorder
; O
right B-Biological_structure
renal I-Biological_structure
agenesis B-Disease_disorder
with O
moderate B-Severity
left B-Detailed_description
hydronephrosis B-Disease_disorder
and O
vesicoureteral B-Disease_disorder
reflux I-Disease_disorder
. O

She O
had O
no O
cardiac B-Disease_disorder
or I-Disease_disorder
limb I-Disease_disorder
malformations I-Disease_disorder
, O
and O
no O
other B-Disease_disorder
major I-Disease_disorder
organ I-Disease_disorder
anomalies I-Disease_disorder
. O

Both O
she B-Other_entity
and O
her B-Subject
father I-Subject
were O
additionally O
clinically O
diagnosed O
with O
hypermobile B-Detailed_description
type I-Detailed_description
Ehlers B-Disease_disorder
– I-Disease_disorder
Danlos I-Disease_disorder
syndrome I-Disease_disorder
, O
but O
family O
history O
was O
otherwise O
noncontributory O
. O

The O
diagnosis O
of O
hypermobile B-Detailed_description
type I-Detailed_description
Ehlers B-Disease_disorder
– I-Disease_disorder
Danlos I-Disease_disorder
was O
based O
on O
the O
patient O
’s O
hypermobility B-Disease_disorder
( O
9/9 B-Lab_value
on O
the O
Beighton B-Diagnostic_procedure
hypermobility I-Diagnostic_procedure
scale I-Diagnostic_procedure
) O
, O
very B-Lab_value
soft B-Texture
, O
fragile B-Texture
skin B-Biological_structure
with O
unusual B-Detailed_description
scarring I-Detailed_description
, O
and O
poor B-Lab_value
skin B-Detailed_description
healing I-Detailed_description
. O

Skin B-Biological_structure
biopsy B-Diagnostic_procedure
was O
not O
performed O
, O
but O
testing B-Diagnostic_procedure
on O
peripheral B-Biological_structure
blood I-Biological_structure
did O
not O
reveal O
mutations B-Diagnostic_procedure
associated O
with O
other B-Detailed_description
forms I-Detailed_description
of O
Ehlers B-Disease_disorder
– I-Disease_disorder
Danlos I-Disease_disorder
syndrome I-Disease_disorder
. O

Microarray B-Diagnostic_procedure
analysis I-Diagnostic_procedure
initially O
showed O
a O
maternally-inherited B-Detailed_description
deletion B-Diagnostic_procedure
at O
4q35 B-Biological_structure
.1 I-Biological_structure
detected O
with O
one B-Diagnostic_procedure
clone I-Diagnostic_procedure
and O
confirmed O
by O
FISH B-Diagnostic_procedure
( B-Diagnostic_procedure
RP11-173M11 I-Diagnostic_procedure
) I-Diagnostic_procedure
. O

Subsequent O
performance O
of O
an O
180K B-Diagnostic_procedure
custom I-Diagnostic_procedure
oligonucleotide I-Diagnostic_procedure
microarray I-Diagnostic_procedure
( O
Baylor B-Nonbiological_location
College I-Nonbiological_location
of I-Nonbiological_location
Medicine I-Nonbiological_location
Medical I-Nonbiological_location
Genetics I-Nonbiological_location
Laboratories I-Nonbiological_location
) O
refined O
the O
deleted B-Diagnostic_procedure
region I-Diagnostic_procedure
deletion I-Diagnostic_procedure
to O
a O
maximum B-Lab_value
size I-Lab_value
of I-Lab_value
1.37 I-Lab_value
Mb I-Lab_value
, O
with O
karyotype B-Diagnostic_procedure
revised O
to O
46 B-Detailed_description
, I-Detailed_description
XX I-Detailed_description
, I-Detailed_description
arr I-Detailed_description
cgh I-Detailed_description
4q35 I-Detailed_description
.1 I-Detailed_description
q35 I-Detailed_description
.2 I-Detailed_description
( I-Detailed_description
187,321-768-188,694-589 I-Detailed_description
) I-Detailed_description
3 I-Detailed_description
1 I-Detailed_description
. O

Genes B-Diagnostic_procedure
in O
the O
deleted B-Detailed_description
region I-Detailed_description
, O
which O
contains O
a O
number O
of O
much O
smaller O
copy O
number O
variations O
( O
CNVs O
) O
identified O
in O
normal O
controls O
, O
include O
CYP4V2 B-Diagnostic_procedure
, O
KLKB2 B-Diagnostic_procedure
, O
F11 B-Diagnostic_procedure
, O
MTRNR1A B-Diagnostic_procedure
, O
and O
FAT1 B-Diagnostic_procedure
, O
none O
of O
which O
can O
be O
clearly O
related O
to O
her O
phenotype O
, O
especially O
as O
her B-Subject
mother I-Subject
, O
from B-Detailed_description
whom I-Detailed_description
the I-Detailed_description
deletion I-Detailed_description
was I-Detailed_description
inherited I-Detailed_description
, O
is O
unaffected B-Disease_disorder
. O

Evidence O
for O
mitochondrial B-Disease_disorder
dysfunction I-Disease_disorder
began O
at O
13 B-Age
months I-Age
of I-Age
age I-Age
with O
progressive B-Detailed_description
muscle B-Sign_symptom
weakness I-Sign_symptom
, O
autonomic B-Disease_disorder
dysregulation I-Disease_disorder
, O
hypoglycemic B-Disease_disorder
episodes I-Disease_disorder
, O
exocrine B-Disease_disorder
pancreatic I-Disease_disorder
dysfunction I-Disease_disorder
, O
and O
decline B-Detailed_description
of O
gastrointestinal B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
eventually O
leading O
to O
total B-Severity
parenteral B-Detailed_description
nutrition B-Disease_disorder
dependency I-Disease_disorder
due O
to O
visceral B-Biological_structure
hyperalgesia B-Disease_disorder
, O
dysmotility B-Disease_disorder
, O
and O
malabsorption B-Disease_disorder
. O

Muscle B-Biological_structure
biopsy B-Diagnostic_procedure
showed O
a O
mild B-Severity
increase B-Lab_value
in O
fiber B-Diagnostic_procedure
size I-Diagnostic_procedure
variability I-Diagnostic_procedure
but O
no O
other B-Diagnostic_procedure
findings I-Diagnostic_procedure
consistent B-Detailed_description
with I-Detailed_description
mitochondrial I-Detailed_description
disease I-Detailed_description
, O
including O
via O
electron B-Diagnostic_procedure
microscopy I-Diagnostic_procedure
. O

However O
, O
analysis O
of O
electron B-Diagnostic_procedure
transport I-Diagnostic_procedure
chain I-Diagnostic_procedure
( I-Diagnostic_procedure
ETC I-Diagnostic_procedure
) I-Diagnostic_procedure
activity I-Diagnostic_procedure
showed O
normal B-Lab_value
activity O
of O
complexes B-Diagnostic_procedure
I I-Diagnostic_procedure
, B-Diagnostic_procedure
II I-Diagnostic_procedure
, B-Diagnostic_procedure
and I-Diagnostic_procedure
III I-Diagnostic_procedure
, O
but O
complex B-Diagnostic_procedure
IV I-Diagnostic_procedure
, O
or O
cytochrome B-Diagnostic_procedure
c I-Diagnostic_procedure
oxidase I-Diagnostic_procedure
, O
activity O
was O
45.4 B-Lab_value
lmol/min/g I-Lab_value
weight I-Lab_value
, O
well B-Detailed_description
below I-Detailed_description
the I-Detailed_description
control I-Detailed_description
range I-Detailed_description
( O
148.9 O
+ O
/ O
− O
67.2 O
lmol/min/g O
weight O
) O
. O

Repeat B-Detailed_description
ETC B-Diagnostic_procedure
analysis I-Diagnostic_procedure
in O
isolated B-Detailed_description
mitochondria B-Biological_structure
confirmed O
a O
profound B-Severity
and O
reproducible B-Detailed_description
complex B-Disease_disorder
IV I-Disease_disorder
deficiency I-Disease_disorder
. O

Citrate B-Diagnostic_procedure
synthase I-Diagnostic_procedure
activity I-Diagnostic_procedure
and B-Diagnostic_procedure
content I-Diagnostic_procedure
in O
both B-Coreference
ETC I-Coreference
analyses I-Coreference
were O
normal B-Lab_value
, O
confirming O
good B-Lab_value
sample B-Diagnostic_procedure
quality I-Diagnostic_procedure
and O
normal B-Lab_value
mitochondrial B-Diagnostic_procedure
content I-Diagnostic_procedure
. O

Whole B-Detailed_description
mitochondrial B-Biological_structure
genome B-Diagnostic_procedure
sequencing I-Diagnostic_procedure
, O
and O
sequencing B-Diagnostic_procedure
of O
DNA B-Diagnostic_procedure
Polymerase I-Diagnostic_procedure
Gamma I-Diagnostic_procedure
1 I-Diagnostic_procedure
and B-Diagnostic_procedure
2 I-Diagnostic_procedure
( O
POLG1 B-Diagnostic_procedure
and O
POLG2 B-Diagnostic_procedure
) O
and O
Thymidine B-Diagnostic_procedure
Phosphorylase I-Diagnostic_procedure
did O
not O
reveal O
abnormalities O
. O

A O
52-year-old B-Age
man B-Sex
( O
body B-History
surface I-History
area I-History
: I-History
1.3 I-History
m2 I-History
) O
known O
to O
have O
dilated B-Disease_disorder
cardiomyopathy I-Disease_disorder
( O
DCM B-Disease_disorder
) O
, O
was O
admitted B-Clinical_event
for O
worsening O
heart B-Disease_disorder
failure I-Disease_disorder
( O
NYHA B-Lab_value
class I-Lab_value
IV I-Lab_value
) O
. O

He O
presented O
with O
a O
5-month B-Duration
history O
of O
cough B-Sign_symptom
, O
progressive B-Detailed_description
dyspnoea B-Sign_symptom
, O
orthopnea B-Sign_symptom
and O
recurrent B-Detailed_description
upper B-Biological_structure
abdominal I-Biological_structure
pain B-Sign_symptom
started O
from B-Duration
2 I-Duration
months I-Duration
ago I-Duration
. O

On O
examination B-Diagnostic_procedure
his O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
37 B-Lab_value
°C I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
80/40 B-Lab_value
mmHg I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
24 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
and O
electrocardiogram B-Diagnostic_procedure
showed O
atrial B-Disease_disorder
fibrillation I-Disease_disorder
with O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
50 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
the O
jugular B-Biological_structure
venous I-Biological_structure
distension B-Sign_symptom
, O
significant B-Severity
tender B-Detailed_description
hepatomegaly B-Sign_symptom
and O
bilateral B-Detailed_description
pitting B-Detailed_description
edema B-Sign_symptom
at O
lower B-Biological_structure
limbs I-Biological_structure
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
elevated B-Lab_value
pro-NT B-Diagnostic_procedure
brain I-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
of O
22145 B-Lab_value
pg/ml I-Lab_value
( O
normal O
0 O
to O
227 O
pg/ml O
) O
and O
unremarkable B-Lab_value
D-dimer B-Diagnostic_procedure
. O

X-ray B-Diagnostic_procedure
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
chest B-Biological_structure
demonstrated O
consolidation B-Sign_symptom
of O
bilateral B-Biological_structure
lower I-Biological_structure
lobes I-Biological_structure
with O
pleural B-Sign_symptom
effusion I-Sign_symptom
, O
while O
his O
venous B-Biological_structure
Doppler B-Diagnostic_procedure
of O
lower B-Biological_structure
extremities I-Biological_structure
was O
normal B-Lab_value
. O

Based O
on O
his O
clinical O
condition O
, O
echocardiography B-Diagnostic_procedure
was O
immediately O
inserted O
. O

There O
were O
severe B-Severity
dilated B-Sign_symptom
cardiac I-Sign_symptom
chambers I-Sign_symptom
, O
especially O
enlargement B-Sign_symptom
of O
the O
left B-Biological_structure
ventricle I-Biological_structure
( O
LV B-Biological_structure
) O
( O
58 B-Lab_value
mm/m2 I-Lab_value
) O
with O
spherical B-Sign_symptom
shape I-Sign_symptom
, O
decreased B-Sign_symptom
wall I-Sign_symptom
thickness I-Sign_symptom
, O
impaired B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
22 B-Lab_value
% I-Lab_value
and O
severe B-Severity
mitral B-Sign_symptom
regurgitation I-Sign_symptom
on O
two-dimensional B-Diagnostic_procedure
transthoracic I-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
2DTTE B-Diagnostic_procedure
) O
. O

Parasternal O
short O
axis O
and O
subxyphoid O
view O
( O
Figure O
1 O
) O
showed O
the O
mobile B-Detailed_description
right B-Biological_structure
atrial I-Biological_structure
mass B-Sign_symptom
highly O
suspicious O
of O
a O
thrombus B-Disease_disorder
traversing O
the O
right B-Biological_structure
atrial I-Biological_structure
cavity I-Biological_structure
during O
the O
cardiac O
cycle O
accompanying O
with O
free-floating B-Detailed_description
small B-Detailed_description
parts I-Detailed_description
of O
the O
thrombi B-Disease_disorder
. O

Real-time B-Diagnostic_procedure
three I-Diagnostic_procedure
dimensional I-Diagnostic_procedure
transthoracic I-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
RT-3DTTE B-Diagnostic_procedure
) O
was O
performed O
to O
further O
confirm O
the O
nature O
of O
mass B-Sign_symptom
. O

It B-Coreference
showed O
a O
highly B-Detailed_description
mobile I-Detailed_description
thrombus B-Disease_disorder
, O
irregular B-Shape
in I-Shape
contour I-Shape
, O
measured O
2.6 B-Area
× I-Area
1.0 I-Area
cm I-Area
which O
floating O
around O
the O
orifice B-Biological_structure
of I-Biological_structure
inferior I-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
and O
protruding B-Biological_structure
into I-Biological_structure
the I-Biological_structure
right I-Biological_structure
atrial I-Biological_structure
cavity I-Biological_structure
( O
Figure O
2 O
) O
. O

In O
addition O
, O
RT-3DTTE B-Diagnostic_procedure
evaluated O
right B-Biological_structure
ventricle I-Biological_structure
( O
RV B-Biological_structure
) O
systolic B-Sign_symptom
dysfunction I-Sign_symptom
with O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
15.7 B-Lab_value
% I-Lab_value
( O
Figure O
3 O
) O
. O

He O
was O
maintained O
on O
digoxin B-Medication
, O
spironolactone B-Medication
, O
furosemide B-Medication
, O
sotalol B-Medication
and O
dopamine B-Medication
. O

At O
the O
same O
time O
therapeutic B-Therapeutic_procedure
anticoagulation I-Therapeutic_procedure
was O
started O
with O
low-molecular-weight B-Detailed_description
heparin B-Medication
and O
warfarin B-Medication
. O

The O
patient O
had O
an O
uneventful B-Lab_value
hospital B-Therapeutic_procedure
course I-Therapeutic_procedure
and O
one B-Date
week I-Date
follow-up B-Clinical_event
echocardiography B-Diagnostic_procedure
confirmed O
adequate O
removal O
of O
the O
thrombus B-Disease_disorder
( O
Figures O
4A O
and O
4B O
) O
. O

A O
75 B-Age
– I-Age
year I-Age
– I-Age
old I-Age
female B-Sex
presented B-Clinical_event
in O
the O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
of I-Nonbiological_location
Ilfov I-Nonbiological_location
Clinical I-Nonbiological_location
Hospital I-Nonbiological_location
, I-Nonbiological_location
Bucharest I-Nonbiological_location
, I-Nonbiological_location
Romania I-Nonbiological_location
, O
with O
dyspnea B-Sign_symptom
, O
orthopnea B-Sign_symptom
, O
lower B-Biological_structure
extremities I-Biological_structure
swelling B-Sign_symptom
, O
palpitations B-Sign_symptom
. O

She O
had O
a O
3 B-Duration
years I-Duration
history O
of O
atrial B-Sign_symptom
fibrillation I-Sign_symptom
diagnosed O
by O
her O
family B-Subject
doctor I-Subject
and O
one-year B-Duration
history O
of O
cardiac B-Disease_disorder
failure I-Disease_disorder
NYHA B-Lab_value
( I-Lab_value
New I-Lab_value
York I-Lab_value
Heart I-Lab_value
Association I-Lab_value
) I-Lab_value
class I-Lab_value
Ⅱ I-Lab_value
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
irregular B-Sign_symptom
pulse I-Sign_symptom
80 B-Lab_value
beats/min I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
100/60 B-Lab_value
mmHg I-Lab_value
, O
bi B-Sign_symptom
– I-Sign_symptom
basal I-Sign_symptom
crackles I-Sign_symptom
on O
chest B-Biological_structure
auscultation B-Diagnostic_procedure
, O
lower B-Biological_structure
extremities I-Biological_structure
swelling B-Coreference
. O

Heart B-Diagnostic_procedure
sounds I-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
IVth B-Lab_value
degree I-Lab_value
pansystolic B-Sign_symptom
murmur I-Sign_symptom
at O
the O
left B-Biological_structure
border I-Biological_structure
of I-Biological_structure
the I-Biological_structure
stern I-Biological_structure
. O

The O
jugular B-Biological_structure
veins I-Biological_structure
were O
dilated B-Sign_symptom
. O

The O
patient O
complained O
of O
pain B-Sign_symptom
in O
the O
upper B-Biological_structure
right I-Biological_structure
abdominal I-Biological_structure
region I-Biological_structure
, O
enhanced B-Detailed_description
by I-Detailed_description
palpation I-Detailed_description
. O

The O
liver B-Diagnostic_procedure
margin I-Diagnostic_procedure
was O
tender B-Texture
, O
round B-Shape
, O
of O
6 B-Distance
cm I-Distance
below I-Distance
the I-Distance
costal I-Distance
rib I-Distance
, O
with O
a O
smooth B-Texture
liver B-Diagnostic_procedure
surface I-Diagnostic_procedure
. O

The O
spleen O
could O
not O
be O
felt O
. O

EKG B-Diagnostic_procedure
: O
atrial B-Sign_symptom
fibrillation I-Sign_symptom
of O
80/min B-Lab_value
, O
right B-Sign_symptom
bundle I-Sign_symptom
branch I-Sign_symptom
block I-Sign_symptom
, O
infero-lateral B-Biological_structure
ischemia B-Sign_symptom
. O

Transabdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
homogenous B-Detailed_description
, O
enlarged B-Sign_symptom
liver I-Sign_symptom
. O

The O
suprahepatic B-Biological_structure
veins I-Biological_structure
were O
dilated B-Sign_symptom
, O
as O
well O
as O
the O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
( O
30 B-Lab_value
mm I-Lab_value
, O
without O
respiratory O
variations O
) O
. O

Transthoracic B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
revealed O
a O
dilated B-Sign_symptom
right B-Biological_structure
atrium I-Biological_structure
of O
74,2 B-Lab_value
mm I-Lab_value
( O
Figure O
1 O
) O
, O
dilated B-Sign_symptom
left B-Biological_structure
atrium I-Biological_structure
of O
55,2 B-Lab_value
mm I-Lab_value
, O
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
of O
64/72 B-Lab_value
,3 I-Lab_value
mm I-Lab_value
, O
dilated B-Sign_symptom
right B-Biological_structure
ventricle I-Biological_structure
of O
44,4 B-Lab_value
mm I-Lab_value
. O

Atrial B-Disease_disorder
septal I-Disease_disorder
defect I-Disease_disorder
ostium B-Detailed_description
secundum I-Detailed_description
type I-Detailed_description
, O
of O
6 B-Distance
cm I-Distance
( O
Figure O
2 O
) O
, O
with O
left B-Sign_symptom
– I-Sign_symptom
to I-Sign_symptom
– I-Sign_symptom
right I-Sign_symptom
shunt I-Sign_symptom
. O

Severe B-Severity
tricuspid B-Disease_disorder
insufficiency I-Disease_disorder
with O
maximum O
gradient O
of O
55,4 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

4th B-Lab_value
degree I-Lab_value
mitral B-Disease_disorder
insufficiency I-Disease_disorder
. O

Severe B-Severity
pulmonary B-Biological_structure
hypertension B-Sign_symptom
of O
75 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

The O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
29 B-Lab_value
% I-Lab_value
. O

Atrial B-Sign_symptom
fibrillation I-Sign_symptom
. O

Interventricular B-Biological_structure
sept I-Biological_structure
with O
paradoxical B-Sign_symptom
motion I-Sign_symptom
. O

Flattening B-Sign_symptom
of O
the O
interventricular B-Biological_structure
septum I-Biological_structure
( O
Figure O
3 O
) O
. O

The O
diagnosis O
was O
IVth B-Lab_value
degree I-Lab_value
chronic B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
NYHA O
. O

Atrial B-Other_event
septal I-Other_event
defect I-Other_event
ostium I-Other_event
secundum I-Other_event
type I-Other_event
with I-Other_event
left I-Other_event
– I-Other_event
to I-Other_event
– I-Other_event
right I-Other_event
shunt I-Other_event
. I-Other_event

Severe B-Other_event
tricuspid I-Other_event
insufficiency I-Other_event
. I-Other_event

4th B-Other_event
degree I-Other_event
mitral I-Other_event
insufficiency I-Other_event
. I-Other_event

Severe B-Other_event
pulmonary I-Other_event
hypertension I-Other_event
of I-Other_event
75 I-Other_event
mm I-Other_event
Hg I-Other_event
. I-Other_event

Chronic B-Other_event
atrial I-Other_event
fibrillation I-Other_event
. I-Other_event

Right B-Other_event
bundle I-Other_event
branch I-Other_event
block I-Other_event
. O

An O
81-year-old B-Age
female B-Sex
with O
hypertension B-Sign_symptom
and O
gout B-Disease_disorder
was O
admitted B-Clinical_event
to O
Taichung B-Nonbiological_location
Veterans I-Nonbiological_location
General I-Nonbiological_location
Hospital I-Nonbiological_location
due O
to O
abdominal B-Biological_structure
pain B-Sign_symptom
and O
hematemesis B-Sign_symptom
. O

She O
began O
to O
suffer O
from O
intermittent B-Detailed_description
epigastralgia B-Sign_symptom
more B-Date
than I-Date
10 I-Date
years I-Date
ago I-Date
, O
and O
a O
4 B-Distance
cm I-Distance
gastric B-Biological_structure
tumor B-Sign_symptom
was O
found O
. O

The O
abdominal B-Biological_structure
pain B-Sign_symptom
got B-Lab_value
worse I-Lab_value
2 B-Date
years I-Date
before I-Date
admission O
, O
and O
she O
went B-Clinical_event
to O
a O
local B-Nonbiological_location
hospital I-Nonbiological_location
where O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
revealed O
a O
gastric B-Biological_structure
tumor B-Sign_symptom
about O
6 B-Distance
cm I-Distance
in O
length O
with O
well-circumscribed B-Detailed_description
calcification I-Detailed_description
( O
figure O
1 O
) O
. O

Surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
suggested O
, O
but O
she O
declined O
. O

About O
10 B-Date
days I-Date
before I-Date
admission O
, O
tarry B-Sign_symptom
stool I-Sign_symptom
passage O
was O
noted O
, O
and O
bloody B-Sign_symptom
vomitus I-Sign_symptom
was O
found O
1 B-Date
day I-Date
later I-Date
. O

UGI B-Diagnostic_procedure
scope I-Diagnostic_procedure
revealed O
submucosal B-Biological_structure
gastric B-Biological_structure
tumor B-Sign_symptom
with O
central B-Detailed_description
ulceration I-Detailed_description
and O
she O
was O
then O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
upper B-Biological_structure
abdominal I-Biological_structure
tenderness B-Sign_symptom
with O
mild B-Severity
muscle B-Biological_structure
guarding B-Sign_symptom
. O

The O
plain B-Detailed_description
radiography B-Diagnostic_procedure
showed O
an O
irregular B-Shape
shape I-Shape
calcification B-Sign_symptom
over O
upper B-Biological_structure
abdomen I-Biological_structure
. O

UGI B-Diagnostic_procedure
scope I-Diagnostic_procedure
revealed O
deep B-Biological_structure
gastric I-Biological_structure
ulcer B-Sign_symptom
with O
foreign B-Sign_symptom
body I-Sign_symptom
. O

CT B-Diagnostic_procedure
scan O
showed O
an O
irregularly B-Shape
shaped I-Shape
space-occupying B-Detailed_description
lesion B-Sign_symptom
in O
front O
of O
the O
stomach B-Biological_structure
with O
plate B-Detailed_description
calcifications I-Detailed_description
and O
localized B-Detailed_description
free B-Sign_symptom
air I-Sign_symptom
( O
figures O
2 O
and O
3 O
) O
. O

Under O
the O
impression O
of O
perforated O
gastric O
tumor O
, O
emergent B-Detailed_description
laparotomy B-Diagnostic_procedure
was O
performed O
. O

An O
infiltrative B-Detailed_description
mass B-Sign_symptom
between O
the O
stomach B-Biological_structure
and O
transverse B-Biological_structure
colon I-Biological_structure
was O
noted O
during O
operation O
. O

A O
sharp B-Detailed_description
, O
bone-like B-Detailed_description
and O
thick B-Detailed_description
calcified B-Sign_symptom
plate I-Sign_symptom
penetrating O
into O
the O
gastric B-Biological_structure
mucosa I-Biological_structure
and O
pericolic B-Biological_structure
soft I-Biological_structure
tissue I-Biological_structure
was O
observed O
. O

A O
submucosal B-Biological_structure
tumor B-Sign_symptom
about O
2.3 B-Distance
cm I-Distance
in O
size O
adherent O
to O
the O
calcified B-Coreference
plate I-Coreference
was O
also O
noted O
( O
figures O
4 O
and O
5 O
) O
. O

Distal B-Detailed_description
subtotal B-Detailed_description
gastrectomy B-Therapeutic_procedure
and O
partial B-Detailed_description
colectomy B-Therapeutic_procedure
were O
performed O
. O

The O
patient O
was O
discharged B-Clinical_event
13 B-Date
days I-Date
after I-Date
operation O
uneventfully O
. O

Microscopically B-Diagnostic_procedure
, O
spindle-shaped B-Shape
tumor B-Sign_symptom
cells I-Sign_symptom
with O
low B-Lab_value
mitotic B-Diagnostic_procedure
frequency I-Diagnostic_procedure
( O
4/50 B-Lab_value
HPF I-Lab_value
) O
were O
found O
. O

Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
of O
the O
tumor B-Coreference
demonstrated O
diffusely B-Lab_value
strong I-Lab_value
positive I-Lab_value
reactivity O
for O
CD B-Diagnostic_procedure
117 I-Diagnostic_procedure
, O
positive B-Lab_value
reactivity O
for O
CD34 B-Diagnostic_procedure
, O
but O
negative B-Lab_value
reactivity O
for O
S100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
and O
desmin B-Diagnostic_procedure
. O

The O
diagnosis O
of O
the O
tumor O
was O
established O
as O
GIST B-Disease_disorder
. O

Due O
to O
the O
small O
size O
and O
the O
paucity O
of O
mitotic O
figures O
of O
the O
tumor O
located O
in O
the O
stomach O
, O
it O
was O
classified O
as O
very B-Lab_value
low I-Lab_value
risk I-Lab_value
[ O
4 O
] O
. O

Sporadic O
GIST O
was O
impressed O
due O
to O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
GIST I-Family_history
nor O
other O
GIST O
presented O
in O
this O
patient O
. O

A O
33 B-Age
- I-Age
year I-Age
old I-Age
woman B-Sex
presented B-Clinical_event
to O
our O
cardiology B-Nonbiological_location
service I-Nonbiological_location
with O
signs O
and O
symptoms O
of O
congestive B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
. O

Her O
medical B-History
history I-History
was O
unremarkable B-Detailed_description
, O
however O
a B-History
year I-History
ago I-History
and O
soon O
after O
her O
third B-Quantitative_concept
child B-Other_event
delivery I-Other_event
, O
she O
had O
been O
admitted B-Clinical_event
in O
another O
hospital B-Nonbiological_location
for O
acute B-Disease_disorder
pulmonary I-Disease_disorder
oedema I-Disease_disorder
after O
labor B-Other_event
. O

Cor B-Disease_disorder
triatriatum I-Disease_disorder
with O
obstructive O
behavior O
causing O
pulmonary B-Sign_symptom
hypertension I-Sign_symptom
had O
bee O
diagnosed B-Clinical_event
, O
while O
the O
left B-Biological_structure
ventricle I-Biological_structure
was O
structurally B-Diagnostic_procedure
and O
functionally B-Diagnostic_procedure
intact B-Lab_value
. O

The O
patient O
at O
that O
time O
denied O
surgey B-Clinical_event
and O
had O
been O
discharged B-Clinical_event
on O
medical B-Detailed_description
therapy B-Therapeutic_procedure
. O

At O
present O
admission O
the O
patient O
presented B-Clinical_event
with O
NYHA B-Diagnostic_procedure
functional I-Diagnostic_procedure
class I-Diagnostic_procedure
III B-Lab_value
, O
symptoms O
of O
heart B-Sign_symptom
failure I-Sign_symptom
and I-Sign_symptom
palpittions I-Sign_symptom
as O
a O
result O
of O
persistent B-Sign_symptom
atrial I-Sign_symptom
flutter I-Sign_symptom
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
a O
loud B-Sign_symptom
pulmonary I-Sign_symptom
component I-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
2nd I-Sign_symptom
heart I-Sign_symptom
sound I-Sign_symptom
and O
a O
diastolic B-Detailed_description
murmur B-Sign_symptom
was O
heard O
in O
the O
mitral B-Biological_structure
area I-Biological_structure
. O

Signs O
of O
right-sided B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
were O
absent O
. O

A O
transthoracic B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
revealed O
a O
moderately B-Severity
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
( O
LV B-Biological_structure
) O
, O
globally B-Detailed_description
hypokinetic B-Disease_disorder
, O
with O
severely B-Lab_value
impaired I-Lab_value
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
( O
EF B-Diagnostic_procedure
estimated O
≥ O
30 B-Lab_value
% I-Lab_value
) O
. O

Left B-Biological_structure
atrium I-Biological_structure
( O
LA B-Biological_structure
) O
was O
dilated B-Sign_symptom
, O
with O
a O
mobile B-Detailed_description
, I-Detailed_description
membrane-like I-Detailed_description
echogenic B-Sign_symptom
structure I-Sign_symptom
into O
it O
. O

Transesophageal B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
documented O
a O
fibromuscular B-Sign_symptom
membrane I-Sign_symptom
across O
the O
LA B-Coreference
, O
dividing O
it O
into O
two O
compartments B-Sign_symptom
, O
a O
proximal B-Detailed_description
one I-Detailed_description
receiving I-Detailed_description
the I-Detailed_description
pulmonary I-Detailed_description
venous I-Detailed_description
flow I-Detailed_description
and O
a O
distal B-Detailed_description
one I-Detailed_description
containing O
the O
left B-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
( O
LAA B-Biological_structure
) O
. O

The O
two O
chambers B-Coreference
communicated O
via O
a O
non-restrictive B-Detailed_description
orifice B-Biological_structure
, O
but O
the O
membrane B-Biological_structure
prolapsed B-Sign_symptom
towards O
the O
mitral B-Biological_structure
valve I-Biological_structure
inflow O
causing O
severe B-Severity
obstruction B-Sign_symptom
. O

Mitral B-Biological_structure
valve I-Biological_structure
appeared B-Diagnostic_procedure
normal B-Lab_value
, O
with O
mild B-Severity
regurgitation B-Sign_symptom
. O

Patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
( O
PFO B-Disease_disorder
) O
, O
atrial B-Disease_disorder
septal I-Disease_disorder
defect I-Disease_disorder
( O
ASD B-Disease_disorder
) O
and O
anomalous B-Sign_symptom
venous B-Biological_structure
connections I-Biological_structure
were O
ruled O
out O
and O
the O
diagnosis O
of O
cor B-Disease_disorder
triatriatum I-Disease_disorder
was O
reconfirmed O
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
of O
the O
heart O
also O
revealed O
the O
fibromuscular B-Sign_symptom
septum I-Sign_symptom
into O
the O
left B-Biological_structure
atrium I-Biological_structure
and O
the O
low B-Lab_value
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
[ O
( O
LVEF B-Diagnostic_procedure
) O
30 B-Lab_value
% I-Lab_value
, O
cardiac B-Diagnostic_procedure
index I-Diagnostic_procedure
1,6 B-Lab_value
L/min/m2 I-Lab_value
, O
cardiac B-Diagnostic_procedure
output I-Diagnostic_procedure
2,7 B-Lab_value
L/min I-Lab_value
] O
( O
figure O
1 O
) O
. O

Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
showed O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O

With O
these O
findings O
the O
patient O
was O
scheduled B-Clinical_event
for O
surgery B-Therapeutic_procedure
. O

Anesthetic B-Medication
induction O
was O
achieved O
with O
standard O
technique O
including O
administration O
of O
sodium B-Medication
pentothal I-Medication
, O
sevofluorane B-Medication
, O
fentanyl B-Medication
and O
muscle B-Medication
relaxant I-Medication
. O

Invasive B-Diagnostic_procedure
monitoring I-Diagnostic_procedure
included O
the O
use O
of O
right B-Diagnostic_procedure
radial I-Diagnostic_procedure
arterial I-Diagnostic_procedure
lines I-Diagnostic_procedure
, O
a O
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
catheter I-Diagnostic_procedure
and O
a O
foley B-Diagnostic_procedure
catheter I-Diagnostic_procedure
with O
temperature B-Diagnostic_procedure
probe I-Diagnostic_procedure
to O
measure O
bladder B-Diagnostic_procedure
temperature I-Diagnostic_procedure
as O
an O
indicator O
of O
core B-Diagnostic_procedure
body I-Diagnostic_procedure
temperature I-Diagnostic_procedure
. O

Transesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
was O
also O
instituted O
. O

Surgery O
was O
performed O
through O
a O
median B-Therapeutic_procedure
sternotomy I-Therapeutic_procedure
. O

Connection O
to O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
( O
CPB B-Therapeutic_procedure
) O
was O
achieved O
by O
standard O
ascending B-Biological_structure
aorta I-Biological_structure
and O
bicaval B-Biological_structure
cannulation B-Therapeutic_procedure
. O

Mildly B-Severity
hypothermic B-Sign_symptom
( O
32 B-Lab_value
°C I-Lab_value
) O
CPB B-Therapeutic_procedure
was O
established O
. O

Cold B-Detailed_description
blood I-Detailed_description
cardioplegia B-Therapeutic_procedure
was O
administered O
in O
an O
antegrade B-Detailed_description
fashion O
through O
the O
aortic B-Biological_structure
root I-Biological_structure
after O
clamping B-Therapeutic_procedure
the O
aorta B-Biological_structure
. O

The O
interatrial B-Biological_structure
groove I-Biological_structure
was O
developed O
and O
the O
common B-Biological_structure
pulmonary I-Biological_structure
venous I-Biological_structure
chamber I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
atrium I-Biological_structure
was O
opened B-Therapeutic_procedure
through O
a O
vertical B-Detailed_description
incision I-Detailed_description
anterior B-Biological_structure
to I-Biological_structure
the I-Biological_structure
right I-Biological_structure
pulmonary I-Biological_structure
veins I-Biological_structure
, O
exactly O
as O
for O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O

After O
insertion O
of O
a O
self-retaining B-Detailed_description
retractor B-Therapeutic_procedure
to O
facilitate O
exposure B-Therapeutic_procedure
, O
the O
diaphragm B-Biological_structure
was O
exposed B-Therapeutic_procedure
and O
the O
central B-Detailed_description
hole B-Sign_symptom
in O
it O
was O
identified O
. O

A O
preliminary B-Detailed_description
incision B-Therapeutic_procedure
out O
from O
the O
hole B-Sign_symptom
improved B-Qualitative_concept
exposure B-Therapeutic_procedure
for O
the O
definitive B-Detailed_description
excision B-Therapeutic_procedure
. O

Orifices B-Biological_structure
of O
the O
pulmonary B-Biological_structure
veins I-Biological_structure
on O
both O
sides O
were O
located B-Diagnostic_procedure
. O

Position O
of O
the O
atrial B-Biological_structure
septum I-Biological_structure
was O
also O
identified B-Diagnostic_procedure
by O
a O
small B-Qualitative_concept
opening B-Therapeutic_procedure
in O
the O
right B-Biological_structure
atrium I-Biological_structure
and O
by O
inserting O
a O
curved B-Other_entity
clamp I-Other_entity
to O
displace B-Therapeutic_procedure
the O
septum B-Biological_structure
into O
the O
common B-Biological_structure
pulmonary I-Biological_structure
venous I-Biological_structure
chamber I-Biological_structure
of O
the O
left B-Biological_structure
atrium I-Biological_structure
. O

There O
was O
no O
atrial B-Disease_disorder
septal I-Disease_disorder
defect I-Disease_disorder
or O
patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
. O

The O
diaphragm B-Biological_structure
was O
then O
easily O
completely B-Detailed_description
excised B-Therapeutic_procedure
exposing B-Therapeutic_procedure
the O
mitral B-Biological_structure
valve I-Biological_structure
( O
figure O
2 O
) O
. O

The O
left B-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
was O
closed B-Therapeutic_procedure
from O
inside O
the O
left B-Biological_structure
atrium I-Biological_structure
using O
a O
running B-Detailed_description
3-0 I-Detailed_description
polypropylene I-Detailed_description
suture I-Detailed_description
to O
prevent O
future O
thrombus B-Sign_symptom
formation I-Sign_symptom
. O

The O
atriotomy B-Therapeutic_procedure
incisions I-Therapeutic_procedure
were O
closed B-Therapeutic_procedure
, O
the O
heart B-Biological_structure
having O
been O
filled B-Other_event
with O
blood B-Biological_structure
before O
the O
last O
few O
sutures B-Therapeutic_procedure
were O
placed O
. O

The O
patient O
was O
rewarmed B-Therapeutic_procedure
, O
the O
aortic B-Biological_structure
cross-clamp B-Therapeutic_procedure
was O
removed O
and O
additional O
de-airing B-Therapeutic_procedure
was O
carried O
out O
in O
the O
usual O
manner O
. O

CPB B-Therapeutic_procedure
was O
terminated O
with O
minimal B-Detailed_description
inotropic B-Medication
support I-Medication
, O
involving O
milrinone B-Medication
and O
levophed B-Medication
with O
good B-Lab_value
hemodynamics B-Diagnostic_procedure
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
and O
the O
patient O
was O
extubated B-Therapeutic_procedure
after B-Duration
12 I-Duration
hours I-Duration
and O
discharged B-Clinical_event
from O
the O
hospital O
on O
the O
fifth B-Date
postoperative I-Date
day I-Date
. O

At O
3 B-Date
months I-Date
follow-up B-Clinical_event
, O
the O
patient O
was O
asymptomatic B-Outcome
( O
NYHA B-Diagnostic_procedure
class I-Diagnostic_procedure
I B-Lab_value
) O
, O
in O
sinus B-Lab_value
rhythm B-Diagnostic_procedure
. O

TTE B-Diagnostic_procedure
and O
MRI B-Diagnostic_procedure
revealed O
a O
mildly B-Severity
dilated B-Sign_symptom
LV B-Biological_structure
with O
great O
improvement B-Lab_value
in O
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
an O
estimated O
LVEF B-Diagnostic_procedure
of O
50 B-Lab_value
% I-Lab_value
. O

In O
February B-Date
2010 I-Date
, O
a O
77-year-old B-Age
man B-Sex
with O
a O
history O
of O
stroke B-Disease_disorder
and O
peripheral B-Disease_disorder
vascular I-Disease_disorder
disease I-Disease_disorder
presented B-Clinical_event
at O
our O
emergency B-Nonbiological_location
department I-Nonbiological_location
in O
florid B-Detailed_description
pulmonary B-Disease_disorder
edema I-Disease_disorder
. O

He O
had O
a O
6-month B-Duration
history I-Duration
of O
worsening B-History
dyspnea I-History
on I-History
exertion I-History
, O
paroxysmal B-Detailed_description
nocturnal B-History
dyspnea I-History
, O
and O
leg B-Biological_structure
edema B-History
. O

Upon O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
he O
had O
diffuse B-Detailed_description
rales B-Sign_symptom
and O
a O
murmur B-Sign_symptom
of I-Sign_symptom
aortic I-Sign_symptom
stenosis I-Sign_symptom
. O

A O
2-dimensional B-Detailed_description
Doppler I-Detailed_description
transthoracic B-Biological_structure
echocardiogram B-Diagnostic_procedure
revealed O
severe B-Severity
aortic B-Disease_disorder
valve I-Disease_disorder
stenosis I-Disease_disorder
with O
a O
peak B-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
70 B-Lab_value
mmHg I-Lab_value
and O
a O
mean B-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
45 B-Lab_value
mmHg I-Lab_value
, O
a O
calculated B-Diagnostic_procedure
aortic I-Diagnostic_procedure
valve I-Diagnostic_procedure
area I-Diagnostic_procedure
of O
0.7 B-Lab_value
cm2 I-Lab_value
, O
severe B-Severity
mitral B-Disease_disorder
regurgitation I-Disease_disorder
, O
and O
a O
severely B-Severity
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
( O
LV B-Biological_structure
) O
with O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
0.20 B-Lab_value
. O

After O
the O
pulmonary B-Disease_disorder
edema I-Disease_disorder
had O
resolved O
, O
cardiac B-Diagnostic_procedure
catheterization I-Diagnostic_procedure
confirmed O
the O
echocardiographic B-Coreference
findings I-Coreference
and O
showed O
nonobstructive B-Detailed_description
coronary B-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
. O

Given O
these O
findings O
and O
the O
patient O
's O
comorbidities O
, O
we O
decided O
on O
a O
minimally B-Detailed_description
invasive I-Detailed_description
surgical B-Therapeutic_procedure
approach I-Therapeutic_procedure
. O

The O
patient O
was O
placed O
in O
the O
supine B-Therapeutic_procedure
position I-Therapeutic_procedure
and O
underwent O
anesthetic B-Medication
induction O
and O
intubation B-Therapeutic_procedure
with O
a O
single-lumen B-Detailed_description
endotracheal I-Detailed_description
tube I-Detailed_description
and O
a O
bronchial B-Detailed_description
blocker I-Detailed_description
. O

Intraoperative O
transesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
confirmed O
the O
previous O
findings O
, O
also O
showing O
that O
the O
mitral B-Biological_structure
valve I-Biological_structure
leaflets I-Biological_structure
were O
free O
of O
significant B-Disease_disorder
disease I-Disease_disorder
and O
that O
the O
mitral B-Disease_disorder
regurgitation I-Disease_disorder
originated O
in O
the O
A2 B-Biological_structure
– I-Biological_structure
P2 I-Biological_structure
portion I-Biological_structure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
( O
Fig. O
1 O
) O
. O

The O
mitral B-Disease_disorder
regurgitation I-Disease_disorder
was O
thought O
to O
be O
functional B-Detailed_description
, O
caused O
by O
mitral B-Sign_symptom
annular I-Sign_symptom
dilation I-Sign_symptom
and O
tethering B-Sign_symptom
of O
the O
papillary B-Biological_structure
muscles I-Biological_structure
by O
the O
severely B-Severity
dilated B-Sign_symptom
LV B-Biological_structure
. O

We O
decided O
to O
perform O
edge-to-edge B-Detailed_description
repair B-Therapeutic_procedure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
from O
a O
transaortic B-Detailed_description
approach I-Detailed_description
. O

A O
femoral B-Therapeutic_procedure
platform I-Therapeutic_procedure
was O
used O
to O
establish O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
. O

A O
2 B-Distance
- I-Distance
to I-Distance
3-cm I-Distance
incision B-Therapeutic_procedure
was O
made O
in O
the O
left B-Biological_structure
inguinal I-Biological_structure
crease I-Biological_structure
. O

A O
5 B-Detailed_description
– I-Detailed_description
0 I-Detailed_description
Prolene I-Detailed_description
purse-string I-Detailed_description
suture B-Therapeutic_procedure
( O
Ethicon B-Detailed_description
Inc. I-Detailed_description
, I-Detailed_description
a I-Detailed_description
Johnson I-Detailed_description
& I-Detailed_description
Johnson I-Detailed_description
company I-Detailed_description
; I-Detailed_description
Somerville I-Detailed_description
, I-Detailed_description
NJ I-Detailed_description
) O
was O
placed O
in O
the O
femoral B-Biological_structure
artery I-Biological_structure
and I-Biological_structure
vein I-Biological_structure
. O

The O
left B-Biological_structure
femoral I-Biological_structure
artery I-Biological_structure
was O
cannulated B-Therapeutic_procedure
with O
a O
16F B-Detailed_description
– I-Detailed_description
18F I-Detailed_description
arterial I-Detailed_description
cannula I-Detailed_description
. O

The O
left B-Biological_structure
femoral I-Biological_structure
vein I-Biological_structure
was O
cannulated B-Therapeutic_procedure
with O
a O
25F B-Detailed_description
Bio-Medicus I-Detailed_description
® I-Detailed_description
femoral I-Detailed_description
venous I-Detailed_description
cannula I-Detailed_description
( O
Medtronic B-Detailed_description
, I-Detailed_description
Inc. I-Detailed_description
; I-Detailed_description
Minneapolis I-Detailed_description
, I-Detailed_description
Minn I-Detailed_description
) O
, O
which O
was O
placed O
in O
the O
superior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
with O
the O
aid O
of O
TEE B-Diagnostic_procedure
. O

We O
then O
made O
a O
4 B-Distance
- I-Distance
to I-Distance
5-cm I-Distance
transverse B-Detailed_description
parasternal I-Detailed_description
incision B-Therapeutic_procedure
over O
the O
3rd B-Biological_structure
intercostal I-Biological_structure
space I-Biological_structure
and O
transected O
the O
4th B-Biological_structure
costochondral I-Biological_structure
cartilage I-Biological_structure
to O
enable O
adequate O
exposure B-Therapeutic_procedure
of O
the O
aorta B-Biological_structure
. O

This O
interspace O
was O
chosen O
in O
the O
event O
that O
the O
left O
atrium O
needed O
to O
be O
entered O
. O

The O
pericardium B-Biological_structure
was O
opened B-Therapeutic_procedure
above B-Biological_structure
the I-Biological_structure
phrenic I-Biological_structure
nerve I-Biological_structure
and O
over B-Biological_structure
the I-Biological_structure
aorta I-Biological_structure
to O
facilitate O
exposure B-Therapeutic_procedure
. O

A O
retrograde B-Detailed_description
coronary B-Biological_structure
sinus I-Biological_structure
catheter B-Therapeutic_procedure
was O
inserted O
directly O
through O
the O
incision B-Therapeutic_procedure
, O
and O
a O
purse-string B-Detailed_description
suture B-Therapeutic_procedure
was O
placed O
in O
the O
right B-Biological_structure
atrium I-Biological_structure
. O

A O
LV B-Biological_structure
vent B-Therapeutic_procedure
was O
inserted O
via O
a O
purse-string B-Detailed_description
suture B-Therapeutic_procedure
in O
the O
right B-Biological_structure
superior I-Biological_structure
pulmonary I-Biological_structure
vein I-Biological_structure
. O

A O
transverse B-Detailed_description
aortotomy B-Therapeutic_procedure
was O
performed O
to O
expose B-Therapeutic_procedure
the O
aortic B-Biological_structure
valve I-Biological_structure
, O
which O
was O
removed B-Therapeutic_procedure
under O
direct B-Diagnostic_procedure
vision I-Diagnostic_procedure
. O

The O
A2 B-Biological_structure
and I-Biological_structure
P2 I-Biological_structure
segments I-Biological_structure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
were O
identified B-Diagnostic_procedure
, O
and O
an O
edge-to-edge B-Detailed_description
repair B-Therapeutic_procedure
was O
carried O
out O
with O
a O
5 B-Detailed_description
– I-Detailed_description
0 I-Detailed_description
Prolene I-Detailed_description
mattress I-Detailed_description
suture B-Therapeutic_procedure
that O
was O
reinforced B-Detailed_description
with I-Detailed_description
pericardial I-Detailed_description
pledgets I-Detailed_description
on O
the O
ventricular B-Biological_structure
side I-Biological_structure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
( O
Fig. O
2 O
) O
. O

Next O
, O
a O
27-mm B-Detailed_description
Hancock I-Detailed_description
® I-Detailed_description
II I-Detailed_description
bioprosthetic B-Therapeutic_procedure
aortic I-Therapeutic_procedure
valve I-Therapeutic_procedure
( O
Medtronic B-Detailed_description
) O
was O
implanted B-Therapeutic_procedure
by O
use O
of O
standard B-Detailed_description
techniques I-Detailed_description
. O

The O
aortotomy B-Therapeutic_procedure
was O
closed B-Therapeutic_procedure
in O
2-layer B-Detailed_description
fashion I-Detailed_description
, O
and O
the O
patient O
was O
weaned O
from O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
. O

The O
transected O
rib B-Biological_structure
was O
reattached B-Therapeutic_procedure
to O
the O
sternum B-Biological_structure
with O
a O
1-cm B-Detailed_description
metal I-Detailed_description
plate I-Detailed_description
( O
Synthes B-Detailed_description
, I-Detailed_description
Inc. I-Detailed_description
; I-Detailed_description
West I-Detailed_description
Chester I-Detailed_description
, I-Detailed_description
Pa I-Detailed_description
) O
, O
and O
a O
fiber B-Detailed_description
wire I-Detailed_description
was O
placed B-Therapeutic_procedure
in O
figure-8 B-Detailed_description
fashion I-Detailed_description
. O

A O
single B-Quantitative_concept
chest B-Detailed_description
tube I-Detailed_description
was O
left B-Therapeutic_procedure
in O
the O
pleural B-Biological_structure
space I-Biological_structure
. O

The O
thoracotomy B-Therapeutic_procedure
was O
closed B-Therapeutic_procedure
in O
routine B-Detailed_description
fashion I-Detailed_description
. O

Postoperative O
TEE B-Diagnostic_procedure
showed O
no O
mitral B-Disease_disorder
regurgitation I-Disease_disorder
( O
Fig. O
3 O
) O
; O
“ O
elbowing B-Sign_symptom
” O
of O
the O
anterior B-Biological_structure
leaflet I-Biological_structure
during O
mid-diastole O
due O
to O
tethering B-Sign_symptom
of O
the O
anterior B-Biological_structure
leaflet I-Biological_structure
to O
the O
posterior B-Biological_structure
leaflet I-Biological_structure
( O
Fig. O
4 O
) O
; O
and O
the O
double-orifice B-Sign_symptom
mitral B-Biological_structure
valve I-Biological_structure
that O
resulted O
from O
the O
edge-to-edge B-Detailed_description
repair B-Therapeutic_procedure
( O
Fig. O
5 O
) O
. O

After O
surgery B-Therapeutic_procedure
, O
the O
patient O
did B-Sign_symptom
well I-Sign_symptom
. O

His O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
resolved O
, O
and O
he O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
on O
postoperative B-Date
day I-Date
6 I-Date
. O

Upon O
follow-up B-Clinical_event
evaluation O
in O
March B-Date
2011 I-Date
, O
he O
was O
asymptomatic B-Sign_symptom
, O
and O
echocardiography B-Diagnostic_procedure
showed O
grade B-Lab_value
1 I-Lab_value
+ I-Lab_value
mitral B-Disease_disorder
regurgitation I-Disease_disorder
. O

A O
59-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
the O
general B-Nonbiological_location
surgery I-Nonbiological_location
department I-Nonbiological_location
of O
our O
hospital B-Nonbiological_location
for O
a O
one-month B-Duration
history I-Duration
of O
progressive B-Detailed_description
dysphagia B-Sign_symptom
for O
solids B-Detailed_description
, O
which O
was O
not O
associated O
with O
malnutrition B-Disease_disorder
or O
significant O
weight B-Sign_symptom
loss I-Sign_symptom
. O

The O
patient O
had O
recently O
undergone O
esophagogastroduodenoscopy B-Diagnostic_procedure
in O
another B-Nonbiological_location
hospital I-Nonbiological_location
, O
which O
revealed O
a O
bleeding B-Detailed_description
, O
ulcerative B-Detailed_description
lesion B-Sign_symptom
in O
the O
middle B-Detailed_description
third I-Detailed_description
of O
the O
esophagus B-Biological_structure
, O
but O
no O
biopsy B-Diagnostic_procedure
had O
been O
collected O
. O

The O
medical O
past O
history O
included O
COPD B-Disease_disorder
diagnosed O
in O
1999 B-Date
and O
a O
myocardial B-Disease_disorder
infarction I-Disease_disorder
in O
2002 B-Date
. O

The O
patient O
had O
smoked B-Activity
approximately O
25 B-Detailed_description
cigarettes I-Detailed_description
per I-Detailed_description
day I-Detailed_description
for O
several O
years O
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
chest B-Biological_structure
and O
abdomen B-Biological_structure
revealed O
stenosis B-Sign_symptom
involving O
a O
5-cm B-Distance
segment B-Detailed_description
of I-Detailed_description
the I-Detailed_description
middle I-Detailed_description
third I-Detailed_description
of O
the O
esophagus B-Biological_structure
with O
no O
other O
lesions B-Sign_symptom
in O
the O
thoracic B-Biological_structure
or I-Biological_structure
abdominal I-Biological_structure
organs I-Biological_structure
. O

Barium B-Diagnostic_procedure
studies I-Diagnostic_procedure
disclosed O
a O
swelling B-Sign_symptom
in O
the O
esophageal B-Biological_structure
wall I-Biological_structure
7 B-Distance
cm I-Distance
above B-Biological_structure
the I-Biological_structure
cardia I-Biological_structure
with O
an O
ulcerative B-Detailed_description
pattern I-Detailed_description
, O
which O
reduced B-Lab_value
the O
diameter B-Diagnostic_procedure
of O
the O
lumen B-Biological_structure
to O
5 B-Lab_value
mm I-Lab_value
. O

An O
endoscopic B-Detailed_description
biopsy B-Diagnostic_procedure
of O
the O
oesophageal B-Biological_structure
mass B-Sign_symptom
demonstrated O
poorly B-Detailed_description
differentiated I-Detailed_description
( O
G3 B-Lab_value
) O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
. O

Mid-distal B-Detailed_description
esophagectomy B-Therapeutic_procedure
was O
performed O
with O
oesophagogastric B-Therapeutic_procedure
anastomosis I-Therapeutic_procedure
and O
gastric B-Biological_structure
tube I-Biological_structure
reconstruction B-Therapeutic_procedure
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
surgical B-Coreference
specimen I-Coreference
confirmed O
the O
biopsy B-Diagnostic_procedure
diagnosis O
of O
poorly B-Detailed_description
differentiated I-Detailed_description
( O
G3 B-Lab_value
) O
SCC B-Disease_disorder
. O

The O
tumor B-Coreference
, O
which O
measured O
3 B-Distance
cm I-Distance
of I-Distance
length I-Distance
, O
had O
infiltrated B-Sign_symptom
the O
oesophageal B-Biological_structure
wall I-Biological_structure
and O
the O
surrounding O
paraesophageal B-Biological_structure
fat I-Biological_structure
. O

Surgical B-Diagnostic_procedure
margins I-Diagnostic_procedure
were O
tumor-free B-Lab_value
, O
as O
the O
seven B-Quantitative_concept
perigastric B-Biological_structure
limph-nodes I-Biological_structure
dissected B-Diagnostic_procedure
( O
pT3 B-Lab_value
N0 I-Lab_value
) O
. O

The O
postoperative B-Diagnostic_procedure
period I-Diagnostic_procedure
was O
quite O
unremarkable B-Lab_value
, O
and O
a O
contrast B-Detailed_description
enhanced I-Detailed_description
x-ray B-Diagnostic_procedure
obtained O
on O
the O
9th B-Date
POD I-Date
showed O
normal B-Lab_value
esophageal B-Diagnostic_procedure
and I-Diagnostic_procedure
gastric I-Diagnostic_procedure
transit I-Diagnostic_procedure
. O

On O
the O
14th B-Date
POD I-Date
, O
the O
patient O
was O
discharged B-Clinical_event
with O
an O
oncology B-Nonbiological_location
referral B-Clinical_event
for O
routine O
medical O
follow-up B-Clinical_event
. O

Nine B-Date
months I-Date
after I-Date
the O
operation O
, O
CT B-Diagnostic_procedure
and O
esophagogastroduodenoscopy B-Diagnostic_procedure
were O
repeated O
. O

The O
imaging B-Diagnostic_procedure
study I-Diagnostic_procedure
revealed O
mild B-Severity
splenomegaly B-Sign_symptom
with O
multiple B-Quantitative_concept
nonspecific O
nodules B-Sign_symptom
within O
the O
organ B-Biological_structure
( O
Figure O
1 O
) O
. O

The O
patient O
was O
virtually O
asymptomatic B-Sign_symptom
with O
the O
exception O
of O
a O
vague O
sensation O
of O
mild B-Severity
discomfort B-Sign_symptom
in O
the O
left B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
of I-Biological_structure
the I-Biological_structure
abdomen I-Biological_structure
. O

FNAC B-Diagnostic_procedure
of O
the O
spleen B-Biological_structure
revealed O
a O
pattern O
of O
numerous O
inflammatory B-Sign_symptom
cells I-Sign_symptom
admixed I-Sign_symptom
with I-Sign_symptom
large I-Sign_symptom
cells I-Sign_symptom
displaying O
immunohistochemical O
positivity B-Lab_value
for O
several O
cytokeratins B-Diagnostic_procedure
( O
Figure O
2 O
) O
. O

The O
specimen O
was O
Gram B-Diagnostic_procedure
stain-negative I-Diagnostic_procedure
. O

A O
bone-marrow B-Biological_structure
biopsy B-Diagnostic_procedure
was O
negative B-Lab_value
for O
metastatic B-Diagnostic_procedure
involvement I-Diagnostic_procedure
. O

The O
diagnosis O
was O
isolated O
metastases B-Disease_disorder
of O
the O
spleen B-Biological_structure
with O
inflammatory B-Detailed_description
and O
necrotic B-Detailed_description
alterations B-Sign_symptom
. O

The O
patient O
was O
referred B-Clinical_event
to O
our O
centre B-Nonbiological_location
for O
splenectomy B-Therapeutic_procedure
, O
which O
was O
performed O
as O
a O
routine O
procedure O
to O
role O
out O
, O
also O
, O
a O
spontaneous B-Detailed_description
rupture B-Sign_symptom
of O
the O
spleen B-Biological_structure
. O

On O
12th B-Date
December I-Date
2007 I-Date
, O
the O
patient O
had O
transabdominal B-Detailed_description
total B-Detailed_description
splenectomy B-Therapeutic_procedure
with O
splenic B-Biological_structure
and O
celiac B-Biological_structure
artery I-Biological_structure
lymph B-Therapeutic_procedure
node I-Therapeutic_procedure
dissection I-Therapeutic_procedure
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
. O

On O
the O
7th B-Date
postoperative I-Date
day I-Date
, O
Doppler B-Detailed_description
ultrasonography B-Diagnostic_procedure
revealed O
portal-tree B-Detailed_description
patency B-Sign_symptom
with O
no O
signs O
of O
thrombosis B-Disease_disorder
. O

Ten B-Date
days I-Date
later I-Date
, O
the O
patient O
was O
discharged B-Clinical_event
with O
a O
stable B-Lab_value
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
( O
780,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
) O
, O
Hb B-Diagnostic_procedure
10.9 B-Lab_value
g/dL I-Lab_value
, O
and O
a O
WBC B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
16,500 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
spleen B-Biological_structure
described O
multiple B-Quantitative_concept
nodules B-Sign_symptom
containing O
medium B-Detailed_description
to I-Detailed_description
large-sized I-Detailed_description
cells I-Detailed_description
, O
some B-Detailed_description
of I-Detailed_description
which I-Detailed_description
were I-Detailed_description
keratinized I-Detailed_description
. O

The O
nodules B-Sign_symptom
were O
mostly B-Texture
solid I-Texture
with O
areas B-Detailed_description
of I-Detailed_description
central I-Detailed_description
necrosis I-Detailed_description
( O
Figure O
3 O
) O
. O

The O
findings O
were O
consistent O
with O
metastases B-Disease_disorder
of O
SCC B-Disease_disorder
. O

Thereafter O
, O
the O
patient O
was O
referred B-Clinical_event
to O
the O
oncology B-Nonbiological_location
department I-Nonbiological_location
of O
our O
hospital B-Nonbiological_location
, O
where O
he O
received O
two B-Dosage
3-day I-Dosage
cycles I-Dosage
( O
separated B-Detailed_description
by I-Detailed_description
a I-Detailed_description
3-week I-Detailed_description
interval I-Detailed_description
) O
of O
systemic B-Detailed_description
chemotherapy B-Medication
based O
on O
5-fluorouracil B-Medication
( O
800 B-Dosage
mg/day I-Dosage
IV B-Administration
) O
and O
cisplatin B-Medication
( O
20 B-Dosage
mg/day I-Dosage
) O
. O

Three B-Date
months I-Date
after I-Date
the O
splenectomy B-Therapeutic_procedure
, O
multiple B-Quantitative_concept
liver B-Biological_structure
metastases B-Disease_disorder
were O
seen O
on O
the O
CT B-Diagnostic_procedure
scan O
, O
and O
cutaneous B-Biological_structure
metastases B-Disease_disorder
were O
also O
present O
. O

The O
patient O
died B-Outcome
9 B-Date
months I-Date
later I-Date
. O

A O
26-year-old B-Age
man B-Sex
of O
Portuguese B-Personal_background
descent I-Personal_background
with O
no B-History
significant I-History
past I-History
medical I-History
history I-History
presents B-Clinical_event
with O
subacute O
onset O
of O
right-sided B-Detailed_description
hemiparesis B-Sign_symptom
and O
aphasia B-Disease_disorder
, O
with O
marked B-Severity
expressive B-Detailed_description
aphasia B-Disease_disorder
, O
word-finding B-Sign_symptom
difficulty I-Sign_symptom
, O
and O
rare B-Frequency
paraphrasic B-Sign_symptom
errors I-Sign_symptom
. O

Examination B-Diagnostic_procedure
demonstrated O
right B-Biological_structure
central I-Biological_structure
facial I-Biological_structure
weakness B-Sign_symptom
, O
2 B-Lab_value
– I-Lab_value
3/5 I-Lab_value
strength B-Diagnostic_procedure
in O
the O
right B-Detailed_description
arm B-Biological_structure
and O
leg B-Biological_structure
, O
and O
dysmetria B-Sign_symptom
in O
the O
right B-Detailed_description
upper B-Detailed_description
and O
lower B-Detailed_description
extremities B-Biological_structure
. O

Reflexes B-Diagnostic_procedure
were O
hyperactive B-Lab_value
on O
the O
right B-Detailed_description
with O
a O
right-sided B-Lab_value
Babinski B-Diagnostic_procedure
response I-Diagnostic_procedure
. O

MRI B-Diagnostic_procedure
of O
the O
brain B-Biological_structure
showed O
multiple B-Detailed_description
bilateral B-Detailed_description
concentric B-Detailed_description
ring-like B-Shape
structures B-Sign_symptom
in O
the O
centrum B-Biological_structure
semiovale I-Biological_structure
and O
the O
corona B-Biological_structure
radiata I-Biological_structure
on O
T2 B-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
figure O
, O
A O
) O
, O
consistent O
with O
the O
pattern O
of O
Balo B-Disease_disorder
concentric I-Disease_disorder
sclerosis I-Disease_disorder
. O

There O
was O
associated B-Detailed_description
restricted I-Detailed_description
diffusion I-Detailed_description
in O
3 B-Lab_value
lesions B-Sign_symptom
and O
incomplete B-Detailed_description
ring I-Detailed_description
enhancement I-Detailed_description
in O
1 B-Lab_value
lesion B-Sign_symptom
. O

CSF B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
30 B-Lab_value
leukocytes B-Diagnostic_procedure
( O
79 B-Lab_value
% I-Lab_value
lymphocytes B-Diagnostic_procedure
, O
4 B-Lab_value
% I-Lab_value
monocytes B-Diagnostic_procedure
) O
, O
erythrocyte B-Diagnostic_procedure
count O
was O
850 B-Lab_value
, O
and O
oligoclonal B-Diagnostic_procedure
bands I-Diagnostic_procedure
were O
absent B-Lab_value
. O

He O
was O
treated O
with O
1 B-Dosage
g I-Dosage
of O
IV B-Administration
methylprednisolone B-Medication
daily B-Dosage
for O
5 B-Duration
days I-Duration
, O
with O
little O
improvement O
. O

He O
then O
underwent O
5 B-Lab_value
plasmapheresis B-Therapeutic_procedure
exchanges I-Therapeutic_procedure
, O
with O
significant B-Lab_value
improvement I-Lab_value
of O
motor B-Diagnostic_procedure
, O
sensory B-Diagnostic_procedure
, O
speech B-Disease_disorder
deficits I-Disease_disorder
, O
and O
gait B-Diagnostic_procedure
. O

Forty-five B-Date
days I-Date
after I-Date
discharge B-Clinical_event
, O
his O
examination B-Diagnostic_procedure
showed O
4 B-Lab_value
+ I-Lab_value
/ I-Lab_value
5 I-Lab_value
strength B-Diagnostic_procedure
in O
the O
right B-Biological_structure
intrinsic I-Biological_structure
muscles I-Biological_structure
of I-Biological_structure
the I-Biological_structure
hand I-Biological_structure
and O
a O
right-sided B-Detailed_description
positional B-Sign_symptom
tremor I-Sign_symptom
. O

Gait B-Diagnostic_procedure
and O
tandem B-Detailed_description
gait B-Diagnostic_procedure
were O
normal B-Lab_value
. O

He O
was O
placed O
on O
β-interferon-1a B-Medication
44 B-Dosage
μg I-Dosage
subcutaneously B-Administration
3 B-Dosage
times I-Dosage
a I-Dosage
week I-Dosage
, O
for O
treatment O
of O
presumed O
clinically B-Disease_disorder
isolated I-Disease_disorder
syndrome I-Disease_disorder
, O
with O
good B-Lab_value
response B-Diagnostic_procedure
. O

One B-Date
year I-Date
later I-Date
, O
his O
neurologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
essentially B-Lab_value
normal I-Lab_value
. O

There O
was O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
demyelinating I-Family_history
or I-Family_history
autoimmune I-Family_history
disorders I-Family_history
. O

His O
mother B-Subject
has O
a O
significant O
history O
of O
headaches B-Family_history
and O
early-onset B-Family_history
strokes I-Family_history
, O
and O
was O
found O
to O
be O
a O
carrier B-Family_history
of I-Family_history
the I-Family_history
Notch3 I-Family_history
mutation I-Family_history
consistent O
with O
cerebral B-Family_history
autosomal I-Family_history
dominant I-Family_history
arteriopathy I-Family_history
with I-Family_history
subcortical I-Family_history
infarcts I-Family_history
and I-Family_history
leukoencephalopathy I-Family_history
( O
CADASIL B-Family_history
) O
. O

His O
sister B-Subject
had O
a O
stroke B-Family_history
in I-Family_history
her I-Family_history
30s I-Family_history
, O
and O
a O
history O
of O
migraine B-Family_history
headaches I-Family_history
, O
but O
has O
not B-Family_history
undergone I-Family_history
medical I-Family_history
evaluation I-Family_history
. O

Testing B-Diagnostic_procedure
for I-Diagnostic_procedure
CADASIL I-Diagnostic_procedure
in O
the O
patient O
showed B-Lab_value
the O
Notch3 B-Diagnostic_procedure
mutation I-Diagnostic_procedure
associated B-Detailed_description
with I-Detailed_description
CADASIL I-Detailed_description
( O
transition B-Detailed_description
C I-Detailed_description
> I-Detailed_description
T I-Detailed_description
, I-Detailed_description
nucleotide I-Detailed_description
position I-Detailed_description
1750 I-Detailed_description
, I-Detailed_description
codon I-Detailed_description
558 I-Detailed_description
) O
. O

Skin B-Biological_structure
biopsy B-Diagnostic_procedure
showed O
electron-dense B-Detailed_description
extracellular B-Detailed_description
material B-Sign_symptom
in O
close O
apposition O
to O
the O
smooth B-Biological_structure
muscle I-Biological_structure
of I-Biological_structure
the I-Biological_structure
vascular I-Biological_structure
media1 I-Biological_structure
( O
figure O
, O
B O
) O
. O

A O
53 B-Age
year I-Age
old I-Age
female B-Sex
without B-History
significant I-History
past I-History
medical I-History
history I-History
developed O
severe B-Severity
viral B-Detailed_description
pneumonia B-Disease_disorder
, O
with O
rapid B-Detailed_description
, O
progressive B-Detailed_description
deterioration B-Lab_value
in O
her O
respiratory B-Diagnostic_procedure
status I-Diagnostic_procedure
. O

She O
developed O
ARDS B-Disease_disorder
and O
mechanical B-Therapeutic_procedure
ventilatory I-Therapeutic_procedure
management I-Therapeutic_procedure
using O
ARDS B-Detailed_description
protocol I-Detailed_description
were O
unable B-Lab_value
to I-Lab_value
maintain I-Lab_value
adequate I-Lab_value
oxygenation B-Diagnostic_procedure
. O

As O
a O
result O
, O
bedside B-Detailed_description
VV-ECMO B-Detailed_description
was O
planned O
. O

Transesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
was O
performed O
to O
visualize O
proper O
positioning B-Therapeutic_procedure
of I-Therapeutic_procedure
the I-Therapeutic_procedure
guidewire I-Therapeutic_procedure
and O
cannula B-Therapeutic_procedure
. O

Using O
the O
Seldinger B-Detailed_description
technique I-Detailed_description
, O
the O
right B-Biological_structure
internal I-Biological_structure
jugular I-Biological_structure
vein I-Biological_structure
was O
accessed O
and O
a O
guide B-Coreference
wire I-Coreference
was I-Coreference
placed I-Coreference
. O

Placement B-Coreference
of I-Coreference
the I-Coreference
guidewire I-Coreference
into O
the O
IVC B-Coreference
proved O
difficult O
due O
to O
repeated O
migration B-Detailed_description
of I-Detailed_description
the I-Detailed_description
guidewire I-Detailed_description
into O
the O
right B-Biological_structure
ventricle I-Biological_structure
. O

After O
multiple O
attempts O
, O
the O
guidewire O
was O
visualized O
to O
course O
properly O
from O
the O
SVC O
to O
the O
IVC O
. O

After O
a O
bolus B-Detailed_description
dose O
of O
5000 B-Dosage
units I-Dosage
of O
intravenous B-Administration
heparin B-Medication
was O
given O
, O
the O
right B-Biological_structure
internal I-Biological_structure
jugular I-Biological_structure
venous I-Biological_structure
access O
site O
was O
dilated B-Therapeutic_procedure
. O

Just O
as O
the O
final O
dilatation O
was O
completed O
and O
upon O
dilator B-Therapeutic_procedure
exchange I-Therapeutic_procedure
with O
simultaneous O
advancement O
of O
the O
23 B-Detailed_description
French I-Detailed_description
Avalon I-Detailed_description
cannula B-Coreference
, O
TEE B-Diagnostic_procedure
lost B-Lab_value
visualization I-Lab_value
of I-Lab_value
the I-Lab_value
guidewire I-Lab_value
. O

Multiple B-Detailed_description
premature B-Sign_symptom
ventricular I-Sign_symptom
beats I-Sign_symptom
were O
noted O
and O
immediately O
, O
a O
new O
, O
rapidly B-Detailed_description
enlarging I-Detailed_description
pericardial B-Disease_disorder
effusion I-Disease_disorder
was O
detected O
( O
Figure O
( O
Figure2 O
) O
.2 O
) O
. O

Emergent O
preparations O
were O
made O
for O
bedside O
surgical B-Therapeutic_procedure
decompression I-Therapeutic_procedure
of O
the O
pericardial B-Biological_structure
space I-Biological_structure
. O

Quickly O
the O
patient O
lost B-Lab_value
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
from O
acute B-Detailed_description
cardiac B-Disease_disorder
tamponade I-Disease_disorder
. O

The O
Avalon B-Detailed_description
cannula B-Coreference
was O
immediately O
clamped B-Detailed_description
at I-Detailed_description
the I-Detailed_description
end I-Detailed_description
but I-Detailed_description
not I-Detailed_description
removed I-Detailed_description
. O

A O
emergent O
subxiphoid B-Biological_structure
pericardial B-Therapeutic_procedure
window I-Therapeutic_procedure
was O
performed O
, O
resulting O
in O
drainage B-Sign_symptom
of O
venous B-Biological_structure
blood I-Biological_structure
and O
restoration B-Lab_value
of O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
. O

Transfusion B-Therapeutic_procedure
was O
initiated O
and O
the O
patient O
was O
emergently O
transported B-Clinical_event
to O
the O
operating B-Nonbiological_location
room I-Nonbiological_location
for O
surgical B-Diagnostic_procedure
exploration I-Diagnostic_procedure
. O

The O
Avalon B-Detailed_description
cannula B-Coreference
was O
found O
to O
have O
perforated B-Disease_disorder
the O
apex B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
ventricle I-Biological_structure
. O

The O
injury B-Coreference
was O
repaired B-Therapeutic_procedure
primarily O
and O
the O
Avalon B-Detailed_description
cannula B-Coreference
was O
repositioned O
toward O
the O
IVC B-Biological_structure
again O
by O
TEE B-Diagnostic_procedure
with O
additional B-Detailed_description
direct I-Detailed_description
manipulation I-Detailed_description
. O

VV-ECMO B-Detailed_description
was O
initiated O
and O
the O
oxygenation B-Diagnostic_procedure
improved B-Lab_value
. O

Due O
to O
excessive O
coagulopathies B-Disease_disorder
, O
the O
sternum B-Biological_structure
was O
left B-Therapeutic_procedure
open I-Therapeutic_procedure
but O
was O
closed B-Therapeutic_procedure
on O
postoperative O
day B-Date
2 I-Date
. O

From O
that O
point O
, O
she O
remained O
free O
from O
any O
cardiac B-Biological_structure
or O
infectious B-Detailed_description
complications B-Sign_symptom
and O
her O
pulmonary B-Diagnostic_procedure
condition I-Diagnostic_procedure
slowly B-Lab_value
improved I-Lab_value
. O

She O
was O
successfully O
weaned O
from O
VV-ECMO B-Detailed_description
on O
postoperative O
day B-Date
9 I-Date
and O
was O
discharged B-Clinical_event
home B-Nonbiological_location
on O
postoperative O
day B-Date
24 I-Date
without O
the O
need O
for O
home B-Therapeutic_procedure
oxygen I-Therapeutic_procedure
. O

She O
regained O
full B-Lab_value
physical B-Diagnostic_procedure
functions I-Diagnostic_procedure
at O
home O
and O
recovered O
normal B-Lab_value
pulmonary B-Diagnostic_procedure
function I-Diagnostic_procedure
by O
3 B-Date
months I-Date
following O
discharge B-Clinical_event
from O
the O
hospital B-Nonbiological_location
. O

A O
60-year-old B-Age
male B-Sex
patient O
had O
previously O
undergone O
a O
radical B-Detailed_description
resection B-History
of I-History
a I-History
T2bN0M0G3 I-History
Stage I-History
III I-History
retroperitoneal I-History
sarcoma I-History
, I-History
including I-History
right I-History
nephrectomy I-History
and I-History
cholecystectomy I-History
, I-History
in I-History
2002 I-History
. O

Pathologic B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
demonstrated O
a O
25 B-Distance
cm I-Distance
high-grade B-History
liposarcoma I-History
with O
different B-Detailed_description
histologic I-Detailed_description
components I-Detailed_description
, O
including O
myxoid B-Detailed_description
, O
round B-Detailed_description
cell I-Detailed_description
, O
well-differentiated B-Detailed_description
, O
sclerosing B-Detailed_description
and O
pleomorphic B-Detailed_description
patterns I-Detailed_description
. O

Surgical B-Diagnostic_procedure
margins I-Diagnostic_procedure
were O
negative B-Lab_value
as O
the O
tumor B-Sign_symptom
did O
not O
invade B-Sign_symptom
the O
kidney B-Biological_structure
, O
and O
since O
the O
renal B-Biological_structure
vein I-Biological_structure
and O
ureter B-Biological_structure
were O
free O
of O
tumor B-Sign_symptom
as O
well O
. O

The O
patient O
did O
not O
undergo O
any O
additional B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

Surveillance B-Detailed_description
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
in O
2007 B-Date
revealed O
an O
isolated B-Detailed_description
tumor B-Sign_symptom
recurrence I-Sign_symptom
in O
the O
retroperitoneum B-Biological_structure
. O

An O
exploratory B-Detailed_description
celiotomy B-Diagnostic_procedure
revealed O
tumor B-Sign_symptom
involvement I-Sign_symptom
of O
the O
duodenum B-Biological_structure
, O
head B-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreas I-Biological_structure
, O
superior B-Biological_structure
mesenteric I-Biological_structure
vein I-Biological_structure
, O
vena B-Biological_structure
cava I-Biological_structure
and O
left B-Biological_structure
renal I-Biological_structure
vein I-Biological_structure
with O
severe B-Severity
adhesive B-Detailed_description
changes I-Detailed_description
, O
leading O
to O
the O
intraoperative O
assessment O
of O
unresectable B-Disease_disorder
disease I-Disease_disorder
. O

Subsequently O
, O
the O
patient O
underwent O
stereotactic B-Detailed_description
body I-Detailed_description
radiation B-Therapeutic_procedure
to O
the O
retroperitoneal B-Biological_structure
tumor B-Sign_symptom
in O
five B-Dosage
fractions I-Dosage
for O
a O
total B-Dosage
dose I-Dosage
of I-Dosage
30 I-Dosage
Gy I-Dosage
, O
without O
complication B-Sign_symptom
. O

Postradiation O
imaging B-Diagnostic_procedure
revealed O
near O
complete O
resolution O
of O
the O
retroperitoneal B-Biological_structure
mass B-Sign_symptom
. O

One B-Date
year I-Date
later I-Date
, O
the O
patient O
presented B-Clinical_event
with O
weight B-Sign_symptom
loss I-Sign_symptom
, O
postprandial B-Detailed_description
abdominal B-Biological_structure
pain B-Sign_symptom
, O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
. O

Cross-sectional B-Diagnostic_procedure
imaging I-Diagnostic_procedure
revealed O
a O
7 B-Distance
cm I-Distance
mass B-Sign_symptom
with O
involvement O
of O
the O
third B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
duodenum I-Biological_structure
( O
Figure O
1 O
) O
. O

However O
, O
there O
was O
no O
obvious O
involvement B-Sign_symptom
of O
the O
pancreatic B-Biological_structure
head I-Biological_structure
or O
the O
other B-Biological_structure
structures I-Biological_structure
that O
were O
noted O
to O
be O
involved O
during O
the O
previous O
laparotomy O
. O

We O
elected O
to O
perform O
another O
resection B-Therapeutic_procedure
attempt O
, O
including O
a O
possible O
pancreatoduodenectomy B-Therapeutic_procedure
or O
retroperitoneal B-Biological_structure
vascular I-Biological_structure
resection B-Therapeutic_procedure
if O
necessary O
. O

At O
exploration B-Diagnostic_procedure
, O
the O
residual O
tumor B-Sign_symptom
was O
an O
entirely O
intraduodenal B-Biological_structure
, O
pedunculated B-Detailed_description
mass B-Coreference
at O
the O
posterior B-Biological_structure
duodenal I-Biological_structure
wall I-Biological_structure
distal O
to O
the O
ampulla B-Biological_structure
that O
filled O
the O
entire O
duodenal B-Biological_structure
lumen I-Biological_structure
. O

The O
patient O
underwent O
a O
duodenotomy B-Therapeutic_procedure
and O
stalk B-Therapeutic_procedure
transection I-Therapeutic_procedure
of O
the O
polypoid B-Detailed_description
mass B-Sign_symptom
, O
followed O
by O
partial B-Detailed_description
duodenal B-Biological_structure
resection B-Therapeutic_procedure
with O
hand-sewn B-Detailed_description
duodenojejunal B-Biological_structure
anastomosis B-Therapeutic_procedure
( O
Figure O
2 O
) O
. O

Surgical B-Diagnostic_procedure
pathology I-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
9.5 B-Distance
cm I-Distance
recurrent B-Detailed_description
high-grade B-Severity
liposarcoma B-Disease_disorder
with O
polypoid B-Detailed_description
intraluminal I-Detailed_description
growth I-Detailed_description
containing O
myxoid B-Detailed_description
, O
round B-Detailed_description
cell I-Detailed_description
, O
well-differentiated B-Detailed_description
, O
sclerosing B-Detailed_description
and O
focally B-Detailed_description
pleomorphic I-Detailed_description
areas I-Detailed_description
. O

Surgical B-Diagnostic_procedure
margins I-Diagnostic_procedure
were O
negative B-Lab_value
as O
the O
tumor B-Sign_symptom
came O
within B-Distance
0.1 I-Distance
cm I-Distance
of O
the O
stalk B-Biological_structure
margin I-Biological_structure
and O
there O
was O
no O
evidence O
of O
additional O
neoplastic B-Sign_symptom
components I-Sign_symptom
within O
the O
remaining O
resected O
duodenum B-Biological_structure
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uncomplicated B-Lab_value
, O
and O
the O
patient O
has O
demonstrated O
no O
recurrence B-Sign_symptom
up O
to O
30 B-Date
months I-Date
from I-Date
this O
resection O
. O

A O
5-year-old B-Age
Caucasian B-Personal_background
male B-Age
presented B-Clinical_event
to O
the O
Children B-Nonbiological_location
’s I-Nonbiological_location
Emergency I-Nonbiological_location
Department I-Nonbiological_location
with O
epistaxis B-Sign_symptom
, O
bleeding B-Sign_symptom
from O
the O
dental B-Therapeutic_procedure
extraction I-Therapeutic_procedure
site B-Biological_structure
and O
a O
widespread B-Detailed_description
purpuric B-Detailed_description
rash B-Sign_symptom
, O
secondary O
to O
acute B-Detailed_description
idiopathic B-Detailed_description
thrombocytopenia B-Sign_symptom
. O

Two B-Date
days I-Date
prior I-Date
to O
this O
, O
he O
developed O
a O
generalised B-Detailed_description
chickenpox B-Sign_symptom
rash I-Sign_symptom
. O

While O
in O
the O
department O
it O
was O
noted O
that O
his O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
ranged O
between B-Lab_value
50 I-Lab_value
and I-Lab_value
60 I-Lab_value
beats I-Lab_value
per I-Lab_value
min I-Lab_value
, O
he O
was O
otherwise O
haemo-dynamically B-Sign_symptom
stable I-Sign_symptom
with O
a O
normal B-Lab_value
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
and O
oxygen B-Diagnostic_procedure
saturations I-Diagnostic_procedure
in O
air B-Detailed_description
. O

He O
had O
a O
short B-Detailed_description
systolic B-Detailed_description
murmur B-Sign_symptom
grade B-Lab_value
2/6 I-Lab_value
at O
the O
left B-Biological_structure
sternal I-Biological_structure
border I-Biological_structure
. O

He O
had O
no O
clinical O
evidence O
of O
myocarditis B-Disease_disorder
or O
heart B-Disease_disorder
failure I-Disease_disorder
. O

He O
had O
extensive B-Severity
generalised B-Detailed_description
petechiae B-Sign_symptom
and O
purpuric B-Detailed_description
rash B-Sign_symptom
( O
figure O
1 O
) O
secondary O
to O
acute B-Detailed_description
thrombocytopenia B-Sign_symptom
presumed O
to O
be O
due O
to O
varicella B-Disease_disorder
infection I-Disease_disorder
. O

Apparently O
he O
was O
healthy B-Sign_symptom
prior O
to O
this O
admission O
. O

There O
was O
no B-Family_history
history I-Family_history
of I-Family_history
maternal I-Family_history
lupus I-Family_history
. O

An O
ECG B-Diagnostic_procedure
was O
performed O
which O
showed O
complete B-Severity
heart B-Disease_disorder
block I-Disease_disorder
( O
figure O
2 O
) O
. O

He O
was O
admitted B-Clinical_event
to O
the O
high B-Nonbiological_location
dependency I-Nonbiological_location
unit I-Nonbiological_location
for O
close B-Detailed_description
overnight B-Duration
monitoring B-Therapeutic_procedure
. O

The O
presumed O
diagnosis O
was O
complete O
heart B-Disease_disorder
block I-Disease_disorder
secondary O
to O
varicella B-Disease_disorder
infection I-Disease_disorder
.1 O
2 O
The O
initial O
investigation O
showed O
normal B-Lab_value
electrolytes B-Diagnostic_procedure
, O
calcium B-Diagnostic_procedure
, O
phosphate B-Diagnostic_procedure
, O
glucose B-Diagnostic_procedure
and O
magnesium B-Diagnostic_procedure
levels O
. O

The O
full B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
showed O
a O
normal B-Lab_value
haemoglobin B-Diagnostic_procedure
and O
white B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
. O

But O
the O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
low B-Lab_value
that O
is O
, O
13 B-Lab_value
× I-Lab_value
109/l I-Lab_value
. O

The O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
normalised B-Lab_value
within B-Date
10 I-Date
days I-Date
without O
any O
intervention B-Therapeutic_procedure
. O

The O
antinuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
titres O
and O
the O
autoimmune B-Diagnostic_procedure
screen I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Maternal B-Subject
autoimmune B-Detailed_description
screen I-Detailed_description
was I-Detailed_description
negative I-Detailed_description
. O

The O
echocardiogram B-Diagnostic_procedure
showed O
a O
structurally B-Sign_symptom
normal I-Sign_symptom
heart B-Biological_structure
and O
follow-up B-Clinical_event
24 B-Date
h I-Date
tape O
showed O
persistence O
of O
complete B-Severity
heart B-Disease_disorder
block I-Disease_disorder
. O

Following O
these O
investigations O
a O
diagnosis O
of O
congenital B-Detailed_description
complete B-Severity
heart B-Disease_disorder
block I-Disease_disorder
was O
made O
. O

On O
follow-up B-Clinical_event
after B-Date
6 I-Date
months I-Date
his O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
remains O
between B-Lab_value
50 I-Lab_value
and I-Lab_value
60 I-Lab_value
beats I-Lab_value
per I-Lab_value
min I-Lab_value
, O
but O
he O
remains O
asymptomatic B-Sign_symptom
without O
any O
intervention B-Therapeutic_procedure
. O

The O
need O
for O
a O
pacemaker B-Therapeutic_procedure
is O
being O
considered O
on O
follow-up B-Clinical_event
. O

The O
incidental O
finding O
of O
complete O
heart O
block O
was O
congenital O
in O
aetiology O
with O
no O
association O
with O
varicella O
infection O
or O
acute O
thrombocytopenia O
. O

This O
case O
highlights O
that O
asymptomatic O
late-presenting O
congenital O
complete O
heart O
block O
must O
be O
considered O
as O
a O
differential O
diagnosis O
in O
children O
presenting O
with O
asymptomatic O
bradycardia O
to O
the O
emergency O
department O
. O

In O
January B-Date
2009 I-Date
, O
a O
57-year-old B-Age
woman B-Sex
emergently O
presented B-Clinical_event
with O
acute B-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
. O

She O
had O
a O
1-month B-Duration
history O
of O
progressive B-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
and O
a O
gradual B-Lab_value
decrease I-Lab_value
in O
exercise B-Diagnostic_procedure
capacity I-Diagnostic_procedure
secondary O
to O
mild B-Severity
dyspnea B-Sign_symptom
. O

She O
reported O
no O
additional B-Sign_symptom
symptoms I-Sign_symptom
. O

At O
age B-Date
40 I-Date
, O
she O
had O
been O
diagnosed B-Clinical_event
with O
a O
stage B-Lab_value
IIA I-Lab_value
, B-History
T1bN1 I-History
, I-History
left-sided I-History
breast I-History
cancer I-History
. O

Initial O
treatment O
had O
included O
a O
lumpectomy B-Therapeutic_procedure
and O
axillary B-Biological_structure
node B-Therapeutic_procedure
dissection I-Therapeutic_procedure
. O

She O
subsequently O
underwent O
4 B-Dosage
cycles I-Dosage
of O
DOX B-Medication
therapy I-Medication
( O
75 B-Dosage
mg/m2 I-Dosage
) O
, O
followed O
by O
8 B-Dosage
cycles I-Dosage
of O
cyclophosphamide B-Medication
, O
methotrexate B-Medication
, O
and O
5-fluorouracil B-Medication
. O

Multigated B-Diagnostic_procedure
acquisition I-Diagnostic_procedure
scans I-Diagnostic_procedure
before O
and O
after O
chemotherapy B-Medication
showed O
normal B-Lab_value
cardiac B-Diagnostic_procedure
function I-Diagnostic_procedure
. O

After O
chemotherapy B-Medication
, O
she O
underwent O
left B-Biological_structure
whole-breast I-Biological_structure
radiation B-Therapeutic_procedure
with O
an O
axillary B-Detailed_description
boost I-Detailed_description
. O

Because O
the O
tumor B-Sign_symptom
had O
been O
estrogen B-Detailed_description
receptor-positive I-Detailed_description
, O
her O
subsequent O
medical O
regimen O
consisted O
only O
of O
anti-estrogen B-Medication
therapy I-Medication
. O

She O
took O
tamoxifen B-Medication
for O
5 B-Duration
years I-Duration
, O
and O
, O
ever O
since O
, O
the O
aromatase O
inhibitor O
letrozole B-Medication
. O

In O
the O
17 B-Duration
years I-Duration
after I-Duration
chemotherapy O
, O
she O
had O
been O
active B-Sign_symptom
and O
in O
relatively B-Lab_value
good I-Lab_value
health B-Diagnostic_procedure
. O

In O
addition O
to O
her O
other O
symptoms O
, O
she O
now O
presented O
with O
tachycardia B-Sign_symptom
, O
tachypnea B-Sign_symptom
, O
and O
hypertension B-Sign_symptom
. O

She O
had O
marked O
jugular B-Biological_structure
venous I-Biological_structure
distention B-Sign_symptom
, O
an O
S3 B-Sign_symptom
, O
pulmonary B-Sign_symptom
rales I-Sign_symptom
, O
and O
trace B-Severity
peripheral B-Detailed_description
edema B-Sign_symptom
. O

Initial O
laboratory B-Diagnostic_procedure
values I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
except O
for O
an O
elevated B-Lab_value
level O
of O
N-terminal B-Diagnostic_procedure
pro-brain I-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
> B-Lab_value
2,000 I-Lab_value
pg/mL I-Lab_value
) O
. O

Results O
of O
investigation O
into O
the O
new-onset O
cardiomyopathy B-Disease_disorder
included O
normal B-Lab_value
cardiac B-Diagnostic_procedure
enzyme I-Diagnostic_procedure
levels O
, O
an O
electrocardiogram B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
that O
revealed O
no O
ischemic B-Sign_symptom
changes I-Sign_symptom
, O
and O
a O
coronary B-Biological_structure
angiogram B-Diagnostic_procedure
of O
normal B-Lab_value
appearance O
. O

The O
ECG B-Diagnostic_procedure
showed O
sinus B-Detailed_description
tachycardia B-Sign_symptom
with O
frequent B-Frequency
premature B-Sign_symptom
ventricular I-Sign_symptom
complexes I-Sign_symptom
, O
left-axis B-Sign_symptom
deviation I-Sign_symptom
, O
left B-Biological_structure
atrial I-Biological_structure
enlargement B-Sign_symptom
, O
and O
low-voltage B-Detailed_description
QRS B-Sign_symptom
complexes I-Sign_symptom
with O
nonspecific B-Detailed_description
ST B-Sign_symptom
changes I-Sign_symptom
( O
Fig. O
1 O
) O
. O

A O
2-dimensional B-Detailed_description
echocardiogram B-Diagnostic_procedure
revealed O
a O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
LVEF B-Diagnostic_procedure
) O
of O
0.20 B-Lab_value
, O
severe B-Severity
diffuse B-Detailed_description
left B-Biological_structure
ventricular I-Biological_structure
( O
LV B-Biological_structure
) O
hypokinesis B-Sign_symptom
, O
and O
a O
mildly B-Severity
dilated B-Sign_symptom
left B-Biological_structure
atrium I-Biological_structure
. O

To O
better O
define O
the O
cause O
of O
the O
LV O
systolic O
dysfunction O
, O
cardiovascular B-Diagnostic_procedure
magnetic I-Diagnostic_procedure
resonance I-Diagnostic_procedure
( O
CMR B-Diagnostic_procedure
) O
was O
performed O
. O

It O
confirmed O
the O
LVEF B-Diagnostic_procedure
of O
0.20 B-Lab_value
. O

The O
T2-weighted B-Diagnostic_procedure
sequence I-Diagnostic_procedure
showed O
slow B-Lab_value
flow B-Diagnostic_procedure
secondary O
to O
LV B-Biological_structure
dysfunction B-Disease_disorder
, O
and O
no O
myocardial B-Biological_structure
edema B-Sign_symptom
( O
Fig. O
2A O
) O
. O

Late B-Detailed_description
gadolinium B-Diagnostic_procedure
enhancement I-Diagnostic_procedure
disclosed O
diffuse B-Detailed_description
myocardial B-Biological_structure
thinning B-Sign_symptom
and O
no O
scarring B-Sign_symptom
( O
Fig. O
2B O
) O
. O

The O
patient O
was O
treated B-Therapeutic_procedure
medically I-Therapeutic_procedure
. O

Her O
symptoms B-Sign_symptom
progressively O
improved B-Lab_value
during O
therapy B-Therapeutic_procedure
, O
which O
consisted O
of O
a O
β-blocker B-Medication
, O
an O
angiotensin-converting B-Medication
enzyme I-Medication
inhibitor I-Medication
, O
digoxin B-Medication
, O
and O
a O
diuretic B-Medication
. O

The O
therapy B-Coreference
was O
slowly O
tapered B-Lab_value
, O
and O
her O
LVEF B-Diagnostic_procedure
increased B-Lab_value
from O
0.20 B-Lab_value
to O
0.55 B-Lab_value
during O
an O
8-month B-Duration
period I-Duration
. O

All O
medications B-Medication
except O
for O
low-dose B-Dosage
metoprolol B-Medication
were O
discontinued B-Lab_value
after B-Date
1 I-Date
year I-Date
, O
and O
she O
remained O
asymptomatic B-Sign_symptom
. O

This O
16-year-old B-Age
boy B-Sex
was O
the O
first O
child O
to O
non-consanguineous B-Family_history
parents I-Family_history
. O

His B-Family_history
parents I-Family_history
and I-Family_history
two I-Family_history
younger I-Family_history
siblings I-Family_history
were I-Family_history
healthy I-Family_history
. O

He O
was O
well O
until O
starting O
school O
at O
7 B-Date
years I-Date
of I-Date
age I-Date
when O
he O
was O
found O
to O
be O
short B-Sign_symptom
in I-Sign_symptom
height I-Sign_symptom
, O
slightly B-Sign_symptom
myopic I-Sign_symptom
, O
astigmatic B-Sign_symptom
and O
to O
have O
subnormal B-Sign_symptom
visual I-Sign_symptom
acuity I-Sign_symptom
. O

Endocrinological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
were O
performed O
that O
initially O
revealed O
borderline B-Lab_value
values I-Lab_value
for O
growth B-Sign_symptom
hormone I-Sign_symptom
( I-Sign_symptom
GH I-Sign_symptom
) I-Sign_symptom
deficiency I-Sign_symptom
and O
he O
was O
therefore O
treated B-Clinical_event
for O
a O
period O
with O
GH B-Medication
without O
any O
beneficiary B-Sign_symptom
effect I-Sign_symptom
on I-Sign_symptom
his I-Sign_symptom
growth I-Sign_symptom
. O

At O
age O
16 B-Date
years I-Date
, O
height B-Sign_symptom
and I-Sign_symptom
weight I-Sign_symptom
was I-Sign_symptom
− I-Sign_symptom
3 I-Sign_symptom
SD I-Sign_symptom
below I-Sign_symptom
the I-Sign_symptom
mean I-Sign_symptom
compared O
with O
a O
standardized O
Swedish O
growth O
chart O
. O

Ophthalmological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
at O
10 B-Date
years I-Date
of I-Date
age I-Date
showed O
pigmentary B-Sign_symptom
retinopathy I-Sign_symptom
and O
optic B-Sign_symptom
atrophy I-Sign_symptom
. O

An O
electroretinogram B-Diagnostic_procedure
was O
performed O
and O
showed O
a O
severe B-Severity
rod B-Sign_symptom
cone I-Sign_symptom
dystrophy I-Sign_symptom
. O

He O
had O
decreased B-Lab_value
visual B-Sign_symptom
acuity I-Sign_symptom
, O
visual B-Sign_symptom
fields I-Sign_symptom
, O
color B-Sign_symptom
vision I-Sign_symptom
, O
and O
dark B-Sign_symptom
adaption I-Sign_symptom
. O

Nystagmus B-Sign_symptom
has O
been O
noted O
since O
14 B-Date
years I-Date
of I-Date
age I-Date
. O

A B-Date
year I-Date
later I-Date
, O
photophobia B-Sign_symptom
and O
bilateral B-Sign_symptom
cataracts I-Sign_symptom
were O
developed O
. O

The O
cataracts B-Therapeutic_procedure
were I-Therapeutic_procedure
operated I-Therapeutic_procedure
on I-Therapeutic_procedure
at O
16 B-Date
years I-Date
of I-Date
age I-Date
. O

He O
is O
now B-Date
blind B-Sign_symptom
. O

At O
14 B-Date
years I-Date
of I-Date
age I-Date
, O
he O
was O
referred O
for O
neurological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
. O

A O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
mild B-Severity
ataxia B-Sign_symptom
with I-Sign_symptom
tremor I-Sign_symptom
, O
dysmetria B-Sign_symptom
and O
gait B-Sign_symptom
instability I-Sign_symptom
together O
with O
mild B-Severity
to I-Severity
moderate I-Severity
muscle B-Sign_symptom
weakness I-Sign_symptom
, O
weak B-Severity
to I-Severity
absent I-Severity
tendon B-Sign_symptom
reflexes I-Sign_symptom
in O
the O
lower B-Biological_structure
extremities I-Biological_structure
, O
and O
exercise B-Sign_symptom
intolerance I-Sign_symptom
. O

Audiometric B-Diagnostic_procedure
investigations I-Diagnostic_procedure
revealed O
a O
mild B-Severity
bilateral B-Detailed_description
sensorineural B-Sign_symptom
hearing I-Sign_symptom
impairment I-Sign_symptom
. O

At O
15 B-Date
years I-Date
of I-Date
age I-Date
, O
he O
had O
an O
unprovoked B-Detailed_description
epileptic B-Sign_symptom
seizure I-Sign_symptom
and O
he O
has O
since O
then O
been O
treated B-Clinical_event
with O
levetiracetam B-Medication
. O

Decreased B-Sign_symptom
renal I-Sign_symptom
function I-Sign_symptom
was O
identified O
at O
15 B-Date
years I-Date
of I-Date
age I-Date
, O
with O
increased B-Lab_value
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
to O
145 B-Lab_value
μmol/l I-Lab_value
( O
reference O
interval O
30 O
– O
90 O
μmol/l O
) O
, O
proteinuria B-Sign_symptom
with O
urine B-Diagnostic_procedure
albumine I-Diagnostic_procedure
at O
244 B-Lab_value
– I-Lab_value
538 I-Lab_value
mg/l I-Lab_value
( O
reference O
interval O
< O
20 O
mg/l O
) O
, O
and O
urine B-Diagnostic_procedure
albumine/creatinine I-Diagnostic_procedure
ratio O
at O
44 B-Lab_value
– I-Lab_value
59 I-Lab_value
g/mol I-Lab_value
( O
reference O
interval O
< O
3 O
g/mol O
) O
. O

A O
renal B-Biological_structure
scintigraphy B-Diagnostic_procedure
demonstrated O
reduced B-Sign_symptom
kidney I-Sign_symptom
size I-Sign_symptom
. O

Cr51-EDTA B-Diagnostic_procedure
clearance I-Diagnostic_procedure
showed O
a O
decreased B-Lab_value
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
42 B-Lab_value
% I-Lab_value
of I-Lab_value
normal I-Lab_value
. I-Lab_value

The O
filtration B-Coreference
rate I-Coreference
decreased B-Lab_value
over O
time O
to O
29 B-Lab_value
% I-Lab_value
of I-Lab_value
normal I-Lab_value
at O
16 B-Date
years I-Date
of I-Date
age I-Date
. O

Since O
14 B-Date
years I-Date
of I-Date
age I-Date
, O
cardiac B-Diagnostic_procedure
investigations I-Diagnostic_procedure
have O
demonstrated O
hypertrophy B-Sign_symptom
of O
the O
walls B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
ventricle I-Biological_structure
( O
+3 O
SD O
compared O
with O
normal O
) O
with O
normal B-Severity
systolic B-Sign_symptom
and I-Sign_symptom
diastolic I-Sign_symptom
function I-Sign_symptom
and O
without O
obstruction B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
outflow I-Sign_symptom
. O

Mitochondrial B-Diagnostic_procedure
investigations I-Diagnostic_procedure
were O
performed O
at O
14 B-Date
years I-Date
of I-Date
age I-Date
. O

Blood B-Diagnostic_procedure
levels I-Diagnostic_procedure
of O
lactate B-Diagnostic_procedure
and O
pyruvate B-Diagnostic_procedure
were O
1.6 B-Lab_value
and O
0.096 B-Lab_value
mmol/l I-Lab_value
, O
respectively O
, O
leading O
to O
a O
ratio B-Diagnostic_procedure
of O
33 B-Lab_value
( O
reference O
interval O
< O
20 O
) O
, O
while O
cerebrospinal B-Diagnostic_procedure
fluid I-Diagnostic_procedure
( O
CSF B-Diagnostic_procedure
) O
levels O
of O
lactate B-Diagnostic_procedure
and O
pyruvate B-Diagnostic_procedure
were O
3.6 B-Lab_value
and O
0.137 B-Lab_value
mmol/l I-Lab_value
, I-Lab_value
respectively O
, O
leading O
to O
a O
lactate B-Diagnostic_procedure
to I-Diagnostic_procedure
pyruvate I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
26 B-Lab_value
. O

The O
urinary B-Diagnostic_procedure
lactate I-Diagnostic_procedure
excretion I-Diagnostic_procedure
was O
normal B-Lab_value
. O

The O
CSF B-Diagnostic_procedure
albumin I-Diagnostic_procedure
was O
increased B-Lab_value
to O
258 B-Lab_value
mg/l I-Lab_value
( O
reference O
level O
< O
225 O
mg/l O
) O
and O
he O
also O
had O
an O
increased B-Lab_value
CSF/plasma B-Diagnostic_procedure
albumin I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
7.4 B-Lab_value
( O
reference O
level O
< O
5 O
) O
. O

The O
serum B-Diagnostic_procedure
acyl I-Diagnostic_procedure
carnitine I-Diagnostic_procedure
profile I-Diagnostic_procedure
and O
muscle B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
serum B-Diagnostic_procedure
creatine I-Diagnostic_procedure
kinase I-Diagnostic_procedure
activity I-Diagnostic_procedure
was O
mildly B-Lab_value
increased I-Lab_value
to O
5.4 B-Lab_value
μkat/l I-Lab_value
( O
reference O
interval O
< O
3.5 O
μkat/l O
) O
. O

A O
51-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Biological_structure
due O
to O
severe B-Severity
congestive B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
and O
ventricular B-Biological_structure
arrhythmias B-Disease_disorder
in O
March B-Date
2008 I-Date
. O

He O
had O
been O
suffering O
from O
heart B-Disease_disorder
failure I-Disease_disorder
and O
ventricular B-Biological_structure
tachycardia B-Sign_symptom
for B-Duration
years I-Duration
despite O
receiving O
the O
conventional B-Therapeutic_procedure
treatment I-Therapeutic_procedure
( O
ie O
, O
furosemide B-Medication
, O
lisinopril B-Medication
hydrate I-Medication
, O
pimobendan B-Medication
, O
warfarin B-Medication
potassium I-Medication
, O
carvedilol B-Medication
, O
metildigoxin B-Medication
and O
amiodarone B-Medication
hydrochloride I-Medication
) O
. O

His O
height O
was O
161 B-Height
cm I-Height
and O
body O
weight O
was O
83 B-Weight
kg I-Weight
. O

Blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
110/60 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

The O
fasting B-Diagnostic_procedure
blood I-Diagnostic_procedure
glucose I-Diagnostic_procedure
was O
107 B-Lab_value
mg/dl I-Lab_value
and O
HbA1c B-Diagnostic_procedure
was O
6.3 B-Lab_value
% I-Lab_value
. O

The O
chest B-Biological_structure
x-ray B-Diagnostic_procedure
showed O
cardiomegaly B-Sign_symptom
with O
a O
cardiothoracic B-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
0.67 B-Lab_value
( O
figure O
1A O
) O
. O

ECG B-Diagnostic_procedure
, O
as O
shown O
in O
video O
1 O
, O
revealed O
a O
diffused B-Detailed_description
hypokinetic B-Sign_symptom
left I-Sign_symptom
ventricle I-Sign_symptom
with O
markedly B-Lab_value
dilated I-Lab_value
left B-Diagnostic_procedure
ventricle I-Diagnostic_procedure
dimension I-Diagnostic_procedure
( O
end-diastole B-Diagnostic_procedure
: O
95 B-Lab_value
mm I-Lab_value
) O
and O
reduced B-Lab_value
EF B-Diagnostic_procedure
( O
0.11 B-Lab_value
) O
. O

The O
coronary B-Biological_structure
angiogram B-Diagnostic_procedure
was O
normal B-Lab_value
. O

A O
myocardial B-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
that O
over B-Lab_value
50 I-Lab_value
% I-Lab_value
of I-Lab_value
cardiomyocytes I-Lab_value
were O
replaced O
by O
fibrosis B-Sign_symptom
( O
figure O
2 O
) O
. O

An O
implantable B-Detailed_description
cardioverter-defibrillator B-Therapeutic_procedure
was O
implanted O
. O

Due O
to O
the O
typical B-Lab_value
facial B-Diagnostic_procedure
appearance I-Diagnostic_procedure
and O
thickening B-Sign_symptom
of I-Sign_symptom
hands I-Sign_symptom
, O
he O
was O
referred B-Clinical_event
to O
the O
endocrinology B-Nonbiological_location
department I-Nonbiological_location
. O

The O
plasma B-Diagnostic_procedure
level I-Diagnostic_procedure
of I-Diagnostic_procedure
GH I-Diagnostic_procedure
was O
8.2 B-Lab_value
ng/ml I-Lab_value
and O
IGF-1 B-Diagnostic_procedure
was O
504 B-Lab_value
ng/ml I-Lab_value
. O

MRI B-Diagnostic_procedure
demonstrated O
a O
macroadenoma B-Disease_disorder
in O
the O
pituitary B-Biological_structure
. O

Thus O
, O
he O
was O
diagnosed O
as O
acromegaly B-Disease_disorder
. O

He O
was O
treated O
with O
octreotide B-Medication
long-acting-release B-Detailed_description
( O
LAR B-Detailed_description
) O
for O
8 B-Duration
months I-Duration
. O

Thereafter O
, O
he O
underwent O
trans-sphenoidal B-Therapeutic_procedure
surgery I-Therapeutic_procedure
in O
January B-Date
2009 I-Date
( O
figure O
3 O
) O
. O

The O
plasma B-Diagnostic_procedure
levels I-Diagnostic_procedure
of I-Diagnostic_procedure
GH I-Diagnostic_procedure
and O
IGF-1 B-Diagnostic_procedure
were O
decreased B-Lab_value
with O
octreotide B-Medication
LAR B-Detailed_description
, O
but O
basal B-Diagnostic_procedure
plasma I-Diagnostic_procedure
levels I-Diagnostic_procedure
of I-Diagnostic_procedure
GH I-Diagnostic_procedure
were O
always O
more B-Lab_value
than I-Lab_value
4 I-Lab_value
ng/ml I-Lab_value
and O
plasma B-Diagnostic_procedure
IGF-1 I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
above B-Lab_value
the I-Lab_value
appropriate I-Lab_value
age I-Lab_value
range I-Lab_value
( O
figure O
3 O
) O
. O

After O
surgery B-Coreference
, O
both O
plasma B-Diagnostic_procedure
levels I-Diagnostic_procedure
of I-Diagnostic_procedure
GH I-Diagnostic_procedure
and O
IGF-1 B-Diagnostic_procedure
further B-Lab_value
decreased I-Lab_value
. O

Basal B-Diagnostic_procedure
plasma I-Diagnostic_procedure
levels I-Diagnostic_procedure
of I-Diagnostic_procedure
GH I-Diagnostic_procedure
were O
mostly B-Lab_value
less I-Lab_value
than I-Lab_value
0.5 I-Lab_value
ng/ml I-Lab_value
and O
IGF-1 B-Diagnostic_procedure
levels O
were O
within B-Lab_value
normal I-Lab_value
ranges I-Lab_value
( O
figure O
3 O
) O
. O

With O
the O
treatment O
of O
LAR B-Coreference
, O
the O
cardiac B-Diagnostic_procedure
function I-Diagnostic_procedure
improved B-Lab_value
partially I-Lab_value
( O
cardiothoracic B-Diagnostic_procedure
ratio I-Diagnostic_procedure
= O
0.58 B-Lab_value
; O
EF B-Diagnostic_procedure
= O
0.20 B-Lab_value
in O
September B-Date
2008 I-Date
) O
. O

After O
surgery B-Coreference
, O
the O
cardiac B-Diagnostic_procedure
function I-Diagnostic_procedure
improved B-Lab_value
drastically I-Lab_value
( O
cardiothoracic B-Diagnostic_procedure
ratio I-Diagnostic_procedure
= O
0.47 B-Lab_value
; O
EF B-Diagnostic_procedure
= O
0.55 B-Lab_value
in O
April B-Date
2009 I-Date
; O
figures O
1B O
and O
and2B O
) O
.2 O
B O
) O
. O

Frequency B-Lab_value
of I-Lab_value
ventricular I-Lab_value
arrhythmias I-Lab_value
decreased I-Lab_value
and O
pimobendan B-Medication
was O
tapered O
off O
. O

A O
26-year-old B-Age
woman B-Sex
was O
seen B-Clinical_event
in O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
( O
ED B-Nonbiological_location
) O
for O
chest B-Biological_structure
pain B-Sign_symptom
and O
hypertension B-Sign_symptom
. O

She O
was O
found O
to O
have O
a O
urinary B-Biological_structure
tract I-Biological_structure
infection B-Disease_disorder
and O
was O
sent O
home O
with O
an O
antibiotic B-Medication
and O
thiazide B-Medication
diuretic B-Medication
. O

Two B-Date
days I-Date
later I-Date
, O
she O
returned O
with O
epigastric B-Biological_structure
pain B-Sign_symptom
, O
nausea B-Sign_symptom
, O
emesis B-Sign_symptom
and O
myalgias B-Sign_symptom
. O

The O
patient O
had O
no B-History
significant I-History
medical I-History
history I-History
and O
denied O
cardio-respiratory B-Sign_symptom
symptoms I-Sign_symptom
; O
however O
, O
she O
complained O
of O
a O
low B-Sign_symptom
exercise I-Sign_symptom
tolerance I-Sign_symptom
for O
the O
last B-Duration
year I-Duration
. O

There O
was O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
cardiac I-Family_history
or I-Family_history
pulmonary I-Family_history
disease I-Family_history
or I-Family_history
of I-Family_history
sudden I-Family_history
cardiac I-Family_history
death I-Family_history
. O

She O
was O
born B-Personal_background
in I-Personal_background
the I-Personal_background
USA I-Personal_background
and O
had O
neither B-History
travelled I-History
recently I-History
nor I-History
had I-History
any I-History
sick I-History
contacts I-History
. O

On O
examination O
, O
she O
was O
hypertensive B-Sign_symptom
( O
170/105 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
) O
, O
tachycardic B-Sign_symptom
( O
125 B-Lab_value
bpm I-Lab_value
) O
, O
had O
dry B-Sign_symptom
mucous B-Biological_structure
membranes I-Biological_structure
and O
appeared B-Diagnostic_procedure
ill B-Lab_value
looking O
. O

She O
was O
found O
to O
have O
an O
elevated B-Lab_value
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
of O
160 B-Lab_value
μmol/l I-Lab_value
( O
normal O
60 O
– O
110 O
μmol/l O
) O
. O

After O
receiving O
1.5 B-Volume
l O
of O
intravenous B-Administration
fluids B-Medication
for O
presumed O
volume B-Disease_disorder
depletion I-Disease_disorder
and O
prerenal B-Detailed_description
azotaemia B-Sign_symptom
she O
became O
short B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
. O

Crackles B-Sign_symptom
were O
noted O
on O
auscultation B-Diagnostic_procedure
of O
her O
chest B-Biological_structure
and O
a O
portable B-Detailed_description
chest B-Biological_structure
film B-Diagnostic_procedure
demonstrated O
hazy B-Texture
infiltrates B-Sign_symptom
that O
likely O
represented O
pulmonary B-Disease_disorder
oedema I-Disease_disorder
. O

She O
then O
developed O
hypotension B-Sign_symptom
with O
systolic B-Diagnostic_procedure
pressures I-Diagnostic_procedure
in O
the O
90s B-Lab_value
. O

Non-invasive B-Detailed_description
positive B-Detailed_description
pressure I-Detailed_description
ventilation B-Therapeutic_procedure
was O
initiated O
. O

An O
ECG B-Diagnostic_procedure
demonstrated O
sinus B-Sign_symptom
tachycardia I-Sign_symptom
with O
a O
rate B-Diagnostic_procedure
of O
130 B-Lab_value
bpm I-Lab_value
and O
minimal B-Severity
ST B-Sign_symptom
depression I-Sign_symptom
on O
the O
precordial B-Diagnostic_procedure
leads I-Diagnostic_procedure
. O

In O
consultation B-Clinical_event
with O
a O
cardiologist B-Subject
, O
the O
patient O
received O
40 B-Dosage
mg I-Dosage
of O
intravenous B-Administration
furosemide B-Medication
. O

An O
echocardiogram B-Diagnostic_procedure
demonstrated O
global B-Detailed_description
hypokinesis B-Sign_symptom
with O
a O
left-ventricular B-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
< B-Lab_value
10 I-Lab_value
% I-Lab_value
( O
see O
figure O
1 O
) O
. O

The O
patient O
was O
transferred B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
where O
she O
became O
more O
anxious B-Sign_symptom
and O
tachycardic B-Sign_symptom
to O
170 B-Lab_value
bpm I-Lab_value
. O

She O
was O
intubated B-Therapeutic_procedure
and O
sedated B-Medication
. O

Despite O
the O
placement O
of O
a O
Foley B-Detailed_description
catheter B-Therapeutic_procedure
and O
administration O
of O
intravenous B-Administration
loop I-Administration
diuretics B-Medication
, O
she O
remained O
anuric B-Sign_symptom
for O
the O
first B-Duration
12 I-Duration
h I-Duration
of O
hospitalisation B-Clinical_event
. O

She O
developed O
signs O
of O
acute B-Detailed_description
kidney B-Disease_disorder
injury I-Disease_disorder
with O
a O
creatinine B-Diagnostic_procedure
that O
increased B-Lab_value
to O
350 B-Lab_value
μmol/l I-Lab_value
within B-Time
the I-Time
first I-Time
24 I-Time
h I-Time
of O
hospitalisation B-Clinical_event
. O

She O
received O
norepinephrine B-Medication
and O
milrinone B-Medication
to O
improve B-Lab_value
cardiac B-Diagnostic_procedure
output I-Diagnostic_procedure
. O

On O
the O
second B-Date
day I-Date
of O
hospitalisation B-Clinical_event
, O
she O
was O
evaluated B-Diagnostic_procedure
by O
a O
cardiologist B-Subject
and O
cardiothoracic B-Subject
surgeon I-Subject
for O
emergent B-Detailed_description
circulatory B-Therapeutic_procedure
support I-Therapeutic_procedure
as O
she O
had O
developed O
signs O
of O
poor B-Sign_symptom
tissue I-Sign_symptom
perfusion I-Sign_symptom
with O
a O
lactic B-Sign_symptom
acidosis I-Sign_symptom
( O
8.4 B-Lab_value
mmol/l I-Lab_value
; O
normal O
< O
2.2 O
mmol/l O
) O
and O
transaminitis B-Sign_symptom
with O
aspartate B-Diagnostic_procedure
aminotransferase/alanine I-Diagnostic_procedure
transaminase I-Diagnostic_procedure
> B-Lab_value
150 I-Lab_value
IU/l I-Lab_value
( O
normal O
< O
40 O
U/l O
) O
. O

She O
was O
taken B-Clinical_event
to O
the O
cardiac B-Nonbiological_location
catheterisation I-Nonbiological_location
laboratory I-Nonbiological_location
for O
emergent B-Detailed_description
right B-Detailed_description
heart B-Therapeutic_procedure
catheterisation I-Therapeutic_procedure
and O
biopsy B-Diagnostic_procedure
to O
exclude O
acute B-Detailed_description
myocarditis B-Disease_disorder
. O

Over B-Duration
the I-Duration
next I-Duration
few I-Duration
days I-Duration
, O
she O
was O
gently B-Detailed_description
fluid B-Therapeutic_procedure
resuscitated I-Therapeutic_procedure
( O
guided B-Detailed_description
by I-Detailed_description
bioreactance I-Detailed_description
non-invasive I-Detailed_description
cardiac I-Detailed_description
output I-Detailed_description
) O
, O
the O
pressors B-Medication
were O
gradually O
weaned O
off O
and O
she O
became O
non-oliguric B-Sign_symptom
. O

She O
slowly B-Lab_value
regained I-Lab_value
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
organ B-Diagnostic_procedure
perfusion I-Diagnostic_procedure
improved B-Lab_value
with O
resolution O
of O
the O
lactic B-Sign_symptom
acidosis I-Sign_symptom
and O
a O
decrease B-Lab_value
in O
liver B-Diagnostic_procedure
transaminases I-Diagnostic_procedure
. O

On O
hospital O
day B-Date
5 I-Date
she O
was O
transferred B-Clinical_event
to O
the O
medical B-Nonbiological_location
ward I-Nonbiological_location
and O
was O
eventually O
discharged B-Clinical_event
home B-Nonbiological_location
on O
non-selective B-Detailed_description
β B-Medication
blockade I-Medication
, O
an O
ACE B-Medication
inhibitor I-Medication
and O
nitrate B-Medication
with O
planned O
follow-up B-Clinical_event
at O
the O
heart-failure B-Nonbiological_location
clinic I-Nonbiological_location
. O

The O
patient O
returned B-Clinical_event
to O
the O
ED B-Nonbiological_location
4 B-Date
days I-Date
later I-Date
with O
an O
elevated B-Lab_value
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
nausea B-Sign_symptom
and O
abdominal B-Biological_structure
pain B-Sign_symptom
. O

A O
contrast B-Diagnostic_procedure
scan I-Diagnostic_procedure
of O
her O
abdomen B-Biological_structure
revealed O
pancreatitis B-Disease_disorder
and O
an O
adrenal B-Biological_structure
mass B-Sign_symptom
. O

During O
her O
treatment B-Therapeutic_procedure
for O
pancreatitis B-Disease_disorder
she O
began O
to O
have O
paroxysms B-Sign_symptom
of O
headaches B-Sign_symptom
, O
nausea B-Sign_symptom
, O
emesis B-Sign_symptom
and O
abdominal B-Biological_structure
pain B-Sign_symptom
with O
corresponding O
hypertension B-Sign_symptom
to O
the O
220s B-Lab_value
systolic B-Detailed_description
and O
tachycardia B-Sign_symptom
to O
120s B-Lab_value
with O
a O
baseline O
systolic B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
90 B-Lab_value
– I-Lab_value
110 I-Lab_value
mm I-Lab_value
Hg I-Lab_value
( O
see O
figure O
2 O
) O
. O

Her O
urinary B-Detailed_description
and O
plasma B-Detailed_description
catecholamines B-Diagnostic_procedure
were O
elevated B-Lab_value
and O
confirmed O
on O
repeat O
testing O
. O

She O
was O
given O
aggressive B-Detailed_description
fluid B-Therapeutic_procedure
rehydration I-Therapeutic_procedure
and O
α B-Medication
and I-Medication
β I-Medication
blockade I-Medication
for O
a O
planned O
adrenalectomy B-Therapeutic_procedure
. O

Prior O
to O
surgery B-Coreference
her O
left-ventricular B-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
had O
improved B-Lab_value
to O
55 B-Lab_value
% I-Lab_value
on O
medical B-Therapeutic_procedure
management I-Therapeutic_procedure
( O
see O
figure O
1 O
) O
. O

Pathology B-Diagnostic_procedure
of O
her O
adrenal B-Biological_structure
gland I-Biological_structure
was O
consistent O
with O
a O
non-malignant B-Detailed_description
pheochromocytoma B-Disease_disorder
( O
see O
figure O
3 O
) O
. O

The O
31-year-old B-Age
white B-Personal_background
primipara B-History
with I-History
twin I-History
pregnancy I-History
was O
admitted B-Clinical_event
to O
hospital O
in O
the O
38th B-Date
week I-Date
of I-Date
gestation I-Date
with O
elevated B-Sign_symptom
blood I-Sign_symptom
pressure I-Sign_symptom
( O
150/100 B-Lab_value
mmHg I-Lab_value
) O
. O

After O
receiving O
antihypertensive B-Medication
treatment I-Medication
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
120/80 B-Lab_value
. O

All O
laboratory B-Diagnostic_procedure
variables I-Diagnostic_procedure
, I-Diagnostic_procedure
including I-Diagnostic_procedure
plasma I-Diagnostic_procedure
proteins I-Diagnostic_procedure
, O
were O
within B-Lab_value
their I-Lab_value
respective I-Lab_value
reference I-Lab_value
intervals I-Lab_value
. O

Few B-Time
hours I-Time
after I-Time
admission I-Time
to I-Time
the I-Time
hospital I-Time
the O
contractions B-Sign_symptom
started I-Sign_symptom
, O
and O
the O
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
was O
performed O
because O
of O
vertex-transverse B-Sign_symptom
presentation I-Sign_symptom
of I-Sign_symptom
twins I-Sign_symptom
. O

Liveborn B-Subject
female I-Subject
and I-Subject
male I-Subject
were O
delivered B-Therapeutic_procedure
. O

The O
postoperative B-Detailed_description
course I-Detailed_description
was O
initially O
inconspicuous B-Sign_symptom
. O

Four B-Time
hours I-Time
postpartum I-Time
she O
experienced O
sudden B-Detailed_description
epigastric B-Sign_symptom
pain I-Sign_symptom
. O

The O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
rose O
to O
190/130 B-Lab_value
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
showed O
haemolysis B-Sign_symptom
, O
thrombocytopenia B-Sign_symptom
, O
and O
an O
increase B-Lab_value
in O
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
and O
aminotransferases B-Diagnostic_procedure
( O
Table O
I O
) O
. O

Intravenous B-Administration
magnesium B-Medication
sulphate I-Medication
was O
administered O
. O

Abdominal B-Diagnostic_procedure
ultrasound I-Diagnostic_procedure
disclosed O
an O
empty B-Detailed_description
uterine B-Biological_structure
cavity I-Biological_structure
without O
placenta B-Sign_symptom
residue I-Sign_symptom
. O

Five B-Time
hours I-Time
postpartum I-Time
, O
the O
patient O
was O
transferred B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
because O
of O
poor B-Sign_symptom
urine I-Sign_symptom
output I-Sign_symptom
, O
drowsiness B-Sign_symptom
, O
and O
suspicion B-Detailed_description
of O
DIC B-Disease_disorder
. O

On O
examination B-Diagnostic_procedure
she O
was O
sleepy B-Sign_symptom
and O
disoriented B-Sign_symptom
. O

The O
combination O
of O
haemolysis B-Coreference
, O
thrombocytopenia B-Coreference
, O
and O
elevated B-Coreference
liver I-Coreference
enzymes I-Coreference
suggested O
a O
postpartum B-Disease_disorder
HELLP I-Disease_disorder
syndrome I-Disease_disorder
, O
complicated O
by O
DIC B-Coreference
. O

The O
patient O
was O
rehydrated B-Therapeutic_procedure
, O
and O
treatment B-Therapeutic_procedure
was O
instituted O
with O
fresh B-Detailed_description
frozen B-Detailed_description
plasma B-Therapeutic_procedure
, O
red B-Biological_structure
cell I-Biological_structure
transfusion B-Therapeutic_procedure
, O
fresh B-Detailed_description
platelets B-Therapeutic_procedure
, O
and O
kybernin B-Therapeutic_procedure
P I-Therapeutic_procedure
( O
antithrombin B-Coreference
III I-Coreference
) O
. O

High B-Lab_value
serum B-Diagnostic_procedure
urea I-Diagnostic_procedure
, O
creatinine B-Diagnostic_procedure
, O
and O
persistent B-Detailed_description
anuria B-Sign_symptom
were O
compatible O
with O
acute B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
. O

A O
high B-Dosage
dose I-Dosage
of O
furosemide B-Medication
failed O
to O
increase B-Therapeutic_procedure
diuresis I-Therapeutic_procedure
. O

Sixteen B-Time
hours I-Time
postpartum I-Time
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
60/40 B-Lab_value
and O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
70 B-Lab_value
% I-Lab_value
. O

Few B-Time
minutes I-Time
later I-Time
the O
patient O
had O
acute B-Detailed_description
cardiac B-Disease_disorder
arrest I-Disease_disorder
, O
and O
resuscitation B-Therapeutic_procedure
started O
. O

Resuscitation B-Coreference
was O
successful B-Detailed_description
, O
and O
normal B-Sign_symptom
heart I-Sign_symptom
action I-Sign_symptom
was O
re-established O
; O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
rose O
to O
150/110 B-Lab_value
, O
and O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
was O
90 B-Lab_value
% I-Lab_value
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
deteriorated B-Lab_value
, O
and O
development O
of O
acute B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
indicated O
the O
necessity O
of O
urgent B-Detailed_description
dialysis B-Therapeutic_procedure
. O

Following B-Time
dialysis I-Time
, O
the O
patient O
was O
stable B-Sign_symptom
, O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
98 B-Lab_value
% I-Lab_value
. O

Twenty B-Time
hours I-Time
postpartum I-Time
patient O
developed O
again O
cardiopulmonary B-Disease_disorder
arrest I-Disease_disorder
. O

Despite O
resuscitation B-Therapeutic_procedure
attempts I-Therapeutic_procedure
the O
outcome O
was O
lethal B-Outcome
. O

Due O
to O
the O
fact O
that O
death B-Coreference
occurred O
in O
the O
hospital B-Nonbiological_location
a O
short B-Time
time I-Time
after I-Time
a I-Time
surgical I-Time
intervention I-Time
, O
a O
medico-legal B-Diagnostic_procedure
autopsy I-Diagnostic_procedure
was O
ordered B-Clinical_event
. O

An O
autopsy B-Coreference
revealed O
oedema B-Sign_symptom
of O
the O
brain B-Biological_structure
and O
lungs B-Biological_structure
as O
well O
as O
dilatation B-Sign_symptom
of O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
ventricles I-Biological_structure
. O

Hydrothorax B-Sign_symptom
( O
900 B-Lab_value
mL I-Lab_value
) O
, O
hydroperitoneum B-Sign_symptom
( O
2500 B-Lab_value
mL I-Lab_value
) O
, O
and O
hydropericardium B-Sign_symptom
( O
200 B-Lab_value
mL I-Lab_value
) O
were O
present O
. O

The O
field O
of O
operation O
of O
the O
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
was O
unremarkable B-Sign_symptom
. O

Petechial B-Sign_symptom
and I-Sign_symptom
suffusional I-Sign_symptom
haemorrhages I-Sign_symptom
were O
observed O
under O
the O
pleura B-Biological_structure
, O
endocardium B-Biological_structure
, O
in O
the O
mucosae B-Biological_structure
of O
the O
renal B-Biological_structure
pelvis I-Biological_structure
, O
and O
peritoneum B-Biological_structure
of O
the O
small B-Biological_structure
and I-Biological_structure
large I-Biological_structure
bowel I-Biological_structure
. O

Histology B-Diagnostic_procedure
revealed O
periportal B-Detailed_description
hepatocellular B-Biological_structure
necrosis B-Sign_symptom
, O
bloodless B-Detailed_description
glomeruli B-Sign_symptom
with I-Sign_symptom
swollen I-Sign_symptom
and I-Sign_symptom
vacuolated I-Sign_symptom
intracapillary I-Sign_symptom
cells I-Sign_symptom
, O
as O
well O
as O
confluent B-Detailed_description
haemorrhages B-Sign_symptom
in O
kidneys B-Biological_structure
, O
liver B-Biological_structure
, O
and O
spleen B-Biological_structure
. O

Death B-Outcome
was O
attributed O
to O
multiple B-Detailed_description
organ B-Disease_disorder
failure I-Disease_disorder
due O
to O
DIC B-Disease_disorder
as O
a O
consequence O
of O
HELLP B-Disease_disorder
syndrome I-Disease_disorder
. O

A O
45-year-old B-Age
lady B-Sex
sought O
dermatology B-Clinical_event
consultation I-Clinical_event
for O
severely B-Texture
tender I-Texture
erythematous B-Detailed_description
vesicles B-Sign_symptom
and O
bullae B-Sign_symptom
over O
back B-Biological_structure
, O
chest B-Biological_structure
and O
arms B-Biological_structure
. O

These B-Coreference
were O
sudden B-Detailed_description
in I-Detailed_description
onset I-Detailed_description
associated O
with O
fever B-Sign_symptom
, O
nausea B-Sign_symptom
and O
malaise B-Sign_symptom
. O

Along O
with O
this O
she O
also O
complained O
of O
pain B-Sign_symptom
in O
upper B-Biological_structure
abdomen I-Biological_structure
. O

There O
was O
no B-History
history I-History
of I-History
receiving I-History
any I-History
drugs I-History
prior I-History
to I-History
the I-History
onset I-History
of I-History
lesions I-History
. O

She O
did O
not O
report O
any O
significant B-Detailed_description
weight B-Sign_symptom
loss I-Sign_symptom
or O
loss B-Sign_symptom
of I-Sign_symptom
appetite I-Sign_symptom
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
her O
temperature B-Diagnostic_procedure
was O
38 B-Lab_value
°C I-Lab_value
, O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
100/min B-Lab_value
and O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
126/72 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

There O
were O
multiple B-Lab_value
coalescing B-Detailed_description
vesicles B-Coreference
and O
bullae B-Coreference
over O
upper B-Biological_structure
back I-Biological_structure
, O
chest B-Biological_structure
and O
arms B-Biological_structure
distributed B-Detailed_description
symmetrically I-Detailed_description
showing O
areas O
of O
pustulation B-Sign_symptom
and O
necrosis B-Sign_symptom
. O

Surrounding B-Other_entity
them B-Coreference
were O
multiple B-Lab_value
pseudovesicular B-Detailed_description
satellite B-Detailed_description
papule B-Sign_symptom
( O
figure O
1A O
, O
B O
) O
. O

On O
per O
abdominal B-Diagnostic_procedure
examination I-Diagnostic_procedure
mild B-Severity
tenderness B-Sign_symptom
was O
present O
in O
the O
right B-Biological_structure
hypochondrium I-Biological_structure
. O

Patient O
's O
initial O
laboratory B-Diagnostic_procedure
investigations I-Diagnostic_procedure
showed O
a O
total B-Diagnostic_procedure
leucocyte I-Diagnostic_procedure
count I-Diagnostic_procedure
of O
12 B-Lab_value
000 I-Lab_value
cells/mm3 I-Lab_value
with O
75 B-Lab_value
% I-Lab_value
neutrophils I-Lab_value
. O

The O
haemoglobin B-Diagnostic_procedure
level O
was O
14.3 B-Lab_value
gm I-Lab_value
% I-Lab_value
and O
erythrocyte B-Diagnostic_procedure
sedimentation I-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
30 B-Lab_value
mm/h I-Lab_value
. O

Liver B-Diagnostic_procedure
function I-Diagnostic_procedure
test I-Diagnostic_procedure
, O
kidney B-Diagnostic_procedure
function I-Diagnostic_procedure
test I-Diagnostic_procedure
and O
C B-Diagnostic_procedure
reactive I-Diagnostic_procedure
protein I-Diagnostic_procedure
levels O
were O
within O
normal B-Lab_value
limits O
. O

Gram B-Diagnostic_procedure
stain I-Diagnostic_procedure
from O
purulent B-Diagnostic_procedure
exudates I-Diagnostic_procedure
showed O
only O
neutrophils B-Biological_structure
without O
any O
organisms B-Sign_symptom
and O
culture B-Diagnostic_procedure
did O
not O
show O
any O
growth B-Sign_symptom
after O
72 B-Duration
h I-Duration
of I-Duration
incubation I-Duration
. O

A O
lesional B-Detailed_description
skin B-Biological_structure
biopsy B-Diagnostic_procedure
taken O
from O
the O
satellite B-Detailed_description
papule B-Coreference
showed O
neutrophilic B-Sign_symptom
infiltration I-Sign_symptom
in O
dermis B-Biological_structure
with O
papillary B-Sign_symptom
dermal I-Sign_symptom
oedema I-Sign_symptom
and O
spongiosis B-Sign_symptom
( O
figure O
2A O
, O
B O
) O
. O

Abdominal B-Biological_structure
ultrasonography B-Diagnostic_procedure
revealed O
intraluminal B-Detailed_description
gall B-Biological_structure
bladder I-Biological_structure
mass B-Sign_symptom
suggestive O
of O
malignancy B-Sign_symptom
. O

On O
the O
basis O
of O
these O
findings O
a O
final O
diagnosis O
of O
SS B-Disease_disorder
associated O
with O
gall B-Coreference
bladder I-Coreference
malignancy B-Coreference
was O
made O
. O

She O
was O
started O
on O
oral B-Administration
prednisolone B-Medication
in O
dose O
of O
40 B-Dosage
mg I-Dosage
daily B-Frequency
along O
with O
symptomatic B-Detailed_description
treatment B-Medication
. O

Her O
cutaneous B-Detailed_description
lesions B-Sign_symptom
responded O
dramatically O
and O
subsided B-Detailed_description
completely I-Detailed_description
after O
1 B-Duration
week I-Duration
of O
treatment B-Medication
( O
figure O
3A O
, O
B O
) O
. O

Dose O
of O
prednisolone B-Coreference
was O
tapered B-Clinical_event
and O
an O
open B-Detailed_description
cholecystectomy B-Therapeutic_procedure
was O
performed O
. O

Histopathology B-Diagnostic_procedure
of O
excised B-Biological_structure
tissue I-Biological_structure
confirmed O
it O
to O
be O
well-differentiated B-Detailed_description
gall B-Biological_structure
bladder I-Biological_structure
adenocarcinoma B-Disease_disorder
forming O
glands B-Biological_structure
and B-Sign_symptom
papillae I-Sign_symptom
infiltrating I-Sign_symptom
the I-Sign_symptom
muscularis I-Sign_symptom
propria I-Sign_symptom
superficially I-Sign_symptom
. O

Cystic B-Biological_structure
duct I-Biological_structure
cut I-Biological_structure
margins I-Biological_structure
were O
free O
of O
tumour B-Sign_symptom
( O
figure O
2C O
, O
D O
) O
. O

Patient O
's O
postoperative B-Duration
period I-Duration
was O
uneventful B-Sign_symptom
and O
she O
was O
discharged B-Clinical_event
on O
tapering B-Dosage
doses I-Dosage
of O
prednisolone B-Coreference
with O
advice O
to O
follow-up O
periodically O
. O

A O
76-year B-Age
old I-Age
woman B-Sex
presented B-Clinical_event
with O
a O
24-month B-Duration
history I-Duration
of O
enlarging B-Lab_value
mass B-Sign_symptom
involving O
the O
back B-Biological_structure
history O
of O
trauma B-Disease_disorder
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
mass B-Sign_symptom
of O
an O
3x4 B-Area
cm I-Area
in O
diameter O
, O
localized O
in O
the O
right B-Biological_structure
inter-scapular I-Biological_structure
region I-Biological_structure
. O

The O
mass B-Coreference
was O
ulcerative B-Detailed_description
helophytic B-Detailed_description
, O
grayish B-Color
in O
colour O
, O
hard B-Texture
in O
consistency O
and O
easily O
bleeding B-Detailed_description
on I-Detailed_description
manipulation I-Detailed_description
. O

The O
remainder O
of O
the O
examination O
was O
unremarkable O
; O
no O
lymphadenopathy B-Sign_symptom
and O
no O
abdominal B-Biological_structure
masses B-Sign_symptom
were O
felt O
. O

After O
resection B-Therapeutic_procedure
, O
the O
histological B-Diagnostic_procedure
examinations I-Diagnostic_procedure
of O
the O
specimens O
have O
concluded O
for O
basal B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
. O

A O
local B-Detailed_description
recurrence B-Sign_symptom
was O
observed O
18 B-Date
months I-Date
later I-Date
; O
the O
patient O
was O
admitted B-Clinical_event
to O
our O
institution B-Nonbiological_location
for O
Lumpectomy B-Therapeutic_procedure
( O
Figure O
1 O
) O
. O

Histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
syringomatous B-Sign_symptom
pattern I-Sign_symptom
infiltrating O
the O
dermis B-Biological_structure
( O
Figure O
2 O
, O
Figure O
3 O
) O
, O
subcutis B-Biological_structure
and O
skeletal B-Biological_structure
muscle I-Biological_structure
. O

The O
neoplastic B-Coreference
epithelial I-Coreference
cells I-Coreference
were O
arranged B-Detailed_description
in I-Detailed_description
interconnecting I-Detailed_description
cords I-Detailed_description
with O
microcystic B-Detailed_description
areas I-Detailed_description
. O

Nests O
, O
cords O
, O
and O
tubules O
of O
the O
tumour B-Sign_symptom
extended O
into O
the O
dermis B-Biological_structure
and O
into O
the O
adjacent B-Biological_structure
muscle I-Biological_structure
. O

Many O
lobules B-Sign_symptom
showed O
squamous B-Detailed_description
differentiation I-Detailed_description
. O

Sclerosis B-Sign_symptom
of O
stroma B-Biological_structure
around I-Biological_structure
the I-Biological_structure
cords I-Biological_structure
was O
present O
. O

Tumour B-Sign_symptom
cells I-Sign_symptom
were O
not O
connected O
to O
the O
epidermis B-Biological_structure
. O

The O
immunohistochemical B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
positivity B-Lab_value
for O
anti-CK7 B-Diagnostic_procedure
( O
Figure O
4 O
) O
, O
AE1/AE3 B-Diagnostic_procedure
and O
negativity B-Lab_value
for O
anti B-Diagnostic_procedure
CEA I-Diagnostic_procedure
and O
anti B-Diagnostic_procedure
CK20 I-Diagnostic_procedure
. O

Based O
upon O
her O
histological O
and O
immunohistochemical O
presentation O
, O
the O
diagnosis O
of O
syringomatous B-Disease_disorder
eccrine I-Disease_disorder
carcinoma I-Disease_disorder
was O
established O
. O

Radiotherapy B-Therapeutic_procedure
of O
the O
involved O
area O
was O
performed O
( O
70 B-Dosage
Gy I-Dosage
, I-Dosage
35 I-Dosage
sessions I-Dosage
) O

A O
57-year-old B-Age
Jewish B-Personal_background
man B-Sex
with O
Crohn B-Disease_disorder
's I-Disease_disorder
disease I-Disease_disorder
( O
CD B-Disease_disorder
) O
of O
the O
ileum B-Biological_structure
diagnosed O
at O
the O
age B-Date
of I-Date
thirteen I-Date
, O
presented B-Clinical_event
with O
multiple B-Detailed_description
nonmelanoma B-Disease_disorder
skin I-Disease_disorder
cancers I-Disease_disorder
( O
NMSCs B-Disease_disorder
) O
; O
these O
had O
developed O
over B-Duration
the I-Duration
past I-Duration
16 I-Duration
years I-Duration
coinciding O
with O
the O
initiation O
of O
a O
prolonged B-Dosage
course I-Dosage
of O
the O
thiopurine B-Medication
6-mercaptopurine B-Medication
( O
mercaptopurine B-Medication
, O
6-MP B-Medication
) O
. O

He O
was O
diagnosed O
with O
a O
total O
of O
84 B-Quantitative_concept
NMSC B-Disease_disorder
: O
72 B-Quantitative_concept
NMSC B-Coreference
at O
our B-Nonbiological_location
clinic I-Nonbiological_location
, O
12 B-Quantitative_concept
from O
other B-Nonbiological_location
clinics I-Nonbiological_location
. O

He O
was O
also O
awaiting O
biopsy B-Diagnostic_procedure
and O
removal B-Therapeutic_procedure
for O
additional O
lesions B-Sign_symptom
. O

His O
CD B-Disease_disorder
was O
initially O
treated O
with O
sulfasalazine B-Medication
and O
intermittent B-Frequency
steroids B-Medication
at O
diagnosis O
, O
but O
for O
the O
past B-Duration
20 I-Duration
years I-Duration
he O
had O
been O
taking O
6-MP B-Medication
daily B-Frequency
. O

In O
the O
first B-Duration
ten I-Duration
years I-Duration
after O
beginning O
6-MP B-Medication
he O
developed O
30 B-Quantitative_concept
NMSC B-Disease_disorder
; O
14 B-Quantitative_concept
were O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
( O
SCC B-Disease_disorder
) O
and O
16 B-Quantitative_concept
were O
basal B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
( O
BCC B-Disease_disorder
) O
. O

The O
patient O
was O
then O
treated B-Therapeutic_procedure
elsewhere B-Nonbiological_location
for O
the O
subsequent B-Duration
ten I-Duration
years I-Duration
. O

This O
past B-Date
year I-Date
, O
however O
, O
he O
returned B-Clinical_event
to O
the O
clinic B-Nonbiological_location
with O
over O
100 B-Quantitative_concept
new B-Detailed_description
lesions B-Sign_symptom
suggestive O
of O
malignancy B-Disease_disorder
on O
his O
torso B-Biological_structure
and O
extremities B-Biological_structure
. O

Subsequent O
to O
this O
exam O
, O
he O
had O
42 B-Quantitative_concept
biopsy-proven B-Diagnostic_procedure
lesions B-Sign_symptom
of O
NMCS B-Disease_disorder
; O
20 B-Quantitative_concept
were O
SCC B-Disease_disorder
and O
22 B-Quantitative_concept
were O
BCC B-Disease_disorder
. O

In O
addition O
, O
three B-Quantitative_concept
of O
the O
SCCs B-Disease_disorder
were O
moderately B-Detailed_description
differentiated I-Detailed_description
and O
two B-Quantitative_concept
were O
poorly B-Detailed_description
differentiated I-Detailed_description
and O
some O
of O
his O
larger O
skin B-Disease_disorder
cancers I-Disease_disorder
have O
necessitated O
Mohs B-Therapeutic_procedure
surgery I-Therapeutic_procedure
and O
xenografting B-Therapeutic_procedure
. O

The O
largest B-Quantitative_concept
of O
his O
lesions B-Sign_symptom
was O
pretibial B-Biological_structure
and O
measured O
64x53 B-Area
mm I-Area
( O
Figure O
1 O
) O
. O

He O
was O
awaiting O
biopsy B-Diagnostic_procedure
for O
many O
other O
suspicious O
lesions B-Sign_symptom
. O

The O
patient O
had O
Fitzpatrick B-Lab_value
II I-Lab_value
skin B-Diagnostic_procedure
type I-Diagnostic_procedure
and O
admitted O
to O
excessive B-Detailed_description
sun B-History
exposure I-History
for I-History
25 I-History
years I-History
in O
Hawai‘i B-Nonbiological_location
. O

Early B-Date
on I-Date
he O
did B-History
not I-History
use I-History
sunscreen I-History
, O
and O
would O
sail B-Activity
a B-History
catamaran I-History
during I-History
peak I-History
sun I-History
hours I-History
. O

He O
also O
revealed O
that O
his O
mother B-Subject
had B-Family_history
one I-Family_history
skin I-Family_history
cancer I-Family_history
lesion I-Family_history
removed I-Family_history
and O
denied B-History
ever I-History
having I-History
been I-History
a I-History
smoker I-History
. O

Within O
the O
past B-Date
year I-Date
he O
discontinued O
6-MP B-Medication
and O
began O
using O
mesalamine B-Medication
( O
Pentasa B-Medication
) O
and O
later O
adalimumab B-Medication
( O
Humira B-Medication
) O
hoping O
to O
attenuate O
the O
progression O
of O
NMSC O
, O
and O
continued O
to O
have O
monthly B-Frequency
skin B-Diagnostic_procedure
exams I-Diagnostic_procedure
. O

Overall O
, O
he O
was O
hospitalized B-Clinical_event
16 B-Quantitative_concept
times I-Quantitative_concept
for O
his O
CD B-Disease_disorder
, O
but O
never O
required O
any O
intestinal B-Biological_structure
resection B-Therapeutic_procedure
. O

Unfortunately O
, O
in O
his O
most O
recent O
hospitalization B-Clinical_event
he O
was O
diagnosed O
with O
metastatic B-Detailed_description
adenocarcinoma B-Disease_disorder
of O
the O
small B-Biological_structure
bowel I-Biological_structure
, O
and O
passed B-Outcome
away I-Outcome
shortly B-Date
after I-Date
. O

An O
18-year-old B-Age
lady B-Sex
presented B-Clinical_event
with O
history B-History
of I-History
progressive I-History
swaying I-History
while I-History
walking I-History
, I-History
worse I-History
in I-History
night I-History
since I-History
5 I-History
years I-History
. O

Speech B-Diagnostic_procedure
was O
normal B-Lab_value
and O
there O
was O
not O
any O
tremulousness B-Sign_symptom
of O
upper B-Biological_structure
limbs I-Biological_structure
. O

Also O
, O
there O
was O
no B-History
history I-History
of I-History
weakness I-History
or I-History
numbness I-History
. O

The O
family O
history O
was O
significant O
as O
her B-Family_history
elder I-Family_history
sister I-Family_history
had I-Family_history
similar I-Family_history
difficulty I-Family_history
in I-Family_history
walking I-Family_history
of I-Family_history
7-year I-Family_history
duration I-Family_history
and I-Family_history
died I-Family_history
because I-Family_history
of I-Family_history
poorly I-Family_history
controlled I-Family_history
diabetes I-Family_history
mellitus I-Family_history
at I-Family_history
an I-Family_history
age I-Family_history
of I-Family_history
20 I-Family_history
years I-Family_history
. O

No B-Family_history
other I-Family_history
members I-Family_history
of I-Family_history
the I-Family_history
kin I-Family_history
were I-Family_history
affected I-Family_history
and O
there O
was O
no B-Family_history
history I-Family_history
of I-Family_history
consanguinity I-Family_history
in I-Family_history
the I-Family_history
parents I-Family_history
. O

The O
cognitive B-Diagnostic_procedure
function I-Diagnostic_procedure
was O
normal B-Lab_value
and O
her O
Mini B-Diagnostic_procedure
Mental I-Diagnostic_procedure
Status I-Diagnostic_procedure
Score I-Diagnostic_procedure
was O
30/30 B-Lab_value
. O

Visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
and O
fundus B-Diagnostic_procedure
examination I-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
extraocular B-Diagnostic_procedure
movements I-Diagnostic_procedure
including O
saccades B-Diagnostic_procedure
, O
pursuits B-Diagnostic_procedure
were O
normal B-Lab_value
, O
and O
no O
saccadic B-Disease_disorder
intrusions I-Disease_disorder
or O
nystagmus B-Disease_disorder
were O
noticed O
. O

The O
tone B-Diagnostic_procedure
and O
power B-Diagnostic_procedure
were O
normal B-Lab_value
in O
all B-Biological_structure
four I-Biological_structure
limbs I-Biological_structure
; O
however O
, O
there O
was O
generalised O
exaggeration B-Lab_value
of O
myotatic B-Diagnostic_procedure
reflexes I-Diagnostic_procedure
along O
with O
bilateral B-Sign_symptom
extensor I-Sign_symptom
plantar I-Sign_symptom
response I-Sign_symptom
. O

Vibration B-Diagnostic_procedure
and O
joint B-Diagnostic_procedure
position I-Diagnostic_procedure
sense I-Diagnostic_procedure
were O
intact B-Lab_value
but O
Romberg B-Diagnostic_procedure
's I-Diagnostic_procedure
was O
positive B-Lab_value
. O

Patient O
swayed B-Sign_symptom
to B-Detailed_description
either I-Detailed_description
side I-Detailed_description
while O
performing B-Activity
tandem I-Activity
walk I-Activity
. O

Fasting B-Detailed_description
and O
postprandial B-Detailed_description
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
levels O
were O
normal B-Lab_value
. O

Haemogram B-Diagnostic_procedure
, O
renal B-Diagnostic_procedure
, O
liver B-Diagnostic_procedure
and O
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
normal B-Lab_value
. O

Serum B-Diagnostic_procedure
vitamin I-Diagnostic_procedure
B12 I-Diagnostic_procedure
and O
folic B-Diagnostic_procedure
acid I-Diagnostic_procedure
levels O
were O
within O
normal B-Lab_value
limits O
. O

Nerve B-Diagnostic_procedure
conduction I-Diagnostic_procedure
study I-Diagnostic_procedure
showed O
absent B-Lab_value
sensory B-Diagnostic_procedure
nerve I-Diagnostic_procedure
action I-Diagnostic_procedure
potential I-Diagnostic_procedure
with O
normal B-Lab_value
distal B-Diagnostic_procedure
latency I-Diagnostic_procedure
, O
conduction B-Diagnostic_procedure
velocity I-Diagnostic_procedure
and O
amplitude B-Diagnostic_procedure
of I-Diagnostic_procedure
compound I-Diagnostic_procedure
muscle I-Diagnostic_procedure
action I-Diagnostic_procedure
potential I-Diagnostic_procedure
( O
CMAP B-Diagnostic_procedure
) O
in O
all O
nerves B-Biological_structure
trunks I-Biological_structure
. O

MRI B-Diagnostic_procedure
showed O
marked B-Severity
atrophy B-Sign_symptom
of O
the O
cervical B-Biological_structure
cord I-Biological_structure
as O
compared O
to O
cerebellum B-Biological_structure
which O
was O
normal B-Lab_value
( O
figure O
1 O
) O
. O

The O
genetic B-Diagnostic_procedure
testing I-Diagnostic_procedure
using O
PCR B-Diagnostic_procedure
disclosed O
expansion B-Sign_symptom
of I-Sign_symptom
GAA I-Sign_symptom
repeat I-Sign_symptom
in O
both B-Detailed_description
alleles I-Detailed_description
( I-Detailed_description
254 I-Detailed_description
and I-Detailed_description
298 I-Detailed_description
) I-Detailed_description
of I-Detailed_description
FXN I-Detailed_description
gene I-Detailed_description
. O

A O
variety O
of O
causes O
of O
autosomal B-Disease_disorder
recessive I-Disease_disorder
ataxias I-Disease_disorder
need O
to O
be O
considered O
in O
the O
differential O
diagnosis O
of O
FRDA B-Disease_disorder
. O

These O
were O
systemically O
excluded O
here O
. O

Ataxia B-Disease_disorder
with I-Disease_disorder
vitamin I-Disease_disorder
E I-Disease_disorder
deficiency I-Disease_disorder
( O
AVED B-Disease_disorder
) O
has O
a O
phenotype O
quite O
similar O
to O
FRDA B-Coreference
, O
though O
titubation B-Sign_symptom
and O
hyperkinesia B-Sign_symptom
are O
more O
common O
in O
AVED B-Coreference
.4 O
A O
strong B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
ataxia I-Family_history
and I-Family_history
diabetes I-Family_history
mellitus I-Family_history
in I-Family_history
elder I-Family_history
sister I-Family_history
favoured O
FRDA B-Coreference
. O

Ataxia B-Disease_disorder
with I-Disease_disorder
oculomotor I-Disease_disorder
apraxia I-Disease_disorder
( O
AOA B-Disease_disorder
) O
types B-Detailed_description
1 I-Detailed_description
and I-Detailed_description
2 I-Detailed_description
were O
not O
considered O
owing O
to O
lack O
of O
apraxia B-Sign_symptom
of I-Sign_symptom
ocular I-Sign_symptom
movements I-Sign_symptom
, O
distal B-Sign_symptom
amyotrophy I-Sign_symptom
( O
severe B-Severity
axonal B-Sign_symptom
sensorimotor I-Sign_symptom
polyneuropathy I-Sign_symptom
) O
, O
atrophy B-Sign_symptom
of O
cerebellum B-Biological_structure
and O
involuntary B-Sign_symptom
movements I-Sign_symptom
.5 O
Ataxia B-Disease_disorder
telengiectesia I-Disease_disorder
has O
presentation O
very O
similar O
to O
AOA B-Coreference
types I-Coreference
1 I-Coreference
and I-Coreference
2 I-Coreference
. O

Muco-cutaneous B-Sign_symptom
markers I-Sign_symptom
, O
sino-pulmonary B-Biological_structure
infections B-Sign_symptom
, O
hypogammaglobulinaemia B-Sign_symptom
and O
radiosensitivity B-Sign_symptom
along O
with O
predisposition O
to O
development O
of O
a O
variety O
of O
neoplasms B-Sign_symptom
are O
features O
of O
ataxia B-Coreference
telengiectasia I-Coreference
not O
seen O
in O
AOAs B-Coreference
and O
FRDA B-Coreference
. O

The O
other O
important O
causes O
of O
autosomal B-Disease_disorder
recessive I-Disease_disorder
spastic I-Disease_disorder
ataxia I-Disease_disorder
apart O
from O
FRDA B-Coreference
would O
be O
autosomal B-Disease_disorder
recessive I-Disease_disorder
spastic I-Disease_disorder
ataxia I-Disease_disorder
of I-Disease_disorder
Charlevoix-Saguenay I-Disease_disorder
and O
Marinesco-Sjögren B-Disease_disorder
syndrome I-Disease_disorder
. O

Charcot-Marie-Tooth B-Disease_disorder
disease I-Disease_disorder
, O
an O
inherited B-Detailed_description
polyneuropathy B-Disease_disorder
has O
gait B-Sign_symptom
ataxia I-Sign_symptom
in O
common O
with O
FRDA B-Coreference
; O
however O
, O
in O
this O
case O
, O
CMT B-Disease_disorder
was O
improbable O
due O
to O
following O
features O
in O
this O
case O
: O
lack O
of O
motor B-Sign_symptom
weakness I-Sign_symptom
, O
retained B-Sign_symptom
reflexes I-Sign_symptom
, O
bilaterally B-Sign_symptom
extensor I-Sign_symptom
plantar I-Sign_symptom
and O
pure B-Sign_symptom
sensory I-Sign_symptom
neuropathy I-Sign_symptom
on O
nerve B-Diagnostic_procedure
conduction I-Diagnostic_procedure
study I-Diagnostic_procedure
. O

Idebenone B-Medication
was O
started O
at O
a O
dose O
of O
450 B-Dosage
mg I-Dosage
twice I-Dosage
a I-Dosage
day I-Dosage
for O
its O
antioxidant B-Detailed_description
properties I-Detailed_description
. O

For O
gait O
ataxia O
, O
physiotherapy B-Therapeutic_procedure
— O
Frenkel B-Therapeutic_procedure
's I-Therapeutic_procedure
exercise I-Therapeutic_procedure
— O
was O
initiated O
. O

Blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
is O
monitored O
regularly B-Frequency
. O

At O
4 B-Date
months I-Date
, O
there O
was O
no B-Severity
significant I-Severity
change I-Severity
in O
the O
gait B-Diagnostic_procedure
difficulty I-Diagnostic_procedure
. O

A O
54 B-Age
year-old I-Age
diabetic B-History
woman B-Sex
complained O
of O
blurred B-Sign_symptom
vision I-Sign_symptom
in O
the O
left B-Biological_structure
eye I-Biological_structure
for O
5 B-Duration
days I-Duration
without O
scalp B-Biological_structure
tenderness B-Sign_symptom
or O
headache B-Sign_symptom
. O

Visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
( O
VA B-Diagnostic_procedure
) O
was O
20/20 B-Lab_value
right B-Biological_structure
eye I-Biological_structure
and O
20/30 B-Lab_value
left B-Biological_structure
eye I-Biological_structure
. O

Intraocular B-Diagnostic_procedure
pressures I-Diagnostic_procedure
were O
normal B-Lab_value
. O

Funduscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
left B-Biological_structure
optic I-Biological_structure
nerve I-Biological_structure
edema B-Sign_symptom
and O
a O
small B-Severity
disc B-Biological_structure
margin I-Biological_structure
hemorrhage B-Sign_symptom
. O

WBC B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
12,700 B-Lab_value
, O
ESR B-Diagnostic_procedure
was O
7 B-Lab_value
( O
normal O
0 O
– O
20 O
mm/hr O
) O
and O
CRP B-Diagnostic_procedure
was O
2.4 B-Lab_value
( O
normal O
0 O
– O
1.0 O
mg/dL O
) O
. O

Three B-Date
days I-Date
later I-Date
, O
she O
noted O
new O
left B-Biological_structure
eye I-Biological_structure
pain B-Sign_symptom
and O
her O
vision B-Diagnostic_procedure
declined O
to O
counting B-Lab_value
fingers I-Lab_value
. O

There O
was O
no O
pain B-Sign_symptom
on B-Detailed_description
eye I-Detailed_description
movement I-Detailed_description
. O

The O
right B-Diagnostic_procedure
pupil I-Diagnostic_procedure
was O
4 B-Distance
mm I-Distance
and O
reacted B-Lab_value
to I-Lab_value
light I-Lab_value
; O
the O
left B-Diagnostic_procedure
pupil I-Diagnostic_procedure
was O
4 B-Distance
mm I-Distance
, O
and O
there O
was O
a O
relative B-Detailed_description
left B-Biological_structure
afferent I-Biological_structure
pupillary I-Biological_structure
defect B-Sign_symptom
. O

The O
left B-Biological_structure
optic I-Biological_structure
nerve I-Biological_structure
was O
swollen B-Sign_symptom
with O
a O
few B-Detailed_description
peripapillary B-Biological_structure
nerve I-Biological_structure
fiber I-Biological_structure
layer I-Biological_structure
hemorrhages B-Sign_symptom
along O
with O
a O
cherry B-Color
red I-Color
spot B-Sign_symptom
and O
mild B-Severity
macular B-Biological_structure
edema B-Sign_symptom
consistent O
with O
central B-Disease_disorder
retinal I-Disease_disorder
artery I-Disease_disorder
occlusion I-Disease_disorder
; O
there O
were O
no O
posterior B-Biological_structure
pole I-Biological_structure
or O
peripheral B-Biological_structure
retinal I-Biological_structure
hemorrhages B-Sign_symptom
. O

Trace B-Diagnostic_procedure
cells I-Diagnostic_procedure
were O
seen B-Lab_value
in O
the O
anterior B-Biological_structure
chamber I-Biological_structure
, O
but O
not B-Lab_value
in O
the O
vitreous B-Biological_structure
fluid I-Biological_structure
. O

Repeat O
WBC B-Diagnostic_procedure
, O
ESR B-Diagnostic_procedure
and O
CRP B-Diagnostic_procedure
were O
normal B-Lab_value
. O

Treponemal B-Detailed_description
and O
Bartonella B-Detailed_description
antibodies B-Diagnostic_procedure
, O
the O
QuantiFERON-TB B-Diagnostic_procedure
test I-Diagnostic_procedure
, O
blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
, O
EKG B-Diagnostic_procedure
and O
carotid B-Biological_structure
Doppler B-Detailed_description
ultrasound B-Diagnostic_procedure
were O
unremarkable B-Lab_value
. O

Brain B-Biological_structure
contrast B-Detailed_description
MRI B-Diagnostic_procedure
demonstrated O
no B-Lab_value
optic B-Biological_structure
nerve I-Biological_structure
enhancement O
. O

Twelve B-Date
days I-Date
later I-Date
, O
left B-Biological_structure
eye I-Biological_structure
pain B-Sign_symptom
and O
vision B-Diagnostic_procedure
worsened B-Lab_value
, O
and O
the O
patient O
complained O
of O
jaw B-Biological_structure
claudication B-Sign_symptom
and O
scalp B-Biological_structure
pain B-Sign_symptom
. O

VA B-Diagnostic_procedure
declined O
to O
no B-Lab_value
light I-Lab_value
perception I-Lab_value
in O
the O
left B-Biological_structure
eye I-Biological_structure
with O
1 B-Lab_value
+ I-Lab_value
cells B-Diagnostic_procedure
and I-Diagnostic_procedure
flare I-Diagnostic_procedure
in O
anterior B-Biological_structure
chamber I-Biological_structure
and O
2 B-Lab_value
+ I-Lab_value
vitreous B-Diagnostic_procedure
cells I-Diagnostic_procedure
and I-Diagnostic_procedure
haze I-Diagnostic_procedure
. O

Funduscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
extensive B-Severity
retinal B-Biological_structure
necrosis B-Sign_symptom
and O
diffuse B-Detailed_description
hemorrhages B-Sign_symptom
with O
multiple B-Detailed_description
areas I-Detailed_description
of O
focal B-Detailed_description
venous B-Sign_symptom
beading I-Sign_symptom
( O
Fig. O
1 O
) O
, O
consistent O
with O
acute B-Disease_disorder
retinal I-Disease_disorder
necrosis I-Disease_disorder
. O

Vitreous B-Biological_structure
fluid I-Biological_structure
was O
examined O
by O
PCR B-Diagnostic_procedure
for O
amplifiable O
HSV B-Diagnostic_procedure
, O
VZV B-Diagnostic_procedure
, O
CMV B-Diagnostic_procedure
and O
toxoplasma B-Diagnostic_procedure
sequences O
and O
returned O
positive B-Lab_value
for O
VZV B-Diagnostic_procedure
DNA B-Detailed_description
. O

She O
was O
treated O
with O
a O
one-time B-Frequency
intravitreal B-Administration
injection I-Administration
of O
ganciclovir B-Medication
2000 B-Dosage
mcg/0 I-Dosage
.5 I-Dosage
ml I-Dosage
in O
the O
left B-Biological_structure
eye I-Biological_structure
, O
oral B-Administration
acyclovir B-Medication
800 B-Dosage
mg I-Dosage
5 I-Dosage
times I-Dosage
daily I-Dosage
for O
14 B-Duration
days I-Duration
and O
oral B-Administration
prednisone B-Medication
60 B-Dosage
mg I-Dosage
daily I-Dosage
for O
7 B-Duration
days I-Duration
followed O
by O
20 B-Dosage
mg I-Dosage
for O
7 B-Duration
days I-Duration
. O

Eleven B-Date
days I-Date
after I-Date
starting O
treatment O
, O
because O
she O
had O
recently O
developed O
jaw B-Biological_structure
claudication B-Sign_symptom
and O
intermittent B-Frequency
scalp B-Biological_structure
pain B-Sign_symptom
, O
a O
temporal B-Biological_structure
artery I-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
( O
Fig. O
2 O
) O
while O
immunohistochemical B-Diagnostic_procedure
analysis I-Diagnostic_procedure
demonstrated B-Lab_value
VZV B-Diagnostic_procedure
antigen I-Diagnostic_procedure
in O
the O
arterial B-Biological_structure
adventitia I-Biological_structure
; O
evaluation O
of O
adjacent O
sections O
for O
HSV-1 B-Diagnostic_procedure
antigen I-Diagnostic_procedure
and O
infiltrating B-Diagnostic_procedure
leukocytes I-Diagnostic_procedure
( O
CD45 O
, O
not O
shown O
) O
was O
negative B-Lab_value
( O
Fig. O
3 O
) O
. O

Antiviral O
therapy O
was O
altered O
to O
intravenous B-Administration
acyclovir B-Medication
, O
10 B-Dosage
mg/kg I-Dosage
every I-Dosage
8 I-Dosage
h I-Dosage
for O
14 B-Duration
days I-Duration
, O
and O
steroids B-Medication
were O
discontinued O
. O

A O
14-month-old B-Age
boy B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
from B-Nonbiological_location
another I-Nonbiological_location
hospital I-Nonbiological_location
because O
of O
dilated B-Sign_symptom
and O
hypertrophied B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
( O
LV B-Biological_structure
) O
, O
neutropenia B-Sign_symptom
, O
and O
developmental B-Disease_disorder
delay I-Disease_disorder
on O
27 B-Date
October I-Date
2011 I-Date
. O

He O
was O
born B-Clinical_event
at O
full B-Detailed_description
term I-Detailed_description
, O
with O
a O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
of O
3.2 B-Lab_value
kg I-Lab_value
. O

Sixteen B-Date
days I-Date
after I-Date
birth O
, O
he O
was O
hospitalized B-Clinical_event
owing O
to O
persistent B-Detailed_description
irritability B-Sign_symptom
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
showed O
cardiomegaly B-Sign_symptom
, O
and O
an O
echocardiogram B-Diagnostic_procedure
revealed O
decreased B-Qualitative_concept
LV B-Diagnostic_procedure
contractility I-Diagnostic_procedure
( O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
: O
24 B-Lab_value
% I-Lab_value
) O
. O

Under O
the O
impression O
of O
myocarditis B-Disease_disorder
, O
he O
had O
been O
managed B-Therapeutic_procedure
for O
1 B-Duration
yr I-Duration
before O
presentation B-Clinical_event
in O
our O
hospital B-Nonbiological_location
. O

Moreover O
, O
the O
patient O
showed O
feeding B-Sign_symptom
difficulty I-Sign_symptom
and O
developmental B-Sign_symptom
delay I-Sign_symptom
from O
birth B-Clinical_event
. O

Before O
referral B-Clinical_event
, O
he O
had O
been O
admitted B-Clinical_event
to O
other B-Nonbiological_location
hospitals I-Nonbiological_location
7 B-Frequency
times I-Frequency
because O
of O
infection B-Disease_disorder
episodes O
. O

He O
was O
taking O
furosemide B-Medication
, O
spironolactone B-Medication
, O
enalapril B-Medication
, O
and O
carvedilol B-Medication
before O
referral B-Clinical_event
. O

When O
he O
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
at O
14 B-Date
months I-Date
old I-Date
, O
his O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
was O
6 B-Lab_value
kg I-Lab_value
( O
less B-Lab_value
than I-Lab_value
3rd I-Lab_value
percentile I-Lab_value
) O
and O
his O
height B-Diagnostic_procedure
was O
71 B-Lab_value
cm I-Lab_value
( O
less B-Lab_value
than I-Lab_value
3rd I-Lab_value
percentile I-Lab_value
) O
. O

His O
overall O
motor B-Diagnostic_procedure
development I-Diagnostic_procedure
was O
delayed B-Lab_value
, O
and O
he O
could O
not O
sit B-Activity
alone I-Activity
. O

He O
could B-Activity
say I-Activity
" I-Activity
mama I-Activity
" I-Activity
and I-Activity
" I-Activity
papa I-Activity
. I-Activity
" I-Activity

The O
recorded O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
and O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
were O
94/30 B-Lab_value
mmHg I-Lab_value
and O
132 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
respectively O
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
no O
definite O
heart B-Sign_symptom
murmur I-Sign_symptom
was O
audible O
and O
the O
liver B-Biological_structure
was O
not O
palpable B-Sign_symptom
. O

He O
also O
showed O
persistent B-Detailed_description
neutropenia B-Sign_symptom
, O
which O
started O
during O
his O
stay B-Clinical_event
in O
the O
previous B-Nonbiological_location
hospital I-Nonbiological_location
. O

His O
WBC B-Diagnostic_procedure
and O
neutrophil B-Diagnostic_procedure
counts O
were O
8,800 B-Lab_value
/ I-Lab_value
µL I-Lab_value
and O
only O
2 B-Lab_value
% I-Lab_value
( O
176/µL B-Lab_value
) O
, O
respectively O
. O

The O
B-natriuretic B-Diagnostic_procedure
peptide I-Diagnostic_procedure
level O
was O
1,045 B-Lab_value
pg/mL I-Lab_value
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
showed O
mild B-Severity
cardiomegaly B-Sign_symptom
( O
cardiothoracic B-Diagnostic_procedure
ratio I-Diagnostic_procedure
: O
62.8 B-Lab_value
% I-Lab_value
; O
Fig. O
1A O
) O
, O
and O
an O
electrocardiogram B-Diagnostic_procedure
showed O
a O
low B-Lab_value
QRS B-Diagnostic_procedure
voltage I-Diagnostic_procedure
at O
the O
limb B-Diagnostic_procedure
leads I-Diagnostic_procedure
. O

An O
echocardiogram B-Diagnostic_procedure
revealed O
a O
dilated B-Sign_symptom
and O
hypertrophied B-Sign_symptom
globular B-Sign_symptom
LV B-Biological_structure
with O
a O
hypertrophied B-Sign_symptom
papillary B-Biological_structure
muscle I-Biological_structure
and O
hyper-trabeculation B-Sign_symptom
, O
which O
did O
not O
meet O
the O
criteria O
of O
LV B-Biological_structure
non-compaction B-Disease_disorder
. O

The O
other O
echocardiographic B-Diagnostic_procedure
parameters I-Diagnostic_procedure
were O
as O
follows O
: O
LV B-Biological_structure
internal B-Diagnostic_procedure
diameter I-Diagnostic_procedure
at I-Diagnostic_procedure
diastole I-Diagnostic_procedure
, O
37.7 B-Lab_value
mm I-Lab_value
( O
Z O
= O
10.2 O
) O
; O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
, O
36.6 B-Lab_value
% I-Lab_value
; O
and O
LV B-Biological_structure
mass B-Diagnostic_procedure
index I-Diagnostic_procedure
, O
75.6 B-Lab_value
g I-Lab_value
( O
Z O
= O
6.3 O
; O
Fig. O
1B O
) O
. O

To O
rule O
out O
the O
systemic O
cause O
of O
the O
dilated B-Sign_symptom
and O
hypertrophied B-Sign_symptom
LV B-Biological_structure
, O
we O
performed O
a O
thoraco-abdominal B-Detailed_description
computed B-Diagnostic_procedure
tomographic I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
angiography B-Diagnostic_procedure
with O
contrast B-Detailed_description
dye I-Detailed_description
. O

The O
CT B-Diagnostic_procedure
findings O
showed O
no O
abnormality B-Sign_symptom
in O
the O
kidney B-Biological_structure
and O
other O
organs B-Biological_structure
and O
vessels B-Biological_structure
. O

However O
, O
after O
undergoing O
CT B-Diagnostic_procedure
angiography B-Diagnostic_procedure
, O
the O
patient O
showed O
abrupt B-Detailed_description
high-grade B-Severity
spiking B-Detailed_description
fever B-Sign_symptom
( O
Fig. O
2 O
) O
and O
developed O
secretory B-Detailed_description
diarrhea B-Sign_symptom
( O
800 B-Volume
cc I-Volume
per I-Volume
day I-Volume
) O
associated O
with O
metabolic B-Disease_disorder
acidosis I-Disease_disorder
. O

At O
this O
time O
, O
his O
WBC B-Diagnostic_procedure
and O
neutrophil B-Diagnostic_procedure
counts O
decreased B-Lab_value
to O
3,290 B-Lab_value
/ I-Lab_value
µL I-Lab_value
and O
1 B-Lab_value
% I-Lab_value
( O
33/µL B-Lab_value
) O
, O
respectively O
. O

The O
B-natriuretic B-Diagnostic_procedure
peptide I-Diagnostic_procedure
level O
was O
greater B-Lab_value
than I-Lab_value
4,901 I-Lab_value
pg/mL I-Lab_value
. O

He O
did O
not O
show O
associated O
respiratory B-Sign_symptom
symptoms I-Sign_symptom
. O

The O
results O
of O
the O
respiratory B-Detailed_description
and O
gastrointestinal B-Detailed_description
viral B-Diagnostic_procedure
studies I-Diagnostic_procedure
were O
negative B-Lab_value
, O
and O
the O
blood B-Detailed_description
and O
stool B-Detailed_description
cultures B-Diagnostic_procedure
were O
negative B-Lab_value
for O
pathogens O
. O

The O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
level O
was O
7.08 B-Lab_value
mg/dL I-Lab_value
. O

Despite O
supportive B-Therapeutic_procedure
care I-Therapeutic_procedure
including O
intravenous B-Administration
fluid B-Medication
resuscitation I-Medication
and O
empirical B-Detailed_description
antibiotics B-Medication
, O
the O
patient O
's O
condition B-Diagnostic_procedure
worsened B-Lab_value
, O
with O
aggravated O
metabolic B-Disease_disorder
acidosis I-Disease_disorder
and O
respiratory B-Sign_symptom
difficulty I-Sign_symptom
, O
requiring O
transfer B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
( O
ICU B-Nonbiological_location
) O
. O

Just O
before O
the O
ICU B-Nonbiological_location
transfer B-Clinical_event
, O
the O
serum B-Detailed_description
pH B-Diagnostic_procedure
was O
6.881 B-Lab_value
; O
bicarbonate B-Diagnostic_procedure
level O
, O
7.8 B-Lab_value
mmol/L I-Lab_value
; O
and O
total O
CO2 B-Diagnostic_procedure
was O
41.4 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

Although O
the O
patient O
had O
been O
treated O
with O
intensive O
ventilator B-Therapeutic_procedure
care O
, O
several B-Quantitative_concept
inotropic B-Medication
agents I-Medication
, O
and O
other O
supportive B-Therapeutic_procedure
care I-Therapeutic_procedure
measures O
, O
he O
eventually O
died B-Outcome
from O
the O
aggravated B-Detailed_description
metabolic B-Disease_disorder
acidosis I-Disease_disorder
and O
acutely B-Detailed_description
decompensated I-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
7 B-Date
days I-Date
after I-Date
the O
ICU B-Nonbiological_location
care B-Clinical_event
. O

During O
the O
stay B-Clinical_event
in O
ICU B-Nonbiological_location
, O
we O
performed O
genetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
for B-Detailed_description
Barth I-Detailed_description
syndrome I-Detailed_description
from O
the O
evidence O
of O
displayed O
cardiomyopathy B-Disease_disorder
, O
neutropenia B-Sign_symptom
, O
and O
developmental B-Disease_disorder
delay I-Disease_disorder
. O

The O
gene B-Diagnostic_procedure
sequence I-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
that O
his O
TAZ B-Detailed_description
gene I-Detailed_description
harbored O
a O
novel O
hemizygous B-Detailed_description
frameshift B-Detailed_description
mutation B-Lab_value
, O
c. B-Lab_value
227delC I-Lab_value
( O
p.Pro76LeufsX7 B-Lab_value
) O
, O
which O
he O
inherited B-Detailed_description
from O
his O
mother B-Subject
( O
Fig. O
3 O
) O
. O

An O
84-year-old B-Age
male B-Sex
patient O
with O
a O
history O
of O
coronary B-History
artery I-History
disease I-History
and I-History
right I-History
coronary I-History
artery I-History
( I-History
RCA I-History
) I-History
stenting I-History
was O
admitted B-Clinical_event
to O
our O
university B-Nonbiological_location
hospital I-Nonbiological_location
in O
February B-Date
2012 I-Date
because O
of O
progressive B-Detailed_description
dyspnoea B-Sign_symptom
and O
recurring B-Detailed_description
syncopes B-Sign_symptom
. O

Cardiological B-Diagnostic_procedure
work-up I-Diagnostic_procedure
revealed O
a O
grade B-Lab_value
III I-Lab_value
severe B-Severity
symptomatic B-Detailed_description
aortic B-Disease_disorder
stenosis I-Disease_disorder
. O

Due O
to O
relevant O
comorbidities O
( O
logistic B-Diagnostic_procedure
EuroSCORE I-Diagnostic_procedure
of O
19 B-Lab_value
points I-Lab_value
) O
and O
severe B-Severity
femoral B-Biological_structure
arteriopathy B-Disease_disorder
, O
he O
was O
scheduled O
for O
trans-subclavian B-Detailed_description
TAVI B-Therapeutic_procedure
. O

After O
successful O
implantation B-Coreference
of O
a O
CoreValve B-Detailed_description
prosthesis I-Detailed_description
( O
Medtronic B-Detailed_description
) O
[ O
Medtronic B-Detailed_description
World I-Detailed_description
Headquarters I-Detailed_description
Medtronic I-Detailed_description
Parkway I-Detailed_description
Minneapolis I-Detailed_description
, I-Detailed_description
Minnesota I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
] O
( O
diameter B-Detailed_description
31 I-Detailed_description
mm I-Detailed_description
) O
and O
initial O
discharge B-Clinical_event
, O
he O
was O
referred B-Clinical_event
back O
to O
the O
hospital B-Biological_structure
because O
of O
dyspnoea B-Sign_symptom
due O
to O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusions I-Disease_disorder
. O

Transoesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
showed O
a O
severe B-Severity
mitral B-Sign_symptom
regurgitation I-Sign_symptom
( O
MR B-Sign_symptom
) O
, O
which O
was O
subsequently O
treated O
by O
interventional B-Detailed_description
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
repair I-Therapeutic_procedure
using O
the O
MitraClip B-Biological_structure
( O
Abbott B-Detailed_description
Vascular I-Detailed_description
, I-Detailed_description
Abbott I-Detailed_description
Laboratories I-Detailed_description
, I-Detailed_description
Abbott I-Detailed_description
Park I-Detailed_description
, I-Detailed_description
Illinois I-Detailed_description
, I-Detailed_description
U.S.A. I-Detailed_description
) O
and O
procedurally O
dependent O
atrial B-Therapeutic_procedure
septal I-Therapeutic_procedure
defect I-Therapeutic_procedure
( I-Therapeutic_procedure
ASD I-Therapeutic_procedure
) I-Therapeutic_procedure
closure I-Therapeutic_procedure
AMPLATZER B-Detailed_description
™ I-Detailed_description
PFO I-Detailed_description
Occluder I-Detailed_description
( O
St. O
Jude O
Medical O
GmbH O
, O
Helfmann-Park O
7 O
, O
Eschborn O
, O
Germany O
) O
. O

Two B-Date
weeks I-Date
after I-Date
secondary B-Detailed_description
discharge B-Clinical_event
, O
the O
patient O
developed O
progressive B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
in O
combination O
with O
acute B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
. O

Immediate B-Detailed_description
echocardiography B-Diagnostic_procedure
revealed O
a O
moderate-to-severe B-Severity
aortic B-Sign_symptom
regurgitation I-Sign_symptom
and O
recurrent B-Detailed_description
severe B-Severity
MR. B-Sign_symptom
Valvular I-Sign_symptom
defects I-Sign_symptom
resulted O
from O
a O
slight B-Severity
but I-Severity
significant I-Severity
aortic B-Sign_symptom
valve I-Sign_symptom
prosthesis I-Sign_symptom
migration I-Sign_symptom
towards O
the O
left B-Biological_structure
ventricular I-Biological_structure
outflow I-Biological_structure
tract I-Biological_structure
, O
which O
had O
caused O
aortic B-Sign_symptom
paravalvular I-Sign_symptom
leakage I-Sign_symptom
and O
partial B-Detailed_description
posterior B-Detailed_description
mitral B-Sign_symptom
leaflet I-Sign_symptom
detachment I-Sign_symptom
( O
Fig. O
1 O
) O
. O

As O
a O
consequence O
of O
these O
findings O
, O
the O
patient O
was O
transferred B-Clinical_event
to O
our O
cardiac B-Nonbiological_location
surgery I-Nonbiological_location
department I-Nonbiological_location
. O

Preoperative O
coronary B-Biological_structure
angiography B-Diagnostic_procedure
revealed O
a O
progression O
of O
the O
coronary B-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
. O

Consequently O
the O
patient O
was O
scheduled O
for O
conventional B-Detailed_description
aortic B-Biological_structure
and O
mitral B-Biological_structure
valve B-Therapeutic_procedure
replacement I-Therapeutic_procedure
, O
as O
well O
as O
coronary B-Therapeutic_procedure
artery I-Therapeutic_procedure
bypass I-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O

The O
operation O
was O
performed O
via O
median B-Therapeutic_procedure
sternotomy I-Therapeutic_procedure
. O

On O
initialization O
of O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
, O
the O
ascending B-Biological_structure
aorta I-Biological_structure
was O
opened B-Therapeutic_procedure
for O
exploration B-Therapeutic_procedure
of O
the O
aortic B-Biological_structure
valve I-Biological_structure
( O
Fig. O
2A O
) O
. O

After O
careful O
removal B-Therapeutic_procedure
of O
the O
CoreValve B-Detailed_description
prosthesis I-Detailed_description
, O
an O
Edwards B-Detailed_description
Perimount I-Detailed_description
aortic B-Detailed_description
valve I-Detailed_description
prosthesis I-Detailed_description
( O
diameter B-Detailed_description
25 I-Detailed_description
mm I-Detailed_description
) O
was O
implanted B-Therapeutic_procedure
. O

After O
vein-grafting B-Therapeutic_procedure
of O
the O
circumflex B-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
, O
the O
mitral B-Biological_structure
valve I-Biological_structure
was O
explored B-Detailed_description
via I-Detailed_description
the I-Detailed_description
left I-Detailed_description
atrium I-Detailed_description
and O
excised B-Therapeutic_procedure
with O
the O
attached B-Detailed_description
clip I-Detailed_description
. O

Thereafter O
, O
an O
Edwards B-Detailed_description
Perimount I-Detailed_description
mitral B-Detailed_description
valve I-Detailed_description
prosthesis I-Detailed_description
( O
diameter B-Detailed_description
31 I-Detailed_description
mm I-Detailed_description
) O
was O
implanted B-Therapeutic_procedure
. O

More O
recently O
, O
the O
atrial B-Therapeutic_procedure
septal I-Therapeutic_procedure
occluder I-Therapeutic_procedure
was I-Therapeutic_procedure
removed I-Therapeutic_procedure
prior O
to O
direct O
closure B-Therapeutic_procedure
of O
the O
resulting O
septal B-Sign_symptom
defect I-Sign_symptom
with O
a O
single-suture B-Detailed_description
line I-Detailed_description
( O
Fig. O
2B O
) O
. O

Intraoperative B-Detailed_description
echocardiography B-Diagnostic_procedure
revealed O
adequate B-Lab_value
function I-Lab_value
of I-Lab_value
both I-Lab_value
prostheses I-Lab_value
and O
the O
operation O
was O
completed O
in O
the O
usual O
manner O
. O

During O
the O
postoperative O
phase O
, O
the O
patient O
recovered B-Sign_symptom
well B-Lab_value
from O
surgery O
although O
hospitalization B-Clinical_event
was I-Clinical_event
prolonged I-Clinical_event
by O
transient B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
and O
recurring B-Detailed_description
pleural B-Disease_disorder
effusions I-Disease_disorder
. O

After B-Date
a I-Date
month I-Date
of O
postoperative B-Therapeutic_procedure
care I-Therapeutic_procedure
, O
the O
patient O
was O
discharged B-Clinical_event
from O
hospital B-Nonbiological_location
to O
rehabilitation B-Therapeutic_procedure
in O
a O
good B-Lab_value
condition B-Diagnostic_procedure
, O
without O
signs B-Sign_symptom
for I-Sign_symptom
heart I-Sign_symptom
failure I-Sign_symptom
. O

At O
follow-up B-Clinical_event
three B-Date
months I-Date
after I-Date
surgery O
, O
the O
patient O
was O
still O
in O
a O
cardiopulmonary B-Lab_value
stable I-Lab_value
condition B-Diagnostic_procedure
, O
undergoing O
additional O
physiotherapy B-Therapeutic_procedure
. O

A O
60-year-old B-Age
Caucasian B-Personal_background
woman B-Sex
with O
no B-History
significant I-History
medical I-History
history I-History
developed O
exercise B-Sign_symptom
intolerance I-Sign_symptom
, O
fatigue B-Sign_symptom
and O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
on O
exertion B-Detailed_description
over O
the O
several B-Duration
months I-Duration
prior I-Duration
to O
her O
presentation B-Clinical_event
to O
our O
outpatient B-Nonbiological_location
clinic I-Nonbiological_location
. O

At O
the O
time O
of O
presentation O
, O
she O
also O
reported O
of O
dry B-Detailed_description
cough B-Sign_symptom
, O
orthopnea B-Sign_symptom
, O
paroxysmal B-Detailed_description
nocturnal B-Detailed_description
dyspnoea B-Sign_symptom
, O
generalised B-Detailed_description
weakness B-Sign_symptom
and O
intermittent B-Detailed_description
numbness B-Sign_symptom
of O
her O
hands B-Biological_structure
and O
feet B-Biological_structure
. O

Social B-History
history I-History
was I-History
negative I-History
for I-History
smoking I-History
, I-History
alcohol I-History
or I-History
illicit I-History
drugs I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
, O
except O
for O
jugular B-Biological_structure
venous I-Biological_structure
distension B-Sign_symptom
, O
audible O
S1 B-Sign_symptom
and I-Sign_symptom
S2 I-Sign_symptom
sounds I-Sign_symptom
, O
bilateral B-Detailed_description
crackles B-Sign_symptom
on O
lung B-Diagnostic_procedure
auscultation I-Diagnostic_procedure
and O
bilateral B-Detailed_description
pitting B-Detailed_description
oedema B-Sign_symptom
. O

Chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
cardiomegaly B-Sign_symptom
, O
pulmonary B-Sign_symptom
oedema I-Sign_symptom
and O
small-sized B-Severity
bilateral B-Detailed_description
pleural B-Sign_symptom
effusions I-Sign_symptom
. O

A O
12-lead B-Detailed_description
ECG B-Diagnostic_procedure
demonstrated O
normal B-Lab_value
sinus B-Diagnostic_procedure
rhythm I-Diagnostic_procedure
, O
low-voltage B-Sign_symptom
complexes I-Sign_symptom
and O
extreme B-Severity
right-axis B-Sign_symptom
deviation I-Sign_symptom
( O
figure O
1 O
) O
. O

Transthoracic B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
) O
demonstrated O
asymmetric B-Detailed_description
biventricular B-Biological_structure
hypertrophy B-Sign_symptom
with O
preserved B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
60 B-Lab_value
% I-Lab_value
, O
elevated B-Lab_value
right-ventricular B-Biological_structure
systolic B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
36 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
abnormal B-Lab_value
myocardial B-Diagnostic_procedure
texture I-Diagnostic_procedure
, O
described O
as O
‘ O
granular B-Texture
sparkling I-Texture
’ O
( O
figure O
2 O
) O
. O

Coronary B-Biological_structure
CT B-Diagnostic_procedure
angiogram I-Diagnostic_procedure
demonstrated O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O

Subsequently O
, O
cardiac B-Biological_structure
MRI B-Diagnostic_procedure
demonstrated O
early B-Detailed_description
and O
diffuse B-Detailed_description
subendocardial B-Biological_structure
delayed B-Sign_symptom
enhancement I-Sign_symptom
, O
concerning O
for O
infiltrative B-Disease_disorder
myocardial I-Disease_disorder
disease I-Disease_disorder
and O
for O
diffuse B-Detailed_description
biventricular B-Biological_structure
hypertrophy B-Sign_symptom
, O
with O
normal B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
figure O
3 O
) O
. O

The O
patient O
underwent O
right B-Detailed_description
heart B-Therapeutic_procedure
catheterisation I-Therapeutic_procedure
with O
endomyocardial B-Biological_structure
biopsy B-Diagnostic_procedure
, O
revealing O
diffuse B-Detailed_description
amyloidosis B-Disease_disorder
with O
amorphous B-Detailed_description
proteinaceous B-Sign_symptom
material I-Sign_symptom
around O
cardiac B-Biological_structure
myocytes I-Biological_structure
and O
within O
blood B-Biological_structure
vessels I-Biological_structure
, O
which O
was O
positive B-Lab_value
for O
Congo B-Diagnostic_procedure
red I-Diagnostic_procedure
stain I-Diagnostic_procedure
( O
figure O
4 O
) O
. O

Subsequent O
laboratory B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
registered O
elevated B-Lab_value
, O
free B-Diagnostic_procedure
λ I-Diagnostic_procedure
light I-Diagnostic_procedure
chains I-Diagnostic_procedure
( O
86.3 B-Lab_value
mg/L I-Lab_value
( O
normal O
: O
5.7 O
– O
26.3 O
mg/L O
) O
) O
and O
positive B-Lab_value
Bence-Jones B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
0.37 B-Lab_value
g/24 I-Lab_value
h I-Lab_value
) O
in O
the O
urine B-Detailed_description
. O

Bone B-Biological_structure
marrow I-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
greater B-Lab_value
than I-Lab_value
10 I-Lab_value
% I-Lab_value
infiltration B-Diagnostic_procedure
of O
CD19 B-Detailed_description
− I-Detailed_description
CD56 I-Detailed_description
+ I-Detailed_description
CD138 I-Detailed_description
+ I-Detailed_description
plasma I-Detailed_description
cells I-Detailed_description
with O
reversal B-Lab_value
of O
marrow B-Diagnostic_procedure
κ/λ I-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
< B-Lab_value
1:2 I-Lab_value
, O
normal O
: O
2:1 O
) O
, O
consistent O
with O
MM B-Disease_disorder
. O

The O
patient O
was O
eventually O
diagnosed O
with O
systemic B-Detailed_description
AL B-Detailed_description
amyloidosis B-Disease_disorder
with O
advanced B-Severity
, O
stage B-Detailed_description
III I-Detailed_description
, O
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
due O
to O
underlying O
MM B-Disease_disorder
. O

Given O
her O
advanced B-Severity
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
, O
the O
patient O
was O
deemed O
a O
poor O
candidate O
for O
autologous B-Therapeutic_procedure
stem-cell I-Therapeutic_procedure
transplantation I-Therapeutic_procedure
. O

The O
patient O
was O
started O
on O
systemic B-Detailed_description
chemotherapy B-Medication
with O
melphalan B-Medication
and O
dexamethasone B-Medication
. O

Despite O
receiving O
standard O
therapy O
for O
heart O
failure O
— O
including O
diuretics B-Medication
, O
β-blockers B-Medication
and O
ACE B-Medication
inhibitors I-Medication
— O
the O
patient O
's O
condition B-Diagnostic_procedure
continued O
to O
worsen B-Lab_value
and O
she O
succumbed B-Outcome
to O
sudden B-Disease_disorder
cardiac I-Disease_disorder
death I-Disease_disorder
. O

A O
24-year-old B-Age
Malay B-Personal_background
male B-Sex
patient O
was O
referred B-Clinical_event
to O
the O
respiratory B-Nonbiological_location
clinic I-Nonbiological_location
because O
of O
an O
abnormal B-Lab_value
pre-employment B-Detailed_description
chest B-Biological_structure
radiograph B-Diagnostic_procedure
. O

He O
had O
been O
smoking B-Activity
about B-History
10 I-History
cigarettes I-History
a I-History
day I-History
since I-History
he I-History
was I-History
21 I-History
years I-History
of I-History
age I-History
. O

He O
stopped B-History
smoking I-History
10 I-History
months I-History
ago I-History
after I-History
he I-History
noticed I-History
he I-History
had I-History
being I-History
having I-History
reduced I-History
effort I-History
tolerance I-History
for I-History
the I-History
past I-History
three I-History
years I-History
. O

He O
was O
an O
office B-Occupation
worker I-Occupation
and O
did B-History
not I-History
have I-History
a I-History
history I-History
of I-History
exposure I-History
to I-History
organic I-History
or I-History
inorganic I-History
dusts I-History
. O

His O
two B-Family_history
siblings I-Family_history
were I-Family_history
asymptomatic I-Family_history
. O

On O
examination B-Diagnostic_procedure
, O
the O
patient O
was O
not O
tachypnoeic B-Sign_symptom
. O

There O
were O
no O
signs O
of O
finger B-Sign_symptom
clubbing I-Sign_symptom
or O
pulmonary B-Detailed_description
hypertension B-Disease_disorder
. O

His O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
on O
room B-Detailed_description
air I-Detailed_description
at B-Detailed_description
rest I-Detailed_description
was O
94 B-Lab_value
% I-Lab_value
and O
dropped B-Lab_value
to O
92 B-Lab_value
% I-Lab_value
after O
climbing B-Activity
up O
four B-Detailed_description
flights I-Detailed_description
of I-Detailed_description
stairs I-Detailed_description
. O

Spirometry B-Diagnostic_procedure
testing I-Diagnostic_procedure
revealed O
a O
restrictive B-Detailed_description
pattern I-Detailed_description
of O
lung B-Disease_disorder
disease I-Disease_disorder
with O
a O
forced B-Diagnostic_procedure
expiratory I-Diagnostic_procedure
volume I-Diagnostic_procedure
in I-Diagnostic_procedure
1 I-Diagnostic_procedure
second I-Diagnostic_procedure
( O
FEV1 B-Diagnostic_procedure
) O
and O
a O
forced B-Diagnostic_procedure
vital I-Diagnostic_procedure
capacity I-Diagnostic_procedure
( O
FVC B-Diagnostic_procedure
) O
of O
2.7 B-Lab_value
L I-Lab_value
( O
69 O
% O
of O
predicted O
) O
and O
3.2 B-Lab_value
L I-Lab_value
( O
68 O
% O
of O
predicted O
) O
, O
respectively O
. O

The O
FEV1/FVC B-Diagnostic_procedure
ratio I-Diagnostic_procedure
was O
85 B-Lab_value
% I-Lab_value
. O

His O
haemoglobin B-Diagnostic_procedure
( O
168 B-Lab_value
g/L I-Lab_value
) O
, O
serum B-Detailed_description
parathyroid B-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
2.9 B-Lab_value
pmol/L I-Lab_value
[ O
normal O
, O
1.1-7.3 O
] O
) O
and O
calcium B-Diagnostic_procedure
( O
2.34 B-Lab_value
mmol/L I-Lab_value
) O
levels O
were O
normal B-Lab_value
. O

24-hour B-Detailed_description
urine B-Detailed_description
calcium B-Diagnostic_procedure
was O
also O
normal B-Lab_value
6.9 B-Lab_value
mmol I-Lab_value
with O
a O
24-hour B-Detailed_description
urine B-Diagnostic_procedure
volume I-Diagnostic_procedure
of O
2.8 B-Lab_value
L. I-Lab_value
His O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
( O
Fig. O
1A O
) O
revealed O
dense B-Detailed_description
micronodular B-Detailed_description
opacities B-Sign_symptom
distributed B-Detailed_description
symmetrically I-Detailed_description
and O
predominantly O
in O
the O
middle B-Biological_structure
to I-Biological_structure
lower I-Biological_structure
zones I-Biological_structure
of I-Biological_structure
both I-Biological_structure
lungs I-Biological_structure
giving O
the O
classical B-Texture
" I-Texture
sandstorm I-Texture
" I-Texture
appearance I-Texture
. O

The O
cardiac B-Biological_structure
borders I-Biological_structure
were O
obscured B-Sign_symptom
by O
the O
sand-like B-Texture
opacities B-Sign_symptom
. O

A O
high-resolution B-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
HRCT B-Diagnostic_procedure
) O
scan O
of O
the O
lungs B-Biological_structure
( O
Fig. O
1B O
) O
showed O
widespread B-Detailed_description
tiny B-Detailed_description
microcalcifications B-Sign_symptom
throughout O
the O
lungs B-Biological_structure
with O
a O
preponderance O
of O
microliths B-Sign_symptom
in O
the O
lower B-Biological_structure
lobes I-Biological_structure
. O

There O
were O
associated O
areas O
of O
interlobular B-Biological_structure
septal B-Sign_symptom
thickening I-Sign_symptom
and O
ground-glass B-Sign_symptom
changes I-Sign_symptom
. O

Subpleural B-Biological_structure
cystic B-Sign_symptom
changes I-Sign_symptom
were O
also O
seen O
in O
both B-Biological_structure
lower I-Biological_structure
lobes I-Biological_structure
giving O
rise O
to O
the O
' O
black B-Sign_symptom
pleura I-Sign_symptom
sign I-Sign_symptom
' O
( O
Fig. O
1C O
) O
( O
2 O
) O
. O

No O
pneumothorax B-Disease_disorder
or O
pleural B-Disease_disorder
effusion I-Disease_disorder
was O
present O
. O

Both O
the O
bronchial B-Diagnostic_procedure
system I-Diagnostic_procedure
( O
including O
the O
small B-Biological_structure
bronchioles I-Biological_structure
) O
and O
the O
size B-Diagnostic_procedure
of O
the O
pulmonary B-Biological_structure
vessels I-Biological_structure
were O
normal B-Lab_value
. O

As O
this O
was O
diffuse B-Disease_disorder
parenchymal I-Disease_disorder
lung I-Disease_disorder
disease I-Disease_disorder
, O
videoassisted B-Therapeutic_procedure
thoracic I-Therapeutic_procedure
surgical I-Therapeutic_procedure
( O
VATS B-Therapeutic_procedure
) O
lung B-Biological_structure
biopsy B-Diagnostic_procedure
was O
planned O
but O
the O
procedure O
was O
converted O
into O
a O
mini-thoracotomy B-Therapeutic_procedure
because O
there O
was O
difficulty B-Other_event
in I-Other_event
manoeuvering I-Other_event
the I-Other_event
endostapler I-Other_event
. O

There O
was O
a O
moderate B-Severity
pneumothorax B-Disease_disorder
postmini-thoracotomy B-Therapeutic_procedure
from O
which O
the O
patient O
fully O
recovered B-Outcome
after O
5 B-Duration
days I-Duration
in O
the O
ward B-Nonbiological_location
. O

The O
lung B-Biological_structure
biopsy B-Diagnostic_procedure
specimen O
revealed O
features O
consistent O
with O
PAM B-Disease_disorder
, O
with O
numerous O
calcospherites B-Sign_symptom
within O
the O
alveolar B-Biological_structure
spaces I-Biological_structure
( O
Fig. O
1D O
) O
. O

The O
intervening O
alveolar B-Biological_structure
septae I-Biological_structure
were O
congested B-Sign_symptom
and O
showed O
mild B-Severity
fibrosis B-Sign_symptom
with O
infiltrates B-Sign_symptom
of O
mainly O
lymphoplasmacytic B-Detailed_description
cells I-Detailed_description
. O

This O
young B-Age
boy B-Sex
is O
the O
first O
child O
of O
healthy B-Detailed_description
non-consanguineous B-Detailed_description
, O
white B-Personal_background
British B-Personal_background
parents B-Subject
. O

He O
was O
born B-Clinical_event
at B-Detailed_description
term I-Detailed_description
following O
an O
uneventful B-Detailed_description
pregnancy I-Detailed_description
weighing O
3132 B-Weight
g I-Weight
( O
9th O
– O
25th O
centile O
) O
. O

Early B-Diagnostic_procedure
development I-Diagnostic_procedure
was O
thought O
to O
be O
normal B-Lab_value
. O

At O
approximately B-Date
6 I-Date
months I-Date
of I-Date
age I-Date
he O
developed O
tonic B-Detailed_description
upward I-Detailed_description
eye B-Sign_symptom
deviation I-Sign_symptom
associated O
with O
flexion B-Sign_symptom
of O
his O
arms B-Biological_structure
and O
neck B-Biological_structure
consistent O
with O
infantile B-Disease_disorder
spasms I-Disease_disorder
. O

An O
electroencephalograph B-Diagnostic_procedure
( O
EEG B-Diagnostic_procedure
) O
at O
this O
time O
was O
grossly B-Lab_value
abnormal I-Lab_value
( O
hypsarrhythmia B-Sign_symptom
) O
and O
strongly O
supported O
a O
diagnosis O
of O
West B-Disease_disorder
Syndrome I-Disease_disorder
. O

Cranial B-Biological_structure
MRI B-Diagnostic_procedure
was O
reported O
as O
normal B-Lab_value
. O

Prednisolone B-Medication
was O
prescribed O
and O
treated O
the O
seizures B-Sign_symptom
effectively O
. O

Steroids B-Medication
were O
weaned O
over B-Duration
6 I-Duration
weeks I-Duration
and O
he O
remained O
seizure B-Sign_symptom
free O
for O
a O
further B-Duration
6 I-Duration
months I-Duration
. O

By O
the O
age B-Date
of I-Date
1 I-Date
year I-Date
, O
it O
was O
apparent O
that O
his O
early O
developmental B-Diagnostic_procedure
progress I-Diagnostic_procedure
was O
not B-Lab_value
being I-Lab_value
maintained I-Lab_value
and O
that O
he O
was O
functioning O
at O
the O
6 B-Lab_value
– I-Lab_value
8 I-Lab_value
month I-Lab_value
developmental B-Diagnostic_procedure
stage I-Diagnostic_procedure
. O

Seizures B-Sign_symptom
returned O
shortly O
after B-Date
his I-Date
first I-Date
birthday I-Date
and O
were O
prolonged B-Detailed_description
, O
frequent B-Detailed_description
and O
on B-Detailed_description
occasion I-Detailed_description
focal I-Detailed_description
, O
involving O
his O
right B-Biological_structure
arm I-Biological_structure
, O
leg B-Biological_structure
and O
right B-Biological_structure
side I-Biological_structure
of I-Biological_structure
face I-Biological_structure
. O

Clonazepam B-Medication
briefly O
improved O
seizure B-Sign_symptom
frequency O
, O
but O
subsequently O
his O
epilepsy B-Disease_disorder
has O
proved O
refractory B-Detailed_description
to I-Detailed_description
various I-Detailed_description
combinations I-Detailed_description
of I-Detailed_description
anticonvulsant I-Detailed_description
therapy I-Detailed_description
. O

Prolonged B-Detailed_description
seizures B-Sign_symptom
of O
more B-Detailed_description
than I-Detailed_description
60 I-Detailed_description
min I-Detailed_description
have O
been O
associated O
with O
a O
stepwise B-Lab_value
regression I-Lab_value
in O
his O
neurodevelopment B-Diagnostic_procedure
. O

Seizure B-Sign_symptom
semiology O
is O
now O
predominantly O
one O
of O
epilepsia B-Disease_disorder
partialis I-Disease_disorder
continua I-Disease_disorder
involving O
the O
right B-Biological_structure
side I-Biological_structure
of I-Biological_structure
his I-Biological_structure
face I-Biological_structure
, O
right B-Biological_structure
arm I-Biological_structure
and O
right B-Biological_structure
leg I-Biological_structure
. O

The O
development O
of O
focal B-Detailed_description
seizures B-Sign_symptom
and O
the O
progressive B-Detailed_description
nature O
of O
the O
condition B-Coreference
prompted O
a O
second O
cranial B-Biological_structure
MRI B-Diagnostic_procedure
at O
the O
age B-Date
of I-Date
2 I-Date
years I-Date
6 I-Date
months I-Date
. O

By O
contrast O
with O
the O
previous O
scan O
, O
this O
MRI B-Diagnostic_procedure
revealed O
symmetrical B-Detailed_description
subcortical B-Biological_structure
white I-Biological_structure
matter I-Biological_structure
lesions B-Sign_symptom
( O
Fig. O
1A O
) O
with O
thinning B-Sign_symptom
of O
the O
anterior B-Biological_structure
and I-Biological_structure
genu I-Biological_structure
of I-Biological_structure
the I-Biological_structure
corpus I-Biological_structure
callosum I-Biological_structure
( O
Fig. O
1B O
) O
. O

On O
examination B-Diagnostic_procedure
, O
the O
patient O
had O
small B-Detailed_description
, O
round B-Shape
, O
anteriorly B-Detailed_description
rotated I-Detailed_description
ears B-Biological_structure
and O
a O
broad B-Detailed_description
nasal B-Biological_structure
root I-Biological_structure
. O

He O
demonstrated O
no B-Lab_value
visual B-Diagnostic_procedure
awareness I-Diagnostic_procedure
but O
startled B-Sign_symptom
to I-Sign_symptom
loud I-Sign_symptom
noise I-Sign_symptom
. O

Tone B-Diagnostic_procedure
was O
increased B-Lab_value
in O
all B-Biological_structure
4 I-Biological_structure
limbs I-Biological_structure
with O
internal B-Sign_symptom
rotation I-Sign_symptom
of O
both B-Biological_structure
legs I-Biological_structure
at I-Biological_structure
the I-Biological_structure
hips I-Biological_structure
. O

Reflexes B-Diagnostic_procedure
were O
pathologically B-Lab_value
brisk I-Lab_value
. O

Brief B-Detailed_description
myoclonic B-Sign_symptom
jerks I-Sign_symptom
were O
evident O
throughout O
the O
examination O
. O

A O
67-year-old B-Age
Japanese B-Personal_background
female B-Sex
presented B-Clinical_event
with O
a O
left B-Biological_structure
buttock I-Biological_structure
tumor B-Sign_symptom
, O
which O
had O
been O
first O
detected O
approximately O
1 B-Date
year I-Date
earlier I-Date
, O
and O
had O
recently O
gradually B-Detailed_description
enlarged I-Detailed_description
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
relatively O
well-circumscribed B-Detailed_description
skin-colored B-Color
tumor B-Sign_symptom
with O
hyperkeratosis B-Detailed_description
, O
measuring O
43 B-Area
x I-Area
38 I-Area
mm I-Area
in I-Area
diameter I-Area
, O
in O
her O
left B-Biological_structure
buttock I-Biological_structure
. O

The O
biopsy B-Diagnostic_procedure
specimen O
revealed O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
( O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
in I-Disease_disorder
situ I-Disease_disorder
) O
, O
and O
subsequently O
, O
total B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
tumor B-Sign_symptom
was O
performed O
. O

Histopathological B-Diagnostic_procedure
study I-Diagnostic_procedure
of O
the O
resected O
specimen O
revealed O
proliferation B-Sign_symptom
of O
atypical B-Detailed_description
squamous I-Detailed_description
cells I-Detailed_description
in O
the O
entire O
layer O
of O
the O
acanthotic B-Sign_symptom
epidermis B-Biological_structure
accompanied O
by O
hyperparakeratosis B-Sign_symptom
( O
Figure O
1A O
) O
. O

These O
atypical O
squamous B-Biological_structure
cells I-Biological_structure
had O
enlarged B-Lab_value
and O
hyperchromatic B-Lab_value
nuclei B-Diagnostic_procedure
( O
Figure O
1B O
) O
, O
and O
multinucleated B-Sign_symptom
atypical O
squamous B-Biological_structure
cells I-Biological_structure
were O
also O
present O
. O

Mitotic B-Sign_symptom
figures I-Sign_symptom
were O
scattered O
and O
present O
in O
the O
upper B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
epidermis I-Biological_structure
. O

Atypical O
mitotic B-Sign_symptom
figures I-Sign_symptom
were O
also O
observed O
( O
Figure O
1B O
) O
. O

No O
invasive B-Detailed_description
neoplastic B-Sign_symptom
growth I-Sign_symptom
was O
noted O
( O
Figure O
1A O
) O
. O

Approximately O
95 B-Quantitative_concept
% I-Quantitative_concept
of O
the O
lesion B-Sign_symptom
was O
composed O
of O
the O
above-mentioned O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
( O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
in I-Disease_disorder
situ I-Disease_disorder
) O
, O
and O
superficial B-Detailed_description
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
was O
present O
in O
the O
central B-Detailed_description
area I-Detailed_description
of O
the O
lesion B-Sign_symptom
. O

This O
latter O
component O
was O
composed O
of O
proliferation O
of O
nests O
of O
atypical O
cells B-Sign_symptom
with I-Sign_symptom
vacuolated I-Sign_symptom
clear I-Sign_symptom
cytoplasm I-Sign_symptom
and O
large O
nuclei B-Sign_symptom
containing I-Sign_symptom
conspicuous I-Sign_symptom
nucleoli I-Sign_symptom
( O
Figure O
1C O
, O
,1 O
D O
) O
.1 O
D O
) O
. O

Sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
had O
invaded B-Sign_symptom
into O
the O
superficial B-Biological_structure
reticular I-Biological_structure
dermis I-Biological_structure
( O
Figure O
1C O
) O
. O

Moreover O
, O
atypical O
cells B-Sign_symptom
containing I-Sign_symptom
vacuolated I-Sign_symptom
cytoplasm I-Sign_symptom
were O
present O
within O
the O
lesion O
of O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
adjacent O
to O
the O
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
( O
Figure O
1E O
) O
. O

Immunohistochemical B-Diagnostic_procedure
studies I-Diagnostic_procedure
were O
performed O
using O
an O
autostainer B-Detailed_description
( O
Ventana B-Detailed_description
) O
by O
the O
same O
method O
as O
previously O
reported O
[ O
9-12 O
] O
. O

Epithelial B-Diagnostic_procedure
membrane I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
EMA B-Diagnostic_procedure
) O
, O
cytokeratin B-Diagnostic_procedure
7 I-Diagnostic_procedure
, O
and O
adipophilin B-Diagnostic_procedure
were O
expressed B-Lab_value
in O
the O
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
component O
, O
but O
not B-Lab_value
in O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
( O
Figure O
2A O
) O
. O

Androgen B-Diagnostic_procedure
receptor I-Diagnostic_procedure
was O
also O
expressed B-Lab_value
in O
some O
of O
the O
tumor O
cells O
of O
the O
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
, O
but O
not B-Lab_value
in O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
. O

Moreover O
, O
atypical O
vacuolated B-Sign_symptom
cells I-Sign_symptom
within O
the O
lesion O
of O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
were O
also O
positive B-Lab_value
for O
adipophilin B-Diagnostic_procedure
( O
Figure O
2B O
) O
. O

Overexpression B-Lab_value
of O
p53 B-Diagnostic_procedure
protein I-Diagnostic_procedure
was O
observed O
in O
both O
the O
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
and O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
. O

Accordingly O
, O
an O
ultimate O
diagnosis O
of O
sebaceous B-Disease_disorder
carcinoma I-Disease_disorder
associated O
with O
Bowen B-Disease_disorder
’s I-Disease_disorder
disease I-Disease_disorder
was O
made O
. O

A O
44-year-old B-Age
Chinese B-Personal_background
man B-Sex
with O
a O
7 B-History
pack-year I-History
smoking I-History
history I-History
was O
referred B-Clinical_event
to O
Shanghai B-Nonbiological_location
Pulmonary I-Nonbiological_location
Hospital I-Nonbiological_location
in O
February B-Date
2013 I-Date
for O
a O
left B-Biological_structure
upper I-Biological_structure
lobe I-Biological_structure
lung B-Biological_structure
mass B-Sign_symptom
with O
multiple B-Detailed_description
bilateral B-Detailed_description
intrapulmonary B-Biological_structure
metastases B-Sign_symptom
, O
left B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
, O
and O
2R/4R/10L B-Lab_value
/ I-Lab_value
11L I-Lab_value
lymphadenopathy B-Disease_disorder
. O

Pleural B-Biological_structure
fluid I-Biological_structure
cytology B-Diagnostic_procedure
revealed O
adenocarcinoma B-Disease_disorder
and O
Scorpion B-Diagnostic_procedure
Amplification I-Diagnostic_procedure
Refractory I-Diagnostic_procedure
Mutation I-Diagnostic_procedure
system I-Diagnostic_procedure
( O
AmoyDx B-Detailed_description
Co. I-Detailed_description
, I-Detailed_description
Xiamen I-Detailed_description
, I-Detailed_description
China I-Detailed_description
) O
. O

showed O
no O
detectable O
epidermal B-Sign_symptom
growth I-Sign_symptom
factor I-Sign_symptom
receptor I-Sign_symptom
mutation I-Sign_symptom
. O

He O
commenced O
chemotherapy B-Medication
with O
gemcitabine B-Medication
and O
cisplatin B-Medication
. O

However O
, O
after O
a O
single O
cycle O
, O
his O
symptoms B-Sign_symptom
worsened O
and O
imaging O
confirmed O
progressive B-Detailed_description
disease B-Disease_disorder
. O

A O
second B-Clinical_event
opinion I-Clinical_event
was I-Clinical_event
requested I-Clinical_event
from O
the O
University B-Nonbiological_location
of I-Nonbiological_location
Colorado I-Nonbiological_location
and O
a O
computed B-Detailed_description
tomography I-Detailed_description
– I-Detailed_description
guided I-Detailed_description
biopsy B-Diagnostic_procedure
of O
the O
left B-Biological_structure
upper I-Biological_structure
lobe I-Biological_structure
lesion B-Sign_symptom
was O
performed O
to O
permit O
additional O
molecular O
testing O
. O

In O
the O
interim O
, O
the O
patient O
commenced O
pemetrexed B-Medication
and O
nedaplatin B-Medication
. O

Unfortunately O
, O
after O
two O
cycles O
his O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
worsened O
, O
with O
evidence O
of O
further B-Sign_symptom
progression I-Sign_symptom
on O
his O
scans B-Diagnostic_procedure
( O
Fig. O
1A O
) O
. O

Molecular O
testing O
on O
his O
repeat O
biopsy B-Diagnostic_procedure
specimen O
revealed O
no O
mutations B-Sign_symptom
by O
SNaPshot B-Detailed_description
multiplex I-Detailed_description
PCR B-Diagnostic_procedure
testing I-Diagnostic_procedure
( O
Life O
Technologies O
, O
Carlsbad O
, O
CA O
) O
. O

However O
, O
although O
technically O
negative O
, O
the O
ALK B-Detailed_description
break-apart I-Detailed_description
FISH B-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
an O
atypical B-Lab_value
negative I-Lab_value
pattern I-Lab_value
. O

Specifically O
, O
68 B-Lab_value
% I-Lab_value
of I-Lab_value
cells I-Lab_value
demonstrated I-Lab_value
single I-Lab_value
copies I-Lab_value
of I-Lab_value
the I-Lab_value
5 I-Lab_value
′ I-Lab_value
ALK I-Lab_value
signal I-Lab_value
and O
numerous B-Lab_value
cells I-Lab_value
with I-Lab_value
doublets I-Lab_value
of I-Lab_value
the I-Lab_value
5 I-Lab_value
′ I-Lab_value
ALK I-Lab_value
signal I-Lab_value
combined I-Lab_value
with I-Lab_value
one I-Lab_value
3 I-Lab_value
′ I-Lab_value
ALK I-Lab_value
signal I-Lab_value
( O
Fig. O
2A O
) O
. O

Subsequently O
, O
confirmatory O
diagnostic B-Diagnostic_procedure
assays I-Diagnostic_procedure
demonstrated O
ALK B-Lab_value
protein I-Lab_value
expression I-Lab_value
by O
IHC B-Diagnostic_procedure
using O
the O
D5F3 B-Detailed_description
antibody I-Detailed_description
( O
Cell B-Detailed_description
Signaling I-Detailed_description
Technology I-Detailed_description
Inc. I-Detailed_description
, I-Detailed_description
Danvers I-Detailed_description
, I-Detailed_description
MA I-Detailed_description
; O
H O
score O
= O
150 O
; O
Fig. O
2B O
) O
and O
the O
presence B-Lab_value
of I-Lab_value
an I-Lab_value
echinoderm I-Lab_value
microtubule-associated I-Lab_value
protein-like I-Lab_value
4 I-Lab_value
( I-Lab_value
EML4 I-Lab_value
) I-Lab_value
- I-Lab_value
ALK I-Lab_value
transcript I-Lab_value
( O
E13 O
; O
A20 O
) O
by O
RT-PCR B-Diagnostic_procedure
( O
Fig. O
2C O
) O
. O

The O
patient O
then O
received O
crizotinib B-Medication
( O
250 B-Dosage
mg I-Dosage
twice I-Dosage
daily I-Dosage
) O
as O
third-line O
therapy O
in O
May B-Date
2013 I-Date
with O
an O
impressive O
symptomatic B-Sign_symptom
improvement I-Sign_symptom
and O
CT O
response O
after B-Date
1 I-Date
month I-Date
of O
therapy O
( O
Fig. O
1B O
) O
. O

He O
remains O
on O
treatment O
with O
crizotinib B-Medication
with O
no O
evidence O
of O
progression B-Sign_symptom
as O
of O
September B-Date
2013 I-Date
. O

A O
35-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
the O
medical B-Nonbiological_location
emergency I-Nonbiological_location
department I-Nonbiological_location
with O
low-grade B-Severity
fever B-Sign_symptom
for O
3 B-Duration
weeks I-Duration
, O
vomiting B-Sign_symptom
for O
1 B-Duration
week I-Duration
and O
anuria B-Sign_symptom
for O
3 B-Duration
days I-Duration
. O

She O
also O
reported O
dysuria B-Sign_symptom
and O
breathlessness B-Sign_symptom
for O
1 B-Duration
week I-Duration
. O

There O
was O
no B-History
history I-History
of I-History
decreased I-History
urine I-History
output I-History
, I-History
dialysis I-History
, I-History
effort I-History
intolerance I-History
, I-History
chest I-History
pain I-History
or I-History
palpitation I-History
, I-History
dyspnoea I-History
and I-History
weight I-History
loss I-History
. O

Menstrual B-Diagnostic_procedure
history I-Diagnostic_procedure
was O
within B-Lab_value
normal I-Lab_value
limit I-Lab_value
but O
she O
reported O
gradually B-Lab_value
progressive I-Lab_value
loss B-Sign_symptom
of I-Sign_symptom
appetite I-Sign_symptom
. O

Family O
history O
included O
smoky B-Family_history
urine I-Family_history
in I-Family_history
her I-Family_history
younger I-Family_history
brother I-Family_history
in I-Family_history
his I-Family_history
childhood I-Family_history
, I-Family_history
who I-Family_history
died I-Family_history
in I-Family_history
an I-Family_history
accident I-Family_history
. O

On O
general B-Diagnostic_procedure
survey I-Diagnostic_procedure
, O
the O
patient O
was O
conscious B-Sign_symptom
and O
alert B-Sign_symptom
. O

She O
was O
dyspnoeic B-Sign_symptom
and O
febrile B-Sign_symptom
. O

Severe B-Severity
pallor B-Sign_symptom
was O
present O
with O
mild B-Severity
pedal B-Biological_structure
oedema B-Sign_symptom
. O

Blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
180/100 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
116/min B-Lab_value
regular B-Lab_value
. O

No O
evidence O
of O
jaundice B-Sign_symptom
, O
clubbing B-Detailed_description
cyanosis B-Sign_symptom
or O
lymphadenopathy B-Disease_disorder
was O
found O
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
bibasilar B-Biological_structure
end-inspiratory B-Detailed_description
crepitations B-Sign_symptom
in O
lungs B-Biological_structure
and O
suprapubic B-Biological_structure
tenderness B-Sign_symptom
. O

There O
was O
no O
hepatosplenomegaly B-Sign_symptom
or O
ascites B-Sign_symptom
. O

Cardiac B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
. O

She O
was O
found O
to O
have O
severe B-Severity
bilateral B-Detailed_description
hearing B-Sign_symptom
loss I-Sign_symptom
, O
which O
was O
gradually B-Lab_value
progressive I-Lab_value
for O
5 B-Duration
years I-Duration
. O

The O
fundi B-Biological_structure
were O
bilaterally B-Detailed_description
pale B-Sign_symptom
. O

The O
patient O
was O
referred B-Clinical_event
to O
the O
department B-Nonbiological_location
of I-Nonbiological_location
ophthalmology I-Nonbiological_location
for O
a O
comprehensive O
eye B-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

Her O
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
was O
documented O
as O
6/18 B-Lab_value
in O
both B-Biological_structure
eyes I-Biological_structure
with O
no O
obvious O
lenticular B-Sign_symptom
opacity I-Sign_symptom
. O

Slit-lamp B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
bilateral B-Detailed_description
anterior B-Sign_symptom
lentiglobus I-Sign_symptom
( O
figure O
1 O
) O
with O
posterior B-Sign_symptom
lenticonus I-Sign_symptom
( O
figure O
2 O
) O
. O

Distant B-Detailed_description
direct I-Detailed_description
ophthalmoscopy B-Diagnostic_procedure
revealed O
oil B-Sign_symptom
droplet I-Sign_symptom
sign I-Sign_symptom
( O
a O
suggestive O
confirmation O
of O
the O
presence O
of O
lenticonus B-Sign_symptom
) O
; O
and O
peripheral B-Biological_structure
retina I-Biological_structure
revealed O
multiple B-Detailed_description
yellowish B-Color
white I-Color
lesion-like B-Sign_symptom
flecks I-Sign_symptom
in O
the O
mid-periphery B-Biological_structure
, O
and O
few B-Detailed_description
blot B-Sign_symptom
haemorrhages I-Sign_symptom
indicative O
of O
hypertensive B-Sign_symptom
changes I-Sign_symptom
( O
figures O
3 O
and O
4 O
) O
. O

A O
30-year-old B-Age
woman B-Sex
with O
a O
history O
of O
HIV B-History
and O
HCV B-History
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
a O
4-month B-Duration
history O
of O
gradual B-Detailed_description
but O
progressive B-Detailed_description
swelling B-Sign_symptom
of O
her O
lower B-Biological_structure
limbs I-Biological_structure
and O
abdomen B-Biological_structure
. O

She O
denied O
any O
chest B-Biological_structure
pain B-Sign_symptom
, O
dyspnoea B-Sign_symptom
, O
paroxysmal B-Detailed_description
nocturnal B-Detailed_description
dyspnoea B-Sign_symptom
or O
orthopnoea B-Sign_symptom
. O

Vitals B-Diagnostic_procedure
were O
stable B-Lab_value
. O

Cardiovascular B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
remarkable O
for O
an O
elevated B-Lab_value
jugular B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
JVP B-Diagnostic_procedure
) O
of O
about O
12 B-Lab_value
cm I-Lab_value
with O
a O
pronounced B-Lab_value
‘ I-Lab_value
y I-Lab_value
’ I-Lab_value
descent I-Lab_value
. O

There O
was O
a O
prominent B-Severity
pericardial B-Sign_symptom
knock I-Sign_symptom
sound I-Sign_symptom
heard O
over O
the O
praecordium B-Biological_structure
. O

There O
was O
no O
pericardial B-Sign_symptom
rub I-Sign_symptom
or O
murmur B-Sign_symptom
. O

The O
lungs B-Biological_structure
were O
clear B-Lab_value
to O
auscultation B-Diagnostic_procedure
. O

The O
patient O
was O
markedly O
oedematous B-Sign_symptom
from O
the O
abdomen B-Biological_structure
to O
the O
lower B-Biological_structure
limbs I-Biological_structure
. O

She O
was O
admitted B-Clinical_event
for O
further O
diagnostic B-Diagnostic_procedure
work-up I-Diagnostic_procedure
and O
management B-Therapeutic_procedure
. O

She O
was O
diagnosed O
with O
HIV B-Disease_disorder
around O
May B-Date
2010 I-Date
and O
had O
been O
on O
antiretroviral B-Medication
therapy I-Medication
. O

She O
had O
not O
used O
illicit B-Activity
drugs I-Activity
for O
approximately B-Duration
5 I-Duration
– I-Duration
6 I-Duration
years I-Duration
. O

Renal B-Disease_disorder
and I-Disease_disorder
hepatic I-Disease_disorder
diseases I-Disease_disorder
were O
ruled O
out O
through O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
and O
imaging B-Diagnostic_procedure
. O

Peritoneal B-Biological_structure
fluid I-Biological_structure
was O
negative O
for O
malignancy B-Disease_disorder
. O

Echocardiogram B-Diagnostic_procedure
showed O
a O
thickened B-Lab_value
bright B-Lab_value
pericardium B-Biological_structure
adjacent O
to O
the O
right B-Biological_structure
heart I-Biological_structure
border I-Biological_structure
( O
figure O
1 O
) O
with O
parallel B-Lab_value
separation I-Lab_value
between I-Lab_value
epicardial I-Lab_value
and I-Lab_value
pericardial I-Lab_value
echoes I-Lab_value
( O
railroad O
track O
sign O
) O
, O
septal B-Lab_value
bounce I-Lab_value
and O
lack O
of O
pericardial B-Lab_value
slide I-Lab_value
. O

Annulus B-Sign_symptom
paradoxus I-Sign_symptom
was O
demonstrated O
on O
tissue B-Biological_structure
Doppler B-Diagnostic_procedure
( O
figure O
2 O
) O
. O

Left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
was O
64 B-Lab_value
% I-Lab_value
. O

The O
right B-Biological_structure
ventricle I-Biological_structure
was O
normal B-Lab_value
in O
size B-Diagnostic_procedure
and O
function B-Diagnostic_procedure
. O

There O
was O
moderate B-Severity
tricuspid B-Sign_symptom
regurgitation I-Sign_symptom
. O

There O
was O
no O
pericardial B-Sign_symptom
effusion I-Sign_symptom
, O
but O
the O
pericardial B-Biological_structure
space I-Biological_structure
was O
remarkable O
for O
debris B-Sign_symptom
. O

Constrictive B-Disease_disorder
physiology I-Disease_disorder
was O
demonstrated O
by O
Doppler B-Diagnostic_procedure
study O
of O
tricuspid B-Other_event
and I-Other_event
mitral I-Other_event
inflows I-Other_event
( O
figure O
3 O
) O
during O
inspiration B-Activity
and O
expiration B-Activity
; O
diastolic B-Sign_symptom
flow I-Sign_symptom
reversal I-Sign_symptom
was O
also O
demonstrated O
in O
the O
hepatic B-Biological_structure
veins I-Biological_structure
during O
expiration B-Activity
. O

There O
was O
marked O
dilatation B-Sign_symptom
of O
the O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
with O
no O
change O
during O
inspiration B-Activity
or O
expiration B-Activity
. O

CT B-Diagnostic_procedure
of O
the O
chest B-Biological_structure
revealed O
thickening B-Sign_symptom
of O
the O
pericardium B-Biological_structure
with O
no O
evidence O
of O
calcification B-Sign_symptom
. O

There O
were O
no O
lung B-Biological_structure
nodules B-Sign_symptom
. O

Bilateral B-Detailed_description
pleural B-Disease_disorder
effusions I-Disease_disorder
and O
interstitial B-Detailed_description
thickening B-Sign_symptom
were O
present O
in O
the O
lung B-Biological_structure
bases I-Biological_structure
. O

Cardiac B-Biological_structure
MRI B-Diagnostic_procedure
confirmed O
the O
presence O
of O
a O
diffusely B-Detailed_description
thickened B-Sign_symptom
pericardium B-Biological_structure
at O
5 B-Lab_value
mm I-Lab_value
. O

The O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
and O
hepatic B-Biological_structure
veins I-Biological_structure
appeared O
plethoric B-Sign_symptom
. O

There O
was O
a O
rapid B-Lab_value
early B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
filling I-Diagnostic_procedure
and O
associated O
diastolic B-Sign_symptom
septal I-Sign_symptom
bounce I-Sign_symptom
secondary O
to O
hindered B-Lab_value
late B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
filling I-Diagnostic_procedure
( O
figure O
4 O
) O
. O

The O
patient O
showed O
a O
good B-Lab_value
response B-Diagnostic_procedure
to O
diuresis B-Therapeutic_procedure
. O

She O
underwent O
right B-Detailed_description
and O
left B-Detailed_description
heart B-Biological_structure
catheterisation B-Therapeutic_procedure
to O
confirm O
constrictive B-Disease_disorder
physiology I-Disease_disorder
. O

The O
affected O
individual O
, O
a O
male B-Sex
, O
was O
the O
fourth B-Family_history
child I-Family_history
born O
to O
an O
Arab B-Family_history
Muslim I-Family_history
family I-Family_history
of I-Family_history
Palestinian I-Family_history
origin I-Family_history
. O

Parents B-Subject
are B-Family_history
first I-Family_history
cousins I-Family_history
. O

One B-Family_history
sibling I-Family_history
, I-Family_history
a I-Family_history
girl I-Family_history
died I-Family_history
at I-Family_history
the I-Family_history
age I-Family_history
of I-Family_history
1 I-Family_history
month I-Family_history
due I-Family_history
to I-Family_history
SIDS I-Family_history
according I-Family_history
to I-Family_history
parents I-Family_history
, O
without O
any O
investigation O
. O

Informed O
consent O
for O
muscle B-Biological_structure
, O
skin B-Biological_structure
biopsy B-Diagnostic_procedure
and O
exome B-Detailed_description
sequencing B-Diagnostic_procedure
was O
obtained O
from O
the O
parents O
, O
and O
the O
study O
was O
approved O
by O
the O
local O
institutional O
review O
board O
. O

During O
pregnancy O
, O
the O
patient O
was O
suspected O
to O
have O
IUGR B-Disease_disorder
and O
was O
delivered B-Clinical_event
by O
Cesarian B-Therapeutic_procedure
section I-Therapeutic_procedure
at O
36 B-Date
+2 I-Date
gestational I-Date
weeks I-Date
with O
Apgar B-Diagnostic_procedure
scores O
9 B-Lab_value
and O
10 B-Lab_value
. O

Birth B-Diagnostic_procedure
weight I-Diagnostic_procedure
was O
2.3 B-Lab_value
kg I-Lab_value
( O
10th B-Lab_value
percentile I-Lab_value
) O
and O
head B-Diagnostic_procedure
circumference I-Diagnostic_procedure
32 B-Lab_value
cm I-Lab_value
( O
10th B-Lab_value
percentile I-Lab_value
) O
. O

Physical B-Diagnostic_procedure
exam I-Diagnostic_procedure
after O
birth B-Clinical_event
, O
detected O
a O
systolic B-Sign_symptom
murmur I-Sign_symptom
3/6 B-Lab_value
. O

On O
the O
first B-Date
day I-Date
of I-Date
life I-Date
, O
the O
patient O
developed O
metabolic B-Disease_disorder
acidosis I-Disease_disorder
with O
lactate B-Diagnostic_procedure
level O
of O
27 B-Lab_value
mm I-Lab_value
( O
normal O
range O
0.5 O
– O
2.4 O
mm O
) O
and O
elevated B-Lab_value
ammonia B-Diagnostic_procedure
levels O
277 B-Lab_value
μm I-Lab_value
( O
normal O
range O
10 O
– O
60 O
μm O
) O
. O

Metabolic B-Diagnostic_procedure
work I-Diagnostic_procedure
up I-Diagnostic_procedure
showed O
normal B-Lab_value
acylcarnitines B-Diagnostic_procedure
, O
elevated B-Lab_value
alanine B-Diagnostic_procedure
level O
1400 B-Lab_value
μm I-Lab_value
( O
normal O
< O
700 O
μm O
) O
, O
and O
urine B-Detailed_description
organic B-Diagnostic_procedure
acids I-Diagnostic_procedure
showed O
increased O
lactic B-Sign_symptom
acidosis I-Sign_symptom
and O
ketones B-Sign_symptom
. O

Chest B-Biological_structure
X-ray B-Diagnostic_procedure
revealed O
cardiomegaly B-Sign_symptom
, O
and O
cardiac B-Biological_structure
Echo B-Diagnostic_procedure
revealed O
symmetrical B-Detailed_description
left B-Sign_symptom
ventricular I-Sign_symptom
hypertrophy I-Sign_symptom
tricuspid B-Sign_symptom
regurge I-Sign_symptom
and O
pulmonary B-Sign_symptom
hypertension I-Sign_symptom
. O

The O
patient O
was O
transported B-Clinical_event
to O
the O
NICU B-Nonbiological_location
and O
treated O
with O
bicarbonate B-Medication
, O
acetate B-Medication
and O
diuretics B-Medication
. O

At O
the O
age O
of O
4 B-Date
days I-Date
, O
quadriceps B-Biological_structure
muscle I-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
. O

Pathology B-Diagnostic_procedure
showed O
decreased B-Lab_value
cytochrome B-Diagnostic_procedure
c I-Diagnostic_procedure
oxidase I-Diagnostic_procedure
stain I-Diagnostic_procedure
. O

Brain B-Biological_structure
ultrasound B-Diagnostic_procedure
performed O
at O
age O
5 B-Date
days I-Date
was O
normal B-Lab_value
. O

Subsequently O
, O
head B-Diagnostic_procedure
circumference I-Diagnostic_procedure
grew B-Lab_value
rapidly I-Lab_value
adding B-Lab_value
13 I-Lab_value
centimeters I-Lab_value
by O
age O
35 B-Date
days I-Date
, O
repeated O
brain B-Biological_structure
US B-Diagnostic_procedure
revealed O
dilated B-Sign_symptom
ventricles B-Biological_structure
confirmed O
by O
head B-Biological_structure
CT B-Diagnostic_procedure
, O
which O
also O
showed O
subcortical B-Biological_structure
and O
white B-Biological_structure
matter I-Biological_structure
cortical I-Biological_structure
hemorrhage B-Sign_symptom
in O
the O
occipital B-Biological_structure
region I-Biological_structure
. O

At O
15 B-Date
weeks I-Date
, O
a O
ventriculoperitoneal B-Detailed_description
( O
VP B-Detailed_description
) O
shunt B-Therapeutic_procedure
was O
inserted O
. O

Head B-Biological_structure
CT B-Diagnostic_procedure
performed O
at O
age O
2 B-Date
years I-Date
showed O
prominent O
dilatation B-Sign_symptom
of O
the O
ventricles B-Biological_structure
( O
Figure O
1 O
) O
. O

Due O
to O
hypotonia B-Disease_disorder
with O
feeding B-Disease_disorder
difficulties I-Disease_disorder
and O
recurrent B-Detailed_description
aspirations B-Disease_disorder
, O
a O
percutaneous B-Detailed_description
endoscopic I-Detailed_description
gastrostomy I-Detailed_description
( O
PEG B-Detailed_description
) O
feeding B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
inserted O
at O
age O
10 B-Date
weeks I-Date
. O

Eye B-Biological_structure
examination B-Diagnostic_procedure
at O
the O
age O
of O
15 B-Date
weeks I-Date
revealed O
cortical B-Biological_structure
blindness B-Disease_disorder
. O

Hearing B-Diagnostic_procedure
test I-Diagnostic_procedure
ABR B-Diagnostic_procedure
was O
normal B-Lab_value
. O

Repeated O
cardiac B-Biological_structure
Echo B-Diagnostic_procedure
continued O
to O
show O
mild B-Severity
tricuspid B-Sign_symptom
regurge I-Sign_symptom
, O
mild B-Severity
left B-Sign_symptom
ventricular I-Sign_symptom
hypertrophy I-Sign_symptom
( O
LVH B-Sign_symptom
) O
and O
pulmonary B-Sign_symptom
hypertension I-Sign_symptom
( O
PHTN B-Sign_symptom
) O
in O
the O
first B-Date
months I-Date
of I-Date
life I-Date
. O

At O
the O
age O
of O
4 B-Date
months I-Date
, O
he O
started O
developing O
hypertrophic B-Detailed_description
obstructive B-Detailed_description
cardiomyopathy B-Disease_disorder
, O
he O
was O
started O
on O
diuretics B-Medication
and O
beta B-Medication
blockers I-Medication
and O
later O
calcium B-Medication
channel I-Medication
blockers I-Medication
were O
added O
; O
follow-up O
Echo B-Diagnostic_procedure
at O
the O
age O
of O
2 B-Date
years I-Date
revealed O
improvement O
in O
the O
LVH B-Sign_symptom
and O
no O
PHTN B-Sign_symptom
. O

Coenzyme B-Medication
Q10 I-Medication
supplementation O
( O
60 B-Dosage
mg I-Dosage
twice I-Dosage
daily I-Dosage
) O
was O
initiated O
at O
4 B-Date
months I-Date
but O
discontinued B-Detailed_description
by O
the O
parents B-Subject
. O

In O
the O
following B-Duration
months I-Duration
, O
the O
patient O
was O
admitted B-Clinical_event
several B-Frequency
times I-Frequency
to O
the O
hospital B-Nonbiological_location
mainly O
due O
to O
chest B-Biological_structure
infections B-Disease_disorder
, O
shunt B-Disease_disorder
malfunctioning I-Disease_disorder
and O
fevers B-Sign_symptom
. O

He O
died B-Outcome
at O
the O
age B-Date
of I-Date
30 I-Date
months I-Date
due O
to O
severe B-Severity
hypoxemia B-Sign_symptom
after O
a O
febrile B-Disease_disorder
illness I-Disease_disorder
with O
chest B-Biological_structure
infection B-Disease_disorder
and O
pulmonary B-Biological_structure
edema B-Sign_symptom
; O
parents B-Subject
refused B-Detailed_description
mechanical B-Therapeutic_procedure
ventilation I-Therapeutic_procedure
and O
refused B-Detailed_description
reanimation B-Therapeutic_procedure
. O

A O
woman B-Sex
in O
her O
60s B-Age
was O
found O
to O
have O
screen B-Diagnostic_procedure
detected O
invasive B-Detailed_description
lobular B-Detailed_description
breast B-Disease_disorder
carcinoma I-Disease_disorder
of O
the O
right B-Biological_structure
breast I-Biological_structure
and O
invasive B-Detailed_description
ductal B-Disease_disorder
carcinoma I-Disease_disorder
, O
no B-Detailed_description
special I-Detailed_description
type I-Detailed_description
, O
of O
the O
left B-Biological_structure
breast I-Biological_structure
. O

Staging O
CT B-Diagnostic_procedure
imaging I-Diagnostic_procedure
prior O
to O
mastectomy B-Therapeutic_procedure
showed O
a O
12 B-Distance
cm I-Distance
pelvic B-Biological_structure
mass B-Sign_symptom
which O
on O
initial O
impression O
was O
thought O
to O
be O
a O
fibroid B-Sign_symptom
uterus B-Biological_structure
. O

Associated O
postmenopausal B-Detailed_description
bleeding B-Sign_symptom
led O
to O
pelvic B-Biological_structure
ultrasound B-Diagnostic_procedure
, O
hysteroscopy B-Diagnostic_procedure
and O
biopsy B-Diagnostic_procedure
. O

The O
biopsy B-Diagnostic_procedure
showed O
undifferentiated B-Detailed_description
sarcoma B-Disease_disorder
, O
unclassifiable B-Lab_value
with O
immunohistochemistry B-Diagnostic_procedure
. O

Following O
discussion O
at O
a O
multidisciplinary O
team O
meeting O
it O
was O
felt O
that O
the O
uterine B-Biological_structure
tumour B-Sign_symptom
was O
a O
separate O
primary B-Detailed_description
malignancy I-Detailed_description
rather O
than O
metastasis B-Disease_disorder
from O
the O
breast B-Biological_structure
. O

Hysterectomy B-Therapeutic_procedure
and O
bilateral B-Detailed_description
salpingo-oophorectomy B-Therapeutic_procedure
was O
performed O
for O
both O
treatment O
purposes O
and O
to O
fully O
categorise O
the O
malignancy O
to O
guide O
further O
adjuvant B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
resection O
specimen O
showed O
a O
partially B-Detailed_description
necrotic I-Detailed_description
tumour B-Sign_symptom
with O
a O
discrete B-Detailed_description
outline I-Detailed_description
located O
within O
and O
extending O
throughout O
the O
myometrium B-Biological_structure
. O

The O
tumour B-Coreference
was O
composed O
of O
malignant B-Detailed_description
spindle I-Detailed_description
cells I-Detailed_description
( O
figure O
1A O
) O
, O
with O
an O
intermittent O
component O
of O
pleomorphic B-Detailed_description
cells I-Detailed_description
with O
abundant O
eosinophilic B-Detailed_description
cytoplasm I-Detailed_description
. O

Plentiful B-Detailed_description
osteoclast-like B-Detailed_description
giant B-Sign_symptom
cells I-Sign_symptom
were O
present O
( O
figure O
1B O
) O
. O

Mitoses B-Diagnostic_procedure
were O
numerous B-Lab_value
and O
structurally B-Sign_symptom
abnormal I-Sign_symptom
forms I-Sign_symptom
were O
common O
. O

Neoplastic B-Coreference
cells I-Coreference
were O
surrounded O
by O
hyaline O
osteoid O
matrix O
and O
foci O
of O
coarse O
neoplastic O
woven O
bone O
( O
figure O
1C O
) O
. O

Generous O
sampling O
of O
the O
tumour O
showed O
no O
admixed O
neoplastic B-Sign_symptom
epithelial I-Sign_symptom
elements I-Sign_symptom
, O
thus O
ruling O
out O
the O
more O
common O
carcinosarcoma O
( O
malignant B-Disease_disorder
mixed I-Disease_disorder
Müllerian I-Disease_disorder
tumour I-Disease_disorder
) O
. O

Tumour B-Coreference
cells I-Coreference
showed O
immunohistochemical B-Diagnostic_procedure
expression B-Lab_value
for O
vimentin B-Diagnostic_procedure
, O
smooth B-Diagnostic_procedure
muscle I-Diagnostic_procedure
actin I-Diagnostic_procedure
( O
SMA B-Diagnostic_procedure
) O
, O
desmin B-Diagnostic_procedure
( O
focally B-Lab_value
) O
and O
CD99 B-Diagnostic_procedure
. O

Epithelial B-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
not B-Lab_value
expressed I-Lab_value
. O

The O
morphological O
and O
immunohistochemical O
appearances O
were O
in O
keeping O
with O
primary B-Detailed_description
uterine I-Detailed_description
osteoblastic I-Detailed_description
variant I-Detailed_description
of O
osteosarcoma B-Disease_disorder
. O

Unfortunately O
, O
despite O
treatment O
, O
further O
CT B-Diagnostic_procedure
imaging I-Diagnostic_procedure
showed O
the O
development O
of O
multiple B-Detailed_description
peritoneal B-Biological_structure
and O
pulmonary B-Biological_structure
deposits B-Sign_symptom
, O
confirmed O
on O
biopsy B-Diagnostic_procedure
to O
be O
metastatic B-Detailed_description
osteosarcoma B-Disease_disorder
. O

The O
patient O
received O
palliative B-Detailed_description
chemotherapy B-Therapeutic_procedure
and O
died B-Outcome
several B-Date
months I-Date
later I-Date
. O

A O
56-year-old B-Age
African B-Personal_background
American I-Personal_background
man B-Sex
who O
initially O
presented B-Clinical_event
with O
diarrhea B-Sign_symptom
, O
weight B-Sign_symptom
loss I-Sign_symptom
and O
painless B-Detailed_description
jaundice B-Sign_symptom
, O
was O
subsequently O
found O
to O
have O
adenocarcinoma B-Disease_disorder
of O
the O
head B-Biological_structure
of I-Biological_structure
pancreas I-Biological_structure
. O

An O
initial B-Diagnostic_procedure
workup I-Diagnostic_procedure
revealed O
localized B-Detailed_description
cancer B-Disease_disorder
with O
no O
evidence O
of O
distant B-Detailed_description
metastases B-Disease_disorder
. O

He O
then O
underwent O
pancreaticoduodenectomy B-Therapeutic_procedure
with O
complete B-Detailed_description
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
of O
a O
5 B-Distance
cm I-Distance
moderately B-Detailed_description
differentiated I-Detailed_description
pancreatic B-Biological_structure
adenocarcinoma B-Disease_disorder
. O

Although O
our O
patient O
underwent O
complete B-Detailed_description
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
, O
a O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
neoplastic B-Sign_symptom
invasion I-Sign_symptom
of O
the O
resected O
adjacent B-Biological_structure
organs I-Biological_structure
, O
and O
one B-Quantitative_concept
out I-Quantitative_concept
of I-Quantitative_concept
the I-Quantitative_concept
seven I-Quantitative_concept
resected O
lymph B-Biological_structure
nodes I-Biological_structure
contained O
cancer B-Sign_symptom
( O
T3N1M0 B-Lab_value
) O
. O

At O
that O
point O
, O
the O
oncology B-Nonbiological_location
department I-Nonbiological_location
recommended B-Clinical_event
to O
proceed O
with O
adjuvant B-Detailed_description
chemotherapy B-Medication
with O
gemcitabine B-Medication
( O
1000mg/m2 B-Dosage
IV B-Administration
on O
days B-Frequency
1 I-Frequency
, I-Frequency
8 I-Frequency
, I-Frequency
15 I-Frequency
on I-Frequency
a I-Frequency
28-day I-Frequency
cycle I-Frequency
for I-Frequency
six I-Frequency
cycles I-Frequency
) O
to O
try O
to O
reduce O
the O
likelihood O
of O
recurrence B-Sign_symptom
. O

However O
, O
after O
completing O
two B-Quantitative_concept
cycles I-Quantitative_concept
( O
a O
total O
of O
six B-Quantitative_concept
doses I-Quantitative_concept
) O
of O
chemotherapy B-Medication
, O
he O
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
worsening O
exertional B-Detailed_description
dyspnea B-Sign_symptom
, O
three-pillow B-Detailed_description
orthopnea B-Sign_symptom
, O
paroxysmal B-Detailed_description
nocturnal B-Detailed_description
dyspnea B-Sign_symptom
and O
fatigue B-Sign_symptom
. O

His O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
elevated B-Lab_value
jugular B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
JVP B-Diagnostic_procedure
) O
( O
10 B-Lab_value
cm I-Lab_value
above I-Lab_value
the I-Lab_value
sternal I-Lab_value
angle I-Lab_value
) O
, O
bibasilar B-Detailed_description
rales B-Sign_symptom
and O
+2 B-Lab_value
pitting B-Detailed_description
edema B-Sign_symptom
of O
both B-Biological_structure
lower I-Biological_structure
extremities I-Biological_structure
. O

Cardiac B-Biological_structure
auscultation B-Diagnostic_procedure
revealed O
a O
gallop B-Sign_symptom
rhythm I-Sign_symptom
with O
an O
S3 B-Detailed_description
and O
a O
grade B-Lab_value
3 I-Lab_value
holosystolic B-Detailed_description
murmur B-Sign_symptom
over O
precordium B-Biological_structure
. O

A O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
cardiomegaly B-Sign_symptom
with O
mild B-Severity
to O
moderate-sized B-Severity
right-sided B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
. O

It O
was O
thought O
that O
his O
presentation O
was O
consistent O
with O
fluid B-Sign_symptom
overload I-Sign_symptom
secondary O
to O
congestive B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
( O
CHF B-Disease_disorder
) O
and O
he O
was O
started O
on O
intravenous B-Administration
( O
IV B-Administration
) O
furosemide B-Medication
with O
partial O
improvement O
in O
his O
symptoms B-Sign_symptom
. O

The O
next B-Date
day I-Date
, O
a O
two-dimensional B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
2D B-Diagnostic_procedure
Echo I-Diagnostic_procedure
) O
was O
performed O
, O
which O
showed O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
LVEF B-Diagnostic_procedure
) O
of O
15 B-Lab_value
to I-Lab_value
20 I-Lab_value
percent I-Lab_value
with O
global B-Detailed_description
hypokinesia B-Sign_symptom
along O
with O
moderate B-Severity
mitral B-Sign_symptom
regurgitation I-Sign_symptom
. O

Given O
the O
findings O
of O
2D B-Diagnostic_procedure
Echo I-Diagnostic_procedure
and O
the O
absence O
of O
significant O
risk B-Sign_symptom
factors I-Sign_symptom
for I-Sign_symptom
coronary I-Sign_symptom
artery I-Sign_symptom
disease I-Sign_symptom
( O
CAD B-Disease_disorder
) O
and O
ischemic B-Detailed_description
cardiomyopathy B-Disease_disorder
( O
CMP B-Disease_disorder
) O
, O
it O
was O
concluded O
that O
our O
patient O
’s O
CMP B-Disease_disorder
was O
related O
to O
the O
recent O
use O
of O
gemcitabine B-Medication
. O

Our O
patient O
was O
then O
started O
on O
carvedilol B-Medication
and O
an O
angiotensin-converting B-Medication
enzyme I-Medication
inhibitor I-Medication
in O
addition O
to O
diuretics B-Medication
and O
he O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
two B-Date
days I-Date
later I-Date
in O
a O
euvolemic B-Sign_symptom
state O
. O

At O
that O
point O
, O
the O
cardiology B-Nonbiological_location
department I-Nonbiological_location
recommended B-Clinical_event
stopping O
further O
chemotherapy B-Medication
with O
gemcitabine B-Medication
. O

The O
oncology B-Nonbiological_location
department I-Nonbiological_location
advised B-Clinical_event
further O
testing B-Diagnostic_procedure
to O
rule O
out O
ischemia B-Sign_symptom
as O
a O
cause O
of O
CMP B-Disease_disorder
as O
, O
in O
their O
opinion O
, O
chemotherapy B-Medication
with O
gemcitabine B-Medication
was O
the O
only O
option O
to O
reduce O
the O
risk O
of O
recurrence B-Sign_symptom
in O
this O
patient O
. O

Two B-Date
weeks I-Date
later I-Date
, O
our O
patient O
underwent O
myocardial B-Diagnostic_procedure
perfusion I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MPI B-Diagnostic_procedure
) O
, O
which O
showed O
a O
fixed B-Detailed_description
small B-Severity
- I-Severity
to I-Severity
moderate-sized I-Severity
inferior B-Biological_structure
wall I-Biological_structure
defect B-Sign_symptom
without O
any O
evidence O
of O
active O
ischemia B-Sign_symptom
. O

The O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
EF B-Diagnostic_procedure
) O
on O
MPI B-Diagnostic_procedure
was O
calculated O
to O
be O
around O
17 B-Lab_value
to I-Lab_value
20 I-Lab_value
percent I-Lab_value
with O
severe B-Severity
global B-Detailed_description
hypokinesia B-Sign_symptom
. O

Our O
patient O
was O
continued O
on O
standard O
heart B-Therapeutic_procedure
failure I-Therapeutic_procedure
therapy I-Therapeutic_procedure
with O
one O
more O
admission B-Clinical_event
to O
the O
hospital B-Nonbiological_location
for O
CHF B-Disease_disorder
exacerbation B-Detailed_description
about O
two B-Date
months I-Date
later I-Date
. O

He O
responded O
well O
to O
IV B-Administration
furosemide B-Medication
and O
adjustment B-Detailed_description
of O
heart B-Therapeutic_procedure
failure I-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

A O
2D B-Diagnostic_procedure
Echo I-Diagnostic_procedure
was O
repeated O
a B-Date
few I-Date
months I-Date
later I-Date
and O
it O
showed O
improvement B-Lab_value
in O
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
with O
an O
LVEF B-Diagnostic_procedure
of O
40 B-Lab_value
percent I-Lab_value
. O

Due O
to O
his O
poor B-Lab_value
functional B-Diagnostic_procedure
status I-Diagnostic_procedure
and O
underlying O
CMP B-Disease_disorder
, O
further O
gemcitabine B-Medication
chemotherapy B-Medication
was O
stopped O
. O

Later O
, O
our O
patient O
developed O
a O
recurrence B-Sign_symptom
of O
his O
pancreatic B-Disease_disorder
cancer I-Disease_disorder
; O
he O
refused O
further O
chemotherapy B-Medication
and O
decided O
to O
proceed O
with O
palliative B-Therapeutic_procedure
care I-Therapeutic_procedure
. O

Although O
the O
exact O
etiology O
of O
our O
patient O
’s O
dilated B-Detailed_description
cardiomyopathy B-Disease_disorder
remains O
unclear O
, O
gemcitabine B-Medication
remains O
the O
most O
likely O
culprit O
. O

The O
temporal O
relationship O
of O
his O
symptoms O
to O
the O
initiation O
of O
gemcitabine B-Medication
chemotherapy B-Medication
; O
the O
lack O
of O
risk B-Sign_symptom
factors I-Sign_symptom
for I-Sign_symptom
ischemic I-Sign_symptom
CMP I-Sign_symptom
and O
prior O
history B-History
of I-History
CAD I-History
, O
finding O
of O
global B-Detailed_description
hypokinesia B-Sign_symptom
on O
2D B-Diagnostic_procedure
Echo I-Diagnostic_procedure
, O
absence O
of O
ischemia B-Sign_symptom
on O
MPI B-Diagnostic_procedure
; O
and O
improvement B-Lab_value
in O
his O
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
after O
discontinuation O
of O
gemcitabine B-Medication
were O
all O
consistent O
with O
gemcitabine-induced B-Medication
cardiomyopathy B-Disease_disorder
. O

A O
66-year-old B-Age
Caucasian B-Personal_background
woman B-Sex
with O
a O
history O
of O
hypertension B-History
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
a O
recent O
diagnosis O
of O
Burkitt B-Disease_disorder
lymphoma I-Disease_disorder
. O

Her O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
level O
was O
high B-Qualitative_concept
and O
the O
diameter O
of O
her O
mediastinal B-Biological_structure
mass B-Sign_symptom
was O
more B-Distance
than I-Distance
10 I-Distance
cm I-Distance
. O

Her O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
, O
and O
basal B-Detailed_description
electrocardiography B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
showed O
sinus B-Sign_symptom
rhythm I-Sign_symptom
with O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
72 B-Lab_value
beats/minute I-Lab_value
. O

Two-dimensional B-Diagnostic_procedure
transthoracic I-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
; O
Siemens B-Detailed_description
, O
Acuson B-Detailed_description
Sequoia I-Detailed_description
, O
C512 B-Detailed_description
) O
revealed O
normal B-Lab_value
biventricular B-Diagnostic_procedure
functions I-Diagnostic_procedure
with O
an O
LV B-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
LVEF B-Diagnostic_procedure
) O
of O
60 B-Lab_value
% I-Lab_value
, O
mild B-Severity
mitral B-Biological_structure
and O
tricuspid B-Biological_structure
regurgitation B-Sign_symptom
, O
and O
moderate B-Severity
pericardial B-Sign_symptom
effusion I-Sign_symptom
. O

A O
risk B-Diagnostic_procedure
assessment I-Diagnostic_procedure
of O
the O
patient O
put O
her O
into O
a O
high-risk B-Qualitative_concept
category O
and O
she O
underwent O
rituximab-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-dexamethasone B-Medication
( O
R-Hyper-CVAD B-Medication
) O
chemotherapy B-Medication
protocol O
. O

Her O
laboratory B-Diagnostic_procedure
values I-Diagnostic_procedure
are O
summarized O
in O
Table O
1 O
. O

She O
received O
high-dose B-Dosage
cyclophosphamide B-Medication
300mg/m2 B-Dosage
twice I-Dosage
daily I-Dosage
for O
3 B-Duration
days I-Duration
, O
doxorubicin B-Medication
25mg/m2/day B-Dosage
for O
2 B-Duration
days I-Duration
, O
rituximab B-Medication
375mg/m2/day B-Dosage
for O
1 B-Duration
day I-Duration
, O
dexamethasone B-Medication
40mg/day B-Dosage
for O
4 B-Duration
days I-Duration
, O
and O
vincristine B-Medication
2mg/day B-Dosage
for O
2 B-Duration
days I-Duration
. O

The O
total O
treatment O
dose O
of O
cyclophosphamide B-Medication
and O
doxorubicin B-Medication
received O
was O
1800mg/m2 B-Dosage
and O
50mg/m2 B-Dosage
, O
respectively O
. O

She O
was O
given O
allopurinol B-Medication
300mg/day B-Dosage
perorally B-Administration
, O
sodium B-Medication
bicarbonate I-Medication
( O
8.4 B-Dosage
% I-Dosage
, O
10 B-Dosage
flacon/day I-Dosage
) O
infusion B-Administration
for O
24 B-Duration
hours I-Duration
before I-Duration
chemotherapy B-Medication
, O
and O
mesna B-Medication
600mg/m2/day B-Dosage
for O
2 B-Duration
days I-Duration
as O
prophylaxis B-Therapeutic_procedure
against O
tumor B-Disease_disorder
lysis I-Disease_disorder
syndrome I-Disease_disorder
and O
hemorrhagic B-Disease_disorder
cystitis I-Disease_disorder
, O
respectively O
. O

She O
also O
received O
granisetron B-Medication
2mg/day B-Dosage
and O
lansoprazole B-Medication
30mg/day B-Dosage
as O
antiemetogenic B-Detailed_description
and O
gastric B-Biological_structure
prophylaxis B-Therapeutic_procedure
, O
respectively O
. O

The O
patient O
developed O
dyspnea B-Sign_symptom
on O
the O
seventh B-Date
day I-Date
of O
therapy O
. O

A O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
100/60mmHg B-Lab_value
and O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
110 B-Lab_value
beats/minute I-Lab_value
. O

On O
chest B-Biological_structure
auscultation B-Diagnostic_procedure
, O
no O
inspiratory B-Sign_symptom
sounds I-Sign_symptom
were O
heard O
at O
lower B-Biological_structure
zones I-Biological_structure
and O
inspiratory B-Sign_symptom
crackles I-Sign_symptom
were O
heard O
at O
middle B-Biological_structure
zones I-Biological_structure
. O

Neither O
cardiac B-Sign_symptom
murmurs I-Sign_symptom
nor O
S3 B-Sign_symptom
were O
heard O
. O

An O
ECG B-Diagnostic_procedure
showed O
low B-Lab_value
voltage I-Lab_value
in O
the O
limb B-Diagnostic_procedure
and I-Diagnostic_procedure
precordial I-Diagnostic_procedure
leads I-Diagnostic_procedure
. O

TTE B-Diagnostic_procedure
showed O
diffusely B-Lab_value
increased I-Lab_value
myocardial B-Biological_structure
echogenicity B-Diagnostic_procedure
, O
mild B-Severity
pericardial B-Sign_symptom
effusion I-Sign_symptom
, O
and O
generally B-Lab_value
impaired I-Lab_value
biventricular B-Detailed_description
systolic B-Diagnostic_procedure
functions I-Diagnostic_procedure
with O
an O
LVEF B-Diagnostic_procedure
31 B-Lab_value
% I-Lab_value
and O
right B-Biological_structure
ventricular I-Biological_structure
mid-apical B-Detailed_description
akinesis B-Sign_symptom
. O

Manifest B-Detailed_description
pleural B-Sign_symptom
effusion I-Sign_symptom
was O
also O
detected O
. O

Drug-induced B-Disease_disorder
cardiotoxicity I-Disease_disorder
( O
myocarditis B-Disease_disorder
) O
was O
suspected O
. O

Furosemide B-Medication
and O
ramipril B-Medication
were O
started O
. O

The O
beta-blocker B-Medication
therapy O
the O
patient O
was O
already O
taking O
for O
hypertension B-Sign_symptom
was O
continued O
. O

After B-Date
12 I-Date
days I-Date
, O
TTE B-Diagnostic_procedure
showed O
an O
LVEF B-Diagnostic_procedure
of O
37 B-Lab_value
% I-Lab_value
and O
normal B-Lab_value
right B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
functions I-Diagnostic_procedure
. O

Her O
dyspnea B-Sign_symptom
decreased O
and O
she O
was O
discharged B-Activity
on O
day B-Date
20 I-Date
. O

After B-Date
1 I-Date
month I-Date
, O
TTE B-Diagnostic_procedure
showed O
normal B-Lab_value
biventricular B-Diagnostic_procedure
functions I-Diagnostic_procedure
with O
an O
LVEF B-Diagnostic_procedure
of O
60 B-Lab_value
% I-Lab_value
. O

After O
the O
first O
course O
of O
the O
R-Hyper-CVAD B-Medication
chemotherapy B-Medication
protocol O
, O
she O
underwent O
a O
high-dose B-Dosage
methotrexate B-Medication
and O
cytarabine B-Medication
cycle O
. O

She O
had O
severe O
neutropenia B-Sign_symptom
and O
pneumonia B-Disease_disorder
. O

She O
had O
no O
cardiac B-Sign_symptom
failure I-Sign_symptom
symptoms I-Sign_symptom
during O
this O
chemotherapy B-Medication
course O
, O
but O
she O
declined O
another B-Detailed_description
course I-Detailed_description
of O
chemotherapy B-Medication
. O

She O
is O
still O
in O
remission B-Sign_symptom
despite O
the O
abbreviated O
course O
of O
chemotherapy B-Medication
. O

A O
29-year-old B-Age
primipara B-History
presented B-Clinical_event
with O
complaints O
of O
persistent B-Detailed_description
, O
severe B-Severity
right B-Detailed_description
- I-Detailed_description
sided I-Detailed_description
upper B-Biological_structure
abdominal I-Biological_structure
pain B-Sign_symptom
during B-Detailed_description
deep I-Detailed_description
inspiration I-Detailed_description
, O
physical B-Activity
exercise I-Activity
and O
on B-Detailed_description
local I-Detailed_description
pressure I-Detailed_description
. O

These O
complaints B-Coreference
had O
developed B-Detailed_description
gradually I-Detailed_description
after O
giving B-Clinical_event
birth I-Clinical_event
one B-Date
year I-Date
earlier I-Date
. O

This O
pregnancy B-Clinical_event
had O
been O
complicated O
by O
HELLP B-Disease_disorder
syndrome I-Disease_disorder
with O
a O
subcapsular B-Detailed_description
liver B-Biological_structure
hematoma B-Sign_symptom
sized O
20 B-Area
cm I-Area
× I-Area
5 I-Area
cm I-Area
, O
which O
had O
resolved B-Detailed_description
spontaneously I-Detailed_description
. O

At O
current O
presentation O
, O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
normal B-Lab_value
. O

She O
assured O
having O
never O
experienced O
signs O
suggestive O
of O
sexually B-Disease_disorder
transmitted I-Disease_disorder
diseases I-Disease_disorder
or O
pelvic B-Disease_disorder
inflammatory I-Disease_disorder
disease I-Disease_disorder
( B-Disease_disorder
PID I-Disease_disorder
) I-Disease_disorder
. O

She O
had O
never O
undergone O
intra-abdominal B-Biological_structure
interventions B-Therapeutic_procedure
. O

An O
upper-abdominal B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
revealed O
a O
density B-Sign_symptom
between B-Biological_structure
liver I-Biological_structure
and I-Biological_structure
diaphragm I-Biological_structure
at O
the O
site B-Biological_structure
of I-Biological_structure
the I-Biological_structure
former I-Biological_structure
subcapsular I-Biological_structure
hematoma I-Biological_structure
, O
suspect O
of O
perihepatic B-Sign_symptom
adhesions I-Sign_symptom
( O
Figure O
1 O
) O
. O

She O
was O
referred B-Clinical_event
to O
the O
hepatobiliary B-Nonbiological_location
surgeon I-Nonbiological_location
, O
who O
performed O
a O
laparoscopy B-Diagnostic_procedure
and O
confirmed O
the O
presence O
of O
a O
thick B-Detailed_description
adhesion B-Sign_symptom
between B-Biological_structure
liver I-Biological_structure
segment I-Biological_structure
V/VIII I-Biological_structure
and I-Biological_structure
the I-Biological_structure
diaphragm I-Biological_structure
( O
Figure O
2 O
) O
. O

Adhesiolysis B-Therapeutic_procedure
was O
performed O
in O
the O
same O
session O
by O
monopolar B-Therapeutic_procedure
diathermia I-Therapeutic_procedure
and O
sharp B-Therapeutic_procedure
dissection I-Therapeutic_procedure
, O
followed O
by O
the O
instillation O
of O
1.5 B-Dosage
L I-Dosage
Adept B-Medication
( O
4 B-Medication
% I-Medication
icodextrin I-Medication
solution I-Medication
) O
into B-Administration
the I-Administration
peritoneal I-Administration
cavity I-Administration
to O
prevent O
the O
formation O
of O
new O
adhesions O
. O

On O
follow-up B-Clinical_event
until B-Duration
three I-Duration
years I-Duration
post-surgery I-Duration
, O
she O
was O
free O
of O
symptoms B-Sign_symptom
. O

A O
45-year-old B-Age
woman B-Sex
presents B-Clinical_event
to O
her O
general B-Nonbiological_location
practitioner I-Nonbiological_location
because O
of O
left-sided B-Detailed_description
neck B-Biological_structure
and O
shoulder B-Biological_structure
pain B-Sign_symptom
. O

The O
pain B-Sign_symptom
was O
mild B-Severity
and O
non-specific B-Detailed_description
and O
the O
patient O
's O
history B-History
was I-History
unremarkable I-History
. O

She O
denied B-History
a I-History
history I-History
of I-History
smoking I-History
, I-History
excessive I-History
alcohol I-History
use I-History
and I-History
radiation I-History
exposure I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
mild B-Severity
left B-Detailed_description
sided I-Detailed_description
cervical B-Biological_structure
lymphadenopathy B-Sign_symptom
. O

Routine O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
borderline B-Lab_value
elevated I-Lab_value
calcium B-Diagnostic_procedure
of O
10.5 B-Lab_value
mg/dL I-Lab_value
and O
subsequent O
work B-Diagnostic_procedure
up I-Diagnostic_procedure
exhibited O
a O
markedly O
elevated B-Lab_value
parathyroid B-Diagnostic_procedure
hormone I-Diagnostic_procedure
level O
of O
286 B-Lab_value
pg/mL I-Lab_value
, O
so O
the O
patient O
was O
referred B-Clinical_event
to O
otolaryngology B-Nonbiological_location
for O
further O
evaluation O
. O

Thyroid B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
hypoechoic B-Detailed_description
nodule B-Sign_symptom
in O
the O
left B-Biological_structure
lower I-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
thyroid I-Biological_structure
. O

CT B-Diagnostic_procedure
scan O
of O
the O
neck B-Biological_structure
revealed O
a O
2 B-Distance
cm I-Distance
hypodense B-Detailed_description
nodule B-Sign_symptom
on O
the O
posterior B-Biological_structure
inferior I-Biological_structure
aspect I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
lower I-Biological_structure
thyroid I-Biological_structure
and O
sestamibi B-Diagnostic_procedure
scan O
showed O
increased B-Sign_symptom
uptake I-Sign_symptom
along O
the O
lower B-Biological_structure
pole I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
thyroid I-Biological_structure
lobe I-Biological_structure
. O

Elevated B-Lab_value
PTH B-Diagnostic_procedure
along O
with O
an O
aberrant B-Sign_symptom
parathyroid B-Biological_structure
gland I-Biological_structure
on O
imaging B-Diagnostic_procedure
suggests O
primary B-Detailed_description
hyperparathyroidism B-Disease_disorder
. O

Historically O
, O
hyperparathyroidism B-Disease_disorder
is O
associated O
with O
bone B-Disease_disorder
disease I-Disease_disorder
, O
renal B-Disease_disorder
stones I-Disease_disorder
and O
neuromuscular B-Disease_disorder
dysfunction I-Disease_disorder
, O
however O
, O
with O
the O
current O
screening B-Diagnostic_procedure
modalities I-Diagnostic_procedure
, O
most O
patients O
are O
caught O
early O
and O
often O
asymptomatic B-Sign_symptom
.3 O
Primary B-Detailed_description
hyperparathyroidism B-Disease_disorder
is O
most O
commonly O
caused O
by O
a O
parathyroid B-Biological_structure
adenoma B-Disease_disorder
. O

Infrequent O
causes O
include O
parathyroid B-Biological_structure
hyperplasia B-Disease_disorder
, O
which O
would O
affect O
all O
four O
glands O
and O
rarely O
caused O
by O
parathyroid B-Biological_structure
carcinoma B-Disease_disorder
. O

Markedly O
elevated B-Lab_value
serum B-Detailed_description
PTH B-Diagnostic_procedure
and O
calcium B-Diagnostic_procedure
levels O
leading O
to O
severe B-Severity
renal B-Biological_structure
and O
bone B-Biological_structure
manifestations B-Sign_symptom
are O
helpful O
in O
the O
diagnosis O
of O
cancer B-Disease_disorder
, O
however O
, O
it O
is O
usually O
discovered O
operatively B-Therapeutic_procedure
based O
on O
local O
invasion B-Sign_symptom
and O
metastases B-Disease_disorder
.3 O
The O
primary O
indication O
for O
parathyroidectomy B-Therapeutic_procedure
, O
historically O
, O
is O
for O
symptomatic O
patients O
. O

Currently O
, O
since O
most O
patients O
are O
caught O
earlier O
, O
there O
are O
newer O
indications O
for O
surgery B-Therapeutic_procedure
. O

These O
include O
an O
asymptomatic O
patient O
with O
any O
of O
the O
following O
: O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
< O
60 O
mL/min O
, O
bone B-Diagnostic_procedure
density I-Diagnostic_procedure
T-score I-Diagnostic_procedure
< O
− O
2.5 O
at O
any O
site O
and/or O
previous O
fractures B-Disease_disorder
, O
age O
< O
50 O
, O
and O
serum B-Detailed_description
calcium B-Diagnostic_procedure
1.0 O
ng/dL O
above O
the O
upper O
limit O
of O
normal O
.3 O
This O
patient O
presented O
with O
pain B-Sign_symptom
, O
markedly O
elevated B-Lab_value
PTH B-Diagnostic_procedure
, O
and O
was O
younger B-Age
than I-Age
50 I-Age
years I-Age
old I-Age
, O
so O
it O
was O
decided O
that O
surgery B-Therapeutic_procedure
was O
the O
best O
choice O
in O
management O
. O

The O
patient O
was O
brought B-Clinical_event
to O
the O
operating B-Nonbiological_location
room I-Nonbiological_location
and O
underwent O
a O
parathyroidectomy B-Therapeutic_procedure
. O

The O
surgeon O
found O
the O
parathyroid B-Biological_structure
gland I-Biological_structure
to O
be O
firm B-Sign_symptom
and O
densely B-Detailed_description
adherent B-Sign_symptom
to O
the O
thyroid B-Biological_structure
capsule I-Biological_structure
and O
overlying O
strap B-Biological_structure
muscle I-Biological_structure
, O
making O
it O
difficult O
to O
dissect B-Therapeutic_procedure
. O

There O
was O
no O
visible O
invasion B-Sign_symptom
into O
the O
capsule B-Biological_structure
, O
surrounding O
muscle B-Biological_structure
or O
regional O
lymph B-Biological_structure
nodes I-Biological_structure
. O

The O
resected B-Diagnostic_procedure
specimen I-Diagnostic_procedure
was O
noted O
to O
be O
brownish B-Color
grey I-Color
in O
colour O
with O
scattered B-Detailed_description
necrotic B-Sign_symptom
foci I-Sign_symptom
, O
and O
irregular B-Texture
texture I-Texture
. O

On O
postoperative O
pathology B-Diagnostic_procedure
, O
the O
specimen O
was O
confirmed O
positive O
for O
parathyroid B-Disease_disorder
carcinoma I-Disease_disorder
with O
capsular B-Biological_structure
invasion B-Sign_symptom
, O
focal B-Detailed_description
tumour B-Sign_symptom
necrosis I-Sign_symptom
, O
reactive B-Detailed_description
fibrosis B-Sign_symptom
and O
local O
skeletal B-Biological_structure
muscle I-Biological_structure
invasion B-Sign_symptom
( O
figures O
1 O
and O
2 O
) O
. O

Margins B-Therapeutic_procedure
were I-Therapeutic_procedure
resected I-Therapeutic_procedure
. O

Immunohistochemical B-Diagnostic_procedure
stains I-Diagnostic_procedure
showed O
increased B-Lab_value
Ki-67 B-Diagnostic_procedure
reactivity O
as O
well O
as O
strong B-Lab_value
Bcl-1 B-Diagnostic_procedure
( O
cyclin B-Diagnostic_procedure
D1 I-Diagnostic_procedure
) O
reactivity O
, O
which O
support O
the O
diagnosis O
of O
parathyroid B-Disease_disorder
carcinoma I-Disease_disorder
( O
figure O
3 O
) O
. O

Additionally O
, O
P57 B-Diagnostic_procedure
staining I-Diagnostic_procedure
was O
negative B-Lab_value
. O

Although O
most O
reports O
of O
parathyroid B-Disease_disorder
carcinomas I-Disease_disorder
are O
associated O
with O
marked O
hypercalcaemia B-Sign_symptom
, O
non-functioning O
cancers O
in O
patients O
tend O
to O
behave O
more O
aggressively O
.1 O
Owing O
to O
the O
severity O
and O
uncertainty O
of O
the O
lesion O
, O
the O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
postoperatively O
for O
repeat O
imaging B-Diagnostic_procedure
to O
determine O
if O
residual B-Detailed_description
tumour B-Sign_symptom
remained O
. O

Repeat O
sestamibi B-Diagnostic_procedure
and O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
scan O
revealed O
residual O
activity O
along O
the O
surgical O
area O
so O
the O
patient O
subsequently O
underwent O
a O
second O
operation B-Therapeutic_procedure
for O
a O
radical B-Detailed_description
left B-Detailed_description
neck B-Biological_structure
dissection B-Therapeutic_procedure
and O
left B-Detailed_description
hemithyroidectomy B-Therapeutic_procedure
. O

The O
patient O
recovered B-Sign_symptom
very O
well O
postoperatively O
and O
it O
has O
now O
been O
3 B-Date
years I-Date
since O
the O
second O
surgery B-Therapeutic_procedure
. O

The O
patient O
continues B-Outcome
to I-Outcome
do I-Outcome
very I-Outcome
well I-Outcome
and O
is O
followed B-Clinical_event
up I-Clinical_event
every B-Frequency
3 I-Frequency
months I-Frequency
to O
monitor O
serum B-Detailed_description
PTH B-Diagnostic_procedure
and O
calcium B-Diagnostic_procedure
levels O
. O

She O
no O
longer O
reports O
of O
neck B-Biological_structure
and O
shoulder B-Biological_structure
pain B-Sign_symptom
. O

Sometimes B-Frequency
the O
patient O
's O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
show O
marginally B-Lab_value
elevated I-Lab_value
PTH B-Diagnostic_procedure
levels O
, O
however O
, O
she O
remains O
eucalcaemic B-Sign_symptom
and O
follow-up O
nuclear B-Diagnostic_procedure
scans I-Diagnostic_procedure
and O
PET B-Diagnostic_procedure
scans O
continue O
to O
be O
negative B-Lab_value
. O

The O
patient O
will O
continue O
to O
be O
monitored B-Clinical_event
every B-Frequency
3 I-Frequency
months I-Frequency
indefinitely O
. O

A O
20-year-old B-Age
male B-Sex
with O
cystic B-History
fibrosis I-History
was O
transferred B-Clinical_event
to O
Houston B-Nonbiological_location
Methodist I-Nonbiological_location
Hospital I-Nonbiological_location
in O
January B-Date
2013 I-Date
to O
be O
evaluated B-Clinical_event
for O
lung B-Biological_structure
and O
kidney B-Biological_structure
transplant B-Therapeutic_procedure
. O

Patients O
with O
cystic O
fibrosis O
are O
known O
to O
develop O
chronic O
lung O
infections O
that O
adapt O
over O
time O
to O
this O
unique O
anatomic O
niche O
( O
14 O
, O
15 O
) O
. O

His O
complicated O
medical O
history O
included O
pancreatic B-Disease_disorder
insufficiency I-Disease_disorder
, O
liver B-Biological_structure
transplantation B-History
in I-History
2004 I-History
, O
steroid-induced B-Medication
diabetes B-History
, O
end-stage B-Disease_disorder
renal I-Disease_disorder
disease I-Disease_disorder
, O
and O
testicular B-Disease_disorder
cancer I-Disease_disorder
. O

He O
had O
a O
long O
history O
of O
respiratory B-Disease_disorder
infections I-Disease_disorder
with B-History
several I-History
multidrug-resistant I-History
bacteria I-History
, I-History
including I-History
MRSA I-History
. O

He O
was O
treated O
with O
ceftaroline B-Medication
at O
an O
outside B-Nonbiological_location
hospital I-Nonbiological_location
immediately O
prior O
to O
transfer B-Clinical_event
to O
Houston B-Nonbiological_location
Methodist I-Nonbiological_location
Hospital I-Nonbiological_location
. O

The O
patient O
was O
periodically B-Frequency
hospitalized B-Clinical_event
from O
January B-Duration
to I-Duration
July I-Duration
2013 I-Duration
and O
was O
treated O
for O
recurrent O
respiratory B-Biological_structure
and O
catheter-related B-Detailed_description
infections B-Disease_disorder
caused O
by O
MRSA B-Disease_disorder
and O
multidrug-resistant B-Disease_disorder
Pseudomonas I-Disease_disorder
aeruginosa I-Disease_disorder
. O

His O
antibiotic B-Medication
exposure O
included O
long O
treatment O
courses O
with O
various O
agents O
, O
including O
meropenem B-Medication
, O
ceftazidime B-Medication
, O
doxycycline B-Medication
, O
vancomycin B-Medication
, O
linezolid B-Medication
, O
cefepime B-Medication
, O
ciprofloxacin B-Medication
, O
and O
inhaled B-Administration
and O
systemic B-Administration
colistin B-Medication
and O
tobramycin B-Medication
. O

Shortly O
after O
being O
readmitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
in O
June B-Date
2013 I-Date
, O
MRSA B-Disease_disorder
was O
grown O
from O
cultures B-Diagnostic_procedure
of O
blood B-Biological_structure
and O
respiratory B-Biological_structure
specimens I-Biological_structure
. O

These O
two O
isolates B-Coreference
were O
resistant B-Lab_value
to O
clindamycin B-Diagnostic_procedure
, O
linezolid B-Diagnostic_procedure
, O
oxacillin B-Diagnostic_procedure
, O
and O
trimethoprim-sulfamethoxazole B-Diagnostic_procedure
and O
susceptible B-Lab_value
to O
minocycline B-Diagnostic_procedure
, O
rifampin B-Diagnostic_procedure
, O
and O
vancomycin B-Diagnostic_procedure
. O

His O
blood B-Biological_structure
isolate B-Diagnostic_procedure
grew B-Lab_value
confluently I-Lab_value
around O
the O
ceftaroline B-Diagnostic_procedure
Etest I-Diagnostic_procedure
strip I-Diagnostic_procedure
, O
yielding O
an O
MIC B-Lab_value
of I-Lab_value
> I-Lab_value
32 I-Lab_value
mg/liter I-Lab_value
. O

Five B-Lab_value
additional O
S. B-Disease_disorder
aureus I-Disease_disorder
respiratory B-Biological_structure
tract I-Biological_structure
isolates B-Diagnostic_procedure
were O
available O
for O
further O
study O
. O

All O
MRSA O
isolates O
from O
this O
patient O
had O
a O
small-colony-variant O
( O
SCV O
) O
phenotype O
. O

A O
19-year-old B-Age
woman B-Sex
presented O
with O
a O
lump B-Sign_symptom
in O
her O
right B-Biological_structure
breast I-Biological_structure
. O

She O
had O
macrocephaly B-Disease_disorder
and O
milimetric B-Biological_attribute
papules B-Sign_symptom
on O
the O
tongue B-Biological_structure
giving O
a O
cobble B-Texture
stone I-Texture
appearance O
. O

The O
breast B-Biological_structure
ultrasonography B-Diagnostic_procedure
( O
US B-Diagnostic_procedure
) O
showed O
more B-Lab_value
than I-Lab_value
twenty I-Lab_value
circumscribed B-Detailed_description
, O
oval B-Shape
masses B-Disease_disorder
in O
each O
breast B-Biological_structure
. O

An O
US-guided B-Detailed_description
core I-Detailed_description
biopsy B-Diagnostic_procedure
was O
performed O
for O
the O
palpable B-Detailed_description
masses B-Disease_disorder
which O
were O
confirmed O
as O
juvenile B-Detailed_description
fibroadenomas B-Disease_disorder
. O

After O
the O
biopsy O
, O
a O
breast B-Biological_structure
US B-Diagnostic_procedure
was O
done O
as O
follow-up O
every B-Frequency
6 I-Frequency
or I-Frequency
12 I-Frequency
months I-Frequency
for O
3 B-Duration
years I-Duration
. O

During O
the O
surveillance O
period O
, O
core B-Detailed_description
biopsies B-Diagnostic_procedure
were O
performed O
six B-Quantitative_concept
times I-Quantitative_concept
, O
followed O
by O
US-guided B-Detailed_description
vacuum-assisted B-Detailed_description
core B-Detailed_description
needle B-Diagnostic_procedure
excisions I-Diagnostic_procedure
or O
surgical B-Diagnostic_procedure
excisions I-Diagnostic_procedure
of O
lesions B-Disease_disorder
with O
increased B-Lab_value
sizes I-Lab_value
. O

Pathologic B-Coreference
results I-Coreference
were O
fibroadenoma B-Disease_disorder
, O
tubular B-Disease_disorder
adenoma I-Disease_disorder
or O
atypical B-Disease_disorder
ductal I-Disease_disorder
hyperplasia I-Disease_disorder
( O
ADH B-Disease_disorder
) O
involving O
fibroadenoma B-Disease_disorder
. O

At B-Date
the I-Date
age I-Date
of I-Date
19 I-Date
years I-Date
, O
the O
patient O
underwent O
a O
neck B-Biological_structure
US B-Diagnostic_procedure
for O
a O
palpable B-Detailed_description
mass B-Disease_disorder
in O
the O
left B-Biological_structure
neck I-Biological_structure
. O

Several O
indeterminate B-Detailed_description
nodules B-Sign_symptom
were O
revealed O
in O
both B-Lab_value
thyroid B-Biological_structure
glands I-Biological_structure
. O

A O
follow-up B-Detailed_description
US B-Diagnostic_procedure
revealed O
that O
some B-Lab_value
of O
those O
nodules B-Sign_symptom
increased B-Lab_value
in I-Lab_value
size I-Lab_value
. O

The O
patient O
underwent O
a O
total B-Detailed_description
thyroidectomy B-Therapeutic_procedure
and O
the O
pathologic O
result O
revealed O
an O
invasive B-Detailed_description
follicular B-Disease_disorder
carcinoma I-Disease_disorder
in O
the O
left B-Biological_structure
thyroid I-Biological_structure
and O
follicular B-Disease_disorder
adenoma I-Disease_disorder
in O
the O
right B-Biological_structure
thyroid I-Biological_structure
( O
Fig. O
1A O
) O
. O

At B-Date
the I-Date
age I-Date
of I-Date
21 I-Date
years I-Date
, O
she O
visited B-Clinical_event
the O
hospital B-Nonbiological_location
due O
to O
a O
swelling B-Sign_symptom
of O
her O
left B-Biological_structure
cheek I-Biological_structure
. O

Head B-Biological_structure
and O
neck B-Biological_structure
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
revealed O
a O
vascular B-Biological_structure
mass B-Disease_disorder
in O
the O
left B-Biological_structure
parotid I-Biological_structure
gland I-Biological_structure
extended O
into O
the O
left B-Biological_structure
forehead I-Biological_structure
. O

An O
external B-Biological_structure
carotid I-Biological_structure
angiography B-Diagnostic_procedure
confirmed O
the O
diagnosis O
of O
an O
AVM B-Disease_disorder
with O
feeder B-Biological_structure
vessel I-Biological_structure
arising O
from O
the O
left B-Biological_structure
internal I-Biological_structure
maxillary I-Biological_structure
artery I-Biological_structure
( O
Fig. O
1B O
) O
. O

A O
partial B-Detailed_description
embolization B-Therapeutic_procedure
decreased B-Lab_value
the O
blood B-Diagnostic_procedure
flow I-Diagnostic_procedure
through O
the O
AVM B-Disease_disorder
, O
alleviating O
the B-Coreference
patient I-Coreference
's I-Coreference
symptom I-Coreference
. O

She O
was O
referred O
to O
genetic B-Therapeutic_procedure
counseling I-Therapeutic_procedure
under O
the O
suggestion O
of O
a O
Cowden B-Disease_disorder
syndrome I-Disease_disorder
and O
the O
PTEN B-Diagnostic_procedure
DNA B-Diagnostic_procedure
sequencing I-Diagnostic_procedure
test I-Diagnostic_procedure
of O
her O
blood B-Diagnostic_procedure
sample I-Diagnostic_procedure
revealed O
a O
frameshift B-Diagnostic_procedure
mutation I-Diagnostic_procedure
, O
c. B-Diagnostic_procedure
301dupA I-Diagnostic_procedure
( O
p.I101NfsX6 B-Diagnostic_procedure
) O
. O

At B-Date
the I-Date
age I-Date
of I-Date
22 I-Date
years I-Date
, O
the O
patient O
presented O
with O
a O
mass B-Disease_disorder
with O
increased B-Lab_value
size I-Lab_value
and O
increased B-Lab_value
vascularity I-Lab_value
in O
the O
left B-Biological_structure
breast I-Biological_structure
. O

An O
US-guided B-Detailed_description
vacuum-assisted B-Detailed_description
core B-Detailed_description
needle B-Diagnostic_procedure
excision I-Diagnostic_procedure
revealed O
a O
ductal B-Disease_disorder
carcinoma I-Disease_disorder
in I-Disease_disorder
situ I-Disease_disorder
( O
DCIS B-Disease_disorder
) O
of O
non-comedo B-Detailed_description
type I-Detailed_description
and O
a O
low B-Lab_value
grade I-Lab_value
involving O
fibroadenoma B-Disease_disorder
( O
Fig. O
1C O
) O
. O

The O
contrast-enhanced B-Detailed_description
breast B-Biological_structure
MRI B-Diagnostic_procedure
for O
the O
preoperative O
evaluation O
demonstrated O
multiple B-Lab_value
, O
well-circumscribed B-Detailed_description
, O
enhancing B-Lab_value
masses B-Disease_disorder
in O
both B-Lab_value
breasts B-Biological_structure
( O
Fig. O
1D O
) O
. O

All B-Lab_value
masses B-Disease_disorder
showed O
high B-Severity
or O
intermediate B-Severity
signal B-Diagnostic_procedure
intensity I-Diagnostic_procedure
on O
T2-weighted B-Diagnostic_procedure
images I-Diagnostic_procedure
( O
Fig. O
1E O
) O
. O

Several B-Lab_value
masses B-Disease_disorder
showed O
an O
early B-Detailed_description
rapid I-Detailed_description
enhancement I-Detailed_description
with O
washout B-Diagnostic_procedure
kinetic I-Diagnostic_procedure
pattern I-Diagnostic_procedure
on O
time-signal B-Diagnostic_procedure
intensity I-Diagnostic_procedure
curve I-Diagnostic_procedure
evaluation I-Diagnostic_procedure
, O
which O
tends O
to O
be O
associated O
with O
malignancy B-Disease_disorder
( O
Fig. O
1F O
) O
. O

A O
bilateral B-Detailed_description
prophylactic I-Detailed_description
mastectomy B-Therapeutic_procedure
with O
immediate B-Detailed_description
breast B-Therapeutic_procedure
reconstruction I-Therapeutic_procedure
was O
performed O
in O
view O
of O
multiple B-Lab_value
bilateral B-Detailed_description
breast B-Biological_structure
masses B-Disease_disorder
with O
suspicious B-Detailed_description
kinetic B-Diagnostic_procedure
features I-Diagnostic_procedure
on O
breast B-Biological_structure
MRI B-Diagnostic_procedure
and O
a O
high O
risk O
for O
breast B-Disease_disorder
cancer I-Disease_disorder
of O
Cowden B-Disease_disorder
syndrome I-Disease_disorder
. O

The O
surgical B-Diagnostic_procedure
histopathology I-Diagnostic_procedure
revealed O
ADH B-Disease_disorder
involving O
tubular B-Disease_disorder
adenoma I-Disease_disorder
without O
residual B-Detailed_description
carcinoma B-Disease_disorder
in O
the O
left B-Biological_structure
breast I-Biological_structure
and O
multiple B-Lab_value
tubular B-Disease_disorder
adenomas I-Disease_disorder
, O
fibroadenomas B-Disease_disorder
and O
intraductal B-Disease_disorder
papillomas I-Disease_disorder
in O
both B-Lab_value
breasts B-Biological_structure
. O

The O
patient O
had O
no O
family O
history O
of O
breast B-Disease_disorder
cancer I-Disease_disorder
or O
Cowden B-Disease_disorder
syndrome I-Disease_disorder
. O

Our O
patient O
( O
ID O
73387 O
) O
is O
a O
female B-Sex
child B-Age
, O
born B-Clinical_event
by O
an O
emergency B-Detailed_description
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
at O
34 B-Quantitative_concept
weeks I-Quantitative_concept
of I-Quantitative_concept
gestation I-Quantitative_concept
to O
consanguineous B-Family_history
, I-Family_history
first-cousin I-Family_history
British I-Family_history
Pakistani I-Family_history
parents I-Family_history
. O

Antenatal B-Diagnostic_procedure
scans I-Diagnostic_procedure
showed O
that O
she O
was O
small B-Lab_value
for O
her O
gestation O
, O
weighing B-Diagnostic_procedure
1.19 B-Lab_value
kg I-Lab_value
at O
birth B-Clinical_event
with O
a O
head B-Diagnostic_procedure
circumference I-Diagnostic_procedure
of O
26.7 B-Lab_value
cm I-Lab_value
, O
considerably B-Lab_value
below I-Lab_value
the I-Lab_value
0.4 I-Lab_value
th I-Lab_value
centile I-Lab_value
. O

Induction B-Therapeutic_procedure
of I-Therapeutic_procedure
labour I-Therapeutic_procedure
had O
been O
attempted O
because O
of O
the O
growth B-Sign_symptom
retardation I-Sign_symptom
but O
had O
failed B-Qualitative_concept
, O
leading O
to O
the O
emergency B-Detailed_description
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
. O

The O
Apgar B-Diagnostic_procedure
scores I-Diagnostic_procedure
were O
4 B-Lab_value
at O
1 B-Detailed_description
min I-Detailed_description
, O
7 B-Lab_value
at O
5 B-Detailed_description
min I-Detailed_description
and O
9 B-Lab_value
at O
10 B-Detailed_description
min I-Detailed_description
. O

She O
was O
admitted B-Clinical_event
to O
the O
neonatal B-Nonbiological_location
intensive I-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
for O
continuous B-Therapeutic_procedure
positive I-Therapeutic_procedure
airway I-Therapeutic_procedure
pressure I-Therapeutic_procedure
ventilation I-Therapeutic_procedure
. O

At O
a O
few B-Time
hours I-Time
of I-Time
age I-Time
, O
she O
developed O
a O
severe B-Severity
lactic B-Sign_symptom
acidosis I-Sign_symptom
. O

The O
initial O
lactic B-Diagnostic_procedure
acid I-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
22 B-Lab_value
mmol/l I-Lab_value
and O
subsequently B-Detailed_description
increased B-Lab_value
to O
63 B-Lab_value
mmol/l I-Lab_value
( O
normal O
range O
, O
0.7 O
– O
2.1 O
mmol/l O
) O
. O

She O
was O
treated O
with O
intravenous B-Administration
infusions I-Administration
of O
sodium B-Medication
bicarbonate I-Medication
and O
Tris-hydroxymethyl B-Medication
aminomethane I-Medication
( O
THAM B-Medication
) O
, O
but O
it O
was O
never O
possible O
to O
correct O
the O
metabolic B-Sign_symptom
acidosis I-Sign_symptom
. O

She O
also O
developed O
hypoglycaemia B-Sign_symptom
within B-Time
hours I-Time
of O
birth B-Clinical_event
that O
was O
corrected O
with O
an O
intravenous B-Administration
infusion I-Administration
of O
15 B-Dosage
% I-Dosage
glucose B-Medication
( O
7.8 B-Dosage
mg/kg/min I-Dosage
) O
. O

The O
ammonia B-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Urine B-Detailed_description
organic B-Diagnostic_procedure
acid I-Diagnostic_procedure
profile I-Diagnostic_procedure
showed O
massive B-Severity
excretion B-Lab_value
of O
lactic B-Diagnostic_procedure
acid I-Diagnostic_procedure
and O
increased B-Lab_value
phenolic B-Diagnostic_procedure
acids I-Diagnostic_procedure
, O
especially B-Lab_value
hydroxyphenyllactate I-Lab_value
. O

Plasma B-Detailed_description
amino B-Diagnostic_procedure
acids I-Diagnostic_procedure
showed O
raised B-Lab_value
concentrations O
of O
alanine B-Diagnostic_procedure
and O
glutamine B-Diagnostic_procedure
( O
1567 B-Lab_value
and O
1369 B-Lab_value
μmol/l I-Lab_value
, O
respectively O
) O
, O
consistent O
with O
the O
lactic B-Sign_symptom
acidosis I-Sign_symptom
; O
several O
other B-Diagnostic_procedure
amino I-Diagnostic_procedure
acids I-Diagnostic_procedure
were O
also O
mildly O
increased B-Lab_value
. O

There O
was O
gross B-Severity
generalised B-Detailed_description
aminoaciduria B-Sign_symptom
. O

Blood B-Detailed_description
acylcarnitine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Echocardiography B-Diagnostic_procedure
showed O
a O
structurally B-Lab_value
normal I-Lab_value
heart B-Biological_structure
and O
good B-Lab_value
ventricular B-Diagnostic_procedure
function I-Diagnostic_procedure
. O

Cranial B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
bilateral B-Detailed_description
intraventricular B-Biological_structure
cysts B-Sign_symptom
within O
the O
frontal B-Biological_structure
horns I-Biological_structure
and I-Biological_structure
anterior I-Biological_structure
portions I-Biological_structure
of I-Biological_structure
the I-Biological_structure
lateral I-Biological_structure
ventricles I-Biological_structure
. O

The O
left-sided B-Detailed_description
cysts B-Sign_symptom
were O
larger O
, O
up B-Distance
to I-Distance
15 I-Distance
mm I-Distance
in I-Distance
diameter I-Distance
, O
whereas O
the O
largest O
cyst B-Sign_symptom
on O
the O
right O
was O
8 B-Distance
mm I-Distance
in I-Distance
diameter I-Distance
. O

The O
choroid B-Biological_structure
plexuses I-Biological_structure
were O
hyperechoic B-Sign_symptom
and O
irregular B-Sign_symptom
, O
suggesting O
previous O
intraventricular B-Disease_disorder
haemorrhage I-Disease_disorder
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
distended B-Sign_symptom
urinary B-Biological_structure
bladder I-Biological_structure
but O
was O
otherwise O
unremarkable O
. O

There O
was O
severe B-Severity
coagulopathy B-Disease_disorder
with O
an O
extended B-Lab_value
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
of O
47.7 B-Lab_value
s I-Lab_value
( O
normal O
12.3 O
– O
16.6 O
s O
) O
, O
a O
very B-Lab_value
low I-Lab_value
plasma B-Diagnostic_procedure
albumin I-Diagnostic_procedure
of O
7 B-Lab_value
g/l I-Lab_value
( O
normal O
35 O
– O
50 O
g/l O
) O
, O
otherwise O
normal B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
but O
a O
raised B-Lab_value
creatine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
of O
2700 B-Lab_value
U/l I-Lab_value
( O
normal O
< O
300 O
U/l O
) O
. O

She O
was O
transferred B-Clinical_event
to O
a O
tertiary B-Nonbiological_location
centre I-Nonbiological_location
because O
of O
her O
worsening O
metabolic B-Sign_symptom
acidosis I-Sign_symptom
. O

She O
started O
having O
seizures B-Sign_symptom
at O
∼ B-Date
48 I-Date
h I-Date
of I-Date
age I-Date
. O

Despite O
infusions B-Administration
of O
bicarbonate B-Medication
and O
THAM B-Medication
, O
her O
acidosis B-Sign_symptom
continued O
to O
worsen O
. O

Muscle B-Biological_structure
and O
skin B-Biological_structure
biopsies B-Diagnostic_procedure
were O
performed O
and O
the O
family O
agreed O
to O
the O
withdrawal O
of O
intensive B-Therapeutic_procedure
care I-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O

She O
died B-Clinical_event
aged O
55 B-Date
h. I-Date
All O
documented O
studies O
were O
approved O
and O
performed O
under O
the O
ethical O
guidelines O
issued O
by O
each O
of O
our O
Institutions O
for O
clinical O
studies O
, O
with O
written O
informed O
consent O
obtained O
from O
the O
family O
. O

The O
patient O
is O
a O
57-year-old B-Age
woman B-Sex
who O
had O
noted O
a O
rapidly B-Lab_value
enlarging I-Lab_value
mass B-Sign_symptom
on O
the O
left B-Biological_structure
side I-Biological_structure
of I-Biological_structure
her I-Biological_structure
neck I-Biological_structure
in O
2010 B-Date
. O

She O
underwent O
a O
total B-Detailed_description
thyroidectomy B-Therapeutic_procedure
and O
central B-Biological_structure
neck I-Biological_structure
dissection B-Therapeutic_procedure
, O
which O
revealed O
a O
3.8-cm B-Distance
anaplastic B-Detailed_description
thyroid B-Disease_disorder
cancer I-Disease_disorder
arising O
in O
a O
background O
of O
an O
oncocytic B-Detailed_description
variant I-Detailed_description
of O
poorly B-Detailed_description
differentiated I-Detailed_description
thyroid B-Disease_disorder
cancer I-Disease_disorder
( O
Fig. O
1A O
, O
and O
Fig.S1 O
in O
Supplementary O
Appendix O
1 O
, O
available O
with O
the O
full O
text O
of O
this O
article O
at O
NEJM.org O
) O
. O

Resection B-Diagnostic_procedure
margins I-Diagnostic_procedure
were O
positive B-Lab_value
, O
and O
3 B-Lab_value
of I-Lab_value
12 I-Lab_value
lymph B-Biological_structure
nodes I-Biological_structure
were O
involved B-Sign_symptom
. O

At O
3 B-Date
weeks I-Date
after I-Date
surgery O
, O
the O
serum B-Detailed_description
thyroglobulin B-Diagnostic_procedure
level O
was O
17.2 B-Lab_value
ng I-Lab_value
per I-Lab_value
milliliter I-Lab_value
, O
with O
undetectable B-Lab_value
thyroglobulin B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
. O

The O
patient O
received O
concurrent O
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
and O
weekly O
carboplatin B-Medication
and O
paclitaxel B-Medication
chemotherapy B-Medication
. O

The O
serum B-Detailed_description
thyroglobulin B-Diagnostic_procedure
level O
at O
4 B-Date
weeks I-Date
after I-Date
the O
completion O
of O
chemotherapy O
and O
radiation O
therapy O
was O
12.0 B-Lab_value
ng I-Lab_value
per I-Lab_value
milliliter I-Lab_value
. O

Restaging O
scans B-Diagnostic_procedure
obtained O
3 B-Date
months I-Date
later I-Date
revealed O
a O
new O
, O
right-sided B-Biological_structure
hilar I-Biological_structure
mass B-Sign_symptom
( O
Fig. O
1C O
) O
, O
and O
the O
patient O
enrolled O
in O
a O
phase B-Detailed_description
2 I-Detailed_description
clinical B-Clinical_event
trial I-Clinical_event
of O
everolimus B-Medication
, O
which O
was O
administered O
at O
a O
dose O
of O
10 B-Dosage
mg I-Dosage
daily I-Dosage
. O

Within B-Date
6 I-Date
months I-Date
, O
follow-up B-Clinical_event
scans B-Diagnostic_procedure
showed O
that O
the O
lesion B-Coreference
had O
greatly O
diminished B-Sign_symptom
in I-Sign_symptom
size I-Sign_symptom
( O
from O
3.0 B-Area
by I-Area
2.6 I-Area
cm I-Area
to O
1.1 B-Area
by I-Area
0.8 I-Area
cm I-Area
) O
( O
Fig. O
1D O
) O
. O

After O
18 B-Duration
months I-Duration
of O
a O
sustained O
response B-Sign_symptom
to O
everolimus B-Medication
, O
scans B-Diagnostic_procedure
revealed O
progressive B-Disease_disorder
disease I-Disease_disorder
( O
Fig. O
1E O
) O
. O

The O
patient O
underwent O
a O
mediastinoscopy B-Diagnostic_procedure
with O
removal B-Therapeutic_procedure
of O
an O
enlarged B-Sign_symptom
lymph B-Biological_structure
node I-Biological_structure
, O
which O
contained O
metastatic B-Detailed_description
anaplastic B-Detailed_description
thyroid B-Disease_disorder
cancer I-Disease_disorder
( O
Fig. O
1B O
, O
and O
Fig.S1 O
in O
Supplementary O
Appendix O
1 O
) O
. O

Whole-exome B-Detailed_description
sequencing B-Diagnostic_procedure
was O
performed O
on O
biopsy B-Diagnostic_procedure
samples O
of O
the O
pretreatment B-Detailed_description
and I-Detailed_description
resistant I-Detailed_description
tumors I-Detailed_description
as O
well O
as O
on O
a O
blood B-Detailed_description
sample I-Detailed_description
. O

A O
46-year-old B-Age
Caucasian B-Personal_background
woman B-Sex
of O
Ashkenazi B-Personal_background
Jewish I-Personal_background
descent O
presented B-Activity
with O
the O
chief O
complaint O
of O
severe B-Severity
and O
constant B-Detailed_description
throbbing B-Detailed_description
pain B-Sign_symptom
in O
her O
left B-Biological_structure
posterior I-Biological_structure
mandible I-Biological_structure
. O

She O
reported O
that O
her O
pain B-Sign_symptom
was O
aggravated O
by O
chewing B-Activity
, O
and O
started O
months B-Date
before I-Date
the O
initial O
consultation B-Clinical_event
visit O
. O

Visual B-Diagnostic_procedure
analog I-Diagnostic_procedure
scale I-Diagnostic_procedure
of I-Diagnostic_procedure
pain I-Diagnostic_procedure
was O
reported O
7/10 B-Quantitative_concept
at O
the O
day B-Date
of I-Date
the I-Date
visit I-Date
. O

Past O
medical O
history O
was O
remarkable O
for O
Gaucher B-Disease_disorder
disease I-Disease_disorder
, O
left B-History
hip I-History
replacement I-History
, O
gall B-Biological_structure
bladder I-Biological_structure
removal B-History
, O
herniorrhaphy B-Therapeutic_procedure
, O
spleen B-Biological_structure
abscess B-History
drainage I-History
, O
hepatitis B-Disease_disorder
C I-Disease_disorder
infection I-Disease_disorder
, O
and O
asthma B-Disease_disorder
. O

Social O
history O
was O
significant O
for O
20 B-Quantitative_concept
pack-years I-Quantitative_concept
of O
cigarette B-Activity
smoking I-Activity
. O

Her O
family O
history O
was O
unremarkable B-Family_history
for I-Family_history
any I-Family_history
hereditary I-Family_history
or I-Family_history
systemic I-Family_history
diseases I-Family_history
. O

Her O
medications O
included O
the O
oral B-Administration
antiresorptive B-Detailed_description
drug O
alendronate B-Medication
for O
early O
osteoporosis B-Disease_disorder
associated O
with O
Gaucher B-Disease_disorder
disease I-Disease_disorder
( O
70 B-Dosage
mg I-Dosage
weekly I-Dosage
for O
2 B-Duration
years I-Duration
) O
, O
calcium B-Medication
supplements I-Medication
, O
loratadine B-Medication
, O
hydromorphone B-Medication
, O
esomeprazole B-Medication
, O
promethazine B-Medication
, O
levalbuterol B-Medication
, O
carisoprodol B-Medication
, O
fluticasone B-Medication
and O
ibuprofen B-Medication
. O

She O
reported O
that O
she O
had O
been O
on O
enzyme B-Medication
replacement I-Medication
therapy I-Medication
( O
ERT B-Medication
) O
intermittently B-Frequency
for O
several B-Duration
years I-Duration
to O
treat O
her O
Gaucher B-Disease_disorder
disease I-Disease_disorder
which B-History
was I-History
diagnosed I-History
20 I-History
years I-History
prior I-History
. O

She O
received O
intravenous B-Administration
injections I-Administration
twice B-Frequency
a I-Frequency
month I-Frequency
for O
ERT B-Coreference
and O
recounted O
fatigue B-Sign_symptom
after O
each O
infusion O
. O

She O
also O
reported O
receiving O
antibiotic B-Medication
and O
analgesic B-Medication
medications O
for O
her O
pain O
months B-Date
ago I-Date
but O
they O
were O
not O
helpful.Head B-Diagnostic_procedure
and I-Diagnostic_procedure
neck I-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
cranial B-Diagnostic_procedure
nerve I-Diagnostic_procedure
examination I-Diagnostic_procedure
and O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
within B-Qualitative_concept
normal I-Qualitative_concept
limits I-Qualitative_concept
. O

Intraoral B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
completed O
using O
percussion B-Diagnostic_procedure
testing I-Diagnostic_procedure
, O
vitality B-Diagnostic_procedure
testing I-Diagnostic_procedure
and O
probing B-Diagnostic_procedure
for O
evaluation O
of O
her O
mandibular B-Biological_structure
posterior I-Biological_structure
teeth I-Biological_structure
in O
the O
region O
of O
the O
chief O
complaint O
. O

Her O
left B-Biological_structure
mandibular I-Biological_structure
first I-Biological_structure
molar I-Biological_structure
was O
endodontically B-Therapeutic_procedure
treated I-Therapeutic_procedure
3 B-Date
years I-Date
prior I-Date
and O
tested B-Diagnostic_procedure
non-vital B-Lab_value
, O
while O
her O
remaining O
mandibular B-Biological_structure
teeth I-Biological_structure
were O
normal B-Lab_value
on O
vitality B-Diagnostic_procedure
testing I-Diagnostic_procedure
with O
evaluation B-Diagnostic_procedure
of O
several B-Detailed_description
opposing B-Detailed_description
non-restored B-Detailed_description
and O
non-carious B-Sign_symptom
teeth B-Biological_structure
as O
internal O
controls O
. O

Gingival B-Biological_structure
tissues I-Biological_structure
in O
both O
jaws B-Biological_structure
were O
non-inflamed B-Sign_symptom
and O
there O
was O
no O
gross O
evidence O
of O
plaque B-Sign_symptom
or O
calculus B-Sign_symptom
. O

Periodontal B-Sign_symptom
pockets I-Sign_symptom
in O
her O
mandible B-Biological_structure
ranged O
from O
4 B-Quantitative_concept
to I-Quantitative_concept
6 I-Quantitative_concept
mm I-Quantitative_concept
with O
no O
significant O
bony B-Sign_symptom
defects I-Sign_symptom
. O

Full B-Biological_structure
mouth I-Biological_structure
dental B-Diagnostic_procedure
X-rays I-Diagnostic_procedure
and O
a O
panoramic B-Detailed_description
radiograph B-Diagnostic_procedure
were O
taken O
and O
showed O
relatively B-Detailed_description
well-defined I-Detailed_description
radiolucent B-Detailed_description
lesions B-Sign_symptom
in O
multiple B-Detailed_description
regions I-Detailed_description
of O
the O
mandible B-Biological_structure
bilaterally B-Detailed_description
, O
with O
a O
pseudocystic B-Detailed_description
( O
multilocular B-Detailed_description
) O
appearance O
; O
cone-beam B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
confirmed O
these O
findings O
and O
revealed O
a O
large B-Severity
lytic B-Detailed_description
lesion B-Sign_symptom
of O
her O
left B-Biological_structure
posterior I-Biological_structure
mandible I-Biological_structure
in O
the O
region O
of O
her O
chief O
complaint O
( O
Figure O
1 O
) O
. O

Our O
clinical O
and O
radiographic O
differential O
diagnosis O
for O
her O
chief O
complaint O
included O
chronic B-Detailed_description
apical B-Disease_disorder
periodontitis I-Disease_disorder
, O
radicular B-Disease_disorder
cyst I-Disease_disorder
, O
central B-Disease_disorder
giant I-Disease_disorder
cell I-Disease_disorder
granuloma I-Disease_disorder
, O
keratocystic B-Detailed_description
odontogenic B-Disease_disorder
tumor I-Disease_disorder
, O
ameloblastoma B-Disease_disorder
, O
odontogenic B-Disease_disorder
fibroma I-Disease_disorder
, O
neuralgia/neuropathy B-Sign_symptom
or O
mandibular B-Biological_structure
involvement O
of O
Gaucher B-Disease_disorder
disease I-Disease_disorder
given O
her O
medical O
history O
. O

Our O
findings O
were O
discussed B-Clinical_event
with O
the O
patient O
and O
written O
consent O
was O
obtained O
for O
surgical O
biopsy B-Diagnostic_procedure
of O
her O
left B-Biological_structure
mandible I-Biological_structure
with O
local B-Medication
anesthesia I-Medication
for O
more O
definitive O
diagnosis O
. O

A O
four-corner B-Detailed_description
gingival B-Therapeutic_procedure
flap I-Therapeutic_procedure
buccally B-Biological_structure
was O
reflected O
in O
her O
posterior B-Biological_structure
left I-Biological_structure
mandible I-Biological_structure
extending O
from O
the O
canine B-Biological_structure
to O
the O
second B-Biological_structure
molar I-Biological_structure
, O
and O
cortical B-Biological_structure
bone I-Biological_structure
was O
removed B-Therapeutic_procedure
with O
a O
surgical B-Therapeutic_procedure
bur I-Therapeutic_procedure
to O
create B-Therapeutic_procedure
a I-Therapeutic_procedure
window I-Therapeutic_procedure
for O
access O
to O
the O
lesion B-Sign_symptom
. O

Pathologic B-Sign_symptom
soft B-Biological_structure
tissue I-Biological_structure
was O
evident O
through O
the O
access O
window O
. O

The O
entire O
pathologic B-Sign_symptom
soft B-Biological_structure
tissue I-Biological_structure
along O
with O
the O
bone O
from O
the O
access O
window O
was O
submitted O
to O
the O
pathology B-Nonbiological_location
laboratory I-Nonbiological_location
for O
histological B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
. O

Histopathological B-Diagnostic_procedure
findings I-Diagnostic_procedure
revealed O
infiltration B-Sign_symptom
of O
jawbone B-Biological_structure
marrow I-Biological_structure
with O
fibrous B-Detailed_description
connective I-Detailed_description
tissue I-Detailed_description
containing O
abundant O
Gaucher B-Sign_symptom
cells I-Sign_symptom
( O
Figure O
2 O
) O
. O

There O
was O
no O
evidence O
of O
abscess B-Sign_symptom
or O
neutrophils B-Sign_symptom
, O
granuloma B-Disease_disorder
or O
malignancy B-Sign_symptom
. O

Postoperative B-Diagnostic_procedure
healing I-Diagnostic_procedure
was O
uneventful B-Lab_value
, O
and O
the O
patient O
reported O
resolution B-Outcome
of O
her O
chief O
complaint O
and O
symptomatology O
at O
1-month B-Date
follow-up B-Clinical_event
. O

She O
was O
referred B-Clinical_event
to O
her O
physician B-Nonbiological_location
for O
consultation B-Clinical_event
and O
further O
evaluation B-Diagnostic_procedure
as O
related O
to O
her O
Gaucher B-Disease_disorder
disease I-Disease_disorder
status O
following O
our O
findings O
. O

She O
was O
again O
treated O
with O
ERT B-Medication
and O
at O
1-year B-Date
re-evaluation B-Clinical_event
was O
still O
symptom B-Sign_symptom
free O
in O
her O
oral B-Biological_structure
cavity I-Biological_structure
. O

A O
21-year-old B-Age
man B-Sex
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
a O
rash B-Sign_symptom
on O
his O
arms B-Biological_structure
and O
neck B-Biological_structure
( O
figure O
1 O
) O
. O

It B-Coreference
had O
developed O
over B-Duration
the I-Duration
course I-Duration
of I-Duration
36 I-Duration
h I-Duration
from O
discrete B-Detailed_description
‘ I-Detailed_description
pin I-Detailed_description
prick I-Detailed_description
’ I-Detailed_description
areas I-Detailed_description
of O
erythema B-Sign_symptom
into O
a O
maculopapular B-Detailed_description
rash B-Sign_symptom
with O
vesicles B-Detailed_description
( O
figure O
2 O
) O
. O

It B-Coreference
covered O
his O
forearms B-Biological_structure
from O
the O
dorsal B-Biological_structure
aspect I-Biological_structure
of I-Biological_structure
the I-Biological_structure
hands I-Biological_structure
to O
the O
flexor B-Biological_structure
surface I-Biological_structure
of I-Biological_structure
the I-Biological_structure
elbows I-Biological_structure
. O

It B-Coreference
was O
also O
beginning O
to O
develop O
around O
his O
neck B-Biological_structure
( O
figure O
3 O
) O
. O

He O
described O
the O
rash B-Sign_symptom
as O
itchy B-Detailed_description
and O
painful B-Detailed_description
, O
and O
was O
feeling B-Diagnostic_procedure
‘ O
under B-Lab_value
the I-Lab_value
weather I-Lab_value
’ O
. O

The O
patient O
had O
no B-History
previous I-History
dermatological I-History
or I-History
other I-History
medical I-History
history I-History
of I-History
note I-History
. O

He O
took O
no O
medication B-Medication
. O

He O
worked B-Occupation
in I-Occupation
a I-Occupation
supermarket I-Occupation
handling I-Occupation
food I-Occupation
items I-Occupation
but O
there O
was O
no B-History
history I-History
of I-History
occupational I-History
chemical I-History
exposure I-History
. O

He O
had B-History
not I-History
recently I-History
had I-History
any I-History
change I-History
in I-History
washing I-History
powder I-History
or I-History
personal I-History
hygiene I-History
products I-History
. O

Physiological B-Diagnostic_procedure
observations I-Diagnostic_procedure
were O
entirely O
normal B-Lab_value
and O
systemic B-Diagnostic_procedure
examination I-Diagnostic_procedure
unremarkable B-Lab_value
. O

Closer O
examination B-Diagnostic_procedure
of O
the O
rash B-Sign_symptom
revealed O
that O
it O
was O
present O
only O
on O
skin B-Biological_structure
exposed B-Activity
to I-Activity
the I-Activity
sun I-Activity
when O
wearing B-Activity
a I-Activity
short-sleeved I-Activity
shirt I-Activity
; O
the O
most O
striking O
feature O
was O
the O
‘ B-Other_entity
V I-Other_entity
’ I-Other_entity
shape I-Other_entity
on I-Other_entity
the I-Other_entity
patient I-Other_entity
's I-Other_entity
chest I-Other_entity
in O
keeping O
with O
the O
neck O
line O
of O
a O
polo O
shirt O
. O

On O
further O
questioning O
the O
patient O
described O
a O
period O
of O
time O
48 B-Date
h I-Date
prior I-Date
to O
presentation O
( O
and O
12 B-Date
h I-Date
prior I-Date
to O
the O
development O
of O
the O
rash B-Sign_symptom
) O
spent O
strimming B-Activity
the I-Activity
grass I-Activity
under O
the O
hedges O
in O
his O
garden O
. O

Blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
including O
full B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
urea B-Diagnostic_procedure
and O
electrolytes B-Diagnostic_procedure
, O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
test I-Diagnostic_procedure
and O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
were O
all O
within B-Lab_value
normal I-Lab_value
reference I-Lab_value
ranges I-Lab_value
. O

The O
list O
of O
potential O
differential O
diagnoses O
for O
a O
maculopapular O
rash O
is O
long O
, O
but O
given O
the O
distribution O
of O
the O
rash O
and O
the O
history O
of O
plant O
material O
exposure O
a O
diagnosis O
of O
phytophotodermatitis B-Disease_disorder
was O
made O
. O

The O
patient O
was O
discharged B-Clinical_event
with O
chlorphenamine B-Medication
, O
simple B-Medication
analgesia I-Medication
and O
the O
advice B-Other_event
to I-Other_event
wear I-Other_event
a I-Other_event
long-sleeved I-Other_event
t-shirt I-Other_event
and I-Other_event
sunscreen I-Other_event
when O
gardening O
in O
the O
future O
. O

The O
rash B-Sign_symptom
resolved O
over O
a O
period B-Duration
of I-Duration
3 I-Duration
weeks I-Duration
. O

It B-Coreference
remained O
pruritic B-Detailed_description
throughout O
healing O
but O
the O
associated O
pain B-Sign_symptom
settled O
over B-Duration
a I-Duration
few I-Duration
days I-Duration
. O

Residual O
scarring B-Sign_symptom
is O
beginning O
to O
fade O
2 B-Date
months I-Date
after I-Date
presentation O
. O

A O
77-year-old B-Age
woman B-Sex
with O
dysphagia B-Sign_symptom
presented B-Clinical_event
with O
a O
two-week B-Duration
history I-Duration
of O
rash B-Sign_symptom
characterized O
by O
brown B-Color
plaques B-Sign_symptom
with O
erythematous B-Detailed_description
borders I-Detailed_description
and O
overlying B-Detailed_description
thick I-Detailed_description
scales I-Detailed_description
involving O
the O
face B-Biological_structure
and O
a O
prior O
percutaneous B-Diagnostic_procedure
endoscopic I-Diagnostic_procedure
gastrostomy I-Diagnostic_procedure
( O
PEG B-Diagnostic_procedure
) O
tube O
site B-Biological_structure
( O
Fig. O
1a O
, O
c O
) O
. O

No O
oral B-Biological_structure
or O
conjunctival B-Biological_structure
involvement B-Sign_symptom
was O
present O
. O

She O
had O
been O
receiving O
parenteral B-Medication
nutrition I-Medication
for O
two B-Duration
months I-Duration
following O
removal O
of O
the O
PEG B-Diagnostic_procedure
tube I-Diagnostic_procedure
due O
to O
infection B-Disease_disorder
. O

Although O
the O
differential O
diagnosis O
included O
drug B-Disease_disorder
hypersensitivity I-Disease_disorder
, O
autoimmune B-Disease_disorder
disorders I-Disease_disorder
and O
nutritional B-Disease_disorder
deficiency I-Disease_disorder
, O
the O
rash B-Sign_symptom
appearance O
was O
most O
consistent O
with O
acrodermatitis B-Disease_disorder
enteropathica-like I-Disease_disorder
eruption B-Sign_symptom
secondary O
to O
zinc B-Disease_disorder
deficiency I-Disease_disorder
. O

Her O
serum B-Detailed_description
zinc B-Diagnostic_procedure
level O
was O
12 B-Lab_value
mcg/dL I-Lab_value
( O
normal O
, O
55 O
– O
150 O
mcg/dL O
) O
, O
and O
the O
rash B-Sign_symptom
resolved O
within B-Date
one I-Date
week I-Date
of O
parenteral B-Administration
zinc B-Medication
supplementation I-Medication
( O
Fig. O
1b O
, O
d O
) O
. O

Zinc O
is O
essential O
for O
protein O
synthesis O
and O
wound O
healing O
. O

Acrodermatitis O
enteropathica O
presents O
in O
infancy O
as O
a O
periorificial O
desquamative O
dermatitis O
, O
resulting O
from O
an O
autosomal O
recessive O
mutation O
that O
impairs O
zinc O
absorption O
. O

A O
similar O
syndrome O
may O
occur O
due O
to O
nutritional O
zinc O
deficiency O
, O
and O
has O
been O
reported O
in O
the O
setting O
of O
parenteral O
nutrition O
that O
fails O
to O
include O
zinc O
supplementation O
; O
a O
prompt O
response O
to O
supplementation O
helps O
to O
confirm O
the O
diagnosis O
. O

A O
recent O
national B-Other_event
shortage I-Other_event
of I-Other_event
parenteral I-Other_event
zinc I-Other_event
in O
the O
United B-Nonbiological_location
States I-Nonbiological_location
likely O
contributed O
to O
this O
patient O
’s O
presentation O
. O

A O
42 B-Age
year-old I-Age
man B-Sex
with O
chronic B-Detailed_description
lymphocytic B-Disease_disorder
leukemia I-Disease_disorder
underwent O
allogeneic B-Detailed_description
bone B-Therapeutic_procedure
marrow I-Therapeutic_procedure
transplant I-Therapeutic_procedure
in O
September B-Date
2013 I-Date
. O

The O
graft B-Coreference
was O
mismatched B-Detailed_description
at I-Detailed_description
a I-Detailed_description
single I-Detailed_description
human I-Detailed_description
leukocyte I-Detailed_description
antigen I-Detailed_description
allele I-Detailed_description
( O
DQB1 B-Detailed_description
) O
, O
and O
was O
T-cell B-Detailed_description
depleted I-Detailed_description
using O
in B-Detailed_description
vivo I-Detailed_description
alemtuzumab B-Medication
. O

He O
engrafted B-Therapeutic_procedure
on O
day B-Date
12 I-Date
after O
transplant B-Therapeutic_procedure
. O

Aside O
from O
persistent B-Detailed_description
lymphopenia B-Sign_symptom
and O
diarrhea B-Sign_symptom
from O
norovirus B-Disease_disorder
infection O
, O
his O
posttransplant B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
unremarkable B-Lab_value
until O
mid-October B-Date
when O
he O
developed O
tinnitus B-Sign_symptom
and O
rapidly B-Detailed_description
progressive I-Detailed_description
sensorineural B-Disease_disorder
deafness I-Disease_disorder
, O
resulting O
in O
subtotal B-Detailed_description
hearing B-Sign_symptom
loss I-Sign_symptom
bilaterally B-Detailed_description
( O
> B-Lab_value
95 I-Lab_value
dB I-Lab_value
) O
over B-Duration
2 I-Duration
– I-Duration
3 I-Duration
weeks I-Duration
. O

Brain B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
was O
unremarkable O
, O
as O
was O
cerebrospinal B-Diagnostic_procedure
fluid I-Diagnostic_procedure
( O
CSF B-Diagnostic_procedure
) O
analysis O
( O
4 B-Lab_value
leukocytes/µL I-Lab_value
with O
50 B-Lab_value
% I-Lab_value
neutrophils B-Diagnostic_procedure
and O
50 B-Lab_value
% I-Lab_value
lymphocytes B-Diagnostic_procedure
, O
6 B-Lab_value
red I-Lab_value
blood I-Lab_value
cells/µL I-Lab_value
, O
glucose B-Diagnostic_procedure
2.4 B-Lab_value
mmol/L I-Lab_value
[ O
normal O
range O
, O
2.2 O
– O
4.7 O
mmol/L O
] O
, O
protein B-Diagnostic_procedure
61 B-Lab_value
mg/dL I-Lab_value
[ O
normal O
range O
, O
15 O
– O
45 O
mg/L O
] O
, O
absence B-Lab_value
of O
oligoclonal B-Diagnostic_procedure
bands I-Diagnostic_procedure
) O
. O

Viral B-Detailed_description
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction I-Diagnostic_procedure
( O
PCR O
) O
testing O
of O
CSF B-Detailed_description
was O
negative O
for O
enterovirus B-Disease_disorder
and O
herpesvirus B-Disease_disorder
infection O
. O

The O
patient O
was O
treated O
empirically O
with O
high-dose O
valacyclovir B-Medication
, O
broad-spectrum O
antibiotics B-Medication
, O
and O
2 B-Dosage
g/kg I-Dosage
intravenous B-Administration
immunoglobulin B-Medication
( O
IVIG B-Medication
) O
. O

Despite O
these O
interventions O
, O
he O
developed O
new O
symptoms O
of O
central O
dyspnea B-Sign_symptom
, O
postural B-Detailed_description
hypotension B-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
gradually B-Lab_value
worsening I-Lab_value
balance B-Diagnostic_procedure
. O

Repeat O
neurological B-Diagnostic_procedure
assessment I-Diagnostic_procedure
confirmed O
persistent B-Detailed_description
vestibulocochlear B-Disease_disorder
dysfunction I-Disease_disorder
6 B-Date
weeks I-Date
after I-Date
symptom B-Sign_symptom
onset O
. O

By O
mid-December B-Date
, O
the O
patient O
had O
become O
increasingly O
withdrawn B-Sign_symptom
, O
irritable B-Sign_symptom
, O
and O
intermittently B-Detailed_description
agitated B-Sign_symptom
. O

He O
remained O
lymphopenic B-Sign_symptom
( O
lymphocytes B-Diagnostic_procedure
0.54 B-Lab_value
× I-Lab_value
106/μL I-Lab_value
[ O
normal O
range O
, O
1.2 O
– O
3.6 O
× O
106/μL O
] O
) O
. O

MRI B-Diagnostic_procedure
scans O
of O
the O
brain B-Biological_structure
were O
unremarkable B-Lab_value
, O
as O
was O
serum B-Detailed_description
testing I-Detailed_description
for O
antineuronal B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
; O
an O
electroencephalogram B-Diagnostic_procedure
revealed O
only O
diffuse O
encephalopathy B-Disease_disorder
. O

Given O
continued O
suspicion O
for O
a O
viral B-Disease_disorder
etiology O
, O
the O
patient O
was O
treated O
with O
high-dose B-Dosage
glucocorticoids B-Medication
and O
again O
with O
IVIG B-Medication
. O

He O
began O
refusing O
fluids B-Activity
, O
food B-Activity
, O
and O
medication B-Medication
, O
and O
was O
detained B-Clinical_event
under O
the O
UK B-Detailed_description
Mental I-Detailed_description
Health I-Detailed_description
Act I-Detailed_description
. O

Repeat O
MRI B-Diagnostic_procedure
scanning O
showed O
interval O
development O
of O
new B-Detailed_description
, O
nonenhancing B-Detailed_description
signal B-Sign_symptom
abnormalities I-Sign_symptom
in O
both B-Biological_structure
thalami I-Biological_structure
and O
midbrain B-Biological_structure
with O
cranial B-Biological_structure
nerve I-Biological_structure
involvement O
but O
no O
meningeal B-Biological_structure
enhancement B-Sign_symptom
( O
Figure O
1A O
) O
. O

Near B-Date
the I-Date
end I-Date
of I-Date
December I-Date
, O
a O
frontal B-Biological_structure
lobe I-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
. O

Histology B-Diagnostic_procedure
revealed O
reactive B-Detailed_description
gliosis B-Sign_symptom
and O
diffuse B-Detailed_description
infiltration B-Sign_symptom
with O
CD3 B-Detailed_description
+ I-Detailed_description
/ I-Detailed_description
8 I-Detailed_description
+ I-Detailed_description
lymphocytes I-Detailed_description
( O
Figure O
1B O
) O
. O

Extensive O
microbiological B-Diagnostic_procedure
testing I-Diagnostic_procedure
of O
the O
biopsy B-Detailed_description
tissue I-Detailed_description
for O
an O
infectious B-Detailed_description
etiology I-Detailed_description
was O
negative B-Lab_value
( O
Supplementary O
Table O
1 O
) O
. O

Given O
the O
absence O
of O
a O
diagnosis O
and O
the O
patient O
's O
progressive O
neurological B-Disease_disorder
deterioration I-Disease_disorder
, O
CSF B-Detailed_description
and I-Detailed_description
brain I-Detailed_description
biopsy I-Detailed_description
tissue I-Detailed_description
were O
analyzed O
in O
January B-Date
2014 I-Date
by O
metagenomic B-Detailed_description
next-generation B-Diagnostic_procedure
sequencing I-Diagnostic_procedure
( O
NGS B-Diagnostic_procedure
) O
[ O
2 O
] O
. O

NGS B-Diagnostic_procedure
analysis O
of O
the O
brain B-Detailed_description
biopsy I-Detailed_description
, O
genome B-Diagnostic_procedure
assembly I-Diagnostic_procedure
, O
and O
in B-Diagnostic_procedure
situ I-Diagnostic_procedure
hybridization I-Diagnostic_procedure
revealed O
findings O
of O
neuroinvasive B-Detailed_description
astrovirus B-Disease_disorder
( O
AstV B-Disease_disorder
) O
infection O
. O

Despite O
lack O
of O
approved O
therapies O
, O
the O
patient O
was O
treated O
with O
ribavirin B-Medication
and O
IVIG B-Medication
. O

However O
, O
he O
did O
not O
respond O
to O
these O
interventions O
, O
and O
remained O
in O
a O
minimally B-Sign_symptom
conscious I-Sign_symptom
state I-Sign_symptom
following O
withdrawal O
of O
sedation B-Medication
in O
March B-Date
2014 I-Date
. O

He O
eventually O
died B-Outcome
at O
the O
end B-Date
of I-Date
May I-Date
, O
4 B-Date
months I-Date
after I-Date
the O
NGS B-Diagnostic_procedure
diagnosis O
and O
approximately O
7.5 B-Date
months I-Date
after I-Date
onset O
of O
symptoms B-Sign_symptom
. O

An O
8-year-old B-Age
boy B-Sex
was O
referred B-Activity
for O
evaluation O
of O
fatigue B-Sign_symptom
. O

He O
was O
born B-Clinical_event
at O
term O
weighing B-Diagnostic_procedure
4 B-Lab_value
kg I-Lab_value
to O
non-consanguineous B-Family_history
parents I-Family_history
and O
attained O
normal B-Lab_value
early B-Diagnostic_procedure
developmental I-Diagnostic_procedure
milestones I-Diagnostic_procedure
. O

Height B-Diagnostic_procedure
and O
weight B-Diagnostic_procedure
were O
on O
the O
10th B-Lab_value
and O
50th B-Lab_value
centiles B-Detailed_description
, O
respectively O
. O

Preliminary O
examination B-Diagnostic_procedure
was O
remarkable O
only O
for O
hepatomegaly B-Sign_symptom
extending O
3.5 B-Distance
cm I-Distance
below I-Distance
the O
right B-Biological_structure
costal I-Biological_structure
margin I-Biological_structure
. O

Initial O
laboratory B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
revealed O
normochromic B-Detailed_description
normocytic B-Detailed_description
anaemia B-Sign_symptom
( O
haemoglobin B-Diagnostic_procedure
7.8 B-Lab_value
g/dL I-Lab_value
( O
11.5 O
– O
16 O
) O
, O
mean B-Diagnostic_procedure
corpuscular I-Diagnostic_procedure
volume I-Diagnostic_procedure
( O
MCV B-Diagnostic_procedure
) O
85.8 B-Lab_value
fL I-Lab_value
( O
75 O
– O
87 O
) O
and O
mean B-Diagnostic_procedure
corpuscular I-Diagnostic_procedure
haemoglobin I-Diagnostic_procedure
( O
MCH B-Diagnostic_procedure
) O
25.4 B-Lab_value
pg I-Lab_value
( O
25 O
– O
35 O
) O
) O
with O
marked O
anisocytosis B-Sign_symptom
( O
red-cell B-Diagnostic_procedure
distribution I-Diagnostic_procedure
width I-Diagnostic_procedure
( O
RDW B-Diagnostic_procedure
) O
29 B-Lab_value
% I-Lab_value
( O
11 O
– O
14.5 O
) O
) O
. O

Hypochromia B-Sign_symptom
and O
teardrops B-Sign_symptom
were O
evident O
on O
a O
blood B-Diagnostic_procedure
film I-Diagnostic_procedure
. O

Leucopoenia B-Sign_symptom
was O
also O
a O
feature O
( O
white B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
2.9 B-Lab_value
× I-Lab_value
109/L I-Lab_value
( O
4.5 O
– O
13.5 O
) O
, O
neutrophils B-Diagnostic_procedure
1.7 B-Lab_value
× I-Lab_value
109/L I-Lab_value
( O
2 O
– O
7.5 O
) O
and O
lymphocytes B-Diagnostic_procedure
0.8 B-Lab_value
× I-Lab_value
109/L I-Lab_value
( O
1.5 O
– O
4 O
) O
) O
. O

A O
bone B-Biological_structure
marrow I-Biological_structure
aspirate B-Diagnostic_procedure
and O
biopsy B-Diagnostic_procedure
revealed O
a O
hypercellular B-Sign_symptom
marrow B-Biological_structure
with O
erythroid B-Sign_symptom
hyperplasia I-Sign_symptom
. O

An O
iron B-Diagnostic_procedure
stain I-Diagnostic_procedure
revealed O
that O
approximately O
50 B-Lab_value
% I-Lab_value
of I-Lab_value
erythroblasts I-Lab_value
were I-Lab_value
ringed I-Lab_value
sideroblasts I-Lab_value
. O

Marrow B-Biological_structure
cytogenetics B-Diagnostic_procedure
were O
normal B-Lab_value
including O
fluorescence B-Diagnostic_procedure
in I-Diagnostic_procedure
situ I-Diagnostic_procedure
hybridisation I-Diagnostic_procedure
studies O
of O
chromosomes B-Detailed_description
5q I-Detailed_description
, I-Detailed_description
7 I-Detailed_description
and I-Detailed_description
8 I-Detailed_description
and O
flow B-Diagnostic_procedure
cytometry I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
detect I-Lab_value
a O
blast B-Diagnostic_procedure
population I-Diagnostic_procedure
. O

Serum B-Detailed_description
copper B-Diagnostic_procedure
and O
lead B-Diagnostic_procedure
were O
normal B-Lab_value
, O
as O
were O
blood B-Diagnostic_procedure
smears I-Diagnostic_procedure
on O
the O
proband O
’s O
parents B-Subject
and O
sister B-Subject
. O

Analysis B-Diagnostic_procedure
of I-Diagnostic_procedure
several I-Diagnostic_procedure
genes I-Diagnostic_procedure
responsible I-Diagnostic_procedure
for I-Diagnostic_procedure
hereditary I-Diagnostic_procedure
SA I-Diagnostic_procedure
( O
ALAS2 B-Diagnostic_procedure
, O
ABC7 B-Diagnostic_procedure
, O
FECH B-Diagnostic_procedure
and O
PUS1 B-Diagnostic_procedure
) O
revealed O
no O
reported O
pathogenic B-Sign_symptom
variants I-Sign_symptom
. O

Fasting B-Detailed_description
lactate B-Diagnostic_procedure
was O
elevated B-Lab_value
at O
3.8 B-Lab_value
mmol/L I-Lab_value
. O

Neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
identified O
upper B-Lab_value
motor I-Lab_value
neuron I-Lab_value
signs I-Lab_value
in O
the O
lower B-Biological_structure
limbs I-Biological_structure
bilaterally B-Detailed_description
; O
however O
, O
cerebellar B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
negative B-Lab_value
. O

MRI B-Diagnostic_procedure
of O
the O
brain B-Biological_structure
demonstrated O
volume B-Sign_symptom
loss I-Sign_symptom
with O
slight B-Severity
prominence B-Sign_symptom
of O
the O
cerebellar B-Biological_structure
folia I-Biological_structure
. O

Urine B-Detailed_description
organic B-Diagnostic_procedure
acids I-Diagnostic_procedure
revealed O
elevated B-Lab_value
3-methylglutaconate B-Diagnostic_procedure
and O
3-methylglutarate B-Diagnostic_procedure
. O

The O
lactate B-Diagnostic_procedure
: I-Diagnostic_procedure
pyruvate I-Diagnostic_procedure
ratio I-Diagnostic_procedure
was O
elevated B-Lab_value
( O
30:1 B-Lab_value
) O
. O

Muscle B-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
a O
structurally B-Lab_value
normal I-Lab_value
muscle B-Biological_structure
and O
biochemical B-Diagnostic_procedure
assay I-Diagnostic_procedure
of O
respiratory B-Diagnostic_procedure
chain I-Diagnostic_procedure
components I-Diagnostic_procedure
resulted O
in O
a O
diagnosis O
of O
partial B-Detailed_description
complex B-Disease_disorder
IV I-Disease_disorder
deficiency I-Disease_disorder
. O

He O
subsequently O
commenced O
a O
high-fat B-Therapeutic_procedure
diet I-Therapeutic_procedure
and O
coenzyme B-Medication
Q I-Medication
with O
a O
resultant O
improvement B-Lab_value
in O
energy B-Diagnostic_procedure
. O

Analysis O
of O
mtDNA B-Diagnostic_procedure
in O
leucocytes B-Biological_structure
and O
muscle B-Biological_structure
utilising O
PCR B-Diagnostic_procedure
did O
not O
reveal O
a O
deletion B-Sign_symptom
. O

Carnitine B-Medication
, O
vitamin B-Medication
A I-Medication
, O
thiamine B-Medication
, O
pyridoxine B-Medication
, O
folate B-Medication
and O
uridine B-Medication
were O
supplemented O
without O
improvement O
in O
his O
anaemia B-Sign_symptom
. O

Haemoglobin B-Diagnostic_procedure
levels O
fell B-Lab_value
to O
4.4 B-Lab_value
g/dL I-Lab_value
, O
leading O
to O
occasional B-Detailed_description
and O
then O
regular O
three-weekly B-Frequency
red B-Detailed_description
cell I-Detailed_description
transfusions B-Therapeutic_procedure
. O

With O
repeated O
transfusions B-Therapeutic_procedure
, O
ferritin B-Diagnostic_procedure
rose B-Lab_value
to O
1700 B-Lab_value
µg/L I-Lab_value
, O
necessitating O
iron B-Medication
chelation I-Medication
. O

Peak B-Detailed_description
growth B-Diagnostic_procedure
hormone I-Diagnostic_procedure
and O
cortisol B-Diagnostic_procedure
to O
insulin-induced B-Medication
hypoglycaemia B-Sign_symptom
were O
30.9 B-Lab_value
mU/L I-Lab_value
( O
normal O
> O
20 O
) O
and O
447 B-Lab_value
nmol/L I-Lab_value
( O
normal O
> O
500 O
) O
, O
respectively O
, O
at O
age B-Date
13 I-Date
years I-Date
. O

Thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Repeat O
peak B-Detailed_description
cortisol B-Diagnostic_procedure
was O
384 B-Lab_value
nmol/L I-Lab_value
following O
adrenocorticotropic B-Medication
hormone I-Medication
( O
ACTH B-Medication
) O
stimulation O
. O

Plasma B-Detailed_description
renin B-Diagnostic_procedure
activity I-Diagnostic_procedure
was O
elevated B-Lab_value
to O
15 B-Lab_value
ng/mL/h I-Lab_value
, O
and O
adrenal B-Diagnostic_procedure
androgens I-Diagnostic_procedure
were O
below B-Lab_value
the I-Lab_value
lower I-Lab_value
limit I-Lab_value
of I-Lab_value
assay I-Lab_value
detection I-Lab_value
. O

A O
urinary B-Detailed_description
steroid B-Diagnostic_procedure
profile I-Diagnostic_procedure
was O
qualitatively B-Lab_value
normal I-Lab_value
, O
as O
was O
an O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
. O

Hydrocortisone B-Medication
5 B-Dosage
mg I-Dosage
twice I-Dosage
daily I-Dosage
and O
fludrocortisone B-Medication
100 B-Dosage
µg I-Dosage
daily I-Dosage
were O
initiated O
. O

Adrenal B-Diagnostic_procedure
autoantibodies I-Diagnostic_procedure
to I-Diagnostic_procedure
21-hydroxylase I-Diagnostic_procedure
were O
negative B-Lab_value
and O
very-long-chain B-Diagnostic_procedure
fatty I-Diagnostic_procedure
acids I-Diagnostic_procedure
were O
normal B-Lab_value
. O

The O
patient O
has O
recently O
developed O
a O
renal B-Biological_structure
tubular I-Biological_structure
Fanconi B-Disease_disorder
syndrome I-Disease_disorder
including O
glycosuria B-Sign_symptom
, O
hypokalaemia B-Sign_symptom
, O
hypophosphataemia B-Sign_symptom
with O
low B-Lab_value
maximal B-Diagnostic_procedure
tubular I-Diagnostic_procedure
reabsorption I-Diagnostic_procedure
of I-Diagnostic_procedure
phosphate I-Diagnostic_procedure
and O
a O
generalised B-Detailed_description
aminoaciduria B-Sign_symptom
. O

In O
addition O
, O
he O
was O
incidentally O
noted O
to O
have O
hyperglycaemia B-Sign_symptom
during O
an O
admission B-Clinical_event
for O
percutaneous B-Detailed_description
endoscopic B-Detailed_description
gastrostomy B-Therapeutic_procedure
insertion O
. O

Glycated B-Detailed_description
haemoglobin B-Diagnostic_procedure
was O
elevated B-Lab_value
to O
62 B-Lab_value
mmol/mol I-Lab_value
( O
7.8 B-Lab_value
% I-Lab_value
) O
despite O
rapid B-Lab_value
red B-Diagnostic_procedure
cell I-Diagnostic_procedure
turnover I-Diagnostic_procedure
. O

Pancreatic B-Diagnostic_procedure
autoantibodies I-Diagnostic_procedure
were O
negative B-Lab_value
( O
glutamic B-Diagnostic_procedure
acid I-Diagnostic_procedure
decarboxylase I-Diagnostic_procedure
, O
anti-insulin B-Diagnostic_procedure
, O
anti-islet B-Diagnostic_procedure
antigen I-Diagnostic_procedure
2 I-Diagnostic_procedure
and O
pancreatic B-Diagnostic_procedure
islet I-Diagnostic_procedure
cell I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
) O
. O

He O
is O
maintained O
on O
twice B-Dosage
daily I-Dosage
insulin B-Medication
detemir I-Medication
with O
satisfactory B-Lab_value
glycaemic B-Diagnostic_procedure
control I-Diagnostic_procedure
with O
fructosamine B-Diagnostic_procedure
161 B-Lab_value
µmol/L I-Lab_value
( O
205 O
– O
285 O
) O
. O

A O
71-year-old B-Age
African-American B-Personal_background
woman B-Sex
presented B-Clinical_event
to O
the O
hospital O
with O
worsening B-Lab_value
exertional B-Detailed_description
dyspnoea B-Sign_symptom
associated O
with O
orthopnoea B-Sign_symptom
and O
lower B-Biological_structure
extremity I-Biological_structure
oedema B-Sign_symptom
for O
3 B-Duration
weeks I-Duration
. O

She O
had O
a O
long-standing O
history O
of O
hypertension B-History
and O
documented O
G6PD B-Disease_disorder
deficiency I-Disease_disorder
with O
prior O
episodes O
of O
haemolysis B-Sign_symptom
. O

She O
was O
a O
former B-History
cigarette I-History
smoker I-History
and O
had O
family B-Subject
members I-Subject
with O
G6PD B-Family_history
deficiency I-Family_history
, O
hypertension B-Family_history
and O
diabetes B-Family_history
mellitus I-Family_history
. O

Vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
measurement I-Diagnostic_procedure
revealed O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
150/73 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
70 B-Lab_value
bpm I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
24 B-Lab_value
breaths/min I-Lab_value
, O
temperature B-Diagnostic_procedure
of O
36.6 B-Lab_value
°C I-Lab_value
and O
97 B-Lab_value
% I-Lab_value
saturation B-Diagnostic_procedure
on O
room B-Detailed_description
air I-Detailed_description
. I-Detailed_description

She O
was O
comfortable B-Sign_symptom
at O
rest B-Detailed_description
. O

Her O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
distended B-Sign_symptom
jugular B-Biological_structure
veins I-Biological_structure
, O
inspiratory B-Detailed_description
crackles B-Sign_symptom
in O
bilateral B-Biological_structure
lung I-Biological_structure
bases I-Biological_structure
, O
a O
laterally B-Lab_value
displaced I-Lab_value
apical B-Diagnostic_procedure
impulse I-Diagnostic_procedure
and O
bipedal B-Biological_structure
oedema B-Sign_symptom
. O

The O
ECG B-Diagnostic_procedure
showed O
left B-Biological_structure
ventricular I-Biological_structure
hypertrophy B-Sign_symptom
and O
inferolateral B-Detailed_description
T-wave B-Sign_symptom
inversions I-Sign_symptom
. O

Chest B-Biological_structure
radiography B-Diagnostic_procedure
revealed O
cardiomegaly B-Sign_symptom
and O
mild B-Severity
pulmonary B-Biological_structure
oedema B-Sign_symptom
. O

The O
metabolic B-Diagnostic_procedure
panel I-Diagnostic_procedure
and O
troponin B-Diagnostic_procedure
levels O
were O
normal B-Lab_value
but O
the O
B-type B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
was O
increased B-Lab_value
at O
826.5 B-Lab_value
pg/mL I-Lab_value
. O

Echocardiography B-Diagnostic_procedure
showed O
a O
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
with O
an O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
EF B-Diagnostic_procedure
) O
of O
30 B-Lab_value
% I-Lab_value
and O
mild B-Severity
right B-Biological_structure
ventricular I-Biological_structure
systolic B-Disease_disorder
dysfunction I-Disease_disorder
. O

Coronary B-Biological_structure
artery I-Biological_structure
catheterisation B-Therapeutic_procedure
revealed O
normal B-Lab_value
coronary B-Diagnostic_procedure
circulation I-Diagnostic_procedure
. O

Ethacrynic B-Medication
acid I-Medication
at O
50 B-Dosage
mg I-Dosage
daily I-Dosage
was O
chosen O
for O
diuresis O
. O

She O
improved B-Sign_symptom
after B-Date
a I-Date
day I-Date
but O
still O
had O
dyspnoea B-Sign_symptom
, O
so O
we O
added O
spironolactone B-Medication
. O

Subsequently O
, O
metoprolol B-Medication
succinate I-Medication
and O
losartan B-Medication
were O
included O
in O
the O
regimen O
. O

Repeat O
chest B-Biological_structure
radiography B-Diagnostic_procedure
showed O
resolution O
of O
pulmonary B-Biological_structure
oedema B-Sign_symptom
. O

The O
patient O
's O
laboratory B-Diagnostic_procedure
results I-Diagnostic_procedure
during O
her O
hospital O
stay O
did O
not O
show O
signs O
of O
haemolysis B-Sign_symptom
nor O
worsening B-Sign_symptom
kidney I-Sign_symptom
function I-Sign_symptom
. O

She O
did O
not O
develop O
ototoxicity B-Sign_symptom
and O
was O
discharged B-Clinical_event
home B-Nonbiological_location
asymptomatic B-Sign_symptom
. O

A O
65-year-old B-Age
woman B-Sex
presented B-Clinical_event
with O
a O
complaint O
of O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
pain B-Sign_symptom
. O

Three B-Date
years I-Date
prior I-Date
, O
the O
patient O
was O
incidentally O
diagnosed O
with O
idiopathic B-Detailed_description
BCS B-Disease_disorder
during O
health O
checkup B-Clinical_event
; O
Doppler B-Detailed_description
ultrasound B-Diagnostic_procedure
( O
US B-Diagnostic_procedure
) O
examination O
showed O
obstruction B-Sign_symptom
of O
the O
middle B-Biological_structure
and I-Biological_structure
left I-Biological_structure
hepatic I-Biological_structure
veins I-Biological_structure
, O
and O
investigations O
for O
underlying O
thrombophilia B-Disease_disorder
were O
unremarkable O
. O

She O
was O
treated O
with O
warfarin B-Medication
to O
maintain O
an O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
between B-Lab_value
2 I-Lab_value
and I-Lab_value
3 I-Lab_value
, O
but O
discontinued B-Other_event
after B-Date
at I-Date
least I-Date
1 I-Date
year I-Date
due O
to O
non-compliance B-Detailed_description
; O
the O
patient O
did O
not O
consult B-Clinical_event
with O
any O
doctors O
for O
2 B-Duration
years I-Duration
. O

She O
has O
remained O
asymptomatic B-Sign_symptom
for O
the O
past B-Duration
3 I-Duration
years I-Duration
until O
recently O
she O
started O
experiencing O
steadily O
worsening B-Detailed_description
, O
intermittent B-Frequency
pain B-Sign_symptom
in O
the O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
of O
her O
abdomen O
, O
with O
no O
associated B-Sign_symptom
or I-Sign_symptom
alleviating I-Sign_symptom
factors I-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
only O
notable O
for O
mild O
right B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
tenderness B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
mildly B-Lab_value
elevated I-Lab_value
bilirubin B-Diagnostic_procedure
( O
2.2 B-Lab_value
mg/dL I-Lab_value
) O
and O
albumin B-Diagnostic_procedure
deficit B-Lab_value
( O
2.38 B-Lab_value
g/dL I-Lab_value
) O
. O

Her O
Child-Pugh B-Diagnostic_procedure
( O
CP B-Diagnostic_procedure
) O
score O
was O
8 B-Lab_value
, O
Model B-Diagnostic_procedure
for I-Diagnostic_procedure
End-Stage I-Diagnostic_procedure
Liver I-Diagnostic_procedure
Disease I-Diagnostic_procedure
( O
MELD B-Diagnostic_procedure
) O
score O
was O
11 B-Lab_value
, O
Rotterdam B-Diagnostic_procedure
score O
was O
0.15 B-Lab_value
, O
and O
BCS-TIPS B-Diagnostic_procedure
prognostic I-Diagnostic_procedure
index I-Diagnostic_procedure
( O
BCS-TIPS B-Diagnostic_procedure
PI I-Diagnostic_procedure
) O
score O
was O
6.3 B-Lab_value
. O

A O
contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
showed O
non-visualized B-Sign_symptom
middle B-Biological_structure
and I-Biological_structure
left I-Biological_structure
hepatic I-Biological_structure
veins I-Biological_structure
, O
hepatomegaly B-Sign_symptom
with O
hypertrophy B-Sign_symptom
of O
the O
caudate B-Biological_structure
lobe I-Biological_structure
, O
splenomegaly B-Sign_symptom
, O
hepatic B-Biological_structure
venous B-Sign_symptom
collaterals I-Sign_symptom
, O
and O
a O
saccular B-Detailed_description
aneurysm B-Sign_symptom
located O
at O
the O
extrahepatic B-Biological_structure
portal I-Biological_structure
vein I-Biological_structure
main I-Biological_structure
branch I-Biological_structure
measuring O
3.2 B-Distance
cm I-Distance
in I-Distance
height I-Distance
and O
2.5 B-Area
cm I-Area
× I-Area
2.4 I-Area
cm I-Area
in I-Area
diameter I-Area
( O
Figure O
1A O
) O
. O

The O
aneurysm B-Sign_symptom
was O
thought O
to O
be O
associated O
with O
BCS B-Disease_disorder
as O
there O
was O
no B-History
preceding I-History
history I-History
of I-History
trauma I-History
and O
it O
had O
not O
been O
present O
on O
Doppler B-Detailed_description
US B-Diagnostic_procedure
examination O
performed O
3 B-Date
years I-Date
previously I-Date
. O

Although O
the O
patient O
had O
no O
ascites B-Sign_symptom
or O
variceal B-Biological_structure
bleeding B-Sign_symptom
, O
the O
decision O
was O
made O
to O
create O
a O
TIPS B-Therapeutic_procedure
to O
relieve O
hepatic B-Biological_structure
venous I-Biological_structure
outflow B-Detailed_description
obstruction B-Sign_symptom
because O
of O
increasing O
pain B-Sign_symptom
and O
concern O
for O
complications B-Disease_disorder
due O
to O
aneurysm B-Sign_symptom
size O
; O
direct B-Therapeutic_procedure
approach I-Therapeutic_procedure
to O
the O
aneurysm B-Sign_symptom
was O
not O
considered O
due O
to O
risk O
of O
associated O
complications O
in O
the O
setting O
of O
portal B-Biological_structure
hypertension B-Sign_symptom
, O
and O
stent-grafting B-Therapeutic_procedure
was O
not O
considered O
due O
to O
concerns O
about O
patency O
in O
the O
settings O
of O
hepatic B-Biological_structure
venous I-Biological_structure
outflow B-Detailed_description
obstruction B-Sign_symptom
and O
underlying O
thrombophilia B-Sign_symptom
. O

After O
informed O
consent O
was O
obtained O
, O
the O
patient O
was O
brought B-Clinical_event
to O
the O
interventional B-Nonbiological_location
radiology I-Nonbiological_location
suite I-Nonbiological_location
. O

The O
procedure O
was O
performed O
with O
the O
patient O
under O
conscious B-Medication
sedation I-Medication
. O

Portal B-Therapeutic_procedure
vein I-Therapeutic_procedure
access I-Therapeutic_procedure
was O
obtained O
via O
the O
right B-Biological_structure
hepatic I-Biological_structure
vein I-Biological_structure
under O
fluoroscopy B-Diagnostic_procedure
, O
and O
portography B-Diagnostic_procedure
showed O
a O
saccular B-Detailed_description
aneurysm B-Sign_symptom
located O
at O
the O
main B-Biological_structure
portal I-Biological_structure
vein I-Biological_structure
, O
extensive B-Severity
intrahepatic B-Biological_structure
portal I-Biological_structure
vein I-Biological_structure
thrombosis B-Sign_symptom
, O
and O
small B-Severity
splenorenal B-Biological_structure
varices B-Sign_symptom
( O
Figure O
2A O
) O
. O

A O
10-mm B-Detailed_description
diameter I-Detailed_description
expanded B-Detailed_description
polytetrafluoroethylene B-Detailed_description
( O
ePTFE B-Detailed_description
) O
covered B-Detailed_description
stent-graft B-Therapeutic_procedure
( O
Fluency B-Detailed_description
Plus I-Detailed_description
; O
Bard B-Detailed_description
Peripheral I-Detailed_description
Vascular I-Detailed_description
, I-Detailed_description
Tempe I-Detailed_description
, I-Detailed_description
Arizona I-Detailed_description
, I-Detailed_description
United I-Detailed_description
States I-Detailed_description
) O
was O
deployed O
across O
the O
liver B-Biological_structure
parenchymal I-Biological_structure
tract I-Biological_structure
; O
deploying O
the O
stent-graft B-Therapeutic_procedure
into O
the O
main B-Biological_structure
portal I-Biological_structure
vein I-Biological_structure
trunk I-Biological_structure
to O
cover O
the O
aneurysm B-Sign_symptom
neck O
was O
not O
considered O
because O
it O
would O
obstruct B-Sign_symptom
blood O
flow O
to O
the O
portal B-Biological_structure
vein I-Biological_structure
branches I-Biological_structure
. O

Completion O
portography B-Diagnostic_procedure
showed O
a O
widely O
patent B-Sign_symptom
shunt I-Sign_symptom
and O
markedly O
decreased O
aneurysm B-Sign_symptom
filling O
( O
Figure O
2B O
) O
. O

The O
portosystemic B-Diagnostic_procedure
pressure I-Diagnostic_procedure
gradient I-Diagnostic_procedure
( O
PPG B-Diagnostic_procedure
) O
was O
decreased B-Lab_value
from O
19 B-Lab_value
mmHg I-Lab_value
to O
8 B-Lab_value
mmHg I-Lab_value
. O

The O
patient O
recovered B-Diagnostic_procedure
uneventfully B-Lab_value
and O
had O
complete O
resolution O
of O
her O
abdominal B-Biological_structure
pain B-Sign_symptom
in O
2 B-Date
d I-Date
. O

She O
was O
discharged B-Clinical_event
on O
long-term O
warfarin B-Medication
and O
remained O
asymptomatic B-Sign_symptom
after O
1 B-Duration
year I-Duration
of O
follow-up B-Clinical_event
. O

Most O
recent O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
normal B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
and O
Doppler B-Detailed_description
US B-Diagnostic_procedure
examination O
performed O
at O
1 B-Date
, I-Date
3 I-Date
, I-Date
6 I-Date
, I-Date
and I-Date
12 I-Date
mo I-Date
postprocedure I-Date
confirmed O
a O
patent B-Sign_symptom
shunt I-Sign_symptom
. O

Her O
CP B-Diagnostic_procedure
score O
was O
5 B-Lab_value
, O
MELD B-Diagnostic_procedure
score O
was O
8 B-Lab_value
, O
Rotterdam B-Diagnostic_procedure
score O
was O
0.12 B-Lab_value
, O
and O
TIPS-BCS B-Diagnostic_procedure
PI I-Diagnostic_procedure
score O
was O
6.1 B-Lab_value
. O

CT B-Diagnostic_procedure
scans O
showed O
that O
the O
aneurysm B-Sign_symptom
had O
decreased O
in O
size O
to O
2.4 B-Distance
cm I-Distance
in I-Distance
height I-Distance
and O
2.0 B-Area
cm I-Area
× I-Area
1.9 I-Area
cm I-Area
in I-Area
diameter I-Area
at O
3 B-Date
mo I-Date
after I-Date
TIPS B-Therapeutic_procedure
( O
Figure O
1B O
) O
, O
and O
had O
further O
decreased O
to O
1.9 B-Distance
cm I-Distance
in I-Distance
height I-Distance
and O
1.6 B-Area
cm I-Area
× I-Area
1.5 I-Area
cm I-Area
in I-Area
diameter I-Area
at O
1 B-Date
year I-Date
( O
Figure O
1C O
) O
. O

Our O
patient O
was O
a O
68-year-old B-Age
woman B-Sex
with O
chronic B-History
obstructive I-History
pulmonary I-History
disease I-History
. O

She O
had O
no B-History
history I-History
of I-History
gastroesophageal I-History
reflux I-History
disease I-History
or I-History
esophageal I-History
disorders I-History
but O
was O
found O
to O
have O
a O
progressive B-Detailed_description
solitary B-Detailed_description
pulmonary B-Biological_structure
nodule B-Sign_symptom
( O
1 B-Area
× I-Area
1.3 I-Area
cm I-Area
) O
. O

A O
right B-Detailed_description
lower I-Detailed_description
wedge I-Detailed_description
resection B-Therapeutic_procedure
was O
performed O
in O
December B-Date
2011 I-Date
and O
the O
University B-Nonbiological_location
of I-Nonbiological_location
Iowa I-Nonbiological_location
pathology I-Nonbiological_location
department I-Nonbiological_location
identified O
the O
tumor B-Coreference
as O
a O
LCNEC B-Disease_disorder
. O

Approximately O
six B-Date
months I-Date
after I-Date
her O
operation O
, O
our O
patient O
started O
having O
slowly B-Detailed_description
progressing I-Detailed_description
dysphagia B-Sign_symptom
for B-Detailed_description
both I-Detailed_description
solids I-Detailed_description
and I-Detailed_description
liquids I-Detailed_description
. O

A O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
scan O
performed O
in O
2012 B-Date
, O
one B-Date
year I-Date
post I-Date
surgery I-Date
, O
was O
unremarkable B-Lab_value
for O
recurrence O
or O
metastasis O
. O

Repeat O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
in O
June B-Date
2013 I-Date
( O
18 B-Date
months I-Date
post I-Date
surgery I-Date
) O
did O
not O
show O
any O
recurrence B-Sign_symptom
( O
Figure O
1 O
) O
. O

Our O
patient O
had O
an O
esophagogastroduodenoscopy B-Diagnostic_procedure
( O
EGD B-Diagnostic_procedure
) O
and O
barium B-Diagnostic_procedure
swallow I-Diagnostic_procedure
that O
revealed O
no O
stricture B-Sign_symptom
of O
her O
esophagus B-Biological_structure
but O
failure B-Sign_symptom
of O
primary B-Biological_structure
and I-Biological_structure
secondary I-Biological_structure
peristaltic I-Biological_structure
waves I-Biological_structure
and O
reflux B-Biological_structure
. O

In O
July B-Date
2013 I-Date
, O
esophageal B-Diagnostic_procedure
manometry I-Diagnostic_procedure
found O
failure B-Sign_symptom
of O
the O
lower B-Detailed_description
esophageal I-Detailed_description
sphincter I-Detailed_description
to I-Detailed_description
relax I-Detailed_description
, O
with O
a O
residual B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
32mmHg B-Lab_value
. O

Our O
patient O
was O
treated O
with O
calcium B-Medication
channel I-Medication
blockers I-Medication
with O
partial O
relief B-Sign_symptom
. O

Thus O
far O
, O
up B-Duration
to I-Duration
18 I-Duration
months I-Duration
post I-Duration
resection O
, O
our O
patient O
had O
been O
able O
to O
maintain B-Lab_value
her O
weight B-Diagnostic_procedure
and O
her O
basic B-Diagnostic_procedure
laboratory I-Diagnostic_procedure
parameters I-Diagnostic_procedure
, O
including O
hemoglobin B-Diagnostic_procedure
, O
albumin B-Diagnostic_procedure
and O
cholesterol B-Diagnostic_procedure
levels O
. O

However O
, O
in O
January B-Date
2014 I-Date
, O
she O
reported O
worsening O
dysphagia B-Sign_symptom
and O
weight B-Sign_symptom
loss I-Sign_symptom
of O
10 B-Lab_value
lbs I-Lab_value
over B-Duration
a I-Duration
period I-Duration
of I-Duration
one I-Duration
month I-Duration
. O

She O
was O
referred B-Clinical_event
to O
our O
center B-Nonbiological_location
for O
further O
treatment B-Therapeutic_procedure
of O
her O
achalasia B-Disease_disorder
. O

A O
repeat O
esophageal B-Diagnostic_procedure
manometry I-Diagnostic_procedure
showed O
an O
elevated B-Lab_value
lower B-Diagnostic_procedure
esophageal I-Diagnostic_procedure
sphincter I-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
50mmHg B-Lab_value
as O
well O
non-propagative B-Detailed_description
, O
non-peristaltic B-Detailed_description
contractions B-Sign_symptom
throughout O
her O
esophageal B-Biological_structure
musculature I-Biological_structure
( O
Figure O
2 O
) O
. O

A O
repeat O
EGD B-Diagnostic_procedure
with O
an O
intention O
to O
perform O
therapeutic O
pneumatic B-Therapeutic_procedure
dilation I-Therapeutic_procedure
showed O
a O
nearly B-Detailed_description
circumferential I-Detailed_description
ulcerated B-Detailed_description
, O
fungating B-Detailed_description
mass B-Sign_symptom
from O
approximately B-Distance
36 I-Distance
cm I-Distance
that O
extended O
to O
her O
gastroesophageal B-Biological_structure
junction I-Biological_structure
at B-Distance
39 I-Distance
cm I-Distance
. O

Biopsies B-Diagnostic_procedure
revealed O
a O
LCNEC B-Disease_disorder
with O
similar B-Detailed_description
features I-Detailed_description
to I-Detailed_description
the I-Detailed_description
primary I-Detailed_description
tumor I-Detailed_description
resected I-Detailed_description
in I-Detailed_description
2011 I-Detailed_description
, O
and O
was O
concluded O
to O
be O
a O
metastasis B-Sign_symptom
. O

Subsequently O
, O
a O
repeat O
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
revealed O
progressive B-Detailed_description
diffuse B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
. O

Our O
patient O
underwent O
two B-Detailed_description
courses I-Detailed_description
of O
chemotherapy B-Medication
but O
died B-Outcome
from O
the O
disease O
after B-Date
six I-Date
months I-Date
. O

A O
35-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
the O
ear B-Nonbiological_location
, I-Nonbiological_location
nose I-Nonbiological_location
and I-Nonbiological_location
throat I-Nonbiological_location
outpatient I-Nonbiological_location
department I-Nonbiological_location
with O
headache B-Sign_symptom
and O
a O
blocked B-Sign_symptom
left-sided I-Sign_symptom
nasal I-Sign_symptom
canal I-Sign_symptom
with O
epistaxis B-Sign_symptom
for O
2 B-Duration
years I-Duration
. O

Medical O
history O
revealed O
secondary B-History
amenorrhoea I-History
for I-History
the I-History
past I-History
19 I-History
years I-History
with O
regression B-Sign_symptom
of I-Sign_symptom
secondary I-Sign_symptom
sexual I-Sign_symptom
characteristics I-Sign_symptom
with B-History
no I-History
galactorrhoea I-History
. O

Physical B-Diagnostic_procedure
and O
ophthalmological B-Diagnostic_procedure
examinations I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

Nasal B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
left-sided B-Biological_structure
choanal B-Biological_structure
mass B-Sign_symptom
. O

As O
the O
mass B-Coreference
was O
bleeding B-Detailed_description
on I-Detailed_description
palpation I-Detailed_description
, O
imaging B-Diagnostic_procedure
was O
advised O
prior O
to O
performing O
a O
biopsy O
. O

MRI B-Diagnostic_procedure
of O
the O
head B-Biological_structure
showed O
a O
sellar B-Biological_structure
and O
infra-sellar B-Biological_structure
mass B-Sign_symptom
extending B-Biological_structure
into I-Biological_structure
the I-Biological_structure
nasopharynx I-Biological_structure
( O
figure O
1 O
) O
. O

The O
patient O
was O
then O
referred B-Clinical_event
to O
the O
endocrinologist B-Nonbiological_location
for O
further O
hormonal B-Diagnostic_procedure
investigation I-Diagnostic_procedure
. O

Her O
serum B-Diagnostic_procedure
prolactin I-Diagnostic_procedure
was O
very B-Lab_value
high I-Lab_value
— O
7443 B-Lab_value
µg/L I-Lab_value
( O
N O
< O
20 O
) O
. O

Other B-Diagnostic_procedure
pituitary I-Diagnostic_procedure
hormones I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

A O
final O
diagnosis O
of O
giant B-Disease_disorder
prolactinoma I-Disease_disorder
was O
made O
and O
the O
patient O
was O
prescribed O
cabergoline B-Medication
0.25 B-Dosage
mg I-Dosage
twice I-Dosage
per I-Dosage
week I-Dosage
with O
the O
associated O
risks O
explained O
in O
advance O
. O

A O
38-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
our O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
with O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
. O

She O
had O
no B-History
history I-History
of I-History
drug I-History
use I-History
or I-History
constipation I-History
. O

She O
said O
that O
she O
had O
intermittent B-Detailed_description
bloody B-Detailed_description
diarrhea B-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
rebound B-Detailed_description
tenderness B-Sign_symptom
and O
guarding B-Sign_symptom
over O
the O
abdomen B-Biological_structure
. O

Stool B-Diagnostic_procedure
microscopy I-Diagnostic_procedure
was O
negative B-Lab_value
for O
amoeba B-Diagnostic_procedure
trophozoites I-Diagnostic_procedure
or O
any O
parasites B-Diagnostic_procedure
. O

Fecal B-Diagnostic_procedure
occult I-Diagnostic_procedure
blood I-Diagnostic_procedure
was O
found B-Lab_value
. O

Sedimentation B-Diagnostic_procedure
was O
27 B-Lab_value
mm/s I-Lab_value
, O
CRP B-Diagnostic_procedure
( O
nephelometry B-Diagnostic_procedure
) O
was O
65.6 B-Lab_value
mg/L I-Lab_value
( O
normal O
range O
0 O
– O
5 O
) O
, O
anti-nuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
was O
0.4 B-Lab_value
( O
0 O
– O
0.8 O
negative O
) O
, O
anti-ds B-Diagnostic_procedure
DNA I-Diagnostic_procedure
< B-Lab_value
10 I-Lab_value
( O
< O
20 O
negative O
) O
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
14.98 B-Lab_value
( O
normal O
range O
4 O
– O
10 O
) O
, O
hemoglobin B-Diagnostic_procedure
level O
was O
10.9 B-Lab_value
, O
neutro-phil B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
13.14 B-Lab_value
, O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
473 B-Lab_value
( O
100 O
– O
300 O
) O
, O
urea B-Diagnostic_procedure
level O
was O
17 B-Lab_value
mg/dl I-Lab_value
, O
BUN B-Diagnostic_procedure
level O
was O
7.94 B-Lab_value
mg/dl I-Lab_value
, O
creatinine B-Diagnostic_procedure
level O
was O
0.56 B-Lab_value
mg/dl I-Lab_value
, O
AST B-Diagnostic_procedure
was O
20 B-Lab_value
U/L I-Lab_value
, O
and O
ALT B-Diagnostic_procedure
was O
24 B-Lab_value
U/L I-Lab_value
. O

HIV B-Diagnostic_procedure
was O
negative B-Lab_value
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
scanning O
showed O
free B-Sign_symptom
fluid I-Sign_symptom
at O
the O
right B-Biological_structure
paracolic I-Biological_structure
, O
perihepatic B-Biological_structure
, O
left B-Biological_structure
paracolic I-Biological_structure
gutters B-Biological_structure
and O
pelvis B-Biological_structure
. O

Upon O
detection O
of O
air-fluid B-Sign_symptom
level I-Sign_symptom
and O
free B-Sign_symptom
air I-Sign_symptom
under B-Biological_structure
the I-Biological_structure
diaphragm I-Biological_structure
on O
erect B-Detailed_description
abdominal B-Biological_structure
x-ray B-Diagnostic_procedure
, O
emergency B-Detailed_description
laparotomy B-Therapeutic_procedure
was O
performed O
. O

In O
the O
operation O
, O
multiple B-Detailed_description
perforation B-Sign_symptom
areas O
were O
found O
in O
the O
sigmoid B-Biological_structure
colon I-Biological_structure
, O
descending B-Biological_structure
colon I-Biological_structure
, O
and O
transverse B-Biological_structure
colon I-Biological_structure
. O

Wide B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
transverse B-Biological_structure
colon I-Biological_structure
with O
descending B-Biological_structure
and I-Biological_structure
sigmoid I-Biological_structure
colon I-Biological_structure
resection B-Therapeutic_procedure
was O
undertaken O
( O
Figure O
1 O
) O
. O

Pathergy B-Diagnostic_procedure
test I-Diagnostic_procedure
was O
positive B-Lab_value
. O

The O
patient O
had O
recurrent O
oral B-Biological_structure
and O
genital B-Biological_structure
aphthous B-Detailed_description
ulcers B-Disease_disorder
4 B-Lab_value
– I-Lab_value
5 I-Lab_value
times I-Lab_value
within B-Date
the I-Date
past I-Date
year I-Date
. O

Eye B-Diagnostic_procedure
examination I-Diagnostic_procedure
results O
were O
normal B-Lab_value
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
extensive B-Detailed_description
thrombus B-Disease_disorder
within O
the O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
extending O
through O
the O
right B-Biological_structure
and I-Biological_structure
middle I-Biological_structure
hepatic I-Biological_structure
vein I-Biological_structure
( O
Figure O
2 O
) O
. O

The O
patient O
received O
corticosteroid B-Medication
, O
anticoagulant B-Medication
, O
and O
immunosuppressive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

Our O
patient O
is O
still O
alive B-Sign_symptom
and O
healthy B-Sign_symptom
53 B-Date
weeks I-Date
later I-Date
( O
Figure O
3 O
) O
. O

In O
macroscopy B-Diagnostic_procedure
, O
the O
transverse B-Diagnostic_procedure
colon I-Diagnostic_procedure
was O
50 B-Distance
cm I-Distance
and O
sigmoid B-Lab_value
and O
descending B-Diagnostic_procedure
colon I-Diagnostic_procedure
specimens I-Diagnostic_procedure
were O
27 B-Distance
cm I-Distance
in O
length O
. O

Specimens B-Diagnostic_procedure
of I-Diagnostic_procedure
both I-Diagnostic_procedure
colon I-Diagnostic_procedure
segments I-Diagnostic_procedure
were O
4 B-Distance
cm I-Distance
in O
diameter O
. O

Perforation B-Disease_disorder
areas O
were O
evident O
in O
the O
serosal B-Biological_structure
surface I-Biological_structure
. O

Colonic B-Biological_structure
wall I-Biological_structure
and O
bowel B-Biological_structure
mucosa I-Biological_structure
was O
edematous B-Sign_symptom
and O
hyperemic B-Sign_symptom
. O

Plicae B-Diagnostic_procedure
were O
regular B-Lab_value
in O
their O
course O
. O

There O
were O
3 B-Lab_value
roundish B-Shape
, O
punched-out B-Detailed_description
perforations B-Disease_disorder
in O
the O
transverse B-Biological_structure
colon I-Biological_structure
and O
4 B-Lab_value
in O
the O
descending B-Biological_structure
and I-Biological_structure
sigmoid I-Biological_structure
colon I-Biological_structure
, O
which O
were O
somewhat O
separate B-Detailed_description
from I-Detailed_description
the I-Detailed_description
colonic I-Detailed_description
wall I-Detailed_description
, O
with O
the O
largest B-Distance
being I-Distance
2 I-Distance
cm I-Distance
in O
diameter O
( O
Figure O
4 O
) O
. O

There O
were O
multiple B-Detailed_description
ulcers B-Disease_disorder
( O
the O
largest B-Distance
was I-Distance
1 I-Distance
cm I-Distance
in O
diameter O
) O
in O
different O
locations O
, O
which O
were O
not B-Detailed_description
merging I-Detailed_description
together I-Detailed_description
, O
and O
were O
somewhat B-Detailed_description
separate I-Detailed_description
from I-Detailed_description
the I-Detailed_description
surrounding I-Detailed_description
mucosa I-Detailed_description
via I-Detailed_description
a I-Detailed_description
certain I-Detailed_description
limit I-Detailed_description
, O
covered B-Detailed_description
with I-Detailed_description
exudate I-Detailed_description
and O
surrounded B-Detailed_description
by O
a O
hyperemic B-Sign_symptom
region I-Sign_symptom
. O

There O
were O
no O
macroscopic B-Sign_symptom
lymph I-Sign_symptom
nodes I-Sign_symptom
in O
the O
serosa B-Biological_structure
. O

Numerous O
samples O
were O
taken O
from O
ulcerated O
and O
perforated O
regions O
and O
normal O
mucosa O
. O

The O
samples O
were O
submitted O
for O
routine O
microscopic B-Diagnostic_procedure
tissue I-Diagnostic_procedure
follow-up I-Diagnostic_procedure
. O

Hematoxylin-eosin B-Diagnostic_procedure
, O
tissue B-Diagnostic_procedure
Giemsa I-Diagnostic_procedure
and O
PAS-stained B-Diagnostic_procedure
slides I-Diagnostic_procedure
were O
prepared O
for O
examination O
. O

In O
microscopic B-Coreference
examination I-Coreference
, O
there O
were O
neutrophil B-Biological_structure
leukocyte I-Biological_structure
and O
lymphocyte B-Biological_structure
reaction B-Sign_symptom
around O
and O
within O
the O
walls B-Biological_structure
and I-Biological_structure
lumens I-Biological_structure
of I-Biological_structure
arterioles I-Biological_structure
, O
and O
venules B-Sign_symptom
around O
the O
perforated B-Detailed_description
and O
ulcerated B-Detailed_description
lesions B-Sign_symptom
( O
Figures O
5 O
and O
and6 O
) O
.6 O
) O
. O

There O
were O
well-organized B-Detailed_description
thrombi B-Sign_symptom
and O
intimal B-Sign_symptom
proliferation I-Sign_symptom
within O
some B-Biological_structure
vessels I-Biological_structure
( O
Figures O
7 O
and O
and8 O
) O
.8 O
) O
. O

There O
was O
marked O
acute B-Detailed_description
peritonitis B-Disease_disorder
. O

Surface B-Diagnostic_procedure
epithelium I-Diagnostic_procedure
and O
colonic B-Diagnostic_procedure
crypts I-Diagnostic_procedure
were O
regular B-Lab_value
within O
the O
colonic B-Biological_structure
mucosa I-Biological_structure
apart O
from O
the O
ulcerated O
or O
perforated O
lesions O
. O

Samples O
were O
free O
of O
parasites B-Disease_disorder
or O
their O
eggs O
. O

The O
patient O
was O
a O
38-year-old B-Age
Caucasian B-Personal_background
man B-Sex
of O
Spanish B-Personal_background
origin I-Personal_background
. O

His O
height O
was O
165 B-Height
cm I-Height
and O
his O
parents B-Family_history
were I-Family_history
cousins I-Family_history
. O

Both B-Family_history
parents I-Family_history
were I-Family_history
of I-Family_history
normal I-Family_history
height I-Family_history
and I-Family_history
neither I-Family_history
showed I-Family_history
any I-Family_history
minor I-Family_history
anomalies I-Family_history
of I-Family_history
the I-Family_history
EvC I-Family_history
syndrome I-Family_history
spectrum I-Family_history
. O

The B-Family_history
patient I-Family_history
had I-Family_history
two I-Family_history
healthy I-Family_history
sisters I-Family_history
. O

His O
morphological B-Diagnostic_procedure
features I-Diagnostic_procedure
were O
: O
( O
a O
) O
normal B-Sign_symptom
mouth I-Sign_symptom
opening I-Sign_symptom
with O
missing B-Sign_symptom
lower I-Sign_symptom
incisors I-Sign_symptom
( O
Fig. O
1 O
) O
; O
( O
b O
) O
small B-Sign_symptom
chest I-Sign_symptom
, O
as O
determined O
by O
a O
cardiothoracic B-Diagnostic_procedure
examination I-Diagnostic_procedure
; O
and O
( O
c O
) O
disproportionately O
short B-Sign_symptom
extremities I-Sign_symptom
with O
one B-Detailed_description
additional B-Sign_symptom
postaxial I-Sign_symptom
digit I-Sign_symptom
on O
each B-Biological_structure
hand I-Biological_structure
( O
Fig. O
2 O
) O
. O

Although O
no O
sensory-motor B-Sign_symptom
deficit I-Sign_symptom
was O
noted O
, O
the O
patient O
presented O
with O
mild B-Detailed_description
mental B-Disease_disorder
retardation I-Disease_disorder
. O

Genetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
in O
his O
early O
infancy O
showed O
a O
previously O
reported O
homozygous B-Detailed_description
nonsense B-Detailed_description
mutation B-Sign_symptom
c. B-Detailed_description
1195 I-Detailed_description
C1T I-Detailed_description
, I-Detailed_description
p.Arg399X I-Detailed_description
of I-Detailed_description
EvC2 I-Detailed_description
, O
resulting O
in O
loss B-Detailed_description
of I-Detailed_description
function I-Detailed_description
of I-Detailed_description
the I-Detailed_description
protein I-Detailed_description
. O

( O
5 O
) O
His O
parents B-Subject
were O
heterozygous B-Detailed_description
carriers I-Detailed_description
of O
the O
mutation B-Coreference
. O

In O
1998 B-Date
, O
the O
patient O
underwent O
successful O
ostium B-Biological_structure
primum I-Biological_structure
atrial B-Therapeutic_procedure
septal I-Therapeutic_procedure
defect I-Therapeutic_procedure
closure I-Therapeutic_procedure
through O
a O
midsternotomy B-Therapeutic_procedure
. O

He O
re-presented B-Clinical_event
with O
embolic B-Detailed_description
cerebral B-Biological_structure
ictus B-Sign_symptom
in O
2007 B-Date
, O
and O
cavotricuspid B-Biological_structure
isthmus I-Biological_structure
ablation B-Therapeutic_procedure
for O
common B-Detailed_description
atrial B-Disease_disorder
flutter I-Disease_disorder
was O
performed O
successfully O
. O

There O
were O
no O
serious B-Severity
aftereffects B-Sign_symptom
. O

During O
a O
routine O
examination B-Diagnostic_procedure
in O
2012 B-Date
, O
a O
high-pitched B-Detailed_description
systolic B-Detailed_description
murmur B-Sign_symptom
was O
discovered O
. O

Electrocardiography B-Diagnostic_procedure
showed O
sinus B-Lab_value
rhythm I-Lab_value
with O
hemiblock B-Disease_disorder
and O
right B-Disease_disorder
bundle I-Disease_disorder
branch I-Disease_disorder
block I-Disease_disorder
, O
while O
echocardiography B-Diagnostic_procedure
revealed O
a O
dilated B-Sign_symptom
and O
hypertrophic B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
. O

These O
abnormalities O
produced O
a O
flow B-Sign_symptom
that O
was O
directed B-Biological_structure
to I-Biological_structure
the I-Biological_structure
left I-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
, O
leading O
to O
severe O
mitral B-Sign_symptom
valve I-Sign_symptom
regurgitation I-Sign_symptom
. O

The O
patient O
’s O
systolic B-Detailed_description
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
50 B-Lab_value
mmHg I-Lab_value
and O
his O
aortic B-Sign_symptom
valve I-Sign_symptom
was I-Sign_symptom
normal I-Sign_symptom
. O

His O
medical O
treatment O
included O
ramipril B-Medication
, O
duloxetine B-Medication
, O
alprazolam B-Medication
and O
acenocumarol B-Medication
. O

The O
patient O
was O
scheduled O
for O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O

In O
the O
operating O
theatre O
, O
the O
patient O
’s O
right B-Biological_structure
femoral I-Biological_structure
artery I-Biological_structure
was O
cannulated B-Therapeutic_procedure
. O

A O
right B-Detailed_description
thoracotomy B-Therapeutic_procedure
was O
performed O
on O
the O
fourth B-Biological_structure
intercostal I-Biological_structure
space I-Biological_structure
and O
bicaval B-Detailed_description
cannulation B-Therapeutic_procedure
was O
established O
. O

Both B-Detailed_description
veins I-Detailed_description
were I-Detailed_description
excluded I-Detailed_description
. O

The O
operation O
used O
a O
normothermic B-Detailed_description
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
without B-Detailed_description
cross-clamping I-Detailed_description
of I-Detailed_description
the I-Detailed_description
aorta I-Detailed_description
in I-Detailed_description
the I-Detailed_description
beating I-Detailed_description
heart I-Detailed_description
. O

To O
avoid O
air O
embolisms O
, O
continuous B-Therapeutic_procedure
carbon I-Therapeutic_procedure
dioxide I-Therapeutic_procedure
( I-Therapeutic_procedure
CO2 I-Therapeutic_procedure
) I-Therapeutic_procedure
field I-Therapeutic_procedure
flooding I-Therapeutic_procedure
was O
applied O
using O
a O
CarbonAid B-Detailed_description
CO2 I-Detailed_description
diffuser I-Detailed_description
( O
Cardia B-Detailed_description
Innovation I-Detailed_description
AB I-Detailed_description
, I-Detailed_description
Stockholm I-Detailed_description
, I-Detailed_description
Sweden I-Detailed_description
) O
. O

The O
attempt O
to O
perform O
a O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
repair I-Therapeutic_procedure
was O
unsuccessful O
and O
a O
bileaflet B-Detailed_description
mechanical I-Detailed_description
valve I-Detailed_description
( O
no. B-Detailed_description
29 I-Detailed_description
) O
was O
implanted B-Therapeutic_procedure
. O

No O
complications B-Sign_symptom
associated B-Detailed_description
with I-Detailed_description
anaesthesia I-Detailed_description
occurred O
. O

The O
patient O
’s O
postoperative B-Therapeutic_procedure
recovery I-Therapeutic_procedure
was O
uneventful B-Lab_value
and O
he O
was O
discharged B-Clinical_event
on O
postoperative B-Date
day I-Date
10 I-Date
. O

After O
two B-Duration
years I-Duration
of O
follow-up B-Clinical_event
, O
echocardiography B-Diagnostic_procedure
revealed O
optimal B-Lab_value
function I-Lab_value
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
and O
a O
decrease B-Lab_value
in O
systolic B-Detailed_description
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
30 B-Lab_value
mmHg I-Lab_value
) O
. O

An O
11-year-old B-Age
boy B-Sex
presented B-Clinical_event
with O
a O
history O
of O
headaches B-Sign_symptom
and O
vomiting B-Sign_symptom
that O
had O
been O
present O
for O
several B-Duration
months I-Duration
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
papilledema B-Disease_disorder
without O
the O
presence O
of O
any O
other O
neurological B-Disease_disorder
deficits I-Disease_disorder
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
revealed O
a O
large B-Detailed_description
prepontine B-Biological_structure
mass B-Sign_symptom
with O
dorsal B-Detailed_description
displacement B-Sign_symptom
of O
the O
brainstem B-Biological_structure
and O
a O
secondary B-Detailed_description
obstructive B-Detailed_description
hydrocephalus B-Disease_disorder
due O
to O
compression B-Sign_symptom
of O
the O
aqueduct B-Biological_structure
. O

The O
lesion B-Coreference
had O
an O
inhomogeneous B-Detailed_description
hypointense B-Sign_symptom
aspect I-Sign_symptom
on O
the O
T1-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
( O
T1WI B-Diagnostic_procedure
) O
and O
an O
inhomogeneous B-Detailed_description
hyperintense B-Sign_symptom
aspect I-Sign_symptom
on O
the O
T2-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
( O
T2WI B-Diagnostic_procedure
) O
. O

After O
administration O
of O
IV B-Administration
gadolinium B-Medication
, O
there O
was O
some O
inhomogeneous B-Detailed_description
enhancement B-Sign_symptom
( O
Fig. O
1 O
) O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
imaging O
showed O
no O
bone B-Sign_symptom
involvement I-Sign_symptom
. O

During O
the O
first O
operation O
, O
a O
ventriculoperitoneal B-Detailed_description
shunt B-Therapeutic_procedure
was O
inserted O
into O
the O
right B-Biological_structure
lateral I-Biological_structure
ventricle I-Biological_structure
to O
treat O
the O
hydrocephalus B-Coreference
. O

A O
careful O
study O
of O
the O
MRI O
suggested O
that O
this O
infra O
- O
and O
supratentorially O
located O
tumour O
might O
be O
resected O
through O
a O
single O
approach O
. O

A O
left B-Detailed_description
frontotemporal B-Detailed_description
transsylvian B-Therapeutic_procedure
approach I-Therapeutic_procedure
was O
performed O
to O
gain O
access O
to O
the O
tumour O
. O

The O
tumour B-Sign_symptom
had O
well-defined B-Detailed_description
margins I-Detailed_description
and O
was O
entirely O
located O
in O
the O
intradural B-Biological_structure
plane I-Biological_structure
. O

There O
were O
no O
attachments B-Sign_symptom
to O
the O
cranial B-Biological_structure
nerves I-Biological_structure
or O
brainstem B-Biological_structure
. O

A O
macroscopic B-Detailed_description
complete B-Detailed_description
resection B-Therapeutic_procedure
was O
performed O
. O

Postoperatively O
, O
the O
patient O
had O
developed O
a O
left B-Biological_structure
oculomotor I-Biological_structure
nerve B-Disease_disorder
palsy I-Disease_disorder
, O
which O
completely O
recovered B-Sign_symptom
within B-Date
the I-Date
next I-Date
4 I-Date
weeks I-Date
. O

The O
postoperative O
MRI B-Diagnostic_procedure
showed O
a O
complete B-Detailed_description
removal I-Detailed_description
of O
the O
tumour B-Sign_symptom
( O
Fig. O
2 O
) O
. O

After O
careful O
consideration O
by O
a O
multidisciplinary O
team O
, O
we O
decided O
that O
there O
was O
no O
indication O
for O
postoperative O
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

At O
follow-up B-Clinical_event
one B-Date
and I-Date
a I-Date
half I-Date
years I-Date
later I-Date
, O
the O
patient O
was O
found O
to O
have O
remained O
asymptomatic B-Sign_symptom
. O

There O
were O
no O
signs O
of O
tumour B-Sign_symptom
recurrence I-Sign_symptom
on O
the O
MRI B-Diagnostic_procedure
scan O
. O

At O
a O
follow-up B-Clinical_event
of O
more B-Date
than I-Date
6 I-Date
years I-Date
after O
treatment O
, O
there O
were O
still O
no O
signs O
of O
tumour B-Sign_symptom
recurrence I-Sign_symptom
on O
the O
MRI B-Diagnostic_procedure
scan O
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
slightly B-Shape
lobulated I-Shape
tumour B-Sign_symptom
consisting O
of O
a O
chondromyxoid B-Detailed_description
matrix I-Detailed_description
. O

The O
tumour B-Coreference
cells I-Coreference
showed O
a O
vacuolated B-Lab_value
and O
pale B-Lab_value
cytoplasm B-Diagnostic_procedure
. O

Moderate B-Severity
nuclear B-Sign_symptom
polymorphism I-Sign_symptom
was O
observed O
but O
no O
obvious O
mitotic B-Sign_symptom
activity I-Sign_symptom
( O
Fig. O
3 O
) O
. O

Some O
calcifications B-Sign_symptom
were O
seen O
. O

The O
tumour B-Coreference
cells I-Coreference
stained O
positive B-Lab_value
for O
pan-keratin B-Diagnostic_procedure
, O
S-100 B-Diagnostic_procedure
and O
epithelial B-Diagnostic_procedure
membrane I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
EMA B-Diagnostic_procedure
) O
. O

These O
findings O
suggest O
a O
histopathological O
diagnosis O
of O
chordoma B-Disease_disorder
. O

A O
25-year-old B-Age
female B-Sex
patient O
had O
noticed O
left-sided B-Detailed_description
visual B-Disease_disorder
loss I-Disease_disorder
and O
amenorrhea B-Disease_disorder
2 B-Date
years I-Date
prior I-Date
to O
being O
seen B-Clinical_event
, O
with O
right B-Detailed_description
hemiparesis B-Disease_disorder
developing O
6 B-Date
months I-Date
beforehand I-Date
. O

Aggravated B-Severity
symptoms B-Sign_symptom
( O
drooping B-Sign_symptom
at O
corner B-Biological_structure
of I-Biological_structure
right I-Biological_structure
lip I-Biological_structure
and O
bilateral B-Detailed_description
temporal B-Detailed_description
hemianopia B-Disease_disorder
) O
finally O
prompted O
hospitalization B-Clinical_event
. O

At O
that O
time O
, O
a O
massive B-Severity
( O
> B-Distance
5 I-Distance
cm I-Distance
) O
tumor B-Sign_symptom
of O
intra B-Biological_structure
- I-Biological_structure
and I-Biological_structure
suprasellar I-Biological_structure
location I-Biological_structure
, O
excluding B-Detailed_description
mesencephalon I-Detailed_description
backward I-Detailed_description
, O
was O
seen O
on O
computerized B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
head B-Biological_structure
( O
Fig. O
1a O
) O
. O

Further O
testing O
revealed O
an O
exceedingly B-Lab_value
high-serum I-Lab_value
level O
of O
prolactin B-Diagnostic_procedure
( O
PRL B-Diagnostic_procedure
) O
( O
4408 B-Lab_value
ng/ml I-Lab_value
) O
, O
whereas O
levels O
of O
all O
other B-Diagnostic_procedure
pituitary I-Diagnostic_procedure
hormones I-Diagnostic_procedure
were O
within B-Lab_value
reference I-Lab_value
ranges I-Lab_value
( B-Diagnostic_procedure
growth I-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
GH B-Diagnostic_procedure
) O
, O
0.50 B-Lab_value
ng/ml I-Lab_value
; O
luteinizing B-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
LH B-Diagnostic_procedure
) O
, O
2.60 B-Lab_value
mIU/ml I-Lab_value
; O
follicle-stimulating B-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
FSH B-Diagnostic_procedure
) O
, O
4.57 B-Lab_value
mIU/ml I-Lab_value
; O
adrenocorticotropic B-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
ACTH B-Diagnostic_procedure
) O
, O
37.4 B-Lab_value
pg/ml I-Lab_value
; O
thyroid-stimulating B-Diagnostic_procedure
hormone I-Diagnostic_procedure
( O
TSH B-Diagnostic_procedure
) O
, O
2.68 B-Lab_value
μIU/ml I-Lab_value
) O
. O

T1-weighted B-Detailed_description
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
( O
MR B-Diagnostic_procedure
) O
imaging O
with O
contrast B-Detailed_description
( O
gadolinium B-Detailed_description
) O
showed O
homogeneous B-Detailed_description
tumor B-Sign_symptom
enhancement B-Detailed_description
, O
but O
adjacent B-Biological_structure
tissue I-Biological_structure
was O
not O
edematous B-Sign_symptom
in O
T2-weighted B-Diagnostic_procedure
views I-Diagnostic_procedure
. O

The O
mass B-Sign_symptom
did O
not O
regress B-Sign_symptom
, O
despite O
a O
4-week B-Duration
course O
of O
the O
dopamine B-Medication
analog I-Medication
, O
cabergoline B-Medication
( O
1 B-Dosage
mg/week I-Dosage
) O
, O
and O
serum B-Biological_structure
PRL B-Diagnostic_procedure
level O
( O
2207 B-Lab_value
ng/ml I-Lab_value
) O
remained O
elevated B-Lab_value
. O

Relative O
to O
status O
at O
admission O
, O
the O
right B-Biological_structure
lateral I-Biological_structure
ventricle I-Biological_structure
also O
had O
enlarged B-Sign_symptom
somewhat B-Severity
, O
due O
to O
obstruction B-Sign_symptom
at O
foramen B-Biological_structure
of I-Biological_structure
Monro I-Biological_structure
( O
Fig. O
1b O
) O
. O

In O
light O
of O
this O
intransigence O
, O
surgical B-Detailed_description
debulking B-Therapeutic_procedure
of O
tumor O
was O
elected O
first O
, O
through O
craniotomy B-Therapeutic_procedure
and O
then O
via O
transsphenoidal B-Therapeutic_procedure
approach I-Therapeutic_procedure
. O

The O
hardened B-Texture
elastic I-Texture
quality O
of O
the O
tumor B-Sign_symptom
and O
its O
strong B-Severity
attachments B-Sign_symptom
to O
neighboring B-Biological_structure
structures I-Biological_structure
prevented O
complete B-Therapeutic_procedure
removal I-Therapeutic_procedure
, O
but O
related O
mass B-Sign_symptom
effect I-Sign_symptom
was O
significantly O
reduced O
and O
serum B-Biological_structure
PRL B-Diagnostic_procedure
level O
declined B-Lab_value
( O
to O
250 B-Lab_value
ng/ml I-Lab_value
) O
in O
steps O
at O
each O
procedural O
stage O
. O

But O
the O
normalization B-Lab_value
of O
PRL B-Diagnostic_procedure
level O
had O
not O
been O
achieved O
with O
the O
administration O
of O
cabergoline B-Medication
increased O
up O
to O
0.5 B-Dosage
mg/day I-Dosage
. O

The O
residual O
tumor O
showed O
no O
evidence O
of O
regrowth B-Sign_symptom
or O
distant B-Detailed_description
metastasis B-Sign_symptom
1 B-Date
year I-Date
after I-Date
surgery O
. O

Histopathologically B-Diagnostic_procedure
, O
hematoxylin B-Diagnostic_procedure
and I-Diagnostic_procedure
eosin I-Diagnostic_procedure
( O
H&E B-Diagnostic_procedure
) O
- O
stained O
sections O
of O
specimens B-Biological_structure
from O
the O
first O
and O
second O
surgical O
procedures O
similarly O
were O
composed O
of O
polygonal B-Detailed_description
and O
spindle B-Sign_symptom
cells I-Sign_symptom
with O
round B-Shape
, O
oval B-Shape
, O
or O
elongated B-Shape
nuclei B-Diagnostic_procedure
and O
eosinophilic B-Lab_value
cytoplasm B-Diagnostic_procedure
( O
Fig. O
2a O
– O
c O
) O
. O

The O
cells B-Coreference
formed O
irregular B-Detailed_description
nests I-Detailed_description
or O
short B-Detailed_description
fascicles I-Detailed_description
, O
accompanied O
by O
frequent B-Detailed_description
hyaline I-Detailed_description
changes I-Detailed_description
in I-Detailed_description
vessel I-Detailed_description
walls I-Detailed_description
and I-Detailed_description
vacuolation I-Detailed_description
( O
Fig. O
2d O
) O
. O

Some O
nuclear B-Sign_symptom
pleomorphism I-Sign_symptom
was O
prominent O
; O
on O
the O
other O
hand O
, O
neither O
a O
high B-Sign_symptom
mitotic I-Sign_symptom
rate I-Sign_symptom
nor O
necrosis B-Sign_symptom
was O
evident O
( O
Fig. O
2b O
, O
c O
) O
. O

Conspicuous O
fibrous B-Sign_symptom
change I-Sign_symptom
of O
tumor B-Biological_structure
stroma I-Biological_structure
was O
noted O
focally O
as O
well O
( O
Fig. O
3a O
) O
. O

The O
chromophobic B-Lab_value
nature O
of O
tumor B-Biological_structure
cells I-Biological_structure
was O
confirmed O
by O
Pearse B-Diagnostic_procedure
’s I-Diagnostic_procedure
Periodic I-Diagnostic_procedure
Acid I-Diagnostic_procedure
Schiff I-Diagnostic_procedure
( O
PAS B-Diagnostic_procedure
) O
stain O
( O
Fig. O
3b O
) O
. O

Immunostains B-Diagnostic_procedure
showed O
strong O
diffuse O
positivity B-Lab_value
for O
PRL B-Diagnostic_procedure
( O
Fig. O
3c O
) O
, O
chromogranin-A B-Diagnostic_procedure
, O
and O
synaptophysin B-Diagnostic_procedure
. O

No B-Lab_value
other B-Diagnostic_procedure
hormones I-Diagnostic_procedure
( O
GH B-Diagnostic_procedure
, O
TSH B-Diagnostic_procedure
, O
ACTH B-Diagnostic_procedure
, O
LH B-Diagnostic_procedure
, O
FSH B-Diagnostic_procedure
) O
were O
expressed O
by O
tumor O
cells O
, O
and O
the O
other B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
including O
S-100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
Fig. O
3d O
) O
, O
glial B-Diagnostic_procedure
fibrillary I-Diagnostic_procedure
acidic I-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
GFAP B-Diagnostic_procedure
) O
, O
epithelial B-Diagnostic_procedure
membrane I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
EMA B-Diagnostic_procedure
) O
, O
cytokeratin B-Diagnostic_procedure
AE1/AE3 I-Diagnostic_procedure
( O
CK B-Diagnostic_procedure
AE1/AE3 I-Diagnostic_procedure
) O
, O
vimentin B-Diagnostic_procedure
, O
p53 B-Diagnostic_procedure
, O
and O
bcl-2 B-Diagnostic_procedure
, O
were O
also O
negative B-Lab_value
by O
immunostaining O
. O

Ki-67 B-Diagnostic_procedure
labeling I-Diagnostic_procedure
index I-Diagnostic_procedure
was O
approximately O
2 B-Lab_value
% I-Lab_value
. O

A O
final O
diagnosis O
of O
PRL-producing B-Detailed_description
pituitary B-Disease_disorder
adenoma I-Disease_disorder
was O
reached O
after O
considering O
the O
immunohistochemical O
profile O
, O
suprasellar O
location O
, O
and O
prolactin O
production O
of O
the O
tumor O
, O
as O
well O
as O
the O
absence O
of O
metastatic O
foci O
and O
invasion O
into O
surrounding O
tissue O
. O

A O
62-year-old B-Age
male B-Sex
presented B-Activity
with O
a O
15-day B-Duration
history I-Duration
of O
dyspnea B-Sign_symptom
on O
exertion B-Detailed_description
, O
associated O
with O
both B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
edema B-Sign_symptom
. O

Before O
this O
admission O
, O
he O
also O
had O
suffered O
from O
abdominal B-Biological_structure
bloating B-Sign_symptom
and O
tasteless B-Sign_symptom
for B-Duration
a I-Duration
year I-Duration
with O
noticeable O
body O
weight B-Sign_symptom
loss I-Sign_symptom
at O
the O
same O
time O
( O
up B-Quantitative_concept
to I-Quantitative_concept
20 I-Quantitative_concept
kg I-Quantitative_concept
) O
. O

Over B-Duration
the I-Duration
past I-Duration
6 I-Duration
months I-Duration
, O
he O
developed O
a O
multiple B-Disease_disorder
system I-Disease_disorder
disorder I-Disease_disorder
, O
which O
included O
painless B-Detailed_description
paresthesias B-Sign_symptom
in O
the O
lower B-Biological_structure
limbs I-Biological_structure
, O
erectile B-Disease_disorder
dysfunction I-Disease_disorder
, O
and O
chronic B-Disease_disorder
diarrhea I-Disease_disorder
. O

He O
had O
an O
average O
stool B-Diagnostic_procedure
frequency I-Diagnostic_procedure
of O
up B-Quantitative_concept
to I-Quantitative_concept
ten I-Quantitative_concept
times I-Quantitative_concept
per I-Quantitative_concept
day I-Quantitative_concept
, O
with O
no B-Lab_value
obvious I-Lab_value
blood B-Diagnostic_procedure
or O
mucus B-Diagnostic_procedure
and O
no O
abdominal B-Biological_structure
pain B-Sign_symptom
or O
tenesmus B-Sign_symptom
. O

Unfortunately O
, O
previous O
stomach B-Biological_structure
and O
rectum B-Biological_structure
biopsy B-Diagnostic_procedure
did O
not O
examine O
for O
accumulations O
of O
amyloid B-Diagnostic_procedure
fibril I-Diagnostic_procedure
protein I-Diagnostic_procedure
. O

His O
family B-Family_history
history I-Family_history
was I-Family_history
unremarkable I-Family_history
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
his O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
82/56 B-Lab_value
mmHg I-Lab_value
and O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
52 B-Lab_value
bpm I-Lab_value
. O

Significant B-Severity
jugular B-Biological_structure
venous I-Biological_structure
distention B-Sign_symptom
, O
moderate B-Severity
hepatomegaly B-Sign_symptom
, O
and O
lower B-Biological_structure
extremity I-Biological_structure
edema B-Sign_symptom
were O
noted O
. O

A O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
weakness B-Sign_symptom
and O
muscular B-Biological_structure
atrophy B-Sign_symptom
in O
the O
bilateral B-Biological_structure
tibialis I-Biological_structure
anterior I-Biological_structure
and O
gastrocnemius B-Biological_structure
. O

Hyporeflexia B-Sign_symptom
was O
noted O
on O
both B-Biological_structure
knees I-Biological_structure
and O
ankles B-Biological_structure
. O

Sensory B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
diminished B-Lab_value
tactile B-Diagnostic_procedure
and I-Diagnostic_procedure
pain I-Diagnostic_procedure
sensation I-Diagnostic_procedure
in O
a O
stocking B-Lab_value
and I-Lab_value
glove I-Lab_value
pattern I-Lab_value
and O
vibratory B-Diagnostic_procedure
sensation I-Diagnostic_procedure
was O
distally B-Lab_value
reduced I-Lab_value
in O
the O
lower B-Biological_structure
limbs I-Biological_structure
. O

The O
motor B-Diagnostic_procedure
and I-Diagnostic_procedure
sensory I-Diagnostic_procedure
functions I-Diagnostic_procedure
of O
upper B-Biological_structure
extremities I-Biological_structure
were O
relatively B-Lab_value
spared I-Lab_value
. O

Initial O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
that O
included O
full B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
transaminase B-Diagnostic_procedure
, O
creatinine B-Diagnostic_procedure
, O
electrolytes B-Diagnostic_procedure
, O
cardiac B-Diagnostic_procedure
troponin I-Diagnostic_procedure
, O
and O
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
were O
normal B-Lab_value
or O
negative B-Lab_value
. O

N-terminal B-Diagnostic_procedure
fragment I-Diagnostic_procedure
of I-Diagnostic_procedure
pro-brain I-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
NT-proBNP B-Diagnostic_procedure
) O
was O
3,996 B-Lab_value
pg/mL I-Lab_value
. O

Nerve B-Diagnostic_procedure
conduction I-Diagnostic_procedure
studies I-Diagnostic_procedure
confirmed O
bilateral B-Detailed_description
sensory-motor B-Disease_disorder
neuropathy I-Disease_disorder
( O
Table O
1 O
) O
. O

An O
electromyography B-Diagnostic_procedure
study I-Diagnostic_procedure
demonstrated O
active O
denervation B-Sign_symptom
and O
chronic O
reinnervation B-Sign_symptom
changes I-Sign_symptom
in O
the O
tibialis B-Biological_structure
anterior I-Biological_structure
and O
gastrocnemius B-Biological_structure
. O

Electrocardiogram B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
revealed O
sinus B-Lab_value
rhythm I-Lab_value
, O
low B-Lab_value
voltages I-Lab_value
in O
limb B-Diagnostic_procedure
leads I-Diagnostic_procedure
, O
QS B-Lab_value
waves I-Lab_value
in O
precordial B-Diagnostic_procedure
and I-Diagnostic_procedure
inferior I-Diagnostic_procedure
leads I-Diagnostic_procedure
, O
first-degree B-Detailed_description
atrioventricular B-Sign_symptom
block I-Sign_symptom
, O
and O
prolonged B-Lab_value
QTc B-Diagnostic_procedure
( O
Figure O
1 O
) O
. O

Two-dimensional B-Detailed_description
echocardiography B-Diagnostic_procedure
revealed O
marked O
concentrically B-Detailed_description
thickened B-Sign_symptom
and O
speckled B-Sign_symptom
appearance I-Sign_symptom
of O
ventricular B-Biological_structure
walls I-Biological_structure
, O
biatrial B-Biological_structure
dilatation B-Sign_symptom
, O
and O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
70 B-Lab_value
% I-Lab_value
( O
Figure O
2 O
) O
. O

Doppler B-Diagnostic_procedure
revealed O
a O
severe B-Severity
restrictive B-Sign_symptom
mitral I-Sign_symptom
filling I-Sign_symptom
pattern I-Sign_symptom
with O
E/A B-Diagnostic_procedure
ratio I-Diagnostic_procedure
2.1 B-Lab_value
. O

Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
findings O
were O
normal B-Lab_value
. O

The O
combined O
occurrence O
of O
low B-Lab_value
QRS B-Diagnostic_procedure
voltage I-Diagnostic_procedure
in O
the O
ECG B-Diagnostic_procedure
, O
ventricular B-Biological_structure
thickening B-Sign_symptom
, O
and O
signs O
of O
diastolic B-Sign_symptom
dysfunction I-Sign_symptom
is O
strongly O
suggestive O
of O
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
. O

The O
following O
serum B-Detailed_description
λ B-Diagnostic_procedure
light-chain I-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
1,763 B-Lab_value
( O
normal O
range O
: O
598 O
– O
1,329 O
mg/dL O
, O
and O
κ B-Diagnostic_procedure
light-chain I-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Rectum B-Biological_structure
biopsy B-Diagnostic_procedure
confirmed O
amyloid B-Detailed_description
infiltrate B-Sign_symptom
( O
Figure O
3 O
) O
. O

So O
, O
the O
diagnosis O
of O
AL B-Disease_disorder
amyloidosis I-Disease_disorder
was O
established O
. O

Despite O
chemotherapy B-Medication
administration O
of O
melphalan B-Medication
, O
dexamethasone B-Medication
, O
immunomodulator B-Detailed_description
lenalidomide B-Medication
, O
and O
supportive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
including O
montmorillonite B-Medication
to O
decrease O
diarrhea B-Sign_symptom
and O
low-dose B-Dosage
furosemide B-Medication
to O
alleviate O
fluid B-Sign_symptom
retention I-Sign_symptom
, O
the O
patient O
continued O
to O
deteriorate B-Sign_symptom
and O
died B-Outcome
at O
home B-Nonbiological_location
after B-Date
3 I-Date
months I-Date
after O
the O
initial O
diagnosis O
. O

A O
56-year-old B-Age
man B-Sex
presented B-Clinical_event
with O
a O
2-year B-Duration
history O
of O
dysphagia B-Sign_symptom
. O

He O
was O
diagnosed O
with O
a O
middle B-Biological_structure
thoracic I-Biological_structure
oesophageal B-Biological_structure
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
by O
both O
a O
gastroscopy B-Diagnostic_procedure
and O
a O
biopsy B-Diagnostic_procedure
. O

A O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
showed O
an O
enlarged B-Sign_symptom
azygos B-Biological_structure
vein I-Biological_structure
( O
a O
diameter O
of O
2.5 B-Distance
cm I-Distance
) O
that O
was O
a O
continuation B-Sign_symptom
of O
the O
IVC B-Biological_structure
( O
Fig. O
1a O
, O
b O
) O
. O

A O
CT B-Diagnostic_procedure
scan O
of O
the O
abdomen B-Biological_structure
showed O
a O
defect B-Sign_symptom
in O
the O
suprarenal B-Biological_structure
segment I-Biological_structure
of I-Biological_structure
the I-Biological_structure
inferior I-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
and O
direct B-Detailed_description
drainage B-Sign_symptom
of O
the O
hepatic B-Biological_structure
vein I-Biological_structure
into O
the O
right B-Biological_structure
atrium I-Biological_structure
. O

After O
consultation B-Clinical_event
with O
the O
thoracic B-Nonbiological_location
surgery I-Nonbiological_location
department I-Nonbiological_location
clinicians I-Nonbiological_location
and O
the O
anaesthesiology B-Nonbiological_location
department I-Nonbiological_location
, O
we O
decided O
to O
perform O
a O
McKeown B-Detailed_description
oesophagectomy B-Therapeutic_procedure
. O

The O
patient O
was O
anaesthetised B-Therapeutic_procedure
with O
a O
double-lumen B-Detailed_description
tube I-Detailed_description
and O
underwent O
a O
standard B-Detailed_description
posterolateral B-Detailed_description
thoracotomy B-Therapeutic_procedure
by O
traditional B-Detailed_description
open I-Detailed_description
surgery I-Detailed_description
. O

We O
first O
performed O
the O
jugular B-Biological_structure
and I-Biological_structure
femoral I-Biological_structure
vein I-Biological_structure
percutaneous B-Detailed_description
puncture I-Detailed_description
to O
create O
a O
veno-venous B-Therapeutic_procedure
bypass I-Therapeutic_procedure
and O
then O
connected O
the O
pressure B-Therapeutic_procedure
sensor I-Therapeutic_procedure
system I-Therapeutic_procedure
to O
the O
monitor O
. O

The O
monitor O
displayed O
the O
real-time O
pressure O
value O
of O
the O
jugular O
vein O
and O
the O
femoral O
vein O
. O

Macroscopically B-Diagnostic_procedure
, O
the O
diameter B-Diagnostic_procedure
of O
the O
azygos B-Biological_structure
arch I-Biological_structure
was O
approximately O
2.5 B-Distance
cm I-Distance
( O
Fig. O
1c O
) O
, O
and O
the O
superior B-Detailed_description
edge I-Detailed_description
of O
the O
tumour B-Sign_symptom
adhered O
tightly O
to O
the O
arch B-Biological_structure
of I-Biological_structure
the I-Biological_structure
azygos I-Biological_structure
vein I-Biological_structure
. O

When O
the O
arch B-Biological_structure
of I-Biological_structure
the I-Biological_structure
azygos I-Biological_structure
vein I-Biological_structure
was O
pulled B-Therapeutic_procedure
with O
a O
rubber B-Detailed_description
hose I-Detailed_description
to O
dissociate O
it O
from O
the O
carcinoma B-Coreference
, O
the O
monitor O
showed O
that O
the O
femoral B-Biological_structure
vein I-Biological_structure
pressure B-Diagnostic_procedure
increased B-Lab_value
to O
52 B-Lab_value
mmH2O I-Lab_value
; O
the O
pressure O
returned O
to O
a O
normal B-Lab_value
value I-Lab_value
when O
we O
opened O
the O
bypass B-Coreference
between O
the O
femoral O
vein O
and O
the O
jugular O
vein O
( O
Fig. O
2 O
) O
. O

The O
surgery O
was O
performed O
smoothly O
, O
without O
injury B-Disease_disorder
to O
the O
azygos B-Biological_structure
vein I-Biological_structure
, O
and O
the O
postoperative B-Diagnostic_procedure
recovery I-Diagnostic_procedure
was O
uneventful B-Lab_value
. O

The O
pathology B-Diagnostic_procedure
of O
the O
resected B-Detailed_description
specimen I-Detailed_description
showed O
a O
poorly B-Lab_value
differentiated I-Lab_value
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
and O
no O
evidence O
of O
malignancy B-Sign_symptom
in O
15 B-Lab_value
of O
the O
lymph B-Biological_structure
nodes I-Biological_structure
. O

After O
5 B-Duration
months I-Duration
of O
follow-up B-Clinical_event
, O
the O
patient O
was O
asymptomatic B-Sign_symptom
, O
with O
no O
evidence O
of O
recurrent B-Disease_disorder
disease I-Disease_disorder
either O
clinically O
or O
on O
CT B-Diagnostic_procedure
. O

A O
65-year B-Age
old I-Age
female B-Sex
was O
admitted B-Clinical_event
with O
progressive B-Detailed_description
dysphagia B-Sign_symptom
for O
2 B-Duration
months I-Duration
and O
5 B-Mass
kg I-Mass
weight B-Sign_symptom
loss I-Sign_symptom
. O

Her O
past O
medical O
history O
was O
significant O
for O
osteoporosis B-History
treated O
with O
calcium B-Medication
lactate I-Medication
tablets B-Administration
, O
daily B-Dosage
, O
for O
5 B-Duration
years I-Duration
. O

Upper B-Biological_structure
gastrointestinal I-Biological_structure
endoscopy B-Diagnostic_procedure
described O
a O
4 B-Distance
cm I-Distance
whitish B-Color
firm B-Texture
mass B-Sign_symptom
in O
the O
middle B-Biological_structure
esophagus I-Biological_structure
( O
Fig. O
1 O
) O
and O
a O
semi-circumferential B-Detailed_description
deep B-Severity
ulcer B-Sign_symptom
with O
irregular B-Shape
borders I-Shape
on O
the O
opposite B-Biological_structure
mucosa I-Biological_structure
( O
Fig. O
2 O
) O
. O

During O
endoscopy B-Diagnostic_procedure
a O
pedicle B-Sign_symptom
was O
not O
identify O
by O
handling O
a O
polipectomy B-Diagnostic_procedure
snare I-Diagnostic_procedure
around O
the O
esophageal B-Biological_structure
mass B-Sign_symptom
. O

Upper B-Biological_structure
gastrointestinal I-Biological_structure
series O
with O
gastrografin B-Diagnostic_procedure
( O
Fig. O
3 O
) O
revealed O
an O
ovoid B-Shape
lacunar B-Detailed_description
image B-Sign_symptom
at O
the O
distal B-Biological_structure
part I-Biological_structure
of I-Biological_structure
the I-Biological_structure
esophagus I-Biological_structure
esophageal I-Biological_structure
, O
inhomogeneous B-Detailed_description
, O
with O
calcifications B-Sign_symptom
and O
smooth B-Texture
contours O
. O

During O
peristalsis B-Activity
the O
image B-Sign_symptom
was O
mobile B-Detailed_description
and O
no O
pedicle B-Sign_symptom
was O
identified O
. O

The O
esophageal B-Biological_structure
lumen I-Biological_structure
was O
enlarged B-Sign_symptom
with O
a O
diverticula B-Sign_symptom
development O
at O
the O
posterior B-Biological_structure
wall I-Biological_structure
. O

Also O
computer B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
thorax B-Biological_structure
excluded O
a O
pedunculated B-Detailed_description
tumor B-Sign_symptom
, O
describing O
an O
intra-luminal B-Detailed_description
calcified B-Detailed_description
esophageal B-Biological_structure
mass B-Sign_symptom
( O
Fig. O
4 O
) O
. O

The O
biopsies B-Diagnostic_procedure
obtained O
from O
the O
esophageal B-Biological_structure
ulcerated B-Sign_symptom
mucosa B-Biological_structure
revealed O
inflammatory B-Sign_symptom
cells I-Sign_symptom
, O
without O
malignancy B-Sign_symptom
. O

Based O
on O
these O
endoscopic B-Diagnostic_procedure
and O
imagistic B-Diagnostic_procedure
results O
a O
bezoar B-Sign_symptom
was O
supposed O
to O
have O
been O
developed O
in O
an O
esophageal B-Biological_structure
diverticula B-Sign_symptom
, O
subsequently O
with O
ulcerated B-Sign_symptom
mucosa B-Biological_structure
. O

The O
esophageal B-Biological_structure
mass B-Sign_symptom
was O
removed B-Therapeutic_procedure
with O
an O
endoscopic B-Diagnostic_procedure
snare I-Diagnostic_procedure
in O
one O
piece O
, O
as O
the O
fragmentation B-Therapeutic_procedure
was O
not O
physically O
possible O
. O

The O
macroscopic B-Diagnostic_procedure
appearance I-Diagnostic_procedure
revealed O
a O
4 B-Distance
cm I-Distance
, O
globular B-Shape
mass B-Sign_symptom
, O
heterogeneous B-Detailed_description
, O
dense B-Detailed_description
, O
whitish B-Color
, O
in O
places O
with O
harsh B-Color
yellow I-Color
foci B-Detailed_description
, O
most O
likely O
dystrophic B-Detailed_description
calcification B-Sign_symptom
. O

The O
macroscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
on O
cross O
section O
revealed O
a O
light B-Color
gray I-Color
aspect B-Sign_symptom
( O
fibrous B-Texture
appearance I-Texture
) O
that O
includes O
multiple B-Detailed_description
harsh B-Color
yellow-orange I-Color
structures B-Detailed_description
, O
difficult O
to O
section O
( O
Fig. O
5 O
) O
. O

This O
mass B-Sign_symptom
was O
immersed O
into O
trichloracetic B-Diagnostic_procedure
acid I-Diagnostic_procedure
for O
decalcification B-Diagnostic_procedure
. O

Microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
hyaline B-Sign_symptom
fibrous I-Sign_symptom
tissue I-Sign_symptom
( O
Fig. O
6a O
) O
, O
stained B-Lab_value
in I-Lab_value
green I-Lab_value
in O
Tricrom B-Diagnostic_procedure
Mason I-Diagnostic_procedure
( O
Fig. O
6b O
) O
, O
with O
numerous O
crystalline B-Shape
basophils B-Sign_symptom
deposits B-Sign_symptom
of I-Sign_symptom
minerals I-Sign_symptom
, O
rare B-Lab_value
fibrocytes B-Diagnostic_procedure
and O
very B-Lab_value
few I-Lab_value
vessels B-Diagnostic_procedure
. O

The O
presence O
of O
capillary B-Sign_symptom
structures I-Sign_symptom
, O
rare B-Lab_value
fibroblasts B-Diagnostic_procedure
and O
collagen B-Sign_symptom
fibers I-Sign_symptom
brought O
in O
discussion O
a O
mesenchymal B-Biological_structure
originating I-Biological_structure
mass B-Sign_symptom
, O
most O
likely O
a O
fibrovascular B-Disease_disorder
polyp I-Disease_disorder
. O

A O
definitive O
histological O
diagnosis O
was O
not O
possible O
, O
as O
the O
pedicle B-Sign_symptom
was O
not O
identified O
, O
but O
the O
presence O
of O
the O
connective O
tissue O
suggested O
the O
previous O
presence O
of O
a O
pedicle B-Sign_symptom
into O
the O
lesion O
. O

The O
long O
term O
calcium B-Medication
tablets B-Administration
intake O
might O
explain O
the O
calcification O
process O
developed O
into O
the O
vascular-connective O
tissue O
, O
revealed O
on O
histology O
by O
the O
numerous O
crystalline B-Shape
basophils B-Sign_symptom
deposits B-Sign_symptom
of I-Sign_symptom
minerals I-Sign_symptom
. O

One B-Date
month I-Date
later I-Date
the O
patient O
was O
asymptomatic B-Sign_symptom
. O

The O
endoscopy B-Diagnostic_procedure
did O
not O
revealed O
an O
enlarged B-Sign_symptom
esophagus B-Biological_structure
, O
the O
appearance B-Diagnostic_procedure
of O
the O
esophageal B-Biological_structure
mucosa I-Biological_structure
was O
normal B-Lab_value
( O
without O
ulcerations B-Sign_symptom
) O
and O
no O
diverticula B-Sign_symptom
was O
identified O
. O

No O
motility B-Sign_symptom
disturbances I-Sign_symptom
were O
found O
on O
esophageal B-Biological_structure
manometry B-Diagnostic_procedure
. O

Based O
on O
the O
clinical O
course O
, O
the O
history B-History
of I-History
calcium I-History
lactate I-History
intake I-History
and O
histological B-Diagnostic_procedure
appearance I-Diagnostic_procedure
a O
diagnosis O
of O
an O
esophageal B-Biological_structure
benign B-Severity
mesenchymal B-Biological_structure
originating I-Biological_structure
mass B-Sign_symptom
( O
most O
probably O
a O
fibrovascular B-Disease_disorder
polyp I-Disease_disorder
) O
auto-amputated B-Other_event
and O
calcified B-Sign_symptom
was O
formulated O
. O

A O
58-year-old B-Age
man B-Sex
with O
a O
past O
medical O
history O
of O
poorly B-Detailed_description
controlled I-Detailed_description
hypertension B-Disease_disorder
and O
type B-Disease_disorder
2 I-Disease_disorder
diabetes I-Disease_disorder
, O
presented B-Clinical_event
to O
the O
ICU B-Nonbiological_location
for O
a O
cardiogenic B-Disease_disorder
shock I-Disease_disorder
complicating O
acute B-Detailed_description
myocardial B-Disease_disorder
infarction I-Disease_disorder
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
reduced B-Lab_value
level B-Diagnostic_procedure
of I-Diagnostic_procedure
consciousness I-Diagnostic_procedure
( O
Glasgow B-Diagnostic_procedure
Coma I-Diagnostic_procedure
Scale I-Diagnostic_procedure
10/15 B-Lab_value
) O
and O
weak B-Lab_value
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
; O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
80/50 B-Lab_value
mmHg I-Lab_value
, O
80 B-Lab_value
% I-Lab_value
of O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
, O
capillary B-Detailed_description
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
at O
2.26 B-Lab_value
g/L I-Lab_value
, O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
over B-Lab_value
125 I-Lab_value
bpm I-Lab_value
, O
and O
crackling B-Sign_symptom
in O
pulmonary B-Diagnostic_procedure
auscultation I-Diagnostic_procedure
. O

Cardiovascular B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
neither O
cardiac B-Sign_symptom
murmur I-Sign_symptom
nor O
signs B-Sign_symptom
of I-Sign_symptom
right I-Sign_symptom
heart I-Sign_symptom
failure I-Sign_symptom
. O

ECG B-Diagnostic_procedure
on O
admission B-Clinical_event
showed O
normal B-Lab_value
sinus B-Detailed_description
rhythm B-Diagnostic_procedure
, O
with O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
125 B-Lab_value
bpm I-Lab_value
and O
extended B-Sign_symptom
ST-elevation I-Sign_symptom
in O
anterior B-Detailed_description
territory I-Detailed_description
. O

Laboratory B-Diagnostic_procedure
results I-Diagnostic_procedure
demonstrated O
Troponin B-Diagnostic_procedure
I I-Diagnostic_procedure
level O
of O
6.41 B-Lab_value
ng/ml I-Lab_value
, O
creatinine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
( O
CKMB B-Diagnostic_procedure
) O
was O
67 B-Lab_value
UI/L I-Lab_value
, O
Lactate B-Diagnostic_procedure
deshydrogenase I-Diagnostic_procedure
was O
281 B-Lab_value
UI/L I-Lab_value
, O
glucose B-Diagnostic_procedure
level O
2.70 B-Lab_value
g/l I-Lab_value
, O
urea B-Diagnostic_procedure
0.40 B-Lab_value
g/l I-Lab_value
and O
creatinine B-Diagnostic_procedure
18.6 B-Lab_value
mg I-Lab_value
/ I-Lab_value
L I-Lab_value
. O

The O
patient O
was O
intubated B-Therapeutic_procedure
and O
sedated B-Therapeutic_procedure
, O
inotropic B-Medication
agents I-Medication
were O
started O
( O
norepinephrine B-Medication
0.4 B-Dosage
µg/kg/min I-Dosage
and O
dobutamine B-Medication
20µg/kg/min B-Dosage
) O
. O

Chest B-Biological_structure
X-rays B-Diagnostic_procedure
showed O
diffuse B-Detailed_description
alveolar B-Disease_disorder
syndrome I-Disease_disorder
. O

Transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
revealed O
wall B-Sign_symptom
motion I-Sign_symptom
abnormalities I-Sign_symptom
namely O
extensive B-Severity
akinesis B-Sign_symptom
of O
anteroseptal B-Biological_structure
, O
anterior B-Biological_structure
, O
lateral B-Biological_structure
and O
inferior B-Biological_structure
walls B-Biological_structure
, O
and O
severe B-Severity
left B-Sign_symptom
ventricular I-Sign_symptom
systolic I-Sign_symptom
dysfunction I-Sign_symptom
( O
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
29 B-Lab_value
% I-Lab_value
) O
. O

Medical B-Therapeutic_procedure
management I-Therapeutic_procedure
was O
initiated O
; O
anticoagulant B-Medication
therapy O
for O
acute B-Disease_disorder
coronary I-Disease_disorder
syndrome I-Disease_disorder
was O
started O
( O
500 B-Dosage
mg I-Dosage
of O
acetylsalicylic B-Medication
acid I-Medication
and O
subcutaneous B-Administration
low-molecular-weight B-Medication
heparin I-Medication
( O
0.6 B-Dosage
ml I-Dosage
of O
enoxaparin B-Medication
) O
) O
and O
patient O
was O
prepared O
for O
myocardial B-Therapeutic_procedure
revascularization I-Therapeutic_procedure
by O
coronary B-Biological_structure
angioplasty B-Therapeutic_procedure
. O

Because O
of O
non-improvement B-Lab_value
of O
neurological B-Diagnostic_procedure
status I-Diagnostic_procedure
and O
occurrence O
of O
seizures B-Sign_symptom
, O
a O
brain B-Biological_structure
CT B-Diagnostic_procedure
was O
indicated O
and O
revealed O
infratentorial B-Biological_structure
diffuse B-Detailed_description
hemorrhage B-Sign_symptom
( O
Fisher B-Diagnostic_procedure
grade I-Diagnostic_procedure
III B-Lab_value
) O
( O
Figure O
1 O
) O
. O

Cerebral B-Biological_structure
angiography B-Diagnostic_procedure
confirmed O
a O
dissecting B-Disease_disorder
aneurysm I-Disease_disorder
of O
an O
anastomotic B-Biological_structure
branch I-Biological_structure
between O
left B-Biological_structure
PICA I-Biological_structure
and O
the O
V4 B-Biological_structure
segment I-Biological_structure
of I-Biological_structure
left I-Biological_structure
vertebral I-Biological_structure
artery I-Biological_structure
Figure O
2 O
that O
was O
successfully O
embolized B-Therapeutic_procedure
. O

After B-Date
24 I-Date
hours I-Date
, O
the O
patient O
improved B-Sign_symptom
with O
withdrawal O
of O
vasoactive B-Medication
drugs I-Medication
in O
24 B-Date
hours I-Date
. O

Left B-Biological_structure
hemicorporeal I-Biological_structure
seizures B-Sign_symptom
persisted O
despite O
anticonvulsant B-Medication
treatment O
. O

Control O
brain B-Biological_structure
CT B-Diagnostic_procedure
did O
not O
report O
rebleeding B-Sign_symptom
and O
angiography B-Diagnostic_procedure
showed O
complete O
exclusion O
of O
the O
aneurysm B-Disease_disorder
while O
the O
EEG B-Diagnostic_procedure
revealed O
a O
diffuse B-Detailed_description
brain B-Disease_disorder
damage I-Disease_disorder
. O

10 B-Date
days I-Date
after I-Date
admission O
, O
the O
patient O
was O
discharged B-Clinical_event
in O
stable B-Lab_value
condition B-Diagnostic_procedure
but O
still O
suffers O
from O
amnesia B-Disease_disorder
. O

This O
is O
a O
53-year-old B-Age
male B-Sex
patient O
who O
went B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
chief O
complaint O
of O
massive B-Severity
gum B-Biological_structure
bleeding B-Sign_symptom
for O
1 B-Duration
day I-Duration
. O

The O
patient O
had O
a O
history O
of O
chronic B-History
hepatitis I-History
C. I-History
PEG-IFN-α-2a B-Medication
( O
180 B-Dosage
μg I-Dosage
) O
plus O
ribavirin B-Medication
( O
1200 B-Dosage
mg/day I-Dosage
) O
were O
prescribed O
to O
the O
patient O
since B-Duration
March I-Duration
17 I-Duration
, I-Duration
2014 I-Duration
. O

He O
denied B-History
any I-History
autoimmune I-History
conditions I-History
before O
treatment O
. O

The O
baseline O
virological B-Diagnostic_procedure
data I-Diagnostic_procedure
revealed O
high B-Lab_value
virus B-Diagnostic_procedure
load I-Diagnostic_procedure
( O
HCV B-Diagnostic_procedure
RNA I-Diagnostic_procedure
2.1 B-Lab_value
× I-Lab_value
106 I-Lab_value
IU/mL I-Lab_value
) O
with O
genotype B-Diagnostic_procedure
1b B-Lab_value
. O

Rapid B-Detailed_description
virological B-Sign_symptom
response I-Sign_symptom
was O
not O
achieved O
at O
the O
fourth B-Date
week I-Date
( O
HCV B-Diagnostic_procedure
RNA I-Diagnostic_procedure
: O
2.12 B-Lab_value
× I-Lab_value
106 I-Lab_value
IU/mL I-Lab_value
) O
. O

Partial B-Detailed_description
early B-Detailed_description
virological B-Sign_symptom
response I-Sign_symptom
( O
HCV B-Diagnostic_procedure
RNA I-Diagnostic_procedure
: O
103 B-Lab_value
IU/mL I-Lab_value
at O
week B-Date
12 I-Date
) O
and O
delayed O
virological O
response O
( O
HCV B-Diagnostic_procedure
RNA I-Diagnostic_procedure
: O
< B-Lab_value
15 I-Lab_value
IU/mL I-Lab_value
at O
Week B-Date
24 I-Date
) O
were O
noted O
. O

However O
, O
fatigue B-Sign_symptom
, O
anemia B-Sign_symptom
, O
and O
depression B-Sign_symptom
syndrome I-Sign_symptom
were O
progressed O
at O
30th B-Date
week I-Date
. O

The O
patient O
requested O
to O
stop O
treatment B-Medication
at O
Week B-Date
36 I-Date
. O

The O
viral B-Diagnostic_procedure
load I-Diagnostic_procedure
at O
the O
end-of-treatment B-Date
( O
EOT B-Date
) O
was O
undetectable B-Lab_value
. O

The O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
at O
EOT B-Date
was O
92 B-Lab_value
× I-Lab_value
103 I-Lab_value
cells/μL I-Lab_value
and O
elevated B-Lab_value
to O
159 B-Lab_value
× I-Lab_value
103 I-Lab_value
cells/μL I-Lab_value
1 B-Date
week I-Date
later I-Date
. O

Two B-Date
weeks I-Date
following I-Date
EOT I-Date
, O
the O
patient O
developed O
massive B-Severity
gum B-Biological_structure
bleeding B-Sign_symptom
. O

The O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
the O
multiple B-Quantitative_concept
petechiae B-Sign_symptom
on O
the O
extremities B-Biological_structure
. O

There O
is O
no O
sign O
of O
intracerebral B-Biological_structure
hemorrhage B-Sign_symptom
, O
gastrointestinal B-Biological_structure
bleeding B-Sign_symptom
, O
or O
other O
internal O
bleeding O
. O

The O
initial B-Detailed_description
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
4 B-Lab_value
× I-Lab_value
103cells/μL I-Lab_value
. O

Coagulation B-Diagnostic_procedure
profile I-Diagnostic_procedure
showed O
normal B-Lab_value
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
, O
activated B-Diagnostic_procedure
partial I-Diagnostic_procedure
thromboplastin I-Diagnostic_procedure
time I-Diagnostic_procedure
, O
fibrinogen B-Diagnostic_procedure
, O
d-dimer B-Diagnostic_procedure
, O
and O
fibrin B-Diagnostic_procedure
degradation I-Diagnostic_procedure
product I-Diagnostic_procedure
. O

Peripheral B-Diagnostic_procedure
blood I-Diagnostic_procedure
smear I-Diagnostic_procedure
showed O
neither O
fragmented B-Sign_symptom
red I-Sign_symptom
blood I-Sign_symptom
cells I-Sign_symptom
, O
helmet B-Sign_symptom
cells I-Sign_symptom
nor O
abnormal B-Sign_symptom
platelet I-Sign_symptom
aggregation I-Sign_symptom
. O

Concomitant O
autoimmune O
connective B-Disease_disorder
tissue I-Disease_disorder
diseases I-Disease_disorder
such O
as O
systemic B-Disease_disorder
lupus I-Disease_disorder
erythematosus I-Disease_disorder
or O
cryoglobulinemia B-Disease_disorder
were O
excluded O
due O
to O
negative B-Lab_value
anti-nuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
and O
cryoglobulin B-Diagnostic_procedure
except O
for O
positive B-Lab_value
anti-cardiolipin B-Diagnostic_procedure
IgG I-Diagnostic_procedure
( O
116 B-Lab_value
GPL I-Lab_value
, O
normal O
range O
< O
20 O
GPL O
) O
and O
anti-phospholipid B-Diagnostic_procedure
IgG I-Diagnostic_procedure
( O
165 B-Lab_value
U I-Lab_value
, O
normal O
range O
< O
15 O
U O
) O
. O

Anti-phospholipid B-Disease_disorder
syndrome I-Disease_disorder
was O
excluded O
due O
to O
no B-History
previous I-History
thromboembolic I-History
events I-History
, O
according O
to O
2006 B-Detailed_description
Sapporo B-Diagnostic_procedure
criteria I-Diagnostic_procedure
.12 O
Bone B-Biological_structure
marrow I-Biological_structure
biopsy B-Diagnostic_procedure
was O
also O
performed O
, O
which O
revealed O
hypocellular B-Sign_symptom
marrow B-Biological_structure
with O
even B-Lab_value
cellular B-Diagnostic_procedure
distribution I-Diagnostic_procedure
and O
without O
evidence O
of O
lymphoid B-Disease_disorder
neoplasia I-Disease_disorder
. O

The O
potential O
drugs B-Medication
that I-Medication
may I-Medication
cause I-Medication
platelet I-Medication
lysis I-Medication
were O
ruled O
out O
. O

Blood B-Therapeutic_procedure
transfusion I-Therapeutic_procedure
of O
platelet O
was O
performed O
, O
but O
poor B-Lab_value
response B-Diagnostic_procedure
with O
rapid B-Lab_value
decline I-Lab_value
of O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
in O
the O
next B-Date
day I-Date
of O
transfusion B-Therapeutic_procedure
. O

A O
diagnosis O
of O
immune B-Disease_disorder
thrombocytopenic I-Disease_disorder
purpura I-Disease_disorder
was O
made O
. O

We O
started O
intravenous B-Administration
methylprednisolone B-Medication
therapy O
( O
40 B-Dosage
mg I-Dosage
, I-Dosage
3 I-Dosage
times I-Dosage
daily I-Dosage
) O
on O
November B-Date
27 I-Date
combined O
with O
platelet B-Therapeutic_procedure
transfusion I-Therapeutic_procedure
treatments I-Therapeutic_procedure
. O

It O
still O
showed O
no O
significant O
improvement B-Sign_symptom
. O

Azathioprine B-Medication
( O
100 B-Dosage
mg I-Dosage
, O
oral B-Administration
, O
once B-Dosage
daily I-Dosage
) O
was O
added O
since B-Date
December I-Date
3 I-Date
. O

Hydroxychloroquine B-Medication
( O
400 B-Dosage
mg I-Dosage
, O
oral B-Administration
, O
once B-Dosage
daily I-Dosage
) O
was O
also O
prescribed O
due O
to O
positive B-Lab_value
anti-phospholipid B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
. O

Platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
gradually O
increased B-Lab_value
to O
93 B-Lab_value
× I-Lab_value
103 I-Lab_value
cells/μL I-Lab_value
17 B-Date
days I-Date
after I-Date
admission I-Date
, O
so O
methylprednisolone B-Medication
was O
changed O
to O
oral B-Administration
form O
and O
slowly O
tapered B-Dosage
off I-Dosage
. O

On O
December B-Date
15 I-Date
, O
the O
patient O
was O
discharged B-Clinical_event
due O
to O
stable B-Sign_symptom
condition I-Sign_symptom
with O
platelet B-Diagnostic_procedure
counts I-Diagnostic_procedure
elevating B-Lab_value
to O
117 B-Lab_value
× I-Lab_value
103 I-Lab_value
cells/μL I-Lab_value
( O
Figure O
1 O
) O
. O

Followed O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
after B-Date
5 I-Date
months I-Date
revealed O
sustained B-Detailed_description
virologic B-Sign_symptom
response I-Sign_symptom
, O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
above B-Lab_value
150 I-Lab_value
× I-Lab_value
103 I-Lab_value
cells/μL I-Lab_value
, O
and O
decreased B-Lab_value
anti-cardiolipin B-Diagnostic_procedure
IgG I-Diagnostic_procedure
( O
30.5 B-Lab_value
GPL I-Lab_value
) O
and O
anti-phospholipid B-Diagnostic_procedure
IgG I-Diagnostic_procedure
( O
73.21 B-Lab_value
U I-Lab_value
) O
levels O
. O

A O
66 B-Age
year I-Age
old I-Age
patient O
with O
a O
history B-History
of I-History
UC I-History
treated O
by O
mesalazine B-Medication
since B-Duration
5 I-Duration
years I-Duration
consulted B-Clinical_event
in O
July B-Date
2012 I-Date
for O
a O
painful B-Detailed_description
erythematous B-Detailed_description
swelling B-Sign_symptom
of O
the O
back B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
hand I-Biological_structure
. O

The O
bacteriological B-Diagnostic_procedure
samples I-Diagnostic_procedure
were O
negative B-Lab_value
, O
the O
lesion B-Coreference
was O
considered O
as O
an O
abscesses B-Sign_symptom
and O
the O
patient O
was O
treated O
with O
antibiotics B-Medication
and O
local B-Medication
antiseptics I-Medication
without O
improvement B-Sign_symptom
. O

The O
evolution O
was O
characterized O
by O
the O
appearance O
of O
an O
erythematous B-Detailed_description
vesiculobullous B-Detailed_description
centrifugal B-Sign_symptom
expansion I-Sign_symptom
taking O
the O
whole B-Biological_structure
back I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
hand I-Biological_structure
treated O
several B-Frequency
times I-Frequency
by O
various B-Medication
antibiotics I-Medication
unsuccessfully O
. O

Biopsy B-Diagnostic_procedure
of O
this O
lesion O
was O
initially O
not B-Lab_value
specific I-Lab_value
. O

In O
October B-Date
2012 I-Date
, O
the O
patient O
was O
hospitalized B-Clinical_event
for O
fever B-Sign_symptom
and O
polyarthralgia B-Sign_symptom
in O
the O
context O
of O
impaired B-Sign_symptom
general I-Sign_symptom
condition I-Sign_symptom
. O

He O
had O
a O
quiescent B-Detailed_description
UC B-Disease_disorder
disease I-Disease_disorder
. O

The O
skin B-Diagnostic_procedure
examination I-Diagnostic_procedure
found O
an O
erythematous B-Detailed_description
plaque B-Sign_symptom
of O
10 B-Distance
cm I-Distance
of O
diameter O
, O
with O
a O
raised B-Detailed_description
border I-Detailed_description
and O
vesicules B-Detailed_description
, O
taking O
the O
back B-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
hand I-Biological_structure
and O
wrist B-Biological_structure
( O
Figure O
1 O
) O
. O

There O
was O
also O
an O
infiltrated B-Detailed_description
erythematous B-Detailed_description
plaque B-Sign_symptom
on O
the O
right B-Biological_structure
leg I-Biological_structure
( O
Figure O
2 O
) O
and O
another O
topped B-Detailed_description
with I-Detailed_description
a I-Detailed_description
large I-Detailed_description
pustule I-Detailed_description
at O
the O
left B-Biological_structure
ankle I-Biological_structure
( O
Figure O
3 O
) O
. O

In O
biology O
, O
there O
was O
a O
biological B-Disease_disorder
inflammatory I-Disease_disorder
syndrome I-Disease_disorder
and O
high B-Severity
leukocytosis B-Sign_symptom
with B-Detailed_description
neutrophils I-Detailed_description
. O

Hepatic B-Diagnostic_procedure
and O
renal B-Diagnostic_procedure
functions I-Diagnostic_procedure
were O
normal B-Lab_value
. O

Skin B-Diagnostic_procedure
biopsy I-Diagnostic_procedure
showed O
at O
the O
edge B-Biological_structure
of I-Biological_structure
the I-Biological_structure
back I-Biological_structure
of I-Biological_structure
the I-Biological_structure
closet I-Biological_structure
right I-Biological_structure
hand I-Biological_structure
ulcerated B-Sign_symptom
epidermis I-Sign_symptom
and O
the O
dermis B-Detailed_description
infiltrate I-Detailed_description
rich I-Detailed_description
in I-Detailed_description
neutrophils I-Detailed_description
with O
leukocytoclastic B-Detailed_description
vasculitis B-Sign_symptom
finding O
a O
PG B-Disease_disorder
( O
Figure O
4 O
) O
. O

Other B-Diagnostic_procedure
biopsies I-Diagnostic_procedure
taken O
at O
infiltrated B-Detailed_description
erythematous B-Detailed_description
plaques B-Sign_symptom
of O
the O
ankle B-Biological_structure
showed O
a O
normal B-Lab_value
appearance B-Diagnostic_procedure
of I-Diagnostic_procedure
skin I-Diagnostic_procedure
, O
edema B-Sign_symptom
of O
the O
superficial B-Biological_structure
dermis I-Biological_structure
based O
on O
an O
infiltrate B-Detailed_description
rich I-Detailed_description
in I-Detailed_description
neutrophils I-Detailed_description
without O
vasculitis B-Sign_symptom
confirming O
the O
diagnosis O
of O
SS B-Disease_disorder
( O
Figure O
5 O
) O
. O

Corticosteroid B-Medication
treatment O
was O
then O
started O
with O
prednisolone B-Medication
at O
a O
dose O
of O
1mg/Kg/j B-Dosage
. O

The O
evolution O
was O
marked O
since B-Date
day I-Date
7 I-Date
of I-Date
treatment I-Date
by O
the O
desinfiltration B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
plaques I-Sign_symptom
( O
Figure O
6 O
) O
, O
the O
recovery B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
general I-Sign_symptom
condition I-Sign_symptom
and O
disappearance O
of O
biological B-Disease_disorder
inflammatory I-Disease_disorder
syndrome I-Disease_disorder
. O

A O
35-year-old B-Age
woman B-Sex
was O
admitted B-Clinical_event
with O
a O
5-day B-Duration
history O
of O
increasing O
drowsiness B-Sign_symptom
, O
fatigue B-Sign_symptom
, O
personality B-Sign_symptom
changes I-Sign_symptom
, O
generalised B-Detailed_description
weakness B-Sign_symptom
and O
deteriorating B-Qualitative_concept
mobility B-Diagnostic_procedure
. O

Her O
medical O
history O
included O
a O
10-year B-History
history I-History
of I-History
schizo-affective I-History
disorder I-History
, O
lithium-induced B-History
diabetes I-History
insipidus I-History
and O
hypothyroidism B-History
. O

Her O
medications O
included O
sodium B-Medication
valproate I-Medication
1 B-Dosage
g I-Dosage
twice I-Dosage
daily I-Dosage
, O
carbamazepine B-Medication
, O
quetiapine B-Medication
and O
lithium B-Medication
. O

On O
admission B-Activity
, O
the O
patient O
was O
drowsy B-Sign_symptom
, O
difficult B-Sign_symptom
to I-Sign_symptom
rouse I-Sign_symptom
( O
sleeping B-Activity
all B-Detailed_description
night I-Detailed_description
and I-Detailed_description
in I-Detailed_description
the I-Detailed_description
afternoon I-Detailed_description
) O
. O

Her O
Glasgow B-Diagnostic_procedure
Coma I-Diagnostic_procedure
Scale I-Diagnostic_procedure
( O
GCS B-Diagnostic_procedure
) O
was O
14/15 B-Quantitative_concept
, O
her O
abbreviated O
mini-mental B-Diagnostic_procedure
test I-Diagnostic_procedure
score I-Diagnostic_procedure
was O
6/10 B-Quantitative_concept
and O
she O
was O
noted O
to O
be O
slow B-Qualitative_concept
in O
her O
responses O
. O

Neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
reduced B-Qualitative_concept
power B-Diagnostic_procedure
in O
her O
lower B-Biological_structure
limbs I-Biological_structure
( O
3 B-Quantitative_concept
– I-Quantitative_concept
4/5 I-Quantitative_concept
) O
in O
a O
pyramidal B-Qualitative_concept
distribution I-Qualitative_concept
, O
and O
brisk B-Qualitative_concept
reflexes B-Diagnostic_procedure
with O
intact B-Qualitative_concept
sensation B-Diagnostic_procedure
in O
all B-Detailed_description
modalities I-Detailed_description
. O

Cardiovascular B-Biological_structure
, O
respiratory B-Biological_structure
and O
gastrointestinal B-Biological_structure
examinations B-Diagnostic_procedure
were O
unremarkable B-Lab_value
and O
there O
were O
no O
demonstrable O
features O
of O
hepatic B-Disease_disorder
disease I-Disease_disorder
. O

Routine B-Detailed_description
biochemistry B-Diagnostic_procedure
was O
unremarkable B-Qualitative_concept
. O

The O
patient O
's O
alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
was O
7 B-Lab_value
u/L I-Lab_value
( O
1 O
– O
15 O
) O
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
61 B-Lab_value
u/L I-Lab_value
( O
30 O
– O
130 O
) O
, O
γ-glutamyl B-Diagnostic_procedure
transferase I-Diagnostic_procedure
17 B-Lab_value
u/L I-Lab_value
( O
< O
45 O
) O
and O
bilirubin B-Diagnostic_procedure
was O
6 B-Lab_value
μmol/L I-Lab_value
( O
< O
21 O
) O
. O

She O
had O
normal B-Qualitative_concept
serum B-Detailed_description
B12 B-Diagnostic_procedure
and O
folate B-Diagnostic_procedure
levels O
, O
and O
normal B-Qualitative_concept
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
. O

Serum B-Detailed_description
lithium B-Diagnostic_procedure
levels O
were O
within B-Qualitative_concept
the I-Qualitative_concept
therapeutic I-Qualitative_concept
range I-Qualitative_concept
. O

Her O
serum B-Detailed_description
ammonia B-Diagnostic_procedure
was O
47 B-Lab_value
μmol/L I-Lab_value
( O
11.2 O
– O
35.4 O
) O
and O
valproate B-Diagnostic_procedure
concentrations O
were O
elevated B-Qualitative_concept
140 B-Lab_value
mg/L I-Lab_value
( O
50 O
– O
100 O
) O
. O

Brain B-Biological_structure
imaging B-Diagnostic_procedure
including O
CT B-Diagnostic_procedure
and O
MRI B-Diagnostic_procedure
did O
not O
show O
any O
haemorrhage B-Sign_symptom
or O
intracranial B-Biological_structure
mass B-Sign_symptom
. O

Lumbar B-Diagnostic_procedure
puncture I-Diagnostic_procedure
demonstrated O
clear B-Qualitative_concept
cerebrospinal B-Biological_structure
fluid I-Biological_structure
( O
white B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
< B-Quantitative_concept
1 I-Quantitative_concept
× I-Quantitative_concept
106/L I-Quantitative_concept
, O
protein B-Diagnostic_procedure
0.25 B-Lab_value
g/L I-Lab_value
( O
0.2 O
– O
0.4 O
) O
) O
. O

EEG B-Diagnostic_procedure
demonstrated O
mild B-Severity
variable O
slowing B-Sign_symptom
and O
irregularity B-Sign_symptom
of I-Sign_symptom
background I-Sign_symptom
activity I-Sign_symptom
( O
likely O
due O
to O
medication B-Medication
) O
. O

The O
differential O
diagnosis O
included O
encephalitis B-Disease_disorder
, O
Guillain-Barré B-Disease_disorder
syndrome I-Disease_disorder
and O
acute B-Disease_disorder
disseminated I-Disease_disorder
encephalomyelitis I-Disease_disorder
( O
ADEM B-Disease_disorder
) O
, O
which O
were O
excluded O
through O
our O
investigations O
. O

In O
view O
of O
the O
raised B-Lab_value
valproate B-Diagnostic_procedure
and O
ammonia B-Diagnostic_procedure
levels O
, O
a O
diagnosis O
of O
valproate B-Disease_disorder
hyperammonaemic I-Disease_disorder
encephalopathy I-Disease_disorder
( O
VHE B-Disease_disorder
) O
was O
made O
at O
this O
point O
The O
dose O
of O
sodium B-Medication
valproate I-Medication
was O
reduced B-Dosage
by I-Dosage
half I-Dosage
rather O
than O
being O
completely O
withdrawn O
. O

This O
was O
due O
to O
the O
complex O
and O
challenging O
nature O
of O
managing O
the O
patient O
's O
schizo-affective B-Disease_disorder
disorder I-Disease_disorder
. O

Within B-Date
3 I-Date
days I-Date
, O
there O
was O
evident O
clinical O
improvement B-Lab_value
in O
her O
mental B-Diagnostic_procedure
status I-Diagnostic_procedure
. O

The O
patient O
was O
able O
to O
sit B-Activity
and O
communicate B-Activity
with O
the O
team O
, O
and O
her O
abbreviated B-Diagnostic_procedure
mental I-Diagnostic_procedure
test I-Diagnostic_procedure
score I-Diagnostic_procedure
improved B-Lab_value
to O
10/10 B-Lab_value
. O

The O
serum B-Detailed_description
ammonia B-Diagnostic_procedure
normalised B-Lab_value
and O
valproate B-Diagnostic_procedure
levels O
decreased B-Lab_value
to O
the O
therapeutic B-Lab_value
range I-Lab_value
. O

After B-Date
4 I-Date
days I-Date
she O
was O
discharged B-Clinical_event
home B-Nonbiological_location
. O

Results O
of O
investigations B-Diagnostic_procedure
of O
her O
urea B-Detailed_description
cycle I-Detailed_description
were O
awaited O
. O

Three B-Date
weeks I-Date
postdischarge B-Clinical_event
, O
the O
patient O
was O
clinically O
stable B-Lab_value
in O
terms O
of O
mental B-Diagnostic_procedure
functioning I-Diagnostic_procedure
, O
having O
had O
no O
further O
episodes O
of O
confusion B-Sign_symptom
or O
drowsiness B-Sign_symptom
. O

However O
, O
she O
continued O
to O
have O
fatigue B-Sign_symptom
and O
walking B-Sign_symptom
difficulties I-Sign_symptom
( O
due O
to O
residual B-Detailed_description
leg B-Biological_structure
weakness B-Sign_symptom
) O
. O

Results O
of O
her O
serum B-Detailed_description
amino B-Diagnostic_procedure
acids I-Diagnostic_procedure
revealed O
that O
our O
patient O
had O
carnitine B-Disease_disorder
deficiency I-Disease_disorder
evident O
by O
low B-Lab_value
acyl-carnitine B-Diagnostic_procedure
, O
low B-Lab_value
free B-Detailed_description
serum B-Detailed_description
carnitine B-Diagnostic_procedure
( O
14.2 B-Lab_value
μmol/L I-Lab_value
, O
normal O
range O
: O
23 O
– O
52 O
) O
and O
low B-Lab_value
total B-Detailed_description
serum B-Detailed_description
carnitine B-Diagnostic_procedure
( O
19.9 B-Lab_value
μmol/L I-Lab_value
, O
normal O
range O
: O
27 O
– O
63 O
) O
. O

She O
was O
started O
on O
oral B-Administration
carnitine B-Medication
1 B-Dosage
g I-Dosage
twice I-Dosage
daily I-Dosage
. O

Within B-Date
2 I-Date
weeks I-Date
, O
her O
symptoms B-Sign_symptom
resolved O
completely O
with O
normalisation B-Lab_value
of O
serum B-Detailed_description
carnitine B-Diagnostic_procedure
levels O
( O
free B-Detailed_description
carnitine B-Diagnostic_procedure
25.2 B-Lab_value
μmol/L I-Lab_value
and O
total B-Detailed_description
carnitine B-Diagnostic_procedure
of O
41.3 B-Lab_value
μmol/L I-Lab_value
) O
. O

The O
sodium B-Medication
valproate I-Medication
was O
initially O
stopped O
completely O
, O
but O
due O
to O
a O
serious O
relapse B-Detailed_description
of O
the O
patient O
's O
schizo-affective B-Disease_disorder
disorder I-Disease_disorder
, O
it O
was O
restarted O
and O
she O
is O
now O
well B-Sign_symptom
on O
valproate B-Medication
1 B-Dosage
g I-Dosage
once I-Dosage
daily I-Dosage
and O
long-term B-Detailed_description
carnitine B-Medication
supplements I-Medication
. O

A O
50-year-old B-Age
male B-Sex
patient O
was O
admitted B-Clinical_event
to O
our O
Department B-Nonbiological_location
for O
a O
thyroid B-Biological_structure
nodule B-Sign_symptom
on O
the O
right B-Biological_structure
side I-Biological_structure
of I-Biological_structure
the I-Biological_structure
neck I-Biological_structure
, O
which O
was O
incidentally O
detected O
on O
carotid B-Biological_structure
Doppler B-Detailed_description
ultrasound B-Diagnostic_procedure
scan O
. O

Fine-needle B-Diagnostic_procedure
aspiration I-Diagnostic_procedure
cytology I-Diagnostic_procedure
( O
FNAC B-Diagnostic_procedure
) O
showed O
a O
follicular B-Detailed_description
lesion B-Sign_symptom
. O

At O
the O
time O
of O
our O
evaluation B-Diagnostic_procedure
, O
the O
patient O
was O
in O
good B-Lab_value
health B-Diagnostic_procedure
. O

The O
medical O
history O
revealed O
hypertension B-History
, O
vitiligo B-History
, O
and O
celiac B-History
disease I-History
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
a O
small B-Detailed_description
nodule B-Sign_symptom
( O
1 B-Distance
cm I-Distance
) O
was O
palpable B-Sign_symptom
in O
the O
right B-Biological_structure
thyroid I-Biological_structure
lobe I-Biological_structure
. O

No O
enlarged B-Sign_symptom
neck B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
palpable B-Sign_symptom
. O

Neck B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
1.3 B-Distance
cm I-Distance
hypoechoic B-Detailed_description
nodule B-Sign_symptom
with O
irregular B-Detailed_description
margins I-Detailed_description
in O
the O
right B-Biological_structure
thyroid I-Biological_structure
lobe I-Biological_structure
together O
with O
bilateral B-Detailed_description
small B-Detailed_description
thyroid B-Biological_structure
nodules B-Sign_symptom
( O
4 B-Distance
– I-Distance
5 I-Distance
mm I-Distance
) O
and O
the O
absence O
of O
enlarged B-Sign_symptom
cervical B-Biological_structure
bilateral I-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
. O

Thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
normal B-Lab_value
with O
the O
absence O
of O
thyroid B-Sign_symptom
autoantibodies I-Sign_symptom
. O

Serum B-Detailed_description
calcium B-Diagnostic_procedure
was O
normal B-Lab_value
( O
9.7 B-Lab_value
mg/dl I-Lab_value
; O
normal O
range O
, O
8.4 O
– O
10.4 O
mg/dL O
) O
and O
PTH B-Diagnostic_procedure
, O
routinely O
measured O
together O
with O
serum B-Detailed_description
calcium B-Diagnostic_procedure
in O
our O
Center B-Nonbiological_location
in O
patients O
undergoing O
thyroid B-Biological_structure
surgery B-Therapeutic_procedure
, O
slightly B-Lab_value
elevated I-Lab_value
( O
68 B-Lab_value
pg/mL I-Lab_value
( O
intact O
PTH O
, O
2nd O
generation O
assay O
; O
normal O
range O
, O
10 O
– O
65 O
pg/mL O
) O
) O
. O

The O
re-review O
of O
the O
original O
slides O
of O
FNAC B-Diagnostic_procedure
confirmed O
a O
follicular B-Biological_structure
lesion B-Sign_symptom
. O

In O
particular O
, O
the O
cytology B-Diagnostic_procedure
of O
the O
nodule B-Sign_symptom
showed O
epithelial B-Other_event
cells I-Other_event
with I-Other_event
hyperchromatic I-Other_event
nuclei I-Other_event
organized I-Other_event
in I-Other_event
small I-Other_event
cohesive I-Other_event
clusters I-Other_event
resembling I-Other_event
microfollicles I-Other_event
typically O
observed O
in O
thyroid B-Biological_structure
follicular I-Biological_structure
lesions B-Sign_symptom
were O
evident O
( O
Fig. O
1a O
) O
. O

The O
patients O
underwent O
right B-Detailed_description
lobectomy B-Therapeutic_procedure
. O

During O
neck B-Biological_structure
exploration B-Diagnostic_procedure
, O
there O
were O
no O
macroscopic B-Detailed_description
signs I-Detailed_description
of O
local B-Detailed_description
invasion B-Sign_symptom
. O

The O
intraoperative B-Detailed_description
frozen-section B-Detailed_description
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
raised O
the O
suspicion O
of O
a O
PC B-Disease_disorder
. O

Definitive O
histology B-Diagnostic_procedure
showed O
a O
markedly O
irregular B-Detailed_description
infiltrative B-Sign_symptom
growth I-Sign_symptom
of O
the O
tumor B-Sign_symptom
with O
invasion B-Sign_symptom
of O
the O
thyroid B-Biological_structure
tissue I-Biological_structure
and O
cervical B-Biological_structure
soft I-Biological_structure
tissues I-Biological_structure
( O
Fig. O
1b O
, O
c O
) O
. O

Immunostaining B-Diagnostic_procedure
for O
thyroglobulin B-Diagnostic_procedure
was O
negative B-Lab_value
, O
whereas O
staining O
for O
chromogranin B-Diagnostic_procedure
A I-Diagnostic_procedure
and O
PTH B-Diagnostic_procedure
showed O
a O
strong B-Lab_value
reactivity I-Lab_value
( O
Fig. O
1d O
– O
f O
) O
. O

Based O
on O
the O
light B-Diagnostic_procedure
microscopic I-Diagnostic_procedure
findings I-Diagnostic_procedure
and O
the O
immunohistochemical B-Diagnostic_procedure
profile I-Diagnostic_procedure
, O
the O
tumor O
was O
diagnosed O
as O
a O
PC B-Disease_disorder
. O

Postoperative O
serum B-Detailed_description
calcium B-Diagnostic_procedure
( O
8.7 B-Lab_value
mg/dl I-Lab_value
) O
and O
phosphate B-Diagnostic_procedure
( O
3 B-Lab_value
mg/dl I-Lab_value
) O
levels O
were O
in O
the O
normal B-Lab_value
range I-Lab_value
. O

One B-Date
month I-Date
after I-Date
surgery B-Therapeutic_procedure
, O
serum B-Detailed_description
calcium B-Diagnostic_procedure
and O
plasma B-Detailed_description
PTH B-Diagnostic_procedure
were O
9.6 B-Lab_value
mg/dL I-Lab_value
and O
47 B-Lab_value
pg/mL I-Lab_value
, O
respectively O
. O

Neck B-Biological_structure
ultrasound B-Diagnostic_procedure
and O
total B-Biological_structure
body I-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
were O
negative O
for O
local B-Detailed_description
and O
metastatic B-Detailed_description
disease B-Disease_disorder
. O

Eight B-Date
months I-Date
later I-Date
, O
serum B-Detailed_description
calcium B-Diagnostic_procedure
and O
plasma B-Detailed_description
PTH B-Diagnostic_procedure
levels O
were O
9.1 B-Lab_value
– I-Lab_value
9.2 I-Lab_value
mg/dl I-Lab_value
and O
38 B-Lab_value
– I-Lab_value
44 I-Lab_value
pg/ml I-Lab_value
( O
1 O
– O
84 O
PTH O
3rd O
generation O
assay O
, O
normal O
range O
, O
8 O
– O
40 O
pg/mL O
) O
, O
respectively O
. O

Neck B-Biological_structure
ultrasound B-Diagnostic_procedure
did O
not O
show O
any O
pathological B-Detailed_description
lesions B-Sign_symptom
. O

In O
order O
to O
exclude O
a O
familiar O
form O
of O
PHPT B-Disease_disorder
, O
in O
which O
PC B-Disease_disorder
may O
rarely O
occur O
as O
a O
nonfunctioning B-Detailed_description
tumor B-Sign_symptom
[ O
11 O
] O
, O
the O
screening O
of O
serum B-Detailed_description
calcium B-Diagnostic_procedure
and O
neck B-Biological_structure
ultrasound B-Diagnostic_procedure
in O
the O
first-degree B-Subject
relatives I-Subject
was O
normal B-Lab_value
. O

A O
60-year-old B-Age
male B-Sex
visited B-Activity
our O
outpatient B-Nonbiological_location
clinic I-Nonbiological_location
with O
a O
mass B-Sign_symptom
on O
his O
left B-Biological_structure
hip I-Biological_structure
. O

He O
had O
diabetes B-History
and O
alcoholic B-History
hepatitis I-History
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
a O
large B-Detailed_description
mass B-Sign_symptom
measuring O
10 B-Distance
cm I-Distance
in O
diameter O
was O
observed O
on O
his O
hip B-Biological_structure
and O
an O
approximate O
5 B-Distance
cm I-Distance
left B-Biological_structure
inguinal I-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
was O
palpable B-Sign_symptom
( O
Figure O
1 O
) O
. O

Serum B-Detailed_description
tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
including O
CEA B-Diagnostic_procedure
and O
CA B-Diagnostic_procedure
19-9 I-Diagnostic_procedure
, O
were O
within B-Qualitative_concept
normal I-Qualitative_concept
limits I-Qualitative_concept
, O
whereas O
serum B-Detailed_description
amylase B-Diagnostic_procedure
( O
227 B-Lab_value
IU/L I-Lab_value
, O
normal O
range O
43-116 O
IU/L O
) O
, O
lipase B-Diagnostic_procedure
( O
378 B-Lab_value
IU/L I-Lab_value
, O
normal O
range O
7-60 O
) O
, O
fasting B-Diagnostic_procedure
blood I-Diagnostic_procedure
sugar I-Diagnostic_procedure
( O
144 B-Lab_value
mg/dL I-Lab_value
, O
normal O
range O
, O
70-100 O
mg/dL O
) O
, O
and O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
test I-Diagnostic_procedure
levels O
[ O
including O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
178 B-Lab_value
IU/L I-Lab_value
, O
normal O
range O
, O
7-38 O
IU/L O
) O
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
225 B-Lab_value
IU/L I-Lab_value
; O
normal O
range O
, O
4-43 O
IU/L O
) O
, O
and O
serum B-Detailed_description
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
( O
370 B-Lab_value
IU/L I-Lab_value
, O
normal O
range O
, O
103-335 O
IU/L O
) O
] O
were O
all O
above B-Qualitative_concept
normal I-Qualitative_concept
ranges I-Qualitative_concept
. O

An O
abdominal B-Biological_structure
computerized B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
demonstrated O
not O
only O
a O
left B-Biological_structure
hip I-Biological_structure
mass B-Sign_symptom
and O
an O
enlarged B-Sign_symptom
left B-Biological_structure
inguinal I-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
, O
but O
also O
a O
huge B-Qualitative_concept
heterogeneous B-Detailed_description
enhancing B-Detailed_description
mass B-Sign_symptom
on O
the O
body O
of O
the O
pancreas B-Biological_structure
( O
Figure O
2 O
) O
. O

On O
a O
PET B-Diagnostic_procedure
scan I-Diagnostic_procedure
, O
additional O
metastases B-Disease_disorder
were O
not O
found O
. O

We O
planned O
a O
staged B-Therapeutic_procedure
surgery I-Therapeutic_procedure
and O
performed O
a O
hip B-Biological_structure
and O
inguinal B-Biological_structure
mass B-Therapeutic_procedure
excision I-Therapeutic_procedure
on O
December B-Date
19 I-Date
, I-Date
2014 I-Date
. O

The O
histopathological B-Diagnostic_procedure
report I-Diagnostic_procedure
revealed O
a O
metastatic B-Detailed_description
small B-Detailed_description
cell I-Detailed_description
neuroendocrine B-Disease_disorder
carcinoma I-Disease_disorder
with O
a O
maximal B-Distance
diameter I-Distance
of I-Distance
10.5 I-Distance
cm I-Distance
on O
the O
buttock B-Biological_structure
mass B-Sign_symptom
and O
a O
7 B-Distance
cm I-Distance
growth B-Sign_symptom
on O
an O
inguinal B-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
. O

The O
mitotic B-Diagnostic_procedure
index I-Diagnostic_procedure
was O
over B-Lab_value
50 I-Lab_value
mitoses I-Lab_value
per I-Lab_value
50 I-Lab_value
HPF I-Lab_value
and O
the O
Ki-67 B-Diagnostic_procedure
index I-Diagnostic_procedure
measured O
at O
50 B-Lab_value
% I-Lab_value
. O

On O
January B-Date
21 I-Date
, I-Date
2015 I-Date
, O
we O
performed O
a O
total B-Detailed_description
pancreatectomy B-Therapeutic_procedure
and O
a O
total B-Detailed_description
gastrectomy B-Therapeutic_procedure
, O
with O
the O
findings O
revealing O
a O
tumor B-Sign_symptom
of O
the O
body O
of O
the O
pancreas B-Biological_structure
about O
9 B-Area
cm I-Area
× I-Area
6 I-Area
cm I-Area
in I-Area
diameter I-Area
involving O
the O
left B-Biological_structure
gastric I-Biological_structure
artery I-Biological_structure
, O
splenic B-Biological_structure
artery I-Biological_structure
, O
and O
splenic B-Biological_structure
vein I-Biological_structure
. O

The O
histopathological B-Diagnostic_procedure
report I-Diagnostic_procedure
was O
the O
same O
as O
that O
of O
a O
metastatic B-Detailed_description
lesion B-Sign_symptom
. O

Additionally O
, O
the O
tumor B-Sign_symptom
had O
spread O
to O
8 B-Quantitative_concept
of I-Quantitative_concept
the I-Quantitative_concept
32 I-Quantitative_concept
lymph B-Biological_structure
nodes I-Biological_structure
( O
Figure O
3 O
) O
. O

On O
the O
7th B-Date
post-operative I-Date
day I-Date
, O
the O
patient O
developed O
a O
high B-Severity
fever B-Sign_symptom
and O
leukocytosis B-Sign_symptom
. O

We O
administered O
an O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
, O
which O
revealed O
infected B-Detailed_description
fluid B-Sign_symptom
collection I-Sign_symptom
in O
the O
lesser B-Biological_structure
sac I-Biological_structure
and O
a O
4.7 B-Distance
cm-sized I-Distance
recurring B-Detailed_description
mass B-Sign_symptom
which O
was O
detected O
at O
the O
operative O
bed O
of O
the O
left B-Biological_structure
hip I-Biological_structure
( O
Figure O
( O
Figure4 O
) O
.4 O
) O
. O

After O
infection B-Disease_disorder
of O
the O
abdominal B-Biological_structure
cavity I-Biological_structure
was O
treated O
by O
antibiotics B-Medication
, O
we O
removed B-Therapeutic_procedure
the O
left B-Biological_structure
hip I-Biological_structure
recurring B-Detailed_description
mass B-Sign_symptom
on O
February B-Date
3 I-Date
, I-Date
2015 I-Date
. O

The O
histopathology B-Diagnostic_procedure
was O
the O
same O
as O
in O
the O
previous O
report O
; O
with O
a O
maximum B-Distance
diameter I-Distance
of I-Distance
7.5 I-Distance
cm I-Distance
. O

The O
patient O
was O
discharged B-Clinical_event
without O
other O
complications B-Disease_disorder
on O
February B-Date
9 I-Date
, I-Date
2015 I-Date
. O

He O
is O
currently O
receiving O
chemotherapy B-Medication
based O
on O
etoposide B-Medication
and O
cisplatin B-Medication
treatment O
. O

A O
68-year-old B-Age
female B-Sex
nonsmoker B-History
, O
nondrinker B-History
with O
a O
medical O
history O
of O
hypertension B-Disease_disorder
presented B-Clinical_event
with O
new-onset B-Detailed_description
painless B-Detailed_description
jaundice B-Sign_symptom
and O
pruritus B-Sign_symptom
, O
a O
three-month B-Duration
history O
of O
9.9 B-Lab_value
kg I-Lab_value
weight B-Sign_symptom
loss I-Sign_symptom
and O
chronic B-Detailed_description
diarrhea B-Sign_symptom
with O
four B-Lab_value
to I-Lab_value
five I-Lab_value
loose B-Lab_value
bowel B-Diagnostic_procedure
movements I-Diagnostic_procedure
per B-Detailed_description
day I-Detailed_description
. O

Medications B-Medication
included O
vitamin B-Medication
D I-Medication
, O
amlodipine B-Medication
and O
eprosartan B-Medication
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
normal B-Lab_value
except O
for O
jaundice B-Sign_symptom
and O
muscle B-Disease_disorder
wasting I-Disease_disorder
. O

Recent O
colonoscopy B-Diagnostic_procedure
had O
been O
normal B-Lab_value
. O

Total B-Detailed_description
and O
direct B-Detailed_description
bilirubin B-Diagnostic_procedure
levels O
were O
6.84 B-Lab_value
mg/dL I-Lab_value
( O
116.96 B-Lab_value
μmol/L I-Lab_value
) O
and O
9.18 B-Lab_value
mg/dL I-Lab_value
( O
156.98 B-Lab_value
μmol/L I-Lab_value
) O
, O
respectively O
. O

Other O
results O
included O
an O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
1.0 B-Lab_value
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
level O
247 B-Lab_value
U/L I-Lab_value
( O
normal O
< O
33 O
U/L O
) O
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
level O
139 B-Lab_value
U/L I-Lab_value
( O
normal O
< O
32 O
U/L O
) O
and O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
level O
524 B-Lab_value
U/L I-Lab_value
( O
normal O
35 O
to O
104 O
U/L O
) O
. O

Viral B-Diagnostic_procedure
hepatitis I-Diagnostic_procedure
serologies I-Diagnostic_procedure
, O
and O
antimitochondrial B-Diagnostic_procedure
antibody I-Diagnostic_procedure
and O
anti-smooth B-Diagnostic_procedure
muscle I-Diagnostic_procedure
antibody I-Diagnostic_procedure
tests O
were O
negative B-Lab_value
. O

Her O
alpha-fetoprotein B-Diagnostic_procedure
level O
was O
2.4 B-Lab_value
ng/mL I-Lab_value
( O
normal O
< O
5 O
ng/mL O
) O
, O
total B-Diagnostic_procedure
immunoglobulin I-Diagnostic_procedure
( I-Diagnostic_procedure
Ig I-Diagnostic_procedure
) I-Diagnostic_procedure
G I-Diagnostic_procedure
was O
1880 B-Lab_value
mg/dL I-Lab_value
( O
normal O
< O
640 O
mg/dL O
) O
, O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19-9 I-Diagnostic_procedure
was O
856 B-Lab_value
U/mL I-Lab_value
( O
normal O
< O
33 O
U/mL O
) O
and O
IgG4 B-Diagnostic_procedure
was O
890 B-Lab_value
g/L I-Lab_value
( O
normal O
< O
3 O
g/L O
) O
. O

Doppler B-Detailed_description
ultrasound B-Diagnostic_procedure
, O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
cholangiopancreatography I-Diagnostic_procedure
and O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
of O
the O
liver B-Biological_structure
were O
suspicious O
for O
a O
subtly B-Detailed_description
enhancing I-Detailed_description
mass B-Sign_symptom
( O
2.8 B-Distance
cm I-Distance
to I-Distance
4.2 I-Distance
cm I-Distance
in O
diameter O
) O
in O
the O
region O
of O
the O
hilum B-Biological_structure
and O
porta B-Biological_structure
hepatis I-Biological_structure
, O
obstructing B-Sign_symptom
both O
the O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
hepatic I-Biological_structure
ducts I-Biological_structure
. O

Endoscopic B-Detailed_description
retrograde B-Detailed_description
cholangiopancreatography B-Diagnostic_procedure
identified O
strictures B-Sign_symptom
in O
the O
central B-Biological_structure
portions I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
and I-Biological_structure
left I-Biological_structure
hepatic I-Biological_structure
duct I-Biological_structure
, O
which O
was O
concerning O
for O
cholangiocarcinoma B-Disease_disorder
( O
Figure O
1 O
) O
. O

Biliary B-Diagnostic_procedure
brushings I-Diagnostic_procedure
were O
negative B-Lab_value
for I-Lab_value
malignancy I-Lab_value
. O

Esophagogastroduodenoscopy B-Diagnostic_procedure
was O
normal B-Lab_value
. O

Biopsies B-Diagnostic_procedure
of O
the O
ampulla B-Biological_structure
of I-Biological_structure
Vater I-Biological_structure
revealed O
chronic B-Detailed_description
active B-Detailed_description
duodenitis B-Disease_disorder
( O
Figures O
2 O
and O
and3 O
) O
; O
3 O
) O
; O
an O
ancillary B-Diagnostic_procedure
test I-Diagnostic_procedure
confirmed B-Lab_value
the I-Lab_value
diagnosis I-Lab_value
( O
Figure O
4 O
) O
. O

Treatment O
with O
corticosteroids B-Medication
normalized O
the O
patient O
’s O
biochemical B-Detailed_description
and O
radiological B-Detailed_description
abnormalities B-Disease_disorder
within B-Date
three I-Date
months I-Date
. O

We O
report O
the O
case O
of O
a O
previously B-History
healthy I-History
28-year-old B-Age
woman B-Sex
, O
Afro-Brazilian B-Personal_background
, O
in O
her O
first B-History
pregnancy I-History
. O

Our O
patient O
had O
no O
medical O
records O
until O
the O
36th B-Date
pregnancy I-Date
week I-Date
and O
reported O
allergy B-History
to I-History
diclofenac I-History
. O

She O
presented B-Clinical_event
to O
our O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
an O
acute B-Detailed_description
onset O
of O
abdominal B-Biological_structure
pain B-Sign_symptom
, O
jaundice B-Sign_symptom
, O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
, O
with O
no O
signs O
of O
encephalopathy B-Disease_disorder
. O

Her O
arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
110/60mmHg B-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
98 B-Lab_value
bpm I-Lab_value
, O
axillary B-Diagnostic_procedure
temperature I-Diagnostic_procedure
was O
35 B-Lab_value
°C I-Lab_value
, O
she O
was O
severely B-Severity
dehydrated B-Sign_symptom
and O
with O
decreased B-Lab_value
peripheral B-Diagnostic_procedure
perfusion I-Diagnostic_procedure
. O

The O
laboratory B-Diagnostic_procedure
examinations I-Diagnostic_procedure
revealed O
hemoglobin B-Diagnostic_procedure
12.3 B-Lab_value
g/dL I-Lab_value
, O
leukocytes B-Diagnostic_procedure
13 B-Lab_value
× I-Lab_value
109/mL I-Lab_value
, O
platelets B-Diagnostic_procedure
97 B-Lab_value
× I-Lab_value
103/mm3 I-Lab_value
, O
international B-Diagnostic_procedure
nationalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
INR B-Diagnostic_procedure
) O
6.9 B-Lab_value
, O
fibrinogen B-Diagnostic_procedure
98mg/dL B-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
14.2 B-Lab_value
mg/dL I-Lab_value
, O
serum B-Detailed_description
creatinine B-Diagnostic_procedure
3.4 B-Lab_value
mg/dL I-Lab_value
, O
serum B-Detailed_description
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
AST B-Diagnostic_procedure
) O
306U/L B-Lab_value
, O
serum B-Detailed_description
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
ALP B-Diagnostic_procedure
) O
302U/L B-Lab_value
, O
arterial B-Diagnostic_procedure
bicarbonate I-Diagnostic_procedure
11mEq/L B-Lab_value
, O
arterial B-Diagnostic_procedure
pH I-Diagnostic_procedure
7.21 B-Lab_value
, O
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
65mg/dL B-Lab_value
and O
ionic B-Diagnostic_procedure
calcium I-Diagnostic_procedure
1.02 B-Lab_value
mmol/L I-Lab_value
. O

An O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
depicted O
fatty B-Sign_symptom
infiltration I-Sign_symptom
of O
the O
liver B-Biological_structure
and O
confirmed B-Lab_value
fetal B-Diagnostic_procedure
viability I-Diagnostic_procedure
. O

Our O
patient O
received O
an O
initial O
fluid B-Medication
load I-Medication
with O
crystalloids B-Medication
. O

The O
calcium B-Diagnostic_procedure
, O
glucose B-Diagnostic_procedure
and O
hypothermia B-Disease_disorder
were O
reversed B-Lab_value
. O

The O
diagnosis O
of O
AFLP B-Disease_disorder
was O
confirmed O
following O
the O
Swansea B-Diagnostic_procedure
’s I-Diagnostic_procedure
criteria I-Diagnostic_procedure
[ O
9 O
] O
. O

Therefore O
, O
a O
cesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
was O
indicated O
. O

A O
thromboelastometry B-Therapeutic_procedure
( O
ROTEM B-Detailed_description
® I-Detailed_description
, I-Detailed_description
Pentapharm I-Detailed_description
Co. I-Detailed_description
, I-Detailed_description
Munich I-Detailed_description
, I-Detailed_description
Germany I-Detailed_description
) O
was O
performed O
at O
the O
beginning O
of O
the O
surgery B-Coreference
. O

The O
thromboelastometry B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
an O
intense B-Severity
kinetic B-Detailed_description
and O
structural B-Detailed_description
hypocoagulable B-Sign_symptom
state I-Sign_symptom
( O
Fig. O
1 O
and O
Table O
1 O
) O
. O

The O
FIBTEM B-Diagnostic_procedure
revealed O
an O
impairment B-Disease_disorder
in I-Disease_disorder
fibrinogen I-Disease_disorder
function I-Disease_disorder
quality I-Disease_disorder
while O
the O
EXTEM B-Diagnostic_procedure
depicted O
a O
coagulation B-Disease_disorder
factor I-Disease_disorder
deficiency I-Disease_disorder
( O
Fig.1a-c O
and O
Table O
1 O
) O
. O

Based O
on O
, O
respectively O
, O
FIBTEM B-Diagnostic_procedure
maximum B-Diagnostic_procedure
clot I-Diagnostic_procedure
firmness I-Diagnostic_procedure
( O
MCF B-Diagnostic_procedure
) O
( O
0 B-Lab_value
mm I-Lab_value
; O
Table O
1 O
) O
and O
EXTEM B-Diagnostic_procedure
clotting B-Diagnostic_procedure
time I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
( O
228s B-Lab_value
; O
Table O
1 O
) O
, O
4.0 B-Dosage
g I-Dosage
of O
fibrinogen B-Medication
concentrate B-Administration
( O
Haemocomplettan B-Detailed_description
® I-Detailed_description
P I-Detailed_description
, I-Detailed_description
CSL I-Detailed_description
Behring I-Detailed_description
, I-Detailed_description
Marburg I-Detailed_description
, I-Detailed_description
Germany I-Detailed_description
) O
and O
1000UI B-Dosage
of O
prothrombin B-Medication
complex I-Medication
concentrate B-Administration
( O
Beriplex B-Detailed_description
® I-Detailed_description
P/N I-Detailed_description
500UI I-Detailed_description
, I-Detailed_description
CSL I-Detailed_description
Behring I-Detailed_description
, I-Detailed_description
Marburg I-Detailed_description
, I-Detailed_description
Germany I-Detailed_description
) O
were O
administered O
at O
the O
beginning O
of O
the O
cesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
. O

The O
fluid B-Medication
input I-Medication
( O
crystalloids B-Medication
) O
and O
output B-Diagnostic_procedure
during O
the O
caesarian B-Therapeutic_procedure
section I-Therapeutic_procedure
were O
, O
respectively O
, O
2000mL B-Dosage
and O
200mL B-Lab_value
. O

The O
cesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
succeeded B-Lab_value
with O
no O
major B-Severity
bleeding B-Sign_symptom
after O
the O
hemostatic B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

Additional O
hemocomponent B-Medication
transfusion B-Administration
, O
such O
as O
fresh B-Medication
frozen I-Medication
plasma I-Medication
( O
FFP B-Medication
) O
, O
cryoprecipitate B-Medication
, O
platelets B-Medication
or O
blood B-Medication
concentrates I-Medication
, O
was O
not O
necessary O
. O

A O
second O
thromboelastometry B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
performed O
at O
the O
end O
of O
surgery B-Coreference
( O
Fig.1d-e O
and O
Table O
1 O
) O
, O
showing O
a O
mild B-Severity
hypocoagulation B-Sign_symptom
state I-Sign_symptom
. O

The O
patient O
was O
admitted B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
( O
ICU B-Nonbiological_location
) O
and O
remained O
stable B-Sign_symptom
, O
with O
no O
bleeding B-Sign_symptom
during O
the O
recovery B-Therapeutic_procedure
phase I-Therapeutic_procedure
. O

She O
was O
discharged B-Clinical_event
from O
the O
ICU B-Nonbiological_location
3 B-Date
days I-Date
after I-Date
admission B-Clinical_event
and O
then O
3 B-Date
days I-Date
later I-Date
she O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
. O

A O
58-year-old B-Age
man B-Sex
had O
been O
suffering O
from O
general B-Sign_symptom
fatigue I-Sign_symptom
and O
severe B-Severity
anemia B-Sign_symptom
for O
several B-Duration
months I-Duration
. O

His O
hemoglobin B-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
6.6 B-Lab_value
g/dl I-Lab_value
( O
normal O
range O
: O
12 O
– O
16 O
g/dl O
) O
. O

He O
had O
no B-History
medical I-History
history I-History
and O
did B-History
not I-History
take I-History
any I-History
medicine I-History
. O

Esophagogastroduodenoscopy B-Diagnostic_procedure
and O
colonoscopy B-Diagnostic_procedure
did O
not O
reveal O
any O
significant O
bleeding B-Sign_symptom
. O

Abdominal B-Biological_structure
computer B-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
a O
2-cm B-Distance
hypervascular B-Detailed_description
tumor B-Sign_symptom
in O
the O
small B-Biological_structure
intestine I-Biological_structure
( O
Fig. O
1 O
) O
. O

Oral O
DBE B-Diagnostic_procedure
detected O
a O
2-cm-diameter B-Distance
reddish B-Color
, O
submucosal B-Biological_structure
tumor-like B-Detailed_description
lesion B-Sign_symptom
with O
surface B-Detailed_description
ulceration I-Detailed_description
in O
the O
jejunum B-Biological_structure
, O
approximately O
20 B-Biological_structure
cm I-Biological_structure
away I-Biological_structure
from I-Biological_structure
the I-Biological_structure
Treitz I-Biological_structure
ligament I-Biological_structure
( O
Fig. O
2 O
) O
. O

We O
did O
not O
perform O
biopsy B-Diagnostic_procedure
because O
it O
can O
be O
difficult O
to O
stop O
bleeding O
in O
the O
case O
of O
hypervascular O
lesions O
. O

Under O
the O
diagnosis O
of O
a O
small B-Disease_disorder
bowel I-Disease_disorder
tumor I-Disease_disorder
, O
gastrointestinal B-Disease_disorder
stromal I-Disease_disorder
tumor I-Disease_disorder
( O
GIST B-Disease_disorder
) O
, O
malignant B-Disease_disorder
lymphoma I-Disease_disorder
, O
or O
cancer B-Disease_disorder
, O
we O
performed O
laparoscopic-assisted B-Detailed_description
segmental B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
jejunum B-Biological_structure
with O
the O
dissection B-Detailed_description
of I-Detailed_description
lymph I-Detailed_description
nodes I-Detailed_description
. O

Examination B-Diagnostic_procedure
of O
the O
resected B-Detailed_description
tumor B-Sign_symptom
showed O
that O
it O
measured O
19 B-Area
× I-Area
16 I-Area
mm I-Area
in O
diameter O
( O
Fig. O
3 O
) O
. O

Histology B-Diagnostic_procedure
revealed O
the O
proliferation B-Sign_symptom
of I-Sign_symptom
blood I-Sign_symptom
capillaries I-Sign_symptom
and O
granulation B-Sign_symptom
tissue I-Sign_symptom
, O
which O
was O
consistent O
with O
PG B-Disease_disorder
( O
Fig. O
4 O
) O
. O

The O
patient O
was O
discharged B-Clinical_event
on O
postoperative B-Date
day I-Date
9 I-Date
without O
complication B-Sign_symptom
and O
his O
anemia B-Sign_symptom
improved B-Lab_value
gradually O
without O
the O
need O
for O
oral B-Medication
iron I-Medication
after O
surgery O
. O

A O
33-year-old B-Age
man B-Sex
presented B-Clinical_event
with O
left B-Biological_structure
flank I-Biological_structure
dull B-Detailed_description
ache B-Sign_symptom
. O

On O
the O
abdominal B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
, O
a O
solid B-Detailed_description
renal B-Biological_structure
mass B-Sign_symptom
in O
the O
upper B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
kidney I-Biological_structure
was O
identified O
. O

The O
mass B-Coreference
was O
measured O
2.8 B-Volume
cm I-Volume
× I-Volume
2.8 I-Volume
cm I-Volume
× I-Volume
2.5 I-Volume
cm I-Volume
in O
size O
, O
was O
well-defined B-Detailed_description
. O

The O
patient O
had O
no O
other B-Sign_symptom
abnormal I-Sign_symptom
findings I-Sign_symptom
, O
such O
as O
suspected O
distant B-Detailed_description
metastasis B-Sign_symptom
or O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
. O

Radical B-Detailed_description
nephrectomy B-Therapeutic_procedure
was O
performed O
on O
14/9/2005 B-Date
. O

On O
gross B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
nephrectomy B-Detailed_description
specimen I-Detailed_description
measured O
11.5 B-Volume
cm I-Volume
× I-Volume
6.5 I-Volume
cm I-Volume
× I-Volume
4.5 I-Volume
cm I-Volume
and O
the O
tumor B-Coreference
was O
a O
solid B-Detailed_description
, O
grayish-brown B-Color
mass B-Coreference
measured O
3.5 B-Volume
cm I-Volume
× I-Volume
2.5 I-Volume
cm I-Volume
× I-Volume
2.2 I-Volume
cm I-Volume
in O
size O
. O

Histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
trabecular B-Lab_value
and I-Lab_value
ribbonlike I-Lab_value
patterns I-Lab_value
with O
minimal B-Lab_value
fibrotic I-Lab_value
stroma I-Lab_value
. O

The O
cytoplasm B-Diagnostic_procedure
was O
granular B-Lab_value
and O
eosinophilic B-Lab_value
with O
uniform B-Lab_value
round I-Lab_value
to I-Lab_value
oval I-Lab_value
nuclei I-Lab_value
with O
finely B-Lab_value
stippled I-Lab_value
chromatin I-Lab_value
and O
inconspicuous B-Lab_value
nucleoli I-Lab_value
. O

Mitoses B-Diagnostic_procedure
were O
not B-Lab_value
found I-Lab_value
( O
0 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
fields I-Lab_value
) O
on O
H&E B-Diagnostic_procedure
stain I-Diagnostic_procedure
. O

The O
final O
pathologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
well-differentiated B-Detailed_description
neuroendocrine B-Disease_disorder
( I-Disease_disorder
carcinoid I-Disease_disorder
) I-Disease_disorder
tumor I-Disease_disorder
confined O
to O
the O
kidney B-Biological_structure
( O
Fig. O
1 O
) O
. O

Immunohistochemical B-Diagnostic_procedure
stains I-Diagnostic_procedure
demonstrated O
labeling B-Lab_value
with O
chromogranin B-Diagnostic_procedure
, O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
and O
synaptophysin B-Diagnostic_procedure
( O
Fig. O
2 O
) O
, O
and O
the O
proliferation B-Diagnostic_procedure
index I-Diagnostic_procedure
was O
less B-Lab_value
than I-Lab_value
2 I-Lab_value
% I-Lab_value
as O
measured O
by O
immunohistochemistry B-Diagnostic_procedure
for I-Diagnostic_procedure
Ki-67 I-Diagnostic_procedure
. O

Further O
radiation B-Therapeutic_procedure
and O
chemotherapy B-Medication
were O
not O
received O
. O

Nine B-Date
years I-Date
after I-Date
radical O
nephrectomy O
, O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
abdomen B-Biological_structure
demonstrated O
a O
2 B-Area
cm I-Area
× I-Area
1.8 I-Area
cm I-Area
cyst B-Detailed_description
mass B-Sign_symptom
in O
the O
right B-Biological_structure
liver I-Biological_structure
and O
multiple B-Detailed_description
high B-Sign_symptom
density I-Sign_symptom
shadow I-Sign_symptom
in O
gallbladder B-Biological_structure
. O

No O
enlarged B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
were O
found O
in O
the O
abdominal B-Biological_structure
cavity I-Biological_structure
. O

Cholecystectomy B-Therapeutic_procedure
and O
extirpation B-Therapeutic_procedure
for O
hepatic B-Disease_disorder
cyst I-Disease_disorder
were O
performed O
by O
laparoscopy B-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O

Histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
trabecular B-Lab_value
and I-Lab_value
glandlike I-Lab_value
growth I-Lab_value
( O
Fig. O
3 O
) O
, O
moderate B-Lab_value
and I-Lab_value
uniform I-Lab_value
nuclei I-Lab_value
and O
mitoses B-Diagnostic_procedure
were B-Lab_value
n't I-Lab_value
found I-Lab_value
( O
0 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
fields I-Lab_value
) O
. O

Advanced B-Detailed_description
immunohistochemistry B-Diagnostic_procedure
revealed O
that O
the O
lesion B-Coreference
was O
positive B-Lab_value
for O
synaptophysin B-Diagnostic_procedure
( O
Fig. O
4 O
) O
and O
CD56 O
, O
but O
negative B-Lab_value
for O
chromogranin B-Diagnostic_procedure
and O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
. O

These O
features O
are O
supported O
in O
a O
neuroendocrine B-Disease_disorder
tumor I-Disease_disorder
. O

Due O
to O
the O
similar O
pathologic O
characteristics O
between O
the O
primary O
renal O
carcinoid O
tumor O
and O
liver O
tumor O
. O

The O
final O
pathology O
report O
indicated O
a O
carcinoid B-Disease_disorder
tumor I-Disease_disorder
of O
the O
left B-Biological_structure
kidney I-Biological_structure
with O
liver B-Biological_structure
metastasis B-Sign_symptom
. O

The O
patient O
, O
a O
9 B-Age
year-old I-Age
Caucasian B-Personal_background
female B-Sex
, O
was O
first O
diagnosed O
with O
medulloblastoma B-Disease_disorder
at O
age B-Date
3 I-Date
years I-Date
. O

Treatment B-Therapeutic_procedure
included O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
of O
the O
tumor B-Sign_symptom
followed O
by O
systemic O
chemotherapy B-Medication
( O
Vincristine B-Medication
, O
Lomustine B-Medication
, O
Cisplatin B-Medication
, O
Carboplatin B-Medication
, O
Cyclophosphamide B-Medication
, O
Etoposide B-Medication
) O
, O
and O
craniospinal B-Biological_structure
radiation B-Therapeutic_procedure
( O
2,340 B-Dosage
cGy I-Dosage
) O
with O
boost B-Therapeutic_procedure
to O
the O
posterior B-Biological_structure
fossa I-Biological_structure
( O
total B-Dosage
dose I-Dosage
5,900 I-Dosage
cGy I-Dosage
) O
. O

Cis-RA B-Medication
was O
subsequently O
administered O
for O
eleven B-Dosage
, I-Dosage
14-day I-Dosage
cycles I-Dosage
( O
180mg/m2 B-Dosage
per I-Dosage
day I-Dosage
) O
, O
over O
a O
13-month B-Duration
period I-Duration
for O
a O
cumulative O
dose O
of O
17,360 B-Dosage
mg I-Dosage
( O
24,640 B-Dosage
mg/m2 I-Dosage
) O
. O

She O
completed B-Lab_value
medulloblastoma B-Therapeutic_procedure
therapy I-Therapeutic_procedure
at O
age B-Date
5.6 I-Date
years I-Date
. O

At O
age B-Date
6 I-Date
years I-Date
, O
she O
was O
diagnosed O
with O
radiation-induced B-Detailed_description
central B-Detailed_description
hypothyroidism B-Disease_disorder
and O
growth B-Disease_disorder
hormone I-Disease_disorder
deficiency I-Disease_disorder
( O
GHD B-Disease_disorder
) O
. O

She O
was O
treated O
with O
levothyroxine B-Medication
with O
subsequent O
biochemical B-Detailed_description
euthyroidism B-Sign_symptom
. O

Given O
tumor B-Sign_symptom
remission I-Sign_symptom
status O
and O
an O
abnormal B-Qualitative_concept
height B-Diagnostic_procedure
velocity I-Diagnostic_procedure
of O
0.94 B-Lab_value
cm/year I-Lab_value
, O
growth B-Medication
hormone I-Medication
( O
GH B-Medication
) O
therapy O
was O
initiated O
at O
age B-Date
7 I-Date
years I-Date
( O
0.3 B-Dosage
mg/kg/week I-Dosage
) O
with O
subsequent O
increased B-Qualitative_concept
height B-Diagnostic_procedure
velocity I-Diagnostic_procedure
of O
3.6 B-Lab_value
cm I-Lab_value
growth/seven I-Lab_value
months I-Lab_value
; O
however O
, O
seven B-Date
months I-Date
after I-Date
initiation O
of O
GH B-Medication
, O
increased B-Qualitative_concept
bony B-Sign_symptom
prominence I-Sign_symptom
was O
noted O
at O
wrists B-Biological_structure
and O
knees B-Biological_structure
, O
concomitant O
with O
declining B-Qualitative_concept
height B-Diagnostic_procedure
velocity I-Diagnostic_procedure
( O
1.6 B-Lab_value
cm I-Lab_value
growth/five I-Lab_value
months I-Lab_value
) O
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
and O
radiographs B-Diagnostic_procedure
were O
significant O
for O
leg B-Diagnostic_procedure
length I-Diagnostic_procedure
discrepancy B-Lab_value
: O
the O
right B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
measured B-Diagnostic_procedure
1.75 B-Lab_value
cm I-Lab_value
shorter I-Lab_value
than I-Lab_value
the I-Lab_value
left I-Lab_value
( O
right B-Lab_value
femur I-Lab_value
24.9 I-Lab_value
cm I-Lab_value
, O
right B-Lab_value
tibia I-Lab_value
19.6 I-Lab_value
cm I-Lab_value
, O
right B-Lab_value
lower I-Lab_value
extremity I-Lab_value
44.5 I-Lab_value
cm I-Lab_value
, O
left B-Lab_value
femur I-Lab_value
25.25 I-Lab_value
cm I-Lab_value
, O
left B-Lab_value
tibia I-Lab_value
21 I-Lab_value
cm I-Lab_value
, O
and O
left B-Lab_value
lower I-Lab_value
extremity I-Lab_value
46.25 I-Lab_value
cm I-Lab_value
) O
. O

Prior O
to O
initiation O
of O
GH B-Medication
, O
height B-Diagnostic_procedure
( O
102 B-Lab_value
cm I-Lab_value
) O
( O
Figure O
1 O
) O
and O
armspan B-Diagnostic_procedure
( O
102 B-Lab_value
cm I-Lab_value
) O
were O
similar O
, O
with O
upper B-Diagnostic_procedure
segment/lower I-Diagnostic_procedure
segment I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
one B-Lab_value
; O
seven B-Date
months I-Date
after I-Date
GH B-Medication
, O
height B-Diagnostic_procedure
increased B-Lab_value
minimally I-Lab_value
( O
105.6 B-Lab_value
cm I-Lab_value
) O
compared O
to O
the O
more B-Lab_value
significant I-Lab_value
increase I-Lab_value
in O
armspan B-Diagnostic_procedure
( O
109.2 B-Lab_value
cm I-Lab_value
) O
, O
with O
upper B-Diagnostic_procedure
segment/lower I-Diagnostic_procedure
segment I-Diagnostic_procedure
ratio I-Diagnostic_procedure
remaining O
at O
one B-Lab_value
. O

Radiographs B-Diagnostic_procedure
revealed O
poorly B-Lab_value
visualized I-Lab_value
growth B-Diagnostic_procedure
plates I-Diagnostic_procedure
in O
both O
distal B-Biological_structure
and I-Biological_structure
proximal I-Biological_structure
femurs I-Biological_structure
and I-Biological_structure
tibias I-Biological_structure
( O
Figure O
2A-B O
) O
, O
raising O
concern O
for O
premature B-Disease_disorder
closure I-Disease_disorder
of I-Disease_disorder
the I-Disease_disorder
physes I-Disease_disorder
. O

This O
lower O
limb O
growth O
plate O
closure O
would O
normally O
be O
observed O
at O
the O
time O
of O
late-stage O
puberty O
. O

By O
contrast O
, O
all O
bone B-Diagnostic_procedure
ages I-Diagnostic_procedure
using O
left B-Biological_structure
hand I-Biological_structure
and O
wrist B-Biological_structure
radiographs B-Diagnostic_procedure
over O
the O
preceding B-Duration
two I-Duration
years I-Duration
displayed O
open B-Lab_value
growth B-Diagnostic_procedure
plates I-Diagnostic_procedure
( O
Figure O
2C-D O
) O
. O

A O
73-year-old B-Age
woman B-Sex
was O
initially O
referred B-Clinical_event
19 B-Date
months I-Date
prior I-Date
to O
the O
current O
presentation O
, O
at O
which O
time O
fluorescein B-Detailed_description
and O
indocyanine B-Detailed_description
green I-Detailed_description
angiography B-Diagnostic_procedure
showed O
a O
medium-sized B-Detailed_description
subfoveal B-Detailed_description
classic B-Detailed_description
CNV B-Disease_disorder
in O
the O
left B-Biological_structure
eye I-Biological_structure
, O
which O
had O
not B-Detailed_description
been I-Detailed_description
previously I-Detailed_description
treated I-Detailed_description
. O

She O
did O
not O
return O
for O
treatment B-Therapeutic_procedure
until O
the O
current O
presentation O
, O
when O
she O
noted O
decreased B-Sign_symptom
vision I-Sign_symptom
in O
the O
left B-Biological_structure
eye I-Biological_structure
. O

The O
best-corrected B-Diagnostic_procedure
visual I-Diagnostic_procedure
acuity I-Diagnostic_procedure
( O
BCVA B-Diagnostic_procedure
) O
was O
20/100 B-Lab_value
. O

Slit B-Diagnostic_procedure
lamp I-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
small B-Detailed_description
yellowish B-Color
patch B-Sign_symptom
in O
the O
perifoveal B-Biological_structure
region I-Biological_structure
and O
retinal B-Sign_symptom
edema I-Sign_symptom
. O

Structural B-Detailed_description
OCT B-Diagnostic_procedure
revealed O
the O
retinal B-Sign_symptom
elevation I-Sign_symptom
, O
subretinal B-Sign_symptom
fluid I-Sign_symptom
and O
a O
hyper-reflective B-Biological_structure
elongated B-Sign_symptom
area I-Sign_symptom
above B-Biological_structure
RPE I-Biological_structure
indicating O
type B-Lab_value
II I-Lab_value
CNV B-Disease_disorder
. O

Anti-angiogenic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
with O
intravitreal B-Administration
aflibercept B-Medication
injections B-Administration
were O
administered O
with O
a O
treat-and-extend B-Detailed_description
regimen I-Detailed_description
. O

OCT B-Diagnostic_procedure
angiograms B-Detailed_description
( O
Fig. O
1 O
) O
showed O
noticeable B-Lab_value
reduction I-Lab_value
in O
CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area I-Diagnostic_procedure
by O
1 B-Date
– I-Date
2 I-Date
days I-Date
post I-Date
injection O
, O
with O
continued B-Lab_value
reduction I-Lab_value
at O
1 B-Date
week I-Date
and I-Date
2 I-Date
weeks I-Date
. O

CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area I-Diagnostic_procedure
and O
vessel B-Diagnostic_procedure
density I-Diagnostic_procedure
were O
reduced B-Lab_value
, O
probably O
due O
to O
the O
decreased O
flow O
or O
temporary O
closure O
of O
the O
smaller O
anastomoses O
. O

Significant B-Severity
re-appearance B-Lab_value
of O
CNV B-Disease_disorder
was O
noticeable O
at O
4 B-Date
weeks I-Date
after O
the O
first O
injection O
and O
again O
at O
6 B-Date
weeks I-Date
after O
the O
second O
injection O
. O

The O
vascular O
pattern O
of O
the O
re-enlarged B-Detailed_description
CNV B-Disease_disorder
( O
Fig. O
1A O
) O
was O
very O
similar O
to O
the O
initial O
pretreatment O
CNV O
, O
suggesting O
that O
the O
recurrence O
may O
be O
reopening O
of O
original O
channels O
rather O
than O
growth O
of O
new O
vessels O
. O

Comparing O
the O
CNV O
network O
prior O
to O
the O
3rd O
injection O
to O
the O
baseline O
, O
it O
is O
notable O
that O
there O
were O
fewer O
smaller O
channels O
, O
while O
the O
larger O
caliber O
channels O
remained O
. O

Quantitative O
measurements O
from O
OCT B-Diagnostic_procedure
angiography B-Detailed_description
( O
Fig. O
2A O
) O
showed O
reduction B-Lab_value
in O
CNV B-Diagnostic_procedure
flow I-Diagnostic_procedure
area I-Diagnostic_procedure
and O
flow B-Diagnostic_procedure
index I-Diagnostic_procedure
over B-Duration
the I-Duration
first I-Duration
2 I-Duration
weeks I-Duration
with O
subsequent O
return O
. O

Retinal B-Sign_symptom
thickness I-Sign_symptom
( O
Fig. O
2B O
) O
showed O
the O
fluid O
resorption O
over B-Duration
the I-Duration
first I-Duration
4 I-Duration
weeks I-Duration
in O
the O
first O
treatment O
cycle O
continuing O
at O
least O
2 B-Date
weeks I-Date
into O
the O
second O
treatment O
cycle O
, O
at O
which O
time O
no O
fluid O
remained O
( O
Fig. O
1B O
) O
. O

But O
fluid B-Sign_symptom
re-accumulated I-Sign_symptom
under B-Biological_structure
the I-Biological_structure
retina I-Biological_structure
6 B-Date
weeks I-Date
after O
the O
2nd O
injection O
. O

Visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
( O
Fig. O
2B O
) O
continued B-Lab_value
to I-Lab_value
improve I-Lab_value
over O
the O
3 O
treatment O
cycles O
. O

A O
36-year-old B-Age
female B-Sex
presented B-Clinical_event
at O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
aggravating B-Detailed_description
right B-Biological_structure
upper I-Biological_structure
abdominal I-Biological_structure
pain B-Sign_symptom
for O
2 B-Duration
hours I-Duration
. O

The O
patient O
was O
diagnosed O
hepatitis B-History
B I-History
virus I-History
( I-History
HBV I-History
) I-History
carrier I-History
for I-History
several I-History
years I-History
and O
non-alcoholics B-History
. O

No B-History
other I-History
specific I-History
personal I-History
and I-History
familial I-History
medical I-History
history I-History
was I-History
noted I-History
. O

Initial O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
100/60 B-Lab_value
mmHg I-Lab_value
, O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
70/min B-Lab_value
, O
respiration B-Diagnostic_procedure
rate I-Diagnostic_procedure
20/min B-Lab_value
, O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
37.5 B-Lab_value
℃ I-Lab_value
. O

The O
laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
12,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
( O
poly B-Diagnostic_procedure
: O
70 B-Lab_value
% I-Lab_value
) O
, O
hemoglobin B-Diagnostic_procedure
12.8 B-Lab_value
g/dL I-Lab_value
, O
platelet B-Diagnostic_procedure
198,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
14.3 B-Lab_value
seconds I-Lab_value
, O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
1.11 B-Lab_value
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
22 B-Lab_value
IU/L I-Lab_value
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
12 B-Lab_value
IU/L I-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
0.5 B-Lab_value
mg/dL I-Lab_value
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
134 B-Lab_value
IU/L I-Lab_value
, O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
295 B-Lab_value
IU/L I-Lab_value
, O
gamma-glutamyl B-Diagnostic_procedure
transpeptidase I-Diagnostic_procedure
26 B-Lab_value
IU/L I-Lab_value
, O
protein/albumin B-Diagnostic_procedure
6.4 B-Lab_value
/ I-Lab_value
4.0 I-Lab_value
g/dL I-Lab_value
, O
uric B-Diagnostic_procedure
acid I-Diagnostic_procedure
5.0 B-Lab_value
mg/dL I-Lab_value
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen/creatinine I-Diagnostic_procedure
16.6 B-Lab_value
/ I-Lab_value
0.7 I-Lab_value
mg/dL I-Lab_value
. O

And O
serum B-Diagnostic_procedure
viral I-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
HBsAg B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
anti-HBs B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
anti-HBc B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
HBeAg B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
anti-HBe B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
HBV-DNA B-Diagnostic_procedure
< B-Lab_value
20 I-Lab_value
IU/mL I-Lab_value
, O
anti-HCV B-Diagnostic_procedure
( O
- B-Lab_value
) O
and O
anti-HIV B-Diagnostic_procedure
( O
- B-Lab_value
) O
. O

The O
patient O
's O
serum B-Diagnostic_procedure
α-fetoprotein I-Diagnostic_procedure
( O
AFP B-Diagnostic_procedure
) O
was O
676.5 B-Lab_value
ng/mL I-Lab_value
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19-9 I-Diagnostic_procedure
( O
CA19-9 B-Diagnostic_procedure
) O
< B-Lab_value
0.6 I-Lab_value
U/mL I-Lab_value
. O

She O
took O
an O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
, O
which O
showed O
a O
9 B-Distance
cm I-Distance
sized O
necrotic B-Detailed_description
mass B-Sign_symptom
with B-Detailed_description
internal I-Detailed_description
hemorrhage I-Detailed_description
at O
the O
right B-Biological_structure
hepatic I-Biological_structure
lobe I-Biological_structure
and O
ruptured B-Biological_structure
to I-Biological_structure
peritoneum I-Biological_structure
( O
Fig. O
1A O
) O
, O
so O
an O
emergency B-Detailed_description
hepatic B-Biological_structure
central I-Biological_structure
bisectionectomy B-Therapeutic_procedure
was O
done O
( O
Fig. O
2A O
) O
. O

The O
initial O
histological O
diagnosis O
was O
cHCC-CC B-Disease_disorder
with O
spindle B-Detailed_description
cell I-Detailed_description
metaplasia I-Detailed_description
of I-Detailed_description
cholangiocarcinoma I-Detailed_description
element I-Detailed_description
( O
Fig. O
2B O
) O
. O

The O
serum B-Diagnostic_procedure
AFP I-Diagnostic_procedure
was O
decreased B-Lab_value
to O
7.67 B-Lab_value
ng/mL I-Lab_value
at O
time O
of O
discharge B-Clinical_event
. O

Regarding O
as O
cHCC-CC B-Disease_disorder
, O
postoperative O
adjuvant B-Detailed_description
chemotherapy B-Medication
with O
tegafur/uracil B-Medication
( O
UFT B-Medication
) O
was O
administrated O
for O
3 B-Duration
months I-Duration
. O

3 B-Date
months I-Date
later I-Date
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scanning O
showed O
previously O
unseen O
a O
5.5 B-Distance
cm I-Distance
sized O
left B-Biological_structure
subphrenic I-Biological_structure
mass B-Sign_symptom
with O
mild B-Severity
enhancement B-Sign_symptom
in O
delayed B-Detailed_description
image I-Detailed_description
( O
Fig. O
3A O
, O
B O
) O
and O
AFP B-Diagnostic_procedure
was O
increased B-Lab_value
to O
312.06 B-Lab_value
ng/mL I-Lab_value
. O

She O
underwent O
laparoscopic B-Detailed_description
splenectomy B-Therapeutic_procedure
with O
mass B-Therapeutic_procedure
excision I-Therapeutic_procedure
. O

On O
histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
mesenchymal B-Diagnostic_procedure
elements I-Diagnostic_procedure
consisted O
of O
a O
proliferation B-Lab_value
of I-Lab_value
primitive-appearing I-Lab_value
mesenchymal I-Lab_value
spindle-shaped I-Lab_value
cells I-Lab_value
, O
intimately B-Detailed_description
admixed I-Detailed_description
with I-Detailed_description
the I-Detailed_description
epithelial I-Detailed_description
elements I-Detailed_description
in I-Detailed_description
a I-Detailed_description
highly I-Detailed_description
cellular I-Detailed_description
pattern I-Detailed_description
. O

Cytoplasm B-Diagnostic_procedure
was O
more B-Lab_value
abundant I-Lab_value
than I-Lab_value
that I-Lab_value
of I-Lab_value
mature I-Lab_value
fibroblasts I-Lab_value
, O
and O
the O
nucleus B-Diagnostic_procedure
was O
elongated B-Shape
and O
plump B-Shape
. O

These O
cells B-Lab_value
blended I-Lab_value
progressively I-Lab_value
with I-Lab_value
areas I-Lab_value
of I-Lab_value
less I-Lab_value
intense I-Lab_value
cellular I-Lab_value
mesenchymal I-Lab_value
proliferation I-Lab_value
, O
and O
with O
relatively B-Detailed_description
acellular I-Detailed_description
, I-Detailed_description
fibrous I-Detailed_description
septa I-Detailed_description
. O

Osteoid B-Diagnostic_procedure
was O
present B-Lab_value
either O
within B-Detailed_description
the I-Detailed_description
primitive I-Detailed_description
mesenchyme I-Detailed_description
, O
near B-Detailed_description
the I-Detailed_description
fibrous I-Detailed_description
septa I-Detailed_description
or I-Detailed_description
pseudocapsule I-Detailed_description
, O
or O
admixed B-Detailed_description
within I-Detailed_description
the I-Detailed_description
epithelial I-Detailed_description
elements I-Detailed_description
. O

Osteoid B-Diagnostic_procedure
foci I-Diagnostic_procedure
contained O
cells B-Lab_value
morphologically I-Lab_value
identical I-Lab_value
to I-Lab_value
osteoblasts I-Lab_value
( O
Fig. O
4A O
) O
. O

The O
immunohistochemistry B-Diagnostic_procedure
stains I-Diagnostic_procedure
showed O
expression B-Lab_value
of O
hepatocyte B-Diagnostic_procedure
, O
β-HCG B-Diagnostic_procedure
, O
AFP B-Diagnostic_procedure
, O
vimentin B-Diagnostic_procedure
, O
CK7 B-Diagnostic_procedure
, O
CK19 B-Diagnostic_procedure
, O
CD56 B-Diagnostic_procedure
and O
β-catenin B-Diagnostic_procedure
and O
negativity B-Lab_value
for O
CEA B-Diagnostic_procedure
. O

( O
Fig. O
4B O
, O
C O
, O
D O
, O
E O
, O
F O
, O
G O
) O
. O

Metastatic B-Detailed_description
hepatoblastoma B-Disease_disorder
was O
confirmed O
by O
histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
with O
immunohistochemistry B-Diagnostic_procedure
stains I-Diagnostic_procedure
, O
so O
immunohistochemistrically O
re-examination O
of O
previous O
surgical O
specimens O
was O
also O
confirmed O
as O
hepatoblastoma O
. O

Follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
performed O
1 B-Date
month I-Date
after I-Date
reoperation O
showed O
a O
newly B-Detailed_description
onset I-Detailed_description
1.7 B-Distance
cm I-Distance
sized O
subtle B-Detailed_description
enhancing I-Detailed_description
soft B-Detailed_description
tissue I-Detailed_description
mass B-Sign_symptom
in O
splenic B-Biological_structure
bed I-Biological_structure
, O
and O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
showed O
multiple B-Detailed_description
FDG B-Detailed_description
uptake B-Sign_symptom
( O
max B-Lab_value
SUV I-Lab_value
> I-Lab_value
3.80 I-Lab_value
) O
in O
left B-Detailed_description
upper I-Detailed_description
and O
lower B-Detailed_description
quadrant I-Detailed_description
area O
of O
abdomen B-Biological_structure
, O
paralumbar B-Biological_structure
area I-Biological_structure
including I-Biological_structure
right I-Biological_structure
subphrenic I-Biological_structure
area I-Biological_structure
( O
Fig. O
5A O
, O
B O
, O
C O
) O
. O

Follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
162.69 B-Lab_value
ng/mL I-Lab_value
. O

Systemic B-Detailed_description
chemotherapy B-Medication
started O
with O
cisplatin B-Medication
( O
60 B-Dosage
mg/m2 I-Dosage
) O
, O
5-fluorourasil B-Medication
( O
5-FU B-Medication
) O
( O
600 B-Dosage
mg/m2 I-Dosage
) O
, O
vincristine B-Medication
( O
1.5 B-Dosage
mg/m2 I-Dosage
) O
and O
total O
3 B-Frequency
cycles I-Frequency
of O
chemotherapy O
were O
done O
every B-Frequency
4 I-Frequency
week I-Frequency
. O

Entecavir B-Medication
0.5 B-Dosage
mg I-Dosage
was O
also O
started O
for O
chemoprophylaxis B-Medication
of O
CHB B-Disease_disorder
. O

After O
the O
3rd O
chemotherapy O
cycle O
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
and O
PET B-Diagnostic_procedure
scan O
showed O
progression O
of O
multiple B-Detailed_description
intraperitoneal B-Biological_structure
metastasis B-Sign_symptom
with O
large B-Severity
amount I-Severity
of O
intraperitoneal B-Biological_structure
fluid B-Sign_symptom
( O
Fig. O
6A O
, O
B O
) O
and O
follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
further O
increased B-Lab_value
to O
254 B-Lab_value
ng/mL I-Lab_value
. O

So O
chemotherapy B-Medication
regimen O
was O
changed O
to O
carboplatin B-Medication
( O
350 B-Lab_value
mg/m2 I-Lab_value
) O
with O
doxorubicin B-Medication
( O
30 B-Lab_value
mg/m2 I-Lab_value
) O
every B-Frequency
3 I-Frequency
weeks I-Frequency
. O

The O
patient O
experienced O
neutropenia B-Sign_symptom
after O
the O
new O
regimen O
, O
but O
recovered B-Sign_symptom
shortly O
after O
treatment O
with O
granulocyte B-Medication
colony-stimulating I-Medication
factor I-Medication
( O
G-CSF B-Medication
) O
. O

After O
second O
carboplatin O
with O
doxorubicin O
chemotherapy O
, O
follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
increased B-Lab_value
1510.19 B-Lab_value
ng/mL I-Lab_value
, O
but O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
showed O
that O
amount O
of O
ascites B-Sign_symptom
was O
decreased O
( O
Fig. O
7 O
) O
. O

Because O
of O
radiologic O
improvements O
, O
third O
and O
fourth O
chemotherapy B-Medication
were O
performed O
. O

After O
4th O
chemotherapy O
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
revealed O
progression O
of O
multiple B-Detailed_description
intraperitoneal B-Biological_structure
metastatic B-Detailed_description
masses B-Sign_symptom
, O
newly O
developed O
hepatic B-Biological_structure
metastasis B-Sign_symptom
and O
large B-Severity
amount I-Severity
of O
intraperitoneal B-Biological_structure
fluid B-Sign_symptom
( O
Fig. O
8 O
) O
. O

A O
diagnostic O
paracentesis B-Diagnostic_procedure
was O
performed O
and O
showed O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
310/mm3 B-Lab_value
( O
poly B-Diagnostic_procedure
20 B-Lab_value
% I-Lab_value
, O
lymph B-Diagnostic_procedure
80 B-Lab_value
% I-Lab_value
) O
, O
protein B-Diagnostic_procedure
3.6 B-Lab_value
g/dL I-Lab_value
and O
albumin B-Diagnostic_procedure
2.3 B-Lab_value
g/dL I-Lab_value
on O
ascitic B-Diagnostic_procedure
fluid I-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O

The O
serum B-Diagnostic_procedure
albumin I-Diagnostic_procedure
was O
3.1 B-Lab_value
g/dL I-Lab_value
and O
serum-ascites B-Diagnostic_procedure
albumin I-Diagnostic_procedure
gradient I-Diagnostic_procedure
( O
SAAG B-Diagnostic_procedure
) O
was O
0.8 B-Lab_value
g/dL I-Lab_value
. O

The O
AFB B-Diagnostic_procedure
stain I-Diagnostic_procedure
and I-Diagnostic_procedure
culture I-Diagnostic_procedure
were O
all O
negative B-Lab_value
in O
ascitic B-Detailed_description
fluid I-Detailed_description
. O

The O
AFP B-Diagnostic_procedure
was O
6881.93 B-Lab_value
ng/mL I-Lab_value
on O
serum B-Detailed_description
. O

Regarded O
as O
peritoneal B-Biological_structure
carcinomatosis B-Disease_disorder
, O
the O
patient O
underwent O
conservative B-Therapeutic_procedure
treatments I-Therapeutic_procedure
including O
the O
use O
of O
repeated B-Detailed_description
therapeutic B-Therapeutic_procedure
paracentesis I-Therapeutic_procedure
for O
1 B-Duration
month I-Duration
before O
death B-Outcome
. O

A O
42-year-old B-Age
woman B-Sex
presented B-Clinical_event
with O
a O
right B-Biological_structure
breast I-Biological_structure
lump B-Sign_symptom
, O
lower B-Biological_structure
back I-Biological_structure
pain B-Sign_symptom
, O
loss B-Sign_symptom
of I-Sign_symptom
height I-Sign_symptom
, O
marked O
kyphosis B-Sign_symptom
and O
hepatomegaly B-Sign_symptom
. O

Core O
biopsies B-Diagnostic_procedure
from O
the O
breast B-Biological_structure
lump I-Biological_structure
showed O
ductal B-Disease_disorder
carcinoma I-Disease_disorder
in O
situ O
( O
sample O
labelled O
P1 O
.1 O
; O
Supplementary O
Fig. O
1 O
and O
Supplementary O
Table O
1 O
) O
. O

An O
additional O
biopsy B-Diagnostic_procedure
from O
an O
ipsilateral B-Biological_structure
axillary I-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
( O
P1 O
.2 O
) O
revealed O
metastatic B-Detailed_description
ductal B-Disease_disorder
adenocarcinoma I-Disease_disorder
( O
ER O
+ O
( O
8/8 O
) O
and O
HER2 O
+ O
( O
3 O
+ O
) O
) O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
revealed O
widespread B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
in O
bones B-Biological_structure
, O
pleura B-Biological_structure
and O
liver B-Biological_structure
( O
Supplementary O
Fig. O
2 O
and O
Supplementary O
Table O
2 O
) O
. O

The O
patient O
was O
started O
on O
treatment O
with O
trastuzumab B-Medication
and O
taxane-based B-Medication
chemotherapy I-Medication
, O
with O
a O
significant B-Detailed_description
partial B-Detailed_description
response B-Sign_symptom
( O
Supplementary O
Fig. O
3 O
) O
. O

After O
induction B-Detailed_description
chemotherapy B-Medication
, O
she O
was O
maintained O
on O
tamoxifen B-Medication
and O
trastuzumab B-Medication
. O

After O
19 B-Duration
months I-Duration
on O
treatment O
, O
she O
presented O
with O
seizures B-Sign_symptom
and O
head B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
a O
large O
metastasis B-Sign_symptom
in O
the O
left B-Biological_structure
frontal I-Biological_structure
lobe I-Biological_structure
( O
Supplementary O
Fig. O
4 O
) O
, O
which O
was O
resected B-Therapeutic_procedure
( O
M2 O
.1 O
) O
. O

Therapy O
with O
tamoxifen B-Medication
and O
trastuzumab B-Medication
was O
continued O
and O
collection O
of O
plasma B-Diagnostic_procedure
samples I-Diagnostic_procedure
was O
initiated O
( O
samples O
T1 O
– O
T9 O
) O
. O

Four B-Date
months I-Date
after I-Date
surgery O
, O
she O
had O
enlarging B-Detailed_description
liver B-Biological_structure
lesions B-Sign_symptom
and O
a O
new O
metastatic B-Sign_symptom
deposit I-Sign_symptom
in O
the O
left B-Biological_structure
ovary I-Biological_structure
( O
Supplementary O
Fig. O
5 O
) O
. O

Treatment O
was O
switched O
to O
a O
combination O
of O
lapatinib B-Medication
and O
capecitabine B-Medication
, O
resulting O
in O
stable B-Sign_symptom
disease I-Sign_symptom
for O
12 B-Duration
months I-Duration
( O
Supplementary O
Fig. O
6 O
) O
. O

General B-Sign_symptom
deterioration I-Sign_symptom
then O
occurred O
, O
with O
disease B-Sign_symptom
progression I-Sign_symptom
in O
the O
chest B-Biological_structure
( O
new O
pulmonary B-Biological_structure
nodules B-Sign_symptom
, O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusions I-Disease_disorder
and O
posterior B-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
mass B-Sign_symptom
, O
Supplementary O
Fig. O
7 O
; O
Eastern B-Diagnostic_procedure
Cooperative I-Diagnostic_procedure
Oncology I-Diagnostic_procedure
Group I-Diagnostic_procedure
performance I-Diagnostic_procedure
status I-Diagnostic_procedure
2 B-Lab_value
– I-Lab_value
3 I-Lab_value
) O
. O

Treatment B-Therapeutic_procedure
was O
stopped O
and O
the O
patient O
died B-Outcome
∼ O
4 B-Date
months I-Date
later I-Date
. O

Tumour B-Sign_symptom
samples O
were O
obtained O
at O
diagnosis B-Clinical_event
from O
the O
primary O
breast B-Biological_structure
site O
( O
P1 O
.1 O
) O
and O
an O
axillary B-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
( O
P1 O
.2 O
) O
; O
after B-Date
19 I-Date
months I-Date
from O
the O
brain B-Biological_structure
metastasis B-Disease_disorder
area O
( O
M2 O
.1 O
) O
; O
and O
at O
autopsy B-Diagnostic_procedure
after B-Date
3 I-Date
years I-Date
on O
treatment B-Therapeutic_procedure
( O
from O
the O
primary O
breast O
site O
, O
and O
from O
metastatic O
deposits O
in O
the O
chest O
, O
liver O
, O
ovary O
and O
vertebrae O
, O
labelled O
P3 O
.1 O
and O
M3 O
.1 O
– O
M3 O
.4 O
, O
respectively O
) O
. O

Serial B-Detailed_description
plasma B-Diagnostic_procedure
samples O
were O
obtained O
over O
the O
last B-Duration
500 I-Duration
days I-Duration
of O
clinical O
follow-up B-Clinical_event
( O
T1 O
– O
T9 O
) O
. O

Tumour O
and O
plasma O
samples O
collected O
and O
the O
clinical O
course O
are O
summarized O
in O
Fig. O
1a O
, O
b. O

We O
present O
the O
case O
of O
a O
22-year-old B-Age
woman B-Sex
who O
was O
diagnosed B-History
in I-History
childhood I-History
with I-History
type I-History
IIb I-History
VHL I-History
, O
with O
known O
multiple B-History
retinal I-History
angiomas I-History
, O
pancreatic B-History
cysts I-History
, O
and O
spinal B-History
and I-History
cerebellar I-History
hemangioblastomas I-History
. O

She O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
complaining O
of O
progressive B-Detailed_description
dyspnea B-Sign_symptom
and O
palpitations B-Sign_symptom
. O

On O
examination B-Diagnostic_procedure
, O
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
159/119 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
her O
pulse B-Diagnostic_procedure
was O
123 B-Lab_value
bpm I-Lab_value
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
systolic B-Detailed_description
murmur B-Sign_symptom
at O
the O
mitral B-Biological_structure
focus I-Biological_structure
with O
irradiation B-Biological_structure
to I-Biological_structure
the I-Biological_structure
axilla I-Biological_structure
and O
pulmonary B-Sign_symptom
rales I-Sign_symptom
. O

Electrocardiography B-Diagnostic_procedure
revealed O
no B-Lab_value
remarkable I-Lab_value
findings I-Lab_value
, O
except O
for O
sinus B-Detailed_description
tachycardia B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
an O
elevated B-Lab_value
N-terminal B-Detailed_description
pro-brain B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
and O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
signs O
of O
pulmonary B-Sign_symptom
interstitial I-Sign_symptom
edema I-Sign_symptom
. O

The O
patient O
was O
admitted B-Clinical_event
to O
the O
Department B-Biological_structure
of I-Biological_structure
Cardiology I-Biological_structure
with O
the O
diagnosis O
of O
acute B-Detailed_description
decompensated B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
. O

Transthoracic B-Detailed_description
echocardiography B-Diagnostic_procedure
showed O
a O
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
with O
severely B-Lab_value
depressed I-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
due O
to O
generalized B-Detailed_description
hypokinesia B-Sign_symptom
and O
a O
mild B-Severity
mitral B-Sign_symptom
regurgitation I-Sign_symptom
( O
fig. O
1a O
) O
. O

During O
admission O
, O
the O
patient O
had O
several B-Detailed_description
episodes I-Detailed_description
of O
paroxysmal B-Detailed_description
dyspnea B-Sign_symptom
despite O
treatment O
with O
β-blockers B-Medication
and O
diuretics B-Medication
. O

Due O
to O
the O
clinical O
suspicion O
of O
adrenal B-Disease_disorder
gland I-Disease_disorder
disease I-Disease_disorder
, O
24-hour B-Detailed_description
urinary B-Biological_structure
catecholamine B-Diagnostic_procedure
and O
metanephrine B-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
requested O
. O

Cardiac B-Biological_structure
MRI B-Diagnostic_procedure
was O
performed O
in O
order O
to O
complete O
the O
cardiomyopathy B-Diagnostic_procedure
study I-Diagnostic_procedure
, O
and O
confirmed O
the O
echocardiographic O
findings O
as O
well O
as O
revealed O
an O
incidental O
finding O
of O
a O
great B-Detailed_description
left B-Biological_structure
renal I-Biological_structure
mass B-Sign_symptom
. O

The O
24-hour O
urine O
laboratory B-Coreference
tests I-Coreference
showed O
markedly B-Lab_value
elevated I-Lab_value
levels O
of O
norepinephrine B-Diagnostic_procedure
, O
total B-Diagnostic_procedure
catecholamines I-Diagnostic_procedure
, O
normetanephrine B-Diagnostic_procedure
and O
metanephrine B-Diagnostic_procedure
with O
normal O
epinephrine B-Diagnostic_procedure
values O
: O
24-hour O
norepinephrine B-Coreference
468 B-Lab_value
μg I-Lab_value
( O
normal O
range O
: O
23-105 O
) O
, O
24-hour O
epinephrine B-Coreference
13 B-Lab_value
μg I-Lab_value
( O
normal O
range O
: O
4-20 O
) O
, O
24-hour O
total B-Coreference
catecholamines I-Coreference
658 B-Lab_value
μg I-Lab_value
( O
normal O
range O
: O
217-575 O
) O
, O
24-hour O
normetanephrine B-Coreference
2,988 B-Lab_value
μg I-Lab_value
( O
normal O
range O
: O
105-354 O
) O
, O
24-hour O
total B-Coreference
metanephrine I-Coreference
3,013 B-Lab_value
μg I-Lab_value
( O
normal O
range O
: O
0-1,000 O
) O
. O

Therefore O
, O
an O
abdominal B-Biological_structure
MRI B-Diagnostic_procedure
was O
performed O
, O
which O
showed O
the O
presence O
of O
two B-Detailed_description
cystic B-Detailed_description
masses B-Sign_symptom
( O
fig. O
2 O
) O
located O
at O
the O
left B-Biological_structure
hypochondrium I-Biological_structure
. O

Surgical B-Detailed_description
resection B-Therapeutic_procedure
of O
both B-Coreference
masses I-Coreference
was O
performed O
( O
after O
α-blockade B-Therapeutic_procedure
with O
phenoxybenzamine B-Medication
and O
β-blockade B-Therapeutic_procedure
with O
propranolol B-Medication
) O
through O
a O
laparoscopic B-Therapeutic_procedure
approach I-Therapeutic_procedure
, O
confirming O
the O
diagnosis O
of O
pheochromocytoma B-Disease_disorder
and O
clear B-Detailed_description
cell I-Detailed_description
renal B-Therapeutic_procedure
carcinoma I-Therapeutic_procedure
on O
histology B-Diagnostic_procedure
. O

During O
follow-up B-Clinical_event
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
and O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
values O
normalized B-Lab_value
( O
124/77 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
78 B-Lab_value
bpm I-Lab_value
) O
, O
24-hour B-Detailed_description
urinary B-Biological_structure
catecholamine B-Diagnostic_procedure
values O
returned O
to O
normal B-Lab_value
range I-Lab_value
( O
norepinephrine B-Diagnostic_procedure
69 B-Lab_value
μg/24 I-Lab_value
h O
, O
total B-Diagnostic_procedure
catecholamine I-Diagnostic_procedure
221 B-Lab_value
μg/24 I-Lab_value
h O
, O
normetanephrine B-Diagnostic_procedure
202 B-Lab_value
μg/24 I-Lab_value
h O
and O
total B-Diagnostic_procedure
metanephrine I-Diagnostic_procedure
259 B-Lab_value
μg/24 I-Lab_value
h O
) O
and O
the O
patient O
had O
no O
new O
episodes O
of O
palpitations B-Sign_symptom
or O
dyspnea B-Sign_symptom
. O

Six B-Date
months I-Date
after I-Date
surgical O
resection O
, O
echocardiography B-Diagnostic_procedure
was O
repeated O
and O
showed O
a O
left B-Biological_structure
ventricle I-Biological_structure
with O
normal B-Sign_symptom
diameters I-Sign_symptom
and O
preserved B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
fig. O
1b O
) O
. O

Genetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
a O
germline B-Sign_symptom
mutation I-Sign_symptom
( O
exon B-Detailed_description
3 I-Detailed_description
deletion I-Detailed_description
) O
of O
the O
VHL B-Detailed_description
tumor I-Detailed_description
suppressor I-Detailed_description
gene I-Detailed_description
on O
the O
short B-Detailed_description
arm I-Detailed_description
of I-Detailed_description
chromosome I-Detailed_description
3 I-Detailed_description
. O

As O
the O
patient O
had O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
VHL I-Family_history
, O
it O
was O
concluded O
that O
it O
was O
a O
de B-Detailed_description
novo I-Detailed_description
mutation I-Detailed_description
. O

A O
13 B-Age
year-old I-Age
boy B-Sex
presented B-Clinical_event
with O
a O
1 B-Duration
month I-Duration
history O
of O
intermittent B-Biological_structure
episodes O
of O
small B-Detailed_description
volume I-Detailed_description
epistaxis B-Sign_symptom
. O

There O
was O
no B-History
significant I-History
past I-History
medical I-History
, I-History
surgical I-History
or I-History
family I-History
history I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
left B-Biological_structure
palatal I-Biological_structure
fleshy B-Detailed_description
mass B-Sign_symptom
centered O
at O
left B-Biological_structure
posterior I-Biological_structure
molars I-Biological_structure
. O

A O
nasoendoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
a O
large B-Severity
swelling B-Sign_symptom
on O
the O
floor B-Biological_structure
of I-Biological_structure
left I-Biological_structure
anterior I-Biological_structure
nasal I-Biological_structure
space I-Biological_structure
, O
involving O
the O
left B-Biological_structure
inferior I-Biological_structure
meatus I-Biological_structure
and O
abutting O
the O
inferior B-Biological_structure
turbinate I-Biological_structure
. O

Computed B-Diagnostic_procedure
Tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
paranasal B-Biological_structure
sinuses I-Biological_structure
showed O
a O
lobulated B-Detailed_description
, O
expansile B-Detailed_description
lytic B-Detailed_description
lesion B-Sign_symptom
of O
left B-Biological_structure
maxilla I-Biological_structure
[ O
Fig O
1 O
] O
with O
a O
lucent B-Detailed_description
center I-Detailed_description
and O
peripheral B-Detailed_description
calcifications I-Detailed_description
. O

The O
lesion B-Coreference
was O
associated O
with O
a O
large B-Detailed_description
soft I-Detailed_description
tissue I-Detailed_description
component I-Detailed_description
that O
demonstrated O
mild B-Severity
heterogeneous B-Detailed_description
contrast B-Sign_symptom
enhancement I-Sign_symptom
. O

The O
lesion B-Coreference
was O
centered O
at O
the O
left B-Biological_structure
maxillary I-Biological_structure
alveolus I-Biological_structure
, O
involving O
the O
left B-Biological_structure
hard I-Biological_structure
palate I-Biological_structure
, O
inferior B-Biological_structure
part I-Biological_structure
of I-Biological_structure
the I-Biological_structure
anterior I-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
wall I-Biological_structure
and O
medial B-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
wall I-Biological_structure
. O

The O
lesion B-Coreference
also O
involved O
the O
roots B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
molars I-Biological_structure
and I-Biological_structure
pre-molars I-Biological_structure
and O
was O
abutting O
the O
left B-Biological_structure
orbital I-Biological_structure
floor I-Biological_structure
, O
with O
no O
gross O
orbital B-Biological_structure
invasion B-Sign_symptom
. O

The O
patient O
subsequently O
underwent O
18-FDG B-Diagnostic_procedure
PET-CT I-Diagnostic_procedure
study I-Diagnostic_procedure
. O

The O
mass B-Coreference
centered O
in O
left B-Biological_structure
maxilla I-Biological_structure
was O
hypermetabolic B-Detailed_description
, O
with O
index B-Lab_value
SUVmax I-Lab_value
9.7 I-Lab_value
[ O
Fig O
2 O
] O
. O

There O
was O
no O
FDG-avid B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
. O

A O
trans-oral B-Detailed_description
incisional B-Diagnostic_procedure
biopsy I-Diagnostic_procedure
of O
the O
left B-Biological_structure
palatal I-Biological_structure
mass B-Sign_symptom
was O
performed O
and O
was O
suggestive O
of O
a O
preliminary O
diagnosis O
of O
mesenchymal B-Disease_disorder
chondrosarcoma I-Disease_disorder
, O
as O
evidenced O
by O
a O
biphasic B-Detailed_description
pattern I-Detailed_description
featuring O
sheets B-Detailed_description
of I-Detailed_description
small I-Detailed_description
round I-Detailed_description
cells I-Detailed_description
with O
hemangiopericytoma-like B-Detailed_description
vascular I-Detailed_description
pattern I-Detailed_description
and O
mature B-Detailed_description
cartilaginous I-Detailed_description
islands I-Detailed_description
. O

The O
patient O
underwent O
left B-Detailed_description
subtotal I-Detailed_description
maxillectomy B-Therapeutic_procedure
via O
lateral B-Detailed_description
rhinotomy B-Therapeutic_procedure
and O
translabial B-Detailed_description
approach I-Detailed_description
. O

The O
final O
histology B-Diagnostic_procedure
was O
conclusive O
of O
a O
5 B-Distance
cm I-Distance
high-grade B-Lab_value
( O
Grade B-Lab_value
3 I-Lab_value
) O
mesenchymal B-Disease_disorder
chondrosarcoma I-Disease_disorder
. O

One O
of O
the O
resection B-Biological_structure
margins I-Biological_structure
was O
positive O
for O
tumor B-Sign_symptom
involvement I-Sign_symptom
and O
the O
patient O
was O
planned O
for O
adjuvant B-Detailed_description
chemotherapy B-Medication
. O

This O
case O
report O
was O
approved O
by O
the O
Review O
Board O
of O
Shandong O
Power O
Central O
Hospital O
and O
the O
patient O
's O
parents O
signed O
informed O
consent O
for O
publication O
of O
the O
case O
report O
and O
any O
accompanying O
images O
. O

A O
4-year-old B-Age
female B-Sex
child O
presented B-Clinical_event
at O
the O
outpatients B-Nonbiological_location
department I-Nonbiological_location
with O
slowly B-Detailed_description
enlarging I-Detailed_description
, O
painless B-Detailed_description
, O
symmetrical B-Detailed_description
swelling B-Sign_symptom
of O
both B-Biological_structure
cheeks I-Biological_structure
. O

When B-History
the I-History
girl I-History
was I-History
approximately I-History
2 I-History
years I-History
old I-History
, I-History
the I-History
parents I-History
noticed I-History
a I-History
change I-History
in I-History
her I-History
facial I-History
symmetry I-History
, I-History
which I-History
later I-History
became I-History
more I-History
obvious I-History
. O

On O
palpation B-Diagnostic_procedure
, O
the O
swellings B-Sign_symptom
were O
bony B-Detailed_description
and O
hard B-Detailed_description
in O
consistency O
. O

The O
skin B-Biological_structure
over O
the O
swelling B-Sign_symptom
was O
smooth B-Texture
and O
freely B-Detailed_description
movable I-Detailed_description
, O
with O
no B-Lab_value
increase I-Lab_value
in O
temperature B-Diagnostic_procedure
( O
Fig. O
1 O
) O
. O

There O
was O
no B-History
history I-History
of I-History
any I-History
trauma I-History
, I-History
pain I-History
, I-History
pus I-History
discharge I-History
, I-History
blood I-History
discharge I-History
, I-History
fever I-History
, I-History
paresthesia I-History
, I-History
anorexia I-History
, I-History
or I-History
weight I-History
loss I-History
. O

No B-History
significant I-History
family I-History
history I-History
was I-History
reported I-History
. O

Panoramic B-Detailed_description
radiography B-Diagnostic_procedure
revealed O
involvement B-Sign_symptom
of O
both O
the O
mandible B-Biological_structure
and O
the O
maxilla B-Biological_structure
, O
and O
showed O
a O
soap B-Shape
bubble-like I-Shape
multilocular B-Detailed_description
radiolucency B-Sign_symptom
with O
thin B-Detailed_description
and I-Detailed_description
expanded I-Detailed_description
cortices I-Detailed_description
. O

Unerupted B-Sign_symptom
teeth I-Sign_symptom
included O
: O
15 B-Biological_structure
, I-Biological_structure
25 I-Biological_structure
, I-Biological_structure
35 I-Biological_structure
, I-Biological_structure
37 I-Biological_structure
, I-Biological_structure
45 I-Biological_structure
, O
and O
47 B-Biological_structure
was O
impacted B-Sign_symptom
( O
Fig. O
2 O
) O
. O

Multislice B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
showed O
the O
presence O
of O
multilocular B-Detailed_description
cystic B-Detailed_description
lesions B-Sign_symptom
filled O
with O
soft-tissue B-Detailed_description
density I-Detailed_description
material I-Detailed_description
and O
dental B-Biological_structure
anomalies B-Sign_symptom
affecting O
the O
body B-Biological_structure
and I-Biological_structure
the I-Biological_structure
sides I-Biological_structure
of I-Biological_structure
the I-Biological_structure
mandible I-Biological_structure
. O

Similar O
lesions B-Sign_symptom
were O
also O
observed O
in O
the O
maxilla B-Biological_structure
( O
Fig. O
3 O
) O
. O

A O
biopsy B-Diagnostic_procedure
was O
obtained O
from O
the O
central B-Biological_structure
area I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
rami I-Biological_structure
. O

Histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
many B-Detailed_description
large B-Detailed_description
multinucleated B-Detailed_description
giant B-Sign_symptom
cells I-Sign_symptom
in O
a O
loose B-Detailed_description
, O
delicate B-Detailed_description
fibrillar B-Detailed_description
connective B-Biological_structure
tissue I-Biological_structure
stroma I-Biological_structure
containing O
large B-Biological_structure
numbers I-Biological_structure
of I-Biological_structure
fibroblasts I-Biological_structure
and O
many B-Biological_structure
small I-Biological_structure
blood I-Biological_structure
vessels I-Biological_structure
( O
Fig. O
4 O
) O
. O

As O
the O
child O
grows O
older O
, O
the O
lesions O
often O
become O
static O
and O
may O
show O
regression O
at O
puberty O
. O

In O
the O
current O
case O
, O
no O
surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
under O
taken O
and O
the O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
at O
regular B-Detailed_description
intervals I-Detailed_description
. O

A B-Age
49-year-old I-Age
man B-Sex
, O
with O
no B-History
history I-History
of I-History
cardiac I-History
disease I-History
, O
presented B-Clinical_event
with O
progressive B-Detailed_description
dyspnea B-Sign_symptom
of O
one B-Duration
month I-Duration
's I-Duration
duration I-Duration
. O

Medical O
History O
. O

His O
medical O
history O
included O
blunt B-History
chest I-History
trauma I-History
, I-History
the I-History
result I-History
of I-History
an I-History
accidental I-History
fall I-History
from I-History
scaffolding I-History
15 I-History
months I-History
earlier I-History
. O

He B-History
had I-History
fallen I-History
approximately I-History
8 I-History
feet I-History
and I-History
had I-History
landed I-History
on I-History
the I-History
right I-History
side I-History
of I-History
his I-History
back I-History
and I-History
on I-History
his I-History
right I-History
shoulder I-History
. O

The O
patient O
had O
sustained O
bilateral B-Detailed_description
pneumothorax B-Sign_symptom
, O
right B-Biological_structure
iliopsoas I-Biological_structure
muscle I-Biological_structure
hematoma B-Sign_symptom
, O
multiple B-Detailed_description
right B-Biological_structure
costal I-Biological_structure
fractures B-Sign_symptom
, O
fracture B-Sign_symptom
of O
the O
L3 B-Biological_structure
vertebral I-Biological_structure
body I-Biological_structure
and O
the O
transverse B-Biological_structure
process I-Biological_structure
, O
and O
displaced B-Detailed_description
fractures B-Sign_symptom
of O
the O
right B-Biological_structure
clavicle I-Biological_structure
. O

That O
hospitalization B-Clinical_event
had O
lasted O
40 B-Duration
days I-Duration
, O
during O
which O
time O
the O
clinicians O
had O
not O
detected O
any O
murmur B-Sign_symptom
or O
requested O
a O
cardiac B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
. O

The O
patient O
returned O
to O
normal B-Activity
activities I-Activity
4 B-Date
weeks I-Date
after I-Date
discharge B-Clinical_event
from O
the O
hospital B-Nonbiological_location
and O
remained O
asymptomatic B-Sign_symptom
for O
one B-Duration
year I-Duration
. O

Upon O
his O
arrival B-Clinical_event
at O
our O
department B-Nonbiological_location
, O
auscultation B-Diagnostic_procedure
revealed O
bibasilar B-Detailed_description
rales B-Sign_symptom
and O
a O
pansystolic B-Detailed_description
murmur B-Sign_symptom
. O

Chest B-Biological_structure
radiography B-Diagnostic_procedure
showed O
mild B-Severity
lung B-Biological_structure
congestion B-Sign_symptom
; O
and O
transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
, O
limited B-Detailed_description
by I-Detailed_description
suboptimal I-Detailed_description
acoustic I-Detailed_description
windows I-Detailed_description
, O
revealed O
severe B-Severity
, O
eccentric B-Detailed_description
mitral B-Sign_symptom
regurgitation I-Sign_symptom
. O

The O
valvular B-Biological_structure
and O
subvalvular B-Biological_structure
apparatus I-Biological_structure
appeared O
to O
be O
structurally B-Sign_symptom
normal I-Sign_symptom
, O
and O
the O
left B-Biological_structure
atrium I-Biological_structure
was O
only O
mildly B-Severity
dilated B-Sign_symptom
. O

The O
patient O
was O
treated O
with O
intravenous B-Administration
diuretics B-Medication
until O
the O
signs B-Sign_symptom
and I-Sign_symptom
symptoms I-Sign_symptom
of I-Sign_symptom
congestion I-Sign_symptom
were O
relieved O
. O

Coronary B-Biological_structure
angiography B-Diagnostic_procedure
revealed O
an O
absence O
of O
substantial O
coronary B-Disease_disorder
disease I-Disease_disorder
. O

We O
therefore O
planned B-Clinical_event
an O
elective O
surgical O
procedure O
for O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
repair I-Therapeutic_procedure
. O

Surgical O
Procedure O
. O

During O
intraoperative B-Detailed_description
transesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
, O
we O
observed O
both O
a O
trivial B-Severity
central B-Detailed_description
mitral B-Sign_symptom
regurgitant I-Sign_symptom
jet I-Sign_symptom
and O
a O
severe B-Severity
perivalvular B-Sign_symptom
regurgitant I-Sign_symptom
jet I-Sign_symptom
, O
this O
last O
originating O
from O
a O
ventriculoatrial B-Biological_structure
fistulous B-Sign_symptom
communication I-Sign_symptom
behind B-Biological_structure
the I-Biological_structure
P1 I-Biological_structure
scallop I-Biological_structure
( O
Fig. O
1 O
) O
. O

Further O
examination O
confirmed O
the O
absence O
of O
structural B-Disease_disorder
disease I-Disease_disorder
involving O
the O
mitral B-Biological_structure
leaflets I-Biological_structure
or O
subvalvular B-Biological_structure
apparatus I-Biological_structure
. O

After O
surgical B-Therapeutic_procedure
exposure I-Therapeutic_procedure
of O
the O
mitral B-Biological_structure
valve I-Biological_structure
, O
a O
small B-Lab_value
tear B-Sign_symptom
( O
length B-Distance
, I-Distance
6 I-Distance
– I-Distance
7 I-Distance
mm I-Distance
) O
could O
be O
seen O
behind B-Biological_structure
the I-Biological_structure
posterior I-Biological_structure
leaflet I-Biological_structure
, O
in O
a O
lateral B-Detailed_description
position I-Detailed_description
, O
involving O
also O
the O
annulus B-Biological_structure
and O
the O
left B-Biological_structure
atrial I-Biological_structure
wall I-Biological_structure
. O

The O
absence O
of O
leaflet B-Biological_structure
abnormalities B-Sign_symptom
or O
vegetations B-Sign_symptom
suggested O
the O
posttraumatic B-Detailed_description
origin I-Detailed_description
of O
the O
perivalvular B-Sign_symptom
leak I-Sign_symptom
. O

Valvular B-Therapeutic_procedure
repair I-Therapeutic_procedure
was O
successfully O
achieved O
by O
direct O
suture B-Therapeutic_procedure
of O
the O
tear O
with O
three B-Detailed_description
5-0 B-Detailed_description
Prolene I-Detailed_description
stitches B-Therapeutic_procedure
and O
by O
the O
subsequent O
insertion O
of O
a O
30-mm B-Distance
mitral B-Therapeutic_procedure
annuloplasty I-Therapeutic_procedure
ring I-Therapeutic_procedure
. O

The O
patient O
was O
extubated B-Therapeutic_procedure
the O
next O
day O
and O
his O
postsurgical B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
uncomplicated B-Lab_value
. O

One B-Date
year I-Date
later I-Date
, O
he O
was O
asymptomatic B-Sign_symptom
, O
and O
his O
one-year O
follow-up B-Clinical_event
transthoracic B-Biological_structure
echocardiogram B-Diagnostic_procedure
confirmed B-Lab_value
the I-Lab_value
excellent I-Lab_value
result I-Lab_value
of O
his O
surgical O
treatment O
. O

Our O
patient O
was O
a O
50-year B-Age
old I-Age
man B-Sex
with O
bicuspid B-Detailed_description
aortic B-Sign_symptom
valve I-Sign_symptom
insufficiency I-Sign_symptom
and O
ascending B-Detailed_description
aorta B-Sign_symptom
dilatation I-Sign_symptom
. O

He O
had O
undergone O
a O
free-hand B-Detailed_description
aortic B-Biological_structure
homograft B-Therapeutic_procedure
implantation I-Therapeutic_procedure
with O
replacement B-Therapeutic_procedure
of O
the O
non-coronary B-Biological_structure
sinus I-Biological_structure
using O
a O
24-mm B-Detailed_description
homograft I-Detailed_description
in O
2006 B-Date
( O
at O
the O
age O
of O
41 O
) O
. O

Follow-up B-Clinical_event
evaluations O
were O
performed O
every B-Frequency
6 I-Frequency
months I-Frequency
and O
showed O
mild B-Severity
aortic B-Sign_symptom
valve I-Sign_symptom
insufficiency I-Sign_symptom
. O

After O
8 B-Duration
years I-Duration
of O
follow-up B-Clinical_event
, O
the O
patient O
presented B-Clinical_event
to O
hospital B-Nonbiological_location
with O
fever B-Sign_symptom
and O
the O
echocardiography B-Diagnostic_procedure
showed O
severe B-Severity
aortic B-Sign_symptom
insufficiency I-Sign_symptom
due O
to O
a O
rupture B-Sign_symptom
of O
one B-Biological_structure
of I-Biological_structure
the I-Biological_structure
cusps I-Biological_structure
of I-Biological_structure
the I-Biological_structure
homograft I-Biological_structure
, O
worsening B-Lab_value
of O
cardiac B-Diagnostic_procedure
contractility I-Diagnostic_procedure
with O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
LVEF B-Diagnostic_procedure
) O
depression B-Lab_value
( O
40 B-Lab_value
– I-Lab_value
45 I-Lab_value
% I-Lab_value
) O
and O
dilatation B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
left I-Sign_symptom
ventricle I-Sign_symptom
( O
telediastolic/telesystolic B-Lab_value
diameters I-Lab_value
60/42 I-Lab_value
mm I-Lab_value
, O
respectively O
) O
. O

The O
patient O
presented O
orthopnoea B-Sign_symptom
and O
hypotension B-Sign_symptom
, O
which O
needed O
infusion B-Administration
of O
dopamine B-Medication
and O
diuretics B-Medication
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
showed O
calcifications B-Sign_symptom
on O
the O
homograft B-Biological_structure
, O
pleural B-Sign_symptom
effusions I-Sign_symptom
and O
no O
signs O
of O
pericardial B-Sign_symptom
effusion I-Sign_symptom
( O
Fig. O
1 O
) O
. O

Since O
the O
Dukes B-Diagnostic_procedure
criteria I-Diagnostic_procedure
for I-Diagnostic_procedure
endocarditis I-Diagnostic_procedure
were O
not B-Lab_value
satisfied I-Lab_value
, O
the O
final O
diagnosis O
was O
an O
early O
structural B-Disease_disorder
deterioration I-Disease_disorder
of O
the O
homograft B-Biological_structure
, O
due O
to O
a O
severe B-Severity
calcification B-Sign_symptom
process O
. O

The O
operation B-Therapeutic_procedure
was O
performed O
through O
median B-Detailed_description
resternotomy B-Therapeutic_procedure
and O
with O
standard B-Detailed_description
aorta-right B-Biological_structure
atrium I-Biological_structure
central B-Therapeutic_procedure
cannulation I-Therapeutic_procedure
for O
the O
extracorporeal O
circulation O
. O

The O
leaflets B-Biological_structure
and O
the O
annulus B-Biological_structure
of O
the O
homograft B-Biological_structure
presented O
severe B-Severity
calcifications B-Sign_symptom
and O
no O
signs O
of O
endocarditis B-Disease_disorder
were O
found O
. O

An O
Edwards B-Detailed_description
Intuity I-Detailed_description
bioprosthesis B-Therapeutic_procedure
( O
21 O
mm O
) O
was O
then O
implanted B-Therapeutic_procedure
( O
Fig. O
2 O
) O
. O

The O
cross-clamping B-Therapeutic_procedure
time O
was O
41 B-Duration
min I-Duration
, O
and O
the O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
time O
was O
64 B-Duration
min I-Duration
. O

The O
patient O
required O
dopamine B-Medication
and O
adrenaline B-Medication
at O
low B-Dosage
doses I-Dosage
for O
bypass O
weaning O
. O

No O
complications B-Sign_symptom
occurred O
during O
the O
postoperative B-Therapeutic_procedure
period I-Therapeutic_procedure
. O

Echocardiography B-Diagnostic_procedure
before O
the O
discharge B-Clinical_event
showed O
the O
absence O
of O
paravalvular B-Sign_symptom
leaks I-Sign_symptom
, O
a O
peak/mean B-Diagnostic_procedure
aortic I-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
34/20 B-Lab_value
mmHg I-Lab_value
and O
an O
LVEF B-Diagnostic_procedure
of O
33 B-Lab_value
% I-Lab_value
. O

Follow-up O
echocardiography B-Diagnostic_procedure
after B-Date
3 I-Date
months I-Date
from O
the O
operation O
showed O
neither O
leaks B-Sign_symptom
nor O
malfunctions B-Sign_symptom
of O
the O
Edwards B-Detailed_description
Intuity I-Detailed_description
prosthesis B-Biological_structure
, O
a O
peak/mean B-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
38/22 B-Lab_value
mmHg I-Lab_value
and O
initial B-Lab_value
recovery I-Lab_value
of O
the O
LVEF B-Diagnostic_procedure
( O
valued O
47 B-Lab_value
% I-Lab_value
) O
. O

Patient O
was O
asymptomatic B-Sign_symptom
again O
. O

A O
69-year-old B-Age
woman B-Sex
with O
a O
history O
of O
hypertension B-History
presented B-Clinical_event
with O
a O
generalized B-Detailed_description
petechial B-Detailed_description
rash B-Sign_symptom
and O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
of O
3 B-Duration
days I-Duration
duration I-Duration
. O

The O
rash B-Coreference
was O
nonpruritic B-Detailed_description
, O
painless B-Detailed_description
, O
and O
started O
at O
the O
thighs B-Biological_structure
, O
but O
rapidly O
disseminated O
to O
the O
rest B-Biological_structure
of I-Biological_structure
the I-Biological_structure
body I-Biological_structure
. O

She O
had O
progressive B-Detailed_description
dyspnea B-Sign_symptom
on O
exertion B-Detailed_description
, O
with O
a O
significant O
decrease B-Lab_value
in O
exercise B-Diagnostic_procedure
tolerance I-Diagnostic_procedure
. O

She O
denied O
fever B-Sign_symptom
, O
headache B-Sign_symptom
, O
dizziness B-Sign_symptom
, O
hemoptysis B-Sign_symptom
, O
or O
bleeding B-Sign_symptom
from O
anywhere B-Biological_structure
. O

There O
was O
no B-History
history I-History
of I-History
new I-History
drug I-History
use I-History
, I-History
unusual I-History
food I-History
intake I-History
, I-History
contact I-History
with I-History
any I-History
sick I-History
persons I-History
, I-History
or I-History
recent I-History
travel I-History
. O

Her O
only O
medication O
was O
enalapril B-Medication
, O
which O
she O
had O
been O
taking O
for O
several B-Duration
years I-Duration
. O

The O
patient O
denied B-History
any I-History
use I-History
of I-History
recreational I-History
drugs I-History
, I-History
tobacco I-History
, I-History
or I-History
alcohol I-History
. O

On O
admission O
, O
she O
was O
afebrile B-Sign_symptom
, O
normotensive B-Sign_symptom
with O
mild B-Severity
tachypnea B-Sign_symptom
( O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
22 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute I-Lab_value
) O
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
scattered O
petechial B-Detailed_description
rash B-Sign_symptom
, O
more O
prominent O
in O
lower B-Biological_structure
extremities I-Biological_structure
, O
nonpalpable B-Detailed_description
and O
nonblanching B-Detailed_description
. O

Chest B-Diagnostic_procedure
auscultation I-Diagnostic_procedure
revealed O
coarse B-Detailed_description
crackles B-Sign_symptom
bilaterally B-Detailed_description
. O

Cardiovascular B-Biological_structure
, O
abdominal B-Biological_structure
, O
and O
neurological B-Detailed_description
examinations B-Diagnostic_procedure
were O
normal B-Lab_value
. O

There O
was O
no O
palpable O
lymphadenopathy B-Sign_symptom
or O
visceromegaly B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
thrombocytopenia B-Sign_symptom
( O
platelets B-Diagnostic_procedure
7000/μL B-Lab_value
) O
, O
anemia B-Sign_symptom
( O
hemoglobin B-Diagnostic_procedure
10.8 B-Lab_value
mg/dL I-Lab_value
and O
hematocrit B-Diagnostic_procedure
34 B-Lab_value
% I-Lab_value
) O
, O
and O
leukocytosis B-Sign_symptom
( O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cells I-Diagnostic_procedure
[ O
WBCs B-Diagnostic_procedure
] O
11,600 B-Lab_value
/ I-Lab_value
μL I-Lab_value
) O
. O

The O
coagulation B-Diagnostic_procedure
profile I-Diagnostic_procedure
was O
normal B-Lab_value
, O
which O
excluded O
disseminated B-Disease_disorder
intravascular I-Disease_disorder
coagulation I-Disease_disorder
. O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
on O
ambient B-Detailed_description
air I-Detailed_description
revealed O
a O
partial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of I-Diagnostic_procedure
oxygen I-Diagnostic_procedure
( O
PaO2 B-Diagnostic_procedure
) O
of O
64 B-Lab_value
Torr I-Lab_value
, O
a O
partial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of I-Diagnostic_procedure
carbon I-Diagnostic_procedure
dioxide I-Diagnostic_procedure
( O
PaCO2 B-Diagnostic_procedure
) O
of O
37 B-Lab_value
Torr I-Lab_value
( O
pH B-Diagnostic_procedure
7.45 B-Lab_value
) O
, O
and O
an O
increased B-Lab_value
alveolar-arterial B-Diagnostic_procedure
gradient I-Diagnostic_procedure
( O
44 B-Lab_value
Torr I-Lab_value
) O
. O

Diffuse B-Detailed_description
airspace B-Sign_symptom
consolidation I-Sign_symptom
was O
found O
on O
chest B-Biological_structure
roentgenogram B-Diagnostic_procedure
( O
Fig. O
1A O
) O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
chest B-Biological_structure
showed O
diffuse B-Detailed_description
ground B-Texture
glass I-Texture
alveolar B-Biological_structure
opacities B-Sign_symptom
and O
patchy B-Detailed_description
infiltrates B-Sign_symptom
( O
Fig. O
1B O
, O
C O
) O
. O

She O
was O
started O
on O
broad-spectrum B-Detailed_description
antibiotics B-Medication
and O
received O
intravenous B-Administration
steroids B-Medication
. O

Peripheral B-Diagnostic_procedure
smear I-Diagnostic_procedure
showed O
giant B-Sign_symptom
platelets I-Sign_symptom
and O
occasional B-Detailed_description
small B-Detailed_description
platelet B-Sign_symptom
clumps I-Sign_symptom
, O
with O
no O
schistocytes B-Sign_symptom
. O

A O
flexible B-Diagnostic_procedure
fiber-optic I-Diagnostic_procedure
bronchoscopy I-Diagnostic_procedure
( O
FFB B-Diagnostic_procedure
) O
showed O
normal B-Lab_value
mucosa B-Diagnostic_procedure
with O
no O
endobronchial B-Biological_structure
lesions B-Sign_symptom
( O
Fig. O
2A O
) O
. O

Serial O
aliquots O
of O
BAL B-Diagnostic_procedure
fluid I-Diagnostic_procedure
( O
BALF B-Diagnostic_procedure
) O
turned O
more O
hemorrhagic B-Sign_symptom
, O
confirming O
the O
bronchoscopic O
diagnosis O
of O
DAH B-Disease_disorder
( O
Fig. O
2B O
) O
. O

Cytology B-Diagnostic_procedure
of O
BALF B-Coreference
showed O
a O
substantial O
amount O
of O
hemosiderin-laden B-Detailed_description
macrophages B-Sign_symptom
, O
further O
supporting O
the O
diagnosis O
. O

All O
BALF B-Coreference
cultures B-Diagnostic_procedure
and O
gram B-Diagnostic_procedure
stains I-Diagnostic_procedure
were O
negative B-Lab_value
. O

The O
patient O
remained O
with O
severe B-Severity
thrombocytopenia B-Sign_symptom
and O
hypoxia B-Sign_symptom
despite O
steroids B-Medication
and O
platelets B-Medication
transfusion I-Medication
. O

High B-Dosage
doses I-Dosage
of O
pulse O
steroids B-Medication
and O
intravenous B-Administration
immunoglobulins B-Medication
( O
IVIGs O
) O
were O
added O
with O
clinico-radiological B-Detailed_description
improvement B-Sign_symptom
. O

A O
bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
aspirate I-Diagnostic_procedure
was O
morphologically B-Lab_value
normal I-Lab_value
. O

Additional O
laboratory B-Diagnostic_procedure
studies I-Diagnostic_procedure
failed B-Lab_value
to I-Lab_value
reveal I-Lab_value
an I-Lab_value
etiology I-Lab_value
for O
secondary O
thrombocytopenia B-Sign_symptom
( O
Table O
1 O
) O
, O
supporting O
the O
diagnosis O
of O
ITP B-Disease_disorder
. O

Steroids B-Medication
were O
gradually O
tapered O
. O

Repeat O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
showed O
almost O
complete O
resolution O
of O
bilateral B-Detailed_description
infiltrates B-Sign_symptom
( O
Fig. O
3 O
) O
. O

Platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
returned O
to O
normal B-Lab_value
by O
week B-Date
10 I-Date
after O
admission O
without O
any O
additional B-Therapeutic_procedure
therapies I-Therapeutic_procedure
( O
Fig. O
4 O
) O
. O

A O
24-year-old B-Age
Azeri B-Personal_background
male B-Sex
presented B-Clinical_event
with O
a O
chief O
complaint O
of O
blurred B-Sign_symptom
vision I-Sign_symptom
in O
both B-Biological_structure
eyes I-Biological_structure
. O

He O
was O
diagnosed O
with O
achondroplasia B-History
in O
early O
childhood O
. O

He O
was O
born B-History
at I-History
term I-History
with I-History
normal I-History
birth I-History
weight I-History
. O

There O
was O
no B-History
history I-History
of I-History
hereditary I-History
ocular I-History
or I-History
systemic I-History
disease I-History
. O

This O
patient O
had O
characteristic B-Sign_symptom
features I-Sign_symptom
of I-Sign_symptom
achondroplasia I-Sign_symptom
( O
i.e. O
, O
short O
stature O
, O
lumbar O
lordosis O
, O
short O
proximal O
long O
bones O
, O
large O
hands O
, O
frontal O
bossing O
, O
and O
flat O
nasal O
bridge O
) O
[ O
Figure O
1 O
] O
. O

His O
height O
was O
108 B-Height
cm I-Height
. O

Best O
corrected B-Detailed_description
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
was O
20/70 B-Lab_value
in O
the O
right B-Biological_structure
eye I-Biological_structure
with O
− B-Lab_value
0.75 I-Lab_value
+ I-Lab_value
1.25 I-Lab_value
× I-Lab_value
60 I-Lab_value
° I-Lab_value
and O
20/70 B-Lab_value
in O
the O
left B-Biological_structure
eye I-Biological_structure
with O
OS B-Biological_structure
: O
+0.25 B-Lab_value
+ I-Lab_value
0.50 I-Lab_value
× I-Lab_value
130 I-Lab_value
° I-Lab_value
. O

Pupils B-Biological_structure
were O
equal B-Detailed_description
in I-Detailed_description
size I-Detailed_description
, O
round B-Detailed_description
and O
reactive B-Detailed_description
to I-Detailed_description
light I-Detailed_description
with O
no O
reverse B-Sign_symptom
afferent I-Sign_symptom
pupillary I-Sign_symptom
defect I-Sign_symptom
. O

Ocular B-Diagnostic_procedure
motility I-Diagnostic_procedure
was O
normal B-Lab_value
in O
both B-Biological_structure
eyes I-Biological_structure
and O
slit B-Diagnostic_procedure
lamp I-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O

The O
intraocular B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
12 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
by O
Goldmann B-Detailed_description
applanation I-Detailed_description
tonometry I-Detailed_description
. O

Central B-Diagnostic_procedure
corneal I-Diagnostic_procedure
thickness I-Diagnostic_procedure
values I-Diagnostic_procedure
of O
the O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
eyes I-Biological_structure
were O
, O
561 B-Lab_value
and I-Lab_value
557 I-Lab_value
μ I-Lab_value
, O
respectively O
. O

Dilated B-Diagnostic_procedure
fundus I-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
well-demarcated B-Detailed_description
circular B-Shape
macular B-Biological_structure
lesion B-Sign_symptom
in O
both B-Biological_structure
eyes I-Biological_structure
. O

In O
the O
right B-Biological_structure
eye I-Biological_structure
, O
this O
lesion B-Sign_symptom
was O
approximately O
2.5 B-Distance
disc I-Distance
diameters I-Distance
( I-Distance
DD I-Distance
) I-Distance
in I-Distance
width I-Distance
and O
2.7 B-Distance
DD I-Distance
in I-Distance
length I-Distance
. O

In O
the O
left B-Biological_structure
eye I-Biological_structure
, O
this O
lesion B-Sign_symptom
was O
approximately O
2.5 B-Distance
DD I-Distance
in I-Distance
width I-Distance
and O
2.8 B-Distance
DD I-Distance
in I-Distance
length I-Distance
. O

The O
border B-Detailed_description
of O
the O
lesions B-Sign_symptom
was O
pigmented B-Detailed_description
. O

Underlying O
choroidal B-Biological_structure
and O
overlying O
retinal B-Biological_structure
vasculature B-Biological_structure
appeared O
normal B-Lab_value
. O

In O
addition O
, O
a O
stalk B-Sign_symptom
of I-Sign_symptom
tissue I-Sign_symptom
emanated O
from B-Biological_structure
the I-Biological_structure
optic I-Biological_structure
disc I-Biological_structure
and O
coursed O
into B-Biological_structure
the I-Biological_structure
vitreous I-Biological_structure
[ O
Figure O
2 O
] O
. O

Fluorescein B-Detailed_description
angiography B-Diagnostic_procedure
of O
the O
posterior B-Biological_structure
segment I-Biological_structure
and O
optical B-Diagnostic_procedure
coherence I-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
optic B-Biological_structure
nerve I-Biological_structure
head I-Biological_structure
( O
Stratus O
; O
Carl O
Zeiss O
GmbH O
, O
Jena O
, O
Germany O
) O
were O
performed O
[ O
Figures O
[ O
Figures3 O
and O
4 O
] O
. O

Due O
to O
the O
background O
maculopathy O
, O
the O
patient O
could O
not O
appropriately O
fixate O
on O
the O
target O
during O
image O
acquisition O
resulting O
in O
slightly O
decentered O
fluorescein O
angiography O
images O
[ O
Figure O
3 O
] O
. O

A O
65-year-old B-Age
man B-Sex
was O
admitted B-Clinical_event
to O
the O
China-Japan B-Nonbiological_location
Friendship I-Nonbiological_location
hospital I-Nonbiological_location
with O
a O
chief O
complaint O
of O
progressive B-Detailed_description
dysphagia B-Sign_symptom
for O
3 B-Duration
mo I-Duration
. O

He O
also O
complained O
of O
a O
drastic B-Severity
weight B-Sign_symptom
loss I-Sign_symptom
of O
8 B-Lab_value
kg I-Lab_value
in O
the O
past B-Duration
2 I-Duration
mo I-Duration
. O

He O
denied B-History
a I-History
history I-History
of I-History
smoking I-History
, I-History
alcohol I-History
intake I-History
and I-History
substance I-History
abuse I-History
, O
but O
had O
a O
chronic B-Detailed_description
atrophic B-Detailed_description
gastritis B-History
for O
nearly B-Duration
10 I-Duration
years I-Duration
. O

Also O
, O
there O
was O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
genetic I-Family_history
defect I-Family_history
or I-Family_history
malignancy I-Family_history
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
no B-Lab_value
palpable I-Lab_value
findings I-Lab_value
. O

Admission O
blood B-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
a O
slight B-Lab_value
decrease I-Lab_value
in O
hemoglobin B-Diagnostic_procedure
( O
106 B-Lab_value
g/L I-Lab_value
) O
. O

Upper B-Biological_structure
gastrointestinal I-Biological_structure
( O
GI B-Biological_structure
) O
examination B-Diagnostic_procedure
using O
barium B-Detailed_description
contrasts I-Detailed_description
showed O
a O
large B-Severity
tumor B-Sign_symptom
blocking B-Sign_symptom
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
( O
Figure O
1 O
) O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
revealed O
a O
soft B-Texture
mass B-Sign_symptom
in O
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
with O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
in O
the O
lesser B-Biological_structure
curvature I-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
( O
Figure O
2 O
) O
. O

Endoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
black B-Color
spot B-Sign_symptom
in O
the O
lower B-Biological_structure
esophagus I-Biological_structure
and O
a O
bulky B-Detailed_description
black B-Color
mass B-Sign_symptom
blocking B-Sign_symptom
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
, O
as O
well O
as O
two B-Detailed_description
black B-Color
crater-like B-Shape
ulcers B-Sign_symptom
in O
the O
fundus B-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
( O
Figure O
3 O
) O
. O

Biopsy B-Diagnostic_procedure
specimens O
taken O
from O
the O
tumor B-Sign_symptom
were O
identified O
as O
poorly B-Detailed_description
differentiated I-Detailed_description
adenocarcinoma B-Disease_disorder
. O

Preoperative O
nutrition B-Diagnostic_procedure
status I-Diagnostic_procedure
of O
this O
case O
was O
scored O
2 B-Lab_value
based O
on O
the O
Nutrition B-Detailed_description
Risk I-Detailed_description
Screening I-Detailed_description
2002 I-Detailed_description
( O
NRS O
2002 O
) O
[ O
6 O
] O
. O

Because O
of O
the O
obstructive B-Coreference
symptom I-Coreference
caused O
by O
the O
tumor B-Coreference
, O
a O
debulking B-Therapeutic_procedure
surgery I-Therapeutic_procedure
of O
distal B-Detailed_description
esophagectomy B-Therapeutic_procedure
and O
proximal B-Detailed_description
gastrectomy B-Therapeutic_procedure
was O
performed O
. O

Esophagogastric B-Biological_structure
anastomosis B-Therapeutic_procedure
and O
reconstruction B-Therapeutic_procedure
was O
then O
completed O
with O
stapling B-Therapeutic_procedure
device I-Therapeutic_procedure
. O

Intraoperatively O
, O
the O
tumor B-Sign_symptom
was O
found O
located O
at O
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
and O
the O
tumor B-Coreference
infiltrated B-Sign_symptom
the O
whole B-Biological_structure
layer I-Biological_structure
with O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
at O
station B-Biological_structure
four I-Biological_structure
. O

No O
ascites B-Sign_symptom
or O
dissemination B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
tumor I-Sign_symptom
was O
observed O
in O
the O
peritoneal B-Biological_structure
cavity I-Biological_structure
. O

The O
tumor B-Sign_symptom
measured O
3 B-Area
cm I-Area
× I-Area
6 I-Area
cm I-Area
in O
size O
with O
black B-Color
pigmentation I-Color
( O
Figure O
4 O
) O
. O

There O
were O
several B-Detailed_description
pigmented B-Color
satellite B-Detailed_description
nodules B-Sign_symptom
beside O
the O
main B-Coreference
tumor I-Coreference
lesion I-Coreference
, O
the O
largest B-Coreference
one I-Coreference
being O
1 B-Area
cm I-Area
× I-Area
1 I-Area
cm I-Area
in O
diameter O
. O

Moreover O
, O
two O
ulceration B-Detailed_description
lesions B-Sign_symptom
were O
found O
at O
the O
fundus B-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
. O

Microscopically B-Diagnostic_procedure
, O
the O
excised O
tumor B-Biological_structure
tissue I-Biological_structure
was O
composed O
of O
non-organized B-Lab_value
and O
pleomorphic B-Lab_value
cells B-Diagnostic_procedure
exhibiting O
atypical B-Lab_value
nuclei B-Diagnostic_procedure
, O
and O
abundant B-Lab_value
melanin B-Diagnostic_procedure
granules I-Diagnostic_procedure
( O
Figure O
5 O
) O
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
identified O
this O
case O
at O
a O
stage B-Diagnostic_procedure
of O
IVA B-Lab_value
( O
T4aN1M0 B-Lab_value
) O
. O

Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
showed O
that O
the O
tumor B-Coreference
was O
positive B-Lab_value
for O
S-100 B-Diagnostic_procedure
, O
HMB-45 B-Diagnostic_procedure
, O
mclean-A B-Diagnostic_procedure
and O
Vimentin B-Diagnostic_procedure
, O
but O
negative B-Lab_value
for O
cytokeratin B-Diagnostic_procedure
7 I-Diagnostic_procedure
and O
cytokeratin B-Diagnostic_procedure
20 I-Diagnostic_procedure
( O
Figure O
6 O
) O
. O

Based O
on O
these O
results O
, O
a O
diagnosis O
of O
primary B-Detailed_description
advanced B-Severity
esophago-gastric B-Detailed_description
melanoma B-Disease_disorder
was O
established O
. O

The O
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
smooth B-Lab_value
and O
without O
complications B-Sign_symptom
. O

The O
patient O
gradually O
recovered B-Sign_symptom
and O
was O
discharged B-Clinical_event
14 B-Date
d I-Date
after I-Date
surgery O
. O

As O
the O
patient O
denied O
a O
postoperative O
adjuvant B-Medication
therapy I-Medication
, O
abdominal B-Biological_structure
recurrence B-Sign_symptom
and O
hepatic B-Biological_structure
metastases B-Sign_symptom
were O
found O
within B-Date
one I-Date
month I-Date
by O
a O
postoperative O
follow-up B-Clinical_event
CT B-Diagnostic_procedure
. O

No O
other B-Therapeutic_procedure
effective I-Therapeutic_procedure
treatment I-Therapeutic_procedure
was O
administered O
afterwards O
. O

The O
patient O
died B-Outcome
of O
diffuse B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
2 B-Date
mo I-Date
later I-Date
. O

A O
65-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
evaluation O
of O
stuttering B-Detailed_description
chest B-Biological_structure
pain B-Sign_symptom
for O
10 B-Duration
days I-Duration
, O
and O
he O
was O
a O
common B-Occupation
worker I-Occupation
. O

There O
was O
no B-Lab_value
positive I-Lab_value
finding I-Lab_value
from O
the O
relevant O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

He O
has O
no B-History
medical I-History
, I-History
family I-History
, I-History
and I-History
psychosocial I-History
history I-History
including I-History
co-morbidities I-History
, O
and O
relevant O
genetic O
information O
. O

His O
electrocardiogram B-Diagnostic_procedure
showed O
T-wave B-Sign_symptom
inversion I-Sign_symptom
over O
leads B-Detailed_description
V1 I-Detailed_description
to I-Detailed_description
V4 I-Detailed_description
( O
Figure O
1 O
) O
. O

Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
showed O
90 B-Lab_value
% I-Lab_value
stenosis B-Sign_symptom
in O
the O
mid-left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
( O
LAD B-Biological_structure
) O
, O
which O
was O
stented B-Therapeutic_procedure
( O
Figure O
2 O
) O
. O

T-wave B-Detailed_description
still O
inversion B-Sign_symptom
over O
leads B-Detailed_description
V1 I-Detailed_description
to I-Detailed_description
V4 I-Detailed_description
after O
the O
percutaneous B-Therapeutic_procedure
coronary I-Therapeutic_procedure
intervention I-Therapeutic_procedure
( O
PCI B-Therapeutic_procedure
) O
( O
Figure O
3 O
) O
. O

The O
patient O
discharged B-Clinical_event
after O
the O
PCI O
in O
5 B-Date
days I-Date
and O
recharged B-Clinical_event
in O
the O
hospital B-Nonbiological_location
because O
of O
a O
palpation B-Sign_symptom
. O

His O
electrocardiogram B-Diagnostic_procedure
demonstrated O
ventricular B-Disease_disorder
tachycardia I-Disease_disorder
( O
Figure O
4 O
) O
, O
and O
severe B-Severity
hypertension B-Sign_symptom
, O
remarkable O
blood B-Sign_symptom
pressure I-Sign_symptom
fluctuation I-Sign_symptom
between B-Lab_value
224/76 I-Lab_value
and I-Lab_value
70/50 I-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

Although O
several O
antihypertensive B-Medication
drugs I-Medication
were O
used O
, O
ventricular B-Disease_disorder
tachycardia I-Disease_disorder
still O
occurred O
on O
him O
for O
2 B-Detailed_description
times I-Detailed_description
, O
each O
was O
preceded O
by O
a O
period O
of O
blood B-Sign_symptom
pressure I-Sign_symptom
fluctuation I-Sign_symptom
and O
burst O
out O
concomitantly O
at O
the O
peak O
of O
a O
hypertension B-Disease_disorder
crisis I-Disease_disorder
. O

The O
patient O
felt O
abdominal B-Biological_structure
pain B-Sign_symptom
and O
his O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
suspicious O
right B-Biological_structure
adrenal I-Biological_structure
gland I-Biological_structure
tumor B-Sign_symptom
. O

Enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
adrenal B-Biological_structure
gland I-Biological_structure
conformed O
that O
there O
was O
a O
tumor B-Sign_symptom
in O
right B-Biological_structure
adrenal I-Biological_structure
gland I-Biological_structure
accompanied O
by O
an O
upset B-Lab_value
level O
of O
aldosterone B-Diagnostic_procedure
( O
Figure O
5 O
) O
. O

The O
tumor B-Sign_symptom
was O
removed B-Therapeutic_procedure
by O
laparoscope B-Therapeutic_procedure
, O
and O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
pheochromocytoma B-Disease_disorder
( O
Figure O
6 O
) O
. O

After O
the O
surgery B-Coreference
, O
the O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
turned O
normal B-Lab_value
gradually O
. O

There O
was O
no O
T-wave B-Sign_symptom
inversion I-Sign_symptom
in O
lead B-Detailed_description
V1-V4 I-Detailed_description
( O
Figure O
7 O
) O
. O

A O
50-year-old B-Age
lady B-Sex
presented B-Clinical_event
with O
complaints O
of O
pain B-Sign_symptom
abdomen B-Biological_structure
and O
jaundice B-Sign_symptom
for O
one B-Duration
and I-Duration
a I-Duration
half I-Duration
months I-Duration
; O
she O
also O
complained O
of O
intermittent B-Detailed_description
type O
of O
fever B-Sign_symptom
in O
the O
last B-Duration
1 I-Duration
week I-Duration
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
presence O
of O
icterus B-Sign_symptom
and O
a O
palpable B-Detailed_description
tender B-Detailed_description
globular B-Shape
mass B-Sign_symptom
in O
the O
right B-Biological_structure
hypochondrium I-Biological_structure
measuring O
3 B-Area
× I-Area
3 I-Area
cm I-Area
. O

A O
clinical O
diagnosis O
of O
obstructive B-Detailed_description
jaundice B-Sign_symptom
secondary O
to O
periampullary B-Disease_disorder
carcinoma I-Disease_disorder
was O
made O
. O

Ultrasonographic B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
abdomen B-Biological_structure
and O
pelvis B-Biological_structure
revealed O
dilatation B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
intrahepatic I-Sign_symptom
biliary I-Sign_symptom
radicles I-Sign_symptom
( O
IHBR B-Biological_structure
) O
, O
with O
multiple B-Detailed_description
freely O
mobile B-Detailed_description
gall B-Sign_symptom
stones I-Sign_symptom
and O
a O
dilated B-Sign_symptom
common I-Sign_symptom
bile I-Sign_symptom
duct I-Sign_symptom
( O
CBD B-Biological_structure
) O
measuring O
1.8 B-Distance
cm I-Distance
with O
sudden B-Detailed_description
narrowing I-Detailed_description
at I-Detailed_description
its I-Detailed_description
distal I-Detailed_description
end I-Detailed_description
. O

CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
moderate B-Severity
dilatation B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
extra I-Sign_symptom
and I-Sign_symptom
intrahepatic I-Sign_symptom
biliary I-Sign_symptom
radicles I-Sign_symptom
, O
cholelithiasis B-Sign_symptom
with O
suspicious O
thickening B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
gall I-Sign_symptom
bladder I-Sign_symptom
wall I-Sign_symptom
at O
the O
fundus B-Biological_structure
, O
and O
a O
distal B-Biological_attribute
CBD I-Biological_attribute
stricture B-Sign_symptom
. O

There O
was O
no O
evidence O
of O
any O
distant O
metastasis B-Sign_symptom
( O
Fig. O
1 O
) O
. O

A O
preoperative O
diagnosis O
of O
periampullary B-Disease_disorder
carcinoma I-Disease_disorder
with O
chronic B-Disease_disorder
cholecystitis I-Disease_disorder
was O
made O
, O
and O
the O
patient O
planned B-Clinical_event
for O
a O
pancreaticoduodenectomy B-Therapeutic_procedure
( O
Whipple B-Therapeutic_procedure
’s I-Therapeutic_procedure
procedure I-Therapeutic_procedure
) O
after O
optimization O
. O

The O
patient O
underwent O
a O
classical O
Whipple B-Therapeutic_procedure
’s I-Therapeutic_procedure
procedure I-Therapeutic_procedure
; O
table B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
resected B-Biological_structure
specimen I-Biological_structure
revealed O
multiple B-Detailed_description
gall B-Sign_symptom
stones I-Sign_symptom
in O
the O
gall B-Biological_structure
bladder I-Biological_structure
with O
area O
of O
mucosal B-Sign_symptom
thickening I-Sign_symptom
at O
the O
fundus B-Biological_structure
and O
an O
irregular B-Detailed_description
circumferential B-Detailed_description
growth B-Sign_symptom
involving O
the O
intrapancreatic B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
CBD I-Biological_structure
. O

Postoperative B-Therapeutic_procedure
period I-Therapeutic_procedure
was O
uneventful B-Lab_value
, O
and O
the O
patient O
recovered B-Clinical_event
satisfactorily B-Lab_value
. O

Histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
resected B-Biological_structure
specimen I-Biological_structure
( O
Figs. O
2 O
and O
3 O
) O
revealed O
thickening B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
gall I-Sign_symptom
bladder I-Sign_symptom
wall I-Sign_symptom
at O
the O
fundus B-Biological_structure
with O
multiple B-Detailed_description
small B-Detailed_description
calculi B-Sign_symptom
, O
the O
largest O
measuring O
1.4 B-Distance
cm I-Distance
( O
Fig. O
3 O
) O
. O

Sections O
studied O
from O
the O
area O
of O
thickening O
showed O
features O
suggestive O
of O
adenocarcinoma B-Disease_disorder
limited O
to O
the O
mucosa B-Biological_structure
. O

Microscopic B-Diagnostic_procedure
sections I-Diagnostic_procedure
obtained O
from O
the O
distal B-Biological_structure
CBD I-Biological_structure
region I-Biological_structure
showed O
adenocarcinoma B-Disease_disorder
of O
the O
common B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
with O
invasion B-Detailed_description
into O
the O
muscular B-Biological_structure
wall I-Biological_structure
of I-Biological_structure
the I-Biological_structure
duodenum I-Biological_structure
. O

Sections B-Diagnostic_procedure
studied O
from O
the O
resected B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
free O
of O
tumor B-Sign_symptom
cells I-Sign_symptom
. O

A O
pathological O
staging O
of O
pT1aN0M0 B-Detailed_description
for O
adenocarcinoma B-Disease_disorder
of O
the O
gall B-Biological_structure
bladder I-Biological_structure
and O
pT2N0M0 B-Detailed_description
for O
adenocarcinoma B-Disease_disorder
of O
the O
distal B-Biological_structure
CBD I-Biological_structure
was O
made O
, O
and O
the O
patient O
was O
not O
subjected O
to O
any O
adjuvant B-Medication
therapy I-Medication
. O

The O
patient O
was O
disease-free B-Sign_symptom
2 B-Date
years I-Date
after I-Date
surgery I-Date
. O

A O
53-year-old B-Age
man B-Sex
came B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
signs O
and O
symptoms O
of O
acute B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
after O
a O
2-week B-Duration
history I-Duration
of O
progressive B-Detailed_description
breathlessness B-Sign_symptom
. O

He O
had O
a O
history B-History
of I-History
recurrent I-History
skin I-History
abscesses I-History
and O
atopic B-Detailed_description
dermatitis B-History
and O
regularly B-Frequency
visited B-Clinical_event
a O
dermatologist B-Nonbiological_location
in O
our O
hospital B-Nonbiological_location
. O

On O
arriving B-Clinical_event
at O
our O
hospital B-Nonbiological_location
, O
his O
extremities B-Biological_structure
were O
warm B-Sign_symptom
and O
dry B-Sign_symptom
. O

According O
to O
the O
New B-Diagnostic_procedure
York I-Diagnostic_procedure
Heart I-Diagnostic_procedure
Association I-Diagnostic_procedure
criteria I-Diagnostic_procedure
, O
he O
had O
class B-Lab_value
III I-Lab_value
congestive B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
( O
CHF B-Disease_disorder
) O
. O

An O
electrocardiogram B-Diagnostic_procedure
revealed O
diffuse B-Detailed_description
nonspecific B-Detailed_description
T-wave B-Sign_symptom
changes I-Sign_symptom
, O
low B-Lab_value
voltage B-Diagnostic_procedure
( O
< B-Lab_value
5 I-Lab_value
mm I-Lab_value
) O
in O
the O
extremity B-Diagnostic_procedure
leads I-Diagnostic_procedure
and O
poor B-Lab_value
R-wave B-Diagnostic_procedure
progression I-Diagnostic_procedure
in O
the O
anterior B-Diagnostic_procedure
chest I-Diagnostic_procedure
leads I-Diagnostic_procedure
. O

Multiple B-Quantitative_concept
sporadic B-Frequency
ventricular B-Biological_structure
premature B-Sign_symptom
beats I-Sign_symptom
were O
seen O
( O
Figure O
1 O
) O
. O

Chest B-Biological_structure
x-ray B-Diagnostic_procedure
film O
confirmed O
right B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
, O
and O
mild B-Severity
cardiomegaly B-Sign_symptom
but O
no O
pulmonary B-Disease_disorder
congestion I-Disease_disorder
( O
Figure O
2 O
) O
. O

Blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
severely B-Lab_value
elevated I-Lab_value
B-type B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
901 B-Lab_value
pg/mL I-Lab_value
) O
and O
markedly O
raised B-Lab_value
IgE B-Diagnostic_procedure
( O
12 B-Lab_value
000 I-Lab_value
IU/mL I-Lab_value
) O
without O
eosinophilia B-Sign_symptom
( O
eosinophil B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
1.62 B-Lab_value
× I-Lab_value
108/L I-Lab_value
) O
. O

Biochemical B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
no O
significant O
findings O
: O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
of O
14.3 B-Lab_value
mg/dL I-Lab_value
[ O
reference O
value O
( O
RV O
) O
: O
7.00 O
– O
22.00 O
] O
, O
creatinine B-Diagnostic_procedure
of O
0.90 B-Lab_value
mg/dL I-Lab_value
( O
RV O
: O
0.60 O
– O
1.00 O
) O
, O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
CRP B-Diagnostic_procedure
) O
of O
0.2 B-Lab_value
mg/dL I-Lab_value
( O
RV O
: O
0.00 O
– O
0.50 O
) O
, O
serum B-Diagnostic_procedure
amyloid I-Diagnostic_procedure
A I-Diagnostic_procedure
( O
SAA B-Diagnostic_procedure
) O
of O
7.0 B-Lab_value
μg/mL I-Lab_value
( O
RV O
: O
0 O
– O
8.0 O
) O
, O
and O
troponin B-Diagnostic_procedure
T I-Diagnostic_procedure
of O
0.07 B-Lab_value
ng/mL I-Lab_value
( O
RV O
: O
0 O
– O
0.1 O
) O
. O

Immunology B-Diagnostic_procedure
testing I-Diagnostic_procedure
revealed O
negative B-Lab_value
perinuclear B-Diagnostic_procedure
anti-neutrophil I-Diagnostic_procedure
cytoplasmic I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
and O
no B-Lab_value
elevation I-Lab_value
of O
myeloperoxidase B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
. O

The O
distribution O
of O
albumin B-Diagnostic_procedure
and O
globulin B-Diagnostic_procedure
in O
the O
serum B-Detailed_description
was O
normal B-Lab_value
. O

Serum B-Detailed_description
protein B-Diagnostic_procedure
immuno-electrophoresis I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
reveal I-Lab_value
M-protein B-Diagnostic_procedure
, O
and O
urinalysis B-Diagnostic_procedure
revealed O
no B-Lab_value
Bence-Jones B-Diagnostic_procedure
protein I-Diagnostic_procedure
. O

Transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
( O
Figure O
3 O
) O
showed O
concentric B-Detailed_description
mild B-Severity
left B-Biological_structure
ventricular I-Biological_structure
( O
LV B-Biological_structure
) O
hypertrophy B-Sign_symptom
( O
12 B-Distance
mm I-Distance
) O
without O
the O
characteristic O
granular B-Sign_symptom
sparkling I-Sign_symptom
appearance I-Sign_symptom
and O
pericardial B-Disease_disorder
effusion I-Disease_disorder
, O
preserved B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
60 B-Lab_value
% I-Lab_value
) O
, O
and O
bi-atrial B-Biological_structure
enlargement B-Sign_symptom
with O
normal B-Lab_value
ventricular B-Diagnostic_procedure
chambers I-Diagnostic_procedure
. O

Doppler-derived B-Detailed_description
LV B-Biological_structure
diastolic B-Diagnostic_procedure
filling I-Diagnostic_procedure
demonstrated O
a O
restrictive B-Lab_value
pattern I-Lab_value
with O
a O
trans-mitral B-Biological_structure
early B-Diagnostic_procedure
filling I-Diagnostic_procedure
wave I-Diagnostic_procedure
deceleration I-Diagnostic_procedure
time I-Diagnostic_procedure
of O
160 B-Lab_value
ms I-Lab_value
and O
an O
elevated B-Lab_value
E/A B-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
2.8 B-Lab_value
. O

A O
markedly O
elevation B-Lab_value
of O
E/e B-Diagnostic_procedure
’ I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
27.3 B-Lab_value
indicated O
elevated B-Lab_value
LV B-Diagnostic_procedure
filling I-Diagnostic_procedure
pressure I-Diagnostic_procedure
. O

On O
day B-Date
1 I-Date
of O
hospitalization B-Clinical_event
, O
we O
prescribed O
an O
angiotensin-converting B-Medication
enzyme I-Medication
( I-Medication
ACE I-Medication
) I-Medication
inhibitor I-Medication
and O
low-dose B-Dosage
diuretics B-Medication
. O

On O
day B-Date
3 I-Date
of O
hospitalization B-Clinical_event
, O
after O
initiating O
ACE B-Medication
inhibitor I-Medication
and O
diuretic B-Medication
therapy O
, O
the O
patient O
’s O
symptoms B-Sign_symptom
resolved O
. O

The O
dermatologists B-Nonbiological_location
performed O
a O
biopsy B-Diagnostic_procedure
of O
a O
blue B-Color
macula B-Sign_symptom
of O
the O
forehead B-Biological_structure
skin I-Biological_structure
. O

On O
day B-Date
4 I-Date
, O
we O
introduced O
a O
low-dose B-Dosage
β-blocker B-Medication
and O
performed O
an O
endomyocardial B-Diagnostic_procedure
biopsy I-Diagnostic_procedure
( O
EMB B-Diagnostic_procedure
) O
, O
obtaining O
3 B-Quantitative_concept
fragments I-Quantitative_concept
of O
the O
right B-Biological_structure
ventricular I-Biological_structure
septum I-Biological_structure
because O
diagnostic O
confirmation O
of O
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
requires O
the O
demonstration O
of O
amyloid B-Sign_symptom
deposits I-Sign_symptom
. O

In O
addition O
, O
we O
performed O
right B-Diagnostic_procedure
heart I-Diagnostic_procedure
catheterization I-Diagnostic_procedure
( O
RHC B-Diagnostic_procedure
) O
, O
and O
coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
to O
exclude O
obstructive B-Disease_disorder
coronary I-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
. O

The O
data O
obtained O
from O
the O
RHC B-Diagnostic_procedure
indicated O
subset B-Lab_value
type I-Lab_value
IV I-Lab_value
according O
to O
the O
Forrester B-Diagnostic_procedure
classification I-Diagnostic_procedure
. O

The O
right B-Biological_structure
ventricular I-Biological_structure
pressure B-Diagnostic_procedure
curve I-Diagnostic_procedure
did O
not O
show O
a O
dip-and-plateau B-Sign_symptom
configuration I-Sign_symptom
. O

Skin B-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
hyperkeratosis B-Sign_symptom
in O
the O
epidermis B-Biological_structure
and O
mild B-Severity
inflammatory B-Sign_symptom
changes I-Sign_symptom
throughout O
the O
dermis B-Biological_structure
with O
an O
infiltration B-Sign_symptom
of O
lymphocytes B-Biological_structure
. O

The O
specimen O
exhibited O
apple-green B-Color
birefringence B-Lab_value
with O
polarized B-Detailed_description
light I-Detailed_description
after O
Congo B-Diagnostic_procedure
red I-Diagnostic_procedure
staining I-Diagnostic_procedure
( O
Figure O
4 O
) O
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
myocardial B-Biological_structure
specimen I-Biological_structure
showed O
no O
signs O
suggesting O
myocarditis B-Disease_disorder
, O
eosinophilic B-Detailed_description
granulomas B-Disease_disorder
, O
or O
cardiomyopathy B-Disease_disorder
with O
iron B-Detailed_description
deposition I-Detailed_description
, O
but O
Congo B-Diagnostic_procedure
red I-Diagnostic_procedure
staining I-Diagnostic_procedure
revealed O
amyloid B-Sign_symptom
deposits I-Sign_symptom
( O
Figure O
5 O
) O
. O

In O
addition O
, O
a O
strongly B-Lab_value
positive I-Lab_value
immunohistochemical B-Diagnostic_procedure
reaction I-Diagnostic_procedure
to O
immunoglobulin B-Diagnostic_procedure
λ-chain I-Diagnostic_procedure
in O
the O
myocardial B-Biological_structure
interstitium I-Biological_structure
led O
us O
to O
diagnose O
this O
patient O
’s O
systemic B-Detailed_description
amyloidosis B-Disease_disorder
as O
AL B-Disease_disorder
amyloidosis I-Disease_disorder
. O

The O
patient O
generally O
tolerated O
the O
low-dose O
β-blocker B-Medication
well O
and O
was O
discharged B-Clinical_event
on O
day B-Date
10 I-Date
with O
no O
complications B-Disease_disorder
. O

The O
patient O
is O
currently O
being O
followed-up B-Clinical_event
at O
6-month B-Frequency
intervals I-Frequency
as O
an O
out-patient O
, O
with O
no O
exacerbation O
of O
the O
CHF B-Disease_disorder
thus O
far O
. O

The O
institutional O
review O
board O
( O
Chengdu O
Military O
General O
Hospital O
) O
approved O
this O
work O
and O
waived O
the O
need O
for O
informed O
consent O
. O

In O
2013 B-Date
, O
a O
66-year-old B-Age
farmer B-Occupation
with O
a O
history O
of O
ventricular B-History
tachycardia I-History
( I-History
VT I-History
) I-History
and O
hypertension B-History
presented B-Clinical_event
to O
the O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
with O
continuous B-Detailed_description
palpitation B-Sign_symptom
, O
chest B-Sign_symptom
tightness I-Sign_symptom
, O
profuse B-Severity
sweating B-Sign_symptom
and O
nausea B-Sign_symptom
with O
no O
obvious O
predisposing O
causes B-Disease_disorder
. O

The O
patient O
experienced O
a O
sudden B-Lab_value
drop I-Lab_value
in O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
and O
acute B-Detailed_description
confusion B-Sign_symptom
. O

After O
an O
immediate B-Detailed_description
electrical B-Therapeutic_procedure
conversion I-Therapeutic_procedure
, O
his O
consciousness B-Sign_symptom
was O
gradually O
restored O
, O
and O
symptoms B-Sign_symptom
relieved O
. O

Then O
, O
this O
patient O
was O
transferred B-Clinical_event
to O
the O
Department B-Nonbiological_location
of I-Nonbiological_location
Cardiology I-Nonbiological_location
for O
further O
evaluations B-Diagnostic_procedure
and O
treatments B-Therapeutic_procedure
. O

The O
patient O
's O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
105/75 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
upon O
admission O
, O
with O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
75 B-Lab_value
beats/min I-Lab_value
, O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
of O
36.6 B-Lab_value
°C I-Lab_value
and O
respiration B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
18 B-Lab_value
times/min I-Lab_value
. O

The O
heart B-Biological_structure
border I-Biological_structure
extended B-Sign_symptom
to B-Lab_value
the I-Lab_value
left I-Lab_value
, O
with O
the O
apical B-Diagnostic_procedure
impulse I-Diagnostic_procedure
located O
in O
the O
left B-Lab_value
5th I-Lab_value
intercostal I-Lab_value
space I-Lab_value
, O
1.0 B-Distance
cm I-Distance
lateral I-Distance
to I-Distance
the I-Distance
midclavicular I-Distance
line I-Distance
. O

The O
patient O
had O
a O
history O
of O
hypertension B-Disease_disorder
over B-History
30 I-History
years I-History
without I-History
regular I-History
antihypertensive I-History
medication I-History
. O

The O
highest B-Detailed_description
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
170/110 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

There O
was O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
early I-Family_history
coronary I-Family_history
artery I-Family_history
disease I-Family_history
or I-Family_history
sudden I-Family_history
cardiac I-Family_history
death I-Family_history
. O

He O
did B-History
not I-History
smoke I-History
cigarettes I-History
or I-History
use I-History
illicit I-History
drugs I-History
, I-History
and I-History
rarely I-History
consumed I-History
alcohol I-History
. O

He O
also O
reported O
no B-History
known I-History
contacts I-History
with I-History
sick I-History
persons I-History
and I-History
no I-History
recent I-History
travel I-History
. O

Twelve-lead B-Detailed_description
surface B-Detailed_description
electrocardiogram B-Diagnostic_procedure
( O
ECG B-Diagnostic_procedure
) O
of O
VT B-Disease_disorder
indicated O
that O
the O
origin O
of O
VT O
was O
at O
the O
boundary B-Biological_structure
between I-Biological_structure
right B-Biological_structure
ventricular I-Biological_structure
outflow I-Biological_structure
tract I-Biological_structure
( O
RVOT B-Biological_structure
) O
and O
tricuspid B-Biological_structure
valve I-Biological_structure
. O

When O
VT B-Disease_disorder
increased B-Lab_value
to O
150 B-Lab_value
beats/min I-Lab_value
or I-Lab_value
higher I-Lab_value
, O
no O
epsilon B-Sign_symptom
waves I-Sign_symptom
were O
found O
in O
the O
precordial B-Diagnostic_procedure
leads I-Diagnostic_procedure
( O
Figure1A O
and O
B O
) O
. O

In O
contrast O
, O
when O
VT B-Disease_disorder
decreased B-Lab_value
to O
120 B-Lab_value
beats/min I-Lab_value
or I-Lab_value
lower I-Lab_value
, O
epsilon B-Sign_symptom
waves I-Sign_symptom
appeared O
in O
leads B-Diagnostic_procedure
V1 I-Diagnostic_procedure
– I-Diagnostic_procedure
V2 I-Diagnostic_procedure
( O
Figure1C O
) O
. O

Notably O
, O
the O
epsilon B-Sign_symptom
waves I-Sign_symptom
preceded B-Lab_value
QRS I-Lab_value
waves I-Lab_value
in O
leads B-Diagnostic_procedure
V1 I-Diagnostic_procedure
– I-Diagnostic_procedure
V2 I-Diagnostic_procedure
, O
while O
endocardiac B-Diagnostic_procedure
tracing I-Diagnostic_procedure
confirmed O
that O
the O
corresponding O
local B-Lab_value
potential I-Lab_value
originating O
from O
RVOT B-Biological_structure
appeared O
prior B-Detailed_description
to I-Detailed_description
the I-Detailed_description
ventricular I-Detailed_description
rhythm I-Detailed_description
( O
Figure O
( O
Figure1D O
) O
.1 O
D O
) O
. O

Sinus B-Detailed_description
ECG B-Diagnostic_procedure
in O
the O
year B-Date
of I-Date
2013 I-Date
suggested O
a O
slight B-Lab_value
left I-Lab_value
deviation I-Lab_value
of O
electric B-Diagnostic_procedure
axis I-Diagnostic_procedure
, O
with O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
87 B-Lab_value
beats/min I-Lab_value
and O
flat B-Lab_value
T I-Lab_value
waves I-Lab_value
in O
lead B-Diagnostic_procedure
II I-Diagnostic_procedure
. O

T B-Sign_symptom
wave I-Sign_symptom
inversions I-Sign_symptom
were O
found O
in O
leads B-Diagnostic_procedure
III I-Diagnostic_procedure
, I-Diagnostic_procedure
avF I-Diagnostic_procedure
and I-Diagnostic_procedure
V1 I-Diagnostic_procedure
– I-Diagnostic_procedure
V3 I-Diagnostic_procedure
, O
meanwhile O
epsilon B-Sign_symptom
waves I-Sign_symptom
were O
found O
following B-Lab_value
QRS I-Lab_value
complex I-Lab_value
in O
leads B-Diagnostic_procedure
V1 I-Diagnostic_procedure
– I-Diagnostic_procedure
V3 I-Diagnostic_procedure
( O
Figure O
( O
Figure2B O
) O
.2 O
B O
) O
. O

When O
the O
lead B-Diagnostic_procedure
avR I-Diagnostic_procedure
was O
amplified B-Detailed_description
, O
epsilon B-Sign_symptom
waves I-Sign_symptom
were O
also O
found O
behind B-Lab_value
QRS I-Lab_value
waves I-Lab_value
( O
Figure O
2C O
) O
. O

Atrial B-Biological_structure
premature B-Sign_symptom
beats I-Sign_symptom
appeared O
occasionally B-Frequency
. O

Moreover O
, O
ventricular B-Biological_structure
premature B-Sign_symptom
beats I-Sign_symptom
were O
also O
found O
to O
originate O
from O
the O
right B-Biological_structure
ventricular I-Biological_structure
apex I-Biological_structure
, O
with O
epsilon B-Sign_symptom
waves I-Sign_symptom
appearing O
behind B-Lab_value
QRS I-Lab_value
waves I-Lab_value
( O
Figure O
( O
Figure2B O
) O
.2 O
B O
) O
. O

In O
contrast O
, O
sinus B-Biological_structure
ECG B-Diagnostic_procedure
obtained O
in O
the O
year B-Date
of I-Date
1999 I-Date
revealed O
similar O
left B-Lab_value
deviation I-Lab_value
of O
electric B-Diagnostic_procedure
axis I-Diagnostic_procedure
, O
flat B-Sign_symptom
T I-Sign_symptom
waves I-Sign_symptom
and O
T B-Sign_symptom
wave I-Sign_symptom
inversions I-Sign_symptom
, O
but O
absence O
of O
epsilon B-Sign_symptom
waves I-Sign_symptom
( O
Figure O
( O
Figure2A O
) O
.2 O
A O
) O
. O

Data O
from O
biochemical B-Diagnostic_procedure
assays I-Diagnostic_procedure
were O
as O
follows O
: O
cardiac B-Diagnostic_procedure
troponin I-Diagnostic_procedure
I I-Diagnostic_procedure
level O
was O
0.714 B-Lab_value
μg/L I-Lab_value
( O
normal O
range O
, O
0 O
– O
0.06 O
μg/L O
) O
, O
serum B-Diagnostic_procedure
B-type I-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
level O
was O
466.530 B-Lab_value
pg/mL I-Lab_value
( O
normal O
range O
, O
0 O
– O
100 O
pg/mL O
) O
, O
serum B-Diagnostic_procedure
d-dimer I-Diagnostic_procedure
level O
was O
8.14 B-Lab_value
mg/L I-Lab_value
( O
normal O
range O
, O
0 O
– O
0.55 O
mg/L O
) O
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
level O
was O
11.69 B-Lab_value
mmol/L I-Lab_value
( O
normal O
range O
, O
2.90 O
– O
7.20 O
mmol/L O
) O
, O
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
level O
was O
144.00 B-Lab_value
μmol/L I-Lab_value
( O
normal O
range O
, O
44 O
– O
133 O
μmol/L O
) O
, O
serum B-Diagnostic_procedure
uric I-Diagnostic_procedure
acid I-Diagnostic_procedure
level O
was O
611.40 B-Lab_value
μmol/L I-Lab_value
( O
normal O
range O
, O
100 O
– O
432 O
μmol/L O
) O
, O
and O
endogenous B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
clearing I-Diagnostic_procedure
value O
was O
57.90 B-Lab_value
mL/min I-Lab_value
( O
normal O
range O
, O
> O
80 O
mL/min O
) O
. O

Echo B-Diagnostic_procedure
data O
revealed O
remarkably B-Severity
enlarged B-Sign_symptom
right B-Biological_structure
atrium I-Biological_structure
and O
right B-Biological_structure
ventricle I-Biological_structure
, O
and O
widened B-Sign_symptom
ROVT B-Biological_structure
. O

Uncoordinated B-Sign_symptom
motions I-Sign_symptom
of O
the O
left B-Biological_structure
and I-Biological_structure
right I-Biological_structure
ventricular I-Biological_structure
walls I-Biological_structure
were O
also O
detected O
. O

Moreover O
, O
we O
also O
found O
aortic B-Biological_structure
valve I-Biological_structure
degradation B-Sign_symptom
with O
slight B-Severity
regurgitation B-Sign_symptom
, O
slight B-Severity
mitral B-Biological_structure
regurgitation B-Sign_symptom
, O
and O
moderate B-Severity
to I-Severity
severe I-Severity
tricuspid B-Biological_structure
regurgitation B-Sign_symptom
. O

The O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
diastolic I-Diagnostic_procedure
function I-Diagnostic_procedure
was O
reduced B-Lab_value
to O
55 B-Lab_value
% I-Lab_value
( O
Figure O
3A O
and O
B O
) O
. O

The O
coronary B-Diagnostic_procedure
angiogram I-Diagnostic_procedure
revealed O
no O
vascular B-Disease_disorder
stenosis I-Disease_disorder
( O
Figure O
3C O
– O
E O
) O
. O

Based O
on O
the O
above-mentioned O
examinations O
, O
this O
patient O
met O
at O
least O
2 O
major O
criteria O
, O
the O
bilateral O
ventricular O
dilation O
and O
the O
existence O
of O
epsilon O
waves O
, O
providing O
diagnostic O
support O
for O
ARVC B-Disease_disorder
. O

A O
diet B-Therapeutic_procedure
with O
low B-Detailed_description
salt I-Detailed_description
and O
low B-Detailed_description
fat I-Detailed_description
was O
suggested O
. O

The O
patient O
was O
also O
treated O
with O
metoprolol B-Medication
succinate I-Medication
sustained-release B-Administration
tablets I-Administration
( O
23.75 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
, O
amiodarone B-Medication
( O
200 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
, O
furosemide B-Medication
( O
20 B-Dosage
mg I-Dosage
daily I-Dosage
, O
i.v. B-Administration
) O
, O
and O
compound B-Detailed_description
α-ketoacid B-Medication
tablets B-Administration
( O
2.52 B-Dosage
g I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
. O

Moreover O
, O
VTs B-Disease_disorder
with O
different B-Detailed_description
morphologies I-Detailed_description
and I-Detailed_description
cycle I-Detailed_description
lengths I-Detailed_description
were O
found O
during O
radiofrequency B-Therapeutic_procedure
ablation I-Therapeutic_procedure
( O
Figure O
4 O
) O
. O

The O
substrate B-Diagnostic_procedure
voltage I-Diagnostic_procedure
mapping I-Diagnostic_procedure
revealed O
that O
the O
anterior B-Biological_structure
wall I-Biological_structure
of I-Biological_structure
RVOT I-Biological_structure
was O
wrapped O
by O
circular B-Shape
scar B-Sign_symptom
( O
Figure O
5A O
) O
. O

Considering O
the O
association O
of O
VT O
with O
scar O
areas O
, O
substrate B-Therapeutic_procedure
ablation I-Therapeutic_procedure
was O
chosen O
for O
this O
patient O
. O

The O
residual O
potentials O
in O
the O
scar O
areas O
were O
searched O
, O
and O
then O
linear B-Detailed_description
and O
focal B-Detailed_description
ablations B-Therapeutic_procedure
were O
performed O
( O
Figure O
5B O
) O
. O

Neither O
programmed B-Detailed_description
stimulation B-Diagnostic_procedure
nor O
induced B-Detailed_description
stimulation B-Diagnostic_procedure
could O
induce O
VT B-Disease_disorder
after O
the O
procedure O
was O
completed O
, O
indicating O
the O
success O
of O
operation O
. O

The O
ECG B-Diagnostic_procedure
after O
radiofrequency O
ablation O
showed O
sinus B-Sign_symptom
rhythm I-Sign_symptom
, O
with O
a O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
61 B-Lab_value
beats/min I-Lab_value
, O
T B-Sign_symptom
wave I-Sign_symptom
inversions I-Sign_symptom
in O
leads B-Diagnostic_procedure
III I-Diagnostic_procedure
and I-Diagnostic_procedure
avF I-Diagnostic_procedure
, O
and O
epsilon B-Sign_symptom
waves I-Sign_symptom
and O
T B-Sign_symptom
wave I-Sign_symptom
inversions I-Sign_symptom
in O
leads B-Diagnostic_procedure
V1 I-Diagnostic_procedure
– I-Diagnostic_procedure
V3 I-Diagnostic_procedure
( O
Figure O
2D O
) O
. O

This O
patient O
was O
discharged B-Clinical_event
from O
hospital B-Nonbiological_location
on O
day B-Date
9 I-Date
with O
a O
regimen O
of O
metoprolol B-Medication
succinate I-Medication
sustained-release B-Administration
tablets I-Administration
( O
23.75 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
, O
amiodarone B-Medication
hydrochloride I-Medication
tablets B-Administration
( O
200 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
, O
spironolactone B-Medication
tablets B-Administration
( O
40 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
, O
and O
fosinopril B-Medication
sodium I-Medication
tablets B-Administration
( O
10 B-Dosage
mg I-Dosage
daily I-Dosage
, O
p.o. B-Administration
) O
. O

The O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
3 B-Date
months I-Date
after I-Date
discharge O
. O

He O
had O
no O
recurrent O
palpitation B-Sign_symptom
, O
chest B-Biological_structure
tightness B-Sign_symptom
, O
profuse B-Severity
sweating B-Sign_symptom
or O
nausea B-Sign_symptom
. O

Although B-Other_entity
ARVC I-Other_entity
was I-Other_entity
the I-Other_entity
main I-Other_entity
diagnosis I-Other_entity
at I-Other_entity
the I-Other_entity
time I-Other_entity
of I-Other_entity
this I-Other_entity
patient I-Other_entity
's I-Other_entity
initial I-Other_entity
presentation I-Other_entity
, I-Other_entity
it I-Other_entity
is I-Other_entity
essential I-Other_entity
in I-Other_entity
such I-Other_entity
cases I-Other_entity
to I-Other_entity
perform I-Other_entity
a I-Other_entity
reassessment I-Other_entity
for I-Other_entity
the I-Other_entity
presence I-Other_entity
of I-Other_entity
structural I-Other_entity
heart I-Other_entity
disease I-Other_entity
, I-Other_entity
which I-Other_entity
can I-Other_entity
evolve I-Other_entity
over I-Other_entity
time I-Other_entity
. O

A O
36 B-Age
- I-Age
year I-Age
- I-Age
old I-Age
white B-Personal_background
woman B-Sex
at O
40 B-Lab_value
week I-Lab_value
of O
gestation B-Clinical_event
was O
admitted B-Clinical_event
to O
a O
local B-Nonbiological_location
obstetric I-Nonbiological_location
clinic I-Nonbiological_location
for O
elective B-Detailed_description
repeated B-Detailed_description
cesarean B-Therapeutic_procedure
delivery I-Therapeutic_procedure
due O
to O
slanting B-Detailed_description
position I-Detailed_description
of O
the O
fetus B-Subject
. O

Both O
her O
previous B-History
and I-History
current I-History
pregnancy I-History
were I-History
uncomplicated I-History
. O

Her O
past B-History
medical I-History
history I-History
was I-History
unremarkable I-History
and O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
cardiac I-Family_history
disease I-Family_history
was I-Family_history
reported I-Family_history
. O

The O
caesarean B-Therapeutic_procedure
delivery I-Therapeutic_procedure
was O
performed O
following O
the O
administration O
of O
standard B-Detailed_description
spinal B-Biological_structure
anesthesia B-Medication
. O

During O
surgery B-Coreference
the O
patient O
became O
hypotensive B-Sign_symptom
and O
ephedrine B-Medication
was O
injected B-Administration
to O
maintain O
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
in O
the O
normal B-Lab_value
range I-Lab_value
. O

Three B-Time
hours I-Time
after I-Time
delivery B-Clinical_event
of O
healthy B-Detailed_description
male B-Detailed_description
infant B-Subject
, O
the O
patient O
complained O
of O
nausea B-Sign_symptom
, O
increasing O
dyspnoea B-Sign_symptom
and O
palpitations B-Sign_symptom
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
tachycardia B-Sign_symptom
with O
ventricular B-Biological_structure
extra B-Sign_symptom
systoles I-Sign_symptom
and O
pulmonary B-Biological_structure
rales B-Sign_symptom
were O
detected O
. O

Her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
80/40 B-Lab_value
mmHg I-Lab_value
and O
demanded O
the O
administration O
of O
inotropic B-Medication
agents I-Medication
( O
initially O
continuous B-Administration
infusion I-Administration
of O
norepinephrine B-Medication
0.5 B-Dosage
mg/h I-Dosage
followed O
by O
dobutamine B-Medication
7 B-Dosage
μg/kg/min I-Dosage
) O
. O

Owing O
to O
worsening B-Lab_value
of O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
up B-Lab_value
to I-Lab_value
70 I-Lab_value
% I-Lab_value
and O
gradual B-Severity
deterioration B-Sign_symptom
of I-Sign_symptom
consciousness I-Sign_symptom
, O
mechanical B-Therapeutic_procedure
ventilation I-Therapeutic_procedure
was O
applied O
and O
the O
patient O
was O
transferred B-Clinical_event
to O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
. O

Chest B-Biological_structure
X B-Diagnostic_procedure
ray I-Diagnostic_procedure
indicated O
pulmonary B-Disease_disorder
congestion I-Disease_disorder
. O

Emergency B-Detailed_description
computer B-Diagnostic_procedure
tomography I-Diagnostic_procedure
excluded O
pulmonary B-Disease_disorder
thromboembolism I-Disease_disorder
( O
PE B-Disease_disorder
) O
and O
confirmed O
severe B-Severity
pulmonary B-Disease_disorder
oedema I-Disease_disorder
( O
Fig. O
1 O
) O
. O

The O
patient O
received O
loop B-Medication
diuretic I-Medication
, O
furosemide B-Medication
, O
at O
initial O
daily B-Dosage
dose I-Dosage
80 I-Dosage
mg I-Dosage
, O
which O
was O
progressively B-Lab_value
reduced I-Lab_value
. O

The O
diuretic B-Coreference
was O
discontinued O
after B-Date
12 I-Date
days I-Date
of O
treatment O
. O

The O
electrocardiogram B-Diagnostic_procedure
disclosed O
sinus B-Sign_symptom
tachycardia I-Sign_symptom
with O
ST B-Sign_symptom
- I-Sign_symptom
segment I-Sign_symptom
elevation I-Sign_symptom
of O
1,5 B-Lab_value
mm I-Lab_value
with O
negative B-Sign_symptom
T I-Sign_symptom
waves I-Sign_symptom
in O
aVL B-Diagnostic_procedure
and O
ST B-Sign_symptom
- I-Sign_symptom
segment I-Sign_symptom
depression I-Sign_symptom
of O
1 B-Lab_value
mm I-Lab_value
in O
II B-Diagnostic_procedure
, O
III B-Diagnostic_procedure
, O
aVF B-Diagnostic_procedure
, O
V5-V6 B-Diagnostic_procedure
( O
Fig. O
2 O
) O
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
elevated B-Lab_value
troponin B-Diagnostic_procedure
up B-Lab_value
to I-Lab_value
908 I-Lab_value
pg/ml I-Lab_value
( O
normal O
value O
< O
14 O
pg/ml O
) O
, O
NT B-Diagnostic_procedure
- I-Diagnostic_procedure
pro I-Diagnostic_procedure
BNP I-Diagnostic_procedure
6236 B-Lab_value
pg/ml I-Lab_value
( O
normal O
value O
< O
125 O
pg/ml O
) O
. O

The O
bedside B-Detailed_description
transthoracic B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
) O
revealed O
severe B-Severity
left B-Biological_structure
ventricular I-Biological_structure
( O
LV B-Biological_structure
) O
systolic B-Disease_disorder
dysfunction I-Disease_disorder
. O

Therefore O
the O
patient O
was O
transferred B-Clinical_event
to O
Intensive B-Biological_structure
Cardiac I-Biological_structure
Therapy I-Biological_structure
Clinic I-Biological_structure
. O

Repeated O
TTE B-Diagnostic_procedure
showed O
LV B-Biological_structure
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
30 B-Lab_value
% I-Lab_value
with O
hypokinesis B-Sign_symptom
of O
the O
mid B-Detailed_description
and I-Detailed_description
basal I-Detailed_description
segments I-Detailed_description
of O
posterior B-Biological_structure
, I-Biological_structure
anterior I-Biological_structure
and I-Biological_structure
lateral I-Biological_structure
wall I-Biological_structure
with O
preserved B-Lab_value
contractility B-Diagnostic_procedure
of O
the O
apical B-Biological_structure
segments I-Biological_structure
. O

Urgent B-Detailed_description
coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
presented O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O

The O
diagnosis O
of O
inverted B-Detailed_description
stress B-Detailed_description
- I-Detailed_description
induced I-Detailed_description
cardiomyopathy B-Disease_disorder
was O
set O
upon O
the O
overall O
clinical O
data O
. O

After B-Date
3 I-Date
days I-Date
the O
patient O
was O
weaned O
from O
respirator B-Therapeutic_procedure
and O
extubated B-Therapeutic_procedure
. O

Following O
hemodynamic B-Diagnostic_procedure
improvement B-Lab_value
, O
inotropic B-Medication
agents I-Medication
were O
tapered O
gradually O
. O

Both O
TTE B-Diagnostic_procedure
and O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
Figs. O
3 O
and O
4 O
) O
performed O
on B-Date
the I-Date
fifth I-Date
day I-Date
showed O
complete B-Lab_value
recovery I-Lab_value
of O
myocardial B-Diagnostic_procedure
function I-Diagnostic_procedure
. O

The O
patient O
was O
discharged B-Clinical_event
after B-Date
15 I-Date
days I-Date
in O
good B-Lab_value
overall B-Diagnostic_procedure
condition I-Diagnostic_procedure
. O

At O
12 B-Date
- I-Date
month I-Date
follow B-Clinical_event
- I-Clinical_event
up I-Clinical_event
she O
remained O
asymptomatic B-Sign_symptom
with O
no O
echocardiographic B-Sign_symptom
abnormalities I-Sign_symptom
. O

The O
proband O
is O
a O
19-year-old B-Age
woman B-Sex
, O
first B-Family_history
child I-Family_history
of I-Family_history
healthy I-Family_history
unrelated I-Family_history
parents I-Family_history
. O

Her O
family B-Family_history
history I-Family_history
was I-Family_history
unremarkable I-Family_history
. O

She O
was O
born B-History
at I-History
term I-History
after I-History
a I-History
normal I-History
pregnancy I-History
. O

The O
perinatal B-Diagnostic_procedure
period I-Diagnostic_procedure
was O
uneventful B-Lab_value
and O
her O
early B-Diagnostic_procedure
development I-Diagnostic_procedure
was O
referred O
to O
as O
normal B-Lab_value
, O
but O
after O
1 B-Date
year I-Date
of I-Date
age I-Date
, O
psychomotor B-Disease_disorder
delay I-Disease_disorder
became O
evident B-Severity
. O

She O
started O
walking B-Activity
autonomously B-Detailed_description
at O
22 B-Date
months I-Date
, O
with O
poor B-Lab_value
balance B-Diagnostic_procedure
and O
frequent B-Frequency
falls B-Sign_symptom
. O

At O
3 B-Date
years I-Date
of I-Date
age I-Date
, O
she O
developed O
a O
demyelinating B-Disease_disorder
sensorimotor I-Disease_disorder
neuropathy I-Disease_disorder
and O
a O
brain B-Biological_structure
MRI B-Diagnostic_procedure
disclosed O
supratentorial B-Biological_structure
leukodystrophy B-Disease_disorder
. O

During O
her O
childhood O
, O
the O
clinical B-Diagnostic_procedure
signs I-Diagnostic_procedure
remained O
stable B-Lab_value
. O

At O
10 B-Date
years I-Date
, O
her O
walking B-Disease_disorder
difficulties I-Disease_disorder
worsened B-Lab_value
, O
and O
limb B-Biological_structure
weakness B-Sign_symptom
and O
tremor B-Sign_symptom
ensued O
. O

The O
neurological B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
showed O
dysarthria B-Sign_symptom
, O
dysmetria B-Sign_symptom
, O
ataxic B-Lab_value
gait B-Diagnostic_procedure
and O
hyporeflexia B-Sign_symptom
in O
the O
four B-Biological_structure
limbs I-Biological_structure
with O
muscle B-Disease_disorder
wasting I-Disease_disorder
. O

She O
was O
able O
to O
walk B-Activity
alone B-Detailed_description
only B-Lab_value
for I-Lab_value
a I-Lab_value
few I-Lab_value
steps I-Lab_value
with O
an O
ataxic B-Lab_value
gait B-Diagnostic_procedure
. O

Mild B-Severity
cognitive B-Disease_disorder
impairment I-Disease_disorder
was O
documented O
( O
IQ B-Diagnostic_procedure
75 B-Lab_value
, O
WISC-R B-Detailed_description
scale I-Detailed_description
) O
. O

Histological B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
a O
muscle B-Biological_structure
biopsy B-Diagnostic_procedure
showed O
hypo/atrophy B-Sign_symptom
of O
fibres B-Biological_structure
. O

The O
clinical B-Diagnostic_procedure
evolution I-Diagnostic_procedure
was O
slowly B-Lab_value
progressive I-Lab_value
. O

At O
her O
last O
follow-up B-Clinical_event
examination O
, O
at O
19 B-Date
years I-Date
of I-Date
age I-Date
, O
she O
was O
able O
to O
walk B-Activity
alone B-Detailed_description
only O
with O
ankle-foot B-Detailed_description
orthotic B-Therapeutic_procedure
aids I-Therapeutic_procedure
and O
had O
developed O
a O
marked B-Severity
dorsal-lumbar B-Biological_structure
scoliosis B-Disease_disorder
. O

Other O
clinical B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
stable B-Lab_value
. O

Neurophysiological B-Diagnostic_procedure
studies I-Diagnostic_procedure
confirmed O
worsening B-Lab_value
of O
her O
mixed B-Detailed_description
axonal B-Biological_structure
demyelinating B-Disease_disorder
peripheral I-Disease_disorder
neuropathy I-Disease_disorder
. O

Brain B-Biological_structure
and O
spinal B-Biological_structure
cord I-Biological_structure
MRI B-Diagnostic_procedure
showed O
mild B-Severity
extension B-Lab_value
of O
signal B-Sign_symptom
abnormalities I-Sign_symptom
and O
extensive B-Severity
cavitations B-Sign_symptom
in O
the O
cerebral B-Biological_structure
white I-Biological_structure
matter I-Biological_structure
; O
the O
cerebellum B-Biological_structure
and O
brainstem B-Biological_structure
were O
spared B-Sign_symptom
but O
the O
spinal B-Biological_structure
cord I-Biological_structure
was O
thin B-Sign_symptom
with O
no O
obvious O
focal B-Detailed_description
lesions B-Sign_symptom
( O
figure O
1A O
) O
. O

Plasma B-Diagnostic_procedure
lactate I-Diagnostic_procedure
was O
2.9 B-Lab_value
mM I-Lab_value
( O
n.v. O
< O
2.1 O
) O
. O

A O
54-year-old B-Age
patient O
was O
admitted B-Clinical_event
for O
fever B-Sign_symptom
, O
diarrhea B-Sign_symptom
, O
and O
acute B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
. O

He O
had O
no B-History
significant I-History
medical I-History
history I-History
, O
did O
not O
take O
any O
medication B-Medication
, O
and O
had B-History
not I-History
traveled I-History
recently I-History
. O

He O
had O
no B-Family_history
relevant I-Family_history
familial I-Family_history
history I-Family_history
. O

Fifteen B-Date
days I-Date
before I-Date
his O
admission B-Clinical_event
, O
he O
developed O
fever B-Sign_symptom
, O
fluctuant B-Detailed_description
rash B-Sign_symptom
, O
diarrhea B-Sign_symptom
, O
and O
pain B-Sign_symptom
in O
the O
joints B-Biological_structure
. O

On O
admission B-Clinical_event
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
140/70 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
temperature B-Diagnostic_procedure
39 B-Lab_value
°C I-Lab_value
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
severe B-Severity
edema B-Sign_symptom
involving O
both O
lower B-Biological_structure
and I-Biological_structure
upper I-Biological_structure
limbs I-Biological_structure
, O
as O
well O
as O
ascites B-Sign_symptom
and O
pleural B-Sign_symptom
effusion I-Sign_symptom
. O

Cervical B-Biological_structure
and O
axillar B-Biological_structure
infracentimetric B-Qualitative_concept
lymphadenopathies B-Disease_disorder
were O
present O
, O
together O
with O
hepatosplenomegaly B-Disease_disorder
, O
confirmed O
by O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
. O

Bilateral B-Detailed_description
arthritis B-Disease_disorder
of O
the O
ankles B-Biological_structure
resolved O
spontaneously O
. O

Blood B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
( O
Table O
( O
Table1 O
) O
: O
1 O
) O
: O
leukocytosis B-Sign_symptom
, O
normal B-Lab_value
hemoglobin B-Diagnostic_procedure
and O
platelet B-Diagnostic_procedure
levels O
with O
no O
biologic O
sign O
of O
hemolysis B-Sign_symptom
, O
elevated B-Lab_value
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
, O
low B-Lab_value
albumin B-Diagnostic_procedure
, O
elevated B-Lab_value
serum B-Detailed_description
creatinin B-Diagnostic_procedure
, O
mild B-Severity
proteinuria B-Sign_symptom
and O
no O
hematuria B-Sign_symptom
. O

Despite O
intravenous B-Detailed_description
rehydration B-Therapeutic_procedure
using O
saline B-Medication
and O
albumin B-Medication
, O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
worsened B-Lab_value
and O
the O
patient O
required O
dialysis B-Therapeutic_procedure
. O

While O
diagnostic B-Diagnostic_procedure
investigations I-Diagnostic_procedure
were O
performed O
, O
hemiplegia B-Disease_disorder
occurred O
: O
brain B-Biological_structure
MRI B-Diagnostic_procedure
showed O
multifocal B-Detailed_description
ischemic B-Detailed_description
lesions B-Sign_symptom
. O

Echographic B-Detailed_description
and O
rythmologic B-Detailed_description
studies B-Diagnostic_procedure
ruled O
out O
any O
cardiologic B-Disease_disorder
cause I-Disease_disorder
for O
the O
stroke B-Disease_disorder
. O

A O
renal B-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
( O
Fig. O
1A O
and O
B O
) O
. O

Periodic B-Diagnostic_procedure
acid I-Diagnostic_procedure
– I-Diagnostic_procedure
Schiff I-Diagnostic_procedure
( O
PAS B-Diagnostic_procedure
) O
staining O
showed O
endotheliosis B-Disease_disorder
in O
all O
glomeruli B-Biological_structure
( O
Fig. O
1A O
, O
arrows O
) O
, O
associated O
with O
mesangiolysis B-Disease_disorder
and O
double B-Sign_symptom
contours I-Sign_symptom
on O
silver B-Diagnostic_procedure
staining I-Diagnostic_procedure
( O
Fig. O
1B O
, O
arrows O
) O
, O
and O
no O
arteriolar B-Biological_structure
thrombus B-Sign_symptom
. O

A O
moderate B-Severity
CD20 B-Detailed_description
+ I-Detailed_description
B B-Sign_symptom
lymphocyte I-Sign_symptom
infiltrate I-Sign_symptom
was O
present O
in O
the O
interstitium B-Biological_structure
, O
with O
a O
peritubularcapillaritis B-Sign_symptom
. O

Immunofluorescence B-Diagnostic_procedure
study I-Diagnostic_procedure
did O
not O
show O
any O
deposit B-Sign_symptom
. O

Lymph B-Biological_structure
node I-Biological_structure
biopsy B-Diagnostic_procedure
( O
Fig. O
2A O
and O
B O
) O
showed O
abnormal B-Sign_symptom
follicles B-Biological_structure
with O
hyalinization B-Sign_symptom
of O
germinal B-Biological_structure
center I-Biological_structure
, O
and O
an O
onion-skin B-Sign_symptom
aspect I-Sign_symptom
of O
the O
mantle B-Biological_structure
zone I-Biological_structure
. O

Clinical O
presentation O
and O
lymph B-Biological_structure
node I-Biological_structure
histology B-Diagnostic_procedure
were O
consistent O
with O
hyaline-vascular B-Detailed_description
multicentric B-Disease_disorder
Castleman I-Disease_disorder
disease I-Disease_disorder
( O
MCD B-Disease_disorder
) O
. O

HIV B-Detailed_description
and O
HHV-8 B-Detailed_description
serology B-Diagnostic_procedure
, O
as O
well O
as O
HHV-8 B-Detailed_description
lymph B-Biological_structure
node I-Biological_structure
tissue B-Diagnostic_procedure
staining I-Diagnostic_procedure
, O
were O
negative B-Lab_value
. O

Serum B-Detailed_description
vascular B-Diagnostic_procedure
endothelium I-Diagnostic_procedure
growth I-Diagnostic_procedure
factor I-Diagnostic_procedure
( O
VEGF B-Diagnostic_procedure
) O
was O
highly B-Lab_value
elevated I-Lab_value
. O

There O
was O
no O
biologic O
manifestation O
of O
thrombotic B-Disease_disorder
microangiopathy I-Disease_disorder
( O
TMA B-Disease_disorder
) O
, O
but O
the O
renal B-Biological_structure
biopsy B-Diagnostic_procedure
and O
brain B-Biological_structure
MRI B-Diagnostic_procedure
were O
consistent O
with O
glomerular B-Biological_structure
and O
neurologic B-Biological_structure
TMA B-Disease_disorder
lesions O
. O

No O
other O
apparent O
cause O
of O
thrombotic B-Detailed_description
microvascular B-Sign_symptom
involvement I-Sign_symptom
was O
noted O
. O

Notably O
, O
there O
was O
no O
evidence O
for O
infection O
with O
shiga B-Disease_disorder
toxin-producing I-Disease_disorder
germs I-Disease_disorder
, O
ADAMTS-13 B-Diagnostic_procedure
activity I-Diagnostic_procedure
was O
decreased B-Lab_value
up B-Lab_value
to I-Lab_value
14 I-Lab_value
% I-Lab_value
but O
remained O
above B-Lab_value
5 I-Lab_value
% I-Lab_value
, O
and O
the O
alternative B-Diagnostic_procedure
complement I-Diagnostic_procedure
pathway I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Plasma B-Therapeutic_procedure
exchange I-Therapeutic_procedure
was O
initiated O
due O
to O
the O
kidney B-Biological_structure
histological O
lesions B-Sign_symptom
and O
the O
multifocal B-Detailed_description
ischemic B-Detailed_description
brain B-Biological_structure
lesions B-Sign_symptom
. O

It O
was O
discontinued B-Detailed_description
after B-Date
1 I-Date
month I-Date
after O
the O
onset O
of O
the O
disease O
, O
since O
the O
patient O
's O
condition B-Diagnostic_procedure
remained O
stable B-Lab_value
. O

Furthermore O
, O
chemotherapy B-Medication
including O
6 O
courses O
of O
rituximab B-Medication
( O
375 B-Dosage
mg/m2 I-Dosage
) O
, O
cyclophosphamide B-Medication
( O
750 B-Dosage
mg/m2 I-Dosage
) O
, O
and O
dexamethasone B-Medication
( O
40 B-Dosage
mg/day I-Dosage
from O
day B-Duration
1 I-Duration
to I-Duration
day I-Duration
4 I-Duration
) O
was O
started O
together O
with O
plasma B-Therapeutic_procedure
exchanges I-Therapeutic_procedure
( O
chemotherapy O
was O
performed O
immediately O
after O
plasma O
exchanges O
) O
. O

Courses B-Coreference
were O
performed O
every B-Frequency
3 I-Frequency
weeks I-Frequency
. O

Clinical O
manifestations O
of O
vascular B-Disease_disorder
leak I-Disease_disorder
syndrome I-Disease_disorder
regressed O
, O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
normalized B-Lab_value
, O
and O
serum B-Detailed_description
VEGF B-Diagnostic_procedure
level O
decreased B-Lab_value
to O
825 B-Lab_value
pg/mL I-Lab_value
after O
1 B-Quantitative_concept
course I-Quantitative_concept
of O
chemotherapy B-Medication
. O

The O
patient O
was O
discharged B-Clinical_event
43 B-Date
days I-Date
after I-Date
admission O
. O

No O
neurological B-Disease_disorder
event I-Disease_disorder
occurred O
after O
initiating O
the O
treatment O
. O

Thoraco-abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
was O
performed O
after O
6 B-Quantitative_concept
courses I-Quantitative_concept
of O
chemotherapy B-Medication
, O
showing O
a O
normal B-Lab_value
liver B-Biological_structure
and O
spleen B-Biological_structure
size B-Diagnostic_procedure
and O
no O
lymph B-Biological_structure
node I-Biological_structure
enlargement B-Sign_symptom
. O

One B-Date
year I-Date
after I-Date
the O
diagnosis B-Clinical_event
, O
remission O
of O
MCD B-Disease_disorder
is O
persistent O
and O
plasma B-Detailed_description
creatinine B-Diagnostic_procedure
is O
86 B-Lab_value
μmol/L I-Lab_value
, O
with O
no O
proteinuria B-Sign_symptom
. O

The O
patient O
is O
an O
18-year-old B-Age
Han B-Personal_background
female B-Sex
admitted B-Clinical_event
to O
Peking B-Nonbiological_location
Union I-Nonbiological_location
Medical I-Nonbiological_location
College I-Nonbiological_location
Hospital I-Nonbiological_location
due O
to O
adrenal B-Disease_disorder
crisis I-Disease_disorder
triggered O
by O
pneumonia B-Disease_disorder
. O

She O
has O
developed O
recurrent B-Detailed_description
respiratory B-History
infections I-History
since I-History
age I-History
5 I-History
, O
and O
failed B-History
to I-History
respond I-History
to I-History
multiple I-History
hepatitis I-History
B I-History
virus I-History
( I-History
HBV I-History
) I-History
vaccinations I-History
. O

Reduced B-Lab_value
serum B-History
cortisol I-History
and I-History
ACTH I-History
levels I-History
were I-History
discovered I-History
at I-History
16 I-History
when O
glucocorticoid B-Medication
replacement I-Medication
was O
initiated O
. O

In O
addition O
, O
hair B-Sign_symptom
loss I-Sign_symptom
started B-History
from I-History
age I-History
4 I-History
, O
and O
absence B-Sign_symptom
of I-Sign_symptom
pubic I-Sign_symptom
and I-Sign_symptom
axillary I-Sign_symptom
hair I-Sign_symptom
was B-History
noticed I-History
after I-History
development I-History
of I-History
regular I-History
menstruation I-History
. O

Her O
history O
includes O
nephrotic B-Disease_disorder
syndrome I-Disease_disorder
, O
which O
was O
confirmed O
to O
be O
minimal B-Disease_disorder
change I-Disease_disorder
nephropathy I-Disease_disorder
by B-History
renal I-History
biopsy I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
at O
admission O
revealed O
alopecia B-Disease_disorder
totalis I-Disease_disorder
, O
oral B-Biological_structure
candidiasis B-Disease_disorder
, O
hypohidrosis B-Disease_disorder
, O
and O
trachyonychia B-Sign_symptom
. O

Facial B-Biological_structure
or O
dental B-Biological_structure
abnormalities B-Sign_symptom
was O
not O
noted O
. O

She O
is O
the O
only B-Family_history
child I-Family_history
in O
her O
family O
. O

Symptom B-Family_history
and I-Family_history
signs I-Family_history
of I-Family_history
the I-Family_history
above I-Family_history
disorders I-Family_history
were I-Family_history
not I-Family_history
identified I-Family_history
among I-Family_history
her I-Family_history
nonconsanguineous I-Family_history
parents I-Family_history
. O

Initial O
immunologic B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
remarkable O
panhypogammaglobulinemia B-Sign_symptom
and O
reduced B-Lab_value
cell B-Diagnostic_procedure
counts I-Diagnostic_procedure
of O
B B-Diagnostic_procedure
cells I-Diagnostic_procedure
, O
T B-Diagnostic_procedure
cells I-Diagnostic_procedure
, O
and O
natural B-Diagnostic_procedure
killer I-Diagnostic_procedure
( I-Diagnostic_procedure
NK I-Diagnostic_procedure
) I-Diagnostic_procedure
cells I-Diagnostic_procedure
( O
Table O
( O
Table1 O
) O
.1 O
) O
. O

CD4/CD8 B-Diagnostic_procedure
ratio I-Diagnostic_procedure
, O
as O
well O
as O
expression B-Diagnostic_procedure
levels I-Diagnostic_procedure
of O
various O
T-cell B-Diagnostic_procedure
activation I-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
in O
normal B-Lab_value
range I-Lab_value
, O
except O
increased B-Lab_value
proportion B-Diagnostic_procedure
of I-Diagnostic_procedure
CD8 I-Diagnostic_procedure
+ I-Diagnostic_procedure
/ I-Diagnostic_procedure
HLA-DR I-Diagnostic_procedure
+ I-Diagnostic_procedure
subset I-Diagnostic_procedure
. O

Antinuclear B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
( O
ANA B-Diagnostic_procedure
) O
and O
antineutrophil B-Diagnostic_procedure
cytoplasmic I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
( O
ANCA B-Diagnostic_procedure
) O
were O
negative B-Lab_value
. O

When O
regular O
hydrocortisone B-Medication
replacement I-Medication
was O
suspended O
, O
her O
8:00 B-Time
am I-Time
serum B-Detailed_description
cortisol B-Diagnostic_procedure
was O
measured O
at O
0.93 B-Lab_value
μg/dL I-Lab_value
, O
with O
ACTH B-Diagnostic_procedure
< B-Lab_value
5.00 I-Lab_value
pg/mL I-Lab_value
. O

Serum B-Detailed_description
levels O
of O
other O
anterior B-Diagnostic_procedure
pituitary I-Diagnostic_procedure
hormones I-Diagnostic_procedure
, O
as O
well O
as O
serum B-Detailed_description
and O
urine B-Detailed_description
osmolality B-Diagnostic_procedure
were O
within B-Lab_value
reference I-Lab_value
range I-Lab_value
. O

Both O
antiperoxidase B-Diagnostic_procedure
antibody I-Diagnostic_procedure
and O
antithyroglobulin B-Diagnostic_procedure
antibody I-Diagnostic_procedure
were O
negative B-Lab_value
. O

She O
had O
positive B-Lab_value
antiprotein B-Diagnostic_procedure
tyrosine I-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
antibody I-Diagnostic_procedure
, O
with O
fasting B-Diagnostic_procedure
blood I-Diagnostic_procedure
glucose I-Diagnostic_procedure
at O
5.9 B-Lab_value
mmol/L I-Lab_value
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
with O
contrast B-Detailed_description
suggested O
a O
normal B-Lab_value
pituitary B-Diagnostic_procedure
. O

She O
was O
diagnosed O
with O
CVID B-Disease_disorder
, O
isolated B-Disease_disorder
ACTH I-Disease_disorder
deficiency I-Disease_disorder
, O
and O
ectodermal B-Disease_disorder
dysplasia I-Disease_disorder
. O

Symptoms O
of O
fever B-Sign_symptom
, O
cough B-Sign_symptom
, O
and O
vomiting B-Sign_symptom
cleared O
with O
antibiotics B-Medication
and O
stress-dose B-Detailed_description
hydrocortisone B-Medication
treatment O
. O

Intravenous B-Medication
immunoglobulin I-Medication
( O
IVIG B-Medication
) O
therapy O
was O
suggested O
but O
denied O
by O
the O
parents O
. O

At O
follow-up B-Clinical_event
1 B-Date
year I-Date
after I-Date
her O
discharge O
, O
she O
reported O
no O
infection B-Disease_disorder
events O
during B-Duration
the I-Duration
previous I-Duration
year I-Duration
as O
she O
stayed B-Clinical_event
at O
home B-Nonbiological_location
and O
avoided O
outdoor B-Activity
activities I-Activity
. O

Her O
glucocorticoid B-Medication
replacement I-Medication
was O
withdrawn O
4 B-Date
months I-Date
after I-Date
discharge O
, O
and O
she O
has O
only O
received O
traditional B-Medication
Chinese I-Medication
medicine I-Medication
ever O
since O
. O

Lymphocyte B-Diagnostic_procedure
subsets I-Diagnostic_procedure
test I-Diagnostic_procedure
done O
at O
the O
follow-up O
documented O
increased B-Lab_value
levels O
of O
B B-Diagnostic_procedure
cells I-Diagnostic_procedure
and O
T B-Diagnostic_procedure
cells I-Diagnostic_procedure
, O
while O
NK B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
remained O
below B-Lab_value
normal I-Lab_value
limit I-Lab_value
. O

To O
assess O
her O
NK-cell O
activity O
, O
a O
flow B-Diagnostic_procedure
cytometric I-Diagnostic_procedure
procedure I-Diagnostic_procedure
was O
done O
following O
previously O
described O
method O
. O

[ O
10,11 O
] O
Effector O
to O
target O
cell O
ratio O
was O
set O
at O
10:1 O
. O

Less O
apoptosis O
of O
target O
cell O
line O
( O
12.43 O
% O
, O
reference O
range O
15.11 O
– O
26.91 O
% O
) O
was O
observed O
when O
cocultured O
with O
patient O
's O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
, O
indicating O
a O
deficient O
NK-cell O
cytotoxicity O
. O

A O
70-year-old B-Age
male B-Sex
was O
admitted B-Clinical_event
to O
our O
hospital O
for O
perioperative B-Detailed_description
cardiac B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
of O
abdominal B-Biological_structure
aortic I-Biological_structure
aneurysm B-Disease_disorder
. O

The O
patient O
had O
undergone O
coronary B-Therapeutic_procedure
artery I-Therapeutic_procedure
bypass I-Therapeutic_procedure
grafting I-Therapeutic_procedure
( O
CABG B-Therapeutic_procedure
) O
for O
severe B-Severity
stenosis B-Sign_symptom
of O
the O
left B-Biological_structure
main I-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
( O
LMCA B-Biological_structure
) O
4 B-Date
years I-Date
before I-Date
, O
which O
consisted O
of O
the O
right B-Biological_structure
internal I-Biological_structure
thoracic I-Biological_structure
artery I-Biological_structure
( O
RITA B-Biological_structure
) O
to O
the O
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
( O
LAD B-Biological_structure
) O
and O
saphenous B-Therapeutic_procedure
vein I-Therapeutic_procedure
graft I-Therapeutic_procedure
( O
SVG B-Therapeutic_procedure
) O
to O
the O
left B-Biological_structure
circumflex I-Biological_structure
artery I-Biological_structure
( O
LCX B-Biological_structure
) O
. O

Due O
to O
continual O
growth O
of O
the O
abdominal B-Biological_structure
aortic I-Biological_structure
aneurysm B-Disease_disorder
over O
the O
years O
, O
surgery B-Therapeutic_procedure
was O
indicated O
. O

Left B-Biological_structure
coronary I-Biological_structure
angiogram B-Diagnostic_procedure
showed O
90 B-Lab_value
% I-Lab_value
stenosis B-Sign_symptom
of O
the O
LMCA B-Biological_structure
and O
total B-Severity
occlusion B-Sign_symptom
of O
both B-Detailed_description
grafts B-Coreference
. O

PCI B-Therapeutic_procedure
was O
performed O
for O
LMCA B-Biological_structure
stenosis B-Sign_symptom
( O
Fig. O
1 O
) O
. O

A O
7-Fr B-Detailed_description
sheath B-Therapeutic_procedure
was O
inserted O
into O
the O
right B-Biological_structure
femoral I-Biological_structure
artery I-Biological_structure
, O
and O
a O
CLS4 B-Detailed_description
guiding B-Detailed_description
catheter B-Therapeutic_procedure
( O
Boston B-Detailed_description
Scientific I-Detailed_description
, I-Detailed_description
Natick I-Detailed_description
, I-Detailed_description
MA I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
was O
engaged O
into O
the O
left B-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
( O
LCA B-Biological_structure
) O
ostium B-Biological_structure
. O

A O
guidewire B-Therapeutic_procedure
( O
SION B-Detailed_description
Blue I-Detailed_description
, O
Asahi B-Detailed_description
Intecc I-Detailed_description
, I-Detailed_description
Aichi I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
was O
inserted O
into O
the O
distal B-Biological_structure
LAD I-Biological_structure
, O
and O
another O
guidewire B-Therapeutic_procedure
( O
Hi-Torque B-Detailed_description
Pilot I-Detailed_description
50 I-Detailed_description
, O
Abbott B-Detailed_description
Vascular I-Detailed_description
, I-Detailed_description
Santa I-Detailed_description
Clara I-Detailed_description
, I-Detailed_description
California I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
was O
inserted O
into O
the O
distal B-Biological_structure
LCX I-Biological_structure
. O

Intravascular B-Diagnostic_procedure
ultrasound I-Diagnostic_procedure
( O
IVUS B-Diagnostic_procedure
) O
( O
Intra-focus B-Detailed_description
WR I-Detailed_description
, O
Terumo B-Detailed_description
Corp I-Detailed_description
, I-Detailed_description
Tokyo I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
demonstrated O
heavy B-Severity
circumferential B-Detailed_description
calcification B-Sign_symptom
in O
the O
LMCA B-Biological_structure
lesion B-Sign_symptom
. O

After O
a O
4.0 B-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Quantum B-Detailed_description
Maverick I-Detailed_description
balloon B-Detailed_description
catheter B-Therapeutic_procedure
( O
Boston B-Detailed_description
Scientific I-Detailed_description
) O
was O
inflated O
in O
the O
lesion B-Sign_symptom
, O
LCA B-Biological_structure
angiogram B-Diagnostic_procedure
revealed O
a O
large B-Severity
dissection B-Sign_symptom
( O
Fig. O
2 O
) O
. O

A O
4.0 B-Detailed_description
× I-Detailed_description
28-mm I-Detailed_description
Multi-Link B-Detailed_description
Vision I-Detailed_description
stent B-Therapeutic_procedure
( O
Abbott B-Detailed_description
Vascular I-Detailed_description
) O
was O
immediately O
deployed O
. O

Angiographic B-Diagnostic_procedure
image O
of O
the O
residual B-Detailed_description
dissection B-Sign_symptom
disappeared O
and O
the O
stent B-Therapeutic_procedure
was O
dilated O
by O
a O
5.0 B-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Quantum B-Detailed_description
Maverick I-Detailed_description
balloon B-Therapeutic_procedure
catheter I-Therapeutic_procedure
. O

The O
absence O
of O
residual B-Detailed_description
dissection B-Sign_symptom
was O
confirmed O
by O
angiography B-Diagnostic_procedure
after O
stent B-Therapeutic_procedure
implantation O
. O

Next O
, O
LMCA-LAD B-Biological_structure
and O
LMCA-LCX B-Biological_structure
kissing B-Detailed_description
balloon I-Detailed_description
angioplasty B-Therapeutic_procedure
was O
initiated O
using O
a O
4.0 B-Detailed_description
× I-Detailed_description
28-mm I-Detailed_description
stent B-Detailed_description
delivery I-Detailed_description
balloon B-Therapeutic_procedure
in O
the O
LAD B-Biological_structure
and O
a O
3.0 B-Detailed_description
mm I-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Ikazuchi B-Detailed_description
balloon B-Therapeutic_procedure
( O
Kaneka B-Detailed_description
Medics I-Detailed_description
, I-Detailed_description
Tokyo I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
in O
the O
LCX B-Biological_structure
. O

The O
final O
angiographic B-Diagnostic_procedure
imaging O
showed O
optimal B-Lab_value
results B-Diagnostic_procedure
, O
and O
IVUS B-Diagnostic_procedure
imaging O
of O
the O
lesion B-Sign_symptom
showed O
completely B-Lab_value
sealing B-Diagnostic_procedure
by O
the O
stent B-Therapeutic_procedure
( O
Fig. O
3 O
) O
. O

A O
large B-Severity
hematoma B-Sign_symptom
at O
the O
femoral B-Biological_structure
puncture I-Biological_structure
site I-Biological_structure
and O
local B-Detailed_description
bleeding B-Sign_symptom
was O
observed O
after O
removal O
of O
the O
femoral B-Therapeutic_procedure
sheath I-Therapeutic_procedure
and O
manual B-Therapeutic_procedure
compression I-Therapeutic_procedure
was O
applied O
for O
haemostasis B-Therapeutic_procedure
. O

The O
hematoma B-Sign_symptom
did O
not O
appear O
to O
have O
spread O
the B-Date
next I-Date
day I-Date
and O
the O
patient O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
on O
the O
fifth B-Date
day I-Date
after I-Date
PCI B-Therapeutic_procedure
. O

Unexpectedly O
, O
the O
patient O
was O
admitted B-Clinical_event
to O
our O
emergency B-Nonbiological_location
room I-Nonbiological_location
with O
new-onset O
chest B-Biological_structure
pain B-Sign_symptom
and O
dyspnoea B-Sign_symptom
the O
next B-Date
day I-Date
after I-Date
the O
discharge B-Clinical_event
. O

His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
indicated O
cardiogenic B-Sign_symptom
shock I-Sign_symptom
. O

Electrocardiogram B-Diagnostic_procedure
showed O
ST B-Sign_symptom
elevation I-Sign_symptom
in O
leads B-Diagnostic_procedure
V1-V3 I-Diagnostic_procedure
. O

Although O
echocardiography B-Diagnostic_procedure
could O
not O
detect O
left B-Biological_structure
ventricular I-Biological_structure
asynergy B-Sign_symptom
, O
a O
large O
mass B-Sign_symptom
on O
the O
outflow B-Biological_structure
tract I-Biological_structure
of I-Biological_structure
right I-Biological_structure
ventricular I-Biological_structure
chamber I-Biological_structure
was O
observed O
( O
Fig. O
4 O
) O
. O

Contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
showed O
a O
40-mm B-Distance
hematoma B-Sign_symptom
compressing B-Sign_symptom
the O
main B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
and O
the O
right B-Biological_structure
ventricle I-Biological_structure
( O
Fig. O
5 O
) O
. O

During O
examination B-Diagnostic_procedure
, O
the O
patient O
suffered O
sudden B-Detailed_description
cardiopulmonary B-Disease_disorder
arrest I-Disease_disorder
. O

He O
received O
immediate B-Detailed_description
cardiopulmonary B-Therapeutic_procedure
resuscitation I-Therapeutic_procedure
and O
returned O
to O
spontaneous B-Sign_symptom
circulation I-Sign_symptom
after O
the O
insertion O
of O
a O
percutaneous B-Detailed_description
cardiopulmonary B-Therapeutic_procedure
support I-Therapeutic_procedure
device I-Therapeutic_procedure
. O

The O
patient O
underwent O
emergent B-Detailed_description
surgery B-Therapeutic_procedure
for O
the O
removal O
of O
the O
hematoma B-Sign_symptom
after O
informed O
consent O
was O
obtained O
from O
the O
patient O
's O
family O
. O

During O
surgery B-Therapeutic_procedure
, O
large B-Severity
, O
dark B-Color
red I-Color
clots B-Sign_symptom
between O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
and O
aorta B-Biological_structure
were O
observed O
. O

The O
suspected O
origin O
of O
the O
epicardial B-Biological_structure
hematoma B-Sign_symptom
was O
blood B-Sign_symptom
oozing I-Sign_symptom
from O
the O
LMCA B-Biological_structure
stent I-Biological_structure
site I-Biological_structure
. O

Despite O
successful O
surgical B-Therapeutic_procedure
repair I-Therapeutic_procedure
, O
the O
patient O
died B-Outcome
from O
aortic B-Disease_disorder
rupture I-Disease_disorder
induced O
by O
external B-Therapeutic_procedure
cardiac I-Therapeutic_procedure
massage I-Therapeutic_procedure
. O

The O
patient O
is O
a O
59-year-old B-Age
man B-Sex
diagnosed O
with O
PD B-Disease_disorder
at O
the O
age B-Date
of I-Date
49 I-Date
years I-Date
. O

Fluctuations B-Sign_symptom
with O
recurring O
“ B-Other_event
off I-Other_event
” I-Other_event
states I-Other_event
and O
peak B-Detailed_description
dose I-Detailed_description
dyskinesias B-Disease_disorder
had O
severely O
diminished B-Lab_value
the O
patient O
’s O
quality B-Diagnostic_procedure
of I-Diagnostic_procedure
life I-Diagnostic_procedure
. O

Thus O
, O
the O
patient O
was O
deemed O
a O
candidate O
for O
bilateral B-Detailed_description
subthalamic B-Detailed_description
DBS B-Therapeutic_procedure
. O

Multidisciplinary B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
with O
75 B-Lab_value
% I-Lab_value
positive I-Lab_value
response O
in O
the O
standardized B-Diagnostic_procedure
levodopa I-Diagnostic_procedure
test I-Diagnostic_procedure
, O
exclusion O
of O
cognitive B-Disease_disorder
decline I-Disease_disorder
or O
psychiatric B-Disease_disorder
comorbitity I-Disease_disorder
, O
and O
absence O
of O
structural O
brain B-Disease_disorder
damage I-Disease_disorder
potentially O
relevant O
to O
the O
lead O
placement O
led O
to O
the O
unanimous O
decision O
for O
DBS B-Therapeutic_procedure
placement O
. O

When O
decision O
was O
made O
to O
proceed O
to O
surgery B-Therapeutic_procedure
the O
medication B-Medication
consisted O
of O
1112.5 B-Dosage
mg I-Dosage
of O
levodopa B-Medication
and O
150 B-Dosage
mg I-Dosage
of O
piribedil B-Medication
. O

There O
was O
no B-History
history I-History
of I-History
orofacial I-History
or I-History
cervical I-History
dystonia I-History
. O

In O
the O
“ B-Other_event
on I-Other_event
” I-Other_event
state I-Other_event
the O
patient O
was O
alert B-Sign_symptom
without O
any O
signs B-Sign_symptom
of I-Sign_symptom
psychiatric I-Sign_symptom
comorbidity I-Sign_symptom
. O

Neuropsychological B-Diagnostic_procedure
testing I-Diagnostic_procedure
was O
adequate B-Lab_value
. O

No O
cranial B-Biological_structure
nerve B-Sign_symptom
deficits I-Sign_symptom
were O
found O
and O
swallowing B-Diagnostic_procedure
was O
normal B-Lab_value
. O

Gait B-Diagnostic_procedure
and O
postural B-Diagnostic_procedure
stability I-Diagnostic_procedure
was O
normal B-Lab_value
with O
minimal B-Severity
rigidity B-Sign_symptom
in O
the O
neck B-Biological_structure
and O
right B-Biological_structure
arm I-Biological_structure
. O

Coordinative B-Diagnostic_procedure
motor I-Diagnostic_procedure
skills I-Diagnostic_procedure
such O
as O
rapid O
pro- B-Diagnostic_procedure
and I-Diagnostic_procedure
supination I-Diagnostic_procedure
were O
restricted B-Lab_value
in O
the O
left B-Biological_structure
hand I-Biological_structure
. O

Dyskinesias B-Sign_symptom
were O
evident O
with O
moderate B-Severity
impairment B-Sign_symptom
. O

In O
the O
“ B-Other_event
off I-Other_event
” I-Other_event
state I-Other_event
after O
the O
medication B-Medication
was O
held O
for O
12 B-Duration
h I-Duration
, O
the O
patient O
showed O
mild B-Severity
dysarthria B-Sign_symptom
and O
dysphonia B-Sign_symptom
, O
resting B-Detailed_description
tremor B-Sign_symptom
of O
the O
right B-Biological_structure
arm I-Biological_structure
and O
leg B-Biological_structure
, O
as O
well O
as O
slight B-Severity
action B-Detailed_description
tremor B-Sign_symptom
in O
the O
right B-Biological_structure
hand I-Biological_structure
. O

Rigidity B-Sign_symptom
was O
severe B-Severity
in O
the O
neck B-Biological_structure
, O
marked B-Severity
in O
the O
right B-Biological_structure
, O
and O
mild B-Severity
on O
the O
left B-Biological_structure
side I-Biological_structure
. O

Motor B-Diagnostic_procedure
skills I-Diagnostic_procedure
of O
the O
hands B-Biological_structure
were O
markedly O
impaired B-Lab_value
. O

Gait B-Diagnostic_procedure
was O
slow B-Lab_value
but O
unaided B-Lab_value
and O
comprised O
of O
by O
intermittent B-Frequency
freezing B-Sign_symptom
; O
there O
was O
mild B-Severity
dystonic B-Sign_symptom
posturing I-Sign_symptom
of O
the O
right B-Biological_structure
foot I-Biological_structure
. O

There O
were O
no O
signs O
of O
laryngeal B-Biological_structure
spasms B-Sign_symptom
, O
however O
. O

On O
the O
day B-Date
before I-Date
surgery B-Therapeutic_procedure
, O
the O
last O
dose O
of O
dopaminergic B-Medication
medication I-Medication
was O
administered O
at O
07:00 B-Time
p.m. I-Time
, O
the O
bedtime B-Administration
dose I-Administration
of O
levodopa B-Medication
was O
held O
to O
facilitate O
intraoperative B-Diagnostic_procedure
testing I-Diagnostic_procedure
. O

On O
the O
day B-Date
of I-Date
the O
operation B-Therapeutic_procedure
, O
the O
patient O
underwent O
placement O
of O
the O
stereotactic B-Therapeutic_procedure
frame I-Therapeutic_procedure
under O
local B-Medication
anaesthesia I-Medication
around O
09:00 B-Time
a.m I-Time
. O

After O
planning O
standard O
STN O
coordinates O
and O
trajectories O
, O
the O
patient O
was O
placed O
in O
a O
semi-sitting B-Activity
position I-Activity
on O
the O
O.R. B-Nonbiological_location
table O
, O
with O
the O
frame O
attached O
to O
the O
table O
. O

At O
the O
patient O
’s O
request O
, O
the O
head B-Biological_structure
was O
slightly O
flexed B-Activity
anteriorly B-Detailed_description
for O
comfort O
. O

The O
left B-Detailed_description
electrode B-Therapeutic_procedure
was O
placed O
uneventfully O
. O

When O
performing O
the O
bur B-Therapeutic_procedure
hole I-Therapeutic_procedure
on O
the O
right B-Biological_structure
side I-Biological_structure
, O
the O
patient O
complained O
of O
cramping B-Sign_symptom
in O
the O
neck B-Biological_structure
and O
facial B-Biological_structure
muscles I-Biological_structure
as O
well O
as O
difficulties B-Sign_symptom
breathing I-Sign_symptom
although O
at O
that O
point O
, O
pulse B-Diagnostic_procedure
oximetry I-Diagnostic_procedure
showed O
good B-Lab_value
saturation I-Lab_value
readings O
at O
≥ B-Lab_value
95 I-Lab_value
% I-Lab_value
. O

He O
progressed O
to O
dystonic B-Sign_symptom
dysarthria I-Sign_symptom
[ O
6 O
] O
. O

Microelectrode B-Diagnostic_procedure
recordings I-Diagnostic_procedure
had O
already O
been O
done O
and O
macroelectrode B-Diagnostic_procedure
test I-Diagnostic_procedure
stimulation I-Diagnostic_procedure
was O
about O
to O
begin O
, O
when O
the O
patient O
showed O
high-pitched B-Detailed_description
inspiratory B-Detailed_description
stridor B-Sign_symptom
. O

Pulse B-Diagnostic_procedure
oximetry I-Diagnostic_procedure
showed O
decreasing B-Lab_value
oxygen I-Lab_value
saturation I-Lab_value
at O
02:15 B-Time
p.m. I-Time
and O
, O
shortly O
thereafter O
, O
narrow B-Detailed_description
complex B-Detailed_description
tachycardia B-Sign_symptom
was O
noted O
. O

Within B-Time
a I-Time
minute I-Time
, O
the O
patient O
became O
unresponsive B-Sign_symptom
. O

Cardiac B-Therapeutic_procedure
resuscitation I-Therapeutic_procedure
was O
initiated O
and O
the O
patient O
was O
fiberoptically B-Detailed_description
intubated B-Therapeutic_procedure
after O
removal O
of O
the O
front B-Therapeutic_procedure
bar I-Therapeutic_procedure
of O
the O
stereotactic B-Therapeutic_procedure
frame I-Therapeutic_procedure
. O

During O
fiberoptic B-Detailed_description
intubation B-Therapeutic_procedure
laryngeal B-Biological_structure
spasm B-Sign_symptom
was O
confirmed O
visually O
. O

A O
transthoracic B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
obtained O
immediately O
after O
successful O
resuscitation O
showed O
no O
cardiac B-Biological_structure
pathology B-Sign_symptom
or O
any O
air B-Sign_symptom
bubbles I-Sign_symptom
. O

Stimulation B-Therapeutic_procedure
using O
the O
implanted O
lead O
to O
resolve O
the O
symptoms O
was O
not O
possible O
as O
at O
that O
time O
the O
lead O
was O
subcutaneously O
tunnelled O
with O
no O
impulse O
generator O
attached O
. O

The O
right B-Detailed_description
permanent B-Detailed_description
electrode B-Therapeutic_procedure
was O
placed O
without O
further O
testing O
according O
to O
microelectrode B-Diagnostic_procedure
recordings I-Diagnostic_procedure
. O

50 B-Dosage
mg I-Dosage
levodopa B-Medication
was O
administered O
over O
a O
nasogastric B-Administration
tube I-Administration
every B-Dosage
two I-Dosage
hours I-Dosage
during O
the O
subsequent O
postoperative B-Diagnostic_procedure
period I-Diagnostic_procedure
. O

Postoperative O
head B-Biological_structure
CT B-Diagnostic_procedure
scan O
done O
immediately O
after O
the O
procedure O
was O
normal O
. O

The O
patient O
was O
transferred B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
and O
was O
extubated B-Therapeutic_procedure
at O
02:00 B-Time
p.m. I-Time
the O
following B-Date
day I-Date
without O
any O
neurological B-Sign_symptom
deficit I-Sign_symptom
or O
signs O
of O
laryngeal B-Biological_structure
spasms B-Sign_symptom
. O

By O
then O
, O
the O
nasogastric B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
discontinued O
and O
the O
preoperative O
medication B-Medication
was O
resumed O
. O

Cardiac B-Diagnostic_procedure
workup I-Diagnostic_procedure
was O
negative B-Lab_value
. O

The O
impulse B-Therapeutic_procedure
generator I-Therapeutic_procedure
was O
implanted O
7 B-Date
days I-Date
later I-Date
and O
the O
patient O
showed O
good B-Lab_value
symptom B-Diagnostic_procedure
control I-Diagnostic_procedure
of O
PD B-Disease_disorder
. O

A O
47-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
the O
hospital B-Nonbiological_location
with O
a O
1-month B-Duration
history O
of O
abdominal B-Biological_structure
distention B-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
huge B-Severity
mass B-Sign_symptom
in O
the O
lower B-Biological_structure
abdomen I-Biological_structure
. O

The O
peripheral B-Diagnostic_procedure
blood I-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
elevated B-Lab_value
levels O
of O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
CEA B-Diagnostic_procedure
, O
335.2 B-Lab_value
ng/mL I-Lab_value
[ O
normal O
, O
< O
5 O
ng/mL O
] O
) O
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
CA B-Diagnostic_procedure
) O
125 B-Detailed_description
( O
219 B-Lab_value
U/mL I-Lab_value
[ O
normal O
, O
< O
45 O
U/mL O
] O
) O
but O
a O
normal B-Lab_value
level O
of O
CA19-9 B-Diagnostic_procedure
( O
9 B-Lab_value
U/mL I-Lab_value
[ O
normal O
, O
< O
37 O
U/mL O
] O
) O
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
demonstrated O
a O
large B-Severity
, O
round B-Shape
mass B-Sign_symptom
with O
a O
maximum O
diameter O
of O
15 B-Distance
cm I-Distance
in O
the O
pelvic B-Biological_structure
cavity I-Biological_structure
without O
the O
presence O
of O
ascites B-Sign_symptom
or O
pleural B-Sign_symptom
effusion I-Sign_symptom
( O
Fig. O
1a O
, O
b O
) O
. O

Colonoscopy B-Diagnostic_procedure
identified O
an O
elevated B-Lab_value
lesion B-Sign_symptom
with O
severe B-Severity
stenosis B-Sign_symptom
in O
the O
sigmoid B-Biological_structure
colon I-Biological_structure
, O
and O
histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
biopsy B-Diagnostic_procedure
specimens I-Diagnostic_procedure
from O
the O
tumor B-Coreference
showed O
moderately B-Lab_value
differentiated I-Lab_value
adenocarcinoma B-Disease_disorder
. O

Although O
we O
scheduled O
an O
early O
operation B-Therapeutic_procedure
, O
the O
patient O
developed O
acute B-Lab_value
dyspnea B-Sign_symptom
and O
general B-Lab_value
edema B-Sign_symptom
2 B-Date
weeks I-Date
after I-Date
the O
first O
CT O
scan O
. O

The O
second O
CT B-Diagnostic_procedure
scan O
examination O
demonstrated O
massive B-Severity
bilateral B-Detailed_description
pleural B-Sign_symptom
effusion I-Sign_symptom
with O
atelectasis B-Sign_symptom
and O
ascites B-Sign_symptom
( O
Fig. O
2a O
, O
b O
) O
. O

Thoracic B-Therapeutic_procedure
drainage I-Therapeutic_procedure
and O
laparotomy B-Therapeutic_procedure
were O
emergently O
performed O
. O

Macroscopically B-Diagnostic_procedure
, O
the O
tumor B-Coreference
in O
the O
sigmoid B-Biological_structure
colon I-Biological_structure
had O
invaded B-Sign_symptom
the O
serosa B-Biological_structure
, O
and O
the O
huge B-Severity
pelvic B-Biological_structure
mass B-Sign_symptom
was O
found O
to O
contain O
a O
right B-Detailed_description
ovarian B-Disease_disorder
tumor I-Disease_disorder
. O

Several O
small O
nodules B-Sign_symptom
of O
peritoneal B-Biological_structure
dissemination B-Sign_symptom
were O
distributed O
over O
the O
greater B-Biological_structure
omentum I-Biological_structure
. O

Perioperatively O
, O
3800 B-Volume
mL I-Volume
of O
serous B-Lab_value
ascitic B-Sign_symptom
fluid I-Sign_symptom
was O
drained B-Therapeutic_procedure
. O

Cytodiagnosis B-Diagnostic_procedure
of O
the O
fluid B-Sign_symptom
drained O
from O
the O
ascites B-Sign_symptom
and O
pleural B-Sign_symptom
effusion I-Sign_symptom
revealed O
no B-Lab_value
tumor B-Diagnostic_procedure
cells I-Diagnostic_procedure
. O

Bilateral B-Detailed_description
oophorectomy B-Therapeutic_procedure
, O
total B-Detailed_description
hysterectomy B-Therapeutic_procedure
, O
omentectomy B-Therapeutic_procedure
, O
and O
sigmoidectomy B-Therapeutic_procedure
with O
regional B-Detailed_description
node B-Therapeutic_procedure
dissection I-Therapeutic_procedure
were O
performed O
( O
Fig. O
3a O
) O
. O

Histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
resected O
specimens O
showed O
moderately B-Lab_value
differentiated I-Lab_value
adenocarcinoma B-Disease_disorder
in O
the O
tumors B-Sign_symptom
of O
both O
the O
ovaries B-Biological_structure
and O
the O
sigmoid B-Biological_structure
colon I-Biological_structure
( O
Fig. O
3b O
) O
. O

The O
dissected O
paracolic B-Biological_structure
nodes I-Biological_structure
showed O
malignant B-Sign_symptom
cells I-Sign_symptom
. O

Immunohistochemically B-Diagnostic_procedure
, O
tumor B-Sign_symptom
cells I-Sign_symptom
from O
the O
ovaries B-Biological_structure
and O
the O
colon B-Biological_structure
both O
showed O
positive B-Lab_value
expression I-Lab_value
of O
cytokeratin B-Diagnostic_procedure
20 I-Diagnostic_procedure
( O
CK20 B-Diagnostic_procedure
) O
but O
no B-Lab_value
expression I-Lab_value
of O
cytokeratin B-Diagnostic_procedure
7 I-Diagnostic_procedure
( O
CK7 B-Diagnostic_procedure
) O
, O
confirming O
that O
the O
ovarian B-Disease_disorder
tumors I-Disease_disorder
were O
metastases B-Sign_symptom
from O
primary B-Disease_disorder
colon I-Disease_disorder
cancer I-Disease_disorder
( O
Fig. O
4a O
, O
b O
) O
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
, O
and O
both O
pleural B-Sign_symptom
effusion I-Sign_symptom
and O
ascites B-Sign_symptom
rapidly O
resolved O
. O

Postoperatively O
, O
a O
regimen O
of O
5-fluorouracil B-Medication
( O
5-FU B-Medication
) O
, O
leucovorin B-Medication
, O
and O
oxaliplatin B-Medication
( O
FOLFOX B-Medication
) O
was O
administered O
every B-Frequency
2 I-Frequency
weeks I-Frequency
for I-Frequency
5 I-Frequency
months I-Frequency
. O

At O
29 B-Date
months I-Date
after I-Date
the O
first O
operation O
, O
the O
patient O
required O
curative O
hepatic B-Biological_structure
resection B-Therapeutic_procedure
for O
liver B-Biological_structure
metastases B-Sign_symptom
. O

At O
78 B-Date
months I-Date
after I-Date
the O
first O
operation O
, O
the O
patient O
remains O
alive B-Sign_symptom
with O
no O
evidence O
of O
a O
disease B-Disease_disorder
. O

A O
76-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
complaints O
of O
epigastralgia B-Sign_symptom
since O
a B-Date
day I-Date
prior I-Date
to O
admission B-Clinical_event
. O

Laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
on O
admission O
revealed O
an O
elevation B-Lab_value
of O
aminotransferase B-Diagnostic_procedure
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
, O
ɤ-guanosine B-Diagnostic_procedure
triphosphate I-Diagnostic_procedure
, O
and O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
. O

Serum B-Detailed_description
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
and O
tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
CEA B-Diagnostic_procedure
) O
, O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19-9 I-Diagnostic_procedure
( O
CA19-9 B-Diagnostic_procedure
) O
, O
SPan-1 B-Diagnostic_procedure
, O
and O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
( O
NSE B-Diagnostic_procedure
) O
, O
were O
all O
within B-Lab_value
normal I-Lab_value
ranges I-Lab_value
. O

Abdominal O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
and O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
cholangiopancreatography I-Diagnostic_procedure
( O
MRCP B-Diagnostic_procedure
) O
showed O
a O
mass B-Sign_symptom
in O
an O
enlarged B-Sign_symptom
gallbladder B-Biological_structure
and O
bulky B-Sign_symptom
hepatic B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
surrounding O
the O
hepatic B-Biological_structure
hilum I-Biological_structure
( O
Fig. O
1a O
, O
b O
) O
. O

There O
were O
also O
no O
apparent O
lesions B-Sign_symptom
in O
upper B-Detailed_description
and O
lower B-Detailed_description
gastrointestinal B-Diagnostic_procedure
endoscopy I-Diagnostic_procedure
. O

Endoscopic B-Diagnostic_procedure
ultrasound-guided I-Diagnostic_procedure
fine-needle I-Diagnostic_procedure
aspiration I-Diagnostic_procedure
( O
EUS-FNA B-Diagnostic_procedure
) O
was O
performed O
to O
obtain O
tissue O
from O
the O
hilar B-Biological_structure
lymph I-Biological_structure
node I-Biological_structure
. O

Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
of O
the O
specimen O
identified O
diffuse O
positivity B-Lab_value
for O
keratin B-Diagnostic_procedure
, O
CD56 B-Diagnostic_procedure
, O
and O
synaptophysin B-Diagnostic_procedure
in O
the O
tumor B-Detailed_description
cells I-Detailed_description
, O
which O
is O
consistent O
with O
NEC B-Disease_disorder
. O

An O
endoscopic B-Diagnostic_procedure
naso-gallbladder I-Diagnostic_procedure
drainage I-Diagnostic_procedure
( O
ENGBD B-Diagnostic_procedure
) O
catheter B-Detailed_description
was O
placed O
, O
and O
the O
bile B-Diagnostic_procedure
cytology I-Diagnostic_procedure
revealed O
class B-Sign_symptom
V I-Sign_symptom
malignant I-Sign_symptom
cells I-Sign_symptom
. O

Therefore O
, O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography/computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET/CT B-Diagnostic_procedure
) O
examination O
was O
performed O
to O
evaluate O
other O
primary B-Detailed_description
or O
metastatic B-Detailed_description
lesions B-Sign_symptom
. O

It O
revealed O
that O
no O
other O
accumulated O
lesions B-Sign_symptom
were O
identified O
, O
and O
the O
accumulation B-Lab_value
of O
18F B-Diagnostic_procedure
fluorodeoxyglucose I-Diagnostic_procedure
( O
FDG B-Diagnostic_procedure
) O
was O
in O
the O
gallbladder B-Biological_structure
( O
SUVmax B-Diagnostic_procedure
7.8 B-Lab_value
) O
and O
lymph B-Biological_structure
nodes I-Biological_structure
( O
SUVmax B-Diagnostic_procedure
13.4 B-Lab_value
) O
( O
Fig. O
1c O
, O
d O
) O
. O

On O
the O
basis O
of O
these O
findings O
, O
the O
most O
likely O
diagnosis O
was O
a O
gallbladder B-Biological_structure
NEC B-Disease_disorder
that O
was O
confined O
to O
the O
regional O
hepatic B-Biological_structure
hilar I-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
metastasis B-Disease_disorder
. O

Finally O
, O
we O
decided O
to O
perform O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
prior O
to O
chemotherapy B-Medication
because O
of O
concerns O
about O
complications O
developing O
from O
mechanical B-Detailed_description
obstruction B-Disease_disorder
of O
the O
hepatic B-Biological_structure
hilum I-Biological_structure
by O
the O
enlarged B-Sign_symptom
lymph B-Biological_structure
node I-Biological_structure
. O

She O
underwent O
cholecystectomy B-Therapeutic_procedure
, O
hepatic B-Biological_structure
hilar I-Biological_structure
lymphadenectomy B-Therapeutic_procedure
, O
extrahepatic B-Biological_structure
biliary I-Biological_structure
duct I-Biological_structure
resection B-Therapeutic_procedure
, O
and O
hepaticojejunostomy B-Therapeutic_procedure
. O

The O
bulky B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
were O
totally O
resected B-Therapeutic_procedure
as O
“ O
en B-Detailed_description
bloc I-Detailed_description
” O
. O

There O
were O
no O
apparent O
residual O
lesions B-Sign_symptom
surgically O
. O

The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
and O
she O
was O
discharged B-Clinical_event
on O
the O
tenth B-Date
day I-Date
after I-Date
surgery B-Therapeutic_procedure
. O

Macroscopically B-Diagnostic_procedure
, O
the O
tumor B-Sign_symptom
was O
58 B-Area
× I-Area
42 I-Area
mm I-Area
in O
size O
and O
was O
located O
in O
the O
fundus B-Biological_structure
, O
which O
contained O
a O
yellowish B-Color
gallstone B-Sign_symptom
( O
Fig. O
2a O
) O
. O

A O
portion O
of O
the O
hepatic B-Biological_structure
hilar I-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
( O
71 B-Area
× I-Area
37 I-Area
mm I-Area
) O
was O
also O
excised B-Therapeutic_procedure
separately O
( O
Fig. O
2b O
) O
. O

Microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
gallbladder B-Biological_structure
revealed O
a O
moderate B-Detailed_description
to I-Detailed_description
well I-Detailed_description
differentiated I-Detailed_description
tubular B-Detailed_description
adenocarcinoma B-Disease_disorder
infiltrating O
from O
the O
mucosa B-Biological_structure
to O
the O
muscular B-Biological_structure
layer I-Biological_structure
, O
but O
not B-Biological_structure
the I-Biological_structure
serosal I-Biological_structure
surface I-Biological_structure
, O
without O
any O
NEC B-Disease_disorder
components O
( O
Fig. O
2c O
, O
d O
) O
. O

The O
tumor B-Sign_symptom
cells O
in O
the O
gallbladder B-Biological_structure
are O
slightly B-Lab_value
positive I-Lab_value
for O
synaptophysin B-Diagnostic_procedure
and O
CD56 B-Diagnostic_procedure
, O
but O
negative B-Lab_value
for O
chromogranin B-Diagnostic_procedure
A I-Diagnostic_procedure
( O
Fig. O
2e O
– O
g O
) O
. O

The O
resection B-Diagnostic_procedure
margin I-Diagnostic_procedure
from O
the O
liver B-Biological_structure
bed I-Biological_structure
was O
negative O
for O
tumor B-Sign_symptom
cells O
. O

The O
epithelium B-Biological_structure
around O
the O
carcinoma B-Disease_disorder
showed O
intestinal B-Biological_structure
metaplasia B-Sign_symptom
with O
the O
goblet B-Biological_structure
cells I-Biological_structure
( O
Fig. O
4a O
) O
, O
which O
area O
was O
stained O
by O
alcian B-Diagnostic_procedure
blue I-Diagnostic_procedure
( O
Fig. O
4b O
) O
. O

On O
the O
other O
hand O
, O
the O
hepatic B-Biological_structure
hilar I-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
composed O
of O
small B-Detailed_description
round B-Shape
tumor B-Sign_symptom
cells O
with O
hyperchromatic B-Lab_value
nuclei B-Diagnostic_procedure
and O
scant B-Lab_value
cytoplasm B-Diagnostic_procedure
( O
Fig. O
3a O
) O
. O

Some B-Detailed_description
of O
the O
tumor B-Sign_symptom
cells O
were O
large B-Qualitative_concept
and O
had O
vesicular B-Texture
nuclei B-Diagnostic_procedure
. O

The O
tumor B-Sign_symptom
cells O
were O
arranged O
in O
sheets B-Detailed_description
, O
cords B-Detailed_description
, O
or O
in O
a O
trabecular B-Detailed_description
or O
rosette B-Detailed_description
fashion O
and O
were O
interspersed O
with O
focal B-Detailed_description
necrosis B-Sign_symptom
. O

They O
were O
immunohistochemically B-Diagnostic_procedure
positive B-Lab_value
for O
CD56 B-Diagnostic_procedure
, O
synaptophysin B-Diagnostic_procedure
, O
and O
chromogranin B-Diagnostic_procedure
A I-Diagnostic_procedure
( O
Fig. O
3b O
– O
3d O
) O
. O

The O
mitotic B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
24 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
microscopic I-Lab_value
fields I-Lab_value
, O
and O
the O
Ki-67 B-Diagnostic_procedure
proliferation I-Diagnostic_procedure
index I-Diagnostic_procedure
was O
70 B-Lab_value
– I-Lab_value
80 I-Lab_value
% I-Lab_value
, O
consistent O
with O
NEC B-Disease_disorder
. O

The O
surgical B-Biological_structure
dissection I-Biological_structure
margin I-Biological_structure
of O
the O
hepatic B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
was O
microscopically B-Detailed_description
cauterized B-Therapeutic_procedure
within O
the O
tumor B-Sign_symptom
cells O
. O

There O
was O
no O
invasion B-Sign_symptom
to O
the O
extrahepatic B-Biological_structure
biliary I-Biological_structure
duct I-Biological_structure
. O

As O
the O
result O
of O
thorough O
pathological B-Diagnostic_procedure
re-evaluation I-Diagnostic_procedure
by O
total B-Diagnostic_procedure
segmentation I-Diagnostic_procedure
, O
a O
negligible B-Severity
area I-Severity
of O
adenocarcinoma B-Disease_disorder
was O
detected O
in O
the O
lymph B-Biological_structure
nodes I-Biological_structure
( O
Fig. O
3e O
, O
f O
) O
. O

The O
adenocarcinoma B-Disease_disorder
component O
and O
the O
intestinal B-Biological_structure
metaplastic I-Biological_structure
epithelium I-Biological_structure
in O
the O
gallbladder B-Biological_structure
were O
both O
positive B-Lab_value
for O
CDX2 B-Diagnostic_procedure
( O
Fig. O
4a O
) O
, O
but O
the O
neuroendocrine O
component O
in O
hilar B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
was O
negative B-Lab_value
for O
CDX2 B-Diagnostic_procedure
( O
Fig. O
4b O
) O
. O

Postoperatively O
, O
the O
patient O
received O
three B-Dosage
cycles I-Dosage
of O
carboplatin B-Medication
( O
area B-Dosage
under I-Dosage
the I-Dosage
curve I-Dosage
of I-Dosage
5 I-Dosage
on I-Dosage
day I-Dosage
1 I-Dosage
repeated I-Dosage
every I-Dosage
21 I-Dosage
days I-Dosage
) O
and O
etoposide B-Medication
( O
80 B-Dosage
mg/m2 I-Dosage
on I-Dosage
days I-Dosage
1 I-Dosage
through I-Dosage
3 I-Dosage
repeated I-Dosage
every I-Dosage
21 I-Dosage
days I-Dosage
) O
. O

During B-Date
the I-Date
first I-Date
course I-Date
, O
grade B-Severity
4 I-Severity
neutropenia B-Sign_symptom
occurred O
and O
it O
was O
managed O
with O
prophylactic B-Detailed_description
fluoroquinolones B-Medication
. O

After B-Date
4 I-Date
months I-Date
, O
multiple B-Detailed_description
recurrences B-Sign_symptom
in O
the O
para-aortic B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
detected O
, O
which O
was O
pathologically O
demonstrated O
via O
EUS-FNA B-Diagnostic_procedure
to O
be O
NEC B-Disease_disorder
. O

The O
patient O
underwent O
second-line B-Detailed_description
chemotherapy B-Medication
with O
amrubicin B-Medication
( O
24 B-Dosage
mg/m2 I-Dosage
on I-Dosage
days I-Dosage
1 I-Dosage
through I-Dosage
3 I-Dosage
repeated I-Dosage
every I-Dosage
21 I-Dosage
days I-Dosage
) O
. O

Grade B-Severity
4 I-Severity
neutropenia B-Sign_symptom
and O
anemia B-Sign_symptom
developed O
during O
the O
courses O
, O
and O
she O
needed O
to O
receive O
pegylated B-Detailed_description
granulocyte B-Medication
colony-stimulating I-Medication
factor I-Medication
and O
red B-Detailed_description
blood I-Detailed_description
cell I-Detailed_description
transfusion B-Therapeutic_procedure
. O

However O
, O
she O
died B-Activity
of O
progressive B-Disease_disorder
disease I-Disease_disorder
8 B-Date
months I-Date
after I-Date
surgery O
. O

A O
20-year-old B-Age
previously B-History
healthy I-History
Bengali B-Personal_background
man B-Sex
presented B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
anuria B-Sign_symptom
and O
features O
of O
uremic B-Detailed_description
encephalopathy B-Disease_disorder
. O

Ten B-Date
days I-Date
prior I-Date
to O
this O
presentation O
, O
he O
had O
experienced O
severe B-Severity
upper B-Biological_structure
abdominal I-Biological_structure
pain B-Sign_symptom
and O
vomiting B-Sign_symptom
, O
and O
he O
had O
been O
treated B-Therapeutic_procedure
in O
a O
primary B-Nonbiological_location
care I-Nonbiological_location
facility I-Nonbiological_location
for O
having O
a O
case O
of O
acute B-Detailed_description
pancreatitis B-Disease_disorder
. O

His O
initial B-Sign_symptom
symptoms I-Sign_symptom
improved O
; O
however O
, O
he O
gradually O
became O
anuric B-Sign_symptom
and O
disoriented B-Sign_symptom
. O

Then O
he O
was O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
further O
management O
. O

At O
presentation B-Clinical_event
to O
our O
hospital O
, O
he O
was O
severely B-Severity
agitated B-Sign_symptom
, O
restless B-Sign_symptom
, O
and O
disoriented B-Sign_symptom
. O

He O
was O
tachypneic B-Sign_symptom
with O
acidotic B-Sign_symptom
breath I-Sign_symptom
. O

Mild B-Severity
pedal B-Biological_structure
edema B-Sign_symptom
was O
present O
; O
however O
, O
his O
jugular B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
not B-Lab_value
raised I-Lab_value
. O

His O
pulse B-Diagnostic_procedure
was O
112 B-Lab_value
beats/minute I-Lab_value
, O
his O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
140/90 B-Lab_value
mmHg I-Lab_value
, O
and O
his O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
was O
98 B-Lab_value
°F I-Lab_value
. O

Signs O
of O
meningeal B-Biological_structure
irritation B-Sign_symptom
were O
absent O
, O
and O
his O
plantar B-Diagnostic_procedure
response I-Diagnostic_procedure
was O
bilaterally B-Lab_value
extensor I-Lab_value
. O

His O
fundus B-Diagnostic_procedure
could B-Lab_value
not I-Lab_value
be I-Lab_value
evaluated I-Lab_value
, O
and O
examination B-Diagnostic_procedure
of O
his O
other B-Biological_structure
systems I-Biological_structure
was O
unremarkable B-Lab_value
. O

His O
laboratory B-Diagnostic_procedure
parameters I-Diagnostic_procedure
showed O
features O
of O
renal B-Disease_disorder
dysfunction I-Disease_disorder
( O
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
13 B-Lab_value
mg/dl I-Lab_value
, O
serum B-Diagnostic_procedure
urea I-Diagnostic_procedure
293 B-Lab_value
mg/dl I-Lab_value
) O
, O
raised B-Lab_value
pancreatic B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
( O
serum B-Diagnostic_procedure
amylase I-Diagnostic_procedure
249 B-Lab_value
U/L I-Lab_value
[ O
reference O
up O
to O
100 O
U/L O
] O
, O
serum B-Diagnostic_procedure
lipase I-Diagnostic_procedure
227 B-Lab_value
U/L I-Lab_value
[ O
reference O
13 O
– O
60 O
U/L O
) O
, O
normal B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests O
( O
serum B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
0.9 B-Lab_value
mg/dl I-Lab_value
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
38 B-Lab_value
U/L I-Lab_value
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
35 B-Lab_value
U/L I-Lab_value
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
122 B-Lab_value
U/L I-Lab_value
, O
serum B-Diagnostic_procedure
albumin I-Diagnostic_procedure
37 B-Lab_value
g/L I-Lab_value
) O
, O
normal B-Lab_value
potassium B-Diagnostic_procedure
( O
5.1 B-Lab_value
mmol/L I-Lab_value
) O
, O
normal B-Lab_value
bicarbonate B-Diagnostic_procedure
( O
19 B-Lab_value
mmol/L I-Lab_value
) O
, O
and O
normal B-Lab_value
triglycerides B-Diagnostic_procedure
( O
173 B-Lab_value
mg/dl I-Lab_value
) O
. O

His O
serological B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
including O
antinuclear B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
, O
cytoplasmic B-Diagnostic_procedure
antineutrophil I-Diagnostic_procedure
cytoplasmic I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
, O
perinuclear B-Diagnostic_procedure
antineutrophil I-Diagnostic_procedure
cytoplasmic I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
, O
C3 B-Diagnostic_procedure
, O
and O
C4 B-Diagnostic_procedure
, O
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

An O
ultrasonogram B-Diagnostic_procedure
of O
his O
whole O
abdomen B-Biological_structure
was O
unremarkable B-Lab_value
, O
but O
non-contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
findings O
were O
suggestive O
of O
acute B-Detailed_description
pancreatitis B-Disease_disorder
( O
Fig. O
1 O
) O
. O

His O
kidneys B-Diagnostic_procedure
were O
unremarkable B-Lab_value
, O
however O
. O

The O
patient O
was O
managed O
as O
having O
a O
case O
of O
AKI B-Disease_disorder
and O
acute B-Detailed_description
pancreatitis B-Disease_disorder
. O

Urgent B-Detailed_description
hemodialysis B-Therapeutic_procedure
was O
initiated O
. O

After O
he O
had O
received O
two B-Detailed_description
sessions I-Detailed_description
of O
hemodialysis B-Therapeutic_procedure
, O
his O
level B-Diagnostic_procedure
of I-Diagnostic_procedure
consciousness I-Diagnostic_procedure
improved B-Lab_value
, O
but O
he O
complained O
of O
profound B-Severity
visual B-Disease_disorder
loss I-Disease_disorder
. O

An O
assessment O
revealed O
only O
perception B-Sign_symptom
of I-Sign_symptom
light I-Sign_symptom
. O

A O
funduscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
retinal B-Sign_symptom
whitening I-Sign_symptom
and O
extensive B-Severity
cotton B-Sign_symptom
wool I-Sign_symptom
exudates I-Sign_symptom
as O
well O
as O
Purtscher B-Sign_symptom
’s I-Sign_symptom
flecken I-Sign_symptom
( O
Fig. O
2 O
) O
compatible O
with O
Purtscher B-Disease_disorder
’s I-Disease_disorder
retinopathy I-Disease_disorder
. O

High-dose B-Dosage
parenteral B-Administration
methylprednisolone B-Medication
( O
1 B-Dosage
g I-Dosage
intravenously B-Administration
once B-Dosage
daily I-Dosage
for O
3 B-Duration
days I-Duration
) O
was O
administered O
. O

For O
evaluation B-Diagnostic_procedure
of I-Diagnostic_procedure
renal I-Diagnostic_procedure
dysfunction I-Diagnostic_procedure
, O
a O
renal B-Biological_structure
biopsy B-Diagnostic_procedure
was O
done O
; O
the O
histopathological B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
compatible O
with O
renal B-Disease_disorder
cortical I-Disease_disorder
necrosis I-Disease_disorder
( O
Fig. O
3 O
) O
. O

The O
patient O
denied B-History
substance I-History
abuse I-History
or I-History
alcohol I-History
ingestion I-History
. O

He O
did B-History
not I-History
consume I-History
any I-History
nephrotoxic I-History
drugs I-History
or I-History
herbal I-History
products I-History
in I-History
the I-History
recent I-History
past I-History
. O

No B-History
history I-History
suggesting I-History
connective I-History
tissue I-History
diseases I-History
was I-History
available I-History
, O
nor O
did O
he O
have O
a O
history O
of O
hypotension B-Sign_symptom
throughout O
the O
course O
of O
his O
current O
illness O
. O

The O
patient O
was O
finally O
diagnosed O
with O
acute B-Detailed_description
pancreatitis B-Disease_disorder
complicated O
with O
renal B-Disease_disorder
cortical I-Disease_disorder
necrosis I-Disease_disorder
leading O
to O
AKI B-Disease_disorder
and O
Purtscher B-Disease_disorder
’s I-Disease_disorder
retinopathy I-Disease_disorder
leading O
to O
complete B-Severity
bilateral B-Detailed_description
blindness B-Disease_disorder
. O

He O
died B-Outcome
16 B-Date
months I-Date
after I-Date
his O
initial O
presentation O
as O
a O
result O
of O
a O
recurrent B-Detailed_description
attack O
of O
acute B-Detailed_description
pancreatitis B-Disease_disorder
. O

Before O
that O
, O
he O
had O
been O
undergoing O
maintenance B-Detailed_description
hemodialysis B-Therapeutic_procedure
; O
however O
, O
his O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
recover I-Lab_value
, O
though O
his O
vision B-Diagnostic_procedure
was O
improved B-Lab_value
to O
finger-counting B-Diagnostic_procedure
at O
2 B-Lab_value
feet I-Lab_value
. O

A O
female B-Sex
outpatient O
in O
her B-Date
50s I-Date
had O
routinely O
visited B-Clinical_event
our O
hospital B-Nonbiological_location
because O
of O
liver B-Disease_disorder
cirrhosis I-Disease_disorder
resulting O
from O
hepatitis B-Disease_disorder
B I-Disease_disorder
virus I-Disease_disorder
and O
biliary B-Disease_disorder
duct I-Disease_disorder
stones I-Disease_disorder
. O

At O
65 B-Age
years I-Age
of I-Age
age I-Age
, O
she O
suffered O
from O
HCC B-Disease_disorder
with O
BCLC B-Lab_value
early I-Lab_value
stage I-Lab_value
A I-Lab_value
. O

Her O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
was O
well B-Lab_value
preserved I-Lab_value
, O
and O
Child-Pugh B-Diagnostic_procedure
score I-Diagnostic_procedure
was O
A B-Lab_value
. O

She O
underwent O
left B-Detailed_description
lateral I-Detailed_description
segmentectomy B-Therapeutic_procedure
for O
HCC B-Disease_disorder
, O
without O
other B-Therapeutic_procedure
preoperative I-Therapeutic_procedure
treatments I-Therapeutic_procedure
. O

Histopathological B-Diagnostic_procedure
findings I-Diagnostic_procedure
revealed O
bridging B-Detailed_description
fibrosis B-Disease_disorder
and O
pseudolobule B-Disease_disorder
formation I-Disease_disorder
. O

Serum B-Biological_structure
levels O
of O
alpha-fetoprotein B-Diagnostic_procedure
( O
AFP B-Diagnostic_procedure
) O
and O
protein B-Diagnostic_procedure
induced I-Diagnostic_procedure
by I-Diagnostic_procedure
vitamin I-Diagnostic_procedure
K I-Diagnostic_procedure
absence-II I-Diagnostic_procedure
normalized B-Lab_value
after O
primary O
resection B-Coreference
( O
Figure O
1 O
) O
. O

In O
imaging B-Diagnostic_procedure
studies I-Diagnostic_procedure
, O
no O
LN B-Biological_structure
metastasis B-Sign_symptom
was O
detected O
at O
the O
time O
of O
primary O
resection B-Coreference
of O
HCC O
. O

Two B-Date
and I-Date
a I-Date
half I-Date
years I-Date
postoperatively O
, O
the O
patient O
’s O
AFP B-Diagnostic_procedure
level I-Diagnostic_procedure
increased B-Lab_value
dramatically I-Lab_value
to O
780.2 B-Lab_value
ng/ml I-Lab_value
. O

A O
lobular B-Shape
lesion B-Sign_symptom
with O
fine B-Detailed_description
enhancement I-Detailed_description
was O
detected O
by O
contrast-enhanced B-Detailed_description
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
. O

The O
tumor B-Coreference
measured O
27 B-Distance
mm I-Distance
in I-Distance
diameter I-Distance
and O
was O
located O
caudally B-Biological_structure
on I-Biological_structure
the I-Biological_structure
left I-Biological_structure
kidney I-Biological_structure
. O

In O
contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
, O
the O
tumor B-Coreference
showed O
strong B-Detailed_description
enhancement B-Sign_symptom
in O
the O
arterial B-Biological_structure
phase I-Biological_structure
( O
Figure O
2A O
, O
2B O
) O
and O
a O
relatively B-Detailed_description
low I-Detailed_description
density B-Sign_symptom
in O
the O
portal B-Biological_structure
phase I-Biological_structure
( O
Figure O
2C O
, O
2D O
) O
. O

These O
enhancement O
findings O
appeared O
consistent O
with O
a O
typical B-Detailed_description
HCC B-Disease_disorder
pattern O
. O

Detailed O
imaging O
studies O
of O
both O
magnetic O
resonance O
imaging O
and O
computed O
tomography O
were O
performed O
in O
this O
case O
because O
a O
very O
rare O
metastatic O
LN O
initially O
seemed O
to O
be O
debatable O
and O
we O
needed O
to O
rule O
out O
exclusion O
diagnoses O
. O

Three-dimensional B-Diagnostic_procedure
imaging I-Diagnostic_procedure
proved O
that O
the O
tumor B-Coreference
was O
fed B-Biological_structure
by I-Biological_structure
a I-Biological_structure
main I-Biological_structure
vessel I-Biological_structure
from I-Biological_structure
the I-Biological_structure
inferior I-Biological_structure
mesenteric I-Biological_structure
artery I-Biological_structure
( O
red O
arrow O
) O
and O
by O
an O
accessory B-Biological_structure
feeder I-Biological_structure
from I-Biological_structure
the I-Biological_structure
superior I-Biological_structure
mesenteric I-Biological_structure
artery I-Biological_structure
( O
Figure O
3 O
) O
. O

Fluorine-18-fluorodeoxyglucose B-Diagnostic_procedure
positron I-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
FDG-PET B-Diagnostic_procedure
) O
and O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography-computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
did O
not O
detect O
the O
tumor O
( O
Figure O
4 O
) O
, O
although O
we O
thought O
positron O
emission O
tomography-computed O
tomography O
was O
helpful O
to O
identify O
other O
metastatic O
tumors O
. O

Further O
imaging O
findings O
revealed O
no O
other O
intrahepatic B-Biological_structure
or O
extrahepatic B-Biological_structure
metastasis B-Sign_symptom
. O

Based O
on O
the O
tumor O
location O
, O
the O
clinical O
diagnosis O
was O
solitary B-Detailed_description
metastasis B-Sign_symptom
to O
a O
mesocolic B-Biological_structure
LN I-Biological_structure
or O
HCC B-Disease_disorder
dissemination B-Detailed_description
. O

Determining O
the O
ideal O
therapeutic O
strategy O
for O
solitary O
but O
extrahepatic O
rare O
metastasis O
was O
difficult O
. O

Although O
rapid O
growth O
was O
a O
critical O
concern O
in O
this O
case O
, O
the O
tumor B-Sign_symptom
was O
solitary B-Detailed_description
and O
not O
accompanied O
by O
other B-Detailed_description
metastases B-Sign_symptom
. O

Considering O
both O
diagnostic O
and O
therapeutic O
viewpoints O
, O
we O
finally O
chose O
surgical B-Therapeutic_procedure
resection I-Therapeutic_procedure
in O
this O
case O
. O

No O
disseminative B-Sign_symptom
nodules I-Sign_symptom
, O
lymphadenopathy B-Disease_disorder
, O
or O
ascites B-Sign_symptom
was O
observed O
during O
surgery B-Coreference
. O

The O
tumor B-Coreference
was O
located O
in O
the O
mesocolon B-Biological_structure
nearly O
at B-Biological_structure
the I-Biological_structure
wall I-Biological_structure
of I-Biological_structure
the I-Biological_structure
descending I-Biological_structure
colon I-Biological_structure
, O
and O
partial O
resection B-Coreference
of O
the O
descending B-Biological_structure
colon I-Biological_structure
with O
regional B-Biological_structure
mesocolon I-Biological_structure
was O
performed O
. O

The O
patient O
’s O
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
uneventful B-Lab_value
, O
and O
she O
was O
discharged B-Clinical_event
on O
postoperative O
day B-Date
8 I-Date
. O

Serum B-Biological_structure
levels O
of O
tumor B-Diagnostic_procedure
marker I-Diagnostic_procedure
decreased B-Lab_value
immediately I-Lab_value
after O
surgery B-Coreference
( O
Figure O
1 O
) O
. O

Macroscopically B-Diagnostic_procedure
, O
the O
mesocolic B-Coreference
tumor I-Coreference
was O
a O
solid B-Lab_value
and O
elastic B-Lab_value
mass O
with O
a O
smooth B-Texture
surface I-Texture
( O
Figure O
5A O
) O
. O

A O
yellowish B-Color
nodule B-Sign_symptom
was O
encapsulated B-Detailed_description
in I-Detailed_description
the I-Detailed_description
cut I-Detailed_description
surface I-Detailed_description
( O
Figure O
5B O
) O
. O

The O
enlarged B-Detailed_description
LN I-Detailed_description
contained O
metastatic B-Detailed_description
HCC B-Disease_disorder
with O
a O
ductal B-Detailed_description
structure I-Detailed_description
( O
Figure O
6A O
) O
, O
and O
immunohistochemically B-Diagnostic_procedure
, O
the O
tumor O
was O
positive B-Lab_value
for O
AFP B-Diagnostic_procedure
and O
negative B-Lab_value
for O
CK-20 B-Diagnostic_procedure
, O
which O
was O
consistent O
with O
the O
pattern O
of O
primary B-Detailed_description
HCC B-Disease_disorder
( O
Figure O
6B O
) O
. O

The O
histopathological O
diagnosis O
was O
metastatic B-Detailed_description
HCC B-Disease_disorder
to O
a O
mesocolic B-Biological_structure
LN I-Biological_structure
. O

As O
of O
the O
writing O
of O
this O
report O
, O
the O
patient O
has O
remained O
free O
of O
recurrence B-Sign_symptom
for O
13 B-Date
months I-Date
after I-Date
the O
second O
surgery O
, O
and O
has O
also O
been O
carefully O
followed B-Clinical_event
up I-Clinical_event
. O

No O
adjuvant B-Medication
therapies I-Medication
have O
been O
performed O
. O

This O
is O
the O
case O
of O
a O
58-year-old B-Age
white B-Personal_background
Hispanic B-Personal_background
woman B-Sex
with O
a O
history B-History
of I-History
uveal I-History
melanoma I-History
in I-History
her I-History
right I-History
eye I-History
( O
Fig. O
1 O
) O
. O

She O
was O
admitted B-Clinical_event
to O
the O
hospital O
with O
jaundice B-Sign_symptom
and O
abdominal B-Biological_structure
pain B-Sign_symptom
for O
10 B-Duration
days I-Duration
. O

On O
admission O
, O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
obtained O
( O
a O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
, O
amylase B-Diagnostic_procedure
: O
136 B-Lab_value
U/L I-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
: O
6.37 B-Lab_value
mg/dL I-Lab_value
with O
a O
direct B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
5.30 B-Lab_value
mg/dL I-Lab_value
) O
. O

Cross-sectional B-Detailed_description
, O
abdominal B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
with B-Detailed_description
contrast I-Detailed_description
, O
showed O
a O
low-attenuating B-Detailed_description
lesion B-Sign_symptom
localized O
in O
the O
pancreatic B-Biological_structure
head I-Biological_structure
( O
measuring O
4 B-Area
× I-Area
3 I-Area
cm I-Area
) O
and O
a O
thinner B-Biological_structure
section I-Biological_structure
of I-Biological_structure
the I-Biological_structure
distal I-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
suspicious O
for O
compression O
) O
. O

After O
a O
multidisciplinary B-Clinical_event
meeting I-Clinical_event
, O
our O
patient O
was O
scheduled O
for O
EUS-FNA B-Diagnostic_procedure
. O

EUS B-Coreference
showed O
a O
solid B-Detailed_description
, O
heteroechoic B-Detailed_description
with O
predominantly B-Detailed_description
hypoechoic I-Detailed_description
areas I-Detailed_description
, O
well-defined B-Detailed_description
lesion B-Sign_symptom
with O
regular B-Texture
contours I-Texture
( O
measuring O
3.1 B-Area
× I-Area
2.6 I-Area
cm I-Area
) O
, O
localized O
between B-Biological_structure
the I-Biological_structure
head I-Biological_structure
and I-Biological_structure
neck I-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreas I-Biological_structure
( O
Fig. O
2 O
) O
. O

There O
was O
no O
vascular B-Sign_symptom
or I-Sign_symptom
lymph I-Sign_symptom
node I-Sign_symptom
invasion I-Sign_symptom
identified O
. O

EUS-FNA B-Coreference
was O
performed O
with B-Detailed_description
a I-Detailed_description
22G I-Detailed_description
needle I-Detailed_description
using B-Detailed_description
the I-Detailed_description
fanning I-Detailed_description
technique I-Detailed_description
. O

In O
the O
cytology B-Diagnostic_procedure
specimens I-Diagnostic_procedure
( O
Fig. O
3 O
) O
, O
the O
cells B-Biological_structure
presented O
have O
a O
discohesive B-Lab_value
dispersed I-Lab_value
pattern I-Lab_value
, O
with O
marked O
variation B-Lab_value
in I-Lab_value
size I-Lab_value
and I-Lab_value
shape I-Lab_value
including O
epithelioid B-Shape
and O
spindle-shaped B-Shape
cells B-Biological_structure
with O
plasmacytoid B-Shape
and O
round B-Shape
nuclei B-Biological_structure
. O

The O
nuclear B-Diagnostic_procedure
chromatin I-Diagnostic_procedure
is O
clumping B-Lab_value
and O
irregular B-Lab_value
with O
excessive B-Lab_value
parachromatin I-Lab_value
clearing I-Lab_value
, O
there O
are O
single B-Detailed_description
or O
multiple B-Detailed_description
macronucleoli B-Biological_structure
, O
and O
abundant B-Detailed_description
cytoplasm B-Biological_structure
with O
deep B-Lab_value
brownish-black I-Lab_value
granules I-Lab_value
obscuring O
the O
cell O
details O
. O

The O
background B-Diagnostic_procedure
shows O
necrosis B-Sign_symptom
and O
hemorrhage B-Sign_symptom
. O

Our O
patient O
underwent O
right B-Biological_structure
orbital I-Biological_structure
exenteration B-Therapeutic_procedure
and O
followed O
by O
duodenopancreatectomy B-Therapeutic_procedure
( O
the O
Whipple B-Detailed_description
procedure I-Detailed_description
) O
, O
without O
any O
complications B-Sign_symptom
( O
Fig. O
4 O
) O
. O

The O
surgical B-Diagnostic_procedure
specimen I-Diagnostic_procedure
showed O
undifferentiated B-Detailed_description
cells B-Biological_structure
, O
with O
extended B-Lab_value
disposition I-Lab_value
of I-Lab_value
brown I-Lab_value
pigment I-Lab_value
, O
infiltrating B-Sign_symptom
the O
pancreas B-Biological_structure
and O
the O
serosa B-Biological_structure
of I-Biological_structure
the I-Biological_structure
duodenal I-Biological_structure
wall I-Biological_structure
. O

Immunohistochemistry B-Diagnostic_procedure
was O
positive B-Lab_value
for O
Melan-A B-Diagnostic_procedure
, O
HMB45 B-Diagnostic_procedure
, O
vimentin B-Diagnostic_procedure
, O
S-100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
and O
negative B-Lab_value
for O
cytokeratin B-Diagnostic_procedure
, O
all O
consistent O
with O
metastatic B-Detailed_description
malignant B-Detailed_description
melanoma B-Disease_disorder
. O

At B-Date
the I-Date
moment I-Date
, O
our O
patient O
is O
receiving O
adjuvant B-Detailed_description
chemotherapy B-Medication
at O
an O
outside B-Nonbiological_location
oncology I-Nonbiological_location
clinic I-Nonbiological_location
. O

A O
28-year-old B-Age
African B-Personal_background
American I-Personal_background
woman B-Sex
presented B-Clinical_event
to O
the O
R B-Nonbiological_location
Adams I-Nonbiological_location
Cowley I-Nonbiological_location
Shock I-Nonbiological_location
Trauma I-Nonbiological_location
Center I-Nonbiological_location
in O
Baltimore B-Nonbiological_location
, I-Nonbiological_location
Maryland I-Nonbiological_location
, O
for O
evaluation B-Diagnostic_procedure
of O
right-sided B-Detailed_description
paralysis B-Disease_disorder
and O
left-sided B-Detailed_description
paresthesias B-Sign_symptom
after O
being O
found B-Clinical_event
down B-Detailed_description
in O
her O
home B-Nonbiological_location
between B-Detailed_description
her I-Detailed_description
nightstand I-Detailed_description
and I-Detailed_description
her I-Detailed_description
bed I-Detailed_description
. O

The O
symptoms O
began O
after O
eating B-Activity
at O
a O
local B-Nonbiological_location
restaurant I-Nonbiological_location
chain I-Nonbiological_location
, O
consuming B-Activity
alcohol I-Activity
, O
and O
smoking B-Activity
one O
cigarette B-Detailed_description
dipped O
in O
liquid B-Detailed_description
phencyclidine B-Detailed_description
( O
PCP B-Detailed_description
) O
. O

She O
was O
asymptomatic B-Sign_symptom
that B-Time
night I-Time
and O
went B-Activity
to I-Activity
bed I-Activity
without O
complications B-Sign_symptom
. O

She O
was O
found B-Clinical_event
down B-Detailed_description
next B-Nonbiological_location
to I-Nonbiological_location
the I-Nonbiological_location
bed I-Nonbiological_location
the B-Time
following I-Time
morning I-Time
unable B-Sign_symptom
to I-Sign_symptom
move I-Sign_symptom
. O

The O
patient O
denied O
any O
physical B-Disease_disorder
trauma I-Disease_disorder
other O
than O
falling B-Sign_symptom
from O
the O
bed O
. O

She O
had O
no B-History
history I-History
of I-History
seizures I-History
, I-History
sickle I-History
cell I-History
anemia I-History
, I-History
fever I-History
, I-History
urinary I-History
or I-History
bowel I-History
incontinence I-History
, I-History
or I-History
pain I-History
. O

The O
patient O
had O
a O
history O
of O
viral B-Disease_disorder
meningitis I-Disease_disorder
without B-Detailed_description
residual I-Detailed_description
deficits I-Detailed_description
eight B-Date
years I-Date
prior I-Date
, O
gastric B-History
bypass I-History
surgery I-History
, O
and O
cholecystectomy B-History
, O
and O
she O
was O
treated B-Therapeutic_procedure
for O
a O
presumed O
urinary B-Disease_disorder
tract I-Disease_disorder
infection I-Disease_disorder
five B-Date
days I-Date
prior I-Date
to O
admission O
at O
an O
outside B-Nonbiological_location
institution I-Nonbiological_location
. O

Her O
triage O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
as O
follows O
: O
temperature B-Diagnostic_procedure
36.8 B-Lab_value
°C I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
155/100 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
90 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
16 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
and O
an O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
of O
95 B-Lab_value
% I-Lab_value
on O
room B-Detailed_description
air I-Detailed_description
. O

On O
physical B-Diagnostic_procedure
exam I-Diagnostic_procedure
, O
the O
patient O
was O
alert B-Sign_symptom
and O
oriented B-Sign_symptom
to O
person B-Detailed_description
, O
place B-Detailed_description
, O
and O
time B-Detailed_description
. O

Her O
cranial B-Diagnostic_procedure
nerves I-Diagnostic_procedure
II I-Diagnostic_procedure
– I-Diagnostic_procedure
XII I-Diagnostic_procedure
were O
grossly B-Lab_value
intact I-Lab_value
. O

She O
had O
2/5 B-Lab_value
strength B-Diagnostic_procedure
in O
her O
right B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
, O
3/5 B-Lab_value
in O
her O
left B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
, O
and O
4/5 B-Lab_value
bilaterally B-Biological_structure
in I-Biological_structure
her I-Biological_structure
upper I-Biological_structure
extremities I-Biological_structure
. O

Her O
sensation B-Diagnostic_procedure
was O
intact B-Lab_value
. O

She O
opened B-Lab_value
her O
eyes B-Diagnostic_procedure
spontaneously B-Detailed_description
, O
her O
verbal B-Diagnostic_procedure
response I-Diagnostic_procedure
was O
oriented B-Lab_value
and O
appropriate B-Lab_value
, O
and O
she O
obeyed B-Lab_value
commands B-Diagnostic_procedure
, O
resulting O
in O
a O
Glasgow B-Diagnostic_procedure
Coma I-Diagnostic_procedure
Scale I-Diagnostic_procedure
score O
of O
15 B-Lab_value
. O

Pupils B-Diagnostic_procedure
were O
equal B-Detailed_description
, O
round B-Shape
, O
and O
reactive B-Lab_value
to I-Lab_value
light I-Lab_value
. O

She O
had O
tenderness B-Sign_symptom
to O
palpation B-Detailed_description
over O
the O
cervical B-Biological_structure
, O
thoracic B-Biological_structure
, O
and O
lumbar B-Biological_structure
spine B-Biological_structure
without O
obvious O
external O
signs B-Sign_symptom
of I-Sign_symptom
trauma I-Sign_symptom
. O

Her O
anal B-Diagnostic_procedure
sphincter I-Diagnostic_procedure
tone I-Diagnostic_procedure
was O
intact B-Lab_value
. O

Multiple O
laboratory B-Diagnostic_procedure
abnormalities B-Lab_value
were O
noted O
on O
admission O
, O
including O
hyperlactemia B-Sign_symptom
, O
elevated B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests O
, O
and O
electrolyte B-Sign_symptom
derangements I-Sign_symptom
. O

Her O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
and O
remainder O
of O
her O
complete B-Diagnostic_procedure
metabolic I-Diagnostic_procedure
panel I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

These B-Other_entity
values I-Other_entity
are I-Other_entity
summarized I-Other_entity
along I-Other_entity
with I-Other_entity
reference I-Other_entity
ranges I-Other_entity
in I-Other_entity
Table I-Other_entity
1 I-Other_entity
. O

Her O
toxicology B-Diagnostic_procedure
screen I-Diagnostic_procedure
was O
positive B-Lab_value
for O
PCP B-Diagnostic_procedure
. O

Blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
drawn O
on O
admission O
grew O
the O
aerobic B-Detailed_description
bacteria I-Detailed_description
Salmonella B-Disease_disorder
enterica I-Disease_disorder
serotype B-Detailed_description
4,12 I-Detailed_description
: I-Detailed_description
i I-Detailed_description
, O
and O
then O
repeat B-Diagnostic_procedure
cultures I-Diagnostic_procedure
drawn O
two B-Date
days I-Date
later I-Date
grew O
group B-Detailed_description
B I-Detailed_description
streptococcus B-Disease_disorder
( O
aerobic B-Detailed_description
and O
non-aerobic B-Detailed_description
) O
. O

Subsequent O
blood B-Diagnostic_procedure
cultures I-Diagnostic_procedure
were O
negative B-Lab_value
, O
as O
were O
stool B-Diagnostic_procedure
cultures I-Diagnostic_procedure
. O

Metronidazole B-Medication
and O
vancomycin B-Medication
therapy O
was O
initiated O
empirically O
, O
with O
transition O
to O
ceftriaxone B-Medication
upon O
learning O
of O
the O
culture O
results O
. O

In O
addition O
, O
she O
had O
a O
detailed O
autoimmunity B-Diagnostic_procedure
workup I-Diagnostic_procedure
including O
anti-nuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
( O
ANA B-Diagnostic_procedure
) O
and O
HLA-B27 B-Diagnostic_procedure
, O
all O
of O
which O
returned O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

Admission O
computerized B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
of O
her O
cervical B-Biological_structure
, O
thoracic B-Biological_structure
, O
and O
lumbar B-Biological_structure
spine B-Biological_structure
revealed O
no O
spinal B-Biological_structure
fractures B-Disease_disorder
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
revealed O
no O
acute O
intracranial B-Biological_structure
abnormalities B-Sign_symptom
, O
but O
enhancement B-Diagnostic_procedure
within I-Diagnostic_procedure
the I-Diagnostic_procedure
central I-Diagnostic_procedure
aspect I-Diagnostic_procedure
of I-Diagnostic_procedure
C3 I-Diagnostic_procedure
– I-Diagnostic_procedure
T2 I-Diagnostic_procedure
suggested O
spinal B-Biological_structure
cord I-Biological_structure
edema B-Sign_symptom
, O
disc B-Sign_symptom
protrusions I-Sign_symptom
at O
C3 B-Biological_structure
– I-Biological_structure
4 I-Biological_structure
, O
C4 B-Biological_structure
– I-Biological_structure
5 I-Biological_structure
, O
and O
C5 B-Biological_structure
– I-Biological_structure
6 I-Biological_structure
, O
and O
bilateral B-Biological_structure
posterior I-Biological_structure
neck I-Biological_structure
muscle I-Biological_structure
edema B-Sign_symptom
. O

A O
lumbar B-Therapeutic_procedure
puncture I-Therapeutic_procedure
was O
not O
initially O
performed O
upon O
patient O
admission O
due O
to O
concerns O
about O
raised O
intracranial O
pressure O
from O
suspected O
trauma O
. O

Four B-Time
hours I-Time
after I-Time
presentation O
, O
her O
strength B-Diagnostic_procedure
had O
progressively O
deteriorated B-Lab_value
to O
1/5 B-Lab_value
in O
all B-Biological_structure
extremities I-Biological_structure
. O

She O
lost B-Lab_value
proprioception B-Diagnostic_procedure
in O
her O
toes B-Biological_structure
bilaterally B-Detailed_description
and O
developed O
absent B-Lab_value
anal B-Diagnostic_procedure
sphincter I-Diagnostic_procedure
tone I-Diagnostic_procedure
. O

The O
patient O
was O
admitted B-Clinical_event
to O
the O
neurotrauma B-Nonbiological_location
intensive I-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
with O
further O
deterioration O
ultimately O
requiring O
endotracheal B-Detailed_description
intubation B-Therapeutic_procedure
due O
to O
respiratory B-Disease_disorder
failure I-Disease_disorder
. O

Upon O
her O
positive O
blood O
culture O
results O
, O
lumbar B-Therapeutic_procedure
puncture I-Therapeutic_procedure
was O
performed O
, O
which O
demonstrated O
a O
pattern O
consistent O
with O
ATM B-Disease_disorder
, O
the O
results O
of O
which O
are O
summarized O
in O
Table O
2 O
. O

An O
extensive O
workup B-Diagnostic_procedure
for I-Diagnostic_procedure
infectious I-Diagnostic_procedure
etiologies I-Diagnostic_procedure
was O
also O
completed O
, O
with O
the O
results O
summarized O
in O
Table O
3 O
. O

Plasma B-Therapeutic_procedure
exchange I-Therapeutic_procedure
therapy I-Therapeutic_procedure
was O
initiated O
with O
a O
suspected O
diagnosis O
of O
ATM B-Disease_disorder
. O

Despite O
maximal B-Detailed_description
medical O
therapy B-Therapeutic_procedure
, O
the O
patient O
remains O
quadriplegic B-Disease_disorder
, O
is O
experiencing O
neurologic B-Biological_structure
pain B-Sign_symptom
, O
received O
a O
tracheostomy B-Therapeutic_procedure
due O
to O
prolonged B-Detailed_description
respiratory B-Disease_disorder
failure I-Disease_disorder
, O
and O
required O
a O
feeding O
jejunostomy B-Therapeutic_procedure
tube I-Therapeutic_procedure
placement O
at O
the O
time O
of O
this O
report O
. O

A O
73-year-old B-Age
man B-Sex
who O
had O
been O
transferred B-Clinical_event
to O
our O
emergency B-Nonbiological_location
room I-Nonbiological_location
due O
to O
sudden B-Detailed_description
chest B-Biological_structure
pain B-Sign_symptom
was O
diagnosed O
with O
ST-segment B-Disease_disorder
elevation I-Disease_disorder
myocardial I-Disease_disorder
infarction I-Disease_disorder
( O
STEMI B-Disease_disorder
) O
. O

He O
had O
no O
coronary O
risk O
factors O
except O
for O
a O
history B-History
of I-History
smoking I-History
for I-History
50 I-History
years I-History
. O

Primary B-Detailed_description
percutaneous B-Biological_structure
coronary B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
performed O
, O
and O
a O
long B-Detailed_description
, O
string-shaped B-Shape
contrast B-Sign_symptom
defect I-Sign_symptom
was O
observed O
in O
the O
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
( O
Fig. O
1A O
) O
. O

Optical B-Diagnostic_procedure
coherence I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
OCT B-Diagnostic_procedure
) O
imaging O
revealed O
an O
odd B-Detailed_description
, O
smooth-surfaced B-Texture
50-mm B-Distance
long I-Distance
object B-Sign_symptom
( O
Fig. O
1B O
) O
. O

A O
long B-Detailed_description
, O
white B-Color
object B-Sign_symptom
which O
looked B-Detailed_description
like I-Detailed_description
a I-Detailed_description
parasitic I-Detailed_description
worm I-Detailed_description
was O
retrieved O
via O
intracoronary B-Therapeutic_procedure
aspiration I-Therapeutic_procedure
and O
revascularization B-Therapeutic_procedure
was O
successfully B-Lab_value
completed I-Lab_value
since O
neither O
plaque B-Sign_symptom
rupture I-Sign_symptom
or O
the O
presence O
of O
thrombus B-Sign_symptom
was O
detected O
by O
OCT B-Coreference
( O
Fig. O
1C O
) O
. O

On O
the O
eleventh B-Date
hospital I-Date
day I-Date
, O
transthoracic B-Biological_structure
echocardiography B-Diagnostic_procedure
revealed O
a O
new O
floating B-Detailed_description
object B-Sign_symptom
in O
the O
left B-Biological_structure
atrium I-Biological_structure
. O

Contrast B-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
a O
huge B-Detailed_description
7 B-Area
× I-Area
6 I-Area
cm I-Area
mass B-Sign_symptom
that O
was O
recognized O
at O
admission O
in O
the O
right B-Biological_structure
upper I-Biological_structure
pulmonary I-Biological_structure
lobe I-Biological_structure
with O
direct B-Detailed_description
pulmonary I-Detailed_description
vein I-Detailed_description
invasion I-Detailed_description
( O
Fig. O
1D O
) O
. O

Although O
the O
bronchoscopic B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
negative O
for O
a O
lung B-Sign_symptom
tumor I-Sign_symptom
, O
a O
histopathologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
aspirated B-Detailed_description
coronary B-Biological_structure
object B-Coreference
revealed O
pleomorphic B-Detailed_description
lung B-Biological_structure
carcinoma B-Disease_disorder
( O
Fig. O
2 O
) O
. O

The O
patient O
was O
diagnosed O
with O
STEMI B-Disease_disorder
due O
to O
coronary B-Biological_structure
embolization B-Sign_symptom
associated O
with O
lung B-Biological_structure
carcinoma B-Disease_disorder
. O

Brain B-Biological_structure
MRI B-Diagnostic_procedure
revealed O
that O
the O
patient O
had O
an O
asymptomatic B-Detailed_description
cerebral B-Biological_structure
infarction B-Sign_symptom
in O
the O
right B-Biological_structure
frontal I-Biological_structure
lobe I-Biological_structure
and O
a O
small B-Detailed_description
parietal B-Biological_structure
lobe I-Biological_structure
lesion B-Sign_symptom
was O
diagnosed O
to O
be O
metastasis B-Sign_symptom
. O

Given O
all O
these O
observations O
, O
he O
was O
diagnosed O
with O
right B-Biological_structure
lung I-Biological_structure
carcinoma B-Disease_disorder
, O
stage B-Detailed_description
IV I-Detailed_description
( O
c-T2bN2M1b B-Detailed_description
) O
. O

He O
was O
treated O
according O
to O
the O
chemotherapy B-Medication
regimens O
( O
carboplatin B-Medication
& O
paclitaxel B-Medication
) O
known O
to O
be O
effective O
for O
the O
treatment O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

He O
responded O
to O
the O
treatment O
and O
showed O
a O
good B-Lab_value
clinical B-Diagnostic_procedure
course I-Diagnostic_procedure
afterwards O
( O
Fig. O
3 O
) O
. O

Chemotherapy B-Medication
with O
a O
total O
of O
9 B-Dosage
cycles I-Dosage
of O
the O
same O
regimen O
was O
used O
and O
the O
carcinoma B-Diagnostic_procedure
progression I-Diagnostic_procedure
was O
suppressed B-Lab_value
. O

He O
has O
been O
doing B-Sign_symptom
well I-Sign_symptom
for O
more B-Duration
than I-Duration
two I-Duration
years I-Duration
of O
PCI B-Therapeutic_procedure
and O
has O
been O
followed-up B-Clinical_event
regularly B-Detailed_description
. O

A O
76-year-old B-Age
Japanese B-Personal_background
man B-Sex
had O
experienced O
a O
decreased B-Sign_symptom
appetite I-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
abdominal B-Biological_structure
distension B-Sign_symptom
since B-Date
late I-Date
February I-Date
2011 I-Date
. O

The O
patient O
passed O
loose B-Lab_value
, O
soft B-Lab_value
stools B-Diagnostic_procedure
that O
were O
not B-Lab_value
watery I-Lab_value
once B-Frequency
daily I-Frequency
. O

The O
results O
of O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
performed O
by O
the O
primary B-Nonbiological_location
care I-Nonbiological_location
physician I-Nonbiological_location
( O
PCP B-Nonbiological_location
) O
between B-Date
April I-Date
and I-Date
June I-Date
were O
all O
normal B-Lab_value
, O
but O
upper B-Detailed_description
and I-Detailed_description
lower I-Detailed_description
gastrointestinal B-Diagnostic_procedure
endoscopy I-Diagnostic_procedure
showed O
atrophic B-Detailed_description
gastritis B-Disease_disorder
. O

Therefore O
, O
we O
assessed O
the O
patient O
for O
Helicobacter B-Diagnostic_procedure
pylori I-Diagnostic_procedure
antibodies I-Diagnostic_procedure
and O
performed O
the O
rapid B-Diagnostic_procedure
urease I-Diagnostic_procedure
test I-Diagnostic_procedure
and O
a O
histopathological B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
, O
all O
of O
which O
were O
negative B-Lab_value
. O

In O
June B-Date
, O
the O
patient O
received O
medication B-Medication
from O
a O
mental B-Nonbiological_location
health I-Nonbiological_location
clinic I-Nonbiological_location
, O
but O
because O
the O
symptoms B-Sign_symptom
did O
not O
improve O
and O
his O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
further O
decreased B-Lab_value
by I-Lab_value
23 I-Lab_value
kg I-Lab_value
, O
he O
stopped O
the O
medication B-Medication
; O
he O
was O
referred B-Clinical_event
to O
our O
department B-Nonbiological_location
in O
November B-Date
. O

The O
patient O
had O
been O
suffering O
from O
hypertension B-History
since I-History
his I-History
30s I-History
. O

Amlodipine B-Medication
( O
5 B-Dosage
mg/day I-Dosage
) O
administration O
was O
initiated O
in O
2005 B-Date
, O
and O
olmesartan B-Medication
from O
May B-Date
2008 I-Date
; O
the O
patient O
is O
currently O
receiving O
30 B-Dosage
mg/day I-Dosage
of O
olmesartan B-Coreference
. O

He O
denied O
the O
use O
of O
any O
other O
new B-Medication
medications I-Medication
or O
nonsteroidal B-Medication
anti-inflammatory I-Medication
drugs I-Medication
. O

He O
had O
no B-History
history I-History
of I-History
smoking I-History
or I-History
alcohol I-History
consumption I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
that O
the O
patient O
had O
a O
height O
of O
165 B-Height
cm I-Height
, O
a O
body O
weight O
of O
47 B-Weight
kg I-Weight
, O
and O
body B-Diagnostic_procedure
mass I-Diagnostic_procedure
index I-Diagnostic_procedure
of O
17 B-Lab_value
kg/m2 I-Lab_value
. O

His O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
was O
36.3 B-Lab_value
℃ I-Lab_value
; O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
101/min B-Lab_value
; O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
101/81 B-Lab_value
mmHg I-Lab_value
; O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
12 B-Lab_value
breaths/min I-Lab_value
; O
and O
saturation B-Diagnostic_procedure
from I-Diagnostic_procedure
pulse I-Diagnostic_procedure
oximetry I-Diagnostic_procedure
( O
SpO2 B-Diagnostic_procedure
) O
was O
98 B-Lab_value
% I-Lab_value
. O

The O
patient O
had O
no O
heart B-Sign_symptom
murmur I-Sign_symptom
, O
third B-Sign_symptom
heart I-Sign_symptom
sound I-Sign_symptom
or O
jugular B-Biological_structure
venous I-Biological_structure
distension B-Sign_symptom
. O

The O
patient O
had O
bilateral B-Detailed_description
pitting B-Detailed_description
edema B-Sign_symptom
on O
his O
lower B-Biological_structure
legs I-Biological_structure
and O
presented O
with O
unilateral B-Detailed_description
gaze-evoked B-Detailed_description
nystagmus B-Sign_symptom
as O
well O
as O
a O
mildly B-Severity
reduced B-Sign_symptom
tactile I-Sign_symptom
sensation I-Sign_symptom
and O
thermal B-Detailed_description
nociception B-Sign_symptom
in O
the O
toes B-Biological_structure
and O
dorsal B-Biological_structure
regions I-Biological_structure
of I-Biological_structure
both I-Biological_structure
feet I-Biological_structure
. O

Moreover O
, O
the O
finger-to-nose B-Diagnostic_procedure
test I-Diagnostic_procedure
results O
and O
tandem B-Diagnostic_procedure
gait I-Diagnostic_procedure
were O
poor B-Lab_value
, O
and O
his O
patellar B-Biological_structure
and O
Achilles B-Biological_structure
tendon I-Biological_structure
reflexes B-Diagnostic_procedure
had O
disappeared B-Lab_value
. O

Confabulation B-Sign_symptom
was O
observed O
in O
the O
patient O
, O
and O
the O
revised O
Hasegawa B-Diagnostic_procedure
Dementia I-Diagnostic_procedure
Scale I-Diagnostic_procedure
( O
HDS-R B-Diagnostic_procedure
) O
score O
was O
17/30 B-Lab_value
( O
cut-off O
point O
: O
20 O
) O
. O

The O
hematologic B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
as O
follows O
: O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
6,200 B-Lab_value
/ I-Lab_value
μL I-Lab_value
; O
hemoglobin B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
12.5 B-Lab_value
g/dL I-Lab_value
; O
mean B-Diagnostic_procedure
corpuscular I-Diagnostic_procedure
volume I-Diagnostic_procedure
, O
88.4 B-Lab_value
; O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
, O
230,000 B-Lab_value
/ I-Lab_value
μL I-Lab_value
; O
sodium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
136 B-Lab_value
mEq/L I-Lab_value
; O
potassium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
3.8 B-Lab_value
mEq/L I-Lab_value
; O
chlorine B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
103 B-Lab_value
mEq/L I-Lab_value
; O
iron B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
57 B-Lab_value
μg/dL I-Lab_value
( O
reference O
value O
: O
64-187 O
μg/dL O
) O
; O
ferritin B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
366 B-Lab_value
ng/mL I-Lab_value
( O
reference O
value O
: O
50-200 O
ng/mL O
) O
; O
B-type B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
BNP B-Diagnostic_procedure
) O
level O
, O
125.3 B-Lab_value
pg/mL I-Lab_value
( O
reference O
value O
: O
-18.4 O
pg/mL O
) O
; O
and O
vitamin B-Diagnostic_procedure
B1 I-Diagnostic_procedure
level I-Diagnostic_procedure
, O
8 B-Lab_value
ng/mL I-Lab_value
( O
reference O
value O
: O
24-66 O
ng/mL O
) O
. O

An O
electrocardiogram B-Diagnostic_procedure
was O
normal B-Lab_value
and O
chest B-Biological_structure
X-rays B-Diagnostic_procedure
showed O
a O
normal B-Lab_value
cardiothoracic B-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
40.8 B-Lab_value
% I-Lab_value
) O
without O
either O
pulmonary B-Sign_symptom
congestion I-Sign_symptom
or O
pleural B-Disease_disorder
effusion I-Disease_disorder
. O

Cranial B-Biological_structure
fluid-attenuated B-Detailed_description
inversion I-Detailed_description
recovery-magnetic I-Detailed_description
resonance B-Diagnostic_procedure
imaging I-Diagnostic_procedure
findings O
revealed O
periaqueductal B-Biological_structure
hyperintensities B-Sign_symptom
( O
Fig. O
1 O
) O
; O
therefore O
, O
Wernicke B-Disease_disorder
encephalopathy I-Disease_disorder
was O
diagnosed O
. O

Moreover O
, O
as O
sinus B-Detailed_description
tachycardia B-Sign_symptom
and O
a O
tendency O
towards O
hypotension B-Sign_symptom
were O
noted O
, O
no O
clear O
symptoms O
of O
heart B-Disease_disorder
failure I-Disease_disorder
or O
dehydration B-Sign_symptom
were O
observed O
; O
it O
was O
thus O
inferred O
that O
the O
vitamin B-Disease_disorder
B1 I-Disease_disorder
deficiency I-Disease_disorder
had O
likely O
played O
a O
role O
in O
both O
of O
the O
conditions O
. O

The O
antihypertensive B-Medication
agents I-Medication
were O
discontinued O
, O
and O
10 B-Date
days I-Date
after I-Date
the O
intravenous B-Administration
administration O
of O
vitamin B-Medication
B1 I-Medication
, O
the O
patient O
's O
loss B-Sign_symptom
of I-Sign_symptom
appetite I-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
gait B-Sign_symptom
disturbance I-Sign_symptom
disappeared O
, O
and O
his O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
increased B-Lab_value
by I-Lab_value
3 I-Lab_value
kg I-Lab_value
. O

Nystagmus B-Sign_symptom
was O
ameliorated O
on O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
but O
the O
patient O
still O
had O
confabulations B-Sign_symptom
, O
and O
the O
HDS-R B-Diagnostic_procedure
score I-Diagnostic_procedure
and O
absence B-Lab_value
of O
deep B-Biological_structure
tendon I-Biological_structure
reflexes B-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
improve I-Lab_value
. O

Since O
the O
gastrointestinal B-Sign_symptom
symptoms I-Sign_symptom
were O
ameliorated O
and O
his O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
increased B-Lab_value
to O
160/90 B-Lab_value
mmHg I-Lab_value
, O
the O
PCP B-Nonbiological_location
resumed O
the O
administration O
of O
olmesartan B-Medication
on O
late B-Date
December I-Date
, I-Date
2011 I-Date
. O

One B-Date
week I-Date
later I-Date
, O
the O
patient O
complained O
of O
recurrent O
decreased B-Sign_symptom
appetite I-Sign_symptom
and O
nausea B-Sign_symptom
. O

After O
experiencing O
diarrhea B-Sign_symptom
( O
five B-Lab_value
bowel I-Lab_value
movements I-Lab_value
during I-Lab_value
a I-Lab_value
2-day I-Lab_value
period I-Lab_value
) O
, O
he O
passed O
soft B-Lab_value
stools B-Diagnostic_procedure
once B-Frequency
daily I-Frequency
, O
and O
his O
body B-Diagnostic_procedure
weight I-Diagnostic_procedure
decreased B-Lab_value
to O
47 B-Lab_value
kg I-Lab_value
so O
he O
came B-Clinical_event
to O
our O
hospital B-Nonbiological_location
again O
3 B-Date
weeks I-Date
after I-Date
the O
resumption O
of O
olmesartan B-Medication
for O
treatment O
. O

His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
as O
follows O
: O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
, O
35.1 B-Lab_value
℃ I-Lab_value
; O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
93/min B-Lab_value
; O
and O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
132/75 B-Lab_value
mmHg I-Lab_value
. O

The O
neurologic B-Diagnostic_procedure
findings I-Diagnostic_procedure
showed O
no B-Lab_value
worsening I-Lab_value
of O
his O
symptoms O
. O

The O
laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
as O
follows O
: O
sodium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
139 B-Lab_value
mEq/L I-Lab_value
; O
potassium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
2.9 B-Lab_value
mEq/L I-Lab_value
; O
and O
chlorine B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
116 B-Lab_value
mEq/L I-Lab_value
. O

Hyperchloremia B-Sign_symptom
was O
noted O
, O
and O
the O
serum B-Lab_value
sodium I-Lab_value
level I-Lab_value
minus I-Lab_value
chloride I-Lab_value
level I-Lab_value
( I-Lab_value
139-116 I-Lab_value
) I-Lab_value
was I-Lab_value
23 I-Lab_value
mEq/L I-Lab_value
; O
additionally O
, O
the O
arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
as O
follows O
: O
pH B-Diagnostic_procedure
, O
7.25 B-Lab_value
; O
PCO2 B-Diagnostic_procedure
, O
25 B-Lab_value
mmHg I-Lab_value
, O
and O
HCO3 B-Diagnostic_procedure
, O
11 B-Lab_value
mmol/L I-Lab_value
. O

The O
urinalysis B-Diagnostic_procedure
findings O
were O
as O
follows O
: O
sodium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
15 B-Lab_value
mEq/L I-Lab_value
; O
potassium B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
13 B-Lab_value
mEq/L I-Lab_value
; O
chlorine B-Diagnostic_procedure
level I-Diagnostic_procedure
, O
100 B-Lab_value
mEq/L I-Lab_value
; O
and O
urine B-Diagnostic_procedure
anion I-Diagnostic_procedure
gap I-Diagnostic_procedure
, O
-72 B-Lab_value
mEq/L I-Lab_value
, O
and O
there O
was O
no B-Lab_value
apparent I-Lab_value
increase I-Lab_value
in O
bowel B-Diagnostic_procedure
movements I-Diagnostic_procedure
; O
however O
, O
this O
seemed O
to O
be O
due O
to O
the O
absence B-Sign_symptom
of I-Sign_symptom
HCO3 I-Sign_symptom
- I-Sign_symptom
from O
the O
gastrointestinal B-Biological_structure
tract I-Biological_structure
( O
6 O
) O
. O

Plain O
abdominal B-Biological_structure
radiography B-Diagnostic_procedure
and O
abdominal B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
findings O
revealed O
the O
continuous B-Detailed_description
dilation B-Sign_symptom
of O
the O
entire B-Biological_structure
intestinal I-Biological_structure
tract I-Biological_structure
( O
Fig. O
2 O
) O
; O
therefore O
, O
the O
patient O
was O
diagnosed O
with O
intestinal B-Disease_disorder
pseudo-obstruction I-Disease_disorder
. O

After O
discontinuing O
olmesartan B-Medication
, O
the O
nausea B-Sign_symptom
and O
body B-Sign_symptom
weight I-Sign_symptom
decreases I-Sign_symptom
were O
promptly O
ameliorated O
. O

Duodenal B-Biological_structure
biopsy B-Diagnostic_procedure
findings O
after O
discontinuing O
olmesartan B-Medication
showed O
that O
the O
inflammation B-Sign_symptom
observed O
before O
discontinuation O
as O
well O
as O
the O
fold B-Sign_symptom
structure I-Sign_symptom
had O
both O
clearly O
ameliorated O
( O
Fig. O
3 O
) O
. O

A O
73-year-old B-Age
Hispanic B-Personal_background
male B-Sex
with O
a O
history O
of O
stage B-Detailed_description
IV I-Detailed_description
chronic B-Disease_disorder
kidney I-Disease_disorder
disease I-Disease_disorder
and O
three-vessel B-Detailed_description
coronary B-Disease_disorder
artery I-Disease_disorder
disease I-Disease_disorder
was O
admitted B-Clinical_event
for O
coronary B-Therapeutic_procedure
artery I-Therapeutic_procedure
bypass I-Therapeutic_procedure
graft I-Therapeutic_procedure
surgery I-Therapeutic_procedure
and O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
repair I-Therapeutic_procedure
. O

On O
post-operative O
day B-Date
two I-Date
, O
the O
patient O
developed O
cardiac B-Sign_symptom
tamponade I-Sign_symptom
and O
subsequently O
progressed O
to O
a O
cardiac B-Disease_disorder
arrest I-Disease_disorder
while O
temporary B-Therapeutic_procedure
pacing I-Therapeutic_procedure
wires I-Therapeutic_procedure
were O
being O
removed O
. O

Advanced O
cardiovascular B-Therapeutic_procedure
life I-Therapeutic_procedure
support I-Therapeutic_procedure
and O
emergent O
exploratory B-Detailed_description
sternotomy B-Therapeutic_procedure
were O
performed O
, O
and O
the O
patient O
was O
transferred B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
( O
ICU B-Nonbiological_location
) O
for O
further O
care O
. O

During O
the O
patient O
’s O
ICU B-Nonbiological_location
admission B-Clinical_event
, O
his O
renal B-Disease_disorder
failure I-Disease_disorder
progressed O
, O
requiring O
hemodialysis B-Therapeutic_procedure
. O

A O
nasogastric B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
placed O
on O
post-operative O
day B-Date
two I-Date
for O
establishing O
early O
enteral B-Therapeutic_procedure
nutrition I-Therapeutic_procedure
. O

PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
insertion I-Therapeutic_procedure
was O
suggested O
given O
his O
cognitive B-Sign_symptom
impairment I-Sign_symptom
and O
poor B-Lab_value
swallowing B-Diagnostic_procedure
function I-Diagnostic_procedure
on O
the O
Modified B-Diagnostic_procedure
Barium I-Diagnostic_procedure
Swallow I-Diagnostic_procedure
test I-Diagnostic_procedure
. O

His O
coagulation B-Diagnostic_procedure
profile I-Diagnostic_procedure
prior O
to O
the O
procedure O
revealed O
an O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
1.04 B-Lab_value
and O
partial B-Diagnostic_procedure
thromboplastin I-Diagnostic_procedure
time I-Diagnostic_procedure
of O
36 B-Lab_value
seconds I-Lab_value
. O

A O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
showed O
a O
hemoglobin B-Diagnostic_procedure
of O
11.6 B-Lab_value
grams I-Lab_value
per I-Lab_value
deciliter I-Lab_value
, O
a O
hematocrit B-Diagnostic_procedure
of O
34.9 B-Lab_value
% I-Lab_value
, O
and O
281 B-Lab_value
× I-Lab_value
103 I-Lab_value
platelets B-Diagnostic_procedure
per B-Detailed_description
microliter I-Detailed_description
. O

His O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
was O
55 B-Lab_value
milligrams/deciliter I-Lab_value
, O
and O
his O
serum B-Detailed_description
creatinine B-Diagnostic_procedure
was O
5.22 B-Lab_value
milligrams/deciliter I-Lab_value
. O

The O
patient O
was O
taking O
aspirin B-Medication
81 B-Dosage
mg I-Dosage
per I-Dosage
day I-Dosage
due O
to O
recent O
cardiac B-Therapeutic_procedure
surgery I-Therapeutic_procedure
, O
but O
was O
not O
on O
any O
anticoagulant B-Medication
agents I-Medication
. O

He O
also O
did B-History
not I-History
have I-History
a I-History
history I-History
of I-History
coagulopathy I-History
. O

PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
insertion I-Therapeutic_procedure
was O
performed O
on O
post-operative O
day B-Date
eight I-Date
under O
intravenous B-Administration
anesthesia B-Medication
. O

The O
esophagogastroduodenoscopy B-Diagnostic_procedure
( O
EGD B-Diagnostic_procedure
) O
was O
accomplished O
without O
difficulty B-Other_event
, O
revealing O
diffuse B-Detailed_description
moderately B-Severity
erythematous B-Sign_symptom
mucosa B-Biological_structure
without O
bleeding B-Sign_symptom
in O
the O
gastric B-Biological_structure
antrum I-Biological_structure
. O

While O
attempting O
PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
placement I-Therapeutic_procedure
, O
a O
rapidly B-Severity
expanding I-Severity
hematoma B-Sign_symptom
( O
Figure O
1 O
) O
developed O
at O
the O
needle B-Biological_structure
insertion I-Biological_structure
site I-Biological_structure
. O

The O
procedure B-Coreference
was O
stopped O
and O
the O
patient O
was O
sent B-Clinical_event
back I-Clinical_event
to O
the O
ICU B-Nonbiological_location
with O
a O
nasogastric B-Therapeutic_procedure
tube I-Therapeutic_procedure
. O

A O
single B-Dosage
dose I-Dosage
of O
intravenous B-Administration
desmopressin B-Medication
( O
0.3 B-Dosage
microgram/kilogram I-Dosage
) O
was O
administered O
under O
the O
suspicion O
of O
uremic B-Sign_symptom
bleeding I-Sign_symptom
. O

No O
further O
gastrointestinal B-Biological_structure
bleeding B-Sign_symptom
events O
were O
noted O
. O

To O
assess O
platelet B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
a O
platelet B-Diagnostic_procedure
function I-Diagnostic_procedure
assay I-Diagnostic_procedure
( O
PFA B-Diagnostic_procedure
) O
was O
ordered O
after O
desmopressin B-Medication
injection B-Administration
. O

PFA B-Diagnostic_procedure
collagen/epinephrine B-Diagnostic_procedure
closure I-Diagnostic_procedure
time I-Diagnostic_procedure
was O
195 B-Lab_value
seconds I-Lab_value
( O
normal O
< O
174 O
seconds O
) O
, O
and O
collagen/ADP B-Diagnostic_procedure
closure I-Diagnostic_procedure
time I-Diagnostic_procedure
was O
76 B-Lab_value
seconds I-Lab_value
( O
normal O
< O
120 O
seconds O
) O
, O
indicating O
platelet B-Disease_disorder
dysfunction I-Disease_disorder
due O
to O
either O
aspirin B-Medication
or O
uremia B-Disease_disorder
. O

Aspirin B-Medication
was O
discontinued O
, O
and O
he O
was O
monitored B-Therapeutic_procedure
with O
a O
daily B-Frequency
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
and O
metabolic B-Diagnostic_procedure
panel I-Diagnostic_procedure
. O

Three B-Date
days I-Date
later I-Date
the O
patient O
underwent O
a O
second O
attempt O
at O
PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
placement I-Therapeutic_procedure
. O

PFA B-Diagnostic_procedure
collagen/epinephrine B-Diagnostic_procedure
closure I-Diagnostic_procedure
time I-Diagnostic_procedure
prior O
to O
this O
procedure B-Coreference
had O
gone B-Lab_value
down I-Lab_value
to O
141 B-Lab_value
seconds I-Lab_value
, O
possibly O
due O
to O
withholding O
aspirin B-Medication
and O
an O
improvement B-Lab_value
in O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
. O

EGD B-Diagnostic_procedure
showed O
an O
area O
of O
flat B-Texture
, O
bluish B-Color
gastric B-Biological_structure
submucosal I-Biological_structure
bruising B-Sign_symptom
at O
the O
site O
of O
the O
previous O
hematoma B-Sign_symptom
( O
Figure O
2 O
) O
. O

The O
PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
placed O
successfully O
at O
an O
adjacent B-Biological_structure
site I-Biological_structure
. O

Over O
the O
course O
of O
the O
following B-Duration
month I-Duration
, O
the O
patient O
continued O
to O
undergo O
feeding B-Therapeutic_procedure
through O
the O
PEG B-Therapeutic_procedure
tube I-Therapeutic_procedure
with O
no O
adverse B-Sign_symptom
events I-Sign_symptom
. O

A O
46-year-old B-Age
Caucasian B-Personal_background
woman B-Sex
with O
type B-History
2 I-History
diabetes I-History
mellitus I-History
and O
bipolar B-History
disorder I-History
presented B-Clinical_event
to O
our O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
vague B-Detailed_description
abdominal B-Sign_symptom
symptoms I-Sign_symptom
and O
vomiting B-Sign_symptom
. O

Her O
pertinent O
history O
includes O
left B-History
below I-History
knee I-History
amputation I-History
and O
right B-History
toes I-History
amputation I-History
for O
complications B-History
secondary I-History
to I-History
diabetic I-History
neuropathy I-History
. O

At O
the O
time O
of O
admission O
, O
she O
was O
undergoing O
care O
for O
an O
infected B-Detailed_description
diabetic B-Detailed_description
ulcer B-Sign_symptom
of O
her O
right B-Biological_structure
foot I-Biological_structure
. O

Of O
note O
, O
she O
did O
not O
have O
a O
history O
of O
CAPD B-Disease_disorder
or O
a O
history O
of O
renal B-Disease_disorder
disease I-Disease_disorder
: O
creatinine B-Diagnostic_procedure
1.23 B-Lab_value
mg/dL I-Lab_value
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
( B-Diagnostic_procedure
BUN I-Diagnostic_procedure
) I-Diagnostic_procedure
16 B-Lab_value
mg/dL I-Lab_value
. O

Her O
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
poorly B-Lab_value
controlled I-Lab_value
via O
subcutaneous B-Administration
insulin B-Medication
injection B-Administration
; O
she O
reported O
a O
range B-Lab_value
of I-Lab_value
400 I-Lab_value
to I-Lab_value
500 I-Lab_value
mg/dL I-Lab_value
at I-Lab_value
home I-Lab_value
( O
due O
to O
poor B-Clinical_event
drug I-Clinical_event
compliance I-Clinical_event
) O
. O

Her O
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
decreased O
to O
a O
range O
of O
175 B-Lab_value
to I-Lab_value
378 I-Lab_value
mg/dL I-Lab_value
after O
implementation O
of O
a O
stricter B-Detailed_description
insulin B-Medication
regimen B-Detailed_description
upon O
admission O
. O

A O
non-contrast B-Detailed_description
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
confluent B-Detailed_description
, O
bilobar B-Biological_structure
geographic O
regions O
of O
hypoattenuation B-Sign_symptom
in O
a O
subcapsular B-Detailed_description
distribution I-Detailed_description
throughout O
her O
liver B-Biological_structure
( O
Fig. O
1 O
) O
. O

A O
MRI B-Diagnostic_procedure
liver B-Biological_structure
protocol O
was O
performed O
for O
further O
evaluation O
of O
these O
indeterminate O
findings O
to O
assess O
for O
possible O
vascular O
etiology O
as O
areas O
of O
infarction O
could O
also O
be O
possible O
in O
this O
patient O
. O

In-phase B-Detailed_description
gradient B-Diagnostic_procedure
echo I-Diagnostic_procedure
images O
demonstrated O
hyperintense B-Detailed_description
foci B-Sign_symptom
in O
her O
liver B-Biological_structure
in O
a O
distribution O
corresponding O
to O
the O
hypoattenuating O
regions O
seen O
on O
CT O
. O

On O
the O
opposed-phase B-Diagnostic_procedure
sequence I-Diagnostic_procedure
, O
there O
was O
loss B-Lab_value
in I-Lab_value
signal I-Lab_value
within O
these O
areas O
indicating O
the O
presence B-Sign_symptom
of I-Sign_symptom
intracellular I-Sign_symptom
fat I-Sign_symptom
and I-Sign_symptom
water I-Sign_symptom
( O
Fig. O
2 O
) O
. O

In O
addition O
, O
these O
areas O
were O
hypointense O
to O
the O
remaining O
hepatic B-Biological_structure
parenchyma I-Biological_structure
on O
the O
fat O
suppression O
MR B-Coreference
sequences I-Coreference
, O
confirming O
presence B-Sign_symptom
of I-Sign_symptom
fat I-Sign_symptom
and O
thus O
establishing O
a O
diagnosis O
of O
SHS B-Disease_disorder
. O

Furthermore O
, O
a O
follow-up O
CT B-Diagnostic_procedure
of O
her O
abdomen B-Biological_structure
and O
pelvis B-Biological_structure
was O
performed O
3 B-Date
months I-Date
later I-Date
, O
which O
showed O
near B-Sign_symptom
complete I-Sign_symptom
resolution I-Sign_symptom
of O
these O
findings O
( O
Fig. O
3 O
) O
. O

Of O
note O
, O
stricter O
glucose B-Therapeutic_procedure
control I-Therapeutic_procedure
had O
decreased O
her O
average O
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
level I-Diagnostic_procedure
to O
below B-Lab_value
200 I-Lab_value
mg/dL I-Lab_value
. O

The O
36-year-old B-Age
male B-Sex
patient O
in O
this O
case O
had O
a O
6-year B-Duration
history O
of O
diffuse B-Detailed_description
cutaneous B-History
SSc I-History
( O
Fig. O
1 O
) O
and O
had O
not O
received O
regular O
follow-up B-Clinical_event
or O
medication B-Medication
therapy O
. O

He O
had O
experienced O
malaise B-Sign_symptom
, O
poor B-Sign_symptom
appetite I-Sign_symptom
, O
and O
progressive B-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
for O
1 B-Duration
month I-Duration
and O
oligouria B-Sign_symptom
for O
3 B-Duration
days I-Duration
. O

He O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
renal B-Disease_disorder
failure I-Disease_disorder
and O
pulmonary B-Biological_structure
edema B-Sign_symptom
. O

In O
the O
emergency O
department O
, O
his O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
and O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
were O
174/127 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
88/min B-Lab_value
, O
and O
22/min B-Lab_value
, O
respectively O
. O

Laboratory B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
the O
following O
values O
: O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
, O
7730/μL B-Lab_value
( O
3500 O
– O
11,000 O
/ O
μL O
) O
; O
hemoglobin B-Diagnostic_procedure
, O
8.6 B-Lab_value
g/dL I-Lab_value
( O
12 O
– O
16 O
g/dL O
) O
: O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
, O
87000/μL B-Lab_value
( O
150,000 O
– O
400,000 O
/ O
μL O
) O
; O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
, O
78 B-Lab_value
mg/dL I-Lab_value
( O
6 O
– O
21 O
mg/dL O
) O
; O
creatinine B-Diagnostic_procedure
, O
8.9 B-Lab_value
mg/dL I-Lab_value
( O
1.1 O
– O
1.5 O
mg/dL O
) O
; O
calcium B-Diagnostic_procedure
, O
8.2 B-Lab_value
mg/dL I-Lab_value
( O
8.8 O
– O
10.3 O
mg/dL O
) O
; O
phosphorus B-Diagnostic_procedure
, O
5.4 B-Lab_value
mg/dL I-Lab_value
( O
2.7 O
– O
4.5 O
mg/dL O
) O
; O
haptoglobin B-Diagnostic_procedure
, O
< B-Lab_value
6.56 I-Lab_value
mg/dL I-Lab_value
( O
30 O
– O
200 O
mg/dL O
) O
; O
and O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
, O
547 B-Lab_value
U/L I-Lab_value
( O
106 O
– O
211 O
U/L O
) O
. O

A O
routine O
urinalysis B-Diagnostic_procedure
revealed O
a O
proteinuria B-Lab_value
score I-Lab_value
of I-Lab_value
2 I-Lab_value
+ I-Lab_value
( O
200 B-Lab_value
mg/dL I-Lab_value
) O
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
of O
3 B-Lab_value
– I-Lab_value
5/high I-Lab_value
power I-Lab_value
field I-Lab_value
, O
and O
red B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
of O
25 B-Lab_value
– I-Lab_value
50/high I-Lab_value
power I-Lab_value
field I-Lab_value
. O

The O
autoimmune B-Diagnostic_procedure
profile I-Diagnostic_procedure
indicated O
an O
antinuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
level O
of O
1:320 B-Lab_value
( O
speckles B-Lab_value
; I-Lab_value
normal I-Lab_value
, O
< B-Lab_value
1:40 I-Lab_value
) O
. O

Tests O
for O
anti-Scl70 B-Diagnostic_procedure
, O
anti-double-stranded B-Diagnostic_procedure
DNA I-Diagnostic_procedure
, O
anti-Ro B-Diagnostic_procedure
, O
anti-La B-Diagnostic_procedure
, O
and O
anticardiolipin B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
were O
all O
negative B-Lab_value
. O

Kidney B-Biological_structure
echogram B-Diagnostic_procedure
showed O
a O
decreased B-Sign_symptom
bilateral I-Sign_symptom
kidney I-Sign_symptom
size I-Sign_symptom
without O
hydronephrosis B-Sign_symptom
. O

Despite O
the O
chronic O
changes O
visible O
on O
the O
echogram O
, O
the O
patient O
had O
developed O
acute O
pulmonary B-Biological_structure
edema B-Sign_symptom
and O
oligouria B-Sign_symptom
only O
3 B-Date
days I-Date
before I-Date
admission O
. O

Accordingly O
, O
a O
clinical O
diagnosis O
of O
acute-on-chronic B-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
was O
made O
. O

A O
further O
diagnosis O
of O
SRC B-Disease_disorder
was O
supported O
by O
the O
presence O
of O
renal B-Disease_disorder
failure I-Disease_disorder
with O
microangiopathic B-Detailed_description
hemolytic B-Detailed_description
anemia B-Sign_symptom
and O
hypertension B-Sign_symptom
, O
and O
the O
patient O
was O
started O
on O
captopril B-Medication
therapy O
. O

The O
sustained O
deterioration B-Sign_symptom
in I-Sign_symptom
renal I-Sign_symptom
function I-Sign_symptom
and O
anuria B-Sign_symptom
had O
led O
to O
a O
requirement O
for O
regular B-Detailed_description
hemodialysis B-Therapeutic_procedure
from O
admission O
. O

After B-Date
3 I-Date
days I-Date
, O
captopril B-Medication
was O
changed O
to O
amlodipine B-Medication
because O
the O
patient O
developed O
a O
severe B-Severity
, O
intolerable B-Detailed_description
cough B-Sign_symptom
thought O
to O
be O
associated O
with O
captopril O
. O

His O
systolic B-Diagnostic_procedure
blood I-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
controlled B-Lab_value
between B-Lab_value
140 I-Lab_value
and I-Lab_value
180 I-Lab_value
mm I-Lab_value
Hg I-Lab_value
. O

At O
approximately O
3 B-Date
weeks I-Date
after I-Date
the O
initiation O
of O
maintenance O
hemodialysis B-Coreference
, O
the O
patient O
newly O
developed O
a O
generalized B-Detailed_description
tonic-clonic B-Detailed_description
seizure B-Disease_disorder
disorder I-Disease_disorder
. O

A O
brain B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
revealed O
a O
small B-Severity
lacunar B-Detailed_description
infarct B-Disease_disorder
over O
the O
left B-Biological_structure
basal I-Biological_structure
ganglion I-Biological_structure
without O
intracranial B-Biological_structure
hemorrhage B-Disease_disorder
or O
large B-Severity
infarct B-Disease_disorder
. O

The O
seizure B-Sign_symptom
resolved O
spontaneously O
without O
anticonvulsants B-Medication
, O
and O
the O
patient O
was O
finally O
discharged B-Clinical_event
home B-Nonbiological_location
without O
incident O
and O
scheduled O
for O
regular O
hemodialysis B-Therapeutic_procedure
thrice B-Frequency
weekly I-Frequency
. O

However O
, O
at O
1 B-Date
week I-Date
after I-Date
discharge O
, O
the O
patient O
developed O
a O
sudden-onset B-Detailed_description
headache B-Sign_symptom
and O
vomiting B-Sign_symptom
with O
confusion B-Sign_symptom
and O
recurrence O
of O
the O
generalized B-Detailed_description
tonic-clonic B-Detailed_description
seizure B-Sign_symptom
. O

He O
presented B-Clinical_event
at O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
183/100 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
149,000 B-Lab_value
/ I-Lab_value
μL I-Lab_value
, O
serum B-Diagnostic_procedure
LDH I-Diagnostic_procedure
of O
332 B-Lab_value
U/L I-Lab_value
, O
and O
a O
peripheral B-Diagnostic_procedure
blood I-Diagnostic_procedure
smear I-Diagnostic_procedure
containing B-Lab_value
2 I-Lab_value
– I-Lab_value
3 I-Lab_value
schizocytes/HPF I-Lab_value
( O
Fig. O
2 O
) O
. O

Brain B-Biological_structure
CT B-Diagnostic_procedure
revealed O
no B-Lab_value
interval I-Lab_value
change I-Lab_value
, O
and O
lumbar B-Diagnostic_procedure
puncture I-Diagnostic_procedure
revealed O
traumatic B-Lab_value
tapping I-Lab_value
only I-Lab_value
. O

Cerebrospinal B-Biological_structure
fluid B-Diagnostic_procedure
cultures I-Diagnostic_procedure
were O
negative B-Lab_value
for O
bacteria B-Detailed_description
, O
mycobacteria B-Detailed_description
, O
and O
viruses B-Detailed_description
. O

Brain B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
showed O
bilateral B-Detailed_description
hyperintensity B-Sign_symptom
in O
the O
occipital B-Biological_structure
and I-Biological_structure
parietal I-Biological_structure
lobes I-Biological_structure
on O
a O
fluid-attenuated B-Detailed_description
inversion I-Detailed_description
recovery I-Detailed_description
( I-Detailed_description
FLAIR I-Detailed_description
) I-Detailed_description
sequence I-Detailed_description
( O
Fig. O
3 O
) O
. O

Finally O
, O
the O
patient O
was O
diagnosed O
with O
PRES. B-Disease_disorder
We O
resumed O
captopril B-Medication
therapy O
at O
a O
dose O
of O
25 B-Dosage
mg I-Dosage
thrice I-Dosage
daily I-Dosage
. O

As O
it O
was O
difficult O
to O
differentiate O
SRC O
from O
TTP O
, O
we O
also O
considered O
plasma O
exchange O
treatment O
. O

However O
, O
the O
patient O
's O
mental B-Diagnostic_procedure
status I-Diagnostic_procedure
returned O
to O
normal B-Lab_value
within O
3 B-Date
days I-Date
in O
the O
absence O
of O
plasma B-Therapeutic_procedure
exchange I-Therapeutic_procedure
, O
and O
a O
follow-up O
MRI B-Diagnostic_procedure
of O
the O
brain B-Biological_structure
2 B-Date
months I-Date
later I-Date
showed O
complete O
resolution O
of O
cerebral B-Biological_structure
edema B-Sign_symptom
( O
Fig. O
4 O
) O
. O

Therefore O
, O
SRC-related B-Detailed_description
PRES B-Disease_disorder
was O
confirmed O
. O

Although O
the O
patient O
experienced O
a O
full B-Sign_symptom
neurologic I-Sign_symptom
recovery I-Sign_symptom
, O
his O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
improve I-Lab_value
and O
he O
remained O
dialysis B-Therapeutic_procedure
dependent B-Detailed_description
. O

A O
53-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
our O
institution B-Nonbiological_location
with O
progressive B-Detailed_description
abdominal B-Biological_structure
distention B-Sign_symptom
and O
irregular B-Detailed_description
vaginal B-Biological_structure
bleeding B-Sign_symptom
of O
several B-Duration
weeks I-Duration
’ O
duration O
. O

A O
contrast B-Detailed_description
CT B-Diagnostic_procedure
abdomen B-Biological_structure
and O
pelvis B-Biological_structure
revealed O
an O
ill-defined B-Detailed_description
, O
irregular B-Detailed_description
mass B-Sign_symptom
in O
the O
lower B-Biological_structure
uterine/cervical I-Biological_structure
region I-Biological_structure
( O
Figure O
1 O
) O
. O

There O
were O
multiple B-Detailed_description
peritoneal B-Biological_structure
and O
omental B-Biological_structure
masses B-Sign_symptom
, O
enlarged B-Sign_symptom
pelvic B-Biological_structure
and O
paraaortic B-Biological_structure
lymph B-Biological_structure
nodes I-Biological_structure
, O
and O
large-volume B-Detailed_description
ascites B-Sign_symptom
. O

The O
initial O
CBC B-Diagnostic_procedure
was O
significant O
for O
hemoglobin B-Diagnostic_procedure
of O
9.2 B-Lab_value
g/dL I-Lab_value
, O
leukocytosis B-Sign_symptom
of O
36 B-Lab_value
790 I-Lab_value
per I-Lab_value
microliter I-Lab_value
, O
and O
thrombocytosis B-Sign_symptom
of O
625 B-Lab_value
000 I-Lab_value
per I-Lab_value
microliter I-Lab_value
. O

Serum B-Biological_structure
calcium B-Diagnostic_procedure
was O
elevated B-Lab_value
at O
13.1 B-Lab_value
mg/dL I-Lab_value
. O

BUN B-Diagnostic_procedure
and O
creatinine B-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

Hepatic B-Diagnostic_procedure
function I-Diagnostic_procedure
was O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
. O

A O
pelvic B-Diagnostic_procedure
exam I-Diagnostic_procedure
revealed O
a O
fungating B-Detailed_description
vaginal B-Biological_structure
mass B-Sign_symptom
. O

The O
patient O
underwent O
biopsies B-Diagnostic_procedure
of O
the O
endometrium B-Biological_structure
and O
the O
vaginal B-Biological_structure
mass B-Coreference
, O
which O
revealed O
a O
high-grade B-Severity
tumor B-Sign_symptom
with O
predominantly B-Detailed_description
oval-shaped I-Detailed_description
cells I-Detailed_description
. O

Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
was O
positive B-Lab_value
for O
vimentin B-Diagnostic_procedure
, O
CD10 B-Diagnostic_procedure
, O
and O
cyclin B-Diagnostic_procedure
D1 I-Diagnostic_procedure
, O
consistent O
with O
a O
diagnosis O
of O
high-grade B-Severity
endometrial B-Disease_disorder
stromal I-Disease_disorder
sarcoma I-Disease_disorder
( O
Figure O
2 O
) O
. O

The O
tumor B-Coreference
was O
negative B-Lab_value
for O
ER B-Diagnostic_procedure
, O
with O
rare B-Detailed_description
cells I-Detailed_description
positive B-Lab_value
for O
PR B-Diagnostic_procedure
. O

Although O
immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
for O
cytokeratins B-Diagnostic_procedure
was O
negative B-Lab_value
, O
a O
biphasic B-Sign_symptom
component I-Sign_symptom
could O
not O
be O
entirely O
ruled O
out O
given O
the O
small O
size O
of O
the O
biopsy O
specimen O
relative O
to O
the O
tumor O
. O

The O
patient O
’s O
Ca125 B-Diagnostic_procedure
was O
markedly O
elevated B-Lab_value
at O
1624 B-Lab_value
U/mL I-Lab_value
( O
nl O
≤ O
34 O
) O
. O

Contrast B-Detailed_description
CT B-Diagnostic_procedure
chest B-Biological_structure
revealed O
a O
right-sided B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
but O
no O
suspicious B-Detailed_description
nodules B-Sign_symptom
or O
lymphadenopathy B-Disease_disorder
. O

The O
patient O
was O
deemed O
to O
have O
operable B-Disease_disorder
disease I-Disease_disorder
and O
was O
scheduled O
for O
debulking B-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O

However O
, O
preoperative O
laboratory B-Diagnostic_procedure
studies I-Diagnostic_procedure
showed O
that O
her O
serum B-Biological_structure
calcium B-Diagnostic_procedure
had O
further O
increased B-Lab_value
to O
19.2 B-Lab_value
mg/dL I-Lab_value
. O

She O
had O
also O
developed O
evidence O
of O
acute B-Detailed_description
kidney B-Biological_structure
injury B-Disease_disorder
, O
with O
her O
BUN B-Diagnostic_procedure
rising B-Lab_value
to O
37 B-Lab_value
mg/dL I-Lab_value
and O
creatinine B-Diagnostic_procedure
to O
1.81 B-Lab_value
mg/dL I-Lab_value
. O

On O
physical B-Diagnostic_procedure
exam I-Diagnostic_procedure
, O
she O
was O
noted O
to O
be O
lethargic B-Sign_symptom
, O
with O
dry B-Sign_symptom
mucous B-Biological_structure
membranes I-Biological_structure
. O

The O
surgery B-Therapeutic_procedure
was O
cancelled B-Clinical_event
due O
to O
the O
patient O
’s O
medical B-Disease_disorder
instability I-Disease_disorder
. O

Further O
workup O
revealed O
an O
elevated B-Lab_value
PTHrP B-Diagnostic_procedure
of O
301 B-Lab_value
pg/mL I-Lab_value
( O
nl O
14 O
– O
27 O
) O
, O
a O
depressed B-Lab_value
PTH B-Diagnostic_procedure
level O
of O
3 B-Lab_value
pg/mL I-Lab_value
( O
nl O
15 O
– O
65 O
) O
, O
and O
a O
depressed B-Lab_value
25-OH B-Diagnostic_procedure
vitamin I-Diagnostic_procedure
D I-Diagnostic_procedure
level O
of O
16 B-Lab_value
ng/mL I-Lab_value
( O
nl O
30 O
– O
100 O
) O
, O
consistent O
with O
humoral B-Disease_disorder
hypercalcemia I-Disease_disorder
of I-Disease_disorder
malignancy I-Disease_disorder
. O

The O
patient O
was O
treated O
with O
pamidronate B-Medication
, O
calcitonin B-Medication
, O
and O
intravenous B-Administration
fluids B-Medication
. O

She O
eventually O
required O
temporary B-Detailed_description
hemodialysis B-Therapeutic_procedure
and O
denosumab B-Medication
for O
refractory B-Detailed_description
hypercalcemia B-Sign_symptom
. O

The O
patient O
improved O
with O
regard O
to O
her O
electrolyte B-Coreference
abnormalities I-Coreference
. O

Given O
the O
extent O
of O
her O
disease O
, O
she O
was O
planned O
for O
neoadjuvant O
chemotherapy B-Medication
followed O
by O
surgery B-Therapeutic_procedure
if O
a O
good O
response O
was O
achieved O
. O

She O
was O
started O
on O
a O
regimen O
of O
carboplatin B-Medication
and O
paclitaxel B-Medication
, O
which O
she O
received O
for O
3 B-Dosage
cycles I-Dosage
. O

She O
also O
had O
palliative O
radiation B-Therapeutic_procedure
to O
the O
uterus B-Biological_structure
to O
control O
bleeding B-Sign_symptom
. O

However O
, O
her O
disease O
failed O
to O
respond O
significantly O
to O
chemotherapy O
, O
and O
she O
ultimately O
died B-Outcome
from O
complications B-Disease_disorder
of I-Disease_disorder
malignancy I-Disease_disorder
. O

A O
46-year-old B-Age
woman B-Sex
with O
a O
history O
of O
Graves B-History
' I-History
disease I-History
( I-History
GD I-History
) I-History
was O
transferred B-Clinical_event
to O
our O
emergency B-Nonbiological_location
department I-Nonbiological_location
on O
suspicion O
of O
DKA B-Disease_disorder
. O

She O
had O
noticed O
polydipsia B-Sign_symptom
, O
polyuria B-Sign_symptom
, O
and O
fatigue B-Sign_symptom
approximately O
four B-Duration
months I-Duration
prior I-Duration
to I-Duration
admission I-Duration
. O

She O
had O
also O
been O
suffering O
from O
a O
1-month B-Duration
complaint O
of O
appetite B-Sign_symptom
loss I-Sign_symptom
, O
approximately O
7 B-Lab_value
kg I-Lab_value
weight B-Sign_symptom
loss I-Sign_symptom
, O
fatigue B-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
sweating B-Sign_symptom
. O

Her O
medical O
history O
included O
GD B-History
, I-History
diagnosed I-History
at I-History
42 I-History
years I-History
of I-History
age I-History
and I-History
managed I-History
with I-History
methimazole I-History
. O

However O
, O
she O
had O
poor B-Lab_value
compliance I-Lab_value
with O
anti-thyroid B-Medication
drugs I-Medication
. O

She O
denied B-History
a I-History
family I-History
history I-History
of I-History
thyroid I-History
diseases I-History
or I-History
diabetes I-History
. O

Three B-Date
days I-Date
before I-Date
admission I-Date
, O
she O
was O
also O
diagnosed B-Clinical_event
with O
influenza B-Disease_disorder
A I-Disease_disorder
at O
a O
nearby B-Nonbiological_location
hospital I-Nonbiological_location
, O
and O
oseltamivir B-Medication
phosphate I-Medication
was O
prescribed O
. O

At O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
, O
she O
presented B-Clinical_event
with O
drowsiness B-Sign_symptom
and O
a O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
of O
37.0 B-Lab_value
℃ I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
90/60 B-Lab_value
mmHg I-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
200 B-Lab_value
bpm I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
32 B-Lab_value
breaths/min I-Lab_value
, O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
of O
99 B-Lab_value
% I-Lab_value
in O
5 B-Lab_value
L I-Lab_value
nasal I-Lab_value
air I-Lab_value
, O
and O
a O
Glasgow B-Diagnostic_procedure
coma I-Diagnostic_procedure
scale I-Diagnostic_procedure
( O
GCS B-Diagnostic_procedure
) O
score O
of O
14 B-Lab_value
. O

Her O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
diffuse B-Detailed_description
goiter B-Sign_symptom
with O
bilateral B-Detailed_description
exophthalmoses I-Detailed_description
. O

Her O
lungs B-Biological_structure
were O
clear B-Lab_value
when O
auscultated B-Diagnostic_procedure
. O

Her O
abdomen B-Biological_structure
was O
soft B-Lab_value
and O
non-tender B-Sign_symptom
. O

Her O
skin B-Biological_structure
was O
warm B-Lab_value
and O
wet B-Lab_value
. O

She O
had O
no O
lower B-Biological_structure
extremity I-Biological_structure
edema B-Sign_symptom
. O

The O
electrocardiogram B-Diagnostic_procedure
showed O
marked B-Detailed_description
tachycardia B-Sign_symptom
with O
atrial B-Disease_disorder
fibrillation I-Disease_disorder
, O
and O
a O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
was O
normal B-Lab_value
. O

The O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
are O
shown O
in O
Table O
1 O
. O

Her O
initial O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
demonstrated O
marked O
metabolic B-Sign_symptom
acidosis I-Sign_symptom
, O
an O
increased B-Lab_value
plasma B-Diagnostic_procedure
glucose I-Diagnostic_procedure
level O
of O
472 B-Lab_value
mg/dL I-Lab_value
, O
an O
increased B-Lab_value
HbA1c B-Diagnostic_procedure
level O
of O
13.7 B-Lab_value
% I-Lab_value
, O
an O
increased B-Lab_value
free B-Diagnostic_procedure
triiodothyronine I-Diagnostic_procedure
level O
of O
6.440 B-Lab_value
pg/mL I-Lab_value
, O
and O
a O
free B-Diagnostic_procedure
thyroxine I-Diagnostic_procedure
level O
of O
2.830 B-Lab_value
ng/dL I-Lab_value
, O
with O
a O
suppressed B-Diagnostic_procedure
thyrotropin I-Diagnostic_procedure
( O
TSH O
) O
level O
of O
0.005 B-Lab_value
μIU/mL I-Lab_value
. O

She O
scored O
55 B-Lab_value
on O
the O
diagnostic B-Diagnostic_procedure
criteria I-Diagnostic_procedure
of I-Diagnostic_procedure
Burch I-Diagnostic_procedure
& I-Diagnostic_procedure
Wartofsky I-Diagnostic_procedure
for I-Diagnostic_procedure
thyroid I-Diagnostic_procedure
storm I-Diagnostic_procedure
, O
and O
the O
diagnostic B-Diagnostic_procedure
criteria I-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
Japan I-Diagnostic_procedure
Thyroid I-Diagnostic_procedure
Association I-Diagnostic_procedure
for I-Diagnostic_procedure
thyroid I-Diagnostic_procedure
storm I-Diagnostic_procedure
were O
also O
satisfied B-Lab_value
, O
since O
she O
had O
thyrotoxicosis B-Disease_disorder
, O
symptoms B-Sign_symptom
involving I-Sign_symptom
the I-Sign_symptom
central I-Sign_symptom
nervous I-Sign_symptom
system I-Sign_symptom
, O
tachycardia B-Sign_symptom
, O
and O
gastrointestinal B-Sign_symptom
symptoms I-Sign_symptom
( O
4 O
) O
. O

Accordingly O
, O
she O
was O
diagnosed B-Clinical_event
with O
DKA B-Disease_disorder
and O
thyroid B-Disease_disorder
storm I-Disease_disorder
and O
admitted B-Clinical_event
to O
the O
medical B-Nonbiological_location
intensive I-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
for O
further O
monitoring B-Diagnostic_procedure
and O
treatment B-Therapeutic_procedure
. O

The O
clinical O
course O
is O
shown O
in O
Figure O
. O

She O
was O
treated O
with O
an O
intravenous B-Administration
insulin B-Medication
drip B-Administration
and O
aggressive B-Detailed_description
intravenous B-Administration
fluid B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

The O
thyroid B-Disease_disorder
storm I-Disease_disorder
with O
GD B-Disease_disorder
was O
treated O
with O
intravenous B-Administration
hydrocortisone B-Medication
100 B-Dosage
mg I-Dosage
every I-Dosage
8 I-Dosage
hours I-Dosage
, O
oral B-Administration
potassium B-Medication
iodine I-Medication
50 B-Dosage
mg I-Dosage
every I-Dosage
6 I-Dosage
hours I-Dosage
, O
and O
oral B-Administration
methimazole B-Medication
20 B-Dosage
mg I-Dosage
every I-Dosage
6 I-Dosage
hours I-Dosage
. O

Since O
she O
had O
a O
history O
of O
asthma B-History
, O
landiolol B-Medication
hydrochloride I-Medication
, O
a O
short-acting O
beta-adrenoceptor O
blocker O
, O
was O
used O
at O
4-12 B-Dosage
μg/kg/min I-Dosage
to O
control O
her O
heart O
rate O
. O

By O
Day B-Date
3 I-Date
, O
her O
tachycardia B-Sign_symptom
had O
resolved O
, O
and O
landiolol B-Medication
hydrochloride I-Medication
was O
discontinued O
. O

On O
Day B-Date
6 I-Date
, O
the O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
had O
decreased O
to O
2,800 B-Lab_value
cells/mm3 I-Lab_value
[ O
neutrophils B-Lab_value
, I-Lab_value
44.2 I-Lab_value
% I-Lab_value
( I-Lab_value
1,238 I-Lab_value
cells/mm3 I-Lab_value
) I-Lab_value
] O
. O

Methimazole B-Medication
was O
discontinued O
because O
methimazole-induced B-Detailed_description
neutropenia B-Sign_symptom
was O
suspected O
. O

The O
patient O
was O
referred B-Clinical_event
to O
an O
endocrine B-Nonbiological_location
surgeon I-Nonbiological_location
, O
and O
thyroidectomy B-Therapeutic_procedure
was O
performed O
on O
Day B-Date
32 I-Date
. O

She O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
on O
Day B-Date
37 I-Date
and O
maintained O
on O
multiple B-Dosage
daily I-Dosage
insulin B-Medication
infusion B-Administration
and O
levothyroxine B-Medication
sodium I-Medication
hydrate I-Medication
. O

Further O
immunological B-Diagnostic_procedure
investigation I-Diagnostic_procedure
revealed O
elevated B-Lab_value
levels I-Lab_value
of O
anti-glutamic B-Diagnostic_procedure
acid I-Diagnostic_procedure
decarboxylase I-Diagnostic_procedure
( I-Diagnostic_procedure
GAD I-Diagnostic_procedure
) I-Diagnostic_procedure
antibody I-Diagnostic_procedure
, O
anti-insulinoma B-Diagnostic_procedure
antigen I-Diagnostic_procedure
2 I-Diagnostic_procedure
( I-Diagnostic_procedure
IA-2 I-Diagnostic_procedure
) I-Diagnostic_procedure
antibody I-Diagnostic_procedure
, O
and O
insulin B-Diagnostic_procedure
autoantibody I-Diagnostic_procedure
, O
consistent O
with O
T1D B-Disease_disorder
. O

The O
intravenous B-Diagnostic_procedure
glucagon I-Diagnostic_procedure
stimulation I-Diagnostic_procedure
test I-Diagnostic_procedure
was O
performed O
with O
blood B-Biological_structure
samples I-Biological_structure
for B-Detailed_description
glucose I-Detailed_description
and I-Detailed_description
C-peptide I-Detailed_description
taken I-Detailed_description
at I-Detailed_description
baseline I-Detailed_description
and I-Detailed_description
6 I-Detailed_description
minutes I-Detailed_description
. O

Her O
plasma B-Diagnostic_procedure
glucose I-Diagnostic_procedure
levels O
were O
139 B-Lab_value
and O
152 B-Lab_value
mg/dL I-Lab_value
at O
baseline B-Detailed_description
and O
6 B-Detailed_description
minutes I-Detailed_description
, O
respectively O
. O

The O
corresponding O
serum B-Diagnostic_procedure
C-peptide I-Diagnostic_procedure
levels O
were O
0.8 B-Lab_value
and O
1.3 B-Lab_value
ng/mL I-Lab_value
at O
baseline B-Detailed_description
and O
6 B-Detailed_description
minutes I-Detailed_description
, O
respectively O
. O

A O
39-year-old B-Age
Korean B-Personal_background
male B-Sex
come B-Clinical_event
to O
our O
hospital B-Nonbiological_location
complaining O
of O
cough B-Sign_symptom
, O
myalgia B-Sign_symptom
, O
and O
fever B-Sign_symptom
that O
had O
lasted B-Duration
for I-Duration
5 I-Duration
days I-Duration
. O

He O
was O
a O
company B-Occupation
worker I-Occupation
and O
denied B-History
any I-History
previous I-History
medical I-History
histories I-History
. O

He O
was O
a O
current B-History
smoker I-History
and O
drank B-History
alcohol I-History
about I-History
once I-History
a I-History
month I-History
. O

His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
: O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
100/60 B-Lab_value
mmHg I-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
100/min B-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
25 B-Lab_value
breaths/min I-Lab_value
, O
and O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
, O
39 B-Lab_value
°C I-Lab_value
. O

On O
the O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
decreased B-Lab_value
breathing B-Diagnostic_procedure
sound I-Diagnostic_procedure
was O
noted O
in O
the O
right B-Biological_structure
lower I-Biological_structure
lung I-Biological_structure
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
a O
c-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
CRP B-Diagnostic_procedure
) O
level O
of O
119 B-Lab_value
mg/dL I-Lab_value
, O
a O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
level O
of O
1.8 B-Lab_value
mg/dL I-Lab_value
, O
and O
alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
and O
aspartate B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
levels O
of O
250 B-Lab_value
and O
172 B-Lab_value
IU/L I-Lab_value
, O
respectively O
. O

His O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
98,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
while O
his O
white B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
8150/mm3 B-Lab_value
( O
neutrophil B-Lab_value
: I-Lab_value
85 I-Lab_value
% I-Lab_value
) O
. O

In O
the O
arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gas I-Diagnostic_procedure
analysis I-Diagnostic_procedure
checked O
in B-Detailed_description
room I-Detailed_description
air I-Detailed_description
, O
pH B-Diagnostic_procedure
, O
PaCO2 B-Diagnostic_procedure
, O
PaO2 B-Diagnostic_procedure
, O
bicarbonate B-Diagnostic_procedure
, O
and O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
levels O
were O
7.50 B-Lab_value
, O
34 B-Lab_value
mmHg I-Lab_value
, O
67 B-Lab_value
mmHg I-Lab_value
, O
26.5 B-Lab_value
mmol/L I-Lab_value
, O
and O
95 B-Lab_value
% I-Lab_value
, O
respectively O
. O

A O
test B-Diagnostic_procedure
for I-Diagnostic_procedure
the I-Diagnostic_procedure
human I-Diagnostic_procedure
immunodeficiency I-Diagnostic_procedure
virus I-Diagnostic_procedure
was O
negative B-Lab_value
. O

Mycoplasma B-Detailed_description
and O
Chlamydia B-Detailed_description
antibodies B-Diagnostic_procedure
were O
negative B-Lab_value
. O

Streptococcal B-Detailed_description
and O
Legionella B-Detailed_description
urinary B-Diagnostic_procedure
antigens I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Anti-nuclear B-Detailed_description
and O
anti-neutrophilic B-Detailed_description
cytoplasmic B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
were O
also O
negative B-Lab_value
. O

A O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
consolidation B-Sign_symptom
in O
the O
right B-Biological_structure
mid I-Biological_structure
to I-Biological_structure
lower I-Biological_structure
lung I-Biological_structure
fields I-Biological_structure
. O

Chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
showed O
consolidation B-Sign_symptom
with O
surrounding B-Texture
ground I-Texture
glass I-Texture
opacity I-Texture
in O
the O
right B-Biological_structure
middle I-Biological_structure
lobe I-Biological_structure
with O
a O
small B-Severity
amount I-Severity
of O
pleural B-Disease_disorder
effusion I-Disease_disorder
in O
the O
right B-Biological_structure
hemithorax I-Biological_structure
( O
Fig. O
1 O
) O
. O

Abdominal B-Biological_structure
sonography B-Diagnostic_procedure
revealed O
no B-Lab_value
abnormal I-Lab_value
finding I-Lab_value
in O
the O
hepatobiliary B-Biological_structure
system I-Biological_structure
. O

We O
began O
to O
administer O
4 B-Dosage
L/min I-Dosage
of O
oxygen B-Medication
nasally B-Administration
and O
empirical O
antibiotics B-Medication
with O
third O
generation O
cephalosporin B-Medication
and O
macrolide B-Medication
following O
a O
diagnosis O
of O
community-acquired B-Detailed_description
pneumonia B-Disease_disorder
. O

On O
the O
second B-Date
day I-Date
in O
the O
hospital O
, O
the O
patient O
’s O
fever B-Sign_symptom
was O
sustained O
and O
he O
complained O
of O
dyspnea B-Sign_symptom
. O

His O
hypoxemia B-Sign_symptom
was O
aggravated O
such O
that O
he O
required O
7 B-Dosage
L/min I-Dosage
of O
oxygen B-Medication
via O
a O
simple B-Administration
mask I-Administration
and O
the O
consolidation B-Sign_symptom
and O
pleural B-Disease_disorder
effusion I-Disease_disorder
had O
markedly O
progressed O
( O
Fig. O
2a O
) O
. O

We O
performed O
bronchoscopy B-Diagnostic_procedure
and O
thoracentesis B-Therapeutic_procedure
. O

Multiplex B-Detailed_description
real-time B-Diagnostic_procedure
reverse I-Diagnostic_procedure
transcriptase I-Diagnostic_procedure
polymerase I-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction I-Diagnostic_procedure
( O
RT-PCR B-Diagnostic_procedure
) O
for B-Detailed_description
respiratory I-Detailed_description
viruses I-Detailed_description
using B-Detailed_description
bronchoalveolar I-Detailed_description
lavage I-Detailed_description
fluid I-Detailed_description
was O
positive B-Lab_value
for I-Lab_value
human I-Lab_value
adenovirus I-Lab_value
while O
other O
microbiological B-Diagnostic_procedure
studies I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Pleural B-Diagnostic_procedure
fluid I-Diagnostic_procedure
was O
lymphocyte-dominant B-Lab_value
exudate I-Lab_value
and O
was O
also O
positive B-Lab_value
for I-Lab_value
human I-Lab_value
adenovirus I-Lab_value
. O

Under O
the O
diagnosis O
of O
adenovirus B-Disease_disorder
pneumonia I-Disease_disorder
, O
we O
started O
antiviral B-Medication
therapy I-Medication
with O
oral B-Administration
ribavirin B-Medication
400 B-Dosage
mg I-Dosage
q I-Dosage
12 I-Dosage
h I-Dosage
while O
maintaining O
antibiotics B-Medication
. O

On O
hospital O
day B-Date
4 I-Date
, O
his O
fever B-Sign_symptom
had O
subsided O
and O
symptoms B-Sign_symptom
were O
much O
improved O
. O

The O
transaminase B-Diagnostic_procedure
levels O
, O
CRP B-Diagnostic_procedure
and O
platelet B-Diagnostic_procedure
counts I-Diagnostic_procedure
gradually O
normalized B-Lab_value
( O
Fig. O
3 O
) O
. O

A O
follow-up B-Clinical_event
chest B-Biological_structure
X-ray B-Diagnostic_procedure
was O
clear B-Lab_value
( O
Fig. O
2b O
) O
and O
he O
was O
discharged B-Clinical_event
in O
hospital O
day B-Date
13 I-Date
without O
any O
complications B-Sign_symptom
. O

Our O
patient O
was O
a O
7-year-old B-Age
Italian B-Personal_background
boy B-Sex
born B-History
after I-History
an I-History
uneventful I-History
gestation I-History
of I-History
normal I-History
duration I-History
. O

At B-Date
the I-Date
age I-Date
of I-Date
16 I-Date
months I-Date
, O
he O
presented B-Clinical_event
with O
a O
clinically B-Detailed_description
evident I-Detailed_description
enlarged B-Sign_symptom
abdomen B-Biological_structure
and O
was O
referred B-Clinical_event
for O
oncological B-Nonbiological_location
examination I-Nonbiological_location
. O

Initial O
tests O
revealed O
anemia B-Sign_symptom
, O
thrombocytopenia B-Sign_symptom
, O
and O
splenomegaly B-Sign_symptom
. O

A O
bone B-Biological_structure
marrow I-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
the O
presence O
of O
foam B-Sign_symptom
cells I-Sign_symptom
, O
which O
led O
to O
suspicion O
of O
lysosomal B-Disease_disorder
storage I-Disease_disorder
disease I-Disease_disorder
. O

Biochemical B-Diagnostic_procedure
testing I-Diagnostic_procedure
revealed O
elevated B-Lab_value
level O
of O
acid B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
( O
47.8 B-Lab_value
IU/L I-Lab_value
[ O
normal O
range O
5 O
– O
7 O
IU/L O
] O
) O
and O
chitotriosidase B-Diagnostic_procedure
activity I-Diagnostic_procedure
( O
508 B-Lab_value
nmol/mg I-Lab_value
protein I-Lab_value
[ O
normal O
range O
5.9 O
– O
41.0 O
nmol/mg O
protein O
] O
) O
, O
as O
well O
as O
reduced B-Lab_value
beta-glucosidase B-Diagnostic_procedure
activity I-Diagnostic_procedure
( O
2 B-Lab_value
nmol/mg/protein I-Lab_value
[ O
normal O
range O
4.5 O
– O
18.0 O
nmol/mg/protein O
] O
) O
. O

Molecular B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
homozygous B-Detailed_description
L444P B-Detailed_description
mutations B-Sign_symptom
in I-Sign_symptom
the I-Sign_symptom
GBA I-Sign_symptom
gene I-Sign_symptom
( O
OMIM O
reference O
606463 O
) O
, O
confirming O
the O
diagnosis O
of O
chronic O
NGD B-Disease_disorder
. O

The O
patient O
began O
ERT B-Therapeutic_procedure
at O
a O
dosage O
of O
60 B-Dosage
U/kg I-Dosage
every I-Dosage
2 I-Dosage
weeks I-Dosage
at B-Date
the I-Date
age I-Date
of I-Date
18 I-Date
months I-Date
. O

Thereafter O
, O
when O
the O
patient O
reached O
the O
age B-Date
of I-Date
30 I-Date
months I-Date
, O
we O
decided O
to O
combine O
ERT B-Therapeutic_procedure
with O
SRT B-Therapeutic_procedure
with O
miglustat B-Medication
. O

This O
clinical O
decision O
was O
approved O
by O
our O
institution O
’s O
ethics O
committee O
, O
and O
informed O
consent O
was O
obtained O
from O
the O
patient O
’s O
parents O
before O
commencing O
combination O
therapy O
. O

The O
dose O
of O
miglustat B-Medication
was O
adjusted B-Detailed_description
according I-Detailed_description
to I-Detailed_description
the I-Detailed_description
patient I-Detailed_description
’s I-Detailed_description
body I-Detailed_description
surface I-Detailed_description
area I-Detailed_description
and O
was O
uptitrated O
during O
the O
first O
4 O
weeks O
with O
the O
following O
scheme O
: O
one-third O
of O
target O
dose O
during O
weeks O
1 O
and O
2 O
, O
two-thirds O
of O
target O
dose O
during O
weeks O
3 O
and O
4 O
, O
and O
target O
dose O
( O
100 B-Dosage
mg I-Dosage
three I-Dosage
times I-Dosage
daily I-Dosage
) O
after B-Date
1 I-Date
month I-Date
. O

From B-Date
2 I-Date
weeks I-Date
before I-Date
starting O
miglustat B-Medication
therapy O
, O
the O
patient O
also O
followed O
specific O
dietary B-Therapeutic_procedure
modifications I-Therapeutic_procedure
, O
avoiding B-Detailed_description
high I-Detailed_description
intake I-Detailed_description
of I-Detailed_description
carbohydrate-containing I-Detailed_description
food I-Detailed_description
in I-Detailed_description
single I-Detailed_description
meals I-Detailed_description
, O
especially O
foods B-Detailed_description
high I-Detailed_description
in I-Detailed_description
disaccharides I-Detailed_description
, I-Detailed_description
such I-Detailed_description
as I-Detailed_description
sucrose I-Detailed_description
and I-Detailed_description
maltose I-Detailed_description
, O
to O
ensure O
acceptable O
gastrointestinal O
tolerability O
. O

He O
experienced O
mild B-Severity
episodes O
of O
diarrhea B-Sign_symptom
after O
commencing O
miglustat B-Medication
therapy O
, O
which O
decreased B-Lab_value
in I-Lab_value
frequency/severity I-Lab_value
over I-Lab_value
time I-Lab_value
. O

From O
the O
start O
of O
ERT/miglustat O
combination O
treatment O
, O
we O
observed O
a O
reduction O
in O
splenomegaly B-Sign_symptom
and O
a O
gradual O
normalization B-Lab_value
of O
hematological B-Diagnostic_procedure
values I-Diagnostic_procedure
and O
plasma B-Diagnostic_procedure
angiotensin-converting I-Diagnostic_procedure
enzyme I-Diagnostic_procedure
activity I-Diagnostic_procedure
( O
Table O
1 O
) O
. O

Plasma B-Diagnostic_procedure
chitotriosidase I-Diagnostic_procedure
was O
evaluated O
at O
the O
time O
of O
diagnosis O
and O
then O
approximately O
every B-Frequency
6 I-Frequency
months I-Frequency
during O
follow-up B-Clinical_event
. O

Values O
showed O
an O
initial B-Lab_value
reduction I-Lab_value
after B-Detailed_description
the I-Detailed_description
start I-Detailed_description
of I-Detailed_description
ERT I-Detailed_description
, O
with O
a O
further O
, O
substantial O
, O
and O
sustained B-Lab_value
decrease I-Lab_value
after B-Detailed_description
commencement I-Detailed_description
of I-Detailed_description
miglustat I-Detailed_description
treatment O
( O
Fig. O
1 O
) O
. O

The O
patient O
has O
been O
followed B-Clinical_event
according B-Detailed_description
to I-Detailed_description
recommended I-Detailed_description
guidelines I-Detailed_description
for I-Detailed_description
GD I-Detailed_description
, O
which O
specify O
a O
complete O
neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
clinical O
evaluation B-Diagnostic_procedure
of I-Diagnostic_procedure
ocular I-Diagnostic_procedure
movements I-Diagnostic_procedure
, O
and O
psychological B-Diagnostic_procedure
evaluations I-Diagnostic_procedure
every B-Frequency
6 I-Frequency
– I-Frequency
12 I-Frequency
months I-Frequency
[ O
10 O
] O
. O

After O
5 B-Duration
years I-Duration
of O
combination B-Therapeutic_procedure
therapy I-Therapeutic_procedure
and O
follow-up B-Clinical_event
, O
the O
patient O
did O
not O
show O
any O
signs O
of O
neurological B-Sign_symptom
impairment I-Sign_symptom
. O

As O
of O
February B-Date
2016 I-Date
, O
he O
had O
not O
displayed O
any O
epileptic B-Sign_symptom
crises I-Sign_symptom
and O
had O
demonstrated O
clinical B-Sign_symptom
performance I-Sign_symptom
and O
cooperation B-Activity
. O

He O
showed O
good B-Lab_value
muscular B-Diagnostic_procedure
tone I-Diagnostic_procedure
and I-Diagnostic_procedure
trophism I-Diagnostic_procedure
, O
normal B-Lab_value
reflexes B-Diagnostic_procedure
with O
a O
slight B-Severity
hyperreflexia B-Sign_symptom
in O
his O
legs B-Biological_structure
, O
and O
a O
negative B-Lab_value
Romberg B-Diagnostic_procedure
sign I-Diagnostic_procedure
. O

His O
toe B-Diagnostic_procedure
and I-Diagnostic_procedure
heel I-Diagnostic_procedure
deambulation I-Diagnostic_procedure
was O
normal B-Lab_value
. O

In O
particular O
, O
ocular B-Diagnostic_procedure
evaluations I-Diagnostic_procedure
revealed O
no O
evidence O
of O
saccadic B-Sign_symptom
movement I-Sign_symptom
velocity I-Sign_symptom
reduction I-Sign_symptom
and O
normal B-Lab_value
visual B-Diagnostic_procedure
evoked I-Diagnostic_procedure
potentials I-Diagnostic_procedure
. O

The O
patient O
’s O
auditory B-Diagnostic_procedure
brain I-Diagnostic_procedure
responses I-Diagnostic_procedure
were O
also O
normal B-Lab_value
. O

In O
addition O
, O
he O
has O
not O
demonstrated O
any O
cognitive B-Sign_symptom
impairment I-Sign_symptom
, O
and O
he O
has O
regularly B-Detailed_description
attended B-Activity
school I-Activity
with O
good B-Detailed_description
performance I-Detailed_description
since B-Date
the I-Date
age I-Date
of I-Date
5 I-Date
years I-Date
. O

A O
64-year-old B-Age
female B-Sex
was O
found O
lying B-Activity
down I-Activity
after O
10 B-Duration
– I-Duration
12 I-Duration
hours I-Duration
of O
binge B-Activity
drinking I-Activity
. O

She O
was O
taken B-Clinical_event
to O
an O
outlying O
emergency B-Nonbiological_location
department I-Nonbiological_location
( O
ED B-Nonbiological_location
) O
, O
and O
subsequently O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
mental B-Sign_symptom
status I-Sign_symptom
changes I-Sign_symptom
and O
respiratory B-Sign_symptom
distress I-Sign_symptom
and O
hypoxia B-Sign_symptom
for O
further O
management O
. O

She O
had O
a O
past O
history O
of O
rheumatoid B-History
arthritis I-History
, O
congestive B-History
heart I-History
failure I-History
, O
controlled B-History
hypertension I-History
, O
and O
alcoholism B-History
. O

She O
smoked B-History
two I-History
packs I-History
a I-History
day I-History
for I-History
the I-History
past I-History
50 I-History
years I-History
. O

On O
presentation B-Clinical_event
, O
she O
had O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
176/80 B-Lab_value
mm/Hg I-Lab_value
, O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
80 B-Lab_value
bpm I-Lab_value
, O
respirations B-Diagnostic_procedure
24 B-Lab_value
bpm I-Lab_value
, O
temperature B-Diagnostic_procedure
98 B-Lab_value
°F I-Lab_value
( O
36.7 B-Lab_value
°C I-Lab_value
) O
. O

Arterial B-Diagnostic_procedure
blood I-Diagnostic_procedure
gases I-Diagnostic_procedure
on O
room B-Detailed_description
air I-Detailed_description
showed O
a O
pH B-Diagnostic_procedure
of O
7.30 B-Lab_value
, O
PaCO2 B-Diagnostic_procedure
60 B-Lab_value
, O
PaO2 B-Diagnostic_procedure
61 B-Lab_value
mm/Hg I-Lab_value
, O
H B-Diagnostic_procedure
− I-Diagnostic_procedure
CO3 I-Diagnostic_procedure
29 B-Lab_value
mEq/L I-Lab_value
, O
and O
saturation B-Diagnostic_procedure
92 B-Lab_value
% I-Lab_value
which O
improved O
to O
95 B-Lab_value
% I-Lab_value
with O
oxygen B-Therapeutic_procedure
by O
a O
high B-Detailed_description
flow I-Detailed_description
non-rebreather I-Detailed_description
mask I-Detailed_description
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
she O
was O
lethargic B-Sign_symptom
, O
disoriented B-Sign_symptom
, O
dysarthritic B-Sign_symptom
, O
but O
without O
neurological B-Sign_symptom
focalization I-Sign_symptom
. O

Scattered B-Detailed_description
expiratory B-Sign_symptom
wheezes I-Sign_symptom
were O
noted O
bilaterally B-Biological_structure
along O
with O
normal B-Lab_value
heart B-Diagnostic_procedure
sounds I-Diagnostic_procedure
. O

The O
remaining O
results O
of O
her O
physical O
examination O
and O
routine O
laboratory B-Diagnostic_procedure
results I-Diagnostic_procedure
were O
unremarkable B-Lab_value
with O
the O
exception O
of O
a O
leukocyte B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
14,000 B-Lab_value
/ I-Lab_value
dL I-Lab_value
with O
88 B-Lab_value
% I-Lab_value
neutrophils I-Lab_value
. O

Repeated O
vitals B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
consistent O
with O
a O
normal B-Lab_value
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
but O
evidence O
of O
tachycardia B-Sign_symptom
in O
the O
monitor O
. O

Repeated O
ABG B-Diagnostic_procedure
’s I-Diagnostic_procedure
on O
the O
non-rebreather B-Therapeutic_procedure
mask I-Therapeutic_procedure
showed O
: O
pH B-Diagnostic_procedure
7.22 B-Lab_value
, O
PaCO2 B-Diagnostic_procedure
78 B-Lab_value
, O
PaO2 B-Diagnostic_procedure
140 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
H B-Diagnostic_procedure
− I-Diagnostic_procedure
CO3 I-Diagnostic_procedure
30 B-Lab_value
mEq/L I-Lab_value
, O
and O
hemoglobin B-Diagnostic_procedure
SaO2 I-Diagnostic_procedure
97 B-Lab_value
% I-Lab_value
. O

In O
the O
ED B-Nonbiological_location
she O
was O
started O
on O
IV B-Administration
steroids B-Medication
and O
antibiotics B-Medication
for O
a O
COPD B-Disease_disorder
exacerbation B-Detailed_description
. O

As O
part O
of O
the O
diagnostic B-Diagnostic_procedure
workup I-Diagnostic_procedure
, O
she O
underwent O
a O
chest B-Biological_structure
x B-Diagnostic_procedure
ray I-Diagnostic_procedure
that O
did O
not O
show O
any O
infiltrates B-Sign_symptom
or O
any O
major O
abnormal B-Sign_symptom
findings I-Sign_symptom
. O

The O
ECG B-Diagnostic_procedure
was O
only O
significant O
for O
sinus B-Biological_structure
tachycardia B-Sign_symptom
. O

Given O
the O
negative O
findings O
on O
chest O
x O
ray O
, O
sinus O
tachycardia O
on O
ECG O
, O
and O
an O
increased O
A-a O
gradient O
, O
the O
patient O
was O
sent O
for O
a O
spiral B-Detailed_description
chest B-Biological_structure
CT B-Diagnostic_procedure
with B-Detailed_description
contrast I-Detailed_description
to O
rule O
out O
a O
pulmonary B-Biological_structure
embolism B-Disease_disorder
. O

During O
CT B-Coreference
about O
100 B-Volume
– I-Volume
150 I-Volume
mL I-Volume
of O
air B-Clinical_event
was I-Clinical_event
inadvertently I-Clinical_event
injected I-Clinical_event
through O
the O
right B-Biological_structure
antecubital I-Biological_structure
vein I-Biological_structure
using O
a O
power B-Detailed_description
contrast I-Detailed_description
injector I-Detailed_description
( O
estimated O
by O
the O
technician O
and O
approximation O
of O
volumes O
on O
available O
imaging O
) O
. O

Concurrent B-Detailed_description
imaging B-Diagnostic_procedure
( O
CT O
) O
showed O
a O
significant B-Severity
amount B-Sign_symptom
of I-Sign_symptom
air I-Sign_symptom
in O
the O
right B-Biological_structure
atrium I-Biological_structure
and O
right B-Biological_structure
ventricular I-Biological_structure
cavity I-Biological_structure
( O
Figure O
1 O
) O
, O
and O
air B-Sign_symptom
mixed I-Sign_symptom
with I-Sign_symptom
contrast I-Sign_symptom
in O
the O
main B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
and O
its O
proximal B-Biological_structure
branches I-Biological_structure
divisions I-Biological_structure
of I-Biological_structure
the I-Biological_structure
pulmonary I-Biological_structure
circulation I-Biological_structure
( O
Figure O
2 O
) O
. O

Concurrently O
, O
a O
filling B-Sign_symptom
defect I-Sign_symptom
was O
noted O
in O
the O
right B-Biological_structure
lower I-Biological_structure
lobe I-Biological_structure
artery I-Biological_structure
consistent O
with O
pulmonary B-Biological_structure
thromboembolism B-Disease_disorder
( O
Figures O
3 O
, O
,4 O
) O
.4 O
) O
. O

The O
patient O
maintained O
hemodynamic B-Diagnostic_procedure
stability I-Diagnostic_procedure
with O
Trendelenburg B-Therapeutic_procedure
, O
and O
left B-Therapeutic_procedure
lateral I-Therapeutic_procedure
decubitus I-Therapeutic_procedure
positioning I-Therapeutic_procedure
( O
Durant B-Therapeutic_procedure
’s I-Therapeutic_procedure
maneuver I-Therapeutic_procedure
) O
, O
and O
supportive B-Therapeutic_procedure
care I-Therapeutic_procedure
alone O
and O
she O
was O
transferred B-Clinical_event
to O
the O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
( O
ICU B-Nonbiological_location
) O
for O
observation O
. O

Her O
respiratory B-Sign_symptom
distress I-Sign_symptom
worsened O
, O
and O
she O
was O
placed O
temporarily O
on O
non-invasive B-Therapeutic_procedure
positive I-Therapeutic_procedure
pressure I-Therapeutic_procedure
ventilation I-Therapeutic_procedure
( O
NIPPV B-Therapeutic_procedure
) O
without O
improvement B-Sign_symptom
and O
a B-Time
few I-Time
hours I-Time
later I-Time
she O
was O
intubated B-Therapeutic_procedure
and O
placed O
on O
mechanical B-Therapeutic_procedure
ventilation I-Therapeutic_procedure
. O

Intravenous B-Administration
full B-Detailed_description
dose I-Detailed_description
heparin B-Medication
infusion B-Administration
( O
initial B-Dosage
bolus I-Dosage
, I-Dosage
80 I-Dosage
units/kg I-Dosage
, I-Dosage
followed I-Dosage
by I-Dosage
18 I-Dosage
units/kg/hour I-Dosage
) O
was O
initiated O
for O
treatment O
of O
concurrent O
thromboembolism B-Disease_disorder
. O

Echocardiography B-Diagnostic_procedure
did O
not O
show O
any O
evidence O
of O
right B-Sign_symptom
or I-Sign_symptom
left I-Sign_symptom
ventricular I-Sign_symptom
failure I-Sign_symptom
. O

Subsequent O
echocardiography B-Diagnostic_procedure
done O
24 B-Time
hours I-Time
later I-Time
did O
not O
show O
any O
evidence O
of O
intracardiac B-Biological_structure
air B-Sign_symptom
and O
complete O
resolution O
of O
the O
air O
embolism B-Disease_disorder
. O

During B-Duration
the I-Duration
next I-Duration
48 I-Duration
hours I-Duration
, O
she O
remained O
hemodynamically B-Diagnostic_procedure
stable B-Lab_value
with O
no O
requirements O
of O
vasoactive B-Medication
agents I-Medication
. O

She O
was O
finally O
extubated B-Therapeutic_procedure
48 B-Date
hours I-Date
after I-Date
the I-Date
initial I-Date
presentation I-Date
. O

She O
was O
later O
discharged B-Clinical_event
home B-Nonbiological_location
on O
warfarin B-Medication
with O
subsequent O
outpatient O
follow-up B-Clinical_event
. O

This O
73-year-old B-Age
female B-Sex
, O
with O
a O
history B-History
of I-History
coronary I-History
artery I-History
disease I-History
and O
situs B-History
inversus I-History
, O
had O
recently O
noticed O
left B-Biological_structure
arm I-Biological_structure
exercise B-Detailed_description
weakness B-Sign_symptom
. O

The O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
angiogram I-Diagnostic_procedure
and O
computer B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
upper B-Biological_structure
limb I-Biological_structure
vessels I-Biological_structure
showed O
critical B-Severity
stenosis B-Sign_symptom
of O
the O
left-side B-Biological_structure
SCA I-Biological_structure
with O
calcification B-Sign_symptom
near O
the O
orifice B-Biological_structure
( O
Fig. O
1 O
) O
. O

Percutaneous B-Detailed_description
revascularization B-Therapeutic_procedure
was O
done O
via O
right B-Detailed_description
femoral I-Detailed_description
artery I-Detailed_description
approach I-Detailed_description
, O
and O
severe B-Severity
left B-Biological_structure
SCA I-Biological_structure
stenosis B-Sign_symptom
was O
confirmed O
( O
Fig. O
2A O
) O
( O
Supplementary O
Video O
1 O
, O
only O
online O
) O
. O

Direct B-Detailed_description
stenting B-Therapeutic_procedure
in O
the O
left B-Biological_structure
SCA I-Biological_structure
was O
carried O
out O
with O
a O
balloon-expansible B-Detailed_description
Express I-Detailed_description
LD I-Detailed_description
10 I-Detailed_description
× I-Detailed_description
25 I-Detailed_description
mm I-Detailed_description
stent I-Detailed_description
( O
Boston B-Detailed_description
Scientific I-Detailed_description
Corporation I-Detailed_description
, I-Detailed_description
Natick I-Detailed_description
, I-Detailed_description
MA I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
( O
Fig. O
2B O
) O
up O
to O
8 B-Lab_value
atmospheres I-Lab_value
for I-Lab_value
13 I-Lab_value
seconds I-Lab_value
. O

However O
, O
severe B-Severity
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
and O
hypotension B-Sign_symptom
developed O
after O
stenting B-Coreference
. O

The O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
down O
to O
88/56 B-Lab_value
, O
and O
the O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
up O
to O
90 B-Lab_value
. O

The O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
was O
down O
to O
74 B-Lab_value
% I-Lab_value
. O

Emergent B-Detailed_description
intubation B-Therapeutic_procedure
, O
fluid B-Therapeutic_procedure
infusion I-Therapeutic_procedure
, O
inotropic B-Medication
agent I-Medication
with O
norepinephrine B-Medication
were O
given O
. O

The O
immediate B-Detailed_description
angiography B-Diagnostic_procedure
showed O
vascular B-Sign_symptom
perforation I-Sign_symptom
in O
the O
stented B-Biological_structure
segment I-Biological_structure
of I-Biological_structure
left I-Biological_structure
SCA I-Biological_structure
( O
Fig. O
2C O
) O
( O
Supplementary O
Video O
2 O
, O
only O
online O
) O
. O

Emergency O
balloon B-Therapeutic_procedure
inflation I-Therapeutic_procedure
within B-Biological_structure
the I-Biological_structure
stent I-Biological_structure
was O
done O
with O
an O
8 B-Detailed_description
× I-Detailed_description
40 I-Detailed_description
mm I-Detailed_description
balloon I-Detailed_description
. O

The O
cardiovascular B-Nonbiological_location
surgeon I-Nonbiological_location
was O
also O
consulted B-Clinical_event
. O

However O
, O
due O
to O
the O
high O
surgical O
risk O
of O
bypass O
, O
endovascular B-Therapeutic_procedure
treatment I-Therapeutic_procedure
was O
suggested O
. O

We O
decided O
to O
do O
a O
retrograde B-Therapeutic_procedure
approach I-Therapeutic_procedure
through O
the O
left B-Biological_structure
brachial I-Biological_structure
artery I-Biological_structure
by B-Detailed_description
surgical I-Detailed_description
cut-down I-Detailed_description
. O

Since O
there O
was O
no O
suitable O
graft O
stent O
in O
our O
cath O
lab O
, O
we O
modified B-Detailed_description
and I-Detailed_description
cut I-Detailed_description
the I-Detailed_description
iliac I-Detailed_description
extension I-Detailed_description
of O
self-expanding B-Detailed_description
Endurant B-Detailed_description
II I-Detailed_description
graft I-Detailed_description
stent I-Detailed_description
10 B-Area
× I-Area
82 I-Area
mm I-Area
( O
Medtronic B-Detailed_description
, I-Detailed_description
Inc. I-Detailed_description
, I-Detailed_description
Minneapolis I-Detailed_description
, I-Detailed_description
MN I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
, O
which O
was O
originally O
designed O
to O
treat O
abdominal O
aortic O
aneurysms O
( O
AAA O
) O
, O
to O
a O
suitable O
length O
( O
around B-Detailed_description
30 I-Detailed_description
mm I-Detailed_description
) O
( O
Fig. O
3 O
) O
. O

After O
retrograde O
wiring O
, O
an O
operator-modified O
Endurant O
II O
graft B-Therapeutic_procedure
stent I-Therapeutic_procedure
was O
deployed O
in O
the O
stent O
segment O
( O
Fig. O
2D O
) O
and O
the O
perforation B-Therapeutic_procedure
was I-Therapeutic_procedure
sealed I-Therapeutic_procedure
successfully O
. O

After O
stenting O
of O
the O
graft O
stent O
, O
however O
, O
slow B-Lab_value
flow B-Diagnostic_procedure
of O
left B-Biological_structure
common I-Biological_structure
carotid I-Biological_structure
artery I-Biological_structure
( O
LCCA B-Biological_structure
) O
was O
noted O
, O
and O
angiography B-Diagnostic_procedure
confirmed O
the O
near B-Severity
total I-Severity
occlusion B-Sign_symptom
of O
the O
LCCA B-Biological_structure
, O
occluded B-Detailed_description
by I-Detailed_description
the I-Detailed_description
SCA I-Detailed_description
graft I-Detailed_description
stent I-Detailed_description
( O
Fig. O
2E O
) O
( O
Supplementary O
Video O
3 O
, O
only O
online O
) O
. O

A O
firm B-Therapeutic_procedure
wire I-Therapeutic_procedure
( O
Conquest O
pro O
, O
Asahi O
Inc O
, O
Seto O
, O
Japan O
) O
was O
successfully O
advanced B-Detailed_description
outside B-Biological_structure
the I-Biological_structure
graft I-Biological_structure
stent I-Biological_structure
and O
into O
the O
LCCA B-Biological_structure
. O

Despite O
sequent O
balloon B-Therapeutic_procedure
dilations I-Therapeutic_procedure
at O
the O
bifurcation B-Biological_structure
site I-Biological_structure
, O
the O
flow B-Diagnostic_procedure
to O
the O
LCCA B-Biological_structure
was O
still O
poor B-Lab_value
. O

Intravascular B-Detailed_description
ultrasound B-Diagnostic_procedure
also O
confirmed O
the O
severe B-Severity
compromise B-Sign_symptom
of O
the O
LCCA B-Biological_structure
ostium I-Biological_structure
which O
was O
caused B-Detailed_description
by I-Detailed_description
the I-Detailed_description
graft I-Detailed_description
stent I-Detailed_description
( O
Fig. O
2F O
) O
. O

Therefore O
, O
we O
put O
a O
balloon-expansible B-Detailed_description
carotid B-Therapeutic_procedure
stent I-Therapeutic_procedure
, O
Express B-Detailed_description
7 I-Detailed_description
× I-Detailed_description
37 I-Detailed_description
mm I-Detailed_description
( O
Boston B-Detailed_description
Scientific I-Detailed_description
Corporation I-Detailed_description
) O
, O
from B-Biological_structure
the I-Biological_structure
LCCA I-Biological_structure
to O
the O
left B-Biological_structure
brachiocephalic I-Biological_structure
artery I-Biological_structure
( O
Fig. O
4A O
) O
. O

TIMI B-Diagnostic_procedure
III I-Diagnostic_procedure
flow I-Diagnostic_procedure
of O
the O
LCCA B-Biological_structure
was O
restored B-Lab_value
after O
stenting O
( O
Fig.4B-E O
) O
( O
Supplementary O
Video O
4 O
, O
only O
online O
) O
. O

Intravascular B-Detailed_description
ultrasound B-Diagnostic_procedure
also O
confirmed O
proper B-Lab_value
expansion B-Sign_symptom
of O
the O
LCCA B-Biological_structure
stent I-Biological_structure
( O
Fig. O
4F O
) O
. O

The O
follow-up B-Clinical_event
chest B-Biological_structure
radiography B-Diagnostic_procedure
revealed O
left-side B-Detailed_description
hemothorax B-Sign_symptom
. O

After O
thoracocentesis B-Therapeutic_procedure
with O
drainage B-Detailed_description
and O
proper B-Therapeutic_procedure
care I-Therapeutic_procedure
, O
the O
patient O
was O
discharged B-Clinical_event
. O

Till O
now O
, O
the O
patient O
has O
been O
free O
from O
symptoms B-Sign_symptom
for O
six B-Duration
months I-Duration
. O

A O
68-year-old B-Age
female B-Sex
smoker B-History
with O
a O
history O
of O
pulmonary B-History
embolism I-History
and O
diabetes B-History
mellitus I-History
was O
diagnosed O
with O
Stage B-Detailed_description
IIIB I-Detailed_description
( O
T4N2M0 B-Detailed_description
) O
squamous B-Detailed_description
NSCLC B-Disease_disorder
. O

She O
was O
treated O
by O
definitive B-Detailed_description
chemoradiotherapy B-Therapeutic_procedure
with O
cisplatin B-Medication
and O
vinorelbine B-Medication
until B-Date
September I-Date
2014 I-Date
. O

In B-Date
October I-Date
2014 I-Date
, O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
– I-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( B-Diagnostic_procedure
PET-CT I-Diagnostic_procedure
) I-Diagnostic_procedure
scan O
demonstrated O
a O
good B-Lab_value
response I-Lab_value
in O
the O
primary B-Biological_structure
lesion I-Biological_structure
; O
however O
, O
new O
metastases B-Sign_symptom
in O
the O
right B-Biological_structure
adrenal I-Biological_structure
gland I-Biological_structure
and O
right B-Biological_structure
femur I-Biological_structure
developed O
and O
were O
irradiated B-Therapeutic_procedure
in B-Date
November I-Date
2014 I-Date
. O

A B-Date
month I-Date
later I-Date
the O
disease O
progressed O
with O
development O
of O
multiple B-Detailed_description
bone B-Biological_structure
and O
subcutaneous B-Biological_structure
metastases B-Sign_symptom
. O

At O
that O
point O
, O
the O
patient O
suffered O
from O
severe B-Severity
dyspnea B-Sign_symptom
and O
was O
oxygen-dependent B-Therapeutic_procedure
. O

She O
received O
one B-Dosage
cycle I-Dosage
of O
carboplatin B-Medication
and O
gemcitabine B-Medication
followed O
by O
severe B-Severity
pancytopenia B-Sign_symptom
, O
and O
treatment O
was O
switched O
to O
nivolumab B-Medication
3 B-Dosage
mg/kg I-Dosage
q14 I-Dosage
days I-Dosage
in B-Date
January I-Date
2015 I-Date
. O

One B-Date
week I-Date
after I-Date
the I-Date
first I-Date
cycle I-Date
of I-Date
nivolumab I-Date
, O
a O
subcutaneous B-Biological_structure
lesion B-Sign_symptom
in O
her O
upper B-Biological_structure
back I-Biological_structure
grew B-Detailed_description
substantially I-Detailed_description
, O
accompanied O
by O
severe B-Severity
pain B-Sign_symptom
and O
significant B-Severity
inflammatory B-Sign_symptom
reaction I-Sign_symptom
( O
Fig. O
1 O
) O
. O

Other O
subcutaneous B-Biological_structure
metastases B-Sign_symptom
grew B-Detailed_description
slightly I-Detailed_description
as O
well O
. O

After O
the O
second O
cycle O
of O
treatment O
marked O
symptomatic B-Sign_symptom
improvement I-Sign_symptom
was O
observed O
, O
including O
improvement B-Sign_symptom
in I-Sign_symptom
general I-Sign_symptom
appearance I-Sign_symptom
and O
dyspnea B-Sign_symptom
and O
reduction O
of O
the O
bone B-Biological_structure
pain B-Sign_symptom
. O

The O
patient O
no O
longer O
required O
oxygen B-Therapeutic_procedure
supplementation I-Therapeutic_procedure
. O

The O
subcutaneous B-Biological_structure
lesions B-Sign_symptom
started O
to O
regress O
too O
, O
with O
complete B-Lab_value
resolution I-Lab_value
by B-Date
the I-Date
12th I-Date
week I-Date
as O
well O
as O
improvement O
in O
all O
bone B-Biological_structure
lesions B-Sign_symptom
( O
Figs. O
1 O
and O
2 O
) O
. O

The O
patient O
continued O
on O
nivolumab B-Medication
until B-Date
June I-Date
2015 I-Date
, O
and O
tolerated O
the O
treatment O
well O
. O

Unfortunately O
, O
she O
developed O
bacterial B-Detailed_description
aspiration I-Detailed_description
pneumonia B-Sign_symptom
and O
passed B-Outcome
away I-Outcome
in O
June B-Date
2015 I-Date
. O

A O
60-year-old B-Age
woman B-Sex
patient O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
on O
Feb. B-Date
18 I-Date
, I-Date
2016 I-Date
because O
of O
frequent B-Frequency
episodes O
of O
hemoptysis B-Sign_symptom
for O
2 B-Duration
weeks I-Duration
. O

In O
the O
previous B-Date
decade I-Date
, O
the O
patient O
had O
frequent B-Frequency
but O
less B-Severity
severe I-Severity
episodes O
of O
hemoptysis B-History
, O
which O
typically O
ensued O
following O
an O
upper B-Biological_structure
respiratory I-Biological_structure
tract I-Biological_structure
infection B-Disease_disorder
. O

Ear B-Diagnostic_procedure
, I-Diagnostic_procedure
nose I-Diagnostic_procedure
, I-Diagnostic_procedure
and I-Diagnostic_procedure
throat I-Diagnostic_procedure
examination I-Diagnostic_procedure
and O
laryngoscope B-Diagnostic_procedure
failed O
to O
identify O
an O
apparent O
source B-Sign_symptom
of I-Sign_symptom
bleeding I-Sign_symptom
. O

CT B-Diagnostic_procedure
chest B-Biological_structure
scan O
revealed O
no O
abnormality B-Sign_symptom
. O

The O
most O
recent O
episode O
occurred O
after O
an O
upper B-Biological_structure
respiratory I-Biological_structure
tract I-Biological_structure
infection B-Disease_disorder
2 B-Date
weeks I-Date
ago I-Date
. O

The O
patient O
coughed B-Sign_symptom
up O
as O
much O
as O
about O
500 B-Volume
mL I-Volume
of O
fresh B-Sign_symptom
blood I-Sign_symptom
in O
an O
episode O
of O
hemoptysis B-Sign_symptom
, O
which O
was O
alleviated O
by O
anti-tussive B-Medication
therapy I-Medication
. O

The O
patient O
denied B-History
a I-History
history I-History
of I-History
smoking I-History
and I-History
illicit I-History
drug I-History
use I-History
. O

Diagnostic B-Diagnostic_procedure
workup I-Diagnostic_procedure
revealed O
no O
evidence O
of O
coagulopathy B-Disease_disorder
. O

Upon O
admission B-Clinical_event
, O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
signs O
of O
rhonchi B-Sign_symptom
and O
reduced B-Lab_value
breath B-Diagnostic_procedure
sounds I-Diagnostic_procedure
. O

Bronchoscopy B-Diagnostic_procedure
showed O
a O
1-cm B-Distance
lesion B-Sign_symptom
at O
the O
membranous B-Biological_structure
trachea I-Biological_structure
2 B-Distance
cm I-Distance
to O
the O
carina B-Biological_structure
. O

Tortuous B-Sign_symptom
blood I-Sign_symptom
vessels I-Sign_symptom
were O
observed O
running O
in O
the O
submucosa B-Biological_structure
of I-Biological_structure
the I-Biological_structure
trachea I-Biological_structure
( O
Fig. O
1 O
) O
. O

CT B-Diagnostic_procedure
angiography I-Diagnostic_procedure
was O
performed O
, O
demonstrating O
an O
artery B-Sign_symptom
extending I-Sign_symptom
into O
the O
submucosa B-Biological_structure
from O
the O
descending B-Biological_structure
aorta I-Biological_structure
( O
Fig. O
2 O
) O
. O

A O
diagnosis O
of O
Dieulafoy B-Therapeutic_procedure
disease I-Therapeutic_procedure
of O
the O
trachea B-Biological_structure
was O
entertained O
. O

Since O
the O
blood B-Coreference
vessel I-Coreference
was O
considered O
to O
be O
the O
culprit O
of O
hemoptysis B-Sign_symptom
, O
selective B-Detailed_description
arterial B-Therapeutic_procedure
embolization I-Therapeutic_procedure
was O
performed O
1 B-Date
week I-Date
later I-Date
. O

No O
fresh O
episode O
of O
acute B-Detailed_description
hemoptysis B-Sign_symptom
was O
observed O
and O
the O
patient O
was O
still O
being O
followed B-Clinical_event
up I-Clinical_event
at O
the B-Date
time I-Date
of I-Date
writing I-Date
this I-Date
report I-Date
. O

This O
study O
was O
approved O
by O
Ethics O
Committee O
of O
Shanghai O
Jiao O
Tong O
University O
Affiliated O
Sixth O
People O
's O
Hospital O
, O
and O
also O
got O
an O
informed O
written O
consent O
from O
the O
patient O
. O

A O
65-year-old B-Age
woman B-Sex
reported O
persistent B-Detailed_description
back B-Biological_structure
pain B-Sign_symptom
for O
almost B-Duration
3 I-Duration
months I-Duration
. O

The O
symptoms B-Coreference
would O
be O
severe B-Severity
after O
walking B-Activity
or O
changing B-Activity
positions I-Activity
and O
would O
be O
slightly O
relieve B-Sign_symptom
after O
taking O
painkillers B-Medication
. O

The O
patient O
described O
no O
pain B-Sign_symptom
or O
numbness B-Sign_symptom
in O
her O
legs B-Biological_structure
. O

She O
also O
described O
no O
bowel B-Biological_structure
or O
bladder B-Biological_structure
voiding B-Sign_symptom
difficulties I-Sign_symptom
. O

The O
patient O
reported O
past O
medical O
history O
of O
hypertension B-History
, I-History
coronary I-History
heart I-History
disease I-History
, I-History
cerebral I-History
infarction I-History
, I-History
and I-History
asthma I-History
, I-History
all I-History
of I-History
which I-History
were I-History
well I-History
controlled I-History
. O

Physical B-Diagnostic_procedure
exam I-Diagnostic_procedure
demonstrated O
kyphosis B-Disease_disorder
of O
the O
thoracic B-Biological_structure
spine I-Biological_structure
in B-Detailed_description
standing I-Detailed_description
position I-Detailed_description
and O
lumbar B-Detailed_description
vertebra I-Detailed_description
bend I-Detailed_description
forward I-Detailed_description
and I-Detailed_description
backward I-Detailed_description
straight O
activities O
were O
limited O
. O

There O
is O
obvious O
rap B-Detailed_description
pain B-Sign_symptom
in O
back B-Biological_structure
about O
T12 B-Biological_structure
level O
. O

The O
patient O
's O
general B-Diagnostic_procedure
medical I-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
in O
upper B-Biological_structure
and I-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
motor I-Biological_structure
, O
stretch B-Detailed_description
reflex I-Detailed_description
, O
and O
sensory B-Biological_structure
examinations B-Diagnostic_procedure
. O

X-ray B-Diagnostic_procedure
, O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
, O
and O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
exams O
were O
performed O
after O
the O
patient O
in O
hospital B-Nonbiological_location
( O
Fig. O
1 O
) O
. O

The O
lateral B-Detailed_description
X-ray B-Diagnostic_procedure
showed O
T12 B-Biological_structure
fracture B-Disease_disorder
with O
40 B-Lab_value
° I-Lab_value
kyphotic I-Lab_value
cobb B-Diagnostic_procedure
angle I-Diagnostic_procedure
. O

CT B-Diagnostic_procedure
showed O
an O
intravertebral B-Sign_symptom
vacuum I-Sign_symptom
sign I-Sign_symptom
. O

Sagittal B-Detailed_description
T1-weighted I-Detailed_description
MRI B-Diagnostic_procedure
showed O
a O
decreased B-Detailed_description
signal I-Detailed_description
intravertebral B-Sign_symptom
vacuum I-Sign_symptom
cleft I-Sign_symptom
and O
posterior B-Biological_structure
cortex I-Biological_structure
breakage B-Disease_disorder
with O
cord B-Sign_symptom
compression I-Sign_symptom
in O
T12 B-Biological_structure
. O

Sagittal B-Detailed_description
T2-weighted I-Detailed_description
MRI B-Diagnostic_procedure
showed O
an O
increased B-Detailed_description
signal I-Detailed_description
in O
the O
intravertebral B-Sign_symptom
vacuum I-Sign_symptom
cleft I-Sign_symptom
. O

The O
patient O
was O
diagnosed O
with O
Kümmell B-Disease_disorder
disease I-Disease_disorder
( O
Stage B-Lab_value
III I-Lab_value
) O
. O

[ O
9 O
] O
The O
operation B-Therapeutic_procedure
was O
performed O
under O
general B-Medication
anesthesia I-Medication
and O
prone B-Detailed_description
position I-Detailed_description
. O

A O
standard B-Detailed_description
posterior B-Therapeutic_procedure
exposure I-Therapeutic_procedure
of O
the O
spine B-Biological_structure
was O
given O
, O
pedicle B-Therapeutic_procedure
screws I-Therapeutic_procedure
were O
inserted O
in O
target O
vertebrae B-Biological_structure
T10 B-Biological_structure
, O
T11 B-Biological_structure
, O
L1 B-Biological_structure
, O
and O
L2 B-Biological_structure
under O
C-arm B-Detailed_description
guidance I-Detailed_description
. O

[ O
10 O
] O
The O
screws O
were O
connected B-Detailed_description
on I-Detailed_description
the I-Detailed_description
left I-Detailed_description
side I-Detailed_description
with I-Detailed_description
a I-Detailed_description
temporary I-Detailed_description
stabilizing I-Detailed_description
rod I-Detailed_description
. O

Laminectomy B-Therapeutic_procedure
was O
performed O
to O
decompress O
and O
fully O
visualize O
the O
spinal O
cord O
. O

[ O
10 O
] O
Careful O
subperiosteal B-Therapeutic_procedure
dissection I-Therapeutic_procedure
was O
carried O
out O
on O
the O
right B-Detailed_description
side I-Detailed_description
to O
exposure O
the O
lateral B-Biological_structure
wall I-Biological_structure
of I-Biological_structure
the I-Biological_structure
T12 I-Biological_structure
vertebral I-Biological_structure
body I-Biological_structure
until O
the O
anterior O
aspect O
was O
reached O
. O

The O
right B-Biological_structure
side I-Biological_structure
pedicle I-Biological_structure
and O
articular B-Biological_structure
process I-Biological_structure
of O
the O
T12 B-Biological_structure
vertebral I-Biological_structure
body I-Biological_structure
were O
removed B-Therapeutic_procedure
. O

T11/T12 B-Biological_structure
and O
T12/L1 B-Biological_structure
intervertebral B-Biological_structure
disks I-Biological_structure
were O
also O
removed B-Therapeutic_procedure
. O

Then O
, O
the O
temporary B-Detailed_description
stabilizing I-Detailed_description
rod B-Therapeutic_procedure
was O
replaced O
by O
rod B-Therapeutic_procedure
bended B-Detailed_description
to I-Detailed_description
the I-Detailed_description
desired I-Detailed_description
contour I-Detailed_description
. O

Autologous B-Detailed_description
bone B-Therapeutic_procedure
graft I-Therapeutic_procedure
and O
titanium B-Therapeutic_procedure
mesh I-Therapeutic_procedure
were O
placed O
in O
the O
intervertebral B-Biological_structure
space I-Biological_structure
. O

Another B-Detailed_description
rod B-Therapeutic_procedure
with B-Detailed_description
the I-Detailed_description
desired I-Detailed_description
contour I-Detailed_description
was O
connected O
on O
the O
right B-Detailed_description
side I-Detailed_description
. O

Adequate O
hemostasis B-Therapeutic_procedure
was O
ensured O
and O
wound B-Biological_structure
was O
thoroughly O
irrigated B-Therapeutic_procedure
with I-Therapeutic_procedure
saline I-Therapeutic_procedure
. O

Drainage B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
inserted O
and O
the O
surgical B-Biological_structure
wound I-Biological_structure
was O
closed B-Therapeutic_procedure
layer-by-layer B-Detailed_description
. O

[ O
10 O
] O
Time O
from O
skin O
incision O
to O
completion O
of O
wound O
closure O
lasted O
150 B-Duration
minutes I-Duration
, O
and O
estimated O
blood B-Disease_disorder
loss I-Disease_disorder
totaled O
600 B-Volume
mL I-Volume
. O

Postoperatively O
, O
the O
patient O
was O
given O
preventive O
antibiotic B-Medication
treatment O
for O
1 B-Duration
day I-Duration
, O
pain B-Medication
treatment I-Medication
for O
3 B-Duration
days I-Duration
, O
and O
anticoagulant B-Medication
therapy O
for O
1 B-Duration
week I-Duration
. O

The O
drainage B-Therapeutic_procedure
tube I-Therapeutic_procedure
was O
removed O
at O
3 B-Date
days I-Date
postoperative O
when O
volume B-Diagnostic_procedure
of I-Diagnostic_procedure
drainage I-Diagnostic_procedure
was O
less B-Lab_value
than I-Lab_value
50 I-Lab_value
mL I-Lab_value
per I-Lab_value
24 I-Lab_value
hours I-Lab_value
. O

Patient O
was O
allowed B-Clinical_event
out I-Clinical_event
of O
bed B-Nonbiological_location
with O
a O
custom-made B-Detailed_description
plastic B-Detailed_description
orthosis B-Therapeutic_procedure
at O
1 B-Date
week I-Date
after I-Date
operation O
. O

The O
plastic O
orthosis B-Coreference
was O
kept O
for O
at B-Duration
least I-Duration
3 I-Duration
months I-Duration
. O

The O
patient O
was O
allowed B-Clinical_event
out I-Clinical_event
of O
hospital B-Nonbiological_location
at O
12 B-Date
days I-Date
after I-Date
operation O
when O
surgical B-Therapeutic_procedure
suture I-Therapeutic_procedure
had O
been O
removed O
. O

Pain B-Diagnostic_procedure
assessments I-Diagnostic_procedure
were O
conducted O
using O
the O
visual B-Diagnostic_procedure
analogue I-Diagnostic_procedure
scale I-Diagnostic_procedure
( O
VAS B-Diagnostic_procedure
) O
. O

VAS B-Coreference
for O
preoperative B-Date
, O
1 B-Date
week I-Date
after I-Date
operation O
, O
and O
1 B-Date
year I-Date
after I-Date
operation O
were O
9 B-Lab_value
score I-Lab_value
, O
3 B-Lab_value
score I-Lab_value
, O
and O
2 B-Lab_value
score I-Lab_value
, O
respectively O
, O
which O
demonstrated O
significant O
improvement B-Lab_value
. O

The O
patient O
resumed O
normal B-Activity
activities I-Activity
and O
returned B-Activity
to I-Activity
work I-Activity
at O
3 B-Date
months I-Date
after I-Date
operation O
. O

Kyphotic B-Lab_value
Cobb B-Diagnostic_procedure
angle I-Diagnostic_procedure
for O
preoperative B-Date
, O
1 B-Date
week I-Date
after I-Date
operation O
, O
and O
1 B-Date
year I-Date
after I-Date
operation O
were O
40 B-Lab_value
° I-Lab_value
, O
8 B-Lab_value
° I-Lab_value
, O
and O
17 B-Lab_value
° I-Lab_value
, O
respectively O
, O
which O
demonstrated O
significant O
improvement B-Lab_value
( O
Fig. O
2 O
) O
. O

A O
18-year-old B-Age
man B-Sex
presented B-Clinical_event
with O
a O
history O
of O
a O
palpable B-Detailed_description
lump B-Sign_symptom
in O
the O
presternal B-Biological_structure
area I-Biological_structure
, O
which O
was O
found O
incidentally O
after O
weight B-Sign_symptom
reduction I-Sign_symptom
. O

The O
patient O
had O
no B-History
other I-History
relevant I-History
medical I-History
or I-History
trauma I-History
history I-History
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
lesion B-Coreference
was O
found O
to O
be O
a O
nonmovable B-Detailed_description
, O
firm B-Texture
mass B-Sign_symptom
with O
no O
tenderness B-Sign_symptom
or O
associated O
skin B-Sign_symptom
changes I-Sign_symptom
, O
detected O
at O
the O
midline B-Biological_structure
position I-Biological_structure
over I-Biological_structure
the I-Biological_structure
sternum I-Biological_structure
( O
at O
the O
manubrium B-Biological_structure
level I-Biological_structure
) O
. O

There O
was O
no O
visible O
fistulous B-Sign_symptom
opening I-Sign_symptom
or O
discharge B-Sign_symptom
from O
the O
lesion B-Coreference
. O

On O
ultrasonography B-Diagnostic_procedure
, O
we O
detected O
a O
well-circumscribed B-Detailed_description
, O
oval B-Shape
, O
anechoic B-Lab_value
mass B-Sign_symptom
, O
with O
posterior B-Detailed_description
acoustic I-Detailed_description
enhancement I-Detailed_description
, O
that O
measured O
about O
3.3 B-Volume
× I-Volume
1.7 I-Volume
× I-Volume
3.1 I-Volume
cm I-Volume
, O
and O
was O
located O
in O
the O
subcutaneous B-Biological_structure
fat I-Biological_structure
layer I-Biological_structure
over O
the O
sternum B-Biological_structure
. O

In O
the O
dependent B-Biological_structure
portion I-Biological_structure
of O
the O
mass B-Coreference
was O
an O
internal B-Detailed_description
, O
well-circumscribed B-Detailed_description
, O
heterogeneously B-Detailed_description
hypoechoic B-Lab_value
, O
egg-shaped B-Shape
lesion B-Sign_symptom
( O
Fig. O
1A O
and O
B O
) O
showing O
a O
movement B-Detailed_description
according I-Detailed_description
to I-Detailed_description
patient I-Detailed_description
movement I-Detailed_description
. O

The O
mass B-Coreference
could O
be O
compressed B-Lab_value
using O
the O
linear B-Therapeutic_procedure
transducer I-Therapeutic_procedure
( O
Fig. O
2A O
and O
B O
) O
. O

A O
color B-Detailed_description
Doppler B-Diagnostic_procedure
study I-Diagnostic_procedure
showed O
no O
vascularity B-Sign_symptom
within O
the O
cystic B-Coreference
mass I-Coreference
or O
the O
internal B-Detailed_description
hypoechoic B-Lab_value
lesion B-Coreference
( O
Fig. O
1C O
) O
. O

Surgical B-Therapeutic_procedure
excision I-Therapeutic_procedure
of O
the O
mass B-Sign_symptom
was O
performed O
without O
postoperative B-Disease_disorder
complications I-Disease_disorder
. O

Grossly O
, O
the O
excised O
mass B-Coreference
was O
a O
well-defined B-Lab_value
, O
ovoid B-Shape
, O
cystic B-Lab_value
mass O
gray-tan B-Color
in O
color O
. O

On O
section O
, O
it B-Coreference
was O
found O
to O
be O
a O
unilocular B-Lab_value
cyst B-Sign_symptom
filled O
with O
whitish B-Color
mucous B-Sign_symptom
material I-Sign_symptom
. O

Microscopically O
, O
the O
mass B-Coreference
was O
lined O
with O
ciliated O
pseudostratified O
columnar O
epithelium O
suggestive O
of O
respiratory O
type-mucosa O
( O
Fig. O
3 O
) O
. O

There O
was O
nonspecific B-Lab_value
collagenous B-Detailed_description
fibrosis B-Sign_symptom
around O
the O
cyst O
. O

The O
differential O
diagnosis O
of O
subcutaneous O
cyst O
included O
epidermal B-Disease_disorder
inclusion I-Disease_disorder
cyst I-Disease_disorder
, O
thyroglossal B-Disease_disorder
duct I-Disease_disorder
cyst I-Disease_disorder
, O
branchial B-Disease_disorder
cleft I-Disease_disorder
cyst I-Disease_disorder
, O
and O
dermoid B-Disease_disorder
cyst I-Disease_disorder
. O

There O
was O
no O
histological B-Sign_symptom
evidence I-Sign_symptom
of O
squamous B-Detailed_description
epithelium I-Detailed_description
, O
keratin B-Detailed_description
, O
thyroid B-Detailed_description
tissue I-Detailed_description
, O
or O
skin B-Detailed_description
appendage I-Detailed_description
in O
the O
cystic O
wall O
of O
the O
present O
case O
. O

The O
mass O
was O
diagnosed O
as O
a O
bronchogenic B-Disease_disorder
cyst I-Disease_disorder
. O

A O
23-year-old B-Age
man B-Sex
with O
a O
history O
of O
severe B-Disease_disorder
aplastic I-Disease_disorder
anemia I-Disease_disorder
( O
SAA B-Disease_disorder
) O
underwent O
bone B-Therapeutic_procedure
marrow I-Therapeutic_procedure
transplantation I-Therapeutic_procedure
from O
his O
HLA-haploidentical B-Detailed_description
mother B-Subject
in O
January B-Date
2014 I-Date
. O

The O
conditioning O
regimens O
consisted O
of O
busulphan B-Medication
cyclophosphamide I-Medication
and O
antithymocyte B-Medication
globulin I-Medication
( O
BUCY+ATG B-Medication
) O
( O
10 O
) O
. O

Cyclosporine B-Medication
A I-Medication
( O
CsA B-Medication
) O
and O
short-term B-Detailed_description
methotrexate B-Medication
( O
MTX B-Medication
) O
plus O
mycophenolate B-Medication
mofetil I-Medication
( O
MMF B-Medication
) O
were O
used O
as O
prophylaxis O
against O
graft-versus-host B-Disease_disorder
disease I-Disease_disorder
( O
GVHD B-Disease_disorder
) O
( O
11 O
) O
. O

Standard O
measures O
were O
adopted O
for O
the O
prevention O
of O
infectious B-Disease_disorder
complications I-Disease_disorder
, O
which O
included O
fluconazole B-Medication
for O
antifungal B-Detailed_description
prophylaxis B-Therapeutic_procedure
and O
acyclovir B-Medication
to O
prevent O
herpes-related B-Detailed_description
infections B-Disease_disorder
. O

A O
hemogram B-Diagnostic_procedure
revealed O
the O
reconstruction B-Sign_symptom
of I-Sign_symptom
granulocytes I-Sign_symptom
( O
ANC B-Diagnostic_procedure
> B-Lab_value
0.5 I-Lab_value
× I-Lab_value
109/L I-Lab_value
) O
on O
day B-Date
+12 I-Date
post-transplantation B-Therapeutic_procedure
. O

The O
patient O
developed O
grade B-Detailed_description
II I-Detailed_description
acute B-Detailed_description
GVHD B-Disease_disorder
of O
the O
skin B-Biological_structure
on O
day B-Date
+42 I-Date
post-transplantation B-Therapeutic_procedure
. O

This O
was O
treated O
by O
treatment O
with O
a O
standard-dose B-Dosage
of O
methyl-prednisolone B-Medication
, O
which O
achieved O
a O
complete B-Sign_symptom
response I-Sign_symptom
( O
CR B-Sign_symptom
) O
. O

The O
patient O
's O
chronic B-Disease_disorder
GVHD I-Disease_disorder
( O
cGVHD B-Disease_disorder
) O
of O
the O
skin B-Biological_structure
gradually O
progressed O
from O
day B-Date
+100 I-Date
post-transplantation B-Therapeutic_procedure
and O
he O
was O
treated O
with O
prednisolone B-Medication
and O
CsA B-Medication
. O

On O
day B-Date
120 I-Date
post-transplantation B-Therapeutic_procedure
, O
he O
complained O
of O
a O
cough B-Sign_symptom
and O
antibiotics B-Medication
were O
administered O
. O

A O
blood B-Diagnostic_procedure
analysis I-Diagnostic_procedure
revealed O
the O
following O
: O
WBC B-Diagnostic_procedure
, O
2.34 B-Lab_value
× I-Lab_value
109/L I-Lab_value
; O
ANC B-Diagnostic_procedure
, O
1.72 B-Lab_value
× I-Lab_value
109/L I-Lab_value
; O
hemoglobin B-Diagnostic_procedure
, O
85 B-Lab_value
g/L I-Lab_value
; O
and O
platelets B-Diagnostic_procedure
, O
72 B-Lab_value
× I-Lab_value
109/L I-Lab_value
. O

Although O
both O
a O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
and O
tests B-Diagnostic_procedure
for I-Diagnostic_procedure
pathogens I-Diagnostic_procedure
via B-Detailed_description
routine I-Detailed_description
culturing I-Detailed_description
, O
including O
blood B-Detailed_description
tests O
for O
Beta-D B-Diagnostic_procedure
glucan I-Diagnostic_procedure
( O
G-test B-Diagnostic_procedure
) O
and O
Galactomannan B-Diagnostic_procedure
( O
GM-test B-Diagnostic_procedure
) O
were O
all O
negative B-Lab_value
, O
the O
patient O
's O
cough B-Sign_symptom
did O
not O
respond O
to O
antibiotics B-Medication
and O
we O
empirically O
initiated O
treatment O
with O
voriconazole B-Medication
( O
6 B-Dosage
mg/kg/12h I-Dosage
for I-Dosage
the I-Dosage
first I-Dosage
day I-Dosage
, O
followed O
by O
4 B-Dosage
mg/kg/12h I-Dosage
) O
. O

Liver B-Biological_structure
toxicity B-Sign_symptom
occurred O
during O
voriconazole B-Medication
treatment O
, O
thus O
the O
anti-fungal B-Therapeutic_procedure
regimen I-Therapeutic_procedure
was O
changed O
to O
micafungin B-Medication
( O
100 B-Dosage
mg/d I-Dosage
) O
. O

However O
, O
the O
persistent B-Detailed_description
cough B-Sign_symptom
did O
not O
improve O
and O
hoarseness B-Sign_symptom
developed O
after B-Date
two I-Date
weeks I-Date
of O
treatment O
- O
ulcers B-Sign_symptom
were O
then O
observed O
in O
the O
throat B-Biological_structure
by O
laryngoscopy B-Diagnostic_procedure
( O
Fig. O
1a O
) O
. O

The O
patient O
developed O
severe B-Severity
dyspnea B-Sign_symptom
in B-Date
the I-Date
following I-Date
week I-Date
when O
anti-infection B-Detailed_description
and O
topical B-Detailed_description
treatments B-Therapeutic_procedure
were O
applied O
. O

Fiberoptic B-Detailed_description
bronchoscopy B-Diagnostic_procedure
revealed O
an O
irregular B-Detailed_description
, O
nodular B-Shape
material B-Sign_symptom
with O
white B-Detailed_description
moss I-Detailed_description
, O
which O
nearly B-Detailed_description
obstructed B-Sign_symptom
the O
bronchus B-Biological_structure
; O
however O
, O
chest B-Biological_structure
CT B-Diagnostic_procedure
imaging O
was O
negative B-Lab_value
( O
Fig. O
1b O
and O
c O
) O
. O

The O
histopathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
biopsy B-Diagnostic_procedure
specimens O
revealed O
an O
Aspergillus B-Disease_disorder
species O
( O
Fig. O
1d O
) O
. O

The O
patient O
was O
diagnosed O
with O
pseudomembranous B-Detailed_description
Aspergillus B-Disease_disorder
tracheobronchitis B-Disease_disorder
type B-Detailed_description
ITBA I-Detailed_description
based O
on O
the O
results O
of O
bronchoscopy B-Diagnostic_procedure
and O
a O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
( O
12 O
) O
. O

The O
antibiotic B-Medication
and O
micafungin B-Medication
treatments O
were O
ceased O
and O
liposomal B-Detailed_description
amphotericin B-Medication
B I-Medication
( O
liposomal B-Detailed_description
AmB B-Medication
) O
was O
administered O
daily B-Dosage
at O
a O
target O
dose O
of O
3 B-Dosage
mg/kg I-Dosage
. O

The O
patient O
's O
serum B-Detailed_description
creatinine B-Diagnostic_procedure
level O
rose B-Lab_value
from O
60.4 B-Lab_value
μmol/L I-Lab_value
to O
168 B-Lab_value
μmol/L I-Lab_value
during B-Date
the I-Date
first I-Date
7 I-Date
days I-Date
of O
liposomal B-Detailed_description
AmB B-Medication
treatment O
. O

Due O
to O
progressive B-Severity
renal B-Disease_disorder
dysfunction I-Disease_disorder
, O
the O
anti-fungal B-Medication
regimen O
was O
switched O
to O
a O
combination O
of O
posaconazole B-Medication
( O
400 B-Dosage
mg/12 I-Dosage
h I-Dosage
) O
and O
caspofungin B-Medication
[ O
50 B-Dosage
mg I-Dosage
, I-Dosage
daily I-Dosage
( O
70 B-Dosage
mg I-Dosage
for I-Dosage
the I-Dosage
first I-Dosage
dose I-Dosage
) O
] O
. O

The O
combination B-Medication
therapy I-Medication
continued O
for O
2 B-Duration
weeks I-Duration
, O
until O
the O
previous O
nodules B-Sign_symptom
in O
the O
throat B-Biological_structure
completely O
disappeared O
under O
bronchoscopy B-Diagnostic_procedure
( O
Fig. O
2a O
) O
; O
however O
, O
a O
repeat O
chest B-Biological_structure
CT B-Diagnostic_procedure
scan O
showed O
progression B-Sign_symptom
( O
Fig. O
2b O
) O
. O

The O
symptom O
of O
dyspnea B-Sign_symptom
gradually O
progressed O
, O
thus O
fiberoptic B-Detailed_description
bronchoscopy B-Diagnostic_procedure
was O
performed O
to O
remove B-Therapeutic_procedure
the O
obstructive B-Sign_symptom
material I-Sign_symptom
from O
the O
patient O
's O
airways B-Biological_structure
once B-Frequency
a I-Frequency
week I-Frequency
for O
two B-Duration
weeks I-Duration
. O

All O
of O
the O
symptoms B-Sign_symptom
were O
relieved O
and O
the O
final O
chest B-Biological_structure
CT B-Diagnostic_procedure
scan O
showed O
negative B-Lab_value
results O
before O
the O
discontinuation O
of O
anti-fungal B-Medication
therapy O
, O
and O
all O
of O
the O
tests B-Diagnostic_procedure
were O
negative B-Lab_value
for O
Aspergillus B-Disease_disorder
. O

Posaconazole B-Medication
was O
administered O
as O
a O
secondary O
prophylactic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
and O
the O
patient O
was O
discharged B-Clinical_event
from O
hospital B-Nonbiological_location
. O

The O
patient O
is O
still O
being O
followed B-Clinical_event
and O
remains O
free O
of O
any O
recurrence O
of O
invasive B-Detailed_description
fungal B-Detailed_description
infection B-Disease_disorder
. O

An O
82-year-old B-Age
male B-Sex
was O
admitted B-Clinical_event
in O
our O
outside B-Nonbiological_location
hospital I-Nonbiological_location
’s I-Nonbiological_location
emergency I-Nonbiological_location
room I-Nonbiological_location
due O
to O
abdominal B-Biological_structure
pain B-Sign_symptom
and O
faint B-Sign_symptom
. O

He O
had O
a O
previous O
history O
of O
auricular B-History
fibrillation I-History
in O
treatment O
with O
a O
dicumarinic B-Medication
anticoagulant I-Medication
and O
a O
previous O
episode O
of O
abdominal B-Biological_structure
pain B-Sign_symptom
which O
was O
diagnosed O
as O
spontaneous B-Detailed_description
mesenchimal B-Disease_disorder
haematoma I-Disease_disorder
and O
treated B-Therapeutic_procedure
non I-Therapeutic_procedure
operatively I-Therapeutic_procedure
. O

He O
denied O
any O
kind O
of O
trauma B-Sign_symptom
, O
and O
had O
no O
hematemesis B-Sign_symptom
or O
melena B-Sign_symptom
. O

At O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
the O
patient O
was O
stable B-Lab_value
and O
suffered O
from O
intense B-Severity
pain B-Sign_symptom
at O
the O
right B-Biological_structure
lower I-Biological_structure
abdomen I-Biological_structure
with O
no O
defense O
. O

Blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
a O
haemoglobin B-Diagnostic_procedure
level I-Diagnostic_procedure
of O
10 B-Lab_value
g/dl I-Lab_value
. O

Coagulation B-Diagnostic_procedure
was O
altered B-Lab_value
as O
expected O
. O

CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
massive B-Severity
hemoperitoneum B-Sign_symptom
( O
Figure O
1 O
) O
and O
the O
already O
known O
mesenteric B-Disease_disorder
hematoma I-Disease_disorder
( O
Figure O
2 O
) O
. O

Assuming O
the O
diagnosis O
of O
expansive B-Detailed_description
mesenteric B-Disease_disorder
hematoma I-Disease_disorder
plus O
ongoing B-Detailed_description
bleeding B-Sign_symptom
a O
laparotomy B-Therapeutic_procedure
was O
performed O
. O

During O
first O
exploration O
, O
3 B-Volume
liters I-Volume
of O
fresh B-Sign_symptom
and I-Sign_symptom
old I-Sign_symptom
blood I-Sign_symptom
clots I-Sign_symptom
were O
found O
. O

At O
90 B-Distance
cm I-Distance
from I-Distance
the O
ileocecal B-Biological_structure
valve I-Biological_structure
a O
torsionated B-Detailed_description
and O
perforated B-Detailed_description
meckel B-Disease_disorder
diverticulum I-Disease_disorder
with O
intradiverticular B-Biological_structure
bleeding B-Sign_symptom
was O
found O
( O
Figure O
3 O
) O
and O
a O
diverticular B-Biological_structure
resection B-Therapeutic_procedure
was O
performed O
. O

The O
postoperatory B-Therapeutic_procedure
was O
uneventful B-Lab_value
and O
the O
patient O
was O
discharged B-Clinical_event
home I-Clinical_event
at O
the O
9th B-Date
postoperative I-Date
day I-Date
. O

We O
present O
a O
case O
of O
pancreatic B-Disease_disorder
tumor I-Disease_disorder
without B-History
a I-History
history I-History
of I-History
trauma I-History
or I-History
panceratitis I-History
. O

A O
47-year-old B-Age
Tunisian B-Personal_background
man B-Sex
with O
a O
history O
of O
Crohn B-History
's I-History
disease I-History
was O
admitted B-Clinical_event
to O
the O
University B-Nonbiological_location
Hospital I-Nonbiological_location
in O
2015 B-Date
because O
of O
fluid B-Detailed_description
chronic B-Detailed_description
diarrhea B-Sign_symptom
with O
4 B-Quantitative_concept
stools B-Diagnostic_procedure
per I-Diagnostic_procedure
day I-Diagnostic_procedure
daytime B-Qualitative_concept
only I-Qualitative_concept
with O
out O
ooddebr B-Other_event
is O
associated O
with O
vomiting B-Sign_symptom
with O
out O
abdominal B-Biological_structure
pain B-Sign_symptom
or O
fever B-Sign_symptom
with O
a O
weight B-Sign_symptom
loss I-Sign_symptom
not O
encrypted O
dating O
from B-Duration
6 I-Duration
months I-Duration
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
normal B-Qualitative_concept
. O

Nonspecific O
elevations B-Qualitative_concept
of O
serum B-Biological_structure
pancreatic B-Diagnostic_procedure
enzymes I-Diagnostic_procedure
. O

Patient O
underwent O
an O
abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
that O
revealed O
: O
Aspect O
of O
ileitis B-Disease_disorder
of O
the O
last B-Biological_structure
ileal I-Biological_structure
loop I-Biological_structure
extended B-Sign_symptom
by O
300 B-Distance
mm I-Distance
with O
distended B-Sign_symptom
ileal B-Biological_structure
loops I-Biological_structure
upstream B-Detailed_description
, O
cystic B-Detailed_description
image B-Sign_symptom
at O
the O
tail B-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreas I-Biological_structure
with O
clean O
wall O
uncalcified B-Sign_symptom
and O
hypodense O
content O
of O
fluid O
density O
without O
endoluminal B-Biological_structure
bourgeon B-Sign_symptom
or O
pancreatic B-Biological_structure
duct I-Biological_structure
dilatation B-Sign_symptom
, O
measuring O
28 B-Area
x I-Area
22 I-Area
mm I-Area
( O
Figure O
1 O
) O
. O

The O
size B-Diagnostic_procedure
of O
the O
head B-Biological_structure
was O
normal B-Qualitative_concept
. O

There O
were O
no O
enlarged B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
( O
Figure O
2 O
) O
. O

Aspect O
of O
bilateral B-Detailed_description
sacroiliitis B-Disease_disorder
and O
bilateral B-Detailed_description
coxarthrosis B-Disease_disorder
. O

MRI B-Diagnostic_procedure
show O
an O
aspect O
of O
ileitis B-Disease_disorder
of O
the O
last B-Biological_structure
ileal I-Biological_structure
loop I-Biological_structure
and O
the O
cystic B-Detailed_description
nature I-Detailed_description
of O
a O
pancreatic B-Biological_structure
lesion B-Sign_symptom
, O
with O
parietal B-Detailed_description
enhancement B-Sign_symptom
at O
the O
caudal B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreas I-Biological_structure
with O
a O
slight B-Severity
dilation B-Sign_symptom
of O
the O
Wirsung B-Biological_structure
. O

Otherwise O
, O
gallbladder B-Biological_structure
contains O
multiple B-Detailed_description
gallstones B-Sign_symptom
and O
biliary B-Sign_symptom
sludge I-Sign_symptom
. O

Tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
are O
normal.on B-Lab_value
the O
other O
hand O
, O
in O
colonoscopy B-Diagnostic_procedure
terminal B-Biological_structure
ileum I-Biological_structure
appears O
swollen B-Sign_symptom
, O
inflamed B-Sign_symptom
, O
with O
frequent O
ulcerations B-Sign_symptom
and O
biopsies B-Diagnostic_procedure
were O
made O
. O

The O
biopsies B-Diagnostic_procedure
were O
taken O
and O
show O
a O
subacute B-Detailed_description
and O
ulcerative B-Detailed_description
ileitis B-Disease_disorder
compatible O
with O
Crohn B-Disease_disorder
's I-Disease_disorder
disease I-Disease_disorder
. O

Esophagogastroduodenoscopy B-Diagnostic_procedure
was O
normal B-Lab_value
. O

The O
patient O
was O
operated O
by O
laparoscopy B-Therapeutic_procedure
, O
he O
had O
a O
caudal B-Detailed_description
pancreatectomy B-Therapeutic_procedure
and O
cholecystectomy B-Therapeutic_procedure
.1.5 B-Distance
cm I-Distance
cystic B-Detailed_description
tumor B-Sign_symptom
in O
the O
tail B-Biological_structure
of I-Biological_structure
pancreas I-Biological_structure
was O
resected B-Therapeutic_procedure
and O
sent O
for O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
. O

The O
post-operative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
. O

Patient O
was O
discharged B-Clinical_event
home B-Nonbiological_location
within B-Date
7 I-Date
days I-Date
in O
a O
good B-Lab_value
general B-Diagnostic_procedure
condition I-Diagnostic_procedure
. O

There O
were O
no O
symptoms B-Sign_symptom
of I-Sign_symptom
glucose I-Sign_symptom
intolerance I-Sign_symptom
after O
normal B-Qualitative_concept
diet B-Therapeutic_procedure
administration O
. O

The O
microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
well B-Detailed_description
differentiated I-Detailed_description
cystic B-Detailed_description
neuro B-Disease_disorder
endocrine I-Disease_disorder
tumor I-Disease_disorder
of O
the O
tail B-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreas I-Biological_structure
grade B-Qualitative_concept
I I-Qualitative_concept
according O
to O
the O
classification O
of O
WHO O
2010 O
( O
mitosis B-Diagnostic_procedure
< B-Lab_value
2/10CFG I-Lab_value
and O
Ki67 B-Diagnostic_procedure
< B-Lab_value
2 I-Lab_value
% I-Lab_value
) O
associated O
with O
neuroendocrine B-Disease_disorder
hyperplasia I-Disease_disorder
lesions I-Disease_disorder
of O
islets B-Biological_structure
of I-Biological_structure
Langerhans I-Biological_structure
, O
surgical B-Diagnostic_procedure
limit I-Diagnostic_procedure
was O
healthy B-Lab_value
, O
pTNM B-Diagnostic_procedure
pT2 B-Lab_value
, O
ectopic B-Sign_symptom
spleen B-Biological_structure
, O
chronic B-Detailed_description
cholecystitis B-Disease_disorder
. O

the O
patient O
come O
for O
out-patient B-Clinical_event
consultations I-Clinical_event
at O
the O
hospital B-Biological_structure
, O
he O
felt B-Outcome
well I-Outcome
, O
with O
no O
severe B-Severity
complaints B-Sign_symptom
and O
with O
correct B-Lab_value
periodic B-Diagnostic_procedure
findings I-Diagnostic_procedure
and O
normal B-Lab_value
glucose B-Diagnostic_procedure
metabolism I-Diagnostic_procedure
. O

A O
37-year-old B-Age
African B-Personal_background
American I-Personal_background
female B-Sex
with O
a O
past O
medical O
history O
significant O
for O
stage B-History
1 I-History
sarcoidosis I-History
presented B-Clinical_event
to O
our O
facility B-Nonbiological_location
with O
a O
chief O
complaint O
of O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
. O

Ten B-Date
years I-Date
prior I-Date
, O
she O
presented B-Clinical_event
with O
bilateral B-Detailed_description
uveitis B-Disease_disorder
and O
lupus B-Sign_symptom
pernio I-Sign_symptom
( O
LP B-Sign_symptom
) O
on O
her O
right B-Biological_structure
ear I-Biological_structure
and O
was O
subsequently O
diagnosed O
with O
sarcoidosis B-Disease_disorder
. O

She O
was O
successfully B-Lab_value
treated B-Therapeutic_procedure
for O
these O
conditions O
and O
her O
sarcoidosis B-Disease_disorder
remained O
quiescent B-Lab_value
until O
three B-Date
years I-Date
ago I-Date
, O
when O
, O
at O
an O
outside B-Nonbiological_location
institution I-Nonbiological_location
, O
she O
was O
discovered B-Clinical_event
to O
have O
laryngeal B-Biological_structure
involvement B-Sign_symptom
. O

She O
was O
treated B-Therapeutic_procedure
with O
prednisone B-Medication
60 B-Dosage
mg I-Dosage
daily I-Dosage
for O
several B-Duration
months I-Duration
and O
eventually B-Date
tapered O
to O
10 B-Dosage
mg I-Dosage
daily I-Dosage
. O

Her O
sarcoidosis B-Disease_disorder
remained O
well-controlled B-Lab_value
on O
this O
maintenance B-Dosage
dose I-Dosage
of O
prednisone B-Medication
until O
six B-Date
months I-Date
prior I-Date
, O
at O
which O
time O
she O
self-discontinued B-Lab_value
her O
prednisone B-Medication
in O
favor O
of O
the O
homeopathic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
Nopalea B-Medication
cactus I-Medication
juice I-Medication
, O
which O
unsubstantially O
claimed O
to O
have O
anti-inflammatory O
properties O
[ O
4 O
] O
. O

Subsequently O
, O
she O
developed O
dyspnea B-Sign_symptom
on B-Detailed_description
exertion I-Detailed_description
progressing O
to O
dyspnea B-Sign_symptom
at B-Detailed_description
rest I-Detailed_description
. O

During O
this O
time O
her O
voice B-Activity
became O
increasingly O
hoarse B-Sign_symptom
and O
she O
experienced O
frequent B-Frequency
episodes O
of O
difficulty B-Sign_symptom
swallowing I-Sign_symptom
. O

In O
our O
emergency B-Nonbiological_location
department I-Nonbiological_location
, O
her O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
concerning O
for O
respiratory B-Sign_symptom
distress I-Sign_symptom
as O
she O
presented O
with O
inspiratory B-Sign_symptom
stridor I-Sign_symptom
and O
hoarseness B-Sign_symptom
. O

She O
also O
had O
chronic-appearing B-Lab_value
, O
indurated B-Lab_value
lesions B-Sign_symptom
on O
her O
right B-Biological_structure
ear I-Biological_structure
. O

Given O
that O
she O
had O
signs O
of O
upper B-Disease_disorder
airway I-Disease_disorder
disease I-Disease_disorder
for O
impending B-Lab_value
respiratory B-Disease_disorder
failure I-Disease_disorder
, O
an O
emergent B-Detailed_description
bedside B-Detailed_description
laryngoscopy B-Diagnostic_procedure
was O
performed O
, O
revealing O
an O
obstructed B-Disease_disorder
airway B-Biological_structure
with O
the O
epiglottis B-Biological_structure
retroflexed B-Sign_symptom
over O
the O
glottis B-Biological_structure
and O
significant B-Lab_value
edema B-Sign_symptom
in O
the O
arytenoids B-Biological_structure
and O
aryepiglottic B-Biological_structure
folds I-Biological_structure
. O

She O
was O
immediately O
treated O
with O
high-dose B-Dosage
intravenous B-Administration
dexamethasone B-Medication
and O
taken B-Clinical_event
emergently O
to O
the O
operating B-Nonbiological_location
room I-Nonbiological_location
( O
OR B-Nonbiological_location
) O
to O
secure B-Therapeutic_procedure
her O
airway B-Biological_structure
for O
concern O
for O
complete B-Lab_value
upper B-Biological_structure
airway I-Biological_structure
obstruction B-Disease_disorder
, O
which O
was O
confirmed O
with O
direct B-Diagnostic_procedure
visualization I-Diagnostic_procedure
of O
her O
larynx B-Biological_structure
in O
the O
OR B-Nonbiological_location
. O

She O
was O
intubated B-Therapeutic_procedure
for O
a O
surgical B-Therapeutic_procedure
airway I-Therapeutic_procedure
, O
and O
after O
taking O
biopsies B-Diagnostic_procedure
from O
the O
lingual B-Biological_structure
surface I-Biological_structure
of O
her O
epiglottis B-Biological_structure
, O
a O
# B-Detailed_description
4 I-Detailed_description
cuffed I-Detailed_description
Shiley B-Detailed_description
™ O
tracheostomy B-Therapeutic_procedure
was O
placed O
. O

Her O
respiratory B-Diagnostic_procedure
status I-Diagnostic_procedure
immediately O
stabilized B-Lab_value
, O
was O
extubated B-Therapeutic_procedure
, O
and O
transferred B-Clinical_event
to O
our O
medical B-Nonbiological_location
intensive I-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
. O

Her O
tracheostomy B-Therapeutic_procedure
was O
exchanged O
to O
a O
# B-Detailed_description
4 I-Detailed_description
cuffless I-Detailed_description
Shiley B-Detailed_description
on O
postoperative O
day B-Date
5 I-Date
. O

During O
this O
time O
she O
was O
transitioned O
from O
intravenous B-Administration
dexamethasone B-Medication
to O
prednisone B-Medication
60 B-Dosage
mg I-Dosage
daily I-Dosage
. O

Biopsies B-Diagnostic_procedure
ultimately O
revealed O
non-necrotizing B-Detailed_description
epithelioid B-Detailed_description
granulomas B-Sign_symptom
consistent O
with O
sarcoidosis B-Disease_disorder
( O
Figure O
1 O
) O
. O

She O
was O
prescribed O
this O
high-dose B-Dosage
prednisone B-Medication
for O
three B-Duration
months I-Duration
, O
and O
after O
receiving O
education B-Clinical_event
for O
self-tracheostomy B-Therapeutic_procedure
care I-Therapeutic_procedure
, O
she O
was O
discharged B-Clinical_event
home B-Nonbiological_location
. O

At O
her O
subsequent O
one-month B-Date
and O
three-month B-Date
follow-up B-Clinical_event
visits O
, O
she O
denied O
any O
further O
respiratory B-Sign_symptom
issues I-Sign_symptom
. O

Repeat O
laryngoscopies B-Diagnostic_procedure
showed O
significant O
improvement B-Lab_value
in O
the O
edema B-Sign_symptom
in O
the O
arytenoids B-Biological_structure
and O
aryepiglottic B-Biological_structure
folds I-Biological_structure
, O
but O
the O
epiglottis B-Biological_structure
continued O
to O
obscure B-Disease_disorder
the O
glottis B-Biological_structure
despite O
therapy O
with O
high-dose B-Dosage
prednisone B-Medication
. O

Methotrexate B-Medication
was O
initiated O
while O
prednisone B-Medication
was O
tapered O
to O
10 B-Dosage
mg I-Dosage
daily I-Dosage
; O
however O
, O
this O
regimen O
failed O
and O
her O
prednisone B-Medication
dosage O
was O
increased O
to O
20 B-Dosage
mg I-Dosage
daily I-Dosage
to O
reduce O
edema O
. O

Because O
she O
declined O
surgical B-Therapeutic_procedure
treatment I-Therapeutic_procedure
, O
she O
will O
continue O
with O
medical B-Therapeutic_procedure
management I-Therapeutic_procedure
with O
immunosuppressive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
to O
facilitate O
eventual O
de-cannulation O
. O

A O
3-month-old B-Age
infant O
from B-Personal_background
the I-Personal_background
UAE I-Personal_background
with O
a O
genetically-confirmed B-History
diagnosis I-History
of I-History
Jarcho-Levin I-History
syndrome I-History
and O
dependent B-History
on I-History
mechanical I-History
ventilation I-History
since I-History
birth I-History
was O
admitted B-Clinical_event
to O
our O
centre B-Nonbiological_location
for O
the O
implantation B-Therapeutic_procedure
of I-Therapeutic_procedure
VEPTRs I-Therapeutic_procedure
. O

We O
received O
an O
intubated B-Therapeutic_procedure
patient O
, O
mechanically B-Detailed_description
ventilated B-Therapeutic_procedure
in O
a O
volume-controlled B-Detailed_description
mode I-Detailed_description
, O
with O
a O
0.30 B-Lab_value
– I-Lab_value
0.45 I-Lab_value
fraction I-Lab_value
of I-Lab_value
inspired I-Lab_value
oxygen I-Lab_value
( O
FiO2 O
) O
( O
peak B-Lab_value
inspiratory I-Lab_value
pressures I-Lab_value
( I-Lab_value
PIP I-Lab_value
) I-Lab_value
of I-Lab_value
23 I-Lab_value
– I-Lab_value
45 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
, O
positive B-Lab_value
end-expiratory I-Lab_value
pressure I-Lab_value
( I-Lab_value
PEEP I-Lab_value
) I-Lab_value
of I-Lab_value
7 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
, O
backup B-Lab_value
respiratory I-Lab_value
rate I-Lab_value
( I-Lab_value
RR I-Lab_value
) I-Lab_value
of I-Lab_value
34 I-Lab_value
) O
. O

A O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
of O
the O
thorax B-Biological_structure
was O
performed O
on O
admission B-Clinical_event
( O
figure O
1A O
) O
, O
and O
a B-Date
month I-Date
after I-Date
the O
first O
surgery B-Therapeutic_procedure
( O
figure O
1B O
) O
, O
showing O
improvement O
of O
the O
bilateral B-Detailed_description
posterior B-Detailed_description
atelectasis B-Disease_disorder
in O
the O
base B-Biological_structure
of I-Biological_structure
the I-Biological_structure
lungs I-Biological_structure
. O

Owing O
to O
the O
difficulty O
of O
progressing O
in O
the O
weaning O
process O
from O
mechanical O
ventilation O
after O
the O
VEPTRs O
were O
implanted O
to O
expand O
the O
thorax O
, O
a O
bronchoscopy B-Therapeutic_procedure
was O
performed O
, O
showing O
bronchomalacia B-Disease_disorder
predominantly O
in O
both B-Biological_structure
upper I-Biological_structure
lobar I-Biological_structure
bronchi I-Biological_structure
. O

As O
prolonged B-Detailed_description
mechanical B-Detailed_description
ventilation B-Therapeutic_procedure
was O
expected O
, O
a O
tracheostomy B-Therapeutic_procedure
was O
previously O
performed O
. O

After O
an O
initial O
CT B-Diagnostic_procedure
scan O
( O
figure O
2A O
) O
, O
a O
follow-up O
CT B-Diagnostic_procedure
scan O
( O
figure O
2B O
) O
a B-Date
month I-Date
after I-Date
the O
surgery O
showed O
a O
resolution O
of O
the O
posterior-basal B-Detailed_description
atelectasis B-Disease_disorder
, O
coinciding O
with O
a O
decrease B-Lab_value
of O
FiO2 B-Diagnostic_procedure
to O
0.21 B-Lab_value
. O

Postoperatively O
, O
the O
patient O
was O
on O
the O
Servo-i B-Detailed_description
ventilator B-Therapeutic_procedure
in O
a O
volume-controlled B-Detailed_description
mode I-Detailed_description
and O
needed O
variable B-Detailed_description
PIPs B-Diagnostic_procedure
between B-Lab_value
25 I-Lab_value
and I-Lab_value
45 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
and O
PEEP B-Diagnostic_procedure
values O
of O
7 B-Lab_value
– I-Lab_value
11 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
. O

During O
the O
attempts O
to O
wean O
the O
patient O
off O
the O
ventilator O
in O
the O
following O
months O
, O
he O
was O
unable O
to O
activate O
the O
inspiratory O
flow O
trigger O
and O
required O
significant O
sedoanalgesia B-Medication
to O
adapt O
to O
the O
ventilator O
due O
to O
repeated O
episodes O
of O
desaturation B-Sign_symptom
, O
on O
some O
occasions O
with O
bradycardia B-Sign_symptom
, O
associated O
to O
bronchial B-Disease_disorder
collapse I-Disease_disorder
. O

He O
continued O
to O
have O
asynchrony B-Sign_symptom
which O
required O
boluses O
of O
sedation B-Medication
in O
addition O
to O
existing O
medications O
. O

He O
initially O
received O
fentanyl B-Medication
and O
midazolam B-Medication
through O
a O
continuous B-Administration
infusion I-Administration
pump I-Administration
with O
progressive B-Dosage
increase I-Dosage
in I-Dosage
the I-Dosage
doses I-Dosage
as O
well O
as O
continuous B-Dosage
cisatracurium B-Medication
as O
a O
muscular B-Medication
relaxant I-Medication
to O
adapt O
to O
mechanical O
ventilation O
( O
figure O
3 O
) O
. O

As O
clinical B-Sign_symptom
stabilisation I-Sign_symptom
was O
achieved O
, O
the O
muscular B-Medication
relaxant I-Medication
was O
withdrawn O
and O
a O
progressive B-Dosage
decrease I-Dosage
of O
sedation B-Medication
was O
initiated O
along O
with O
a O
change O
in O
the O
drug O
regimen O
. O

During O
this O
period O
, O
the O
patient O
developed O
an O
ocular B-Sign_symptom
flutter I-Sign_symptom
which O
was O
attributed O
to O
a O
pharmacological O
cause O
after O
neurological O
alterations O
were O
ruled O
out O
with O
normal B-Lab_value
EEG B-Diagnostic_procedure
, O
ophthalmoscopy B-Diagnostic_procedure
, O
metabolic B-Diagnostic_procedure
workup I-Diagnostic_procedure
and O
cranial B-Biological_structure
MRI B-Diagnostic_procedure
. O

At O
5 B-Date
months I-Date
of I-Date
age I-Date
, O
the O
NAVA B-Therapeutic_procedure
mode I-Therapeutic_procedure
started O
to O
improve B-Lab_value
the O
patient O
's O
adaptation B-Diagnostic_procedure
to I-Diagnostic_procedure
the I-Diagnostic_procedure
ventilator I-Diagnostic_procedure
through O
the O
use O
of O
a O
neural B-Therapeutic_procedure
trigger I-Therapeutic_procedure
. O

The O
NAVA B-Therapeutic_procedure
catheter I-Therapeutic_procedure
additionally O
costs B-Detailed_description
around I-Detailed_description
€ I-Detailed_description
200 I-Detailed_description
per I-Detailed_description
catheter I-Detailed_description
; O
according B-Other_entity
to I-Other_entity
the I-Other_entity
manufacturer I-Other_entity
it I-Other_entity
should I-Other_entity
be I-Other_entity
changed I-Other_entity
every I-Other_entity
5 I-Other_entity
days I-Other_entity
. O

It O
was O
required O
for B-Duration
7 I-Duration
months I-Duration
; O
nevertheless O
the O
catheters B-Therapeutic_procedure
were I-Therapeutic_procedure
changed I-Therapeutic_procedure
every B-Frequency
15 I-Frequency
days I-Frequency
without O
observing O
a O
deterioration B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
Edi I-Sign_symptom
signal I-Sign_symptom
. O

According B-Other_entity
to I-Other_entity
the I-Other_entity
literature I-Other_entity
, I-Other_entity
Jarcho-Levin I-Other_entity
syndrome I-Other_entity
does I-Other_entity
not I-Other_entity
appear I-Other_entity
with I-Other_entity
mental I-Other_entity
retardation I-Other_entity
and I-Other_entity
life I-Other_entity
expectancy I-Other_entity
is I-Other_entity
pretty I-Other_entity
long I-Other_entity
, I-Other_entity
so I-Other_entity
ethically I-Other_entity
, I-Other_entity
we I-Other_entity
considered I-Other_entity
that I-Other_entity
this I-Other_entity
patient I-Other_entity
should I-Other_entity
have I-Other_entity
an I-Other_entity
opportunity I-Other_entity
to I-Other_entity
overcome I-Other_entity
his I-Other_entity
thoracic I-Other_entity
insufficiency I-Other_entity
if I-Other_entity
it I-Other_entity
were I-Other_entity
technically I-Other_entity
possible I-Other_entity
. O

Tachypnoea B-Sign_symptom
was O
initially O
observed O
with O
a O
RR B-Diagnostic_procedure
of O
55 B-Lab_value
without O
other O
signs O
of O
increase O
in O
his O
work B-Sign_symptom
of I-Sign_symptom
breathing I-Sign_symptom
and O
his O
RR B-Diagnostic_procedure
eventually O
returned O
to O
normal B-Lab_value
for O
his O
age O
( O
40 B-Lab_value
) O
over O
the O
next O
few O
days O
. O

The O
synchrony B-Sign_symptom
achieved O
with O
the O
ventilator B-Therapeutic_procedure
allowed O
a O
progressive O
decrease O
of O
the O
sedoanalgesia B-Medication
he O
received O
until O
it B-Coreference
was O
completely O
withdrawn O
in O
10 B-Date
days I-Date
; O
and O
the O
need O
for O
extra O
boluses O
of O
sedation B-Medication
was O
reduced O
to O
zero O
. O

Concurrently O
to O
the O
reduction O
of O
sedation O
, O
his O
ocular B-Sign_symptom
flutter I-Sign_symptom
disappeared O
and O
he O
showed O
significant O
progress B-Lab_value
in O
his O
psychomotor B-Diagnostic_procedure
development I-Diagnostic_procedure
. O

The O
settings O
used O
were O
: O
NAVA B-Lab_value
level I-Lab_value
of I-Lab_value
1 I-Lab_value
cm I-Lab_value
H2O/µV I-Lab_value
, O
PEEP B-Lab_value
11 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
, O
Edi B-Lab_value
trigger I-Lab_value
0.5 I-Lab_value
µV I-Lab_value
. O

The O
patient O
had O
tidal B-Diagnostic_procedure
volumes I-Diagnostic_procedure
( O
Vt B-Diagnostic_procedure
) O
of O
6 B-Lab_value
– I-Lab_value
7 I-Lab_value
mL/kg I-Lab_value
( O
figure O
3 O
) O
. O

After B-Date
10 I-Date
days I-Date
on O
the O
NAVA B-Therapeutic_procedure
mode I-Therapeutic_procedure
, O
he O
did O
not O
require O
any O
type O
of O
sedation B-Medication
and O
the O
sporadic O
episodes O
of O
bronchial B-Disease_disorder
collapse I-Disease_disorder
were O
resolved O
with O
a O
quick O
increase O
of O
PEEP B-Diagnostic_procedure
to O
20 B-Lab_value
cm I-Lab_value
H2O I-Lab_value
or O
manual B-Detailed_description
ventilation B-Therapeutic_procedure
with O
the O
self-inflating B-Detailed_description
bag I-Detailed_description
. O

Once O
he O
was O
stabilised O
on O
the O
NAVA B-Therapeutic_procedure
mode I-Therapeutic_procedure
, O
his O
PIPs B-Diagnostic_procedure
oscillated O
between B-Lab_value
15 I-Lab_value
and I-Lab_value
45 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
with O
a O
NAVA B-Lab_value
level I-Lab_value
of I-Lab_value
0.4 I-Lab_value
and O
Edi B-Diagnostic_procedure
peaks I-Diagnostic_procedure
between B-Lab_value
15 I-Lab_value
and I-Lab_value
100 I-Lab_value
µV I-Lab_value
. O

A O
posterior B-Detailed_description
pulmonary B-Biological_structure
CT B-Diagnostic_procedure
scan O
performed O
2 B-Date
months I-Date
after I-Date
the O
first O
surgery O
, O
1 O
month O
after O
starting O
NAVA O
and O
prior O
to O
the O
first O
thoracic O
expansion O
, O
showed O
a O
significant O
reduction O
in O
the O
posterobasal B-Detailed_description
atelectases B-Disease_disorder
previously O
observed O
( O
figure O
2B O
) O
. O

When O
he O
turned O
1 B-Date
year I-Date
old I-Date
, O
after O
several O
attempts O
with O
different B-Therapeutic_procedure
devices I-Therapeutic_procedure
Trilogy B-Detailed_description
100 I-Detailed_description
( I-Detailed_description
Philips I-Detailed_description
) I-Detailed_description
, O
Astral B-Detailed_description
150 I-Detailed_description
( I-Detailed_description
ResMed I-Detailed_description
) I-Detailed_description
, O
the O
patient O
finally O
tolerated O
mechanical B-Detailed_description
ventilation B-Therapeutic_procedure
with O
a O
home B-Detailed_description
ventilator I-Detailed_description
( O
Monnal B-Detailed_description
T-50 I-Detailed_description
, I-Detailed_description
Air I-Detailed_description
Liquide I-Detailed_description
) O
in O
a O
volume B-Detailed_description
assisted/controlled I-Detailed_description
mode I-Detailed_description
with I-Detailed_description
the I-Detailed_description
following I-Detailed_description
settings I-Detailed_description
: O
Vt B-Lab_value
80 I-Lab_value
mL I-Lab_value
( I-Lab_value
9 I-Lab_value
mL/kg I-Lab_value
) I-Lab_value
, O
PEEP B-Lab_value
10 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
, O
flow B-Lab_value
trigger I-Lab_value
0.5 I-Lab_value
L/min I-Lab_value
. O

His O
PIPs B-Diagnostic_procedure
were O
around B-Lab_value
30 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
. O

He O
did O
not O
tolerate B-Sign_symptom
a O
decrease B-Lab_value
of O
PEEP B-Diagnostic_procedure
below B-Lab_value
9 I-Lab_value
cm I-Lab_value
H2O I-Lab_value
or O
short B-Detailed_description
disconnections I-Detailed_description
from O
the O
ventilator B-Therapeutic_procedure
. O

Currently O
, O
the O
patient O
is O
19 B-Date
months I-Date
old I-Date
, O
is O
able B-Sign_symptom
to I-Sign_symptom
walk I-Sign_symptom
and O
his O
neurodevelopment B-Diagnostic_procedure
seems O
to O
be O
normal B-Lab_value
. O

A O
40-year-old B-Age
woman B-Sex
visited B-Clinical_event
the O
Department B-Nonbiological_location
of I-Nonbiological_location
Obstetrics I-Nonbiological_location
and I-Nonbiological_location
Gynecology I-Nonbiological_location
in O
our B-Nonbiological_location
hospital I-Nonbiological_location
because O
of O
a O
complaint O
of O
sudden B-Detailed_description
dyspnea B-Sign_symptom
on B-Detailed_description
effort I-Detailed_description
. O

She O
was O
previously O
diagnosed O
with O
endometriosis B-History
and O
prescribed O
a O
combination B-Detailed_description
oral B-Administration
contraceptive B-Medication
pill B-Administration
( O
drospirenone/ethinylestradiol B-Medication
betadex I-Medication
, O
trade B-Detailed_description
name I-Detailed_description
; I-Detailed_description
Yaz I-Detailed_description
™ I-Detailed_description
, O
Bayer B-Detailed_description
, I-Detailed_description
Leverkusen I-Detailed_description
, I-Detailed_description
Germany I-Detailed_description
) O
. O

Following O
the O
Kumamoto B-Other_event
Earthquakes I-Other_event
and O
subsequent O
aftershocks B-Other_event
in O
April B-Date
2016 I-Date
, O
she O
spent B-Activity
7 B-Duration
nights I-Duration
in O
a O
vehicle B-Nonbiological_location
. O

She O
noticed O
sudden B-Detailed_description
dyspnea B-Sign_symptom
on B-Detailed_description
effort I-Detailed_description
when O
she O
walked B-Clinical_event
outside B-Nonbiological_location
the O
car O
on O
the O
8th B-Date
morning I-Date
after I-Date
the O
first B-Other_event
earthquake I-Other_event
. O

Although O
she O
walked B-Activity
around I-Activity
for O
personal O
reasons O
during O
the O
daytime O
, O
she O
spent B-Activity
nights I-Activity
in O
her O
small B-Nonbiological_location
car I-Nonbiological_location
with O
her O
legs B-Biological_structure
in O
a O
hanging B-Detailed_description
position I-Detailed_description
. O

She O
noticed O
swelling B-Sign_symptom
and O
pain B-Sign_symptom
in O
her O
left B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
, O
and O
her O
serum B-Diagnostic_procedure
D-dimer I-Diagnostic_procedure
levels O
were O
13.2 B-Lab_value
μg/mL I-Lab_value
. O

Deep B-Disease_disorder
vein I-Disease_disorder
thrombosis I-Disease_disorder
( O
DVT B-Disease_disorder
) O
was O
suspected O
by O
her O
home B-Nonbiological_location
doctor I-Nonbiological_location
. O

A O
contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
- O
scan O
revealed O
a O
contrast B-Sign_symptom
deficit I-Sign_symptom
in O
the O
bilateral B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
( O
Fig. O
2A O
) O
and O
in O
the O
left B-Biological_structure
lower I-Biological_structure
extremity I-Biological_structure
( O
posterior B-Detailed_description
tibial I-Detailed_description
, I-Detailed_description
soleus I-Detailed_description
and I-Detailed_description
gastrocnemius I-Detailed_description
vein I-Detailed_description
) O
( O
Fig. O
2B O
) O
. O

Her O
right B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
function I-Diagnostic_procedure
was O
intact B-Lab_value
( O
estimated O
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
pressure I-Diagnostic_procedure
= O
29/8 B-Lab_value
mmHg I-Lab_value
in O
cardiac B-Biological_structure
ultrasound B-Diagnostic_procedure
) O
. O

Her O
plasma B-Detailed_description
brain B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
and O
high-sense B-Detailed_description
troponin B-Diagnostic_procedure
T I-Diagnostic_procedure
concentration I-Diagnostic_procedure
levels O
were O
97.2 B-Lab_value
pg/mL I-Lab_value
and O
0.0061 B-Lab_value
ng/mL I-Lab_value
, O
respectively O
. O

She O
was O
diagnosed O
with O
PTE B-Disease_disorder
and O
admitted B-Clinical_event
to O
our O
department B-Nonbiological_location
. O

On O
admission B-Clinical_event
, O
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
129/80 B-Lab_value
mmHg I-Lab_value
and O
her O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
72 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
. O

Her O
degree O
of O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
( O
SaO2 B-Diagnostic_procedure
) O
in O
arterial B-Detailed_description
blood I-Detailed_description
gas I-Detailed_description
was O
97.7 B-Lab_value
% I-Lab_value
. O

Her O
body B-Diagnostic_procedure
mass I-Diagnostic_procedure
index I-Diagnostic_procedure
was O
24.4 B-Lab_value
kg/m2 I-Lab_value
. O

Electrocardiography B-Diagnostic_procedure
and O
cardiac B-Biological_structure
ultrasound B-Diagnostic_procedure
did O
not O
indicate O
heart B-Disease_disorder
failure I-Disease_disorder
. O

An O
investigation O
of O
most O
factors B-Diagnostic_procedure
related I-Diagnostic_procedure
to I-Diagnostic_procedure
thrombus I-Diagnostic_procedure
formation I-Diagnostic_procedure
( O
including O
protein B-Diagnostic_procedure
C I-Diagnostic_procedure
, O
protein B-Diagnostic_procedure
S I-Diagnostic_procedure
, O
antithrombin B-Diagnostic_procedure
, O
and O
antiphospholipid B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
) O
revealed O
that O
all O
such O
factors O
were O
normal B-Lab_value
. O

The O
discontinuation O
of O
the O
oral B-Administration
contraceptive B-Medication
and O
the O
administration O
of O
rivaroxaban B-Medication
( O
30 B-Dosage
mg I-Dosage
, I-Dosage
daily I-Dosage
) O
, O
a O
direct B-Detailed_description
oral B-Administration
anticoagulant B-Medication
( O
trade B-Detailed_description
name I-Detailed_description
: I-Detailed_description
Xarelto I-Detailed_description
™ I-Detailed_description
, O
Bayer B-Detailed_description
) O
was O
initiated O
according B-Detailed_description
to I-Detailed_description
the I-Detailed_description
results I-Detailed_description
of I-Detailed_description
the I-Detailed_description
EINSTEIN-PE I-Detailed_description
trial I-Detailed_description
( O
3 O
) O
. O

After B-Date
7 I-Date
days I-Date
, O
a O
follow-up B-Clinical_event
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
scan O
revealed O
a O
reduction O
in O
the O
thrombosis B-Disease_disorder
( O
Fig. O
3 O
) O
. O

The O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
with O
rivaroxaban B-Medication
. O

The O
patient O
gave O
her O
consent O
for O
the O
publication O
of O
this O
study O
. O

The O
patient O
was O
a O
48-year-old B-Age
man B-Sex
who O
had O
previously O
been O
hospitalized B-Clinical_event
due O
to O
hemoptysis B-Sign_symptom
at B-Date
42 I-Date
years I-Date
of I-Date
age I-Date
. O

At O
that O
time O
, O
a O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
and O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
revealed O
diffuse B-Detailed_description
ground-glass B-Sign_symptom
opacity I-Sign_symptom
( O
GGO B-Sign_symptom
) O
in O
the O
bilateral B-Biological_structure
lung I-Biological_structure
fields O
( O
Fig. O
1,2 O
) O
, O
and O
a O
bronchoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
the O
accumulation B-Sign_symptom
of O
large B-Severity
amounts I-Severity
of O
blood B-Detailed_description
in O
the O
trachea B-Biological_structure
and O
bronchi B-Biological_structure
( O
Fig. O
3 O
) O
. O

The O
patient O
's O
bronchoalveolar B-Diagnostic_procedure
lavage I-Diagnostic_procedure
fluid I-Diagnostic_procedure
( O
BALF B-Diagnostic_procedure
) O
was O
bloody B-Lab_value
and O
contained O
numerous O
hemosiderin-laden B-Lab_value
macrophages I-Lab_value
. O

A O
culture B-Diagnostic_procedure
test I-Diagnostic_procedure
of O
the O
BALF B-Diagnostic_procedure
revealed O
no B-Lab_value
findings I-Lab_value
. O

An O
electrocardiogram B-Diagnostic_procedure
and O
transthoracic B-Biological_structure
echocardiogram B-Diagnostic_procedure
revealed O
no B-Lab_value
abnormalities I-Lab_value
. O

A O
questionnaire B-Other_event
that O
was O
completed O
at B-Date
that I-Date
time I-Date
did O
not O
reveal O
the O
patient O
's O
hemorrhagic B-Sign_symptom
episode I-Sign_symptom
or O
a O
family O
history O
of O
bleeding O
disease O
, O
with O
the O
exception O
of O
his O
younger B-Family_history
brother I-Family_history
who I-Family_history
had I-Family_history
been I-Family_history
diagnosed I-Family_history
with I-Family_history
hepatitis I-Family_history
C. I-Family_history
Furthermore O
, O
he O
had O
not O
received O
any O
drugs B-Medication
that O
had O
the O
potential B-Detailed_description
to I-Detailed_description
cause I-Detailed_description
DAH I-Detailed_description
. O

Following O
the O
above-mentioned O
examinations O
, O
DAH B-Disease_disorder
due O
to O
some O
sort O
of O
vasculitis B-Disease_disorder
was O
suspected O
. O

Thus O
, O
treatment O
with O
high-dose O
intravenous B-Administration
methylprednisolone B-Medication
( O
1,000 B-Dosage
mg I-Dosage
daily I-Dosage
) O
for O
3 B-Duration
days I-Duration
followed O
by O
prednisolone B-Medication
( O
25 B-Dosage
mg I-Dosage
daily I-Dosage
) O
was O
initiated O
. O

This O
relieved O
his O
symptoms B-Sign_symptom
. O

Chest B-Biological_structure
CT B-Diagnostic_procedure
showed O
the O
resolution O
of O
the O
GGO B-Sign_symptom
. O

The O
patient O
's O
prednisolone B-Medication
dose O
was O
tapered B-Dosage
and O
eventually O
discontinued B-Dosage
at O
two-and-a-half B-Date
years I-Date
after O
his O
discharge B-Clinical_event
from O
our O
hospital B-Nonbiological_location
. O

The O
patient O
was O
readmitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
a O
recurrence O
of O
hemoptysis B-Sign_symptom
at B-Date
46 I-Date
years I-Date
of I-Date
age I-Date
. O

The O
above-described O
therapy O
was O
initiated O
and O
led O
to O
the O
improvement B-Lab_value
of O
his O
condition B-Diagnostic_procedure
. O

The O
prednisolone B-Medication
dose O
was O
tapered B-Dosage
from O
60 B-Dosage
mg I-Dosage
daily I-Dosage
to O
a O
maintenance O
dose O
of O
5 B-Dosage
mg I-Dosage
daily I-Dosage
. O

At B-Date
48 I-Date
years I-Date
of I-Date
age I-Date
, O
he O
was O
readmitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
a O
further O
recurrence O
of O
hemoptysis B-Sign_symptom
. O

At O
this O
point O
, O
he O
had O
steroid-induced B-Medication
diabetes B-Disease_disorder
mellitus I-Disease_disorder
, O
which O
was O
treated O
with O
glimepiride B-Medication
( O
3 B-Dosage
mg I-Dosage
daily I-Dosage
) O
. O

At O
admission B-Clinical_event
, O
his O
weight B-Diagnostic_procedure
was O
75 B-Lab_value
kg I-Lab_value
and O
height B-Diagnostic_procedure
167 B-Lab_value
cm I-Lab_value
; O
his O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
as O
follows O
: O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
, O
178/102 B-Lab_value
mmHg I-Lab_value
; O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
, O
109 B-Lab_value
beats/min I-Lab_value
, O
pulse B-Diagnostic_procedure
oximetry I-Diagnostic_procedure
, O
97 B-Lab_value
% I-Lab_value
in O
room B-Detailed_description
air I-Detailed_description
; O
and O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
, O
36.8 B-Lab_value
°C I-Lab_value
. O

Chest B-Biological_structure
auscultation B-Diagnostic_procedure
revealed O
fine B-Detailed_description
crackles B-Sign_symptom
in O
the O
right B-Biological_structure
lung I-Biological_structure
field O
. O

No O
skin B-Biological_structure
rash B-Sign_symptom
, O
subcutaneous B-Biological_structure
bleeding B-Sign_symptom
or O
joint B-Biological_structure
swelling B-Sign_symptom
were O
present O
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
and O
CT B-Diagnostic_procedure
showed O
the O
presence O
of O
diffuse B-Detailed_description
GGO B-Sign_symptom
in O
the O
bilateral B-Biological_structure
lung I-Biological_structure
fields O
. O

Mild B-Severity
anemia B-Sign_symptom
was O
observed O
( O
hemoglobin B-Diagnostic_procedure
, O
11.3 B-Lab_value
g/dL I-Lab_value
) O
, O
although O
hemoglobin B-Diagnostic_procedure
levels O
had O
been O
14.6 B-Lab_value
g/dL I-Lab_value
prior O
to O
the O
hemoptysis B-Sign_symptom
episode O
. O

The O
activated B-Diagnostic_procedure
partial I-Diagnostic_procedure
thromboplastin I-Diagnostic_procedure
time I-Diagnostic_procedure
( O
APTT B-Diagnostic_procedure
) O
was O
prolonged B-Lab_value
to O
53.5 B-Lab_value
seconds I-Lab_value
( O
normal O
range O
, O
25.1-40.7 O
seconds O
) O
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
that O
the O
patient O
's O
blood B-Diagnostic_procedure
glucose I-Diagnostic_procedure
and O
hemoglobin B-Diagnostic_procedure
A1c I-Diagnostic_procedure
levels O
were O
299 B-Lab_value
mg/dL I-Lab_value
and O
8.2 B-Lab_value
% I-Lab_value
, O
respectively O
, O
due O
to O
the O
steroid-induced B-Medication
diabetes B-Disease_disorder
mellitus I-Disease_disorder
. O

Autoantibodies B-Diagnostic_procedure
for I-Diagnostic_procedure
various I-Diagnostic_procedure
collagen I-Diagnostic_procedure
diseases I-Diagnostic_procedure
were O
negative B-Lab_value
( O
Table O
) O
. O

We O
diagnosed O
the O
condition O
as O
a O
recurrence O
of O
DAH B-Disease_disorder
and O
again O
administered O
high-dose B-Dosage
intravenous B-Administration
methylprednisolone B-Medication
for O
3 B-Duration
days I-Duration
, O
followed O
by O
prednisolone B-Medication
( O
60 B-Dosage
mg I-Dosage
daily I-Dosage
) O
. O

His O
condition B-Diagnostic_procedure
improved B-Lab_value
, O
as O
had O
been O
observed O
during O
the O
previous O
episodes O
. O

A O
further O
detailed O
inquiry O
regarding O
the O
patient O
's O
medical O
history O
revealed O
that O
, O
as B-Date
an I-Date
elementary I-Date
school I-Date
student I-Date
, B-History
he I-History
had I-History
been I-History
hospitalized I-History
and O
had B-History
received I-History
blood I-History
transfusions I-History
twice I-History
following I-History
abnormally I-History
heavy I-History
bleeding I-History
after I-History
tooth I-History
extraction I-History
; O
however O
, O
a O
specific O
congenital B-Detailed_description
bleeding B-Disease_disorder
disorder I-Disease_disorder
had O
not O
been O
diagnosed O
at B-Date
that I-Date
time I-Date
. O

It O
was O
also O
revealed O
that O
his O
younger B-Family_history
brother I-Family_history
had I-Family_history
been I-Family_history
diagnosed I-Family_history
with I-Family_history
hemophilia I-Family_history
B I-Family_history
during I-Family_history
adolescence I-Family_history
. O

Considering O
the O
possibility O
of O
hemophilia B-Disease_disorder
, O
his O
blood B-Diagnostic_procedure
coagulation I-Diagnostic_procedure
factors I-Diagnostic_procedure
were O
examined O
, O
revealing O
that O
his O
factor B-Diagnostic_procedure
IX I-Diagnostic_procedure
activity I-Diagnostic_procedure
was O
3 B-Lab_value
% I-Lab_value
. O

The O
patient O
was O
subsequently O
diagnosed O
with O
moderate B-Severity
hemophilia B-Disease_disorder
B. I-Disease_disorder
By O
the O
time O
of O
this O
diagnosis O
, O
the O
patient O
's O
DAH B-Disease_disorder
had O
already O
resolved O
with O
the O
corticosteroid B-Medication
therapy I-Medication
. O

We O
decided O
to O
continue O
treating O
the O
patient O
using O
prednisolone B-Medication
alone O
, O
without O
coagulation B-Medication
factor I-Medication
IX I-Medication
replacement I-Medication
therapy I-Medication
. O

No O
recurrence O
of O
DAH B-Disease_disorder
or O
hemorrhagic B-Sign_symptom
symptoms I-Sign_symptom
have O
been O
observed O
during B-Duration
3 I-Duration
years I-Duration
since O
the O
tapering O
and O
discontinuation O
of O
prednisolone B-Medication
. O

A O
34-year-old B-Age
Japanese B-Personal_background
woman B-Sex
had O
a O
diagnosis O
of O
MCTD B-Disease_disorder
with O
the O
presence O
of O
Raynaud B-Disease_disorder
's I-Disease_disorder
phenomenon I-Disease_disorder
, O
pancytopenia B-Sign_symptom
, O
elevated B-Lab_value
plasma B-Detailed_description
creatinine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
, O
and O
antibodies B-Lab_value
against I-Lab_value
U1-ribonucleoprotein B-Diagnostic_procedure
in O
2005 B-Date
and O
received O
10 B-Dosage
mg I-Dosage
of O
prednisolone B-Medication
daily B-Dosage
. O

Pulmonary B-Diagnostic_procedure
arterial I-Diagnostic_procedure
systolic I-Diagnostic_procedure
pressure I-Diagnostic_procedure
estimated O
by O
echocardiography B-Diagnostic_procedure
was O
slightly B-Lab_value
elevated I-Lab_value
( O
48 B-Lab_value
mmHg I-Lab_value
) O
in O
2006 B-Date
. O

She O
felt O
progressive B-Detailed_description
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
on O
physical B-Activity
effort I-Activity
in O
2011 B-Date
. O

Pulmonary B-Disease_disorder
arterial I-Disease_disorder
hypertension I-Disease_disorder
was O
diagnosed O
with O
74 B-Lab_value
mmHg I-Lab_value
of O
mean B-Diagnostic_procedure
pulmonary I-Diagnostic_procedure
arterial I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
mPAP B-Diagnostic_procedure
) O
evaluated O
by O
right B-Diagnostic_procedure
heart I-Diagnostic_procedure
catheterization I-Diagnostic_procedure
( O
RHC B-Diagnostic_procedure
) O
in O
2012 B-Date
. O

Cyclophosphamide-based B-Medication
immunosuppressive I-Medication
therapy I-Medication
was O
proposed O
but O
refused O
because O
of O
possible O
early B-Detailed_description
menopausal B-Sign_symptom
symptoms I-Sign_symptom
. O

Treatment O
with O
250 B-Dosage
mg/day I-Dosage
of O
bosentan B-Medication
and O
120 B-Dosage
μg/day I-Dosage
of O
beraprost B-Medication
was O
initiated O
. O

However O
, O
in O
January B-Date
2014 I-Date
, O
her O
dyspnea B-Sign_symptom
deteriorated O
( O
WHO B-Diagnostic_procedure
functional I-Diagnostic_procedure
class I-Diagnostic_procedure
IV B-Lab_value
) O
, O
and O
she O
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
. O

A O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
low B-Lab_value
systemic B-Diagnostic_procedure
blood I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
89/61 B-Lab_value
mmHg I-Lab_value
) O
, O
tachycardia B-Sign_symptom
( O
104/min B-Lab_value
) O
, O
low B-Lab_value
blood B-Diagnostic_procedure
oxygen I-Diagnostic_procedure
level I-Diagnostic_procedure
( O
percutaneous B-Diagnostic_procedure
oxygen I-Diagnostic_procedure
saturation I-Diagnostic_procedure
( O
SpO2 B-Diagnostic_procedure
) O
95 B-Lab_value
% I-Lab_value
) O
, O
jugular B-Biological_structure
venous I-Biological_structure
distension B-Sign_symptom
, O
and O
severe B-Severity
systemic B-Detailed_description
edema B-Sign_symptom
. O

Coarse B-Detailed_description
crackles B-Sign_symptom
and O
loud B-Detailed_description
pulmonic B-Sign_symptom
valve I-Sign_symptom
closure I-Sign_symptom
sounds I-Sign_symptom
were O
detected O
. O

She O
was O
unable O
to O
undergo O
the O
6-minute B-Diagnostic_procedure
walk I-Diagnostic_procedure
test I-Diagnostic_procedure
due O
to O
severe B-Severity
dyspnea B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
examinations I-Diagnostic_procedure
showed O
elevated B-Lab_value
plasma B-Detailed_description
brain B-Diagnostic_procedure
natriuretic I-Diagnostic_procedure
peptide I-Diagnostic_procedure
( O
BNP B-Diagnostic_procedure
) O
level O
( O
929.4 B-Lab_value
pg/mL I-Lab_value
) O
, O
hypoxemia B-Sign_symptom
( O
PaO2 B-Diagnostic_procedure
62.5 B-Lab_value
mmHg I-Lab_value
, O
PaCO2 B-Diagnostic_procedure
27.1 B-Lab_value
mmHg I-Lab_value
) O
, O
and O
the O
presence B-Lab_value
of I-Lab_value
antibodies I-Lab_value
against I-Lab_value
U1-ribonucleoprotein B-Diagnostic_procedure
( O
97.9 B-Lab_value
U/mL I-Lab_value
) O
as O
well O
as O
antinuclear B-Diagnostic_procedure
antibodies I-Diagnostic_procedure
( O
1:640 B-Lab_value
, O
speckled B-Lab_value
pattern I-Lab_value
) O
. O

A O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
enlarged B-Sign_symptom
pulmonary B-Biological_structure
arteries I-Biological_structure
and O
cardiomegaly B-Sign_symptom
( O
Figure O
) O
. O

Electrocardiogram B-Diagnostic_procedure
showed O
P B-Sign_symptom
wave I-Sign_symptom
elevation I-Sign_symptom
in O
the O
V1-V2 B-Detailed_description
leads I-Detailed_description
. O

RHC B-Diagnostic_procedure
demonstrated O
elevated B-Lab_value
mPAP B-Diagnostic_procedure
( O
65 B-Lab_value
mmHg I-Lab_value
) O
with O
normal B-Lab_value
pulmonary B-Diagnostic_procedure
arterial I-Diagnostic_procedure
wedge I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
12 B-Lab_value
mmHg I-Lab_value
) O
, O
high B-Lab_value
pulmonary B-Diagnostic_procedure
vascular I-Diagnostic_procedure
resistance I-Diagnostic_procedure
( O
1,547 B-Lab_value
dyne I-Lab_value
・ I-Lab_value
sec I-Lab_value
・ I-Lab_value
cm-5 I-Lab_value
) O
, O
and O
decreased B-Lab_value
cardiac B-Diagnostic_procedure
output I-Diagnostic_procedure
( O
cardiac B-Lab_value
index I-Lab_value
1.69 I-Lab_value
L/min/m2 I-Lab_value
) O
. O

A O
ventilation/perfusion B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
no O
signs O
of O
pulmonary B-Disease_disorder
thromboembolism I-Disease_disorder
. O

No O
signs O
of O
chronic B-Disease_disorder
obstructive I-Disease_disorder
pulmonary I-Disease_disorder
disease I-Disease_disorder
or O
interstitial B-Disease_disorder
lung I-Disease_disorder
diseases I-Disease_disorder
were O
found O
with O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
. O

Her O
dyspnea B-Sign_symptom
was O
therefore O
considered O
to O
be O
due O
to O
MCTD-associated B-Disease_disorder
PAH I-Disease_disorder
which O
was O
refractory O
to O
bosentan B-Medication
and O
beraprost B-Medication
therapy O
. O

In O
addition O
to O
supportive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
with O
oxygen B-Therapeutic_procedure
supplementation I-Therapeutic_procedure
and O
diuretics B-Medication
( O
40 B-Dosage
mg/day I-Dosage
of O
furosemide B-Medication
) O
, O
initiation O
of O
60 B-Dosage
mg/day I-Dosage
of O
sildenafil B-Medication
as O
well O
as O
gradual B-Dosage
increment I-Dosage
in I-Dosage
the I-Dosage
dose I-Dosage
of O
beraprost B-Medication
was O
chosen O
as O
an O
additional O
treatment O
. O

However O
, O
her O
dyspnea B-Sign_symptom
remained O
unchanged O
, O
and O
her O
plasma B-Detailed_description
BNP B-Diagnostic_procedure
level O
increased B-Lab_value
. O

IVCY B-Medication
( O
750 B-Dosage
mg/m2 I-Dosage
, I-Dosage
every I-Dosage
4 I-Dosage
weeks I-Dosage
) O
was O
initiated O
, O
and O
the O
dose O
of O
prednisolone B-Medication
was O
increased O
to O
60 B-Dosage
mg I-Dosage
daily I-Dosage
. O

Her O
dyspnea B-Sign_symptom
then O
ameliorated O
, O
and O
she O
became O
able O
to O
undergo O
the O
6-minute B-Diagnostic_procedure
walk I-Diagnostic_procedure
test I-Diagnostic_procedure
( O
260 B-Lab_value
m I-Lab_value
, O
minimum B-Diagnostic_procedure
SpO2 I-Diagnostic_procedure
95 B-Lab_value
% I-Lab_value
) O
. O

Her O
plasma B-Detailed_description
BNP B-Diagnostic_procedure
level O
also O
decreased B-Lab_value
after O
the O
initiation O
of O
IVCY B-Medication
( O
Figure O
) O
. O

Six B-Date
months I-Date
after I-Date
the O
admission B-Clinical_event
, O
a O
follow-up O
RHC B-Diagnostic_procedure
revealed O
improved B-Lab_value
mPAP B-Diagnostic_procedure
( O
65 O
to O
53 B-Lab_value
mmHg I-Lab_value
) O
, O
pulmonary B-Diagnostic_procedure
vascular I-Diagnostic_procedure
resistance I-Diagnostic_procedure
( O
1,547 O
to O
1,116 B-Lab_value
dyne I-Lab_value
・ I-Lab_value
sec I-Lab_value
・ I-Lab_value
cm-5 I-Lab_value
) O
, O
and O
cardiac B-Diagnostic_procedure
index I-Diagnostic_procedure
( O
1.69 O
to O
1.83 B-Lab_value
L/min/m2 I-Lab_value
) O
( O
Table O
) O
. O

Since O
she O
remained O
stable B-Sign_symptom
but O
did O
not O
obtain O
further O
improvements O
18 B-Date
months I-Date
after I-Date
the O
admission B-Clinical_event
( O
Table O
) O
, O
we O
consider O
parenteral B-Administration
prostanoids B-Medication
or O
lung B-Therapeutic_procedure
transplantation I-Therapeutic_procedure
as O
a O
subsequent O
treatment O
. O

A O
22-year-old B-Age
Tibetan B-Personal_background
man B-Sex
without B-History
significant I-History
past I-History
medical I-History
history I-History
was O
diagnosed O
with O
pulmonary B-Disease_disorder
tuberculosis I-Disease_disorder
( O
PTB B-Disease_disorder
) O
in O
a O
routine B-Detailed_description
medical O
examination B-Diagnostic_procedure
and O
received O
anti-TB B-Medication
therapy I-Medication
that O
included O
isoniazid B-Medication
( O
INH B-Medication
, O
300 B-Dosage
mg/d I-Dosage
) O
, O
RMP B-Medication
( O
450 B-Dosage
mg/d I-Dosage
) O
, O
ethambutol B-Medication
( O
EMB B-Medication
, O
750 B-Dosage
mg/d I-Dosage
) O
, O
and O
pyrazinamide B-Medication
( O
PZA B-Medication
, O
1500 B-Dosage
mg/d I-Dosage
) O
. O

After O
1 B-Duration
week I-Duration
of O
continuous O
therapy B-Coreference
, O
he O
was O
admitted B-Clinical_event
to O
the O
Tibet B-Nonbiological_location
People I-Nonbiological_location
's I-Nonbiological_location
Hospital I-Nonbiological_location
with O
nasal B-Biological_structure
hemorrhage B-Sign_symptom
and O
the O
platelet B-Diagnostic_procedure
( O
PLT B-Diagnostic_procedure
) O
count O
was O
0.4 B-Lab_value
× I-Lab_value
109/L I-Lab_value
( O
normal O
range O
, O
100 O
– O
300 O
× O
109/L O
) O
. O

Epistaxis B-Sign_symptom
was O
cured O
after O
symptomatic B-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O

Two B-Date
days I-Date
later I-Date
, O
he O
developed O
hematochezia B-Sign_symptom
, O
hematuria B-Sign_symptom
, O
and O
purpura B-Sign_symptom
, O
and O
required O
transfusion B-Therapeutic_procedure
of O
fresh-frozen B-Medication
plasma I-Medication
and O
platelets B-Medication
in O
another B-Nonbiological_location
local I-Nonbiological_location
hospital I-Nonbiological_location
. O

Four B-Date
days I-Date
later I-Date
( O
November B-Date
18 I-Date
, I-Date
2015 I-Date
) O
, O
he O
was O
transferred B-Clinical_event
to O
the O
West B-Nonbiological_location
China I-Nonbiological_location
Hospital I-Nonbiological_location
due O
to O
the O
ineffective B-Qualitative_concept
treatment B-Therapeutic_procedure
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
he O
presented O
with O
pallor B-Sign_symptom
, O
mild B-Severity
jaundice B-Sign_symptom
on O
the O
sclera B-Biological_structure
, O
purpura B-Sign_symptom
, O
tachycardia B-Sign_symptom
( O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
132/min B-Lab_value
) O
and O
weak B-Sign_symptom
breath I-Sign_symptom
sounds I-Sign_symptom
at O
the O
base B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
lung I-Biological_structure
. O

Laboratory B-Diagnostic_procedure
results I-Diagnostic_procedure
on O
admission B-Clinical_event
indicated O
DIC B-Disease_disorder
: O
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
( O
17.8 B-Lab_value
seconds I-Lab_value
; O
normal O
range O
, O
9.6 O
– O
12.8 O
seconds O
) O
, O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
1.53 B-Lab_value
; O
normal O
range O
, O
0.88 O
– O
1.15 O
) O
, O
fibrinogen B-Diagnostic_procedure
( O
1.13 B-Lab_value
g/L I-Lab_value
; O
normal O
range O
, O
2.0 O
– O
4.0 O
g/L O
) O
, O
D-dimers B-Diagnostic_procedure
( O
23.45 B-Lab_value
mg/L I-Lab_value
; O
normal O
range O
, O
< O
0.55 O
mg/L O
) O
, O
fibrin B-Diagnostic_procedure
degradation I-Diagnostic_procedure
product I-Diagnostic_procedure
( O
60.4 B-Lab_value
mg/L I-Lab_value
; O
normal O
range O
, O
< O
5 O
mg/L O
) O
, O
and O
PLT B-Diagnostic_procedure
( O
2 B-Lab_value
× I-Lab_value
109/L I-Lab_value
; O
normal O
range O
, O
100 O
– O
300 O
× O
109/L O
) O
. O

Other O
abnormal O
data O
were O
as O
follows O
: O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
( O
WBC B-Diagnostic_procedure
, O
48.38 B-Lab_value
× I-Lab_value
109/L I-Lab_value
; O
normal O
range O
, O
3.5 O
– O
9.5 O
) O
, O
hemoglobin B-Diagnostic_procedure
( O
65 B-Lab_value
g/L I-Lab_value
; O
normal O
range O
, O
130 O
– O
175 O
g/L O
) O
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
30.8 B-Lab_value
umol/L I-Lab_value
; O
normal O
range O
, O
5.0 O
– O
28.0 O
umol/L O
) O
, O
direct B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
16.6 B-Lab_value
umol/L I-Lab_value
; O
normal O
range O
, O
< O
8.8 O
umol/L O
) O
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
75 B-Lab_value
U/L I-Lab_value
; O
normal O
range O
, O
< O
40 O
U/L O
) O
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
( O
293 B-Lab_value
U/L I-Lab_value
; O
normal O
range O
, O
< O
50 O
U/L O
) O
, O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
( O
380 B-Lab_value
U/L I-Lab_value
; O
normal O
range O
, O
110 O
– O
220 O
U/L O
) O
, O
serum B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
( O
13.01 B-Lab_value
mmol/L I-Lab_value
; O
normal O
range O
, O
3.2 O
– O
7.79 O
mmol/L O
) O
, O
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
16.70 B-Lab_value
mg/L I-Lab_value
; O
normal O
range O
, O
< O
5 O
mg/L O
) O
, O
complement B-Diagnostic_procedure
3 I-Diagnostic_procedure
( O
0.41 B-Lab_value
g/L I-Lab_value
; O
normal O
range O
, O
0.785 O
– O
1.520 O
g/L O
) O
, O
and O
complement B-Diagnostic_procedure
4 I-Diagnostic_procedure
( O
0.0797 B-Lab_value
g/L I-Lab_value
; O
normal O
range O
, O
0.145 O
– O
0.360 O
g/L O
) O
. O

Routine O
urine B-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
blood B-Diagnostic_procedure
cell I-Diagnostic_procedure
> B-Lab_value
330 I-Lab_value
Cell/uL I-Lab_value
, O
leukocyte B-Diagnostic_procedure
250 B-Lab_value
Cell/uL I-Lab_value
, O
protein B-Diagnostic_procedure
2 B-Lab_value
g/L I-Lab_value
, O
and O
urobilinogen B-Diagnostic_procedure
70 B-Lab_value
umol/L I-Lab_value
. O

Routine O
stool B-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
red B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
4 B-Lab_value
+ I-Lab_value
/ I-Lab_value
HP I-Lab_value
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
1 B-Lab_value
+ I-Lab_value
/ I-Lab_value
HP I-Lab_value
, O
occult B-Diagnostic_procedure
blood I-Diagnostic_procedure
test I-Diagnostic_procedure
( O
+ B-Lab_value
) O
. O

T-SPOT B-Diagnostic_procedure
result O
was O
positive B-Lab_value
. O

Real-time B-Detailed_description
polymerase I-Detailed_description
chain I-Detailed_description
reaction I-Detailed_description
analysis B-Diagnostic_procedure
for I-Diagnostic_procedure
mycobacterium I-Diagnostic_procedure
TB I-Diagnostic_procedure
on O
sputum B-Detailed_description
was O
positive B-Lab_value
. O

Acid B-Diagnostic_procedure
fast I-Diagnostic_procedure
stain I-Diagnostic_procedure
test I-Diagnostic_procedure
of O
a O
sputum B-Detailed_description
smear I-Detailed_description
was O
negative B-Lab_value
. O

Chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
on O
admission B-Clinical_event
( O
November B-Date
18 I-Date
, I-Date
2015 I-Date
) O
( O
Fig. O
1 O
) O
showed O
infiltrates B-Sign_symptom
on O
the O
upper B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
lung I-Biological_structure
, O
left B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
, O
and O
pericardial B-Disease_disorder
effusion I-Disease_disorder
, O
accompanied O
by O
enlargement B-Sign_symptom
of O
mediastinal B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
small B-Qualitative_concept
amount I-Qualitative_concept
of O
fluid B-Sign_symptom
adjacent O
to O
the O
liver B-Biological_structure
and O
spleen B-Biological_structure
. O

Serologic B-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
negative B-Lab_value
for O
acute B-Detailed_description
or O
chronic B-Detailed_description
viral B-Disease_disorder
hepatitis I-Disease_disorder
, O
HIV B-Disease_disorder
, O
direct B-Diagnostic_procedure
Coomb I-Diagnostic_procedure
test I-Diagnostic_procedure
, O
and O
autoimmune B-Disease_disorder
hepatitis I-Disease_disorder
. O

Peripheral B-Detailed_description
blood I-Detailed_description
film B-Diagnostic_procedure
and I-Diagnostic_procedure
culture I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Bone B-Detailed_description
marrow I-Detailed_description
smear B-Diagnostic_procedure
and I-Diagnostic_procedure
medulloculture I-Diagnostic_procedure
were O
also O
negative B-Lab_value
. O

The O
antituberculosis B-Medication
drugs I-Medication
were O
discontinued O
immediately O
after O
admission B-Clinical_event
. O

Besides O
fasting B-Therapeutic_procedure
, O
he O
was O
initiated O
with O
infusion B-Administration
of O
fresh-frozen B-Detailed_description
plasma B-Medication
, O
platelet B-Medication
, O
packed B-Medication
red I-Medication
blood I-Medication
cells I-Medication
, O
intravenous B-Administration
immune B-Medication
globulin I-Medication
, O
recombinant B-Detailed_description
human B-Medication
thrombopoietin I-Medication
, O
omeprazole B-Medication
, O
and O
polyene B-Medication
phosphatidylcholine I-Medication
as O
well O
as O
nutrition B-Therapeutic_procedure
supportive I-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O

Five B-Date
days I-Date
after I-Date
fasting B-Therapeutic_procedure
( O
November B-Date
23 I-Date
, I-Date
2015 I-Date
) O
, O
the O
patient O
started O
a O
therapy O
consisting O
of O
EMB B-Medication
, O
moxifloxacin B-Medication
, O
and O
amikacin B-Medication
, O
while O
he O
had O
no O
further O
active O
hemorrhage B-Sign_symptom
. O

Eight B-Date
days I-Date
after I-Date
admission B-Clinical_event
( O
November B-Date
26 I-Date
, I-Date
2015 I-Date
) O
, O
the O
platelet B-Diagnostic_procedure
counts O
had O
risen B-Lab_value
gradually O
. O

INH B-Medication
( O
200 B-Dosage
mg/d I-Dosage
, O
intravenously B-Administration
guttae I-Administration
) O
was O
administered O
on O
24 B-Date
days I-Date
after I-Date
admission B-Clinical_event
( O
December B-Date
11 I-Date
, I-Date
2015 I-Date
) O
, O
while O
his O
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
and O
platelet B-Diagnostic_procedure
counts O
returned O
to O
normal B-Lab_value
. O

The O
main O
laboratory B-Diagnostic_procedure
features I-Diagnostic_procedure
are O
summarized O
in O
Table O
1 O
. O

One B-Date
month I-Date
later I-Date
( O
December B-Date
17 I-Date
, I-Date
2015 I-Date
) O
, O
reviewed O
chest B-Biological_structure
CT B-Diagnostic_procedure
( O
Fig. O
1 O
) O
indicated O
the O
infiltration B-Sign_symptom
, O
hydrothorax B-Sign_symptom
, O
and O
pericardial B-Disease_disorder
effusion I-Disease_disorder
were O
absorbed O
well O
. O

Almost O
about B-Date
4 I-Date
weeks I-Date
after I-Date
admission B-Clinical_event
, O
the O
patient O
recovered B-Outcome
and O
left B-Clinical_event
hospital I-Clinical_event
with O
INH B-Medication
( O
300 B-Dosage
mg/d I-Dosage
) O
, O
EMB B-Medication
( O
750 B-Dosage
mg/d I-Dosage
) O
, O
levofloxacin B-Medication
( O
500 B-Dosage
mg/d I-Dosage
) O
, O
and O
streptomycin B-Medication
( O
750,000 B-Dosage
U/d I-Dosage
, O
intramuscular B-Administration
injection I-Administration
) O
. O

There O
was O
no O
recurrence O
of O
DIC B-Disease_disorder
or O
hemorrhage B-Sign_symptom
during O
8 B-Duration
months I-Duration
of O
follow-up B-Clinical_event
. O

Unfortunately O
, O
the O
patient O
refused O
a O
follow-up O
chest B-Biological_structure
CT B-Diagnostic_procedure
after O
his O
discharge B-Clinical_event
. O

Table O
2 O
shows O
the O
timeline O
of O
this O
case O
. O

A O
34-year-old B-Age
Hispanic B-Personal_background
male B-Sex
without B-History
significant I-History
past I-History
medical I-History
history I-History
presented B-Clinical_event
to O
our O
hospital B-Nonbiological_location
with O
a O
one B-Duration
month I-Duration
history O
of O
cough B-Sign_symptom
; O
productive O
of O
whitish B-Color
sputum B-Sign_symptom
. O

At O
presentation O
, O
he O
denied O
fever B-Sign_symptom
, O
chills B-Sign_symptom
, O
night B-Sign_symptom
sweats I-Sign_symptom
, O
chest B-Biological_structure
pain B-Sign_symptom
, O
hemoptysis B-Sign_symptom
, O
back B-Biological_structure
pain B-Sign_symptom
, O
recent B-Detailed_description
travel B-Clinical_event
or O
sick B-Detailed_description
contacts B-Clinical_event
. O

He O
reported O
that O
he O
had O
approximately O
a O
15 B-Lab_value
– I-Lab_value
20 I-Lab_value
pound I-Lab_value
weight B-Sign_symptom
loss I-Sign_symptom
during O
the O
last B-Duration
six I-Duration
months I-Duration
. O

He O
denied B-History
smoking I-History
, O
socially O
drank B-History
alcohol I-History
, O
and O
had B-History
unprotected I-History
sexual I-History
intercourse I-History
with I-History
multiple I-History
partners I-History
in O
the O
past O
. O

On O
admission O
, O
his O
temperature B-Diagnostic_procedure
was O
97.9 B-Lab_value
°F I-Lab_value
; O
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
85 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
respiratory B-Diagnostic_procedure
rate I-Diagnostic_procedure
was O
16 B-Lab_value
breaths I-Lab_value
per I-Lab_value
minute I-Lab_value
, O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
107/66 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
and O
oxygen B-Diagnostic_procedure
saturation I-Diagnostic_procedure
was O
100 B-Lab_value
% I-Lab_value
on O
room B-Detailed_description
air I-Detailed_description
. O

Examination B-Diagnostic_procedure
showed O
oral B-Biological_structure
thrush B-Sign_symptom
, O
decreased B-Lab_value
breath B-Diagnostic_procedure
sounds I-Diagnostic_procedure
and O
crackles B-Sign_symptom
on O
the O
right B-Biological_structure
lower I-Biological_structure
lung I-Biological_structure
base I-Biological_structure
. O

No O
cutaneous B-Biological_structure
lesions B-Sign_symptom
were O
reported O
and O
the O
rest O
of O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O

His O
complete B-Diagnostic_procedure
blood I-Diagnostic_procedure
count I-Diagnostic_procedure
( O
CBC B-Diagnostic_procedure
) O
showed O
hemoglobin B-Diagnostic_procedure
of O
9.7 B-Lab_value
g/dL I-Lab_value
, O
WBCs B-Diagnostic_procedure
2.3 B-Lab_value
× I-Lab_value
109/L I-Lab_value
, O
and O
platelets B-Diagnostic_procedure
of O
164 B-Lab_value
× I-Lab_value
109/L I-Lab_value
. O

His O
creatinine B-Diagnostic_procedure
was O
0.62 B-Lab_value
mg/dL I-Lab_value
, O
and O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
was O
10 B-Lab_value
mg/dL I-Lab_value
. O

Radiograph B-Diagnostic_procedure
of O
the O
chest B-Biological_structure
showed O
extensive B-Severity
right B-Biological_structure
and O
left B-Biological_structure
perihilar B-Biological_structure
opacity B-Sign_symptom
more B-Biological_structure
on I-Biological_structure
the I-Biological_structure
right I-Biological_structure
side I-Biological_structure
, O
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
of O
the O
chest B-Biological_structure
showed O
a O
right B-Biological_structure
sided I-Biological_structure
large B-Severity
perihilar B-Biological_structure
mass B-Sign_symptom
( O
Figure O
1 O
) O
with O
multiple B-Detailed_description
thoracic B-Biological_structure
and O
lumbar B-Biological_structure
vertebrae B-Biological_structure
, O
ribs B-Biological_structure
, O
and O
sternal B-Biological_structure
tiny B-Severity
lytic B-Detailed_description
lesions B-Sign_symptom
consistent O
with O
bony B-Biological_structure
metastasis B-Disease_disorder
( O
Figure O
2 O
) O
. O

Blood B-Biological_structure
and O
sputum B-Biological_structure
cultures B-Diagnostic_procedure
were O
negative B-Lab_value
. O

Tuberculosis B-Disease_disorder
was O
ruled O
out O
by O
three B-Detailed_description
consecutive I-Detailed_description
negative B-Lab_value
sputum B-Diagnostic_procedure
smears I-Diagnostic_procedure
for O
acid B-Detailed_description
fast I-Detailed_description
bacilli I-Detailed_description
and O
a O
negative B-Lab_value
QUANTIferon B-Diagnostic_procedure
gold I-Diagnostic_procedure
test I-Diagnostic_procedure
. O

He O
tested O
positive B-Lab_value
for O
human B-Diagnostic_procedure
immunodeficiency I-Diagnostic_procedure
virus I-Diagnostic_procedure
( O
HIV B-Diagnostic_procedure
) O
and O
his O
CD4 B-Diagnostic_procedure
counts I-Diagnostic_procedure
came O
back O
at O
7 B-Lab_value
cells/uL I-Lab_value
. O

He O
was O
started O
on O
prophylaxis B-Therapeutic_procedure
with O
bactrim B-Medication
80 B-Dosage
– I-Dosage
160 I-Dosage
mg I-Dosage
daily I-Dosage
and O
azithromycin B-Medication
1200 B-Dosage
mg I-Dosage
weekly I-Dosage
for O
opportunistic O
infections O
. O

Bronchoscopy B-Diagnostic_procedure
with O
biopsy B-Diagnostic_procedure
was O
performed O
but O
was O
unrevealing B-Lab_value
and O
he O
underwent O
a O
video B-Detailed_description
assisted I-Detailed_description
mediastinoscopy B-Diagnostic_procedure
with O
biopsies B-Diagnostic_procedure
of O
the O
right B-Biological_structure
hilar I-Biological_structure
mass B-Sign_symptom
. O

Pathology B-Diagnostic_procedure
showed O
spindle B-Sign_symptom
cells I-Sign_symptom
positive B-Lab_value
for O
CD34 B-Diagnostic_procedure
, O
BCL2 B-Diagnostic_procedure
, O
vimentin B-Diagnostic_procedure
, O
and O
HHV-8 B-Diagnostic_procedure
with O
diffuse B-Detailed_description
positivity B-Lab_value
for O
CD31 B-Diagnostic_procedure
diagnostic O
of O
KS B-Disease_disorder
. O

He O
started O
treatment O
with O
HAART B-Medication
in O
the O
form O
of O
emtricitabine B-Medication
and I-Medication
tenofovir I-Medication
disoproxil I-Medication
fumarate I-Medication
200/300 B-Lab_value
mg I-Lab_value
and O
dolutegravir B-Medication
50 B-Lab_value
mg I-Lab_value
. O

The O
patient O
was O
actively B-Detailed_description
involved I-Detailed_description
in O
decisions B-Clinical_event
regarding O
management B-Detailed_description
options I-Detailed_description
. O

He O
favored O
HAART B-Medication
isolated O
regimen O
without O
additional B-Medication
chemotherapy I-Medication
. O

His O
condition O
showed O
continuing O
clinical B-Sign_symptom
improvement I-Sign_symptom
; O
a O
repeat O
CT B-Diagnostic_procedure
scan O
of O
the O
chest B-Biological_structure
at O
three B-Date
months I-Date
showed O
profound O
regression B-Sign_symptom
of O
the O
disease O
with O
disappearance O
of O
most O
of O
the O
lesions B-Sign_symptom
( O
Figure O
3 O
) O
. O

A O
31-year-old B-Age
man B-Sex
developed O
diabetes B-Disease_disorder
insipidus I-Disease_disorder
with O
urine B-Diagnostic_procedure
volume I-Diagnostic_procedure
up O
to O
10 B-Volume
to I-Volume
20 I-Volume
L I-Volume
every B-Frequency
24 I-Frequency
hours I-Frequency
in O
2003 B-Date
. O

Four B-Date
years I-Date
later I-Date
, O
he O
complained O
of O
fatigue B-Sign_symptom
, O
anorexia B-Sign_symptom
, O
jaundice B-Sign_symptom
and O
pruritus B-Sign_symptom
, O
and O
a O
symptomatic B-Detailed_description
occipital B-Biological_structure
mass B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
showed O
an O
abnormal B-Lab_value
liver B-Diagnostic_procedure
enzyme I-Diagnostic_procedure
( O
Table O
1 O
) O
, O
the O
patient O
was O
negative B-Lab_value
for O
hepatitis B-Diagnostic_procedure
viruses I-Diagnostic_procedure
. O

As O
shown O
in O
Fig. O
1 O
, O
abdominal B-Biological_structure
MRI B-Diagnostic_procedure
showed O
multiple B-Detailed_description
low-density B-Detailed_description
lesions B-Sign_symptom
in O
the O
liver B-Biological_structure
on O
the O
T1-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
and O
obvious B-Severity
expansion B-Sign_symptom
of O
the O
intrahepatic B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
on O
the O
T2-weighted B-Diagnostic_procedure
image I-Diagnostic_procedure
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
cholangiopancreatography I-Diagnostic_procedure
revealed O
multifocal B-Detailed_description
intrahepatic B-Biological_structure
bile I-Biological_structure
duct I-Biological_structure
strictures B-Sign_symptom
and O
dilatation B-Sign_symptom
, O
but O
the O
common B-Diagnostic_procedure
hepatic I-Diagnostic_procedure
duct I-Diagnostic_procedure
was O
normal B-Lab_value
, O
it O
was O
highly O
suggestive O
of O
SC B-Disease_disorder
. O

The O
neurohypophyseal B-Biological_structure
area I-Biological_structure
MRI B-Diagnostic_procedure
showed O
the O
thickened B-Sign_symptom
hypothalamic B-Biological_structure
nuclei I-Biological_structure
and O
a O
low-density B-Detailed_description
signal B-Sign_symptom
of O
4.9 B-Area
× I-Area
5.6 I-Area
mm I-Area
in O
size O
in O
the O
hypothalamic-pituitary B-Biological_structure
area I-Biological_structure
. O

A O
multisystem B-Detailed_description
, O
high-risk B-Severity
organ B-Detailed_description
LCH B-Disease_disorder
was O
confirmed O
after O
occipital B-Biological_structure
mass B-Sign_symptom
was O
biopsied B-Diagnostic_procedure
in O
the O
local B-Nonbiological_location
hospital I-Nonbiological_location
, O
the O
patient O
was O
given O
ursodeoxycholic B-Medication
acid I-Medication
150 B-Dosage
mg I-Dosage
3 I-Dosage
times I-Dosage
a I-Dosage
day I-Dosage
. O

Then O
, O
he O
began O
to O
receive O
a O
course O
of O
COEP B-Medication
chemotherapy I-Medication
( O
cyclophosphamide B-Medication
, O
1000 B-Dosage
mg I-Dosage
; O
vincristine B-Medication
, O
2 B-Dosage
mg I-Dosage
; O
epirubicin B-Medication
, O
90 B-Dosage
mg I-Dosage
; O
and O
prednisone B-Medication
, O
90 B-Dosage
mg I-Dosage
) O
in O
2009 B-Date
. O

However O
, O
on O
the O
5th B-Date
day I-Date
of O
the O
1st O
COEP B-Medication
chemotherapy I-Medication
, O
the O
patient O
appeared O
to O
severe B-Severity
liver B-Biological_structure
function B-Disease_disorder
injury I-Disease_disorder
with O
an O
obvious B-Severity
increase B-Lab_value
of O
serum B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
( O
Table O
1 O
) O
. O

He O
refused O
further O
chemotherapy B-Medication
. O

One B-Date
year I-Date
later I-Date
, O
the O
patient O
developed O
liver B-Biological_structure
decompensation B-Disease_disorder
with O
bleeding B-Detailed_description
esophageal B-Biological_structure
varices B-Sign_symptom
, O
ascites B-Sign_symptom
, O
and O
splenomegaly B-Sign_symptom
, O
and O
he O
was O
referred B-Clinical_event
to O
LT B-Therapeutic_procedure
( O
Model B-Diagnostic_procedure
for I-Diagnostic_procedure
End I-Diagnostic_procedure
Stage I-Diagnostic_procedure
Liver I-Diagnostic_procedure
Disease I-Diagnostic_procedure
score O
17 B-Lab_value
) O
. O

He O
underwent O
successful O
orthotopic B-Detailed_description
LT B-Therapeutic_procedure
in O
November B-Date
2011 I-Date
in O
our O
center B-Nonbiological_location
, O
and O
the O
donor B-Subject
came O
from O
voluntary B-Detailed_description
deceased I-Detailed_description
citizen I-Detailed_description
organ O
donation O
in O
China B-Nonbiological_location
. O

Liver B-Diagnostic_procedure
histopathology I-Diagnostic_procedure
after O
LT B-Therapeutic_procedure
revealed O
micronodular B-Detailed_description
cirrhosis B-Disease_disorder
with O
SC B-Disease_disorder
and O
positive B-Lab_value
immunostaining B-Diagnostic_procedure
( O
CD1a B-Diagnostic_procedure
and O
S100 B-Diagnostic_procedure
) O
, O
suggestive O
of O
LCH B-Disease_disorder
involving O
in O
the O
liver B-Biological_structure
( O
Fig. O
2 O
) O
. O

Postoperatively O
, O
the O
man O
continued O
to O
be O
immunosuppressed B-Disease_disorder
with O
tacrolimus B-Medication
and O
mycofenolate B-Medication
mofetil I-Medication
. O

The O
patient O
is O
currently O
well B-Sign_symptom
with O
normal B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
no O
evidence O
of O
recurrence B-Sign_symptom
of O
LCH B-Disease_disorder
for O
4 B-Date
and I-Date
a I-Date
half I-Date
years I-Date
follow-up B-Clinical_event
. O

On O
December B-Date
28 I-Date
, I-Date
2014 I-Date
, O
a O
70-year-old B-Age
man B-Sex
complaining O
of O
abdominal B-Biological_structure
pain B-Sign_symptom
, O
dizziness B-Sign_symptom
, O
and O
nausea B-Sign_symptom
was O
referred B-Clinical_event
to O
the O
Hebei B-Nonbiological_location
General I-Nonbiological_location
Hospital I-Nonbiological_location
, I-Nonbiological_location
Hebei I-Nonbiological_location
, I-Nonbiological_location
China I-Nonbiological_location
. O

Gastroscopy B-Diagnostic_procedure
showed O
irregular B-Shape
hemorrhagic B-Detailed_description
ulcerative B-Disease_disorder
lesions I-Disease_disorder
extending O
from O
the O
gastric B-Biological_structure
body I-Biological_structure
to O
the O
lesser B-Biological_structure
curvature I-Biological_structure
and O
pyloric B-Disease_disorder
stenosis I-Disease_disorder
of O
the O
stomach B-Biological_structure
. O

Gastric B-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
adenocarcinoma B-Disease_disorder
. O

On O
January B-Date
7 I-Date
, I-Date
2015 I-Date
, O
palliative B-Detailed_description
gastrectomy B-Therapeutic_procedure
plus O
Roux-en-Y B-Therapeutic_procedure
near O
esophagojejunostomy B-Therapeutic_procedure
were O
performed O
. O

Diffuse B-Qualitative_concept
enlarged B-Qualitative_concept
para-aortic B-Biological_structure
and O
anterior B-Biological_structure
superior B-Biological_structure
pancreatic B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
, O
as O
well O
as O
lymph B-Biological_structure
nodes I-Biological_structure
around O
the O
common B-Biological_structure
hepatic I-Biological_structure
artery I-Biological_structure
, O
could O
not O
be O
resected B-Therapeutic_procedure
. O

Postoperative O
pathology B-Diagnostic_procedure
demonstrated O
moderately B-Severity
differentiated I-Severity
gastric B-Disease_disorder
adenocarcinoma I-Disease_disorder
( O
Fig. O
1A O
) O
. O

Immunohistochemistry B-Diagnostic_procedure
showed O
the O
following O
: O
human B-Diagnostic_procedure
epidermal I-Diagnostic_procedure
growth I-Diagnostic_procedure
factor I-Diagnostic_procedure
receptor I-Diagnostic_procedure
2 I-Diagnostic_procedure
( O
HER-2 B-Diagnostic_procedure
) O
( O
+ B-Lab_value
) O
, O
vascular B-Diagnostic_procedure
endothelial I-Diagnostic_procedure
growth I-Diagnostic_procedure
factor I-Diagnostic_procedure
( O
VEGF B-Diagnostic_procedure
) O
( O
+ B-Lab_value
) O
, O
CD31 B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
CD105 B-Diagnostic_procedure
( O
+ B-Lab_value
) O
( O
Fig. O
1B O
– O
E O
) O
, O
triple B-Diagnostic_procedure
positive I-Diagnostic_procedure
( O
TP B-Diagnostic_procedure
) O
( O
+ B-Lab_value
) O
, O
glutathione B-Diagnostic_procedure
S-transferase I-Diagnostic_procedure
π I-Diagnostic_procedure
( O
GST-π B-Diagnostic_procedure
) O
( O
+ B-Lab_value
+ I-Lab_value
+ I-Lab_value
) O
, O
topoisomerase B-Diagnostic_procedure
enzyme I-Diagnostic_procedure
II I-Diagnostic_procedure
α I-Diagnostic_procedure
( O
TOPOII B-Diagnostic_procedure
α I-Diagnostic_procedure
) O
, O
P53 B-Diagnostic_procedure
( O
– B-Lab_value
) O
, O
and O
Ki-67 B-Diagnostic_procedure
( O
70 B-Lab_value
% I-Lab_value
) O
. O

The O
diagnosis O
was O
stage B-Severity
IV I-Severity
gastric B-Disease_disorder
adenocarcinoma I-Disease_disorder
with O
multiple B-Qualitative_concept
lymphnodes B-Biological_structure
metastases B-Disease_disorder
( O
T4N2M1 B-Severity
) O
. O

The O
patient O
was O
administered O
1 B-Dosage
cycle B-Therapeutic_procedure
of I-Therapeutic_procedure
chemotherapy I-Therapeutic_procedure
with O
oxaliplatin B-Medication
and O
S-1 B-Medication
; O
however O
, O
the O
treatment O
was O
terminated B-Detailed_description
, O
as O
the O
patient O
could O
not O
tolerate O
the O
associated O
gastrointestinal B-Sign_symptom
disturbances I-Sign_symptom
. O

On O
February B-Date
2 I-Date
, I-Date
2015 I-Date
, O
adjuvant B-Therapeutic_procedure
radiotherapy I-Therapeutic_procedure
was O
administered O
. O

Before O
radiotherapy O
, O
positron-emission B-Diagnostic_procedure
tomography I-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET-CT B-Diagnostic_procedure
) O
showed O
extensive B-Severity
distant B-Detailed_description
metastasis B-Disease_disorder
( O
left B-Biological_structure
supraclavicular I-Biological_structure
and O
mediastinal B-Biological_structure
lymph B-Biological_structure
nodes I-Biological_structure
, O
and O
lymph B-Biological_structure
nodes I-Biological_structure
throughout O
the O
abdominal B-Biological_structure
cavity I-Biological_structure
) O
. O

The O
patient O
's O
Eastern B-Diagnostic_procedure
Cooperative I-Diagnostic_procedure
Oncology I-Diagnostic_procedure
Group I-Diagnostic_procedure
( O
ECOG B-Diagnostic_procedure
) O
performance O
status O
was O
2 B-Lab_value
, O
and O
his O
body B-Diagnostic_procedure
mass I-Diagnostic_procedure
index I-Diagnostic_procedure
( O
BMI B-Diagnostic_procedure
) O
was O
19 B-Lab_value
; O
therefore O
, O
he O
was O
considered O
to O
be O
at O
risk O
of O
malnutrition B-Sign_symptom
. O

Oral B-Administration
apatinib B-Medication
850 B-Dosage
mg I-Dosage
once B-Frequency
a I-Frequency
day I-Frequency
combined O
with O
and O
following O
radiotherapy B-Therapeutic_procedure
was O
prescribed B-Clinical_event
. O

Informed O
consent O
was O
obtained O
from O
the O
patient O
prior O
to O
treatment O
. O

In O
an O
attempt O
to O
improve O
tolerance O
to O
treatment O
, O
palliative B-Detailed_description
intensity B-Therapeutic_procedure
modulated I-Therapeutic_procedure
radiation I-Therapeutic_procedure
therapy I-Therapeutic_procedure
( O
IMRT B-Therapeutic_procedure
) O
was O
used O
. O

The O
patient O
received O
a O
dose O
of O
64 B-Dosage
Gy I-Dosage
in I-Dosage
30 I-Dosage
fractions I-Dosage
to O
the O
mediastinum B-Biological_structure
and O
doses O
of O
52 B-Dosage
Gy I-Dosage
in I-Dosage
26 I-Dosage
fractions I-Dosage
to O
the O
other O
abdominal B-Biological_structure
metastatic B-Disease_disorder
lesions I-Disease_disorder
( O
n O
= O
5 O
) O
. O

The O
left B-Biological_structure
supraclavicular I-Biological_structure
lymph B-Biological_structure
node I-Biological_structure
was O
treated O
with O
apatinib B-Medication
alone O
( O
Figs. O
2 O
and O
3A O
– O
C O
) O
. O

A O
PET-CT B-Diagnostic_procedure
scan O
performed O
2 B-Date
weeks I-Date
after I-Date
radiotherapy I-Date
showed O
an O
80 B-Lab_value
% I-Lab_value
reduction I-Lab_value
in O
the O
maximum B-Diagnostic_procedure
standardized I-Diagnostic_procedure
uptake I-Diagnostic_procedure
value I-Diagnostic_procedure
( O
SUVmax B-Diagnostic_procedure
) O
of O
2-deoxy-2 B-Diagnostic_procedure
- I-Diagnostic_procedure
[ I-Diagnostic_procedure
[ I-Diagnostic_procedure
18 I-Diagnostic_procedure
] I-Diagnostic_procedure
F I-Diagnostic_procedure
] I-Diagnostic_procedure
fluoro-d-glucose I-Diagnostic_procedure
( O
FDG B-Diagnostic_procedure
) O
. O

FDG B-Diagnostic_procedure
uptake I-Diagnostic_procedure
was O
higher B-Lab_value
in O
the O
left B-Biological_structure
supraclavicular I-Biological_structure
lymph B-Biological_structure
node I-Biological_structure
compared O
to O
the O
metastatic B-Biological_structure
regions I-Biological_structure
treated O
with O
concurrent O
apatinib B-Medication
and O
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O

According O
to O
Response B-Diagnostic_procedure
Evaluation I-Diagnostic_procedure
Criteria I-Diagnostic_procedure
in I-Diagnostic_procedure
Solid I-Diagnostic_procedure
Tumors I-Diagnostic_procedure
( O
RECIST B-Diagnostic_procedure
) O
, O
the O
clinical O
effect O
was O
partial B-Lab_value
response I-Lab_value
( O
Fig. O
2 O
) O
. O

The O
patient O
received O
further O
radiotherapy B-Therapeutic_procedure
( O
66 B-Dosage
Gy I-Dosage
in I-Dosage
28 I-Dosage
fractions I-Dosage
) O
to O
the O
left B-Biological_structure
supraclavicular I-Biological_structure
lymph B-Biological_structure
node I-Biological_structure
due O
to O
residual B-Disease_disorder
metastasis I-Disease_disorder
. O

Tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
and O
biochemical B-Diagnostic_procedure
analyses I-Diagnostic_procedure
were O
evaluated O
every B-Frequency
2 I-Frequency
months I-Frequency
. O

Two B-Date
months I-Date
after I-Date
therapy I-Date
, O
chest B-Biological_structure
, O
and O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scans I-Diagnostic_procedure
indicated O
stable B-Detailed_description
disease B-Disease_disorder
; O
anemia B-Sign_symptom
and O
gastrointestinal B-Sign_symptom
symptoms I-Sign_symptom
had O
improved B-Qualitative_concept
, O
ECOG B-Diagnostic_procedure
performance O
status O
was O
0 B-Lab_value
, O
and O
BMI B-Diagnostic_procedure
was O
22 B-Lab_value
. O

Hematologic B-Sign_symptom
toxicity I-Sign_symptom
, O
hypertension B-Sign_symptom
, O
renal B-Sign_symptom
dysfunction I-Sign_symptom
, O
proteinuria B-Sign_symptom
, O
and O
hand B-Sign_symptom
– I-Sign_symptom
foot I-Sign_symptom
syndrome I-Sign_symptom
were O
not O
observed O
during O
apatinib B-Medication
therapy O
. O

In O
September B-Date
2015 I-Date
, O
a O
follow-up B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
increased B-Lab_value
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( I-Diagnostic_procedure
CA I-Diagnostic_procedure
) I-Diagnostic_procedure
125 I-Diagnostic_procedure
and O
ferritin B-Diagnostic_procedure
; O
however O
, O
gastroscopy B-Diagnostic_procedure
and O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
revealed O
no O
abnormalities B-Sign_symptom
. O

In O
November B-Date
2015 I-Date
, O
the O
patient O
had O
difficulty B-Sign_symptom
swallowing I-Sign_symptom
and O
experienced O
intermittent B-Detailed_description
hematochezia B-Sign_symptom
. O

Apatinib B-Medication
was O
terminated B-Detailed_description
due O
to O
gastrointestinal B-Sign_symptom
bleeding I-Sign_symptom
. O

Gastroscopy B-Diagnostic_procedure
revealed O
anastomotic B-Sign_symptom
stenosis I-Sign_symptom
due O
to O
gastric B-Disease_disorder
cancer I-Disease_disorder
and O
intragastric B-Disease_disorder
hemorrhage I-Disease_disorder
( O
Fig. O
3D O
– O
F O
) O
. O

The O
patient O
and O
his O
family O
refused O
chemoradiotherapy B-Therapeutic_procedure
. O

Symptomatic O
treatment O
with O
a O
hemostatic B-Medication
drug I-Medication
and O
best O
supportive B-Therapeutic_procedure
care I-Therapeutic_procedure
were O
prescribed B-Clinical_event
. O

After B-Date
1 I-Date
week I-Date
of O
therapy O
, O
hemorrhaging B-Disease_disorder
was O
resolved O
. O

One B-Date
month I-Date
later I-Date
, I-Date
the O
patient O
again O
experienced O
intermittent B-Detailed_description
hematochezia B-Sign_symptom
. O

On O
December B-Date
20 I-Date
, I-Date
2015 I-Date
, O
PET-CT B-Diagnostic_procedure
demonstrated O
extensive B-Severity
metastasis B-Disease_disorder
. O

The O
patient O
and O
his O
family O
requested O
best O
supportive B-Therapeutic_procedure
care I-Therapeutic_procedure
. O

On O
April B-Date
16 I-Date
, I-Date
2016 I-Date
, O
the O
patient O
died B-Outcome
due O
to O
pulmonary B-Biological_structure
infection B-Disease_disorder
. O

A O
68-year-old B-Age
man B-Sex
referred B-Clinical_event
to O
the O
Internal B-Nonbiological_location
Medicine I-Nonbiological_location
Department I-Nonbiological_location
of O
Razi B-Nonbiological_location
Hospital I-Nonbiological_location
in O
Rasht B-Nonbiological_location
( O
a B-Nonbiological_location
city I-Nonbiological_location
in I-Nonbiological_location
the I-Nonbiological_location
north I-Nonbiological_location
of I-Nonbiological_location
Iran I-Nonbiological_location
) O
with O
a O
hypogastric B-Biological_structure
region I-Biological_structure
discomfort B-Sign_symptom
, O
especially O
in O
the O
right B-Biological_structure
lower I-Biological_structure
quadrant I-Biological_structure
for O
one B-Duration
month I-Duration
. O

The O
pain B-Coreference
was O
a O
colicky B-Detailed_description
form I-Detailed_description
which O
had O
a B-Frequency
few I-Frequency
episodes I-Frequency
each I-Frequency
day I-Frequency
, O
each B-Detailed_description
episode I-Detailed_description
lasting I-Detailed_description
for I-Detailed_description
4 I-Detailed_description
– I-Detailed_description
5 I-Detailed_description
minutes I-Detailed_description
. O

The O
pain B-Coreference
radiated O
to O
the O
back B-Nonbiological_location
and O
was O
alleviated B-Sign_symptom
by O
resting B-Activity
to I-Activity
one I-Activity
side I-Activity
. O

No B-History
association I-History
between I-History
the I-History
pain I-History
, I-History
defecation I-History
, I-History
and I-History
eating I-History
were O
reported O
. O

Furthermore O
, O
the O
patient O
complained O
of O
a O
2 B-Lab_value
– I-Lab_value
3 I-Lab_value
kg I-Lab_value
weight B-Sign_symptom
loss I-Sign_symptom
over O
the O
last B-Duration
one I-Duration
month I-Duration
followed O
by O
anorexia B-Sign_symptom
. O

However O
, O
no O
symptoms O
of O
nausea B-Sign_symptom
, O
vomiting B-Sign_symptom
, O
fever B-Sign_symptom
, O
or O
shaking B-Sign_symptom
chills I-Sign_symptom
were O
demonstrated O
. O

He O
was O
first O
admitted B-Clinical_event
to O
another B-Nonbiological_location
center I-Nonbiological_location
for O
a B-Duration
week I-Duration
, O
then O
was O
referred B-Clinical_event
to O
our B-Nonbiological_location
hospital I-Nonbiological_location
for O
further O
evaluation O
. O

The O
patient O
had O
undergone O
a O
surgery B-Therapeutic_procedure
for B-History
prostatectomy I-History
seven B-Date
years I-Date
before I-Date
his O
presentation B-Clinical_event
to O
our B-Nonbiological_location
center I-Nonbiological_location
. O

Also O
, O
he O
had O
a O
history O
of O
endoscopy B-History
five B-Date
years I-Date
earlier I-Date
due O
to O
dyspepsia B-Disease_disorder
, O
which O
was O
found O
to O
be O
Helicobacter B-Diagnostic_procedure
pylori I-Diagnostic_procedure
positive B-Lab_value
at O
that O
time O
and O
which O
was O
eradicated B-Sign_symptom
after O
a O
treatment B-Therapeutic_procedure
course I-Therapeutic_procedure
. O

No B-History
history I-History
of I-History
HIV I-History
, I-History
diabetes I-History
, I-History
smoking I-History
, I-History
or I-History
alcohol I-History
consumption I-History
was O
recorded O
. O

His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
normal B-Lab_value
at O
the O
time O
of O
admission O
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
abdomen B-Biological_structure
was O
soft B-Sign_symptom
, O
there O
was O
no O
distention B-Sign_symptom
, O
and O
bowel B-Diagnostic_procedure
sounds I-Diagnostic_procedure
were O
normoactive B-Lab_value
. O

However O
, O
tenderness B-Sign_symptom
in O
the O
right B-Biological_structure
lower I-Biological_structure
quadrant I-Biological_structure
of I-Biological_structure
the I-Biological_structure
abdomen I-Biological_structure
with O
no B-Lab_value
rebound B-Diagnostic_procedure
state I-Diagnostic_procedure
was O
noted O
. O

The O
peripheral B-Diagnostic_procedure
blood I-Diagnostic_procedure
analysis I-Diagnostic_procedure
is O
shown O
in O
Table O
1 O
. O

Stool B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
urine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
, O
and O
evaluation B-Diagnostic_procedure
of I-Diagnostic_procedure
electrolytes I-Diagnostic_procedure
were O
all O
normal B-Lab_value
. O

An O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
showed O
a O
well-demarcated B-Detailed_description
and O
homogenous B-Detailed_description
solitary B-Detailed_description
mass B-Sign_symptom
in O
the O
cecum B-Biological_structure
with O
no O
distention B-Sign_symptom
in O
the O
ileum B-Biological_structure
. O

The O
ileum B-Biological_structure
wall I-Biological_structure
was O
thickened B-Sign_symptom
( O
Figure O
1 O
) O
. O

A O
colonoscopy B-Diagnostic_procedure
revealed O
a O
large B-Lab_value
mass B-Detailed_description
like I-Detailed_description
lesion B-Sign_symptom
in O
the O
cecum B-Biological_structure
( O
Figure O
2 O
) O
; O
during O
the O
procedure O
a O
biopsy B-Diagnostic_procedure
was O
taken O
from O
the O
cecum B-Biological_structure
. O

The O
lamina B-Biological_structure
propria I-Biological_structure
was O
infiltrated B-Sign_symptom
by O
a O
number O
of O
PMNCs B-Biological_structure
admixed O
by O
some O
eosinophils B-Biological_structure
( O
Figure O
3 O
) O
. O

Immunohistochemical B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
was O
positive B-Lab_value
for O
vimentin B-Diagnostic_procedure
and O
CD68 B-Diagnostic_procedure
. O

C-Kit B-Diagnostic_procedure
( O
CD117 B-Diagnostic_procedure
) O
was O
negative B-Lab_value
while O
CD34 B-Diagnostic_procedure
, O
smooth B-Diagnostic_procedure
muscle I-Diagnostic_procedure
actin I-Diagnostic_procedure
( O
SMA B-Diagnostic_procedure
) O
, O
and O
ALK B-Diagnostic_procedure
were O
focally B-Lab_value
positive I-Lab_value
. O

There O
were O
no B-Lab_value
reports I-Lab_value
of O
cyclin B-Diagnostic_procedure
D1 I-Diagnostic_procedure
, O
desmin B-Diagnostic_procedure
, O
or O
pancytokeratin B-Diagnostic_procedure
( O
Figure O
4 O
) O
. O

When O
the O
colonoscopy O
was O
performed O
, O
the O
evidences O
of O
invasive O
obstruction O
lead O
us O
to O
the O
suspicion O
of O
a O
malignant B-Disease_disorder
tumor I-Disease_disorder
. O

After O
pathological O
confirmation O
of O
IMT B-Disease_disorder
, O
the O
patient O
was O
referred B-Clinical_event
for O
surgery B-Therapeutic_procedure
in O
order O
to O
remove O
the O
mass O
. O

On O
surgery B-Coreference
, O
approximately O
40 B-Volume
mL I-Volume
ascites B-Sign_symptom
were O
found O
in O
the O
abdomen B-Biological_structure
. O

A O
mass B-Sign_symptom
was O
seen O
in O
the O
cecum B-Biological_structure
with O
ileocolic B-Biological_structure
intussusception B-Sign_symptom
. O

Afterwards O
, O
the O
patient O
underwent O
right B-Detailed_description
hemicolectomy B-Therapeutic_procedure
with O
an O
end-to-end B-Detailed_description
anastomosis B-Therapeutic_procedure
of I-Therapeutic_procedure
ileocolic I-Therapeutic_procedure
. O

No O
enlarge B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
were O
observed O
. O

The O
patient O
was O
discharged B-Clinical_event
seven B-Date
days I-Date
after I-Date
surgery O
and O
had O
no O
complications B-Sign_symptom
during O
follow-up B-Clinical_event
. O

A O
52-year-old B-Age
man B-Sex
with O
a O
30-year B-History
history I-History
of I-History
smoking I-History
presented B-Clinical_event
with O
an O
abnormal B-Detailed_description
nodule B-Sign_symptom
measuring O
0.8 B-Area
× I-Area
1.5 I-Area
cm I-Area
in O
the O
left B-Biological_structure
upper I-Biological_structure
lung I-Biological_structure
lobe I-Biological_structure
imaged O
through O
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scanning O
in O
March B-Date
2012 I-Date
in O
a O
community B-Nonbiological_location
hospital I-Nonbiological_location
. O

He O
had O
previously B-History
been I-History
well I-History
without I-History
any I-History
additional I-History
relevant I-History
or I-History
abnormal I-History
symptoms I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
suggested O
no O
significant O
abnormalities B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
range I-Lab_value
, O
except O
for O
a O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
CEA B-Diagnostic_procedure
) O
level O
of O
30.25 B-Lab_value
ng/mL I-Lab_value
( O
normal O
range O
, O
0 O
– O
5 O
ng/mL O
) O
found O
in O
the O
serum B-Biological_structure
. O

Subsequently O
, O
a O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
/ O
CT B-Diagnostic_procedure
scan O
showed O
a O
lung B-Biological_structure
lesion B-Sign_symptom
with O
a O
standardized B-Diagnostic_procedure
uptake I-Diagnostic_procedure
value I-Diagnostic_procedure
of O
7.94 B-Lab_value
, O
which O
was O
highly O
suspected O
to O
be O
a O
malignant B-Disease_disorder
tumor I-Disease_disorder
( O
Fig. O
1 O
) O
. O

Subsequently O
, O
he O
underwent O
left B-Biological_structure
upper I-Biological_structure
lung I-Biological_structure
lobectomy B-Therapeutic_procedure
and O
lymph B-Therapeutic_procedure
node I-Therapeutic_procedure
dissection I-Therapeutic_procedure
. O

Postoperative O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
adenocarcinoma B-Disease_disorder
( O
ADC B-Disease_disorder
) O
( O
Fig. O
2A O
) O
. O

Immunohistochemistry B-Diagnostic_procedure
( O
IHC B-Diagnostic_procedure
) O
staining O
results O
were O
positive B-Lab_value
for O
CK7 B-Diagnostic_procedure
, O
TTF-1 B-Diagnostic_procedure
, O
p63 B-Diagnostic_procedure
, O
and O
NapsinA B-Diagnostic_procedure
and O
negative B-Lab_value
for O
CK B-Diagnostic_procedure
5/6 I-Diagnostic_procedure
, O
Syn B-Diagnostic_procedure
, O
cgA B-Diagnostic_procedure
, O
and O
Ki-67 B-Diagnostic_procedure
( O
20 O
% O
– O
30 O
% O
) O
. O

The O
clinical B-Diagnostic_procedure
stage I-Diagnostic_procedure
was O
classified O
as O
IA2 B-Lab_value
( O
pT1bN0M0 B-Lab_value
) O
. O

Because O
the O
tumor B-Coreference
was O
still O
in O
an O
early B-Detailed_description
stage I-Detailed_description
, O
the O
patient O
did O
not O
receive O
adjuvant B-Medication
treatment I-Medication
but O
continued O
to O
be O
monitored B-Therapeutic_procedure
through O
regular O
hospital B-Nonbiological_location
visits B-Clinical_event
every B-Frequency
3 I-Frequency
months I-Frequency
. O

The O
patient O
's O
condition B-Diagnostic_procedure
had O
been O
stable B-Lab_value
until O
the O
onset O
of O
left B-Biological_structure
chest I-Biological_structure
pain B-Sign_symptom
in O
April B-Date
2015 I-Date
. O

The O
patient O
was O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
( O
a O
tertiary B-Nonbiological_location
care I-Nonbiological_location
hospital I-Nonbiological_location
) O
for O
further O
treatment O
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
suggested O
a O
significant B-Severity
tender B-Sign_symptom
point I-Sign_symptom
in O
the O
left B-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
showed O
only O
a O
single O
parameter O
outside O
the O
normal O
range O
: O
the O
cytokeratin19 B-Diagnostic_procedure
fragment I-Diagnostic_procedure
antigen I-Diagnostic_procedure
21 I-Diagnostic_procedure
– I-Diagnostic_procedure
1 I-Diagnostic_procedure
( O
CYFRA21 B-Diagnostic_procedure
– I-Diagnostic_procedure
1 I-Diagnostic_procedure
) O
level O
was O
17.45 B-Lab_value
ng/mL I-Lab_value
in O
the O
serum B-Biological_structure
( O
normal O
range O
= O
0 O
– O
3.3 O
ng/mL O
) O
. O

CT B-Diagnostic_procedure
and O
PET/CT B-Diagnostic_procedure
scans O
highlighted O
the O
serious B-Severity
involvement B-Sign_symptom
of O
left B-Biological_structure
pleura I-Biological_structure
, O
showing O
bilateral B-Detailed_description
lung B-Biological_structure
lesions B-Sign_symptom
( O
Fig. O
3A O
and O
E O
) O
. O

At O
that O
point O
, O
the O
clinical B-Diagnostic_procedure
stage I-Diagnostic_procedure
was O
upgraded B-Lab_value
to O
IVB B-Lab_value
. O

After O
the O
CT-guided B-Detailed_description
left B-Biological_structure
pleura I-Biological_structure
puncture B-Therapeutic_procedure
, O
pathological O
IHC B-Diagnostic_procedure
analysis I-Diagnostic_procedure
showed O
positive B-Lab_value
staining O
for O
p63 B-Diagnostic_procedure
, O
p40 B-Diagnostic_procedure
, O
CK B-Diagnostic_procedure
7 I-Diagnostic_procedure
, O
and O
CK B-Diagnostic_procedure
5/6 I-Diagnostic_procedure
, O
while O
TTF-1 B-Diagnostic_procedure
and O
NapsinA B-Diagnostic_procedure
staining O
were O
absent B-Lab_value
, O
supporting O
a O
diagnosis O
of O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
( O
SCC B-Disease_disorder
) O
( O
Fig. O
2B O
) O
. O

Meanwhile O
, O
molecular B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
confirmed O
an O
L858R B-Sign_symptom
mutation I-Sign_symptom
in O
exon B-Detailed_description
21 I-Detailed_description
and O
a O
T790M B-Sign_symptom
mutation I-Sign_symptom
in O
exon B-Detailed_description
20 I-Detailed_description
( O
Fig. O
4B O
and O
C O
) O
. O

Considering B-Other_entity
the I-Other_entity
pathology I-Other_entity
of I-Other_entity
the I-Other_entity
SCC I-Other_entity
was I-Other_entity
quite I-Other_entity
distinct I-Other_entity
compared I-Other_entity
with I-Other_entity
that I-Other_entity
of I-Other_entity
the I-Other_entity
originally I-Other_entity
resected I-Other_entity
NSCLC I-Other_entity
specimen I-Other_entity
, I-Other_entity
we I-Other_entity
retrospectively I-Other_entity
reassessed I-Other_entity
the I-Other_entity
surgery I-Other_entity
specimen I-Other_entity
to I-Other_entity
verify I-Other_entity
our I-Other_entity
primary I-Other_entity
diagnosis I-Other_entity
. O

The B-Other_entity
morphologic I-Other_entity
and I-Other_entity
IHC I-Other_entity
results I-Other_entity
were I-Other_entity
in I-Other_entity
complete I-Other_entity
agreement I-Other_entity
with I-Other_entity
the I-Other_entity
initial I-Other_entity
diagnoses I-Other_entity
, I-Other_entity
but I-Other_entity
an I-Other_entity
L858R I-Other_entity
mutation I-Other_entity
was I-Other_entity
identified I-Other_entity
using I-Other_entity
the I-Other_entity
newly I-Other_entity
added I-Other_entity
molecular I-Other_entity
evaluation I-Other_entity
( O
Fig. O
4A O
) O
. O

To O
relieve O
the O
acute O
pain O
in O
the O
left O
pleura O
as O
quickly O
as O
possible O
, O
palliative B-Detailed_description
three-dimensional B-Therapeutic_procedure
conformal I-Therapeutic_procedure
radiotherapy I-Therapeutic_procedure
( O
3D-CRT B-Therapeutic_procedure
) O
for O
the O
chest B-Biological_structure
lesion B-Sign_symptom
was O
delivered O
at O
a O
total O
dose O
of O
42 B-Dosage
Gy/14 I-Dosage
fractions I-Dosage
( O
f O
) O
, O
once B-Frequency
daily I-Frequency
and O
5f/week B-Dosage
( O
Fig. O
5 O
) O
. O

The O
volume B-Diagnostic_procedure
over I-Diagnostic_procedure
radiation I-Diagnostic_procedure
dose I-Diagnostic_procedure
5 I-Diagnostic_procedure
Gy I-Diagnostic_procedure
( O
V5 O
) O
values O
of O
the O
left B-Biological_structure
, O
right B-Biological_structure
, O
and O
total B-Biological_structure
lungs I-Biological_structure
were O
20 B-Lab_value
% I-Lab_value
, O
0 B-Lab_value
% I-Lab_value
, O
and O
7.8 B-Lab_value
% I-Lab_value
, O
respectively O
; O
the O
volume B-Diagnostic_procedure
over I-Diagnostic_procedure
radiation I-Diagnostic_procedure
dose I-Diagnostic_procedure
20 I-Diagnostic_procedure
Gy I-Diagnostic_procedure
( O
V20 O
) O
values O
were O
10 B-Lab_value
% I-Lab_value
, O
0 B-Lab_value
% I-Lab_value
, O
and O
5 B-Lab_value
% I-Lab_value
, O
respectively O
; O
the O
mean B-Diagnostic_procedure
lung I-Diagnostic_procedure
dose I-Diagnostic_procedure
( O
MLD B-Diagnostic_procedure
) O
was O
5 B-Lab_value
Gy I-Lab_value
. O

Meanwhile O
, O
considering O
the O
MST O
pathology O
was O
that O
of O
SCC O
, O
the O
patient O
received O
GP B-Medication
chemotherapy I-Medication
( O
cisplatin B-Medication
75 B-Dosage
mg/m2 I-Dosage
d1 I-Dosage
, O
gemcitabine B-Medication
1250 B-Dosage
mg/m2 I-Dosage
d1 I-Dosage
, I-Dosage
d8 I-Dosage
, O
for O
21 B-Detailed_description
days I-Detailed_description
as I-Detailed_description
a I-Detailed_description
cycle I-Detailed_description
) O
for O
4 B-Lab_value
cycles I-Lab_value
, O
and O
the O
patient O
achieved O
partial B-Detailed_description
remission B-Sign_symptom
( O
PR O
) O
after B-Date
2 I-Date
cycles I-Date
, O
followed O
by O
stable B-Disease_disorder
disease I-Disease_disorder
( O
SD B-Disease_disorder
) O
after B-Date
4 I-Date
cycles I-Date
( O
Fig. O
3 O
[ O
B3 O
[ O
B O
and O
F O
] O
and O
[ O
C O
and O
G O
] O
) O
according O
to O
response B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
criteria I-Diagnostic_procedure
in I-Diagnostic_procedure
solid I-Diagnostic_procedure
tumors I-Diagnostic_procedure
( O
RECIST B-Diagnostic_procedure
) O
1.1 B-Detailed_description
. O

Then O
, O
gefitinib B-Medication
( O
150 B-Dosage
mg I-Dosage
qd I-Dosage
) O
was O
used O
as O
maintenance O
treatment O
from B-Date
November I-Date
2015 I-Date
onward O
. O

During O
the O
treatment O
, O
Ibandronate B-Medication
sodium I-Medication
was O
given O
monthly B-Frequency
for O
skeletal-related B-Sign_symptom
events I-Sign_symptom
. O

The O
patient O
is O
currently O
under B-Clinical_event
surveillance I-Clinical_event
with O
SD B-Diagnostic_procedure
( O
Fig. O
3D O
and O
H O
) O
and O
with O
PS B-Diagnostic_procedure
scores O
of O
0 B-Lab_value
. O

A O
64-year-old B-Age
man B-Sex
was O
admitted B-Clinical_event
to O
the O
Department B-Nonbiological_location
of I-Nonbiological_location
Gastroenterology I-Nonbiological_location
of O
the O
Affiliated B-Nonbiological_location
Hospital I-Nonbiological_location
of I-Nonbiological_location
Qingdao I-Nonbiological_location
University I-Nonbiological_location
Medical I-Nonbiological_location
College I-Nonbiological_location
( I-Nonbiological_location
Qingdao I-Nonbiological_location
, I-Nonbiological_location
China I-Nonbiological_location
) I-Nonbiological_location
due O
to O
epigastric B-Biological_structure
pains B-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
no O
palpable O
mass B-Sign_symptom
, O
lymphadenopathy B-Sign_symptom
, O
or O
organomegaly B-Sign_symptom
. O

On O
endoscopy B-Diagnostic_procedure
, O
several B-Detailed_description
submucosal B-Biological_structure
lesions B-Sign_symptom
were O
identified O
in O
the O
gastric B-Biological_structure
antrum I-Biological_structure
and O
the O
duodenal B-Biological_structure
bulb I-Biological_structure
( O
Fig. O
1 O
) O
. O

Endoscopic B-Diagnostic_procedure
ultrasonography I-Diagnostic_procedure
( O
EUS B-Diagnostic_procedure
) O
( O
OLYMPUS B-Detailed_description
EUS I-Detailed_description
EU-ME2 I-Detailed_description
, O
Miniprobe B-Detailed_description
sonography I-Detailed_description
) O
demonstrated O
that O
the O
lesions B-Sign_symptom
were O
almost B-Distance
0.5-cm I-Distance
homogeneously O
hypoechoic B-Detailed_description
neoplasms B-Sign_symptom
originating O
from O
the O
submucous B-Biological_structure
layer I-Biological_structure
( O
Fig. O
2 O
) O
and O
the O
initial O
diagnosis O
was O
digestive B-Biological_structure
neuroendocrine B-Disease_disorder
tumors I-Disease_disorder
. O

Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
enlarged B-Sign_symptom
lymph I-Sign_symptom
nodes I-Sign_symptom
in O
multiple O
regions O
( O
mediastinal B-Biological_structure
, O
retroperitoneal B-Biological_structure
, O
mesenteric B-Biological_structure
, O
and O
inguinal B-Biological_structure
) O
and O
intracavitary B-Detailed_description
nodules B-Sign_symptom
in O
the O
duodenum B-Biological_structure
. O

To O
reach O
a O
definitive O
diagnosis O
, O
the O
patient O
underwent O
repeat B-Detailed_description
EUS B-Diagnostic_procedure
and O
biopsy B-Diagnostic_procedure
was O
performed O
. O

On O
endoscopy B-Diagnostic_procedure
, O
a O
2 B-Area
× I-Area
1-cm I-Area
columnar B-Sign_symptom
uplift I-Sign_symptom
in O
the O
terminal B-Biological_structure
ileum I-Biological_structure
and O
multiple B-Detailed_description
submucosal B-Biological_structure
lesions B-Sign_symptom
in O
the O
rectum B-Biological_structure
were O
identified O
( O
Fig. O
3 O
) O
. O

EUS B-Diagnostic_procedure
revealed O
that O
the O
lesions B-Sign_symptom
in O
the O
terminal B-Biological_structure
ileum I-Biological_structure
were O
sized O
1.6 B-Area
× I-Area
1.2 I-Area
cm I-Area
and O
the O
lesions B-Sign_symptom
in O
the O
rectum B-Biological_structure
were O
sized O
almost O
0.6 B-Area
× I-Area
1.0 I-Area
cm I-Area
, O
they O
were O
all O
homogeneously B-Detailed_description
hypoechoic I-Detailed_description
and O
originated B-Detailed_description
from I-Detailed_description
the I-Detailed_description
muscularis I-Detailed_description
mucosa I-Detailed_description
layer I-Detailed_description
. O

Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
biopsied O
specimens O
from O
the O
lesions B-Sign_symptom
of O
the O
rectum B-Biological_structure
showed O
diffuse O
lymphomatous B-Detailed_description
proliferation I-Detailed_description
and O
dense B-Detailed_description
infiltration I-Detailed_description
by O
monomorphic B-Biological_structure
, I-Biological_structure
small I-Biological_structure
cleaved I-Biological_structure
cells I-Biological_structure
with I-Biological_structure
irregularly I-Biological_structure
shaped I-Biological_structure
nuclei I-Biological_structure
( O
Fig. O
4 O
) O
. O

On O
immunohistochemical B-Diagnostic_procedure
analysis I-Diagnostic_procedure
, O
the O
cells O
were O
positive B-Lab_value
for O
cyclin B-Diagnostic_procedure
D1 I-Diagnostic_procedure
, O
CD20 B-Diagnostic_procedure
, O
CD21 B-Diagnostic_procedure
, O
SOX-11 B-Diagnostic_procedure
, O
and O
Bcl-2 B-Diagnostic_procedure
, O
but O
negative B-Lab_value
for O
CD3 B-Diagnostic_procedure
and O
CD10 B-Diagnostic_procedure
, O
which O
was O
compatible O
with O
the O
diagnosis O
of O
MCL B-Disease_disorder
. O

Ki-67 B-Diagnostic_procedure
staining I-Diagnostic_procedure
revealed O
a O
proliferative B-Lab_value
index I-Lab_value
of I-Lab_value
30 I-Lab_value
% I-Lab_value
. O

Based O
on O
these O
findings O
, O
the O
diagnosis O
of O
Ann B-Lab_value
Arbor I-Lab_value
stage I-Lab_value
IV I-Lab_value
MCL B-Disease_disorder
was O
confirmed O
. O

The O
patient O
was O
referred O
for O
combination O
chemotherapy B-Medication
with O
rituximab B-Medication
, O
cyclophosphamide B-Medication
, O
doxorubicin B-Medication
, O
vincristine B-Medication
, O
and O
prednisone B-Medication
( O
R-CHOP B-Medication
regimen I-Medication
) O
. O

The O
patient O
has O
been O
in O
remission B-Sign_symptom
clinically O
. O

A O
78-year-old B-Age
previously B-History
healthy I-History
male B-Sex
heavy B-History
smoker I-History
presented B-Clinical_event
at O
the O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
with O
generalized B-Detailed_description
jaundice B-Sign_symptom
( O
sclera B-Biological_structure
and O
skin B-Biological_structure
) O
, O
ascites B-Sign_symptom
, O
and O
hepatic B-Disease_disorder
coma I-Disease_disorder
. O

The O
relatives O
declared O
that O
he O
was O
known O
to O
have O
a O
urinary B-Disease_disorder
bladder I-Disease_disorder
carcinoma I-Disease_disorder
that O
was O
diagnosed O
at O
a O
routine O
control O
performed O
3 B-Date
months I-Date
before I-Date
but O
no O
medical O
papers O
to O
prove O
this O
diagnosis O
were O
shown O
. O

They O
also O
mentioned O
a O
2-month B-Duration
history O
of O
progressive B-Detailed_description
jaundice B-History
, O
somnolence B-Sign_symptom
, O
and O
temporary B-Detailed_description
loss B-History
of I-History
consciousness I-History
. O

No O
weight B-Sign_symptom
loss I-Sign_symptom
or O
other O
clinical O
signs O
were O
mentioned O
. O

No O
previously O
viral B-Disease_disorder
hepatitis I-Disease_disorder
or O
drug B-Clinical_event
excess I-Clinical_event
was O
reported O
. O

No B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
cancer I-Family_history
was O
declared O
. O

At O
the O
present O
admission O
, O
the O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan I-Diagnostic_procedure
showed O
marked O
hepatomegaly B-Sign_symptom
with O
multiple B-Detailed_description
small B-Detailed_description
nodules B-Sign_symptom
( O
2 B-Distance
– I-Distance
10 I-Distance
mm I-Distance
in O
diameter O
) O
that O
was O
supposed O
to O
be O
hepatic B-Biological_structure
metastases B-Sign_symptom
from O
the O
bladder B-Disease_disorder
carcinoma I-Disease_disorder
. O

The O
thoracic B-Biological_structure
x-ray B-Diagnostic_procedure
showed O
a O
bilateral B-Detailed_description
bronchopneumonia B-Sign_symptom
without O
abnormal B-Lab_value
opacities B-Sign_symptom
. O

The O
patient O
died B-Clinical_event
with O
hepatic B-Disease_disorder
encephalopathy I-Disease_disorder
at O
7 B-Time
hours I-Time
after I-Time
admission O
. O

Prior O
to O
the O
autopsy B-Diagnostic_procedure
, O
signed O
informed O
consent O
of O
the O
relatives O
was O
obtained O
for O
the O
case O
publication O
. O

Being O
about O
a O
case O
report O
, O
no O
Ethical O
Committee O
approval O
was O
necessary O
. O

At O
autopsy O
, O
the O
macroscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
huge B-Lab_value
liver B-Diagnostic_procedure
( O
6.5 B-Mass
kg I-Mass
) O
with O
widely B-Detailed_description
distributed I-Detailed_description
white B-Color
nodules B-Sign_symptom
of O
varying B-Detailed_description
sizes I-Detailed_description
( O
Fig. O
1 O
) O
. O

The O
urinary B-Diagnostic_procedure
bladder I-Diagnostic_procedure
was O
not B-Lab_value
modified I-Lab_value
, O
but O
a O
30 B-Volume
× I-Volume
30 I-Volume
× I-Volume
50 I-Volume
mm I-Volume
prostate B-Biological_structure
nodule B-Sign_symptom
with O
infiltrative B-Detailed_description
aspect I-Detailed_description
was O
observed O
( O
Fig. O
2 O
) O
. O

The O
bilateral B-Detailed_description
bronchopneumonia B-Sign_symptom
was O
confirmed O
, O
without O
any O
central B-Detailed_description
tumor B-Sign_symptom
mass I-Sign_symptom
. O

A O
10-mm B-Distance
white B-Color
nodule B-Sign_symptom
was O
identified O
encasing O
a O
small B-Biological_structure
bronchus I-Biological_structure
from O
the O
middle B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
lung I-Biological_structure
, O
without O
peripheral B-Sign_symptom
nodules I-Sign_symptom
( O
Fig. O
3 O
) O
. O

Except O
for O
moderate B-Severity
edema B-Sign_symptom
, O
no O
other O
brain B-Biological_structure
lesions B-Sign_symptom
were O
identified O
. O

The O
other B-Biological_structure
organs I-Biological_structure
did O
not O
show O
modifications B-Sign_symptom
. O

The O
tissues O
were O
fixed O
in O
10 O
% O
neutral O
formalin O
and O
embedded O
in O
paraffin O
together O
with O
iliac O
crest O
bone O
grafting O
. O

Microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
prostate B-Biological_structure
showed O
a O
3 B-Diagnostic_procedure
+3 I-Diagnostic_procedure
Gleason I-Diagnostic_procedure
's I-Diagnostic_procedure
grade I-Diagnostic_procedure
2 B-Lab_value
occult B-Detailed_description
adenocarcinoma B-Disease_disorder
( O
Fig. O
2 O
) O
. O

Clusters O
and O
sheets O
of O
small O
round O
cells O
were O
seen O
in O
the O
liver O
parenchyma O
( O
Fig. O
1 O
) O
and O
the O
lymph O
nodes O
from O
the O
hepatic O
hilum O
. O

Examination O
of O
the O
lung O
parenchyma O
showed O
a O
peribronchial B-Biological_structure
SCLC B-Disease_disorder
with O
multiple B-Detailed_description
tumor B-Sign_symptom
emboli I-Sign_symptom
in O
both O
veins B-Biological_structure
and O
lymphatic B-Biological_structure
vessels I-Biological_structure
and O
multiple O
“ O
coin-shaped B-Shape
” O
tumor B-Sign_symptom
nodules O
of O
1 B-Distance
to I-Distance
2 I-Distance
mm I-Distance
in O
diameter O
below B-Biological_structure
the I-Biological_structure
pleura I-Biological_structure
( O
Fig. O
3 O
) O
. O

The O
small O
round O
tumor O
cells O
were O
also O
seen O
in O
bone O
marrow O
from O
the O
iliac O
crest O
bone O
( O
Fig. O
3 O
) O
. O

No O
brain B-Biological_structure
metastases B-Sign_symptom
have O
been O
detected O
. O

Based O
on O
the O
macro O
- O
and O
microscopic O
features O
and O
clinical O
picture O
, O
the O
final O
diagnosis O
was O
“ O
peribronchial B-Biological_structure
and O
coin-like B-Shape
peripheral B-Detailed_description
SCLC B-Disease_disorder
with O
massive B-Severity
angiolymphatic B-Biological_structure
invasion B-Disease_disorder
and O
metastases B-Sign_symptom
in O
the O
lymph B-Biological_structure
nodes I-Biological_structure
, O
liver B-Biological_structure
and O
bone B-Biological_structure
, O
associated O
with O
encephalopathy B-Disease_disorder
and O
synchronous B-Detailed_description
occult B-Detailed_description
adenocarcinoma B-Disease_disorder
of O
the O
prostate B-Biological_structure
. O
” O

An O
18-year-old B-Age
college B-Occupation
student I-Occupation
was O
referred B-Clinical_event
from B-Nonbiological_location
the I-Nonbiological_location
University I-Nonbiological_location
Clinic I-Nonbiological_location
for O
having O
low B-Lab_value
hemoglobin B-Diagnostic_procedure
( O
Hg O
4.7 B-Lab_value
g/dl I-Lab_value
) O
. O

He B-History
was I-History
completely I-History
well I-History
till O
one B-Date
month I-Date
back I-Date
when O
he O
presented B-Clinical_event
with O
easy B-Detailed_description
fatigability B-Sign_symptom
, O
postural B-Detailed_description
dizziness B-Sign_symptom
, O
palpitation B-Sign_symptom
and O
dyspnea B-Sign_symptom
. O

He O
gave O
history O
of O
30 B-Lab_value
kg I-Lab_value
weight B-History
loss I-History
over I-History
the I-History
past I-History
6 I-History
months I-History
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
he O
looked O
pale B-Sign_symptom
, O
not O
jaundiced B-Sign_symptom
or O
cyanosed B-Sign_symptom
. O

His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
were O
all O
within B-Lab_value
normal I-Lab_value
limits I-Lab_value
, O
except O
for O
an O
elevated B-Lab_value
heart B-Diagnostic_procedure
rate I-Diagnostic_procedure
( O
98/min B-Lab_value
) O
. O

Cardiovascular B-Biological_structure
, O
respiratory B-Biological_structure
and O
abdominal B-Biological_structure
examinations B-Diagnostic_procedure
were O
unremarkable B-Lab_value
. O

Primary O
investigations B-Clinical_event
in O
our O
hospital B-Nonbiological_location
revealed O
low B-Lab_value
hemoglobin B-Diagnostic_procedure
level O
( O
5.1 B-Lab_value
g/dl I-Lab_value
) O
, O
low B-Lab_value
iron B-Diagnostic_procedure
( O
< B-Lab_value
10 I-Lab_value
ug/dl I-Lab_value
) O
, O
and O
a O
positive B-Lab_value
occult B-Diagnostic_procedure
blood I-Diagnostic_procedure
test I-Diagnostic_procedure
. O

A O
provisional O
diagnosis O
of O
microcytic B-Disease_disorder
hypochromic I-Disease_disorder
anemia I-Disease_disorder
for O
further O
workup O
was O
made O
. O

Bone B-Diagnostic_procedure
marrow I-Diagnostic_procedure
aspirate I-Diagnostic_procedure
and O
trephine B-Diagnostic_procedure
biopsy I-Diagnostic_procedure
revealed O
normocellular B-Lab_value
marrow I-Lab_value
, O
depicting O
normal B-Lab_value
trilineage I-Lab_value
hematopoiesis I-Lab_value
. O

Upper B-Biological_structure
GI I-Biological_structure
endoscopy B-Diagnostic_procedure
showed O
erosive B-Detailed_description
antral B-Biological_structure
gastritis B-Disease_disorder
with O
patchy B-Detailed_description
ulcerative B-Detailed_description
inflammation B-Sign_symptom
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
slightly B-Severity
enlarged B-Sign_symptom
liver B-Biological_structure
with O
a O
rounded B-Shape
echogenic B-Detailed_description
lesion B-Sign_symptom
in O
the O
anterior B-Biological_structure
wall I-Biological_structure
of I-Biological_structure
the I-Biological_structure
right I-Biological_structure
lobe I-Biological_structure
suggestive O
of O
hemangioma B-Disease_disorder
. O

The O
spleen B-Biological_structure
was O
slightly B-Severity
enlarged B-Sign_symptom
and O
normal B-Lab_value
in I-Lab_value
echogenicity I-Lab_value
with O
no O
focal B-Detailed_description
lesions B-Sign_symptom
. O

Computed B-Diagnostic_procedure
Tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
of O
the O
abdomen B-Biological_structure
and O
pelvis B-Biological_structure
showed O
a O
fairly B-Detailed_description
large I-Detailed_description
well B-Detailed_description
defined I-Detailed_description
soft B-Detailed_description
tissue I-Detailed_description
mass B-Sign_symptom
located O
in O
the O
anterior B-Biological_structure
upper I-Biological_structure
pelvis I-Biological_structure
and O
engulfing O
jejunal B-Biological_structure
loops I-Biological_structure
causing O
bowel B-Biological_structure
wall I-Biological_structure
thickening B-Sign_symptom
. O

The O
patient O
underwent O
an O
exploratory O
laparotomy B-Diagnostic_procedure
and O
excision B-Therapeutic_procedure
of O
the O
jejunal B-Biological_structure
mass B-Sign_symptom
. O

Macroscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
11 B-Volume
× I-Volume
8 I-Volume
× I-Volume
2 I-Volume
cm I-Volume
annular B-Biological_structure
mass B-Sign_symptom
located O
within B-Biological_structure
the I-Biological_structure
jejunal I-Biological_structure
wall I-Biological_structure
ulcerating B-Biological_structure
through I-Biological_structure
the I-Biological_structure
mucosa I-Biological_structure
and O
extending B-Biological_structure
to I-Biological_structure
the I-Biological_structure
serosal I-Biological_structure
surface I-Biological_structure
. O

Microscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
tumor B-Sign_symptom
situated O
in O
the O
muscularis B-Biological_structure
propria I-Biological_structure
and O
extending B-Biological_structure
to I-Biological_structure
the I-Biological_structure
mucosa I-Biological_structure
and O
the O
serosa B-Biological_structure
. O

The O
neoplastic B-Coreference
cells I-Coreference
were O
arranged O
in O
predominantly B-Shape
pseudoalveolar I-Shape
pattern I-Shape
( O
Fig. O
1a O
, O
b O
) O
. O

They B-Coreference
were O
polygonal B-Shape
in O
shape O
with O
variable B-Detailed_description
amount I-Detailed_description
of I-Detailed_description
eosinophilic I-Detailed_description
to I-Detailed_description
clear I-Detailed_description
cytoplasm I-Detailed_description
( O
Fig. O
1c O
) O
. O

The O
nuclei B-Detailed_description
were I-Detailed_description
oval I-Detailed_description
with I-Detailed_description
vesicular I-Detailed_description
chromatin I-Detailed_description
and I-Detailed_description
inconspicuous I-Detailed_description
nucleoli I-Detailed_description
. O

Scattered B-Detailed_description
osteoclast-like B-Detailed_description
multinucleated B-Detailed_description
giant B-Sign_symptom
cells I-Sign_symptom
were O
also O
identified O
( O
Fig. O
1b O
, O
c O
) O
. O

Frequent B-Detailed_description
mitotic B-Sign_symptom
figures I-Sign_symptom
and O
necrosis B-Sign_symptom
were O
noted O
. O

All B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
not O
involved B-Sign_symptom
by I-Sign_symptom
tumor I-Sign_symptom
. O

Immunohistochemically B-Diagnostic_procedure
, O
the O
neoplastic B-Coreference
cells I-Coreference
were O
strongly O
and O
diffusely O
positive B-Lab_value
for O
S-100 B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
Fig. O
1d O
) O
. O

They O
were O
also O
positive B-Lab_value
for O
vimentin B-Diagnostic_procedure
. O

Melanocytic B-Diagnostic_procedure
markers I-Diagnostic_procedure
( O
HMB45 B-Diagnostic_procedure
and O
Melan B-Diagnostic_procedure
A I-Diagnostic_procedure
) O
, O
neuroendocrine B-Diagnostic_procedure
markers I-Diagnostic_procedure
( O
chromogranin B-Diagnostic_procedure
A I-Diagnostic_procedure
, O
synaptophysin B-Diagnostic_procedure
and O
CD56 B-Diagnostic_procedure
) O
, O
smooth B-Diagnostic_procedure
muscle I-Diagnostic_procedure
actin I-Diagnostic_procedure
, O
desmin B-Diagnostic_procedure
, O
CD34 B-Diagnostic_procedure
, O
CD117 B-Diagnostic_procedure
, O
cytokeratin B-Diagnostic_procedure
and O
LCA B-Diagnostic_procedure
were O
all O
negative B-Lab_value
in O
the O
neoplastic B-Coreference
cells I-Coreference
. O

Fluorescein B-Diagnostic_procedure
in I-Diagnostic_procedure
situ I-Diagnostic_procedure
hybridization I-Diagnostic_procedure
( O
FISH B-Diagnostic_procedure
) O
analysis O
for O
EWSR1 B-Detailed_description
break I-Detailed_description
apart I-Detailed_description
probe I-Detailed_description
on O
paraffin-embedded B-Detailed_description
tumor I-Detailed_description
showed O
evidence O
of O
a O
22q12 B-Sign_symptom
rearrangement I-Sign_symptom
in O
197 B-Lab_value
out I-Lab_value
of I-Lab_value
205 I-Lab_value
( I-Lab_value
96 I-Lab_value
% I-Lab_value
) I-Lab_value
of I-Lab_value
interphase I-Lab_value
nuclei I-Lab_value
scored O
. O

The O
native O
state O
of O
EWSR1 O
break O
apart O
probe O
will O
be O
seen O
as O
two O
adjacent O
or O
fused O
( O
overlapping O
) O
red/green O
( O
yellow O
) O
signals O
. O

However O
, O
EWSR1 O
gene O
rearrangement O
presented O
as O
one O
red O
and O
one O
green O
separated O
signal O
( O
Fig. O
1e O
) O
. O

The O
patient O
did O
not O
receive O
chemotherapy B-Medication
or O
radiotherapy B-Therapeutic_procedure
. O

During O
the O
clinical O
follow B-Clinical_event
up I-Clinical_event
, O
the O
patient O
remained O
disease B-Sign_symptom
free I-Sign_symptom
for O
3 B-Duration
years I-Duration
until O
he O
presented B-Clinical_event
with O
local B-Detailed_description
recurrence B-Sign_symptom
. O

The O
treatment O
plan O
was O
surgical O
resection B-Therapeutic_procedure
but O
the O
patient O
sought B-Clinical_event
medical I-Clinical_event
advice I-Clinical_event
in O
a O
different B-Nonbiological_location
institution I-Nonbiological_location
where O
he O
died B-Outcome
of O
the O
disease O
a B-Date
year I-Date
later I-Date
. O

An O
82-year-old B-Age
woman B-Sex
was O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
because O
of O
dyspnea B-Sign_symptom
and O
massive B-Severity
hemoptysis B-Sign_symptom
. O

The O
patient O
had O
a O
history O
of O
bronchial B-History
asthma I-History
that O
was O
well-controlled O
with O
bronchodilator B-History
medications I-History
. O

She O
had O
no B-History
history I-History
of I-History
tuberculosis I-History
, I-History
nontuberculous I-History
mycobacterial I-History
infection I-History
, I-History
or I-History
smoking I-History
. O

The O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
diffuse B-Detailed_description
bilateral B-Detailed_description
crackles B-Sign_symptom
. O

She O
suffered O
from O
severe B-Severity
hypoxemia B-Sign_symptom
( O
pH B-Diagnostic_procedure
7.362 B-Lab_value
, O
PCO2 B-Diagnostic_procedure
35.1 B-Lab_value
mmHg I-Lab_value
, O
PO2 B-Diagnostic_procedure
61.0 B-Lab_value
mmHg I-Lab_value
, O
HCO3 B-Diagnostic_procedure
- I-Diagnostic_procedure
20.1 B-Lab_value
mmHg I-Lab_value
, O
BE B-Diagnostic_procedure
-5.5 B-Lab_value
mmHg I-Lab_value
, O
SpO2 B-Diagnostic_procedure
90.5 B-Lab_value
% I-Lab_value
, O
under B-Lab_value
10 I-Lab_value
L I-Lab_value
O2/min I-Lab_value
, O
reservoir B-Detailed_description
mask I-Detailed_description
) O
. O

After O
the O
tracheal B-Biological_structure
intubation B-Therapeutic_procedure
, O
100 B-Volume
mL I-Volume
of O
bright-red B-Color
blood B-Biological_structure
was O
aspirated B-Sign_symptom
. O

A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
showed O
bilateral B-Detailed_description
infiltrates B-Sign_symptom
( O
Fig. O
1 O
) O
. O

A O
chest B-Biological_structure
CT B-Diagnostic_procedure
further O
demonstrated O
multiple B-Detailed_description
consolidations B-Sign_symptom
and O
ground B-Texture
glass I-Texture
opacity B-Sign_symptom
and O
focal B-Detailed_description
bronchiectasis B-Disease_disorder
in O
right B-Biological_structure
segment I-Biological_structure
4 I-Biological_structure
( O
S4 B-Biological_structure
) O
( O
Fig. O
2 O
) O
. O

There O
were O
no O
space-occupying B-Detailed_description
lesions B-Sign_symptom
. O

Four B-Date
days I-Date
after I-Date
admission O
, O
her O
respiratory B-Diagnostic_procedure
condition I-Diagnostic_procedure
was O
improved B-Lab_value
. O

Since O
there O
was O
no O
active B-Detailed_description
hemorrhaging B-Sign_symptom
from O
the O
tracheal B-Therapeutic_procedure
tube I-Therapeutic_procedure
, O
she O
was O
then O
extubated B-Therapeutic_procedure
. O

After O
that O
, O
only O
a O
small B-Severity
amount I-Severity
of O
bloody B-Detailed_description
sputum B-Sign_symptom
was O
coughed O
up O
. O

To O
determine O
the O
origin O
of O
bleeding O
, O
she O
underwent O
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
, O
which O
showed O
bronchiectasis B-Disease_disorder
in O
right B-Biological_structure
S4 I-Biological_structure
and O
regression O
of O
the O
infiltration B-Sign_symptom
. O

CTA B-Diagnostic_procedure
revealed O
an O
abnormal B-Detailed_description
vascular B-Biological_structure
anastomosis B-Disease_disorder
between O
the O
right B-Biological_structure
inferior I-Biological_structure
phrenic I-Biological_structure
artery I-Biological_structure
and O
right B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
beside O
the O
focal B-Detailed_description
bronchiectasis B-Disease_disorder
at O
the O
right B-Biological_structure
middle I-Biological_structure
lobe I-Biological_structure
( O
Fig. O
3 O
) O
, O
which O
led O
us O
to O
suspect O
it O
as O
the O
possible O
source O
of O
the O
massive B-Severity
hemoptysis B-Sign_symptom
. O

We O
therefore O
performed O
embolization B-Therapeutic_procedure
by O
superselecting B-Therapeutic_procedure
the O
right B-Biological_structure
inferior I-Biological_structure
phrenic I-Biological_structure
artery I-Biological_structure
with O
a O
2.2-Fr B-Detailed_description
. I-Detailed_description

microcatheter B-Detailed_description
( O
Fig. O
4 O
) O
. O

An O
angiogram B-Diagnostic_procedure
of O
the O
right B-Biological_structure
bronchial I-Biological_structure
artery I-Biological_structure
showed O
no O
obvious O
active B-Detailed_description
bleeding B-Sign_symptom
. O

Three B-Date
weeks I-Date
after I-Date
the O
embolization O
, O
she O
was O
successfully O
discharged B-Clinical_event
and O
has O
been O
free O
from O
recurrent B-Detailed_description
hemoptysis B-Sign_symptom
for O
three B-Duration
years I-Duration
. O

A O
65-year-old B-Age
man B-Sex
with O
a O
45-year B-History
history I-History
of I-History
cigarette I-History
smoking I-History
visited B-Clinical_event
our O
hospital B-Nonbiological_location
for O
the O
diagnosis O
of O
an O
abnormal B-Detailed_description
chest B-Biological_structure
shadow B-Sign_symptom
on O
X-ray B-Diagnostic_procedure
. O

He O
did B-History
not I-History
have I-History
any I-History
remarkable I-History
medical I-History
history I-History
and O
had O
not O
been O
prescribed O
anticoagulants B-Medication
or O
antiplatelet B-Medication
agents I-Medication
. O

A O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
revealed O
a O
huge B-Detailed_description
mass B-Sign_symptom
in O
the O
left B-Biological_structure
upper I-Biological_structure
lobe I-Biological_structure
( O
maximum O
size O
: O
11.0 B-Distance
cm I-Distance
in O
diameter O
) O
that O
subsequently O
expanded O
to O
the O
left B-Biological_structure
hilum I-Biological_structure
and O
mediastinum B-Biological_structure
, O
as O
well O
as O
an O
intrapulmonary B-Biological_structure
metastasis B-Sign_symptom
located O
in O
the O
left B-Biological_structure
lower I-Biological_structure
lobe I-Biological_structure
, O
pleural B-Disease_disorder
effusion I-Disease_disorder
on O
the O
left B-Detailed_description
side I-Detailed_description
, O
and O
multiple B-Detailed_description
liver B-Biological_structure
tumors B-Sign_symptom
ranging O
from O
0.5 B-Distance
to I-Distance
4.7 I-Distance
cm I-Distance
in O
diameter O
( O
Fig. O
1 O
) O
. O

Of O
note O
, O
some B-Detailed_description
of O
the O
liver B-Biological_structure
metastases B-Coreference
were O
located B-Detailed_description
subcapsularly I-Detailed_description
, O
and O
the O
liver B-Biological_structure
surface I-Biological_structure
was O
irregularly B-Detailed_description
distorted B-Sign_symptom
. O

The O
laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
as O
follows O
: O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
11,900 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
hemoglobin B-Diagnostic_procedure
14.8 B-Lab_value
g/dL I-Lab_value
, O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
214,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
aspartate B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
31 B-Lab_value
IU/L I-Lab_value
, O
alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
19 B-Lab_value
IU/L I-Lab_value
, O
and O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
( O
LDH B-Diagnostic_procedure
) O
749 B-Lab_value
IU/L I-Lab_value
. O

No O
coagulation B-Sign_symptom
abnormalities I-Sign_symptom
were O
found O
. O

A O
subsequent O
histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
a O
tumor B-Sign_symptom
specimen O
obtained O
by O
bronchoscopy B-Diagnostic_procedure
confirmed O
the O
diagnosis O
of O
small B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
. O

On O
considering O
the O
clinical O
diagnosis O
, O
performance O
status O
, O
and O
age O
of O
the O
patient O
, O
we O
decided O
on O
a O
regimen O
of O
antitumor B-Detailed_description
chemotherapy B-Medication
consisting O
of O
cisplatin B-Medication
( O
60 B-Dosage
mg/m2 I-Dosage
body I-Dosage
surface I-Dosage
area I-Dosage
on O
Day B-Date
1 I-Date
) O
and O
etoposide B-Medication
( O
100 B-Dosage
mg/m2 I-Dosage
body I-Dosage
surface I-Dosage
area I-Dosage
on O
Days B-Date
1-3 I-Date
) O
. O

On O
a B-Date
day I-Date
after I-Date
2 I-Date
weeks I-Date
from O
the O
initial O
CT B-Diagnostic_procedure
scan O
, O
he O
started O
his O
first O
chemotherapy B-Medication
session O
. O

On O
Day B-Date
3 I-Date
after O
initiating O
chemotherapy O
, O
he O
complained O
of O
abdominal B-Biological_structure
discomfort B-Sign_symptom
, O
and O
his O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
showed O
tachycardia B-Sign_symptom
( O
120 B-Lab_value
beats I-Lab_value
per I-Lab_value
minute I-Lab_value
) O
and O
hypotension B-Sign_symptom
( O
85/55 B-Lab_value
mmHg I-Lab_value
) O
. O

A O
hematological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
severe B-Severity
anemia B-Sign_symptom
( O
hemoglobin B-Diagnostic_procedure
6.7 B-Lab_value
g/dL I-Lab_value
) O
that O
had O
dramatically O
dropped B-Lab_value
from O
14.8 B-Lab_value
g/dL I-Lab_value
over B-Duration
10 I-Duration
days I-Duration
. O

We O
attempted O
to O
identify O
the O
bleeding O
site O
on O
gastrointestinal B-Biological_structure
endoscopy B-Diagnostic_procedure
, O
to O
no O
avail O
, O
but O
a O
CT B-Diagnostic_procedure
scan O
revealed O
the O
rapid B-Detailed_description
enlargement B-Sign_symptom
of O
a O
liver B-Biological_structure
tumor B-Sign_symptom
in O
the O
left B-Biological_structure
lobe I-Biological_structure
, O
which O
contained O
partial B-Detailed_description
high-density B-Sign_symptom
areas I-Sign_symptom
on O
the O
plain B-Diagnostic_procedure
scan I-Diagnostic_procedure
, O
and O
also O
a O
novel O
finding O
of O
ascites B-Sign_symptom
showing O
higher B-Detailed_description
density I-Detailed_description
than I-Detailed_description
usual I-Detailed_description
, O
all O
suggesting O
a O
ruptured B-Detailed_description
liver B-Biological_structure
metastasis B-Sign_symptom
and O
associated O
hemorrhagic B-Detailed_description
ascites B-Sign_symptom
( O
Fig. O
2 O
) O
. O

A O
subsequent O
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
image O
was O
negative O
for O
extravasation B-Sign_symptom
. O

He O
underwent O
angiography B-Diagnostic_procedure
for O
the O
left B-Biological_structure
and I-Biological_structure
right I-Biological_structure
hepatic I-Biological_structure
arteries I-Biological_structure
, O
but O
we O
only O
observed O
obscure B-Detailed_description
tumor B-Sign_symptom
vessels I-Sign_symptom
in O
the O
left B-Biological_structure
hepatic I-Biological_structure
lobe I-Biological_structure
without O
extravasation B-Sign_symptom
( O
Fig. O
3A O
) O
. O

We O
suspected O
this O
might O
be O
due O
to O
the O
hypovascularity O
of O
the O
metastatic O
tumors O
and O
inactive O
bleeding O
at O
the O
time O
. O

Although O
the O
benefit O
of O
therapeutic O
embolization O
of O
the O
hepatic O
artery O
was O
uncertain O
based O
on O
the O
findings O
on O
angiography O
, O
we O
performed O
transcatheter B-Therapeutic_procedure
arterial I-Therapeutic_procedure
embolization I-Therapeutic_procedure
( O
TAE B-Therapeutic_procedure
) O
of O
the O
left B-Biological_structure
main I-Biological_structure
hepatic I-Biological_structure
artery I-Biological_structure
using O
gelform B-Therapeutic_procedure
particles I-Therapeutic_procedure
to O
prevent O
future O
re-bleeding O
. O

Post-embolization O
angiography B-Diagnostic_procedure
revealed O
a O
slowed B-Lab_value
blood B-Diagnostic_procedure
flow I-Diagnostic_procedure
in O
the O
left B-Biological_structure
hepatic I-Biological_structure
artery I-Biological_structure
, O
and O
the O
peripheral O
vessels O
were O
weakly O
visualized O
( O
Fig. O
3B O
) O
. O

After O
the O
embolization O
concomitant O
with O
supportive B-Therapeutic_procedure
therapies I-Therapeutic_procedure
, O
including O
RBC B-Medication
transfusions B-Administration
of O
6 B-Dosage
U I-Dosage
in O
total O
, O
the O
clinical B-Diagnostic_procedure
course I-Diagnostic_procedure
of O
the O
patient O
stabilized B-Lab_value
. O

His O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
remained O
around O
120/70 B-Lab_value
mmHg I-Lab_value
, O
tachycardia B-Sign_symptom
disappeared O
, O
and O
the O
anemia B-Sign_symptom
was O
improved O
after O
transfusion O
and O
did O
not O
progress O
again O
. O

Liver B-Biological_structure
dysfunction B-Sign_symptom
did O
not O
appear O
. O

A B-Date
month I-Date
after I-Date
the O
embolization O
, O
he O
was O
in O
relatively B-Lab_value
good I-Lab_value
health B-Diagnostic_procedure
and O
re-started O
his O
antitumor B-Detailed_description
chemotherapy B-Medication
, O
which O
he O
continued O
( O
first-line O
regimen O
) O
for O
six B-Dosage
courses I-Dosage
. O

A O
good B-Lab_value
partial B-Lab_value
response B-Diagnostic_procedure
was O
gained O
after O
chemotherapy B-Medication
for O
both O
the O
lung B-Biological_structure
and O
liver B-Biological_structure
lesions B-Sign_symptom
. O

A O
33-year-old B-Age
Moroccan B-Personal_background
man B-Sex
with O
a O
5-month B-Duration
history O
of O
recurring B-Detailed_description
sinusitis B-Disease_disorder
presented O
with O
temperature B-Sign_symptom
, O
myalgia B-Sign_symptom
, O
cough B-Sign_symptom
, O
and O
hemoptysis B-Sign_symptom
. O

Thoracic B-Biological_structure
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
reduced B-Lab_value
vesicular B-Diagnostic_procedure
murmur I-Diagnostic_procedure
, O
and O
chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
bilateral B-Detailed_description
diffuse B-Detailed_description
alveolar B-Biological_structure
infiltrates B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
analyses I-Diagnostic_procedure
showed O
elevation B-Lab_value
of O
acute-phase B-Diagnostic_procedure
proteins I-Diagnostic_procedure
( O
CRP B-Diagnostic_procedure
26 B-Lab_value
mg/dL I-Lab_value
) O
and O
creatinine B-Diagnostic_procedure
( O
1.2 B-Lab_value
mg/dL I-Lab_value
) O
with O
nonnephrotic B-Detailed_description
proteinuria B-Sign_symptom
and O
microscopic B-Detailed_description
glomerular B-Detailed_description
hematuria B-Sign_symptom
. O

An O
antibiotic B-Medication
therapy I-Medication
for O
community B-Detailed_description
acquired I-Detailed_description
and O
atypical B-Detailed_description
pneumoniae B-Disease_disorder
with O
levofloxacin B-Medication
500 B-Dosage
mg I-Dosage
daily I-Dosage
iv B-Administration
was O
established O
, O
but O
on O
the O
3rd B-Date
day I-Date
from O
admission O
the O
patient O
developed O
respiratory B-Disease_disorder
failure I-Disease_disorder
unresponsive O
to O
noninvasive B-Detailed_description
ventilation B-Therapeutic_procedure
and O
had O
to O
be O
intubated B-Therapeutic_procedure
. O

White B-Color
lung B-Biological_structure
with O
consolidations B-Sign_symptom
and O
ground B-Sign_symptom
glass I-Sign_symptom
areas I-Sign_symptom
at O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
( O
Fig. O
1 O
) O
, O
diffuse B-Detailed_description
airways B-Biological_structure
bleeding B-Sign_symptom
at O
fiberoptic B-Detailed_description
bronchoscopy B-Diagnostic_procedure
, O
mild B-Severity
normocytic B-Detailed_description
anemia B-Sign_symptom
( O
9 B-Lab_value
g/dL I-Lab_value
) O
, O
and O
ANCA-PR3 B-Diagnostic_procedure
positivity B-Lab_value
( O
18.9 B-Lab_value
U/mL I-Lab_value
) O
were O
consistent O
with O
the O
diagnosis O
of O
GPA B-Disease_disorder
. O

Despite O
maximal B-Detailed_description
ventilatory B-Therapeutic_procedure
support I-Therapeutic_procedure
, O
gas B-Diagnostic_procedure
exchange I-Diagnostic_procedure
did B-Lab_value
not I-Lab_value
improve I-Lab_value
( O
pH B-Diagnostic_procedure
7.33 B-Lab_value
, O
PaO2 B-Diagnostic_procedure
71 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
PaCO2 B-Diagnostic_procedure
51 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
HCO3 B-Diagnostic_procedure
– O
25 B-Lab_value
mmol/L I-Lab_value
, O
SaO2 B-Diagnostic_procedure
94 B-Lab_value
% I-Lab_value
) O
requiring O
extracorporeal B-Therapeutic_procedure
membrane I-Therapeutic_procedure
oxygenation I-Therapeutic_procedure
( O
ECMO B-Therapeutic_procedure
) O
. O

Treatment O
with O
high-dose B-Dosage
methylprednisolone B-Medication
( O
1 B-Dosage
g I-Dosage
daily I-Dosage
for O
3 B-Duration
days I-Duration
and O
1 B-Dosage
mg/kg I-Dosage
daily I-Dosage
thereafter O
) O
, O
cyclophosphamide B-Medication
( O
1.2 B-Dosage
g/pulse I-Dosage
every I-Dosage
2 I-Dosage
weeks I-Dosage
for I-Dosage
the I-Dosage
1st I-Dosage
3 I-Dosage
pulses I-Dosage
, O
followed O
by O
infusions O
every B-Dosage
3 I-Dosage
weeks I-Dosage
for I-Dosage
the I-Dosage
next I-Dosage
2 I-Dosage
pulses I-Dosage
) O
, O
and O
plasma B-Therapeutic_procedure
exchange I-Therapeutic_procedure
( O
PE B-Therapeutic_procedure
) O
, O
according O
to O
European B-Detailed_description
vasculitis I-Detailed_description
study I-Detailed_description
group I-Detailed_description
recommendations I-Detailed_description
, O
[ O
4 O
] O
was O
immediately O
started O
with O
respiratory B-Diagnostic_procedure
improvement B-Lab_value
that O
allowed O
ECMO B-Therapeutic_procedure
and O
orotracheal B-Therapeutic_procedure
tube I-Therapeutic_procedure
withdrawal O
and O
subsequent O
discharge B-Clinical_event
from O
intensive B-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
. O

After B-Date
9 I-Date
days I-Date
from O
the O
beginning O
of O
treatment O
ANCA-PR3 B-Diagnostic_procedure
levels O
normalized B-Lab_value
( O
3 B-Lab_value
U/mL I-Lab_value
) O
. O

Two B-Date
months I-Date
later I-Date
, O
after O
the O
5th B-Detailed_description
bolus I-Detailed_description
of O
cyclophosphamide B-Medication
and O
with O
prednisone B-Medication
0.3 B-Dosage
mg/kg/day I-Dosage
, O
the O
patient O
complained O
arthromyalgia B-Sign_symptom
and O
testicular B-Biological_structure
pain B-Sign_symptom
with O
edema B-Sign_symptom
, O
cough B-Sign_symptom
, O
and O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
: O
laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
showed O
worsening B-Lab_value
of O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
mild B-Severity
anemia B-Sign_symptom
, O
and O
hypoxemia B-Sign_symptom
( O
PaO2 B-Diagnostic_procedure
61 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
) O
. O

Epididymitis B-Disease_disorder
was O
confirmed O
by O
ultrasound B-Diagnostic_procedure
. O

Because O
of O
rapidly B-Detailed_description
progressive I-Detailed_description
renal B-Disease_disorder
failure I-Disease_disorder
( O
estimated O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
35 B-Lab_value
mL/min I-Lab_value
) O
renal B-Biological_structure
biopsy B-Diagnostic_procedure
was O
performed O
and O
showed O
prominent B-Severity
intracapillary B-Biological_structure
and O
extracapillary B-Biological_structure
proliferation B-Sign_symptom
, O
with O
the O
formation O
of O
some O
fibrocellular B-Sign_symptom
crescents I-Sign_symptom
and O
focal B-Detailed_description
capillary B-Biological_structure
necrosis B-Sign_symptom
( O
Fig. O
2 O
) O
. O

Lung B-Biological_structure
computed B-Diagnostic_procedure
tomography-scan I-Diagnostic_procedure
and O
fiberoptic B-Detailed_description
bronchoscopy B-Diagnostic_procedure
also O
confirmed O
alveolar B-Biological_structure
hemorrhage B-Sign_symptom
relapse B-Detailed_description
. O

Treatment O
with O
high-dose B-Dosage
methylprednisolone B-Medication
( O
1 B-Dosage
g I-Dosage
daily I-Dosage
for O
3 B-Duration
consecutive I-Duration
days I-Duration
) O
and O
rituximab B-Medication
( O
375 B-Dosage
mg/m2 I-Dosage
weekly I-Dosage
for O
4 B-Duration
weeks I-Duration
) O
was O
started O
with O
rapid O
resolution O
of O
urologic B-Biological_structure
and O
pulmonary B-Biological_structure
involvement B-Sign_symptom
but O
delayed B-Detailed_description
and O
partial B-Lab_value
improvement I-Lab_value
of O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
. O

At O
a O
1-year B-Date
follow-up B-Clinical_event
, O
the O
patient O
is O
alive B-Sign_symptom
and O
under O
treatment O
with O
azathioprine B-Medication
( O
150 B-Dosage
mg I-Dosage
daily I-Dosage
) O
and O
prednisone B-Medication
( O
15 B-Dosage
mg I-Dosage
daily I-Dosage
) O
. O

Renal B-Diagnostic_procedure
function I-Diagnostic_procedure
has O
markedly B-Lab_value
improved I-Lab_value
( O
estimated O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
94 B-Lab_value
mL/min I-Lab_value
) O
same O
as O
gas-exchange B-Diagnostic_procedure
( O
pH B-Diagnostic_procedure
7.42 B-Lab_value
, O
PaO2 B-Diagnostic_procedure
86 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
PaCO2 B-Diagnostic_procedure
36 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
HCO3 B-Diagnostic_procedure
– O
23 B-Lab_value
mmol/L I-Lab_value
, O
SaO2 B-Diagnostic_procedure
95 B-Lab_value
% I-Lab_value
) O
. O

The O
patient O
signed O
institutional O
informed O
consent O
form O
at O
the O
time O
of O
admission O
to O
hospitalization O
. O

An O
approval O
by O
ethics O
committee O
was O
not O
necessary O
because O
of O
the O
routine O
health O
care O
. O

A O
41-year-old B-Age
Caucasian B-Personal_background
woman B-Sex
underwent O
a O
primary B-Detailed_description
double B-Detailed_description
lung B-Therapeutic_procedure
transplantation I-Therapeutic_procedure
for O
cystic B-History
fibrosis I-History
in O
2006 B-Date
. O

Her O
medical B-History
history I-History
was I-History
otherwise I-History
unremarkable I-History
and O
the O
patient O
had O
no B-History
known I-History
history I-History
of I-History
pulmonary I-History
tuberculosis I-History
or I-History
tuberculosis I-History
contact I-History
. O

On O
December B-Date
2015 I-Date
, O
she O
underwent O
retransplantation B-Therapeutic_procedure
for O
chronic B-Detailed_description
lung B-Disease_disorder
allograft I-Disease_disorder
dysfunction I-Disease_disorder
. O

During O
the O
month B-Date
preceding I-Date
retransplantation O
, O
4 B-Lab_value
sputum B-Diagnostic_procedure
specimens I-Diagnostic_procedure
remained O
negative B-Lab_value
for O
acid-fast B-Detailed_description
bacilli I-Detailed_description
and O
specific B-Detailed_description
M. I-Detailed_description
tuberculosis I-Detailed_description
culture I-Detailed_description
and O
real-time B-Detailed_description
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction I-Diagnostic_procedure
( O
PCR B-Diagnostic_procedure
) O
testing O
. O

On O
postoperative O
day B-Date
42 I-Date
, O
deterioration B-Lab_value
of O
her O
respiratory B-Diagnostic_procedure
status I-Diagnostic_procedure
prompted O
a O
chest-computerized B-Biological_structure
tomography B-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
revealing O
sub-centimeter B-Detailed_description
bilateral B-Detailed_description
nodules B-Sign_symptom
primarily O
located O
in O
the O
apical B-Biological_structure
posterior I-Biological_structure
lobes I-Biological_structure
and O
a O
bilateral B-Detailed_description
pleural B-Disease_disorder
effusion I-Disease_disorder
( O
Fig. O
1 O
) O
. O

The O
same O
day O
, O
a O
bronchoalveolar B-Diagnostic_procedure
lavage I-Diagnostic_procedure
( O
BAL B-Diagnostic_procedure
) O
yielded O
a O
positive B-Lab_value
real-time B-Detailed_description
PCR B-Diagnostic_procedure
for O
rifampicin-susceptible B-Detailed_description
M. I-Detailed_description
tuberculosis I-Detailed_description
, O
confirmed B-Lab_value
by O
culture B-Diagnostic_procedure
on O
postoperative O
day B-Date
62 I-Date
. O

Tuberculin B-Diagnostic_procedure
skin I-Diagnostic_procedure
test I-Diagnostic_procedure
( O
TST B-Diagnostic_procedure
) O
or O
interferon-γ B-Diagnostic_procedure
release I-Diagnostic_procedure
assay I-Diagnostic_procedure
( O
IGRA B-Diagnostic_procedure
) O
test O
were O
not O
performed O
. O

All O
the O
BALs B-Diagnostic_procedure
performed O
on O
postoperative O
period O
yielded O
no B-Lab_value
other I-Lab_value
pathogen I-Lab_value
except O
for O
the O
one B-Coreference
performed O
on O
day B-Date
60 I-Date
that O
cultured O
Pseudomonas B-Lab_value
aeruginosa I-Lab_value
; O
the O
adjunctive B-Detailed_description
antibiotic B-Medication
therapy I-Medication
was O
imipenem-cilastatin B-Medication
, O
3 B-Dosage
g/d I-Dosage
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
a O
lung B-Biological_structure
biopsy B-Diagnostic_procedure
performed O
6 B-Date
weeks I-Date
after I-Date
retransplantation O
revealed O
a O
caseating B-Lab_value
granuloma I-Lab_value
and O
necrosis B-Lab_value
. O

Acid-fast B-Lab_value
bacilli I-Lab_value
were O
identified O
as O
rifampicin-susceptible B-Detailed_description
M. I-Detailed_description
tuberculosis I-Detailed_description
by O
real-time B-Detailed_description
PCR B-Diagnostic_procedure
. O

On O
postoperative O
day B-Date
65 I-Date
, O
the O
patient O
's O
status B-Diagnostic_procedure
worsened B-Lab_value
with O
severe B-Severity
hypoxemia B-Sign_symptom
, O
shock B-Disease_disorder
unresponsive O
to O
high B-Dosage
dose I-Dosage
cathecolamines B-Medication
, O
and O
multiorgan B-Disease_disorder
failure I-Disease_disorder
. O

The O
patient O
died B-Outcome
on O
postoperative O
day B-Date
70 I-Date
, O
despite O
treatment O
combining O
isoniazid B-Medication
, O
rifampicin B-Medication
, O
ethambutol B-Medication
, O
and O
pyrazinamide B-Medication
. O

Retrospective O
real-time B-Detailed_description
PCR B-Diagnostic_procedure
testing O
of O
the O
explanted B-Detailed_description
lung I-Detailed_description
and O
BALs B-Detailed_description
performed I-Detailed_description
on I-Detailed_description
postoperative I-Detailed_description
days I-Detailed_description
1 I-Detailed_description
, I-Detailed_description
7 I-Detailed_description
, I-Detailed_description
and I-Detailed_description
21 I-Detailed_description
remained O
negative B-Lab_value
. O

The O
organ B-Subject
donor I-Subject
died B-Detailed_description
of I-Detailed_description
posttraumatic I-Detailed_description
intracerebral I-Detailed_description
hemorrhage I-Detailed_description
. O

He B-Coreference
was O
a B-Detailed_description
47-year-old I-Detailed_description
man I-Detailed_description
with O
no B-Detailed_description
history I-Detailed_description
of I-Detailed_description
lung I-Detailed_description
disease I-Detailed_description
or I-Detailed_description
risk I-Detailed_description
factors I-Detailed_description
for I-Detailed_description
tuberculosis I-Detailed_description
other O
than O
chronic B-Detailed_description
alcohol I-Detailed_description
use I-Detailed_description
and I-Detailed_description
smoking I-Detailed_description
. O

TST B-Detailed_description
results I-Detailed_description
were I-Detailed_description
not I-Detailed_description
available I-Detailed_description
. O

During O
hospitalization O
, O
a O
lung B-Detailed_description
CT-scan I-Detailed_description
showed I-Detailed_description
no I-Detailed_description
signs I-Detailed_description
of I-Detailed_description
active I-Detailed_description
or I-Detailed_description
previous I-Detailed_description
tuberculosis I-Detailed_description
and O
no B-Detailed_description
TST I-Detailed_description
or I-Detailed_description
IGRA I-Detailed_description
test I-Detailed_description
results I-Detailed_description
were I-Detailed_description
available I-Detailed_description
. O

Routine O
cultures B-Detailed_description
of I-Detailed_description
per-transplantation I-Detailed_description
right I-Detailed_description
lung I-Detailed_description
biopsy I-Detailed_description
yielded I-Detailed_description
Candida I-Detailed_description
albicans I-Detailed_description
. O

Retrospective O
M. B-Detailed_description
tuberculosis I-Detailed_description
real-time I-Detailed_description
PCR I-Detailed_description
yielded I-Detailed_description
negative I-Detailed_description
results I-Detailed_description
on I-Detailed_description
the I-Detailed_description
left I-Detailed_description
and I-Detailed_description
right I-Detailed_description
donor-lung I-Detailed_description
biopsies I-Detailed_description
. O

Both B-Detailed_description
kidneys I-Detailed_description
from O
the O
same O
donor B-Coreference
were O
transplanted B-Detailed_description
into I-Detailed_description
2 I-Detailed_description
other I-Detailed_description
recipients I-Detailed_description
. O

Six B-Detailed_description
months I-Detailed_description
after I-Detailed_description
transplantation I-Detailed_description
, O
neither B-Detailed_description
of I-Detailed_description
the I-Detailed_description
kidney I-Detailed_description
recipients I-Detailed_description
had I-Detailed_description
developed I-Detailed_description
any I-Detailed_description
signs I-Detailed_description
or I-Detailed_description
symptoms I-Detailed_description
suggestive I-Detailed_description
of I-Detailed_description
active I-Detailed_description
tuberculosis I-Detailed_description
. O

A O
41-year-old B-Age
man B-Sex
with O
a O
history O
of O
alcoholism B-History
for O
10 B-Duration
years I-Duration
and O
sober B-History
for O
the O
last B-Duration
3 I-Duration
years I-Duration
, O
recurrent B-History
alcoholic I-History
pancreatitis I-History
, O
and O
no B-History
known I-History
liver I-History
disease I-History
, O
presented B-Clinical_event
with O
several B-Detailed_description
episodes I-Detailed_description
of O
hematemesis B-Sign_symptom
and O
abdominal B-Biological_structure
pain B-Sign_symptom
for O
2 B-Duration
days I-Duration
. O

Esophagogastroduodenoscopy B-Diagnostic_procedure
( O
EGD B-Diagnostic_procedure
) O
, O
performed O
3 B-Date
years I-Date
earlier I-Date
for O
abdominal B-Biological_structure
pain B-Sign_symptom
, O
had O
revealed O
no O
esophageal B-Biological_structure
varices B-Sign_symptom
, O
gastric B-Biological_structure
varices B-Sign_symptom
, O
portal B-Biological_structure
hypertensive B-Detailed_description
gastropathy B-Disease_disorder
, O
or O
other O
GI B-Biological_structure
lesions B-Sign_symptom
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
= O
100/60 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
pulse B-Diagnostic_procedure
= O
60 B-Lab_value
beats/min I-Lab_value
, O
no O
jaundice B-Sign_symptom
, O
no O
stigmata B-Sign_symptom
of I-Sign_symptom
chronic I-Sign_symptom
liver I-Sign_symptom
disease I-Sign_symptom
, O
a O
soft B-Sign_symptom
abdomen B-Biological_structure
with O
mild B-Severity
epigastric B-Biological_structure
tenderness B-Sign_symptom
but O
no O
rebound B-Detailed_description
tenderness B-Sign_symptom
, O
no O
abdominal B-Biological_structure
bruit B-Sign_symptom
, O
and O
no O
pulsatile B-Detailed_description
abdominal B-Biological_structure
mass B-Sign_symptom
. O

Rectal B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
gross O
melena B-Sign_symptom
. O

Laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
hemoglobin B-Diagnostic_procedure
= O
12.5 B-Lab_value
g/dL I-Lab_value
, O
platelets B-Diagnostic_procedure
= O
301,000 B-Lab_value
/ I-Lab_value
mL I-Lab_value
, O
INR B-Diagnostic_procedure
( O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
) O
= O
1.0 B-Lab_value
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen I-Diagnostic_procedure
= O
20 B-Lab_value
mg/dL I-Lab_value
, O
and O
creatinine B-Diagnostic_procedure
= O
1.1 B-Lab_value
mg/dL I-Lab_value
. O

Serum B-Diagnostic_procedure
aspartate I-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
= O
21 B-Lab_value
IU/L I-Lab_value
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
= O
16 B-Lab_value
IU/L I-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
= O
0.6 B-Lab_value
mg/dL I-Lab_value
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
= O
64 B-Lab_value
IU/L I-Lab_value
, O
albumin B-Diagnostic_procedure
= O
4.4 B-Lab_value
gm/dL I-Lab_value
, O
and O
lipase B-Diagnostic_procedure
= O
32 B-Lab_value
U/dL I-Lab_value
. O

The O
hemoglobin B-Diagnostic_procedure
declined B-Lab_value
acutely I-Lab_value
to O
9.3 B-Lab_value
g/dL I-Lab_value
. O

Abdomino-pelvic B-Biological_structure
computerized B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
, O
with O
intravenous B-Detailed_description
contrast I-Detailed_description
, I-Detailed_description
revealed O
a O
5-cm B-Distance
wide O
, O
irregular B-Detailed_description
, O
pancreatic/peripancreatic B-Biological_structure
mass B-Sign_symptom
, O
compressing B-Sign_symptom
both O
the O
lesser B-Biological_structure
curvature I-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
and O
the O
SV B-Biological_structure
( O
Fig. O
1A O
, O
B O
) O
, O
a O
normal B-Lab_value
portal B-Diagnostic_procedure
vein I-Diagnostic_procedure
, O
and O
normal B-Lab_value
liver B-Diagnostic_procedure
parenchyma I-Diagnostic_procedure
. O

The O
SV B-Biological_structure
compression B-Sign_symptom
was O
pathophysiologically B-Lab_value
significant I-Lab_value
as O
indicated O
by O
proximal B-Biological_structure
SV I-Biological_structure
dilatation B-Sign_symptom
. O

EGD B-Diagnostic_procedure
revealed O
in O
the O
proximal B-Biological_structure
stomach I-Biological_structure
a O
fine B-Detailed_description
, O
reticular B-Detailed_description
, O
pale-white B-Color
, O
polygonal B-Shape
, O
mucosal B-Biological_structure
, O
network B-Sign_symptom
in O
a O
snakeskin B-Texture
pattern I-Texture
, O
and O
characteristic O
of O
portal B-Disease_disorder
hypertensive I-Disease_disorder
gastropathy I-Disease_disorder
that O
was O
actively O
oozing B-Sign_symptom
; O
extensive B-Severity
coffee-ground B-Texture
, O
blood B-Sign_symptom
clots I-Sign_symptom
in O
the O
stomach B-Biological_structure
; O
small O
gastric B-Biological_structure
cardial B-Biological_structure
and O
fundal B-Biological_structure
varices B-Sign_symptom
without O
stigmata B-Sign_symptom
of I-Sign_symptom
recent I-Sign_symptom
hemorrhage I-Sign_symptom
( O
SRH B-Sign_symptom
) O
; O
and O
no O
esophageal B-Biological_structure
varices B-Sign_symptom
( O
Fig O
. O

2 O
) O
. O

The O
extrinsic O
mass B-Coreference
produced O
a O
large B-Detailed_description
, O
round B-Shape
bulge B-Sign_symptom
extending B-Biological_structure
into I-Biological_structure
the I-Biological_structure
lumen I-Biological_structure
of I-Biological_structure
the I-Biological_structure
proximal I-Biological_structure
gastric I-Biological_structure
body I-Biological_structure
along O
the O
lesser B-Biological_structure
curvature I-Biological_structure
( O
Fig. O
2 O
) O
. O

Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
cholangio-pancreatography I-Diagnostic_procedure
( O
MRCP B-Diagnostic_procedure
) O
revealed O
a O
5-cm B-Distance
wide O
, O
enhancing B-Detailed_description
, O
vascular B-Biological_structure
mass B-Sign_symptom
likely O
arising B-Biological_structure
from I-Biological_structure
the I-Biological_structure
LGA I-Biological_structure
and O
located O
between B-Biological_structure
the I-Biological_structure
gastric I-Biological_structure
lesser I-Biological_structure
curvature I-Biological_structure
and I-Biological_structure
distal I-Biological_structure
pancreatic I-Biological_structure
body I-Biological_structure
; O
compressing B-Sign_symptom
the O
stomach B-Biological_structure
; O
compressing B-Sign_symptom
the O
middle B-Biological_structure
SV I-Biological_structure
; O
and O
resulting O
in O
large B-Detailed_description
collateral B-Sign_symptom
veins I-Sign_symptom
draining O
the O
SV B-Biological_structure
into O
the O
superior B-Biological_structure
mesenteric I-Biological_structure
vein I-Biological_structure
( O
Fig. O
3A O
, O
B O
) O
. O

Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
with O
Doppler B-Detailed_description
studies I-Detailed_description
demonstrated O
large B-Detailed_description
, O
turbulent B-Detailed_description
arterial B-Biological_structure
flow B-Sign_symptom
into O
this O
vascular B-Biological_structure
mass B-Coreference
, O
suggesting O
a O
large B-Detailed_description
PA B-Disease_disorder
( O
Fig. O
4 O
) O
. O

Visceral B-Detailed_description
arteriogram B-Diagnostic_procedure
showed O
a O
5.3 B-Volume
× I-Volume
2.2-cm-wide I-Volume
PA B-Disease_disorder
supplied O
by O
an O
LGA B-Biological_structure
branch I-Biological_structure
( O
Fig. O
5A O
) O
, O
which O
was O
embolized B-Therapeutic_procedure
and O
occluded B-Therapeutic_procedure
with O
microcoils B-Detailed_description
( O
Fig. O
5B O
) O
. O

Eight B-Date
weeks I-Date
later I-Date
, O
the O
patient O
had O
a O
stable B-Lab_value
hemoglobin B-Diagnostic_procedure
level O
with O
no O
further O
GI B-Biological_structure
bleeding B-Sign_symptom
. O

Abdomino-pelvic B-Biological_structure
CT B-Detailed_description
angiography B-Diagnostic_procedure
demonstrated O
the O
PA B-Disease_disorder
had O
markedly O
decreased B-Lab_value
in I-Lab_value
diameter I-Lab_value
, O
contained B-Detailed_description
numerous I-Detailed_description
microcoils I-Detailed_description
, O
and O
had O
no B-Detailed_description
blood I-Detailed_description
flow I-Detailed_description
( O
Fig. O
1C O
) O
. O

A O
75-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
the O
evaluation O
of O
dysphagia B-Sign_symptom
for O
9 B-Duration
months I-Duration
. O

He O
had O
associated O
symptoms O
of O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
but O
denied O
hematemesis B-Sign_symptom
, O
hematochezia B-Sign_symptom
, O
lethargy B-Sign_symptom
, O
and O
dyspnea B-Sign_symptom
. O

He O
was O
an O
active B-History
smoker I-History
and O
consumed B-History
alcohol I-History
for I-History
30 I-History
years I-History
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
no O
peripheral B-Detailed_description
lymphadenopathy B-Sign_symptom
, O
thyromegaly B-Sign_symptom
, O
ascites B-Sign_symptom
, O
or O
mass B-Sign_symptom
in O
the O
abdomen B-Biological_structure
. O

Laboratory B-Diagnostic_procedure
data I-Diagnostic_procedure
were O
normal B-Lab_value
: O
HBs-Ag B-Diagnostic_procedure
negative B-Lab_value
, O
HIV B-Diagnostic_procedure
negative B-Lab_value
, O
and O
syphilis B-Diagnostic_procedure
negative B-Lab_value
. O

Test O
for O
serum B-Diagnostic_procedure
antibody I-Diagnostic_procedure
against I-Diagnostic_procedure
Helicobacter I-Diagnostic_procedure
pylori I-Diagnostic_procedure
was O
negative B-Lab_value
. O

Chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
was O
notable O
for O
a O
huge B-Detailed_description
well-circumscribed B-Detailed_description
and O
homogeneous B-Detailed_description
cylindrical B-Shape
mesenchymal B-Detailed_description
neoplasm B-Sign_symptom
measuring O
15.5 B-Volume
× I-Volume
5.9 I-Volume
× I-Volume
4.0 I-Volume
cm I-Volume
in O
lower B-Biological_structure
and I-Biological_structure
middle I-Biological_structure
esophagus I-Biological_structure
with O
mild B-Detailed_description
contrast I-Detailed_description
enhancement I-Detailed_description
( O
Fig. O
1A O
) O
. O

CT B-Diagnostic_procedure
revealed O
no O
abnormalities B-Sign_symptom
in O
the O
lungs B-Biological_structure
, O
heart B-Biological_structure
, O
ribs B-Biological_structure
, O
or O
mediastinum B-Biological_structure
. O

Endoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
submucosal B-Detailed_description
lesion B-Sign_symptom
in O
the O
esophagus B-Biological_structure
starting O
at O
20 B-Distance
cm I-Distance
from I-Distance
the I-Distance
incisor I-Distance
teeth I-Distance
extending O
up B-Biological_structure
to I-Biological_structure
the I-Biological_structure
cardia I-Biological_structure
( O
Fig. O
1B O
) O
. O

Endoscopic B-Diagnostic_procedure
ultrasonography I-Diagnostic_procedure
( O
EUS B-Diagnostic_procedure
) O
revealed O
hypoechoic B-Detailed_description
lesion B-Sign_symptom
with O
a O
clear B-Detailed_description
boundary I-Detailed_description
located O
in O
the O
4th B-Detailed_description
layer I-Detailed_description
. O

The O
mass B-Coreference
appeared O
as O
a O
benign B-Sign_symptom
tumor I-Sign_symptom
and O
was O
preoperatively O
diagnosed O
as O
esophageal B-Disease_disorder
leiomyoma I-Disease_disorder
based O
on O
chest O
CT O
, O
endoscopic O
examination O
, O
and O
EUS O
findings O
. O

Endoscopic B-Detailed_description
mucosal B-Detailed_description
resection B-Therapeutic_procedure
or O
endoscopic B-Detailed_description
submucosal B-Detailed_description
resection B-Therapeutic_procedure
was O
not O
possible O
because O
of O
large O
size O
. O

Hence O
, O
surgical B-Detailed_description
resection B-Therapeutic_procedure
was O
planned O
and O
informed O
written O
consent O
was O
taken O
. O

The O
patient O
underwent O
thoracoscopic-assisted B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
mass B-Coreference
with O
gastroesophageal B-Detailed_description
anastomosis B-Therapeutic_procedure
, O
thoracic B-Biological_structure
duct I-Biological_structure
ligation B-Therapeutic_procedure
, O
and O
jejunostomy B-Therapeutic_procedure
. O

Postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
uneventful B-Lab_value
. O

Grossly O
, O
a O
spindle B-Shape
shaped I-Shape
lump B-Sign_symptom
measuring O
14 B-Volume
× I-Volume
3.5 I-Volume
× I-Volume
2.5 I-Volume
cm I-Volume
, O
was O
observed O
in O
the O
resected O
esophagus B-Biological_structure
, O
which O
grew O
into O
the O
esophageal B-Biological_structure
lumen I-Biological_structure
and O
blocked B-Sign_symptom
most O
of O
lumen B-Biological_structure
. O

This O
lump B-Coreference
located O
in O
the O
submucosa B-Biological_structure
was O
covered B-Detailed_description
with I-Detailed_description
intact I-Detailed_description
mucosa I-Detailed_description
, O
without O
erosion B-Sign_symptom
, O
ulcer B-Disease_disorder
, O
and O
hemorrhage B-Disease_disorder
. O

Its O
cut O
surface O
was O
homogenously B-Color
white I-Color
to O
grayish-white B-Color
in O
color O
. O

Histological B-Diagnostic_procedure
examination I-Diagnostic_procedure
using O
hematoxylin B-Diagnostic_procedure
and O
eosin B-Diagnostic_procedure
staining I-Diagnostic_procedure
revealed O
that O
tumor B-Coreference
was O
covered B-Detailed_description
with I-Detailed_description
intact I-Detailed_description
squamous I-Detailed_description
epithelium I-Detailed_description
, O
arising O
from B-Biological_structure
the I-Biological_structure
submucosal I-Biological_structure
layer I-Biological_structure
and O
expanding O
in O
to O
the O
muscular B-Biological_structure
layer I-Biological_structure
. O

The O
tumor B-Coreference
was O
composed B-Detailed_description
of I-Detailed_description
many I-Detailed_description
nodules I-Detailed_description
of I-Detailed_description
varying I-Detailed_description
sizes I-Detailed_description
separated I-Detailed_description
by I-Detailed_description
collagen I-Detailed_description
fibers I-Detailed_description
. O

Numerous B-Detailed_description
cytoplasm-rich I-Detailed_description
cells I-Detailed_description
were I-Detailed_description
observed I-Detailed_description
in I-Detailed_description
the I-Detailed_description
collagenous I-Detailed_description
septations I-Detailed_description
with I-Detailed_description
invasive I-Detailed_description
growth I-Detailed_description
pattern I-Detailed_description
( O
Fig. O
2A O
– O
C O
) O
. O

The O
nodules B-Detailed_description
were I-Detailed_description
mainly I-Detailed_description
composed I-Detailed_description
of I-Detailed_description
small I-Detailed_description
to I-Detailed_description
mid-sized I-Detailed_description
centrocyte-like I-Detailed_description
or I-Detailed_description
monocyte-like I-Detailed_description
cells I-Detailed_description
arranged I-Detailed_description
in I-Detailed_description
diffuse I-Detailed_description
pattern I-Detailed_description
. O

These O
atypical B-Detailed_description
lymphocytes I-Detailed_description
possessed O
clear B-Detailed_description
boundary I-Detailed_description
, O
pale B-Detailed_description
cytoplasm I-Detailed_description
, O
irregular B-Detailed_description
nucleus I-Detailed_description
, O
and O
occasional B-Detailed_description
nucleolus I-Detailed_description
( O
Fig. O
2D O
) O
. O

Mitosis B-Diagnostic_procedure
was O
rare B-Lab_value
. O

No O
lymphoepithelial B-Detailed_description
lesion B-Sign_symptom
was O
recognized O
in O
the O
lesion B-Coreference
. O

On O
immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
, O
epithelium B-Biological_structure
was O
diffusely B-Lab_value
positive I-Lab_value
for O
cytokeratin B-Diagnostic_procedure
( O
Fig. O
3A O
) O
, O
and O
the O
tumor B-Coreference
cells I-Coreference
were O
diffusely B-Lab_value
positive I-Lab_value
for O
cluster B-Diagnostic_procedure
of I-Diagnostic_procedure
differentiation I-Diagnostic_procedure
( I-Diagnostic_procedure
CD I-Diagnostic_procedure
) I-Diagnostic_procedure
20 I-Diagnostic_procedure
, O
paired B-Diagnostic_procedure
box I-Diagnostic_procedure
5 I-Diagnostic_procedure
( O
Fig. O
3B O
) O
, O
and O
B-cell B-Diagnostic_procedure
lymphoma I-Diagnostic_procedure
( I-Diagnostic_procedure
Bcl I-Diagnostic_procedure
) I-Diagnostic_procedure
-2 I-Diagnostic_procedure
( O
Fig. O
3D O
) O
. O

Small B-Biological_structure
deposits I-Biological_structure
of I-Biological_structure
tumor I-Biological_structure
cells I-Biological_structure
, O
which O
were O
distributed O
mainly B-Detailed_description
in I-Detailed_description
the I-Detailed_description
collagen I-Detailed_description
fibers I-Detailed_description
, O
were O
positive B-Lab_value
for O
multiple B-Diagnostic_procedure
myeloma I-Diagnostic_procedure
oncogene I-Diagnostic_procedure
1 I-Diagnostic_procedure
, O
CD138 B-Diagnostic_procedure
, O
and O
CD43 B-Diagnostic_procedure
. O

Several B-Biological_structure
tumor I-Biological_structure
cells I-Biological_structure
were O
also O
positive B-Lab_value
for O
CD30 B-Diagnostic_procedure
. O

Small B-Biological_structure
lymphocytes I-Biological_structure
were O
positive B-Lab_value
for O
CD3 B-Diagnostic_procedure
and O
CD5 B-Diagnostic_procedure
. O

Follicular B-Biological_structure
dendritic I-Biological_structure
cells I-Biological_structure
were O
positive B-Lab_value
for O
CD21 B-Diagnostic_procedure
and O
CD23 B-Diagnostic_procedure
( O
Fig. O
3C O
) O
. O

All B-Biological_structure
cells I-Biological_structure
were O
negative B-Lab_value
for O
CyclinD1 B-Diagnostic_procedure
, O
CD10 B-Diagnostic_procedure
, O
Bcl-6 B-Diagnostic_procedure
, O
and O
B B-Diagnostic_procedure
lymphocyte I-Diagnostic_procedure
specific I-Diagnostic_procedure
activation I-Diagnostic_procedure
of I-Diagnostic_procedure
OCT I-Diagnostic_procedure
binding I-Diagnostic_procedure
protein I-Diagnostic_procedure
1 I-Diagnostic_procedure
. O

These O
follicular O
dendritic O
cells O
were O
arranged O
in O
nodules O
in O
which O
the O
tumor O
cells O
were O
relatively O
evenly O
distributed O
. O

This O
pattern O
was O
suggestive O
of O
follicular O
colonizations O
seen O
in O
MALT B-Disease_disorder
lymphoma I-Disease_disorder
. O

In O
this O
case O
, O
gene B-Diagnostic_procedure
rearragements I-Diagnostic_procedure
and I-Diagnostic_procedure
clonality I-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
immunoglobulin B-Diagnostic_procedure
heavy I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene I-Diagnostic_procedure
, O
kappa B-Diagnostic_procedure
light I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene I-Diagnostic_procedure
, O
and O
lambda B-Diagnostic_procedure
light I-Diagnostic_procedure
chain I-Diagnostic_procedure
gene I-Diagnostic_procedure
was O
performed O
using O
the O
IdentiCloneTM B-Detailed_description
IGH/IGK/IGL I-Detailed_description
Gene I-Detailed_description
Clonality I-Detailed_description
Assay I-Detailed_description
( O
InVivoScribe B-Detailed_description
Technologies I-Detailed_description
, I-Detailed_description
CA I-Detailed_description
) O
. O

On O
monoclonal O
gene O
rearrangement O
, O
1 B-Lab_value
band I-Lab_value
appeared I-Lab_value
within I-Lab_value
150 I-Lab_value
to I-Lab_value
175 I-Lab_value
base I-Lab_value
pairs I-Lab_value
( O
bp O
) O
in O
heavy B-Coreference
chain I-Coreference
gene I-Coreference
, O
2 B-Lab_value
discrete I-Lab_value
bands I-Lab_value
within I-Lab_value
225 I-Lab_value
to I-Lab_value
250 I-Lab_value
bp I-Lab_value
in O
kappa B-Coreference
light I-Coreference
chain I-Coreference
gene I-Coreference
, O
and O
1 B-Lab_value
band I-Lab_value
within I-Lab_value
125 I-Lab_value
to I-Lab_value
150 I-Lab_value
bp I-Lab_value
in O
lambda B-Coreference
light I-Coreference
chain I-Coreference
gene I-Coreference
( O
Fig. O
4 O
) O
. O

In O
addition O
, O
no O
Epstein B-Disease_disorder
– I-Disease_disorder
Barr I-Disease_disorder
virus I-Disease_disorder
was O
observed O
in O
this O
lymphoma O
on O
in B-Diagnostic_procedure
situ I-Diagnostic_procedure
hybridization I-Diagnostic_procedure
using O
the O
EB B-Detailed_description
virus-encoded I-Detailed_description
small I-Detailed_description
RNA I-Detailed_description
( O
Fig. O
3E O
, O
F O
) O
. O

Based O
on O
the O
clinical O
data O
, O
pathological O
, O
immunohistochemical O
, O
and O
gene O
rearragements O
analysis O
, O
final O
diagnosis O
of O
primary B-Detailed_description
esophageal B-Biological_structure
MALT B-Disease_disorder
lymphoma I-Disease_disorder
was O
made O
. O

After O
the O
surgical B-Detailed_description
resection B-Therapeutic_procedure
, O
no O
additional O
therapy B-Therapeutic_procedure
in O
the O
form O
of O
chemotherapy B-Medication
or O
radiotherapy B-Therapeutic_procedure
was O
administered O
. O

Over O
the O
8 B-Duration
months I-Duration
of O
follow-up B-Clinical_event
, O
no O
evidence O
of O
recurrence B-Sign_symptom
or O
metastases B-Sign_symptom
was O
found O
on O
CT B-Diagnostic_procedure
and O
the O
patient O
has O
been O
asymptomatic B-Sign_symptom
. O

Ethical O
approval O
for O
this O
study O
was O
obtained O
from O
Medical O
Ethics O
Committee O
of O
the O
Third O
Affiliated O
Hospital O
, O
the O
Third O
Military O
Medical O
University O
. O

Written O
informed O
consent O
was O
obtained O
from O
the O
patient O
for O
the O
publication O
of O
this O
case O
report O
and O
the O
accompanying O
images O
. O

A O
47-year-old B-Age
female B-Sex
patient O
presented B-Clinical_event
progressively B-Detailed_description
worsening I-Detailed_description
pain B-Sign_symptom
in O
the O
chest B-Biological_structure
wall I-Biological_structure
, O
back B-Biological_structure
, O
and O
bilateral B-Biological_structure
lower I-Biological_structure
extremities I-Biological_structure
as O
well O
as O
muscle B-Sign_symptom
weakness I-Sign_symptom
. O

She O
did B-Family_history
not I-Family_history
have I-Family_history
a I-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
bone I-Family_history
disease I-Family_history
or I-Family_history
fractures I-Family_history
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
excluding B-Detailed_description
bone I-Detailed_description
and I-Detailed_description
muscular I-Detailed_description
abnormalities I-Detailed_description
. O

Bone B-Biological_structure
scintigraphy B-Diagnostic_procedure
using B-Detailed_description
technetium-99m I-Detailed_description
methylenediphosphate I-Detailed_description
showed O
increased O
uptake B-Sign_symptom
in O
the O
shoulder B-Biological_structure
, O
multiple B-Biological_structure
ribs I-Biological_structure
, O
thoracic B-Biological_structure
and I-Biological_structure
lumbar I-Biological_structure
spines I-Biological_structure
, O
bilateral B-Biological_structure
sacroiliac I-Biological_structure
joints I-Biological_structure
, O
left B-Biological_structure
ilium I-Biological_structure
, O
and O
left B-Biological_structure
foot I-Biological_structure
( O
Fig. O
1 O
) O
. O

Plain B-Detailed_description
radiographs B-Diagnostic_procedure
revealed O
osteoporosis B-Disease_disorder
change O
of O
thoracic B-Biological_structure
and I-Biological_structure
lumbar I-Biological_structure
spine I-Biological_structure
as O
well O
as O
compression B-Sign_symptom
change O
of O
several B-Biological_structure
spines I-Biological_structure
, O
consistent O
with O
findings O
of O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
( O
Fig. O
1 O
) O
. O

Decreased B-Lab_value
bone B-Diagnostic_procedure
mass I-Diagnostic_procedure
was O
presented O
in O
the O
lumbar B-Biological_structure
spine I-Biological_structure
( O
T-score B-Lab_value
: I-Lab_value
− I-Lab_value
3.4 I-Lab_value
) O
, O
femoral B-Biological_structure
neck I-Biological_structure
( O
T-score B-Lab_value
: I-Lab_value
− I-Lab_value
3.1 I-Lab_value
) O
, O
and O
hip B-Biological_structure
( O
T-score B-Lab_value
: I-Lab_value
− I-Lab_value
3.5 I-Lab_value
) O
. O

Main O
laboratory O
data O
are O
shown O
in O
Table O
1 O
. O

She O
demonstrated O
hypophosphatemia B-Sign_symptom
, O
hypokalemia B-Sign_symptom
, O
hypouricemia B-Sign_symptom
, O
elevated B-Lab_value
level O
of O
ALP B-Diagnostic_procedure
, O
C-telopeptides B-Diagnostic_procedure
and O
chloride B-Diagnostic_procedure
, O
and O
decreased B-Lab_value
carbon B-Diagnostic_procedure
dioxide I-Diagnostic_procedure
combining I-Diagnostic_procedure
power I-Diagnostic_procedure
. O

The O
urinalysis B-Diagnostic_procedure
revealed O
a O
high B-Lab_value
pH B-Diagnostic_procedure
value O
, O
increased B-Lab_value
level O
of O
potassium B-Diagnostic_procedure
, O
and O
decreased B-Lab_value
level O
of O
specific B-Diagnostic_procedure
gravity I-Diagnostic_procedure
, O
chlorine B-Diagnostic_procedure
, O
and O
phosphate B-Diagnostic_procedure
. O

Persistent B-Detailed_description
glycosuria B-Sign_symptom
and O
proteinuria B-Sign_symptom
were O
repeatedly O
found O
, O
despite O
normal B-Lab_value
HbA1c B-Diagnostic_procedure
and O
plasma B-Diagnostic_procedure
glucose I-Diagnostic_procedure
level O
. O

Other O
laboratory B-Diagnostic_procedure
test I-Diagnostic_procedure
results O
including O
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
test O
, O
serum B-Diagnostic_procedure
parathyroid I-Diagnostic_procedure
hormone I-Diagnostic_procedure
, O
25-hydroxyvitamin B-Diagnostic_procedure
D I-Diagnostic_procedure
, O
and O
protein B-Diagnostic_procedure
electrophoresis I-Diagnostic_procedure
were O
within B-Lab_value
normal I-Lab_value
range I-Lab_value
. O

In O
addition O
, O
all O
of O
serum B-Diagnostic_procedure
tumor I-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
negative B-Lab_value
. O

Due O
to O
limited O
technique O
, O
we O
can O
not O
determine O
the O
level O
of O
serum B-Diagnostic_procedure
fibroblast I-Diagnostic_procedure
growth I-Diagnostic_procedure
factor I-Diagnostic_procedure
23 I-Diagnostic_procedure
. O

With O
the O
clinical O
diagnosis O
of O
HO B-Disease_disorder
, O
fluorodeoxyglucose B-Diagnostic_procedure
positron I-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography/computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
18F-FDG B-Diagnostic_procedure
PET/CT I-Diagnostic_procedure
) O
and O
technetium-99m B-Detailed_description
octreotide I-Detailed_description
( O
99mTc-OCT B-Detailed_description
) O
scintigraphy B-Diagnostic_procedure
were O
performed O
to O
confirm O
whether O
the O
occult B-Detailed_description
causative B-Detailed_description
tumor B-Sign_symptom
exist O
. O

However O
, O
the O
results O
of O
these B-Coreference
2 I-Coreference
tests I-Coreference
were O
negative B-Lab_value
except O
that O
mild B-Severity
uptake B-Sign_symptom
in O
the O
seventh B-Biological_structure
rib I-Biological_structure
was O
found O
on O
PET/CT B-Diagnostic_procedure
, O
which O
identified O
no O
evidence O
of O
a O
neoplastic B-Detailed_description
lesion B-Sign_symptom
potentially O
responsible O
for O
HO O
( O
Fig. O
2 O
) O
. O

The O
immunological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
elevated B-Lab_value
level O
of O
serum B-Diagnostic_procedure
IgG I-Diagnostic_procedure
, O
IgM B-Diagnostic_procedure
, O
and O
IgA B-Diagnostic_procedure
, O
as O
well O
as O
positive B-Lab_value
antinuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
, O
anti-SSA B-Diagnostic_procedure
antibody I-Diagnostic_procedure
, O
and O
rheumatic B-Diagnostic_procedure
factor I-Diagnostic_procedure
. O

Subsequently O
, O
Schirmer B-Diagnostic_procedure
test I-Diagnostic_procedure
was O
abnormal B-Lab_value
and O
lip B-Biological_structure
biopsy B-Diagnostic_procedure
supported O
the O
diagnosis O
of O
SS B-Disease_disorder
( O
Fig. O
3 O
) O
. O

Eventually O
, O
this O
patient O
was O
diagnosed O
with O
HO B-Disease_disorder
secondary O
to O
SS B-Disease_disorder
, O
and O
she O
was O
then O
treated O
with O
alkalinization B-Therapeutic_procedure
( O
citrate B-Medication
4 B-Dosage
g/day I-Dosage
and O
potassium B-Medication
citrate I-Medication
3 B-Dosage
g/day I-Dosage
for O
2 B-Duration
weeks I-Duration
) O
, O
steroids B-Medication
( O
prednisone B-Medication
20 B-Dosage
mg/day I-Dosage
for O
1 B-Duration
month I-Duration
, O
10 B-Dosage
mg/day I-Dosage
for O
4 B-Duration
months I-Duration
) O
, O
neutral B-Medication
phosphate I-Medication
( O
1.0 B-Dosage
g/day I-Dosage
for O
5 B-Duration
months I-Duration
) O
, O
calcium B-Medication
supplements I-Medication
( O
600 B-Dosage
mg/day I-Dosage
for O
5 B-Duration
months I-Duration
) O
, O
and O
together O
with O
activated B-Medication
vitamin I-Medication
D I-Medication
( O
0.5 B-Dosage
g/day I-Dosage
for O
5 B-Duration
months I-Duration
) O
. O

So O
far O
, O
she O
recovered B-Sign_symptom
uneventfully O
with O
relieved O
pain B-Sign_symptom
and O
increased B-Lab_value
serum B-Diagnostic_procedure
phosphorus I-Diagnostic_procedure
level O
. O

This O
case O
report O
was O
approved O
by O
the O
ethics O
committee O
of O
West O
China O
Hospital O
of O
Sichuan O
University O
, O
Chengdu O
, O
China O
, O
and O
the O
written O
informed O
consent O
was O
obtained O
. O

n O
March B-Date
2015 I-Date
, O
a O
62-year-old B-Age
woman B-Sex
was O
admitted B-Clinical_event
to O
our O
hospital B-Nonbiological_location
. O

She O
complained O
of O
progressive B-Detailed_description
visual B-Sign_symptom
disturbance I-Sign_symptom
, O
which O
began O
about O
4 B-Date
years I-Date
ago I-Date
and O
was O
treated O
as O
cataract B-Disease_disorder
in O
local B-Nonbiological_location
hospital I-Nonbiological_location
, O
but O
no O
relief B-Sign_symptom
was O
seen O
. O

On O
the O
contrary O
, O
the O
symptoms B-Sign_symptom
aggravated O
half B-Date
a I-Date
year I-Date
ago I-Date
, O
together O
with O
headache B-Sign_symptom
, O
left B-Biological_structure
eye I-Biological_structure
pain B-Sign_symptom
, O
tearing B-Sign_symptom
and O
increased O
secretions B-Sign_symptom
, O
and O
the O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
of O
the O
brain B-Biological_structure
in O
local B-Nonbiological_location
hospital I-Nonbiological_location
showed O
a O
sellar B-Biological_structure
region I-Biological_structure
lesion B-Sign_symptom
. O

Besides O
, O
2 B-Date
years I-Date
earlier I-Date
, O
the O
patient O
underwent O
resection B-Therapeutic_procedure
of O
melanoma B-Disease_disorder
in O
the O
left B-Biological_structure
heel I-Biological_structure
( O
T2N0M0 B-Lab_value
, O
ki67 B-Lab_value
3 I-Lab_value
– I-Lab_value
5 I-Lab_value
% I-Lab_value
, O
Stage B-Lab_value
II I-Lab_value
) O
, O
followed O
by O
resection B-Therapeutic_procedure
of O
the O
recurred B-Detailed_description
melanoma B-Disease_disorder
nearby B-Biological_structure
the I-Biological_structure
primary I-Biological_structure
site I-Biological_structure
15 B-Date
months I-Date
later I-Date
( O
T3N3M0 B-Lab_value
, O
Stage B-Lab_value
III I-Lab_value
) O
, O
without O
lymphadenectomy B-Therapeutic_procedure
. O

She O
had O
no B-Family_history
family I-Family_history
history I-Family_history
of I-Family_history
melanoma I-Family_history
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
patient O
had O
bilateral B-Detailed_description
temporal B-Detailed_description
hemianopsia B-Sign_symptom
, O
the O
right B-Diagnostic_procedure
finger I-Diagnostic_procedure
counting I-Diagnostic_procedure
was O
1 B-Lab_value
m I-Lab_value
, O
and O
the O
left B-Diagnostic_procedure
finger I-Diagnostic_procedure
counting I-Diagnostic_procedure
was O
no B-Lab_value
more I-Lab_value
than I-Lab_value
0.5 I-Lab_value
m. I-Lab_value
Enlarged B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
were O
palpable O
in O
the O
right B-Biological_structure
groin I-Biological_structure
. O

On O
ophthalmologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
patient O
had O
right B-Diagnostic_procedure
vision I-Diagnostic_procedure
of O
0.4 B-Lab_value
and O
left B-Diagnostic_procedure
vision I-Diagnostic_procedure
of O
0.08 B-Lab_value
, O
with O
the O
same O
intraocular B-Diagnostic_procedure
pressure I-Diagnostic_procedure
15 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
bilaterally B-Detailed_description
. O

The O
optometry B-Diagnostic_procedure
found O
the O
right B-Biological_structure
eye I-Biological_structure
of O
+6.00 B-Lab_value
DS I-Lab_value
/ I-Lab_value
+0.25 I-Lab_value
DC I-Lab_value
∗ I-Lab_value
65 I-Lab_value
° I-Lab_value
and O
the O
left B-Biological_structure
eye I-Biological_structure
of O
+6.25 B-Lab_value
DS I-Lab_value
/ I-Lab_value
+0.50 I-Lab_value
DC I-Lab_value
∗ I-Lab_value
20 I-Lab_value
° I-Lab_value
. O

The O
patient O
had O
maculopathy B-Disease_disorder
of O
both B-Biological_structure
eyes I-Biological_structure
and O
optic B-Disease_disorder
atrophy I-Disease_disorder
of O
the O
left B-Biological_structure
eye I-Biological_structure
. O

Light B-Diagnostic_procedure
reflex I-Diagnostic_procedure
and O
eye B-Diagnostic_procedure
movement I-Diagnostic_procedure
of O
both B-Biological_structure
eyes I-Biological_structure
were O
normal B-Lab_value
. O

CT B-Diagnostic_procedure
scans O
of O
the O
brain B-Biological_structure
parenchyma I-Biological_structure
, O
orbital B-Biological_structure
, O
and O
chest B-Biological_structure
were O
unremarkable B-Lab_value
. O

CT B-Diagnostic_procedure
scan O
and O
ultrasound B-Diagnostic_procedure
examination O
of O
the O
abdomen B-Biological_structure
showed O
hepatic B-Biological_structure
portal I-Biological_structure
and O
retroperitoneal B-Biological_structure
lymphadenectasis B-Sign_symptom
and O
enlarged B-Sign_symptom
left B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
with O
substantial B-Severity
placeholder B-Detailed_description
lesions B-Sign_symptom
. O

Ultrasound B-Diagnostic_procedure
examination O
of O
bilateral B-Detailed_description
inguinal B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
discovered O
multiple B-Detailed_description
low B-Sign_symptom
echo I-Sign_symptom
light I-Sign_symptom
groups I-Sign_symptom
, O
the O
largest B-Distance
of I-Distance
which I-Distance
was I-Distance
31 I-Distance
mm I-Distance
in O
diameter O
, O
with O
hilus B-Detailed_description
of I-Detailed_description
the I-Detailed_description
echo I-Detailed_description
and O
asymmetrical B-Detailed_description
thickening B-Sign_symptom
of O
the O
skin B-Biological_structure
. O

CT B-Diagnostic_procedure
scan O
of O
sellar B-Biological_structure
region I-Biological_structure
revealed O
a O
crumby B-Texture
mass B-Sign_symptom
, O
protruding O
out O
of O
the O
sphenoid B-Biological_structure
sinus I-Biological_structure
, O
with O
obscure B-Detailed_description
boundary I-Detailed_description
and O
bone B-Detailed_description
destruction I-Detailed_description
. O

And O
the O
average B-Detailed_description
CT B-Diagnostic_procedure
value I-Diagnostic_procedure
of O
the O
mass B-Sign_symptom
was O
46 B-Lab_value
HU I-Lab_value
. O

Sellar B-Biological_structure
region I-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
revealed O
a O
round B-Shape
mass B-Sign_symptom
of O
30 B-Distance
mm I-Distance
in O
diameter O
in O
the O
enlarged B-Biological_structure
sellae I-Biological_structure
( O
Fig. O
1A O
, O
B O
) O
. O

The O
mass B-Coreference
showed O
isointense B-Sign_symptom
in O
T1-weighted B-Diagnostic_procedure
images I-Diagnostic_procedure
( O
T1-WI B-Diagnostic_procedure
) O
and O
T2-weighted B-Diagnostic_procedure
images I-Diagnostic_procedure
( O
T2-WI B-Diagnostic_procedure
) O
, O
with O
homogeneous B-Detailed_description
enhancement B-Sign_symptom
after O
Gadolinium-DTPA B-Detailed_description
injection I-Detailed_description
, O
and O
dural B-Detailed_description
tail I-Detailed_description
sign I-Detailed_description
was O
seen O
. O

Small O
foci O
inside O
the O
tumor B-Coreference
showed O
hyperintense B-Sign_symptom
signals I-Sign_symptom
in O
T1-WI B-Diagnostic_procedure
and O
hypointense B-Sign_symptom
signals I-Sign_symptom
in O
T2-WI B-Diagnostic_procedure
, O
without B-Detailed_description
enhancement I-Detailed_description
. O

And O
it O
was O
seen O
that O
the O
mass B-Coreference
penetrated O
meninges B-Biological_structure
, O
surrounded O
the O
left B-Biological_structure
internal I-Biological_structure
carotid I-Biological_structure
artery I-Biological_structure
, O
and O
was O
blurred O
with O
the O
left B-Biological_structure
optic I-Biological_structure
nerve I-Biological_structure
. O

Pituitary B-Biological_structure
stalk I-Biological_structure
became O
shorter B-Sign_symptom
with O
a O
right B-Detailed_description
displacement I-Detailed_description
. O

Laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
revealed O
increased B-Lab_value
levels O
of O
prolactin B-Diagnostic_procedure
( O
119.08 B-Lab_value
μg/L I-Lab_value
, O
normal O
range O
5.99 O
– O
30.04 O
μg/L O
) O
and O
cortisol B-Diagnostic_procedure
( O
677.10 B-Lab_value
nmol/L I-Lab_value
, O
normal O
range O
118.60 O
– O
618.00 O
nmol/L O
) O
and O
decreased B-Lab_value
levels O
of O
free B-Diagnostic_procedure
thyroxine I-Diagnostic_procedure
( O
FT4 B-Diagnostic_procedure
) O
( O
6.04 B-Lab_value
pmol/L I-Lab_value
, O
normal O
range O
12.00 O
– O
22.00 O
pmol/L O
) O
and O
free B-Diagnostic_procedure
triiodothyronine I-Diagnostic_procedure
( O
FT3 B-Diagnostic_procedure
) O
( O
2.09 B-Lab_value
pmol/L I-Lab_value
, O
normal O
range O
3.50 O
– O
6.50 O
pmol/L O
) O
. O

The O
patient O
was O
diagnosed O
with O
a O
giant B-Detailed_description
prolactinoma B-Disease_disorder
. O

The O
patient O
underwent O
transnasal B-Detailed_description
transsphenoidal B-Detailed_description
surgery B-Therapeutic_procedure
to O
remove O
the O
tumor O
and O
relieve O
the O
compression O
of O
the O
optic O
nerve O
. O

Intraoperatively O
, O
it O
was O
seen O
that O
the O
tumor B-Sign_symptom
invaded O
and O
filled O
the O
left B-Biological_structure
interval I-Biological_structure
of I-Biological_structure
the I-Biological_structure
sphenoid I-Biological_structure
sinus I-Biological_structure
, O
and O
part O
of O
bone B-Biological_structure
in I-Biological_structure
sellar I-Biological_structure
floor I-Biological_structure
and O
left B-Biological_structure
side I-Biological_structure
parasellar I-Biological_structure
was O
destroyed B-Sign_symptom
and O
absorbed B-Sign_symptom
. O

A O
little B-Detailed_description
normal I-Detailed_description
pituitary I-Detailed_description
tissue I-Detailed_description
was I-Detailed_description
seen I-Detailed_description
in I-Detailed_description
the I-Detailed_description
top I-Detailed_description
right I-Detailed_description
of O
tumor B-Coreference
in O
the O
sellar B-Biological_structure
turcica I-Biological_structure
. O

The O
tumor B-Coreference
was O
reddish B-Color
black I-Color
with O
extremely B-Detailed_description
rich I-Detailed_description
blood I-Detailed_description
supply I-Detailed_description
and O
had O
close B-Detailed_description
adhesion I-Detailed_description
to I-Detailed_description
the I-Detailed_description
surrounding I-Detailed_description
structure I-Detailed_description
. O

The O
texture O
in O
the O
center O
of O
the O
tumor B-Coreference
was O
soft B-Texture
and O
much B-Texture
tougher I-Texture
over I-Texture
the I-Texture
rim I-Texture
. O

Intraoperative B-Detailed_description
frozen-section B-Diagnostic_procedure
examination I-Diagnostic_procedure
found O
melanin B-Sign_symptom
granules I-Sign_symptom
, O
and O
it O
was O
considered O
to O
be O
malignant B-Disease_disorder
melanoma I-Disease_disorder
or O
meningioma B-Disease_disorder
. O

The O
tumor B-Coreference
cells I-Coreference
were O
composed O
of O
eosinophilic B-Detailed_description
staining I-Detailed_description
epithelial I-Detailed_description
cells I-Detailed_description
. O

Most O
of O
cell B-Diagnostic_procedure
nuclei I-Diagnostic_procedure
were O
round B-Shape
, O
a O
few O
were O
reniform B-Lab_value
and O
hippocrepiform B-Lab_value
with O
evident B-Lab_value
nucleoli B-Diagnostic_procedure
, O
and O
nuclear B-Diagnostic_procedure
fission I-Diagnostic_procedure
was O
seen B-Lab_value
. O

The O
tumor B-Coreference
showed O
no O
evidence O
of O
necrosis B-Sign_symptom
( O
Fig. O
2 O
) O
. O

The O
tumor O
was O
immunopositive B-Lab_value
focally B-Detailed_description
for O
melanoma-specific B-Diagnostic_procedure
markers I-Diagnostic_procedure
such O
as O
S-100 B-Diagnostic_procedure
, O
HMB45 B-Diagnostic_procedure
, O
and O
Vimentin B-Diagnostic_procedure
, O
and O
immunopositive B-Lab_value
for O
neuroendocrine B-Diagnostic_procedure
tumor I-Diagnostic_procedure
markers I-Diagnostic_procedure
such O
as O
CgA B-Diagnostic_procedure
and O
Syn B-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

The O
Ki67 B-Diagnostic_procedure
index I-Diagnostic_procedure
was O
3 B-Lab_value
% I-Lab_value
to I-Lab_value
5 I-Lab_value
% I-Lab_value
; O
it O
was O
higher B-Lab_value
in O
metastatic B-Detailed_description
melanoma I-Detailed_description
than I-Detailed_description
in I-Detailed_description
the I-Detailed_description
adenomatous I-Detailed_description
component I-Detailed_description
. O

Taken O
the O
melanoma O
history O
and O
suspected O
lymph O
node O
and O
hepatic O
metastasis O
into O
consideration O
, O
the O
patient O
was O
diagnosised O
with O
MMPA B-Disease_disorder
. O

After O
surgery O
, O
significant O
relief B-Lab_value
was O
seen O
in O
visual B-Diagnostic_procedure
field I-Diagnostic_procedure
and O
headache B-Sign_symptom
, O
and O
the O
level O
of O
prolactin B-Diagnostic_procedure
, O
cortisol B-Diagnostic_procedure
, O
and O
FT4 B-Diagnostic_procedure
returned O
to O
normal B-Lab_value
with O
hormone B-Medication
replacement I-Medication
therapy I-Medication
. O

Because O
the O
focal O
liver O
lesions O
and O
lymphadenectasis O
did O
not O
cause O
much O
discomfort B-Sign_symptom
, O
the O
patient O
refused O
any O
further O
surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
or O
other O
treatment O
. O

She O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
immediately O
and O
was O
disease B-Disease_disorder
free O
until O
2 B-Date
months I-Date
after I-Date
the O
third O
surgery O
. O

The O
patient O
successively O
found O
new O
melanoma B-Disease_disorder
metastatic B-Sign_symptom
sites I-Sign_symptom
in O
the O
skin B-Biological_structure
of I-Biological_structure
lower I-Biological_structure
left I-Biological_structure
leg I-Biological_structure
, O
knees O
, O
the O
upper B-Biological_structure
left I-Biological_structure
leg I-Biological_structure
, O
the O
left B-Biological_structure
groin I-Biological_structure
and O
the O
right B-Biological_structure
groin I-Biological_structure
, O
and O
the O
right B-Biological_structure
leg I-Biological_structure
. O

At O
the O
follow-up B-Clinical_event
in O
late B-Date
January I-Date
2016 I-Date
, O
the O
patient O
could O
not O
walk B-Activity
and O
live B-Activity
by I-Activity
herself I-Activity
and O
was O
depressed B-Disease_disorder
. O

At O
the O
latest O
follow-up B-Clinical_event
, O
in O
late B-Date
January I-Date
, I-Date
2017 I-Date
, O
the O
patient O
was O
alive B-Sign_symptom
with O
worse O
symptoms B-Sign_symptom
, O
she O
had O
sensory B-Sign_symptom
deficits I-Sign_symptom
of O
both B-Biological_structure
legs I-Biological_structure
, O
which O
could B-Sign_symptom
not I-Sign_symptom
move I-Sign_symptom
, O
hyperalgesia B-Sign_symptom
of O
hands B-Biological_structure
and O
mouth B-Biological_structure
, O
impaired B-Sign_symptom
intelligence I-Sign_symptom
, O
but O
she O
lived O
well O
with O
the O
disease O
by O
careful O
nursing B-Clinical_event
of O
her O
daughter B-Subject
. O

In B-Date
2013 I-Date
, O
a O
50-year-old B-Age
man B-Sex
patient O
visited B-Clinical_event
hospital B-Nonbiological_location
complaining O
of O
local B-Detailed_description
bone B-Biological_structure
pain B-Sign_symptom
in O
the O
left B-Biological_structure
leg I-Biological_structure
. O

On O
August B-Date
14 I-Date
, I-Date
2013 I-Date
, O
the O
patient O
underwent O
a O
left B-Biological_structure
distal I-Biological_structure
femoral I-Biological_structure
tumor B-Sign_symptom
en B-Detailed_description
bloc I-Detailed_description
resection B-Therapeutic_procedure
and O
reconstruction B-Therapeutic_procedure
with O
a O
modular B-Detailed_description
femoral I-Detailed_description
prosthetic I-Detailed_description
system I-Detailed_description
. O

Pathology B-Diagnostic_procedure
diagnosis I-Diagnostic_procedure
confirmed O
osteoblastic B-Detailed_description
osteosarcoma B-Disease_disorder
( O
Fig. O
2 O
) O
. O

One B-Dosage
cycle I-Dosage
of O
neoadjuvant B-Detailed_description
chemotherapy B-Medication
and O
4 B-Dosage
cycles I-Dosage
of O
adjuvant B-Detailed_description
chemotherapy B-Medication
with O
MAP B-Medication
regimen I-Medication
( O
high-dose B-Dosage
methotrexate B-Medication
, O
cisplatin B-Medication
, O
and O
doxorubicin B-Medication
) O
were O
administered O
. O

In O
January B-Date
2015 I-Date
, O
a O
mass B-Sign_symptom
was O
found O
on O
the O
left B-Biological_structure
upper I-Biological_structure
crus I-Biological_structure
area I-Biological_structure
. O

Tumor O
recurrence B-Sign_symptom
was O
confirmed O
by O
biopsy B-Diagnostic_procedure
on O
January B-Date
23 I-Date
, I-Date
2015 I-Date
. O

However O
, O
only O
an O
upper B-Biological_structure
femur I-Biological_structure
amputation B-Therapeutic_procedure
was O
carried O
out O
, O
as O
the O
patient O
refused O
hip B-Biological_structure
joint B-Therapeutic_procedure
replacement I-Therapeutic_procedure
. O

After O
wound B-Therapeutic_procedure
healing I-Therapeutic_procedure
, O
the O
patient O
went B-Clinical_event
back I-Clinical_event
to I-Clinical_event
his I-Clinical_event
normal I-Clinical_event
life I-Clinical_event
in O
the O
help O
of O
artificial B-Therapeutic_procedure
limb I-Therapeutic_procedure
, O
but O
refused O
to O
receive O
further O
chemotherapy B-Medication
due O
to O
concerns O
regarding O
the O
chemotherapy O
toxicities O
such O
as O
nausea O
, O
vomiting O
, O
leucopenia O
, O
deadlimb O
, O
and O
headache O
. O

About O
half B-Date
a I-Date
year I-Date
after I-Date
the O
amputation O
, O
the O
patient O
got O
occasional B-Detailed_description
cough B-Sign_symptom
and O
chest B-Biological_structure
tightness B-Sign_symptom
. O

Then O
a O
thin B-Detailed_description
chest B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
was O
performed O
on O
July B-Date
15 I-Date
, I-Date
2015 I-Date
. O

The O
CT O
results O
revealed O
multiple B-Detailed_description
pulmonary B-Biological_structure
nodules B-Sign_symptom
( O
Table O
1 O
) O
, O
considering O
the O
possibility O
of O
metastases B-Sign_symptom
. O

The O
patient O
still O
rejected O
further O
chemotherapy B-Medication
. O

Immunophenotype B-Diagnostic_procedure
was O
suggestive O
of O
CD31 B-Detailed_description
+ I-Detailed_description
and O
CD34 B-Detailed_description
+ I-Detailed_description
tumor B-Sign_symptom
cells O
( O
Fig. O
3 O
) O
. O

Furthermore O
, O
most O
cells B-Coreference
showed O
strong B-Lab_value
positive I-Lab_value
staining B-Diagnostic_procedure
for I-Diagnostic_procedure
VEGFR-2 I-Diagnostic_procedure
( O
Fig. O
3 O
) O
. O

Apatinib B-Medication
was O
administered O
at O
a O
dose O
of O
500 B-Dosage
mg I-Dosage
daily I-Dosage
. O

Half B-Date
a I-Date
month I-Date
later I-Date
, O
the O
symptoms B-Sign_symptom
disappeared O
, O
but O
a O
progressive B-Detailed_description
wound B-Sign_symptom
necrosis I-Sign_symptom
appeared O
. O

A O
debridement B-Therapeutic_procedure
surgery I-Therapeutic_procedure
was O
finally O
conducted O
and O
an O
enlarged B-Sign_symptom
lymph B-Biological_structure
node I-Biological_structure
near B-Biological_structure
iliac I-Biological_structure
vessels I-Biological_structure
was O
resected B-Therapeutic_procedure
on O
February B-Date
24 I-Date
, I-Date
2016 I-Date
( O
Fig O
. O

( O
Fig. O
4 O
) O
.4 O
) O
. O

The O
result O
of O
pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
an O
inflammatory B-Detailed_description
hyperplasia B-Sign_symptom
lymph B-Biological_structure
node I-Biological_structure
. O

Apatinib B-Medication
administration O
was O
stopped O
during O
the O
3 B-Duration
weeks I-Duration
of O
wound B-Therapeutic_procedure
healing I-Therapeutic_procedure
period O
. O

The O
thin B-Detailed_description
chest B-Biological_structure
CT B-Diagnostic_procedure
was O
performed O
7 B-Date
and I-Date
11 I-Date
months I-Date
following O
apatinib O
administration O
. O

At O
the O
7-month B-Date
follow-up B-Clinical_event
time O
point O
, O
2 B-Lab_value
out I-Lab_value
of I-Lab_value
5 I-Lab_value
measurable I-Lab_value
and O
9 B-Lab_value
out I-Lab_value
of I-Lab_value
17 I-Lab_value
non-measurable I-Lab_value
lesions B-Sign_symptom
disappeared O
, O
but O
1 B-Lab_value
new I-Lab_value
measurable I-Lab_value
nodule B-Sign_symptom
and O
6 B-Lab_value
new I-Lab_value
non-measurable I-Lab_value
lesions B-Sign_symptom
were O
observed O
( O
Table O
1 O
, O
Fig. O
5 O
) O
, O
which O
considered O
PD B-Lab_value
according O
to O
the O
Response B-Diagnostic_procedure
Evaluation I-Diagnostic_procedure
Criteria I-Diagnostic_procedure
in I-Diagnostic_procedure
Solid I-Diagnostic_procedure
Tumors I-Diagnostic_procedure
( O
RECIST B-Diagnostic_procedure
) O
1.1 B-Detailed_description
standard O
. O

However O
, O
at O
the O
11-month B-Date
follow-up B-Clinical_event
time O
point O
, O
a O
total O
of O
9 B-Lab_value
lesions B-Sign_symptom
disappeared O
, O
including O
1 B-Lab_value
measurable I-Lab_value
nodule I-Lab_value
and O
2 B-Lab_value
non-measurable I-Lab_value
lesions I-Lab_value
presented O
before O
apatinib O
treatment O
as O
well O
as O
6 B-Lab_value
non-measureable I-Lab_value
lesions I-Lab_value
presented O
7 O
months O
after O
apatinib O
treatment O
. O

No O
new O
lesion O
was O
raised O
. O

After O
target O
lesion B-Detailed_description
measurement B-Diagnostic_procedure
according O
to O
the O
RECIST B-Diagnostic_procedure
1.1 I-Diagnostic_procedure
standard I-Diagnostic_procedure
, O
it O
was O
narrowly O
considered O
PR B-Lab_value
. O

The O
toxicities O
the O
patient O
experienced O
included O
mild B-Severity
hand-foot B-Disease_disorder
syndrome I-Disease_disorder
and O
slight B-Severity
high B-Sign_symptom
blood I-Sign_symptom
pressure I-Sign_symptom
. O

Both O
were O
well B-Lab_value
controlled I-Lab_value
after I-Lab_value
appropriate I-Lab_value
treatment I-Lab_value
. O

No O
severe B-Severity
toxicities B-Sign_symptom
and O
other O
treatment-related B-Detailed_description
adverse B-Sign_symptom
events I-Sign_symptom
were O
observed O
. O

The O
patient O
continued O
to O
use O
apatinib B-Medication
as O
maintenance O
therapy O
without O
major O
toxic B-Sign_symptom
effects I-Sign_symptom
, O
and O
went B-Clinical_event
back I-Clinical_event
to I-Clinical_event
normal I-Clinical_event
life I-Clinical_event
, O
even O
driving B-Activity
an O
automatic B-Detailed_description
car I-Detailed_description
. O

A O
60-year-old B-Age
man B-Sex
presented B-Clinical_event
with O
a O
retroperitoneal B-Biological_structure
metastatic B-Sign_symptom
lymph B-Biological_structure
node I-Biological_structure
in O
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
( O
MR B-Diagnostic_procedure
) O
imaging O
with O
a O
history O
of O
right B-Biological_structure
liver I-Biological_structure
resection B-History
in I-History
2010 I-History
, O
pulmonary B-Biological_structure
wedge I-Biological_structure
resection B-History
in I-History
2012 I-History
, O
and O
transarterial B-Therapeutic_procedure
chemoembolization I-Therapeutic_procedure
twice B-History
in I-History
2014 I-History
, O
in O
which O
the O
postoperative O
pathology B-Diagnostic_procedure
suggested O
the O
mixed B-Detailed_description
liver B-Disease_disorder
cancer I-Disease_disorder
, O
and O
poorly B-Detailed_description
differentiated I-Detailed_description
lung B-Disease_disorder
cancer I-Disease_disorder
from O
liver B-Biological_structure
metastasis B-Sign_symptom
. O

At O
examination B-Diagnostic_procedure
, O
the O
tumor B-Coreference
was O
very O
close O
to O
the O
duodenum B-Biological_structure
, O
pancreas B-Biological_structure
, O
stomach B-Biological_structure
, O
and O
hepatic B-Biological_structure
portal I-Biological_structure
vein I-Biological_structure
. O

The O
patient O
with O
unresectable B-Detailed_description
masses B-Sign_symptom
had O
hypertension B-History
over I-History
10 I-History
years I-History
and O
chronic B-History
HBV-related I-History
cirrhosis I-History
for I-History
30 I-History
years I-History
when O
he O
was O
treated O
with O
lamivudine B-Medication
100 B-Dosage
mg I-Dosage
qd I-Dosage
, O
and O
adefovir B-Medication
dipivoxil I-Medication
10 B-Dosage
mg I-Dosage
qd I-Dosage
for O
6 B-Duration
years I-Duration
. O

He O
kept O
a O
constant B-Lab_value
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
of O
37 B-Lab_value
°C I-Lab_value
, O
the O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
148/96 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
, O
and O
the O
pulse B-Diagnostic_procedure
of O
77 B-Lab_value
beats I-Lab_value
every I-Lab_value
minute I-Lab_value
. O

The O
patient O
had O
no O
obvious O
sense O
of O
abdominal B-Biological_structure
pain B-Sign_symptom
, O
abdominal B-Biological_structure
distention B-Sign_symptom
, O
nausea B-Sign_symptom
, O
and O
vomiting B-Sign_symptom
. O

On O
a O
test O
of O
tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
levels O
, O
the O
results O
were O
normal B-Lab_value
, O
which O
showed O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
3.7 B-Lab_value
ng/mL I-Lab_value
, O
alpha B-Diagnostic_procedure
fetoprotein I-Diagnostic_procedure
17.3 B-Lab_value
ng/mL I-Lab_value
, O
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19 I-Diagnostic_procedure
– I-Diagnostic_procedure
9 I-Diagnostic_procedure
levels O
6.1 B-Lab_value
U/mL I-Lab_value
. O

In O
this O
study O
, O
the O
procedure O
was O
approved O
by O
the O
ethics O
committee O
of O
the O
First O
Affiliated O
Hospital O
of O
Zhejiang O
University O
. O

The O
efficacy O
of O
local B-Detailed_description
ablation B-Therapeutic_procedure
was O
estimated O
with O
Choi B-Diagnostic_procedure
criteria I-Diagnostic_procedure
, O
which O
appraised O
the O
variations O
both O
in O
tumor O
size O
and O
lesion O
density O
on O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
imaging O
: O
complete B-Other_entity
response I-Other_entity
, I-Other_entity
disappearance I-Other_entity
of I-Other_entity
all I-Other_entity
lesions I-Other_entity
and I-Other_entity
no I-Other_entity
new I-Other_entity
lesions I-Other_entity
; I-Other_entity
partial I-Other_entity
response I-Other_entity
( I-Other_entity
PR I-Other_entity
) I-Other_entity
, I-Other_entity
a I-Other_entity
decrease I-Other_entity
in I-Other_entity
size I-Other_entity
of I-Other_entity
10 I-Other_entity
% I-Other_entity
or I-Other_entity
a I-Other_entity
decrease I-Other_entity
in I-Other_entity
tumor I-Other_entity
density I-Other_entity
over I-Other_entity
15 I-Other_entity
% I-Other_entity
on I-Other_entity
CT I-Other_entity
and I-Other_entity
no I-Other_entity
new I-Other_entity
lesions I-Other_entity
; I-Other_entity
stable I-Other_entity
disease I-Other_entity
, I-Other_entity
not I-Other_entity
fit I-Other_entity
for I-Other_entity
complete I-Other_entity
response I-Other_entity
, I-Other_entity
PR I-Other_entity
, I-Other_entity
or I-Other_entity
progressive I-Other_entity
disease I-Other_entity
; I-Other_entity
and I-Other_entity
progressive I-Other_entity
disease I-Other_entity
, I-Other_entity
an I-Other_entity
increase I-Other_entity
in I-Other_entity
tumor I-Other_entity
size I-Other_entity
over I-Other_entity
10 I-Other_entity
% I-Other_entity
and I-Other_entity
not I-Other_entity
fit I-Other_entity
for I-Other_entity
PR I-Other_entity
by I-Other_entity
tumor I-Other_entity
density I-Other_entity
on I-Other_entity
CT I-Other_entity
or I-Other_entity
new I-Other_entity
lesions I-Other_entity
. O

[ O
19 O
] O
Preoperative O
MR B-Diagnostic_procedure
imaging O
scan O
showed O
a O
mass B-Sign_symptom
of O
2.8 B-Area
× I-Area
3.5 I-Area
cm I-Area
in O
size O
close O
to O
the O
duodenum B-Biological_structure
, O
pancreas B-Biological_structure
, O
and O
blood B-Biological_structure
vessels I-Biological_structure
( O
Fig. O
1A O
) O
. O

During O
substance B-Detailed_description
phase I-Detailed_description
, O
MR B-Diagnostic_procedure
images O
indicated O
mildly B-Severity
high I-Severity
signal B-Sign_symptom
intensity I-Sign_symptom
around O
the O
tumor B-Coreference
and O
intermediate B-Severity
low I-Severity
signal B-Sign_symptom
intensity I-Sign_symptom
in O
the O
solid B-Biological_structure
component I-Biological_structure
and O
in O
the O
walls B-Biological_structure
( O
Fig. O
1B O
) O
. O

Before O
the O
initial O
ablation B-Therapeutic_procedure
, O
there O
was O
a O
retroperitoneal B-Biological_structure
mild B-Severity
hyperechoic B-Sign_symptom
area I-Sign_symptom
on O
axial B-Detailed_description
US B-Diagnostic_procedure
image O
( O
Fig. O
1C O
) O
. O

In O
this O
study O
, O
the O
inpatient O
underwent O
percutaneous B-Detailed_description
transhepatic B-Biological_structure
biopsies B-Diagnostic_procedure
and O
ablations B-Therapeutic_procedure
to O
avoid O
the O
nearby O
blood O
vessels O
, O
the O
procedure O
of O
which O
was O
performed O
about B-Duration
40 I-Duration
minutes I-Duration
under O
local B-Medication
anesthesia I-Medication
and O
mild O
sedation B-Medication
. O

We O
used O
ultrasonography B-Diagnostic_procedure
to O
real-timely B-Detailed_description
guide O
the O
inserting O
of O
2 B-Detailed_description
Nd I-Detailed_description
: I-Detailed_description
YAG I-Detailed_description
laser B-Therapeutic_procedure
fibers I-Therapeutic_procedure
( O
Echolaser B-Detailed_description
X4 I-Detailed_description
, I-Detailed_description
ESAOTE I-Detailed_description
, I-Detailed_description
Italy I-Detailed_description
) O
in O
0.3 B-Detailed_description
mm I-Detailed_description
diameter I-Detailed_description
through B-Detailed_description
a I-Detailed_description
21-gauge I-Detailed_description
Chiba I-Detailed_description
needle I-Detailed_description
into O
the O
lesions B-Sign_symptom
( O
Fig. O
1D O
) O
. O

Although O
part O
of O
the O
heat O
ran O
off O
by O
blood O
flow O
, O
[ O
20 O
] O
ablation B-Therapeutic_procedure
could O
keep O
valid O
area B-Detailed_description
from I-Detailed_description
12 I-Detailed_description
to I-Detailed_description
15 I-Detailed_description
mm I-Detailed_description
with O
the O
power B-Detailed_description
of I-Detailed_description
5 I-Detailed_description
W I-Detailed_description
in O
5 B-Detailed_description
to I-Detailed_description
6 I-Detailed_description
minutes I-Detailed_description
. O

Subsequently O
, O
immediate O
ultrasonography B-Diagnostic_procedure
showed O
that O
the O
whole O
lesion B-Sign_symptom
was O
covered O
with O
hyperechoic B-Sign_symptom
zone I-Sign_symptom
( O
Fig O
. O

( O
Fig. O
1E O
and O
F O
) O
. O

However O
, O
the O
next B-Date
day I-Date
contrast-enhanced B-Diagnostic_procedure
ultrasound I-Diagnostic_procedure
( O
CEUS B-Diagnostic_procedure
) O
revealed O
an O
abnormal B-Sign_symptom
residual I-Sign_symptom
of O
proximal B-Biological_structure
part I-Biological_structure
of I-Biological_structure
the I-Biological_structure
pancreatic I-Biological_structure
head I-Biological_structure
( O
Fig. O
2A O
) O
. O

At O
5-day B-Date
follow-up B-Clinical_event
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
images I-Diagnostic_procedure
, O
the O
lower B-Detailed_description
mass B-Sign_symptom
had O
low B-Severity
signal B-Sign_symptom
intensity I-Sign_symptom
and O
upper B-Detailed_description
tumor B-Sign_symptom
revealed O
intermediate B-Severity
high I-Severity
signal B-Sign_symptom
intensity I-Sign_symptom
of O
residual B-Detailed_description
in I-Detailed_description
substance I-Detailed_description
phase I-Detailed_description
( O
Fig. O
2B O
and O
C O
) O
. O

Surprizingly O
, O
1-week B-Date
follow-up B-Clinical_event
CEUS B-Diagnostic_procedure
image O
showed O
an O
enlarged B-Sign_symptom
retroperitoneal B-Biological_structure
lymph B-Biological_structure
node I-Biological_structure
located O
near B-Biological_structure
the I-Biological_structure
pancreatic I-Biological_structure
head I-Biological_structure
, O
which O
could O
be O
fusion O
of O
these O
residuary O
small O
nodules O
( O
Fig. O
2D O
) O
. O

Then O
the O
patient O
undergoing O
the O
2nd B-Detailed_description
ablation B-Therapeutic_procedure
with O
2 B-Detailed_description
laser B-Therapeutic_procedure
fibers I-Therapeutic_procedure
showed O
the O
lesions B-Sign_symptom
well-defined O
hyperechoic B-Sign_symptom
zone I-Sign_symptom
( O
Fig. O
2E O
and O
F O
) O
. O

On O
the O
2nd B-Date
day I-Date
, O
postoperative O
CEUS B-Diagnostic_procedure
images O
showed O
they B-Coreference
were O
still O
remanent O
( O
Fig. O
2G O
and O
I O
) O
. O

At O
the O
corresponding O
MR B-Diagnostic_procedure
imaging O
, O
it O
also O
showed O
this O
in O
left O
of O
tumor B-Sign_symptom
( O
Fig. O
2H O
) O
. O

Thus O
, O
the O
3rd B-Detailed_description
laser B-Detailed_description
ablation B-Therapeutic_procedure
was O
performed O
( O
Fig. O
2J O
) O
2J O
) O
and O
3 B-Date
days I-Date
later I-Date
CEUS B-Diagnostic_procedure
found O
that O
there O
was O
still O
a O
minor B-Severity
lesion B-Sign_symptom
located O
in O
the O
separation O
gap O
of O
last O
2 O
needles O
( O
Fig. O
3A O
) O
. O

Subsequently O
the O
patient O
had O
the O
4th B-Detailed_description
ablation B-Therapeutic_procedure
along O
this O
separation O
gap O
until O
hyperechoic O
overlay O
( O
Fig. O
3B O
– O
D O
) O
, O
then O
3 B-Date
days I-Date
later I-Date
, O
based O
on O
these O
4 O
treatments O
, O
enhanced O
CT B-Diagnostic_procedure
image O
of O
the O
retroperitoneal B-Biological_structure
mass B-Sign_symptom
suggested O
complete O
necrosis B-Sign_symptom
( O
Fig. O
3E O
– O
G O
) O
.3 O
E O
– O
G O
) O
. O

After B-Date
the I-Date
following I-Date
1 I-Date
month I-Date
, O
substance O
phase O
MR B-Diagnostic_procedure
revealed O
low-intensity O
signal B-Sign_symptom
of I-Sign_symptom
tumor I-Sign_symptom
necrosis I-Sign_symptom
with O
resolution O
of O
his O
problems B-Sign_symptom
( O
Fig. O
3H O
) O
. O

Until B-Date
5 I-Date
months I-Date
after O
4 O
ablations O
, O
CT B-Diagnostic_procedure
showed O
the O
tumor B-Sign_symptom
PR O
with O
little O
enhanced O
recurrence B-Sign_symptom
( O
yellow O
arrows O
) O
, O
which O
located O
in O
the O
left O
lower O
edge O
of O
original O
lesions O
( O
Fig. O
4A O
and O
B O
) O
. O

On O
laboratory O
test O
of O
tumor B-Diagnostic_procedure
markers I-Diagnostic_procedure
, O
the O
levels O
of O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
, O
alpha B-Diagnostic_procedure
fetoprotein I-Diagnostic_procedure
, O
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19 I-Diagnostic_procedure
– I-Diagnostic_procedure
9 I-Diagnostic_procedure
indicated O
3.6 B-Lab_value
ng/mL I-Lab_value
, O
26.7 B-Lab_value
ng/mL I-Lab_value
, O
and O
8.1 B-Lab_value
U/mL I-Lab_value
, O
respectively O
. O

No O
obvious O
side B-Sign_symptom
effects I-Sign_symptom
were O
discovered O
in O
this O
case O
during O
these O
procedures O
. O

A O
61-year-old B-Age
male B-Sex
patient O
had O
a O
history O
of O
chronic B-History
obstructive I-History
pulmonary I-History
disease I-History
under O
regular B-History
bronchodilator I-History
treatment I-History
. O

In O
2014 B-Date
, O
he O
suffered O
from O
severe B-Severity
productive B-Detailed_description
cough B-Sign_symptom
with O
mucus B-Detailed_description
sputum I-Detailed_description
for B-Duration
several I-Duration
months I-Duration
and O
unintentional B-Detailed_description
body O
weight B-Sign_symptom
loss I-Sign_symptom
6 B-Lab_value
kg I-Lab_value
within B-Duration
6 I-Duration
months I-Duration
. O

After O
sputum B-Diagnostic_procedure
analysis I-Diagnostic_procedure
and O
chest B-Biological_structure
imaging B-Diagnostic_procedure
examinations I-Diagnostic_procedure
in O
May B-Date
2014 I-Date
, O
he O
was O
diagnosed O
of O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
in O
right B-Biological_structure
upper I-Biological_structure
lobe I-Biological_structure
lung I-Biological_structure
( O
cT3N2M0 B-Lab_value
, O
stage B-Lab_value
IIIa I-Lab_value
) O
. O

Then O
he O
received O
neoadjuvant B-Detailed_description
chemoradiotherapy B-Therapeutic_procedure
( O
etoposide B-Medication
70 B-Dosage
mg I-Dosage
[ I-Dosage
45 I-Dosage
mg/m2 I-Dosage
] I-Dosage
+ O
cisplatin B-Medication
79 B-Dosage
mg I-Dosage
[ I-Dosage
50 I-Dosage
mg/m2 I-Dosage
] I-Dosage
; O
4500 B-Dosage
cGY I-Dosage
in I-Dosage
25 I-Dosage
fractions I-Dosage
) O
from B-Duration
June I-Duration
to I-Duration
July I-Duration
2014 I-Duration
. O

In O
October B-Date
2014 I-Date
, O
surgical B-Therapeutic_procedure
intervention I-Therapeutic_procedure
was O
arranged O
. O

Because O
the O
tumor B-Sign_symptom
was O
located O
at O
right B-Biological_structure
hilum I-Biological_structure
and O
invaded O
main B-Biological_structure
bronchus I-Biological_structure
and O
major B-Biological_structure
vessels I-Biological_structure
, O
video-assisted B-Detailed_description
thoracoscopic B-Detailed_description
surgery B-Therapeutic_procedure
with O
right B-Detailed_description
side I-Detailed_description
intrapericardial B-Biological_structure
pneumonectomy B-Therapeutic_procedure
was O
performed O
. O

Postoperatively O
, O
pathological B-Diagnostic_procedure
exams I-Diagnostic_procedure
revealed O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
, O
T3N0M0 B-Lab_value
, O
stage B-Lab_value
IIB I-Lab_value
. O

The O
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
smooth B-Lab_value
but O
he O
suffered O
from O
severe B-Severity
cough B-Sign_symptom
and O
right B-Biological_structure
chest I-Biological_structure
pain B-Sign_symptom
one B-Date
month I-Date
later I-Date
. O

Laboratory B-Diagnostic_procedure
exams I-Diagnostic_procedure
revealed O
leukocytosis B-Sign_symptom
( O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cells I-Diagnostic_procedure
= O
21,860 B-Lab_value
μL I-Lab_value
) O
and O
elevated B-Lab_value
C-reactive B-Diagnostic_procedure
protein I-Diagnostic_procedure
to O
23.94 B-Lab_value
mg/dL I-Lab_value
. O

Chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
cavitary B-Detailed_description
lesion B-Sign_symptom
and O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
showed O
pleural B-Sign_symptom
effusion I-Sign_symptom
and O
fluid B-Sign_symptom
collection I-Sign_symptom
with O
mottled B-Detailed_description
gas I-Detailed_description
appearance I-Detailed_description
in O
the O
dependent B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
right I-Biological_structure
hemithorax I-Biological_structure
( O
Fig. O
1A O
) O
. O

According O
to O
the O
patient O
's O
history O
, O
results O
of O
laboratory O
exams O
, O
and O
imaging O
findings O
, O
postpneumonectomy B-Detailed_description
empyema B-Sign_symptom
was O
diagnosed O
and O
bronchopleural B-Disease_disorder
fistula I-Disease_disorder
was O
highly O
suspected O
. O

After O
admission B-Clinical_event
, O
chest B-Biological_structure
tube B-Therapeutic_procedure
drainage I-Therapeutic_procedure
was O
inserted O
and O
bronchoscopic B-Detailed_description
tissue B-Therapeutic_procedure
glue I-Therapeutic_procedure
sealing I-Therapeutic_procedure
was O
performed O
. O

However O
, O
persistent B-Detailed_description
air B-Sign_symptom
leakage I-Sign_symptom
was O
presented O
and O
we O
decided O
to O
repair B-Therapeutic_procedure
the O
bronchial B-Biological_structure
stump I-Biological_structure
with O
flap B-Therapeutic_procedure
coverage I-Therapeutic_procedure
. O

Because O
the O
patient O
just O
received O
neoadjuvant B-Detailed_description
chemoradiotherapy B-Therapeutic_procedure
a O
few O
months O
ago O
, O
the O
flaps O
harvested O
from O
chest O
area O
were O
not O
appropriate O
because O
the O
pedicle O
arteries O
might O
have O
been O
injured O
by O
irradiation O
. O

After O
discussing O
with O
the O
plastic O
surgeon O
, O
we O
decided O
to O
repair B-Therapeutic_procedure
the O
bronchial B-Biological_structure
stump I-Biological_structure
by O
a O
TRAM B-Therapeutic_procedure
flap I-Therapeutic_procedure
. O

Intraoperatively O
, O
the O
patient O
was O
placed B-Therapeutic_procedure
in I-Therapeutic_procedure
supine I-Therapeutic_procedure
. O

Right B-Detailed_description
side I-Detailed_description
exploratory B-Detailed_description
thoracotomy B-Diagnostic_procedure
was O
performed O
and O
the O
bronchial B-Biological_structure
stump I-Biological_structure
was O
located O
. O

The O
superior B-Biological_structure
epigastric I-Biological_structure
vascular I-Biological_structure
artery I-Biological_structure
and O
right B-Biological_structure
rectus I-Biological_structure
abdominis I-Biological_structure
muscle I-Biological_structure
was O
identified O
and O
the O
location O
of O
the O
TRAM B-Therapeutic_procedure
flap I-Therapeutic_procedure
was O
marked B-Detailed_description
on I-Detailed_description
the I-Detailed_description
skin I-Detailed_description
( O
Fig. O
2A O
) O
. O

Then O
the O
TRAM B-Therapeutic_procedure
flap I-Therapeutic_procedure
was O
harvested B-Therapeutic_procedure
from O
right B-Biological_structure
rectus I-Biological_structure
abdominis I-Biological_structure
( O
Fig. O
2B O
) O
and O
was O
deepithelialized B-Therapeutic_procedure
( O
Fig. O
2C O
) O
. O

Through O
a O
subcutaneous B-Therapeutic_procedure
tunnel I-Therapeutic_procedure
, O
the O
TRAM B-Therapeutic_procedure
flap I-Therapeutic_procedure
was O
moved O
toward O
the O
right B-Biological_structure
thoracic I-Biological_structure
space I-Biological_structure
with O
no O
tension B-Sign_symptom
or O
kinking B-Sign_symptom
on O
the O
pedicle B-Biological_structure
( O
Fig. O
2D O
) O
. O

Then O
the O
TRAM B-Therapeutic_procedure
flap I-Therapeutic_procedure
was O
fixed O
to O
posterior B-Biological_structure
chest I-Biological_structure
wall I-Biological_structure
to O
cover O
the O
bronchial B-Biological_structure
stump I-Biological_structure
( O
Fig. O
2E O
) O
and O
the O
tissue B-Therapeutic_procedure
glue I-Therapeutic_procedure
was O
also O
applied O
to O
the O
bronchial B-Biological_structure
stump I-Biological_structure
under O
bronchoscope B-Diagnostic_procedure
. O

The O
donor B-Biological_structure
site I-Biological_structure
of I-Biological_structure
flap I-Biological_structure
was O
closed O
with O
mesh B-Therapeutic_procedure
repair I-Therapeutic_procedure
. O

The O
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
smooth B-Lab_value
and O
the O
air B-Sign_symptom
leak I-Sign_symptom
was O
diminished B-Lab_value
gradually O
. O

Then O
the O
patient O
was O
discharge B-Clinical_event
under O
stable B-Sign_symptom
condition I-Sign_symptom
and O
was O
free O
from O
air B-Sign_symptom
leak I-Sign_symptom
after B-Date
following I-Date
for I-Date
12 I-Date
months I-Date
( O
Fig. O
1B O
) O
. O

The O
patient O
provided O
written O
informed O
consent O
for O
publication O
of O
this O
report O
and O
all O
accompanying O
images O
. O

A O
63-year-old B-Age
male B-Sex
patient O
without B-History
smoking I-History
or I-History
drinking I-History
history I-History
was O
admitted B-Clinical_event
on B-Date
June I-Date
11 I-Date
, I-Date
2014 I-Date
. O

His O
major O
complaints O
were O
gradually O
aggravated O
dysphagia B-Sign_symptom
and O
fatigue B-Sign_symptom
, O
on O
suspicion O
of O
obstructive B-Disease_disorder
disease I-Disease_disorder
in O
upper B-Biological_structure
digestive I-Biological_structure
tract I-Biological_structure
. O

He O
had B-Occupation
been I-Occupation
an I-Occupation
athlete I-Occupation
before O
, O
and O
then O
retired B-History
in I-History
good I-History
physical I-History
status I-History
before O
admission O
. O

His B-History
family I-History
and I-History
social I-History
history I-History
indicated I-History
nothing I-History
abnormal I-History
. O

Thorough O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
his O
skin B-Biological_structure
, O
oral B-Biological_structure
mucosa I-Biological_structure
, O
eyes B-Biological_structure
, O
and O
genital B-Biological_structure
areas I-Biological_structure
failed O
to O
identify O
any O
superficial O
lesions B-Sign_symptom
. O

Additionally O
, O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
including O
hepatic B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
renal B-Diagnostic_procedure
function I-Diagnostic_procedure
, O
and O
serum B-Diagnostic_procedure
tumor I-Diagnostic_procedure
markers I-Diagnostic_procedure
such O
as O
carcinoembryonic B-Diagnostic_procedure
antigen I-Diagnostic_procedure
, O
cytokeratin B-Diagnostic_procedure
19 I-Diagnostic_procedure
fragment I-Diagnostic_procedure
, O
squamous B-Diagnostic_procedure
cell I-Diagnostic_procedure
carcinoma I-Diagnostic_procedure
, O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
, O
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
125 I-Diagnostic_procedure
were O
all O
in B-Lab_value
normal I-Lab_value
range I-Lab_value
. O

Therefore O
, O
further O
endoscopic B-Detailed_description
and O
radiological B-Detailed_description
examinations B-Diagnostic_procedure
were O
carried O
out O
for O
accurate O
diagnosis O
. O

Endoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
slightly B-Color
pigmented I-Color
, O
irregular B-Detailed_description
mass B-Sign_symptom
, O
which O
was O
located O
in O
lower B-Biological_structure
esophagus I-Biological_structure
, O
measuring O
5.0 B-Area
cm I-Area
× I-Area
3.0 I-Area
cm I-Area
in O
size O
. O

Fine B-Detailed_description
needle I-Detailed_description
biopsy B-Diagnostic_procedure
of O
the O
lesion B-Coreference
revealed O
esophageal B-Biological_structure
melanoma B-Disease_disorder
, O
which O
was O
confirmed O
by O
histopathology B-Diagnostic_procedure
. O

Besides O
chest B-Biological_structure
and O
abdomen B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
, O
enhanced B-Detailed_description
cranial B-Biological_structure
magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
image I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
and O
bone B-Biological_structure
emission B-Diagnostic_procedure
computed I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
ECT B-Diagnostic_procedure
) O
showed O
enlarged B-Sign_symptom
mediastinal B-Biological_structure
, O
nd O
also O
celiac B-Biological_structure
lymph B-Biological_structure
nodes I-Biological_structure
( O
Fig. O
1A O
) O
, O
without O
obvious O
involvement B-Sign_symptom
of O
supraclavicular B-Biological_structure
lymph B-Biological_structure
nodes I-Biological_structure
. O

Concurrently O
, O
the O
CT B-Diagnostic_procedure
showed O
an O
isolated B-Detailed_description
, O
irregular B-Detailed_description
pulmonary B-Biological_structure
tumor B-Sign_symptom
( O
Fig. O
1B O
) O
. O

Positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
was O
not O
carried O
out O
, O
because O
it O
was O
not O
covered O
by O
health O
insurance O
of O
this O
patient O
. O

Therefore O
, O
this O
patient O
was O
clinically B-Diagnostic_procedure
staged I-Diagnostic_procedure
as O
cT3NxM1 B-Lab_value
according O
to O
the O
7th B-Detailed_description
edition I-Detailed_description
of I-Detailed_description
American I-Detailed_description
Joint I-Detailed_description
Committee I-Detailed_description
on I-Detailed_description
Cancer I-Detailed_description
TNM I-Detailed_description
staging I-Detailed_description
system I-Detailed_description
for O
esophageal B-Disease_disorder
cancer I-Disease_disorder
. O

CT-guided B-Detailed_description
percutaneous B-Detailed_description
pulmonary B-Biological_structure
biopsy B-Diagnostic_procedure
was O
avoided O
, O
with O
the O
aim O
to O
diminish O
the O
risk O
of O
tumor O
dissemination O
. O

Single-stage B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
esophageal B-Biological_structure
and O
pulmonary B-Biological_structure
lesions B-Sign_symptom
was O
assumed O
to O
be O
reasonable O
after O
multidisciplinary O
consultation B-Clinical_event
, O
which O
was O
approved O
by O
Ethical O
Committee O
of O
Xuzhou O
Central O
Hospital O
. O

Because O
the O
prognosis O
of O
this O
patient O
probably O
was O
extremely O
poor O
without O
targeted B-Therapeutic_procedure
antibodies I-Therapeutic_procedure
, O
which O
he O
could O
not O
afford O
for O
financial O
reasons O
. O

After O
his O
informed O
consent O
, O
simultaneous B-Detailed_description
Ivor-Lewis B-Detailed_description
esophagectomy B-Therapeutic_procedure
and O
right B-Detailed_description
upper I-Detailed_description
lobectomy B-Therapeutic_procedure
were O
performed O
successfully O
, O
under O
general B-Medication
anesthesia I-Medication
, O
after O
double-lumen B-Detailed_description
endotracheal B-Detailed_description
intubation B-Therapeutic_procedure
, O
followed O
by O
systemic B-Detailed_description
dissection B-Therapeutic_procedure
of O
lymph B-Biological_structure
nodes I-Biological_structure
located O
in O
mediastinum B-Biological_structure
and O
abdomen B-Biological_structure
, O
in O
accordance O
with O
the O
principles O
of O
oncological O
surgery O
. O

The O
operation O
time O
was O
290 B-Duration
minutes I-Duration
, O
without O
obvious O
bleeding B-Sign_symptom
during O
the O
surgery O
. O

Postoperative O
pathological B-Diagnostic_procedure
staining I-Diagnostic_procedure
of O
the O
specimen O
revealed O
pleomorphic B-Sign_symptom
cells I-Sign_symptom
and O
abundant O
melanin B-Sign_symptom
granules I-Sign_symptom
( O
Fig. O
1C O
) O
, O
whereas O
immunohistochemical B-Diagnostic_procedure
tests I-Diagnostic_procedure
demonstrated O
positive B-Lab_value
expression I-Lab_value
of O
human B-Diagnostic_procedure
melanoma I-Diagnostic_procedure
black I-Diagnostic_procedure
45 I-Diagnostic_procedure
( O
HMB45 B-Diagnostic_procedure
) O
, O
microtubule-associated B-Diagnostic_procedure
protein I-Diagnostic_procedure
tau I-Diagnostic_procedure
1 I-Diagnostic_procedure
( O
MAPT1 B-Diagnostic_procedure
) O
, O
melan B-Diagnostic_procedure
A I-Diagnostic_procedure
and O
S100 B-Diagnostic_procedure
, O
and O
negative B-Lab_value
expression I-Lab_value
of O
desmin B-Diagnostic_procedure
, O
synaptophysin B-Diagnostic_procedure
, O
and O
epithelial B-Diagnostic_procedure
membrane I-Diagnostic_procedure
antigen I-Diagnostic_procedure
( O
EMA B-Diagnostic_procedure
) O
, O
which O
was O
consistent O
with O
melanoma B-Disease_disorder
. O

The O
resection B-Biological_structure
margin I-Biological_structure
and O
dissected B-Biological_structure
lymph I-Biological_structure
nodes I-Biological_structure
were O
pathologically O
tumor-negative B-Sign_symptom
. O

In O
addition O
, O
molecular B-Diagnostic_procedure
study I-Diagnostic_procedure
of O
the O
patient O
indicated O
mutation B-Sign_symptom
of I-Sign_symptom
V-raf I-Sign_symptom
murine I-Sign_symptom
sarcoma I-Sign_symptom
viral I-Sign_symptom
oncogene I-Sign_symptom
homolog I-Sign_symptom
B1 I-Sign_symptom
( O
BRAF O
) O
V600E O
. O

Based O
on O
these O
findings O
, O
a O
diagnosis O
of O
advanced B-Severity
PMME B-Disease_disorder
was O
tentatively O
established O
as O
stage B-Lab_value
IV I-Lab_value
( O
pT3N0M1 B-Lab_value
) O
, O
because O
there O
was O
insufficient O
evidence O
to O
distinguish O
synchronous O
primary O
pulmonary O
melanoma O
from O
metastasis O
for O
this O
patient O
. O

The O
postoperative B-Therapeutic_procedure
recovery I-Therapeutic_procedure
was O
mainly B-Lab_value
uneventful I-Lab_value
, O
and O
the O
patient O
was O
discharged B-Clinical_event
14 B-Date
days I-Date
after I-Date
surgery I-Date
. O

Subsequently O
, O
4 B-Dosage
cycles I-Dosage
of O
adjuvant B-Detailed_description
conventional B-Detailed_description
chemotherapy B-Medication
with O
an B-Dosage
interval I-Dosage
of I-Dosage
3 I-Dosage
weeks I-Dosage
were O
completed O
, O
with O
controlled O
moderate O
toxic O
effects O
including O
thrombocytopenia B-Sign_symptom
, O
leukopenia B-Sign_symptom
, O
nausea B-Sign_symptom
, O
vomiting B-Sign_symptom
, O
and O
diarrhea B-Sign_symptom
. O

The O
detailed O
chemotherapy O
regimen O
is O
as O
follows O
: O
paclitaxel B-Medication
liposome I-Medication
for O
injection B-Administration
on O
day O
1 O
and O
day O
8 O
( O
135 O
mg O
per O
square O
meter O
of O
body O
surface O
area O
; O
Nanjing O
Luye O
Sike O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jiangsu O
, O
China O
. O
) O

, O
tegafur B-Medication
injection B-Administration
on O
day O
2 O
to O
4 O
( O
1000 O
mg O
per O
square O
meter O
of O
body-surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
. O
) O

plus O
cis-platinum B-Medication
on O
day O
2 O
to O
3 O
( O
75 O
mg O
per O
square O
meter O
of O
body-surface O
area O
; O
Shandong O
Qilu O
Pharmaceutical O
Co. O
, O
Ltd. O
, O
Jinan O
, O
China O
) O
. O

This O
patient O
suffered O
from O
moderate B-Severity
leukopenia B-Sign_symptom
/ O
myelosuppression B-Sign_symptom
after O
the O
second O
cycle O
of O
TPF O
chemotherapy B-Medication
, O
and O
he O
recovered B-Sign_symptom
quickly O
after O
the O
administration O
of O
granulocyte B-Medication
colony-stimulating I-Medication
factor I-Medication
( O
G-CSF B-Medication
) O
. O

Concurrently O
, O
recombinant O
human B-Medication
interferon I-Medication
alpha-2b I-Medication
( O
Harbin O
pharmaceutical O
group O
biological O
engineering O
Co. O
, O
Ltd O
, O
Harbin O
, O
China O
) O
was O
administrated O
via O
hypodermic B-Administration
injection I-Administration
thereafter O
( O
6000 B-Dosage
units I-Dosage
every I-Dosage
3 I-Dosage
days I-Dosage
; O
Fig. O
2 O
) O
, O
lasting O
for B-Duration
1 I-Duration
year I-Duration
. O

The O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
continuously O
after O
the O
surgery O
. O

Chest B-Biological_structure
and O
abdomen B-Biological_structure
CT B-Diagnostic_procedure
, O
cranial B-Biological_structure
MRI B-Diagnostic_procedure
, O
bone B-Biological_structure
ECT B-Diagnostic_procedure
, O
and O
thorough O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
were O
carried O
out O
every B-Frequency
3 I-Frequency
months I-Frequency
. O

Encouragingly O
, O
the O
patient O
survived B-Outcome
without O
loco-regional B-Detailed_description
recurrence B-Sign_symptom
or O
remote B-Detailed_description
metastasis B-Sign_symptom
during O
the O
follow-up B-Clinical_event
of O
two B-Duration
and I-Duration
a I-Duration
half I-Duration
years I-Duration
up O
to O
now O
( O
Fig. O
3 O
) O
. O

A O
34-year-old B-Age
woman B-Sex
, O
1 B-History
week I-History
postpartum I-History
, O
presented B-Clinical_event
to O
our O
dermatology B-Nonbiological_location
clinic I-Nonbiological_location
with O
an O
intensely B-Severity
pruritic B-Detailed_description
generalized B-Detailed_description
rash B-Sign_symptom
. O

Two B-Date
days I-Date
after I-Date
delivery B-Clinical_event
of I-Clinical_event
her I-Clinical_event
child I-Clinical_event
, O
the O
patient O
developed O
an O
itchy B-Detailed_description
rash B-Sign_symptom
on O
the O
abdomen B-Biological_structure
. O

On O
discharge B-Clinical_event
, O
she O
was O
instructed O
to O
follow O
up O
with O
the O
dermatology O
department O
if O
the O
rash O
did O
not O
resolve O
. O

After O
leaving O
the O
hospital O
, O
she O
reported O
that O
the O
eruption B-Sign_symptom
had O
progressively B-Detailed_description
spread I-Detailed_description
to O
the O
buttocks B-Biological_structure
and O
legs B-Biological_structure
and O
the O
itching B-Sign_symptom
seemed O
to O
be O
worse O
. O

The O
patient O
's O
prenatal B-Sign_symptom
course I-Sign_symptom
was O
uneventful B-Lab_value
. O

She O
gained B-Sign_symptom
13 B-Lab_value
kg I-Lab_value
during B-Detailed_description
pregnancy I-Detailed_description
, O
with O
a O
prepregnancy B-Detailed_description
weight O
of O
72 B-Weight
kg I-Weight
. O

A O
healthy B-Detailed_description
male B-Detailed_description
neonate B-Subject
was O
delivered O
by O
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
at B-Lab_value
38 I-Lab_value
weeks I-Lab_value
' I-Lab_value
gestation I-Lab_value
without O
complication B-Sign_symptom
. O

The O
patient O
's O
medical B-History
history I-History
was I-History
unremarkable I-History
. O

She O
was O
currently O
not O
taking O
any O
medications B-Medication
, O
and O
she O
reported O
no O
known O
drug B-Sign_symptom
allergies I-Sign_symptom
. O

On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
patient O
was O
afebrile B-Sign_symptom
and O
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
normal B-Lab_value
. O

Examination B-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
skin I-Diagnostic_procedure
revealed O
erythematous B-Detailed_description
papules B-Sign_symptom
and O
urticarial B-Detailed_description
plaques B-Sign_symptom
involving O
the O
abdominal B-Biological_structure
striae I-Biological_structure
with O
periumbilical B-Biological_structure
sparing I-Biological_structure
. O

Similar O
lesions B-Sign_symptom
were O
noted O
on O
the O
legs B-Biological_structure
and O
buttocks B-Biological_structure
( O
Fig. O
1a O
) O
. O

The O
face B-Biological_structure
, O
palms B-Biological_structure
, O
and O
soles B-Biological_structure
were O
uninvolved B-Sign_symptom
. O

No O
vesicles B-Sign_symptom
or O
pustules B-Sign_symptom
were O
noted O
. O

Based O
on O
the O
characteristic O
clinical O
presentation O
and O
disease O
course O
, O
she O
was O
diagnosed O
with O
PUPPP B-Disease_disorder
. O

She O
was O
informed O
of O
the O
safety O
profile O
and O
potential O
benefits O
of O
medications O
but O
remained O
reluctant O
to O
use O
medications B-Medication
during O
lactation O
, O
despite O
her O
severe O
symptoms O
. O

AWB B-Therapeutic_procedure
injection I-Therapeutic_procedure
was O
then O
considered O
for O
her O
treatment O
. O

Venous B-Biological_structure
blood I-Biological_structure
of O
10 B-Volume
mL I-Volume
was O
drawn B-Therapeutic_procedure
from O
the O
patient O
, O
followed O
by O
intramuscular B-Administration
injection B-Therapeutic_procedure
of O
5 B-Volume
mL I-Volume
of O
the O
blood B-Biological_structure
on O
each B-Biological_structure
side I-Biological_structure
of I-Biological_structure
her I-Biological_structure
buttock I-Biological_structure
. O

Seven B-Date
days I-Date
later I-Date
, O
both O
subjective O
and O
objective O
improvements B-Lab_value
of O
symptoms B-Sign_symptom
were O
noticed O
and O
she O
received O
1 B-Lab_value
more I-Lab_value
session I-Lab_value
of O
AWB B-Therapeutic_procedure
injection I-Therapeutic_procedure
( O
Fig. O
1b O
) O
. O

On O
follow-up O
after B-Date
12 I-Date
days I-Date
, O
all O
subjective O
symptoms B-Sign_symptom
had O
improved B-Lab_value
, O
leaving O
only O
postinflammatory B-Detailed_description
hyperpigmentation B-Sign_symptom
( O
Fig. O
1c O
) O
. O

No O
complications O
such O
as O
infection B-Sign_symptom
, O
abscess B-Sign_symptom
formation O
, O
or O
hematoma B-Sign_symptom
were O
observed O
at O
the B-Biological_structure
injection I-Biological_structure
site I-Biological_structure
. O

The O
proband O
( O
II-2 O
in O
Fig. O
2 O
) O
is O
a O
45-year B-Age
old I-Age
woman B-Sex
, O
who O
first O
presented B-Clinical_event
to O
our O
university B-Biological_structure
hospital I-Biological_structure
at B-Date
the I-Date
age I-Date
of I-Date
35 I-Date
and O
was O
referred O
to O
us O
because O
of O
her O
pregnancy B-History
. O

She O
has O
congenital B-History
deafness I-History
, O
first O
experienced O
syncope B-Sign_symptom
at O
the O
age B-Date
of I-Date
3 I-Date
, O
and O
was O
diagnosed O
with O
epilepsy B-History
. O

She O
was O
treated O
with O
anti-epilepsy B-Medication
medications I-Medication
; O
however O
, O
she O
subsequently O
experienced O
several B-Detailed_description
instances I-Detailed_description
of O
syncope B-Sign_symptom
. O

At O
the O
age B-Date
of I-Date
13 I-Date
, O
she O
had O
a O
syncope B-Sign_symptom
event O
, O
and O
was O
suspected O
of O
having O
JLNS B-Disease_disorder
because O
of O
her O
congenital O
deafness O
and O
prolonged B-Sign_symptom
QT I-Sign_symptom
interval I-Sign_symptom
. O

Her O
syncope B-Sign_symptom
was O
diagnosed O
as O
an O
arrhythmic B-Sign_symptom
episode I-Sign_symptom
when O
she O
was O
aware O
of O
tachycardia B-Sign_symptom
and O
as O
epilepsy B-Disease_disorder
when O
she O
was O
not O
. O

She O
also O
had O
a O
subarachnoid B-Sign_symptom
hemorrhage I-Sign_symptom
at O
the O
age B-Date
of I-Date
29 I-Date
. O

When O
she O
first O
presented B-Clinical_event
at O
our O
hospital B-Nonbiological_location
, O
she O
was O
not O
taking O
beta-blockers B-Medication
, O
because O
of O
a O
history O
of O
asthma B-History
, O
but O
was O
taking O
mexiletine B-Medication
in O
addition O
to O
phenytoin B-Medication
. O

Her O
QTc B-Diagnostic_procedure
was O
found O
to O
be O
prolonged B-Lab_value
( O
584 B-Lab_value
ms I-Lab_value
) O
at O
presentation B-Clinical_event
and O
administration O
of O
atenolol B-Medication
was O
initiated O
. O

She O
delivered B-Clinical_event
her O
baby B-Subject
( O
III-1 O
in O
Fig. O
2 O
) O
through O
Caesarean B-Therapeutic_procedure
operation I-Therapeutic_procedure
at O
our O
hospital B-Nonbiological_location
at O
the O
age B-Date
of I-Date
35 I-Date
. O

At B-Date
37 I-Date
, O
she O
delivered B-Clinical_event
her O
second B-Subject
baby I-Subject
( O
III-2 O
in O
Fig. O
2 O
) O
through O
Caesarean B-Therapeutic_procedure
operation I-Therapeutic_procedure
at O
our O
hospital B-Nonbiological_location
. O

Despite O
administration O
of O
beta-blockers B-Medication
, O
her O
QTc B-Diagnostic_procedure
remained O
prolonged B-Lab_value
( O
600 B-Lab_value
msec I-Lab_value
at O
the O
age B-Date
of I-Date
37 I-Date
, B-Date
780 I-Date
msec I-Date
at I-Date
44 I-Date
) O
( O
Figs. O
2 O
and O
3a O
) O
, O
which O
is O
not O
unexpected O
because O
treatment O
with O
beta-blockers O
in O
LQTS1 O
is O
not O
expected O
to O
overtly O
reduce O
QTc O
[ O
18 O
] O
. O

However O
, O
she O
continued O
to O
experience O
occasional B-Detailed_description
syncope B-Sign_symptom
and O
finally O
underwent O
an O
implantable B-Therapeutic_procedure
cardioverter I-Therapeutic_procedure
defibrillator I-Therapeutic_procedure
( O
ICD B-Therapeutic_procedure
) O
operation O
at O
38 B-Date
years I-Date
of I-Date
age I-Date
. O

Subsequently O
, O
she O
is O
in O
a O
stable B-Sign_symptom
clinical I-Sign_symptom
condition I-Sign_symptom
. O

Because O
the O
proband O
was O
suspected O
of O
JLNS B-Disease_disorder
and O
both B-Subject
infants I-Subject
had O
a O
measured B-Family_history
QTc I-Family_history
of I-Family_history
500 I-Family_history
ms I-Family_history
or I-Family_history
greater I-Family_history
within I-Family_history
1 I-Family_history
month I-Family_history
after I-Family_history
birth I-Family_history
, O
beta B-Family_history
blockers I-Family_history
were O
initiated O
and O
both O
children O
remain O
in O
stable B-Family_history
condition I-Family_history
at I-Family_history
ages I-Family_history
10 I-Family_history
and I-Family_history
8 I-Family_history
( O
Figs. O
2 O
and O
3b O
, O
c O
) O
. O

QTc B-Family_history
of O
the O
son B-Subject
( O
III-1 O
in O
Fig. O
2 O
) O
was O
measured O
as O
500 B-Family_history
ms I-Family_history
one I-Family_history
month I-Family_history
after I-Family_history
birth I-Family_history
, O
while O
the O
QTc B-Family_history
of O
his O
sister B-Subject
( O
III-2 O
) O
was O
530 B-Family_history
ms I-Family_history
at I-Family_history
birth I-Family_history
. O

The B-History
father I-History
( I-History
I-1 I-History
) I-History
and I-History
mother I-History
( I-History
I-2 I-History
) I-History
of I-History
the I-History
proband I-History
were I-History
first I-History
cousins I-History
. O

There O
is O
no B-Family_history
history I-Family_history
of I-Family_history
sudden I-Family_history
unexplained I-Family_history
syncope I-Family_history
or I-Family_history
death I-Family_history
of I-Family_history
children I-Family_history
or I-Family_history
adults I-Family_history
in O
the O
immediate B-Subject
family I-Subject
members I-Subject
, O
despite O
the O
prolonged O
QTc O
of O
the O
children O
. O

Clinical B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
and O
consultation B-Clinical_event
of O
the O
proband O
and O
her O
family O
members O
were O
performed O
at O
Chiba B-Nonbiological_location
University I-Nonbiological_location
Hospital I-Nonbiological_location
. O

Clinical O
phenotypes O
were O
deduced O
from O
the O
clinical O
history O
, O
physical B-Diagnostic_procedure
examinations I-Diagnostic_procedure
, O
and O
ECG B-Diagnostic_procedure
. O

Blood B-Diagnostic_procedure
samples I-Diagnostic_procedure
were O
collected O
from O
the O
proband O
and O
her O
family O
members O
following O
genetic B-Clinical_event
counseling I-Clinical_event
, O
and O
written O
informed O
consent O
was O
obtained O
prior O
to O
sample O
collection O
. O

Genomic B-Diagnostic_procedure
DNA I-Diagnostic_procedure
was O
isolated O
from O
peripheral B-Biological_structure
blood I-Biological_structure
lymphocytes I-Biological_structure
according O
to O
established O
protocols O
at O
our O
laboratory O
[ O
19 O
] O
. O

Entire O
coding O
exons O
, O
including O
the O
intronic O
boundaries O
of O
the O
genes O
, O
of O
KCNQ1 B-Detailed_description
( O
NCBI O
ref O
: O
NM O
_ O
000218 O
) O
and O
other O
LQT B-Detailed_description
causative I-Detailed_description
genes I-Detailed_description
( O
KCNH2 B-Detailed_description
, I-Detailed_description
SCN5A I-Detailed_description
, I-Detailed_description
KCNE1 I-Detailed_description
, I-Detailed_description
KCNE2 I-Detailed_description
, I-Detailed_description
KCNJ2 I-Detailed_description
, I-Detailed_description
SCN4B I-Detailed_description
, I-Detailed_description
KCNJ5 I-Detailed_description
) O
were O
amplified O
by O
polymerase B-Diagnostic_procedure
chain I-Diagnostic_procedure
reaction I-Diagnostic_procedure
( O
PCR B-Diagnostic_procedure
) O
, O
according O
to O
established O
protocols O
in O
our O
laboratory O
. O

Briefly O
, O
30 B-Detailed_description
– I-Detailed_description
100 I-Detailed_description
ng I-Detailed_description
of I-Detailed_description
genomic I-Detailed_description
DNA I-Detailed_description
was O
subjected O
to O
PCR B-Coreference
amplification I-Coreference
with O
DNA B-Detailed_description
polymerase I-Detailed_description
( O
PrimeSTAR B-Detailed_description
GXL I-Detailed_description
DNA I-Detailed_description
Polymerase I-Detailed_description
; I-Detailed_description
Takara I-Detailed_description
Bio I-Detailed_description
Inc. I-Detailed_description
, I-Detailed_description
Kusatsu I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
and O
primer B-Detailed_description
sets I-Detailed_description
. O

The O
amplicons B-Detailed_description
were O
subjected O
to O
conventional B-Detailed_description
sequencing B-Diagnostic_procedure
with O
Sanger B-Detailed_description
sequencers I-Detailed_description
( O
Applied B-Detailed_description
Biosystems I-Detailed_description
3730/3130 I-Detailed_description
DNA I-Detailed_description
analyzers I-Detailed_description
; I-Detailed_description
Thermo I-Detailed_description
Fisher I-Detailed_description
Scientific I-Detailed_description
, I-Detailed_description
Waltham I-Detailed_description
, I-Detailed_description
MA I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
. O

The O
sequence O
data O
were O
processed B-Detailed_description
with I-Detailed_description
Gene I-Detailed_description
Codes I-Detailed_description
Sequencher I-Detailed_description
Software I-Detailed_description
( O
Takara B-Detailed_description
Bio I-Detailed_description
Inc. I-Detailed_description
) O
and O
mapped B-Detailed_description
to I-Detailed_description
the I-Detailed_description
human I-Detailed_description
genome I-Detailed_description
sequence I-Detailed_description
( O
build B-Detailed_description
GRCh37/hg19 I-Detailed_description
) O
. O

Genetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
performed O
to O
screen O
all O
coding O
exons O
and O
the O
exon O
– O
intron O
boundaries O
of O
the O
KCNQ1 B-Detailed_description
gene I-Detailed_description
( O
NCBI O
ref O
: O
NM O
_ O
000218.2 O
, O
NP O
_ O
000209.2 O
) O
with O
concurrent O
screening O
of O
other O
LQT B-Detailed_description
causative I-Detailed_description
genes I-Detailed_description
( O
KCNH2 B-Detailed_description
, I-Detailed_description
SCN5A I-Detailed_description
, I-Detailed_description
KCNE1 I-Detailed_description
, I-Detailed_description
KCNE2 I-Detailed_description
, I-Detailed_description
KCNJ2 I-Detailed_description
, I-Detailed_description
SCN4B I-Detailed_description
, I-Detailed_description
KCNJ5 I-Detailed_description
) O
. O

We O
detected O
a O
novel O
homozygous B-Sign_symptom
nonsense I-Sign_symptom
variant I-Sign_symptom
, O
NM B-Detailed_description
_ I-Detailed_description
000218.2 I-Detailed_description
: I-Detailed_description
c. I-Detailed_description
115G I-Detailed_description
> I-Detailed_description
T I-Detailed_description
( O
p.Glu39X O
, O
in O
exon O
1a O
) O
, O
in O
the O
KCNQ1 O
gene O
of O
the O
proband O
, O
as O
well O
as O
a O
homozygous B-Sign_symptom
common I-Sign_symptom
variant I-Sign_symptom
( O
NM B-Detailed_description
_ I-Detailed_description
000218.2 I-Detailed_description
: I-Detailed_description
c. I-Detailed_description
1343C I-Detailed_description
> I-Detailed_description
G I-Detailed_description
, O
p.Pro448Arg O
) O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

Genetic B-Diagnostic_procedure
screening I-Diagnostic_procedure
of O
her O
mother B-Subject
( O
I-2 O
) O
and O
children B-Subject
( O
III-1 O
and O
III-2 O
) O
revealed O
that O
they O
were O
heterozygous B-Family_history
for I-Family_history
the I-Family_history
nonsense I-Family_history
variant I-Family_history
( O
Fig. O
2 O
) O
. O

Her O
husband B-Subject
( O
II-3 O
) O
was O
also O
screened O
and O
found O
to O
be O
heterozygous B-Family_history
for I-Family_history
the I-Family_history
common I-Family_history
variant I-Family_history
( O
NM O
_ O
000218.2 O
: O
c. O
1343C O
> O
G O
, O
p.Pro448Arg O
) O
. O

The B-History
proband I-History
is I-History
a I-History
child I-History
from I-History
a I-History
first-cousin I-History
marriage I-History
, O
and O
we O
have O
concluded O
the O
homozygous B-Sign_symptom
nonsense I-Sign_symptom
variant I-Sign_symptom
in O
the O
proband O
is O
the O
cause O
of O
her O
JLNS1 B-Disease_disorder
. O

The O
proband O
was O
negative O
for O
pathogenic B-Sign_symptom
variants I-Sign_symptom
in I-Sign_symptom
other I-Sign_symptom
LQT I-Sign_symptom
causative I-Sign_symptom
genes I-Sign_symptom
, O
including O
the O
KCNE1 O
gene O
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O

A O
4 B-Age
and I-Age
a I-Age
half I-Age
years I-Age
old I-Age
male B-Sex
child O
presented B-Clinical_event
to O
our O
hospital B-Nonbiological_location
for O
abdominal B-Biological_structure
swelling B-Sign_symptom
. O

The O
child O
occasionally B-Detailed_description
felt O
stomach B-Sign_symptom
ache I-Sign_symptom
that O
was O
relieved B-Detailed_description
for I-Detailed_description
no I-Detailed_description
reason I-Detailed_description
. O

The O
child O
showed O
no O
obvious O
tenderness B-Sign_symptom
and O
rebound B-Sign_symptom
. O

He O
was O
born B-History
as I-History
a I-History
premature I-History
baby I-History
in I-History
the I-History
32nd I-History
week I-History
of I-History
his I-History
mother I-History
's I-History
pregnancy I-History
. O

His O
medical O
history O
included O
inguinal B-History
hernia I-History
on I-History
2 I-History
sides I-History
, O
but O
he O
had O
only O
received O
an O
operation B-History
for I-History
the I-History
left I-History
inguinal I-History
hernia I-History
. O

No B-Family_history
family I-Family_history
or I-Family_history
genetic I-Family_history
history I-Family_history
was I-Family_history
found I-Family_history
. O

Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
this O
child O
showed O
that O
the O
abdomen B-Biological_structure
was O
obviously B-Detailed_description
bulging B-Sign_symptom
. O

The O
mass B-Sign_symptom
could O
be O
touched O
below B-Biological_structure
umbilicus I-Biological_structure
about B-Distance
3 I-Distance
fingers I-Distance
. O

There O
were O
no O
other O
positive O
signs O
. O

The O
results O
of O
laboratory B-Diagnostic_procedure
tests I-Diagnostic_procedure
were O
almost B-Lab_value
normal I-Lab_value
, O
including O
alpha-fetoprotein B-Diagnostic_procedure
( O
AFP B-Diagnostic_procedure
) O
level O
. O

The O
Child B-Diagnostic_procedure
– I-Diagnostic_procedure
Pugh I-Diagnostic_procedure
score I-Diagnostic_procedure
was O
less B-Lab_value
than I-Lab_value
5 I-Lab_value
. O

Abdominal B-Biological_structure
ultrasonography B-Diagnostic_procedure
showed O
an O
uneven B-Detailed_description
lesion B-Sign_symptom
in O
the O
liver B-Biological_structure
and O
a O
diagnosis O
of O
HB B-Disease_disorder
was O
considered O
. O

Enhancement B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scanning O
showed O
a O
large B-Detailed_description
mass B-Sign_symptom
in O
the O
left B-Biological_structure
upper I-Biological_structure
abdomen I-Biological_structure
and O
left B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
with O
an O
irregular B-Shape
edge I-Shape
. O

The O
size O
of O
the O
mass B-Coreference
was O
12.3 B-Volume
× I-Volume
10.2 I-Volume
× I-Volume
7.2 I-Volume
cm I-Volume
( O
Fig. O
1 O
) O
. O

There O
was O
an O
uneven B-Detailed_description
nodular I-Detailed_description
shadow I-Detailed_description
and O
the O
edge B-Detailed_description
was I-Detailed_description
obvious I-Detailed_description
when O
the O
mass B-Coreference
was O
enhanced O
. O

Calcification B-Sign_symptom
and O
an O
expanded B-Sign_symptom
bile I-Sign_symptom
duct I-Sign_symptom
were O
not O
observed O
. O

The O
left B-Biological_structure
branch I-Biological_structure
of I-Biological_structure
the I-Biological_structure
portal I-Biological_structure
was O
pressed B-Detailed_description
and O
the O
distant B-Detailed_description
part I-Detailed_description
was I-Detailed_description
shown I-Detailed_description
to I-Detailed_description
be I-Detailed_description
unclear I-Detailed_description
. O

Abnormal B-Sign_symptom
was O
not O
observed O
in O
the O
right B-Biological_structure
branch I-Biological_structure
. O

According O
to O
the O
medical O
history O
, O
the O
diagnosis O
of O
HB B-Disease_disorder
was O
considered O
. O

We O
did O
not O
recommend O
a O
biopsy B-Diagnostic_procedure
to O
the O
patient O
because O
it O
might O
cause O
bleeding O
and O
tumor O
diffusion O
. O

An O
operation B-Therapeutic_procedure
was O
necessary O
. O

The O
patient O
underwent O
DVSS B-Therapeutic_procedure
surgery I-Therapeutic_procedure
with B-Detailed_description
sufficient I-Detailed_description
preparation I-Detailed_description
. O

Exploration B-Diagnostic_procedure
showed O
an O
extrahepatic B-Detailed_description
12 B-Area
× I-Area
10 I-Area
cm I-Area
mass B-Sign_symptom
in O
the O
left B-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
liver I-Biological_structure
( O
Fig. O
2 O
) O
. O

After O
the O
operation O
, O
the O
sample B-Coreference
was O
split B-Detailed_description
. O

The O
edge B-Shape
of I-Shape
the I-Shape
tumor I-Shape
was I-Shape
clear I-Shape
but O
no B-Detailed_description
envelope I-Detailed_description
. O

Tremelloid B-Detailed_description
mesenchyme B-Biological_structure
was O
seen O
on O
the O
section O
( O
Fig. O
2C O
) O
. O

The O
pathological O
examination O
showed O
that O
the O
sample B-Coreference
was O
grey B-Color
red I-Color
and O
14 B-Volume
× I-Volume
13 I-Volume
× I-Volume
7 I-Volume
cm I-Volume
in O
size O
. O

The O
color O
of O
the O
section B-Coreference
was O
grey B-Color
red I-Color
and O
grey B-Color
white I-Color
. O

MHL B-Disease_disorder
was O
diagnosed O
( O
Fig. O
3 O
) O
. O

Immunohistochemistry B-Diagnostic_procedure
results I-Diagnostic_procedure
( O
Fig. O
4 O
) O
were O
the O
following O
: O
mesenchymal B-Diagnostic_procedure
CD34 I-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
D2 B-Diagnostic_procedure
– I-Diagnostic_procedure
40 I-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
S-100 B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
SMA B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
CD7 B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
epithelium B-Diagnostic_procedure
CK19 I-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
AFP B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
HCG B-Diagnostic_procedure
( O
- B-Lab_value
) O
. O

After O
9 B-Duration
days I-Duration
of O
recovery B-Therapeutic_procedure
, O
the O
patient O
returned B-Clinical_event
home B-Nonbiological_location
without O
complications B-Sign_symptom
. O

A O
follow-up B-Clinical_event
examination O
, O
which O
included O
blood B-Diagnostic_procedure
routine I-Diagnostic_procedure
, O
liver B-Diagnostic_procedure
renal I-Diagnostic_procedure
function I-Diagnostic_procedure
, O
coagulation B-Diagnostic_procedure
routine I-Diagnostic_procedure
, O
and O
ultrasound B-Diagnostic_procedure
scan I-Diagnostic_procedure
at O
30 B-Date
days I-Date
, O
did O
not O
show O
any O
abnormality B-Sign_symptom
. O

No O
adverse B-Sign_symptom
or I-Sign_symptom
unanticipated I-Sign_symptom
event I-Sign_symptom
was O
presented O
. O

